pISSN: 2220-7562
eISSN: 2617-9482
CODEN: JBUMB7
Recognized by HEC & PMDC

JBUMDC

Journal of Bahria University Medical & Dental College

Volume 16 Issue 2, April-June 2026

Bahria University Health Sciences Campus Karachi
Adjacent PNS SHIFA, DHA Phase II, Karachi

JBUMDC
Journal of Bahria University Medical & Dental College
Peer Reviewed Multidisciplinary Quarterly Published Journal
ISSN (print): 2220-7562, ISSN (online): 2617-9482, CODEN: JBUMB7
Recognized by HEC & PMDC
Online edition is available at URL: https://jbumdc.bahria.edu.pk,
Indexed with Index Medicus for the Eastern Mediterranean Region (IMEMR),
https://vlibrary.emro.who.int/journals/jbumdc-journal-of-bahria-university-medical-and-detal-college/
ROAD Directory of Open Access Scholarly Resources at https://portal.issn.org/resource/ISSN/2617-9482
Pakmedinet at www.pakmedinet.com/jbumdc,
Google Scholar at https://scholar.google.com.pk/,
Crossref at https://doi.org/10.51985/aluu2996
ICMJE at https://www.icmje.org/journals-following-the-icmje-recommendations/#J
Bahira University DSpace Repository at http://111.68.99.22:8080/xmlui/handle/123456789/6388,
Pakistan Scientific and Technological Information Center (PASTIC) at http://pastic.gov.pk/

Correspondence Address:
Editor, JBUMDC, Bahria University Medical & Dental College, Adjacent PNS SHIFA, DHA Phase II, Karachi Pakistan
+92-21-35319491-9
https//jbumdc.bahria.edu.pk
editor.bumdc@bahria.edu.pk
https://www.facebook.com/jbumdc/, https://www.facebook.com/journal.bumdc.7
Published by: Bahria University Health Sciences, Campus Karachi

JBUMDC

Journal of Bahria University Medical & Dental College

Recognized by HEC & PMDC

JBUMDC Journal of Bahria University Medical & Dental College
Volume-16, Issue-2. April - June 2026

CONTENTS

CONTENTS

Editorial **Open Access**

Prescribing Lifestyle: Medicine Beyond Pills

Iqbal Hussain Udaipurwala

How to cite this Article:
Udaipurwala IH, Prescribing Lifestyle: Medicine Beyond Pills. J Bahria Uni Med Dental Coll. 2025;16(2):464-5 DOI: https://doi.org/10.51985/JBUMDC2026913

In the modern age, humanity faces a profound paradox, while medical technology has advanced with unprecedented speed, the global burden of chronic diseases continues to climb. Conditions such as diabetes mellitus, cardiovascular disease, obesity, cancer and mental health disorders have reached epidemic proportions. According to the World Health Organization, non-communicable diseases account for 75% of all non-pandemic related deaths globally in the year 2021, many of which are preventable through modifications in behavior and environment.[1] Amid this crisis, lifestyle medicine (LM) has emerged as a scientific, evidence-based discipline that empowers individuals and communities to prevent, treat, and even reverse chronic diseases by addressing their root causes.[2,3] The dominant medical model of the 20th century excelled at acute care, treating infections, trauma and emergencies but it struggles with chronic disease management.[4] This reactive model, heavily reliant on pharmacotherapy and procedures, often treats symptoms rather than underlying causes, leading to rising healthcare costs, physician burnout, and patient disempowerment.[5] Chronic diseases now consume over 80% of healthcare spending in many industrialized nations, making prevention not just a clinical preference but a fiscal and economic necessity. Lifestyle medicine is a paradigm shift in healthcare system, where the physician's role as a disease manager is replaced to a healthcare planner.[6,7] As the Hippocrates famously stated, "Let food be thy medicine and medicine be thy food," a maxim that remains a guiding principle of this modern revival.

The scientific basis of lifestyle medicine depends on the finding that our body is dynamic, responsive and profoundly influenced by our daily routine.[8] A human being is composed of approximately 37 trillion cells, each performing its role in exquisite coordination. Research in biomedicine has demonstrated that our cells listen to what we eat, how we move, how we sleep, and how we think. These chemical, electrical and hormonal signals are translated into molecular language that can turn genes on or off, heal inflammation and reverse pathology. This cellular harmony is conducted by five key systems, metabolic regulation, inflammatory balance, hormonal rhythm, neuroplasticity and epigenetic modulation.

Epigenetics, the master key of lifestyle medicine, reveals that we are not slaves to our genetic code. Lifestyle interventions can literally rewrite the body's biochemical story by switching on protective genes or silencing harmful ones without changing the DNA sequence itself.[9] For instance, comprehensive lifestyle changes have been shown to modify gene expression in men with early-stage prostate cancer, turning on tumor-suppressing genes and turning off those related to inflammation. This systems-biology approach replaces the reductionist model of treating isolated organs, viewing health instead as a dynamic balance between interconnected networks where nutrition influences the microbiome, the microbiome influences immunity and immunity affects mood.

Nutrition serves as the cornerstone of lifestyle medicine which redefines food not merely as fuel or calories but as biochemical information.[10] Every bite delivers thousands of bioactive compounds polyphenols, fibers, and phytochemicals that interact with our genome. While ultra-processed foods dominate modern diets and fuel the lifestyle disease triad of metabolic syndrome, cardiovascular disease and obesity, where whole plant foods rich in fiber and antioxidants have been displaced. Evidence from systematic reviews supports dietary patterns such as the Mediterranean, DASH, and Whole Food Plant-Based (WFPB) diets to reduce risks of heart disease and diabetes. Furthermore, the gut microbiome hosting 100 trillion microbes communicates directly with the brain and immune system.[11] Plant-based diets rich in fiber feed beneficial bacteria that produce short-chain fatty acids (SCFAs), reducing inflammation and strengthening the gut barrier. Conversely, poor nutrition allows harmful species to dominate, fueling metabolic and mood disorders.

Movement is not a fitness trend but a core physiological necessity for restoration of the human design.[12] For 99% of human history, survival depended on daily physical movement however, modern sedentary lifestyles have given rise to "Sedentary Death Syndrome". Regular physical activity triggers a cascade of molecular adaptations, where every movement literally reprograms cells for health. Muscles

Iqbal Hussain Udaipurwala
Senior Professor and Head Department of ENT,
Bahria University Health Sciences campus, Karachi
E-mail: iqbal.bumdc@bahria.edu.pk

Received: 03-02-2026
Accepted: 15-03-2026

are now recognized as endocrine organs, when contracted, release hormone-like molecules called "myokines". These myokines, such as Irisin and BDNF (brain-derived neurotrophic factor), enhance insulin sensitivity, reduce inflammation and promote neuroplasticity, a brisk 30-minute walk can elevate BDNF, protecting against cognitive decline and depression. Crucially, research shows that prolonged sitting (over 8 hours a day) increases all-cause mortality by 20%, even for those who exercise regularly, necessitating movement snacking or frequent breaks throughout the day.

Sleep is the silent healer and it is not a passive state but a highly organized biological restoration process. During deep sleep, the brain's glymphatic system flushes out metabolic waste, including â-amyloid, which is linked to Alzheimer's disease. Sleep also regulates the circadian symphony, synchronized by the suprachiasmatic nucleus (SCN) to the 24-hour light-dark cycle. Disruption in this rhythm, leads to weight gain, insulin resistance and immune suppression. Complementary to sleep is the management of stress, which acts as a low-grade fire smoldering through our body. Chronic stress activates the hypothalamic-pituitary-adrenal axis, leading to elevated cortisol that impairs immunity and accelerates aging. Whereas mindfulness, meditation and breathing exercises have been shown to lower cortisol level and activates the parasympathetic nervous system. By mastering the mind-body connection, patients can find the space between stimulus and response to choose growth over reactivity.

Humans are fundamentally social organisms, and social connection is as vital as nutrition or exercise. Loneliness is now recognized as a public health epidemic with a mortality risk equivalent to smoking 15 cigarettes a day. Positive relationships stimulate the release of oxytocin, which reduces blood pressure, cortisol, and inflammation. Conversely, social isolation upregulates pro-inflammatory genes and activates the same neural threat pathways as physical pain. In the age of abundance, addiction has expanded beyond substances to include behavioral dependencies like digital overuse, gaming, and social media compulsivity. Whether the addiction is chemical or digital, it exploits the same dopaminergic reward pathways in the brain. Constant exposure to hyper-stimulating technology leads to cross-sensitized addiction, characterized by attention fragmentation, anxiety, and sleep disturbance. Digital detoxification has emerged as a substantiated medical intervention to reclaim presence and reset dopamine sensitivity

To conclude, lifestyle medicine restores the timeless truth that our daily choices over years and years, shape our destiny more powerfully than any prescription. By bridging the gap between science and soul, this discipline offers a pathway to a healthcare system that heals individuals. Integrating lifestyle medicine into primary care requires a multidisciplinary team-based approach including physicians, dietitians and psychologists working together to provide personalized lifestyle prescriptions. The healthcare system of the future will not only succeed in treating diseases rather it will teach people how to live healthy.

Authors Contribution:
Iqbal Hussain Udaipurwala: Conception, writing, literature search, proof reading

REFERENCES

1. World Health Organization website Home/Newsroom/Fact sheets/Detail/Noncommunicable diseases. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
2. Lippman D, Stump M, Veazey E, Guimarães ST, Rosenfeld R, Kelly JH, Ornish D, Katz DL. Foundations of Lifestyle Medicine and its Evolution. Mayo Clin Proc Innov Qual Outcomes. 2024; 8(1): 97-111. doi: 10.1016/j.mayocpiqo.2023.11.004.
3. Pearl R. Lifestyle Medicine: Overcoming Systemic and Cultural Barriers to Better, More Affordable Care. Am J Lifestyle Med. 2023; 17(5): 626-631. doi: 10.1177/ 15598276231166321.
4. Bég SA, Reddy KR. Lifestyle Medicine: From Challenges to Opportunities. Am J Lifestyle Med. 2023; 17(5): 624-625. doi: 10.1177/15598276231178212.
5. Srivastava SB. Polypharmacy, Unintended Consequences, and Impact of Lifestyle Medicine. Am J Lifestyle Med. 2023; 18(1): 54-57. doi: 10.1177/15598276231207302.
6. Sadiq IZ. Lifestyle medicine as a modality for prevention and management of chronic diseases. J Taibah Univ Med Sci. 2023; 18(5): 1115-1117. doi: 10.1016/j.jtumed.2023.04.001.
7. Sallis RE, Matuszak JM, Baggish AL, Franklin BA, Chodzko-Zajko W, Fletcher BJ, Gregory A, Joy E, Matheson G, McBride P, Puffer JC, Trilk J, Williams J. Call to Action on Making Physical Activity Assessment and Prescription a Medical Standard of Care. Curr Sports Med Rep. 2016; 15(3): 207-14. doi: 10.1249/JSR.0000000000000249.
8. Rippe JM. The Academic Basis of Lifestyle Medicine. Am J Lifestyle Med. 2023; 18(4): 497-511. doi: 10.1177/15598276231212825.
9. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine. Clin Epigenetics. 2022; 14(1): 44. doi: 10.1186/s13148-022-01263-1.
10. Santos L. The impact of nutrition and lifestyle modification on health. Eur J Intern Med. 2022; 97: 18-25. doi: 10.1016/j.ejim.2021.09.020.
11. Matusheski NV, Caffrey A, Christensen L, Mezgec S, Surendran S, Hjorth MF, McNulty H, Pentieva K, Roager HM, Seljak BK, Vimaleswaran KS, Remmers M, Péter S. Diets, nutrients, genes and the microbiome: recent advances in personalised nutrition. Br J Nutr. 2021; 126(10): 1489-1497. doi: 10.1017/S0007114521000374.
12. Carballo-Fazanes A, Rico-Díaz J, Barcala-Furelos R, Rey E, Rodríguez-Fernández JE, Varela-Casal C, Abelairas-Gómez C. Physical Activity Habits and Determinants, Sedentary Behaviour and Lifestyle in University Students. Int J Environ Res Public Health. 2020; 17(9): 3272. doi: 10.3390/ijerph17093272.

Original Article

Open Access

Outcome of Prophylactic Therapy with LMWH and Aspirin in Pregnancy with Antiphospholipid Syndrome

Farah Hameed, Samia Shuja

Abstract:

Objective:To determine the fetal outcome after prophylactic therapy with low molecular weight hepain and aspirin in pregnant woman with recurrent pregnancy loss (antiphosholipid syndrome)

Study Design and Setting: This is retrospective observational study conducted in Department of obstetrics and gynecology at Indus hospital Karachi from 20 December 2016 to 30 September2022.

Methodology; The study group include 39 pregnant woman with antiphophospholipd syndrome (recurrent pregnancy loss) presented at Sheikh Saeed campus of Indus Hospital Karachi from 2016 to 2022. Patients were diagnosed with APLS on the basis of Sapporo clinical criteria for aPLS. All these patients were treated with prophylactic therapy with aspirin and low molecular weight heparin throughout pregnancy. The primary outcome was live birth. Statistical analysis was done through SPSS version 26.

Result: Prophylactic therapy with low molecular weight heparin and aspirin in pregnant woman with recurrent pregnancy loss has a significant impact on the fetal outcome. 79.5% delivered alive babies. 12.8 % experienced miscarriage. 2.6 % had termination of pregnancy due to congenital malformation. 5.2% were unable to follow-up.

Conclusion; Prophylactic therapy with low molecular weight heparin and aspirin has significantly improved live birth rate (79.5%) in patients with recurrent pregnancy loss with antiphospholipid syndrome.

Keyword; Antiphospholipid syndrome (APS), Aspirin , Low Molecular Weight Heprin (LMWH)

How to cite this Article:
Hameed F, Shuja S. Outcome of Prophylactic Therapy with LMWH and Aspirin in Pregnancy with Antiphospholipid Syndrome. J Bahria Uni Med Dental Coll. 2026;16(2):466-71 DOI: https://doi.org/10.51985/JBUMDC2025529

INTRODUCTION

Antiphospholipid syndrome is a significant and manageable contributor to repeated pregnancy loss. The incindence of antiphospholipid syndrome is 20-40% in women with recurrent miscarriage. [1]Among healthy women without history of recurrent miscarriage, antiphospholipid antibodies are detected between 1-5%.These antibodies are found upto 15% in women with recurrent pregnancy loss. Among general population, prevalence of antiphosphospholipid syndrome is 0.5%.[2]The incidence of recurrent miscarriage is 1%. Recurrent miscarriage can be caused by chromosomal, anatomic, hormonal (progesterone, estrogens, diabetes or thyroid disease), coagulation or rly pregnancy, platelet abnormalities. About 10-15% of such women, the cause of recurrent pregnancy loss is antiphosphospholipid syndrome.

Farah Hameed
Consultant, Department of Obstetrics and Gynaecology
The Indus Hospital, Karachi.
Email: farah_hd@yahoo.com

Samia Shuja
Consultant, Department of Obstetrics and Gynaecology
The Indus Hospital, Karachi.
Email: samia.shuja@tih.org.pk

Received: 06-02-2025
Accepted:19-02-2026
1st Revision: 23-02-2025
2nd Revision: 17-05-2025
3rd Revision: 17-02-2026

Antiphospholipid antibodies can be detected upto 5-20% in women recurrent pregnancy loss. [3]When a woman with APS (antiphosphospholipid syndrome) conceive, the incidence of spontaneous abortion is quite high. Without treatment about 90% of pregnancies end up in miscarriage.[4] APS has a strong impact on pregnancy ,It not only affects early pregnancy but late pregnancy as well, In early pregnancy it is associated with recurrent miscarriage .APS is associated with preterm delivery ,pre-eclampsia ,intrauterine growth restriction and intrauterine fetal death, These complication are mainly due to effect of antiphospholipid antibodies on trophoblast differentiation and invasion leading to placental infarctions, and thrombosis.[5, 6] The Sapporo/Sydney Criteria for diagnosis of definite APS is based on clinical as well as laboratory findings.[7]

1-Vascular thrombosis: One or more episodes of arterial or venous thrombosis, or thrombosis of small vessels in any organ or tissue, confirmed through Doppler. It should exclude vasculitis.

2-Pregnancy outcomes: a) One or more deaths of a morphologically normal fetus after the 10th week of gestation, confirmed by ultrasound or autopsy. b) One or more premature births of a morphologically normal fetus before the 34th week of gestation, due to eclampsia,

preeclampsia, or placental insufficiency. c) Three or more spontaneous abortions before the 10th week of gestation, with maternal hormonal or anatomical abnormalities, and paternal and maternal chromosomal causes excluded.

Laboratory Criteria: (a) Presence of lupus anticoagulant antibody (LA) in the plasma on two or more occasions, at least 12 weeks apart, detected according to the International Society on Thrombosis and Hemostasis (ISTH) guidelines.

(b) Moderate (> 40) to high (> 80) titers of IgG or IgM anticardiolipin antibodies (ACL) on two or more occasions, at least 12 weeks apart, detected via standard ELISA test.

c) Presence of IgG or IgM anti-beta 2-GPI antibodies in the plasma on two or more occasions, at least 12 weeks apart, detected by standard ELISA test

The key pathological process driving APS-associated pregnancy complications is thrombus formation in placenta that leads to compromised placental functions and impaired feto-maternal exchange, The disrupted exchange between mother and fetus ultimately contributes to development of obstetric complications, The presence of placental infarcts as observed in histological studies by DE Wolf further corroborates this understanding of the underlying diseases process,[8] Thrombus formation is a complication associated with suboptimal placentation, leading to restricted fetal growth and development. Studies conducted by Yamada et al have demonstrated a link between antiphospholipid antibodies and compromised pregnancy outcomes specifically low birth weight and preterm labour.[9] Plozin et al have also observed a correlation between antiphospholipid antibodies and fetal growth restrictions.[10] Compromised circulation between the fetus and placenta is a risk factor for late pregnancy complication, such as placental abruption, which can have devastating consequence including fetal death and still birth.[11]

The standard treatment regimen for antiphospholipid syndrome in pregnancy typically centers around heparin administration. Heparin possesses a distinct property that enable it to bind to antiphospholipid antibodies and inhibiting their interaction with trophoblastic tissues. This leads to improved blood flow, reduced risk of placental thrombosis and infarction, and ultimately, fewer complication in late pregnancy. Aspirin exerts a beneficial thromoprophylactic effect by suppressing platelet aggregation thereby reducing risk of thrombotic event.[12]

METHODOLOGY:

This is retrospective observational study. After obtaining approval from the ethical review board of the institution IRB number IHHN -2022-019, data was collected. All pregnant woman with recurrent pregnancy loss (antiphospholipid syndrome) presented at Sheikh Saeed campus of Indus Hospital Karachi from 20 Dec2016 to 30 September 2022. As this was retrospective study so informed consent was not required, Patients were diagnosed with aPLS only on the basis of Sapporo /Sydney clinical criteria for aPLS. No laboratory testing for antiphospholipid syndrome was done as these were already pregnant. All these patients were treated with aspirin and low molecular weight heparin. The time of initiation of treatment was between 7 to 17weeks. All patients were treated with daily Aspirin 75mg and low molecular weight heparin 1mg/kg body weight. Compliance was ensured by recollection of empty ampules. All patients were regularly followed through serial scans and plan was made to deliver at 37 weeks if both mother and fetus doing well. LMWH and Aspirin was stopped one day before elective delivery. The primary outcome was live birth. Total 39 pregnant women meeting inclusion criteria were undergoing prophylactic therapy. Statistical analysis was done through SPSS version 26. Inclusion criteria: All pregnant woman with recurrent pregnancy loss with aPLS only on the basis of Sapporo /Sydney clinical criteria for aPLS. Exclusion criteria: recurrent pregnancy loss due to uterine anomlies, Cervical incompetence, cardiovascular, renal disease, previous history of thromboembolic disasese, BMI >30kg/m2, Pregnancy loss due to known genetic and hormonal factors, any pre-existimg medical disorder that has an impact on pregnancy outcome, Uterine fibroid which might cause complications during pregnancy

As this is retrospective observational study so randomized and controlled groups are not required. As all women with APS were treated with daily Aspirin 75mg and low molecular weight heparin 1mg/kg bodyweight so there was no control and randomized group.

RESULTS:

The median interquartile range (IQR) of start time of their therapy 11 weeks (7-17). Their mean age 29.9±5.6 year. BMI 27.2± 3.8, delivery time was 37(36-37) weeks, still births 2(1-3) and Number of miscarriages was 5(3-4) .Moreover, for current pregnancy 25.6% women develop GDM, 5.1%) develop Pregnancy Induced Hypertension (PIH) while only 1(2.6%) had hypothyroidism. If talk Regarding fetal outcome , 79.5%(31)women delivered alive babies 79.5%(31) and 12.8 (5%)had miscarriage .One woman was diagnosed with anencephaly(2.6%) so termination of pregnancy done as per patient wish. and two(5.2%) patients were lost for follow up.. Furthermore, out of 31 alive babies 17(54.8%) were females. Besides that, all babies had a healthy weight. The median (IQR) of male and female weight was 2.8kg (2.4-2.9) and 2.7 kg(2.1-3.0) kg (Table 1).Additionally, no significant difference was observed between fetal outcome and other comorbidity of patients like gestational diabetes mellitus, pregnancy induced hypertension and BMI

DISCUSSION:

Our study, treatment was initiated between 7-17weeks of pregnancy. Our study found that live birth rate with combine treatment LMWH and aspirin is 79.5 % which is quite high. Almost all patient were delivered at 37weeks.All babies have normal birth weight. The miscarriage rate is 12.8 % after using the therapy which is significantly lower. Around 5% of the women developed pregnancy induced hypertension. So, the combined treatment is not only associated with improved live birth rate but also associated with reduced incidence of miscarriage, pregnancy induced hypertension, pre-eclampsia and fetal growth restriction and preterm delivery.

Table:1 Study participants age ,BMI and time of start of therapy and Time of delivery

Age Years	
Mean ±SD	29.9±5.6
BMI	
Mean ±SD	27.2±3.8
Thrombolytic therapy start time (Weeks)	**n (%)**
Median(IQR)	11(7-17)
Delivery time (Weeks)	**n(%)**
Median (IQR)	37(36-37)

Table 2: Current pregnancy and morbidity

DM	3(7.7)
GDM	10(25.6%)
PIH	2(5.1%)
HTN/ Chronic HTN	3(7.7)
Hypothyroidism	1(2.6)
Fetal Outcome	**n(%)**
Alive	31(79.5)
Miscarriage	5(12.8)
Lost to followup	2(5.2)
Termination	1(2.6)
Gender of Baby	**n(%)**
Male	14(45.2)
Female	17(54.8)
Weight of male (kg)	**n(%)**
Median(IQR)	2.8(2.4-2.9)
Weight of female (kg) Median(IQR)	2.7(2.1-3.0)

By decreasing the trophoblastic apoptosis and increasing generation of proteases essential for trophoblastic-endometrial interaction, Heparin supports a healthy implantation process. In vitro studies have shown that low molecular weight heparin influences angiogenesis in placental villi and modulates vascular endothelial growth factor (VEGF) dysregulation. Additionaly heparin has been found to inhibit complement activation potentially reducing risk of pregnancy complication,

A key point of discussion is the optimal timing for commencing treatment, specifically whether we should begin before pregnancy or be delayed until after conception. Research by Laklouk et al demonstrated enhanced live birth following administration of Heaparin and Aspirin. They compared two groups: one that received therapy 2-3months prior to conception and another that received therapy after pregnancy confirmation. The study found no significant difference in miscarriage and live birth rates between two groups, suggesting that the timing of treatment initiation did not have a substantial impact.[13]

Hamulyak et al conducted a meta-analysis between two groups with recurrent pregnancy loss and antiphopholipid syndrome. [14]Combination treatement with LMWH and Aspirin was associated with increase live birth rate. Yu also conducted a metanalysis on treatment of recurrent miscarriage (associated with APS).Yu found reduced incidence of miscarriage, pre-eclampsia and fetal growth restriction. Furthermore, treatment is associated with markedly improved gestational age at birth and increased live birth rate[,15,] These results are very similar to our study.

Juneja et al has also reported significant improved live birth rate after treatment with Aspirin and LMWH[16,]Rekha et al found that Asprin alone is associated with 82% live birth while combination of Aspirin and LMWH is associated with

Table 3: Association between Fetal outcome and other characteristics of participants

	Fetal Outcome					
	Alive n%	**Misscairrage n%**	**Lost to followup n%**	**Termination n%**	**Total n%**	**p-value**
Age years						
=29.9	16(51.6)	3(60)	2(100)	1(100)	22(56.4)	0.734[?]
>29	15(48.4)	2(40)	-	-	17(43.6)	
DM	3(9.7)	-	-	-	3(7.9)	0.721[?]
GDM	9(29)	1(20)	-	-	10(26.3)	0.721[?]
PIH	2(6.5)	-	-	-	2(5.3)	
HTN	3(9.7)	-	-	-	3(7.9)	

92.5% live birth which is quite satisfactory.[17]

The use of low molecular weight Heparin in conjunction with Asprin is widely viewed as a safe and effective treatment approach. Studies have shown that LMWH can exert a favorable influence on trophoblastic implantation and apoptosis, suggesting a potential role in promoting healthy placental function. The optimal timing for heparin administration to promote implantation success may coincide with the time of implantation itself, aligning with the standard administration schedule for LMWH. LMWHs are given subcutaneously once a day. The subcutaneous delivery of heparin provide considerable benefits compared to unfractionated heparin such as enhanced bioavailability, longer plasma half-life and more reloiable pharmacokinetics and pharmocodynamic profiles, as well as reduced potential for osteoporosis. LMWH is also not associated with thrombocytopenia. The antithrombotic effect of LMWH is to inhibits factor Xa more effectively than factor IIa . Furthermore, LMWH does not cross the placenta and is safe for the fetus.

Aspirin is being used to mitigate the risk of miscarriage and improve pregnancy outcome in women with history of recurrent miscarriage. The main role of aspirin to maintain a balance between thromoboxane A2 and prostacyclin, Thromboxane A1 has platelet aggregation and vasoconstriction properties while prostacyclin promotes vasodilatation. Low dose asprin administration daily shifts balance in favour of prostacyclin leading to vasodilatation and improved blood flow. Manisha et al conducted a study on two groups with recurrent miscarriage. One group received only Aspirin while second group reciceved combination therapy (Aspirin and LMWH).The combination group had a significantly lower number of miscarriages 32%vs. 54%, $P < 0.001$) and a significantly higher number of live births 69% vs 41%. There were no significant differences in the number of preterm deliveries (<37 weeks) between the two groups.[18.] Katarina Jeremiæ et al reported pre-eclampsia occurs 15 % despite treatment with low dose aspirin and LMWH .[19]While in our study 5 % of the women developed PIH (pregnancy induced hypertension).In a study by David MO it was found that in pregnant women (with previous history of miscarriage) after treatment of low dose enoxaparin with low dose aspirin 80% live births and 20% miscarriage.[20]It is almost similar to our study with 79.5% live birth and miscarriage rate is 12.8.

Beta 2-glycoprotein I (b2GPI), a phospholopid binding protein, is a key antigenic target in APS. This protein is expressed on multiple cell types associated with coagulation and placental development. The binding of aPL to beta 2-glycoprotein I (b2GPI) on trophoblast, decidual and endometrial cells, endothelial cells play a critical role in pathogenesis of APS. The presence of aPLs has been found to disrupt trophoblast function, inhibiting diiferentiation and invasiveness while inducing cellular injury and apoptosis which can compromise placental development and pregnancy outcome. These antibodies also promotes pro-inflammatory phenotype in stromal cells. Additionally, aPLs have been found to inhibit angiogenesis in endometrial endothelial cells. Tanimura et al conducted prospective observational study to see effect of low-dose aspirin (LDA) and unfractioned heparin(UFH) in women with recurrent pregnancy loss with antib2glycoproteinI/HLA-DR autoantibodies . The live birth rate in the LDA/UFH group was 87.2 % than that in the non-LDA/non-UFH group 50.0%.This is very significant difference. Furthermore, women with RPL, the pregnancy complication rate in the LDA/UFH group was significantly lower than that in the non-LDA/non-UFH group (5.9% vs 50%). [21]

When a woman present with recurrent pregnancy loss, the most important step is to test for antiphosphopholipid antibodies. Thses antibodies are also underlying cause for rheumatic diseases so patients are referred to rheumatologist to identify early signs of rheumatic diseases, Antiphospholipid syndrome is characterized by thrombus formation in arterial and venous circulation. This thrombus formation is associated with pregnancy morbidity. As per Sydney criteria, obstetric APS is early onset of severe preeclampsia before 34weeks.This clinical criteria emphasize diagnosed clinically on basis of obstetric history, this also includes three consective miscarriages before 12weeks or explained fetal death after 12wks pregnancy provided that there should be no history of thrombus

Altough the connection between APS and pregnancy complications is well established, a 2013 consenses report on 14th International Congress on Antiphospholipid Antibodies noted that many studies investigating the association between APS and miscarriage fail to meet the strict laboratory criteria outlined in the Sydney criteria, making link between RPL and aPL questionable.[22]

The European league against rheumatoid arthritis and American college of rheumatogy (EULAR/ ACR) has introduced new criteria for APS in 2023. It includes clinical and laboratory criteria. This criteria has high specificity. The clinical criteria includes thrombotic event, preganancy morbidity and neurological and cardiac manifestation. The thrombus should be at uncommon sites. The new criteria for pregnancy morbidity has also been changed regarding pregnancy duration and timing of preclamsia. The criteria has extended clinical spectrum of APS by including microvascular and cardiac valve diseases. Furthermore, the laboratory domains includes lupus anticoagulant, anticardiolipin and beta2 glycoprotein1 antibodies. The most important change is the titer of these antibodies. The titer should be medium or high. The new criteria does not include low titer. For EULAR/ACR 2023 a score of three or more than three, both clinical as well as laboratory criteria is required to establish diagnosis of APS. [23]

Mercier et al conducted a comparative study to assess prevalence of APS on basis of Sydney and EULAR criteria, the prevalce was 14% with Sydney criteria and only 1.3% with EULAR crtiteria. The most important aspect of this study is no significant difference in previous pregnancy outcome was found. The high specificity of EULAR/ACR is associated with significant loss of number of cases of APS.[22] So we can treat patients with Oaps (obstetric antiphospholipid syndrome) diagnosed on the basis of clinical Sydney criteria and we can improve live birth rate in such patients with recurrent pregnancy loss.

Limitation; Our limitation was small sample size .

CONCLUSION:

The combine treatment with LMWH and aspirin in woman with antiphospholipid syndrome is associated with significant improvement in fetal outcome.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Farah Hameed: Identified, literature research and prepared the manuscript and take full responsibility for its clinical integrity
Samia Shuja: Final review of manuscript

REFERENCES

1. Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernández OM, Gaybor M, Cordero C, Cabrera S, Soroka NF. Obstetric antiphospholipid syndrome. Autoimmun Rev. 2012 Feb;11(4):288-95. doi: 10.1016/j.autrev.2011.10.006. Epub 2011 Oct 7. PMID: 22001418
2. Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:1125–32. BMJ. 2010 May 14;340:c2541. doi: 10.1136/ bmj.c2541. PMID: 20472677.
3. Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospohlipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012 Feb;26(1):65-76. doi: 10.1016/j.bpobgyn.2011.10.006. Epub 2011 Nov 11. PMID: 22079775.
4. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995 Dec;10(12):3301-4. doi: 10.1093/oxfordjournals.humrep.a135907. PMID: 8822463
5. . Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun. 2009 Sep;33(2):92-8. doi: 10.1016/j.jaut.2009.05.002. Epub 2009 Jun 25. PMID: 19559568.
6. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002859. doi: 10.1002/14651858.CD002859.pub2. PMID: 15846641; PMCID: PMC6768987
7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x. PMID: 16420554.
8. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol. 1982 Apr 1;142(7):829-34. doi: 10.1016/s0002-9378(16)32527-3. PMID: 6801984
9. Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, Ohta K, Yasuda S, Koike T, Minakami H. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol. 2009 Jan;79(2):188-95. doi: 10.1016/j.jri.2008.11.001. Epub 2009 Feb 10. PMID: 19211151
10. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991 Dec;78(6):1108-11. PMID: 1945217.
11. Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, Hunt BJ, Poston L. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta. 2006 Apr-May;27(4-5):457-67. doi: 10.1016/j.placenta.2005.04.006. Epub 2005 Jul 6. PMID: 16005063
12. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol. 2002 May-Jun;55(1-2):163-80. doi: 10.1016/s0165-0378(01)00144-9. PMID: 12062831.
13. Laklouk, Mahmoud; Elshikha, Khaled; and Ellaban, Mostafa (2022) "Timing of initiation of low molecular weight Heparin and Aspirin administration on the pregnancy outcome in women with Antiphospholipid syndrome and recurrent abortion ," Al-Azhar International Medical Journal: Vol. 3: Iss. 9, Article 15. DOI: https://doi.org/10.21608/ aimj.2022.129650.1883
14. Hamulyák EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2. PMID: 32358837; PMCID: PMC7195627.
15. Yu X, He L. Aspirin and heparin in the treatment of recurrent spontaneous abortion associated with antiphospholipid antibody syndrome: A systematic review and meta-analysis. Exp Ther Med. 2021 Jan;21(1):57. doi: 10.3892/etm.2020.9489. Epub 2020 Nov 19. PMID: 33365057; PMCID: PMC7716630.
16. Juneja, S. K., Tandon, P., Kaur, G., Kapoor, B., & Sidhu, G. S. (2020). Comparison of empirical use of low dose aspirin and enoxaprin in the treatment of unexplained recurrent pregnancy loss. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 9(3), 1138–1142. https://doi.org/10.18203/2320-1770.ijrcog20200889
17. Rekha, S. B., & Chandra, K. S. (2020). Comparative study of low dose aspirin versus combination of low dose aspirin and low molecular weight heparin in idiopathic recurrent pregnancy loss. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 9(2), 512–515. https://doi.org/10.18203/2320-1770.ijrcog20200010

18. Manisha M. Laddad, N. S. Kshirsagar, Sanjaykumar P. Patil, Gauri Shinde, Pranjal Nimbalkar. "Low Dose Aspirin in Combination with Low-Molecular-Weight Heparin is better than Low Dose Aspirin Alone in the Treatment of Pregnant Women with Recurrent Miscarriages". Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 21, May 26; Page: 5753-5760, DOI: 10.14260/jemds/2014/2660

19. Jeremiæ K, Pervulov M, Gojniæ M, Dukanac J, Ljubiæ A, Stojniæ J. Comparison of two therapeutic protocols in patients with antiphospholipid antibodies and recurrent miscarriages. Vojnosanit Pregl. 2005 Jun;62(6):435-9. doi: 10.2298/vsp0506435j. PMID: 16047856.

20. Mo D, Saravelos S, Metwally M, Makris M, Li TC. Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. Reprod Biomed Online. 2009 Aug;19(2):216-20. doi: 10.1016/s1472-6483(10)60075-2. PMID: 19712557.

21. Tanimura K, Saito S, Tsuda S, Ono Y,Deguchi M, Nagamatsu T, Fujii T,Nakatsuka M, Kobashi G, Arase H andYamada H (2024) Low-dose aspirin and heparin treatment improves pregnancy outcome in recurrent pregnancy loss women with antib2glycoproteinI/HLA-DR autoantibodies: a prospective,multicenter, observational study.Front. Immunol. 15:1445852. doi: 10.3389/fimmu.2024

22. Mercier, M.; Lescoat, A.;Pierre-Jean, M.; Dumontet, E.; Le Lous, M.; Belhomme, N. Prevalence of Antiphospholipid Antibody Syndrome Among Patients with Recurrent Pregnancy Loss: Impact of the Revised 2023 ACR/EULAR Antiphospholipid Syndrome Criteria. J. Clin. Med. 2024, 13, 7698. https://doi.org/10.3390/ jcm1324769

23. Barbhaiya M, et al. Ann Rheum Dis 2023;82:1258–1270. doi:10.1136/ard-2023-224609

Original Article **Open Access**

Impact of Monoploar Electrocautery Versus Ultrasonic Dissection On Gallbladder Perforation In Laparoscopic Cholecystectomy

Madeeha Shahid, Muhammad Khalid

ABSTRACT

Objective: To compare the outcomes of monopolar electrocautery and ultrasonic gallbladder dissection from the gallbladder bed during laparoscopic cholecystectomy in term of gallbladder perforation.

Study design and setting: This comparative, cross-sectional study conducted in the Department of Surgery, PAF Hospital Mushaf, Sargodha, from August 2021 to December 2022 after obtaining ethical committee approval.

Methodology: A total 320 patients with cholelithiasis undergoing laparoscopic cholecystectomy were divided into two groups. In group A, the dissection of gallbladder from its bed was done with an ultrasonic device that is harmonic scalpel, while in group B, conventional monopolar electrocautery was used. Patients were assessed for gall bladder perforation. A p-value < 0.05 was considered statistically significant.

Results: Out of 320 laparoscopic cholecystectomies, gallbladder perforation occurred in 7 (4.4%) patients in Group A and 28 (17.5%) patients in Group B, a difference that was statistically significant ($p < 0.001$). The mean age was 29.08 ± 8.09 years in Group A and 32.49 ± 9.36 years in Group B (range 20–45 years), with no statistically significant difference between the groups ($p = 0.481$). The male-to-female ratio was 1:4.5 in Group A and 1:7 in Group B, with no significant difference between the groups ($p = 0.792$).

Conclusion: This study revealed that a significantly lower frequency of gall bladder perforation with ultrasonic dissection as compared to monopolar diathermy among patients undergoing laparoscopic cholecystectomy. This can ultimately reduce the early and long-term complications of bile spillage and stone loss in peritoneal cavity.

Keywords: Cholelithiasis, Gallbladder perforation, Laparoscopic cholecystectomy, Monopolar electrocautery,

How to cite this Article:
Shahid M, Khalid M. Impact of Monoploar Electrocautery Versus Ultrasonic Dissection On Gallbladder Perforation In Laparoscopic Cholecystectomy. J Bahria Uni Med Dental Coll. 2026;16(2):472-6 DOI: https://doi.org/10.51985/JBUMDC2025617

INTRODUCTION:

The "gold standard" for treating symptomatic gallstone disease is laparoscopic cholecystectomy (LC). Even when the procedure is standardized, both emergency and elective surgeries can result in complications. After clipping of the cystic duct and artery during LC, gallbladder perforation during dissection from the liver bed leading to bile spillage and stone loss in the peritoneal cavity is a common surgical complication. It has been observed that 20% to 40% of LC procedures result in gallbladder perforation [1]. As the surgeon's competence determines the procedure's safety, it is essential to continuously improve surgical technique and identify any potential risks associated with the devices used.

Madeeha Shahid
Consultant Surgeon, Department of General Surgery
PAF Hospital Mushaf Sargodha
Email: madeeha_87s@hotmail.com

Muhammad Khalid
Consultant Anesthetist, Department of Anesthesiology
PAF Hospital Mushaf, Sargodha
Email: asrozs@yahoo.com

Received: 25-05-2025
Accepted: 10-12-2025
1st Revision: 27-06-2025

Various instruments have been used in laparoscopic surgery to cut and coagulate tissue, including the ultrasonic scalpel, carbon dioxide laser, and bipolar and monopolar cautery. It is challenging to determine the precise frequency of collateral damage; nonetheless, during LC, 15% of biliary tract injuries and 90% of visceral injuries have been directly linked to the use of 18% monopolar electrocautery. Injuries can also result from stray electrical currents, direct interaction between the active electrode and metal tools or tissue, and insulation failure of the active electrode in electrosurgical equipment. Due to potential patient harm, additional research has been done on substitute instruments such as ultrasonic scalpels [2].

More than two decades have passed since the ultrasonically activated scalpel (Harmonic - Ethicon Endo-Surgery INC - Johnson & Johnson Medical SPA, Somerville, NJ 1992) was first used in clinical settings. Its technology is based on applying ultrasonic waves to tissues in the harmonic frequency range. This produces three interdependent effects: cavitation, cutting, and coagulation. Tissue damage is less likely when the temperature is attained and the lateral energy spreads are lower than those found when the monopolar hook is employed. According to FDA certification from

2006, the harmonic scalpel (HS) is also useful for closing biliary ducts and arteries with a diameter of 4 to 5 mm[3]. Friction is produced at the probe of this device by ultrasonic vibrations. It generates vibrations between 20,000 and 50,000 Hz, and when the temperature rises to 200ºC, tissue is transected with negligible collateral damage as a result of the friction that denatures proteins and causes coagulation[4].

The Monopolar diathermy hook is the most commonly used instrument to create a bloodless operating field during LC. However, local consequences such as injury to the liver or common bile duct, gallbladder perforation, and bile or stone leaking into the peritoneal cavity can result in both monopolar and bipolar electric coagulation. These issues can also affect the stomach or small bowel. When it comes to the safe replacement of a diathermy hook for hemostatic tissue dissection, ultrasonically activated HS has proven to be effective and more precise. The primary functions of the HS in LC have been the division of the artery to the cystic duct and the separation of the GB from the liver bed. The coagulating and cavitation effects that occur when various tissues come into contact with a rapidly vibrating blade served as the foundation for this innovative method of slicing tissues. Furthermore, the almost smokeless electronically driven HS maintains visibility of the operating field throughout the procedure, obviating the necessity for frequent lens cleanings or smoke expulsions to recreate the pneumoperitoneum [5].

By lowering the risk of gallbladder perforation and related intraoperative and postoperative complications, ultrasonic dissection of the gallbladder bed during LC may enhance the surgical technique [6]. Ultrasonic dissection's learning curve demonstrates that skill increases with practice, which could eventually lead to safer and more effective methods [7.] Recent studies also supports that harmonic device used for clipless cholecystectomy, ultrasonic shears provided more precision during dissection and reduced complications[8,9]. Recent local data are limited. Since gallbladder perforation can lessen both early and late difficulties linked to bile and gallstone spilling, the current study aimed to compare outcome of monopolar electrocautery and ultrasonic gallbladder dissection during laparoscopic cholecystectomy. It provide locally appropriate evidence and may help in the selection of energy devices in standard practice. It might be linked to better surgical results and easier recovery after surgery [10].

METHODOLOGY: After obtaining approval from the Ethical Committee (ERC: MSF(H)/308/IRB/48) this cross sectional study was conducted in the Department of General Surgery, PAF Hospital Mushaf, Sargodha from March 2021 to December 2022.

The calculated sample size based on gallbladder perforation rate 10% in electrocautery and 3% in ultrasonic dissection reported in a study[11] with 5 % level of significance and 80 % power of study. In this study, 320 patients who fulfilled the inclusion criteria admitted through the outpatient department were enrolled.

Inclusion criteria: All patients diagnosed as symptomatic cholelithiasis, age 20 – 45 years, including both sexes. Exclusion criteria: Patients with cirrhosis of the liver on ultrasound, symptoms of pain, fever, and tenderness in right hypochondrium within the last 05 days duration, Patient refusal for laparoscopic cholecystectomy, patients with evidence of choledocholithiasis, patients with carcinoma of the gallbladder.

After informed consent for this study, a detailed history was taken and a thorough physical examination was done. Ultrasonic evidence of symptomatic cholelithiasis was recorded. A routine laboratory investigation was advised and general anesthesia fitness was taken by the anesthetist. All patients underwent elective LC. Non-probability convenience sampling technique was used. And patient was divided into two equal groups on the patient's arrival at the operation theater. 160 patients in group A received laparoscopic surgery with a HS, and 160 patients in group B received treatment with monopolar electrocautery. The standard four ports laparoscopic cholecystectomy was performed by consultant surgeons with more than 5 years of laparoscopic experience, ensuring uniformity in dissection technique, port placement, energy device usage, and intraoperative decision-making. Procedure starts by creating a pneumoperitoneum using CO_2. Clipping of cystic artery and duct was done by using titanium clips after achieving a Calot's triangle. Dissection of gallbladder from its bed was done with a HS in group A and monopolar electrocautery in group B. During surgery, the patients were observed for outcome parameter i.e. gallbladder perforation or not. This is identified intraoperatively by the surgeon and documented in the operative notes. Gallbladder perforation is defined as any unintended breach or tearing of the gallbladder wall occurring during laparoscopic cholecystectomy, resulting in leakage of bile and/or gallstones into the operative field.

All patients received 3 doses of intravenous antibiotics, one dose at the time of anesthesia induction and the next two 8 hourly. All patients were discharged on the 1st or 2nd post-operative day depending upon the postoperative status of pain and would be followed in the outpatient department on 7th postoperative day. All collected data was recorded in predesigned proforma.

RESULTS

Statistical analysis of data was done by using SPSS version 22. For categorical data (Qualitative) like gender and patients outcome parameters chi-square test was used. Comparison of means between two independent group using student's t-test. P-value <0.05 was considered statistically significant.

Distribution of patients by age: The mean age of the patients in group A was 29.08 + 8.09 years. The mean age of the

patients in group B was 32.49+9.36 years [range 20 – 45 years]. On comparison, the difference between the two groups was not statistically significant (p =0.481) Shown in Table 1 Distribution of patients by gender: In group A, there were 29 male patients and 131 female patients. The male-to-female ratio in this group was 1:4.5. In group B, there were 20 male patients while 140 patients were female. The male-to-female ratio in this group was 1:7. On comparison, the difference between the two groups was not statistically significant (p=0.792). Show in Table 2. Patients by Outcome parameter: Gallbladder perforation:

In group A, gall bladder perforation was present among 7 (4.4%) patients, and in group B, it was present in 28 (17.5%) patients. A chi-square test was applied and the difference between the two groups was statistically significant (p-value 0.000). (Table 3)

DISCUSSION:

Traditionally, Laparoscopic cholecystectomy (LC) has been performed using monopolar electrocautery; however, the harmonic scalpel (HS) has recently emerged as an alternative dissection technique. High-frequency ultrasonic radiation is used by harmonic shears to cut, coagulate, dissect, and ligate tissues. It is thought that this energy source has a safer profile for artery and cystic duct closure, coagulation, and dissection. The device is FDA-approved for ligating blood vessels up to five millimeters [9]. It is associated with less blood loss, minimal smoke production, and a lower risk of gall bladder perforation, common bile duct injuries, and intestinal injuries[7,8].

Table 1: Showing Distribution of patients by age

Age (years)	Group A (n=160)	Group B (n=160)
20 – 25	19 (11.9%)	16 (10.0%)
26 – 30	30 (18.8%)	28 (17.5%)
31 – 35	48 (30.0%)	52 (32.5%)
36 – 40	34 (21.2%)	39 (24.4%)
41 – 45	29 (18.1%)	25 (15.6%)
Mean + SD	29.08 + 8.09	32.49 + 9.36
p-value*	0.481**	

Table:2 : Distribution of patient by gender

Gender	Group A (n=160)	Group B (n=160)
Male	29 (18.1%)	20 (12.5%)
Female	131 (81.9%)	140 (87.5%)
P-value	0.792*	

Table: 3 Gallbladder perforation

Gallbladder perforation	Group A	Group B
Yes	7 (4.4%)	28 (17.5%)
No	153 (95.6%)	132 (82.5%)
P-value	0.000*	

A consistent finding in the literature is the shorter operative time associated with HS. According to a study by Saad et al., HS has multiple uses because it may be used for dissection and vascular and cystic duct closure and it eliminates the need to switch out instruments like L hooks which safe significant time. This study stated mean operative time in electrocautery group was 42.2±8.93 minutes versus 35.7±4.85 minutes in harmonic group (p-value 0.001) [10]. Ibrahim et al. supported these findings in their comparative study, highlighting that ultrasonic dissection led to significantly lower operative time, reduced gallbladder perforation, and fewer intraoperative complications compared to electrocautery.[11] The literature suggests that the use of HS is associated with shorter operative times, although this variable was not assessed in our study.

Gallbladder perforation is a frequent complication during LC that can result in bile spillage, stone loss, and both early and delayed postoperative issues. In this regard, HS has shown clear benefits. In a study by Nashwan K et al, Gallbladder perforation occurred in 15% and lost bile stone in 7% in the EC group patient and 9% and 3% respectively in the HS group patient (P-value is 0.084 and 0.152 respectively). No common bile duct injury was recorded in either group.[12] Similarly, Nadim Khan et al, reported that the incidence of gall bladder perforation was significantly lower in the ultrasonic group than in the electrocautery group (10.9% vs. 29.7% p=0.007) [13]. We observed a similar result in our HS group 3 - 4 times less gallbladder perforation noted which cannot lead to early and long term complication related to bile and stone spillage [14].

An Egyptian study involving 42 children underwent LC; their average age was 8.4 +/- 3.25 years. Each surgery was carried out laparoscopically with HS; no open surgical conversion was observed. The postoperative recovery went well for every patient, except for two cases of gall bladder perforation during liver bed dissection. In all cases, postoperative abdominal ultrasonography revealed no signs of CBD damage or small or large bile leakage [15]. As in our study no significant difference was observed in different age groups.

Beyond operative time and gallbladder integrity, HS offers additional intraoperative and postoperative advantages. HS generates no surgical smoke, ensuring a clear visual field throughout the operation and eliminating the “snow-falling” effect seen with electrocautery. It also ensures effective hemostasis and often obviates the need for irrigation. In contrast, the EC group encounters challenges such as poor hemostasis, obscured vision due to smoke and prolonged operative times. These limitations may contribute to higher rates of gallbladder perforation, bile leakage, wound infections, and the need for drain placement. Postoperatively,

these complications often necessitate increased analgesic requirements, which in turn may lead to further adverse effects.[10]

Schietroma et al emphasized that surgical inflammation and tissue trauma in LC can be influenced by multiple intraoperative factors, including dissection technique. Their study, while focusing on oxygen concentration, indirectly reinforces the importance of minimizing surgical stress and inflammatory markers—an area where HS, with less thermal damage and mechanical trauma, may offer benefits.[16, 17] Jiang et al.'s meta-analysis reinforces these findings by showing that, as compared to electrosurgical methods, ultrasonic dissection consistently lowers gallbladder perforation, operating time, and discomfort following surgery [17].

Finally, ultrasonically operated scissors not only increase safety but also improve overall surgical ergonomics by enabling the surgeon to use both hands and maintain concentration in the operating field without constantly switching instruments. The common LC procedure involves several instrument changes, which could result in either dangerous operations carried out without visual guidance or frequent changes in the direction of the laparoscope to observe instrument insertion [18, 19]. Additionally, HS's enhanced sealing ability reduces micro-leakage from lymphatics and tiny capillaries, which may lessen the formation of seromas and postoperative collections [19]. It was also found that because of its accurate dissection and decreased heat distribution, HS may lead to fewer conversions to open surgery, especially in cases involving extensive adhesions or inflamed gallbladders [12,14].

Limitation of study: The results may not be widely acceptable because this study was only carried out at a single center and only one outcome is measured. The age restriction of 20-45 years is another limitation of our study. Furthermore, variables that might have affected the rate of gallbladder perforation were not examined, including variable gallbladder inflammation severity, surgeon experience, and operating time. In order to assess delayed consequences such abscess formation, retained gallstones, or adhesive intestinal obstruction linked to bile leakage or stone loss, a long-term follow-up of both groups was not conducted.

CONCLUSION:

In a nutshell in the skilled hands of a surgeon with expertise, gall bladder perforation during LC using a HS has been demonstrated to occur far less frequently than with traditional monopolar electrocautery. When dealing with some patients who have a significant risk of surgical morbidity, the HS may be preferred. The main obstacle to HS induction is its very high cost, particularly in struggling medical facilities [20]. A more comprehensive multicenter study with long-term follow up that evaluates these factors is recommended for stronger findings.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Madeeha Shahid: Research conception, data collection and Writing of final draft
Muhammad Khalid: Data collection and Analysis, Review of final draft

REFERENCES:

1. Patel PB, Choksi G, Patel M, Patel N. Comparison of monopolar electrocautery and ultrasonic dissection of gallbladder in laparoscopic cholecystectomy. Int J Life Sci Biotechnol Pharm Res. 2023;12(1):262–5.
2. Mahmoud M, El-Atar H, Aziz H. Dissection by ultrasonic energy versus monopolar electrosurgical energy in laparoscopic cholecystectomy. Egypt J Surg. 2020;39(1):23. doi:10.4103/ejs.ejs_105_19
3. Gelmini R, Franzoni C, Zona S, Andreotti A, Saviano M. Laparoscopic cholecystectomy with Harmonic scalpel. JSLS. 2010;14(1):14–9. doi:10.4293/108680810X12674612014301
4. Anis S, Rehman PM, Ahmad F, Farooq U. Comparative study of conventional electrocautery versus ultrasonic dissector in laparoscopic cholecystectomy. J Islamabad Med Dent Coll. 2019;8(2):70–3.
5. Sai M, Debata PK, Ipsita D, Sushanta KD. Harmonic scalpel versus electrocautery and its outcome in laparoscopic cholecystectomy: a prospective interventional study. J Clin Diagn Res. 2023. doi:10.7860/JCDR/2023/65310.18585
6. Abhey M, Vivek R, Arun C. Comparative study of monopolar electrocautery versus ultrasonic dissection of gallbladder in laparoscopic cholecystectomy: a prospective observational study. Int J Surg Sci. 2022;6(2). doi:10.33545/ surgery. 2022.v6.i2b
7. Byrt M, Gabriel S, Ekbom L. Learning by doing: an observational study of the learning curve for ultrasonic fundus-first dissection in elective cholecystectomy. Surg Endosc. 2022;36:4602–13. doi:10.1007/s00464-021-08976-z
8. Mathur H, Sharma AK, Kalwaniya DS. Comparative study to evaluate ultrasonic versus monopolar electrocautery dissection of gallbladder in laparoscopic cholecystectomy. Int Surg J. 2021;8(7):2054–8. doi:10.18203/2349-2902.isj20212706
9. Ejaz S, Ahmad UQ, Sidra SQ, Cheema KM, Muhammad AC. Effectiveness of ultrasound shear for clipless laparoscopic cholecystectomy versus conventional unipolar electrocautery in patients with cholelithiasis. J Ayub Med Coll Abbottabad. 2017;27(10):611–5.
10. Anis S, Rehman PM, Ahmad F, Farooq U. Comparative study of conventional electrocautery versus ultrasonic dissector in laparoscopic cholecystectomy. J Islamabad Med Dent Coll. 2019;8(2):70–73. (Duplicate removed if needed.)
11. Ibrahim EA, Alsayed MH. Comparative study between traditional dissection with electrocautery versus ultrasonic dissection of the gallbladder in laparoscopic cholecystectomy. Egypt J Hosp Med. 2022;89(1):5871–4.
12. Ahmad M, Alsaffar S, Tahir E, Mahjob NK. Harmonic versus electrocautery in the dissection of gallbladder in laparoscopic cholecystectomy. Ann Coll Med Mosul. 2013;39(2):107–12.

13. Khan N, Ahmad M, Ahmad Z, Khan A, Sadiq M. Safety of ultrasonic dissection versus conventional electrocautery dissection during laparoscopic cholecystectomy in terms of gallbladder perforation. J Postgrad Med Inst. 2013;27(2) :157–63.
14. Samuli A, Harju J, Kinnunen M, Petri J, Hannu K, Matti E. A randomized multicenter study of minilaparotomy cholecystectomy versus laparoscopic cholecystectomy with ultrasonic dissection in both groups. Scand J Gastroenterol. 2015;51(3):354–9. doi:10.3109/00365521.2015.1091496
15. Aboelela A, Abouheba M, Khairi A, Kotb M. Evaluation of the safety of using harmonic scalpel during laparoscopic cholecystectomy in children: a preliminary report. Front Pediatr. 2022;10:998106. doi:10.3389/fped.2022.998106
16. Schietroma M, Colozzi S, Pessia B, Carlei F, Amicucci G. The effects of high-concentration oxygen on inflammatory markers in laparoscopic cholecystectomy: a randomized controlled trial. Surg Laparosc Endosc Percutan Tech. 2017;27(2):83–9. doi:10.1097/SLE.0000000000000326
17. Jiang HP, Liu YD, Li YS, Shen ZL, Ye YJ. Ultrasonic versus electrosurgical device for laparoscopic cholecystectomy: a systematic review with meta-analysis and trial sequential analysis. Int J Surg. 2017;40:24–32. doi:10.1016/j.ijsu.2017.02.020
18. Javed Y, Tariq M, Hussain SM. Comparison between Harmonic Ace versus conventional monopolar diathermy in laparoscopic cholecystectomy in terms of gallbladder perforation. Pak Armed Forces Med J. 2016:258–62.
19. Huscher CGS, Lirici MM, Di Paola M, Crafa F, Napolitano C, Mereu A, et al. Laparoscopic cholecystectomy by ultrasonic dissection without cystic duct and artery ligature. Surg Endosc. 2003;17(3):442–51. doi:10.1007/s00464-002-9068-3
20. Liao G, Wen S, Xie X, Wu Q. Harmonic scalpel versus monopolar electrocauterization in cholecystectomy. JSLS. 2016;20(3). doi:10.4293/JSLS.2016.00037

Original Article **Open Access**

Evaluation of Liver Function Tests and Clinical Outcomes in Dengue Patients: Elevated Alkaline Phosphatase Levels as a Predictor of Mortality

Sherbano Baloch, Muhammad Bilal Arif, Muhammad Irfan Khattak, Jamal Azfar Khan, Saeed Akhtar Khan Khattak, Mohammad Tufail

ABSTRACT

Objectives: To evaluate liver function test abnormalities in patients with dengue infection and determine whether elevated alkaline phosphatase (ALP) levels are associated with mortality and adverse clinical outcomes.

Study Design and Setting: A prospective, descriptive observational study conducted over four months, from April 2 to July 31, 2022, at PNS Shifa Hospital (BUHSC).

Methodology: Demographic, clinical, and laboratory data of confirmed dengue patients were recorded using a structured proforma. Liver function parameters including alanine aminotransferase (ALT), alkaline phosphatase (ALP), and serum bilirubin were analyzed. Data were entered and analyzed using SPSS version 29.

Results: The study included 135 patients with a mean age of 30.9 ± 12.1 years: the majority (60.7%) were under 30. Liver involvement was common, with 64 patients (48.8%) exhibiting liver function test abnormalities. Among these, 27 (42.2%) had elevated ALT, seven (10.9%) showed increased bilirubin, and 30 (46.9%) had elevated ALP. Most patients (83%) maintained normal bilirubin levels, with a mean bilirubin level of 11.7 ± 8.6 µmol/L. Mean ALT was 107 ± 240 IU/L, and mean ALP was 113.6 ± 59.9 IU/L, both above normal ranges. Among liver function parameters, elevated alkaline phosphatase (ALP) levels showed a statistically significant association with mortality (Pearson's r = 0.282, p = 0.01), whereas ALT and bilirubin levels were not significantly associated with death.

Conclusions: Hepatic dysfunction is a frequent finding in dengue patients, with elevated ALP positively correlating with mortality. Although ALT and bilirubin abnormalities are often observed, they do not significantly predict patient outcomes.

Keywords: Alkaline Phosphatase, Dengue, Dengue Hemorrhagic Fever, Hepatic Insufficiency, Liver Function Tests

How to cite this Article:
Baloch S, Arif MB, Khattak MI, Khan JA, Khattak SAK, Tufail M. Evaluation of Liver Function Tests and Clinical Outcomes in Dengue Patients: Elevated Alkaline Phosphatase Levels as a Predictor of Mortality. J Bahria Uni Med Dental Coll. 2026;16(2):477-82 DOI: https://doi.org/10.51985/JBUMDC2025645

Sherbano Baloch
Resident, Department of Internal Medicine
PNS Shifa Hospital, Karachi
Email: drsherbano18@yahoo.com

Muhammad Bilal Arif
Consultant, Department of Internal Medicine
PNS Shifa Hospital, Karachi
Email: doctorbaloch20@gmail.com

Muhammad Irfan Khattak
Consultant, Department of Internal Medicine
PNS Shifa Hospital, Karachi
Email: khattakofficial@outlook.com

Jamal Azfar Khan
Consultant, Department of Internal Medicine
PNS Shifa Hospital, Karachi
Email: jamalazfar@yahoo.com

Saeed Akhtar Khan Khattak
Consultant, Department of Hematology
PNS Shifa Hospital, Karachi
Email: saeedkhattak55@gmail.com

Mohammad Tufail
House Officer, Department of Internal Medicine
PNS Shifa Hospital, Karachi
Email: mohammadtufail1@live.com

Received: 13-07-2025
Accepted: 13-03-2026
1st Revision: 08-08-2025
2nd Revision: 01-01-2026
3rd Revision: 10-02-2026

INTRODUCTION

In the Post-COVID era, dengue fever, transmitted by the *Aedes aegypti* mosquito, has resurfaced as a severe health crisis, especially in underdeveloped countries. In Pakistan, dengue transmission is exacerbated by poor drainage systems, accumulation of solid waste, inadequate sanitation, and densely populated urban areas, all of which create favourable breeding conditions for *Aedes* mosquitoes.[1] These challenging conditions make dengue a persistent and significant threat to communities already facing numerous health and socioeconomic hardships. As the disease continues to thrive, particularly among poorer communities with limited access to timely medical intervention and preventive measures, it is expected to impose a sustained burden on public health and economic stability.[1]

According to the World Health Organization, 4.2 million cases were reported in 2019, up from 2.4 million in 2010 and 505,430 cases in 2000.[2] Dengue transmission is increasingly reported in both endemic and previously low-risk regions, driven by environmental factors such as poor drainage systems, accumulation of solid waste, and inadequate sanitation, which promote *Aedes* mosquito

breeding.[3] Within Pakistan, dengue has transitioned from a sporadic illness to a recurring epidemic, with all four serotypes now in circulation, increasing the risk of severe secondary infections.[8] The co-circulation of multiple serotypes is a major public health concern, as a secondary infection with a heterologous serotype is a primary risk factor for developing severe dengue through mechanisms like antibody-dependent enhancement (ADE).[8]

It is believed that dengue has changed its behaviour over the decades in terms of clinical representation and organ involvement.[3] Liver involvement in dengue fever has gained increasing recognition in recent years, as a notable portion of patients present with symptoms such as jaundice, pain in the hypochondriac region, and liver enlargement. These symptoms indicate that the liver is significantly affected in many dengue cases, reflecting a growing understanding of the disease's impact on this vital organ.[4,5]

The etiology of liver damage in dengue involves multiple complex mechanisms, including a pronounced cytokine storm, immune-mediated hepatocyte injury, and the direct cytopathic action of dengue virus (DENV) itself, which induces hepatocyte apoptosis.[4] DENV primarily targets hepatocytes and Kupffer cells, leading to cellular stress and the release of pro-inflammatory signals that recruit immune cells, further perpetuating the inflammatory cascade. Additionally, hepatic hypoperfusion, resulting from compromised blood flow to the liver, is another significant factor. This hepatic dysfunction can range from mild, asymptomatic transaminase elevation to fulminant acute liver failure, a rare but life-threatening complication.[6,10]

Derangement of liver functions may be used as a predictor of poor outcome in dengue patients.[6] However, while elevated aminotransferases are a hallmark of dengue-related hepatitis, their direct correlation with disease severity and mortality remains inconsistent across studies.[11,13,15] Some research suggests a strong link, while other studies have found that the degree of LFT derangement does not reliably predict the development of severe dengue.[17] This lack of consensus highlights a critical gap in understanding which specific laboratory markers can reliably identify patients at the highest risk. For instance, while some large cohort studies have correlated peak transaminase levels with the development of DHF, others, particularly those focusing on paediatric populations, have found that the degree of elevation does not reliably predict progression to shock.[12,11,13] Similarly, the significance of alkaline phosphatase (ALP) and bilirubin remains contentious. An elevated ALP has been linked to severe outcomes in some adult cohorts, yet it is often considered a non-specific marker of inflammation. This clinical equipoise underscores the need for more granular data from diverse patient populations.[6]

In the mid of 2021 there was outbreak of dengue in Sindh province with majority of cases from provincial capital Karachi.[7] Our primary objective was to investigate various parameters associated with liver involvement in dengue fever and to establish a correlation between the observed patterns of liver involvement and corresponding clinical outcomes. By analyzing these factors, we aimed to gain insights into how liver complications influence the progression and severity of dengue within our local population, contributing to the broader effort to identify reliable prognostic markers. Given the unique epidemiological and demographic characteristics of the region, local data is essential to validate or challenge the prognostic models developed in other parts of the world and to ultimately refine patient management strategies.

METHODOLOGY

This prospective, descriptive observational study was conducted within the Department of Medicine at PNS Shifa Hospital, a major tertiary care teaching hospital affiliated with Bahria University of Medical Sciences in Karachi, Pakistan. The patient enrollment and data collection were carried out over a four-month period corresponding with the regional dengue season, from April 2, 2022, to July 31, 2022. The study protocol, consent forms, and all related documents were formally approved by an independent local review body, the hospital's Institutional Review Board (IRB) and Ethics Committee (Ref: ERC/2022/medicine/11), ensuring full compliance with the ethical principles of the Declaration of Helsinki.

The sample size was prospectively calculated using the WHO sample size calculator (version 2). The calculation based on an anticipated incidence of severe hepatic involvement in dengue infection of approximately 3–5%, as reported in regional literature. This estimate refers to clinically significant hepatic complications such as severe hepatitis or acute liver failure, rather than mild biochemical liver function abnormalities.[8,9] A non-probability convenience sampling technique was utilized for patient enrollment, wherein all consecutive patients meeting the eligibility criteria during the study period were invited to participate. After a thorough explanation of the research objectives, procedures, and potential risks, written informed consent was obtained from all participants or their legal guardians prior to any study-related activities.

A total of 135 patients who fulfilled the established inclusion and exclusion criteria were included in the final analysis. Inclusion criteria required patients to be adults presenting with a clinical syndrome consistent with classic dengue—including symptoms such as headache, retro-orbital pain, myalgias, and high-grade fever—and to have a definitive laboratory-confirmed diagnosis. This confirmation was achieved via a positive result for either the dengue non-structural protein 1 (NS-1) antigen or the presence of IgM antibodies on serology testing. Exclusion criteria were applied to patients with a documented history of any form

of acute or chronic viral hepatitis within the past three months, a known history of regular use of hepatotoxic medications (e.g., high-dose paracetamol, anti-tuberculosis drugs), or a prior diagnosis of cirrhosis from any cause, in order to isolate the hepatic effects of the dengue virus.

Liver involvement was biochemically evaluated by obtaining the levels of ALT (reference <45 IU/L), alkaline phosphatase (reference <145 IU/L), and Serum Bilirubin (reference <17 µmol/L), with any value above the institutional laboratory's normal range classified as an abnormal LFT. All laboratory analyses were performed using standardized automated analyzers in the hospital's central laboratory. All demographic, clinical, and laboratory data were entered into a secure database and analyzed using SPSS Statistics (Version 29.0). Descriptive statistics were used to summarize the data, and a p-value of <0.05 was considered statistically significant for all inferential analyses.

RESULTS

A total of 135 patients were included in the study. The mean age of the participants was 30.9 ± 12.09 years. Most patients belonged to the younger age group, with 82 (60.7%) patients aged less than 30 years, while 106 (80%) were younger than 40 years. The majority of patients were male (107: 79.3%), whereas 28 (20.7%) were female. The male gender and younger age were preferentially involved in dengue fever as there were 107 (79.3 %) males and only 28(20.7%) females in the study.

Overall, 64 (48.8%) patients had some degree of liver involvement indicated by deranged LFTs. These abnormalities predominantly represented mild to moderate biochemical derangements, and no cases of severe hepatitis or acute liver failure were observed during the study period. Among these patients, 27 (42.2%) had elevated ALT, seven (10.9%) had increased bilirubin, and 30 (46.9%) had elevated ALP. Serum bilirubin remained normal in most patients, with 112 (83%) showing values within the reference range and a mean bilirubin level of 11.71 ± 8.60 µmol/L. Mean ALT was 107 ± 240 IU/L, and mean ALP was 113.57 ± 59.91 IU/L. The large standard deviation observed for ALT reflects wide variability in transaminase levels, likely due to a small number of patients with markedly elevated values, consistent with outlier patterns commonly reported in dengue-associated hepatitis (Table I). Regarding hematological parameters, platelet levels were expectedly low, with a mean of 79.71 ± 47.82 $\times 10^3/\mu L$. Total leukocyte count remained within the normal range (4.67 ± 2.61 $\times 10^3/\mu L$), and mean hemoglobin level was also normal at 13.46 ± 1.88 g/dL. Evidence of coagulopathy was observed, with a mean prothrombin time of 14.45 ± 2.17 seconds and activated partial thromboplastin time of 35.87 ± 6.67 seconds. On correlation analysis, elevated alkaline phosphatase (ALP) was the only liver function parameter found to be associated with mortality (Pearson's $r = 0.282$, $p < 0.05$), whereas ALT and bilirubin derangements did not show a significant association with death (Table II). The number of observations (n) varied across liver function parameters due to incomplete laboratory testing in some patients, primarily resulting from early discharge, patient transfer, or unavailability of specific assays at the time of sampling. Among 105 male participants, two (1.9%) patients died, while one death (3.7%) was observed among 27 female participants. The overall mortality rate in the study population was 2.2% (3/135 patients).

Table 1. Descriptive statistics of demographic and laboratory parameters of the study population

	N	Mean	Std. Deviation	Variance
Serum Bilirubin µmol/L	128	11.711	8.602	73.987
AGE	128	30.984	12.029	144.687
Platelets lowest recorded	135	79.711	47.821	2286.813
PT	103	14.447	2.167	4.694
APTT	103	35.874	6.668	44.460
CRP	30	16.747	20.281	411.312
Serum Alanine Transferase (U/L)	128	107.078	240.305	57746.603

Figure 1: Outcomes of Dengue patients



Figure 2: Major presenting complaints of dengue in males and females



Table 2: Correlation analysis of deranged LFTS with mortality

Liver Parameter	LFTS group		Survived	Death	Total	Pearson's R	Significance
Bilirubin	Normal	Count	125	3	128	0.03	0.68
		% Within Normal values	97.7%	2.3%	100.0%		
	Abnormal	Count	7	0	7		
		% Within deranged values	100.0%	0.0%	100.0%		
	Total	Count	132	3	135		
		% Within Total population	97.8%	2.2%	100.0%		
ALT	Normal	Count	106	2	108	0.05	0.55
		% WithinNormal values	98.1%	1.9%	100.0%		
	Abnormal	Count	26	1	27		
		% Withinderanged values	96.3%	3.7%	100.0%		
	Total	Count	132	3	135		
		% Within Total population	97.8%	2.2%	100.0%		
ALP	Normal	Count	105	0	105	0.282	0.01
		% WithinNormal values	100.0%	0.0%	100.0%		
	Abnormal	Count	27	3	30		
		% Within deranged values	90.0%	10.0%	100.0%		
	Total	Count	132	3	135		
		% Within total population	97.8%	2.2%	100.0%		

DISCUSSION

The consensus in the literature is that liver involvement is an almost universal feature in dengue patients, though the extent of this involvement varies widely.[1°] In our study, nearly half of the patients (47.4%) exhibited some form of hepatic derangement, with most experiencing mild to moderate liver involvement and no cases of fulminant liver failure, a finding consistent with many observational cohorts.[3] The majority of patients in our study presented with clinical features consistent with uncomplicated dengue fever as defined by the World Health Organization severity framework, while severe forms such as dengue haemorrhagic fever or dengue shock syndrome were uncommon. In this context, hepatic involvement typically manifested as a transient, self-limiting elevation in liver enzymes without evidence of significant synthetic dysfunction, such as coagulopathy or hypoalbuminemia directly attributable to liver failure. This rate, while clinically significant, underscores that severe hepatitis remains a less common, albeit critical, complication of the disease. The absence of acute liver failure in our cohort is a positive prognostic indicator for the general patient population in this outbreak, but it also highlights that the most severe manifestations of dengue may be underrepresented in single-center studies, particularly those conducted outside of specialized intensive care or transplant units.

The principal finding of this study is the observed positive association between elevated serum alkaline phosphatase (ALP) levels and mortality. While elevated aminotransferases are the most frequently discussed markers of liver injury in dengue, our data suggest that ALP may hold distinct prognostic value. This aligns with findings from Teerasarntipan et al., who identified significant hepatic derangement as a predictor of mortality, particularly in cases progressing to acute liver failure.6 Aspartate aminotransferase (AST), which is often reported to be more markedly elevated than ALT in dengue and has been described as a potential prognostic marker, was not routinely measured in this study due to limitations in the standard laboratory testing protocol during the study period. Consequently, analysis of AST levels and AST/ALT ratios could not be performed and represents an important area for future research[6].The potential mechanism for this association is not fully understood but may reflect a more profound systemic inflammatory response or a degree of cholestatic injury that is not captured by transaminase levels alone. It is plausible that an elevated ALP signifies a more severe, systemic insult rather than isolated hepatocellular damage. This is a critical distinction, as ALT elevation primarily reflects direct hepatocyte damage, whereas ALP can also be released from the biliary epithelium, which may be affected by the systemic inflammation and capillary leakage characteristic of severe dengue. In contrast, our study found no significant association between elevated ALT or bilirubin levels and mortality. This contributes to an ongoing debate in the literature. While some studies have correlated high transaminase levels with severe dengue,[11,13] others have found them to be poor predictors of adverse outcomes, especially when considered in isolation.[15,17] For example, a large study by Samad et al. found a clear pattern

of LFT derangement correlating with severity,[13] whereas our findings are more aligned with studies like Patel et al., which suggest that while transaminitis is common, its prognostic power for mortality is limited.[15] Our results suggest that in our patient population, ALT elevation is a common marker of hepatic inflammation but not necessarily a reliable indicator of impending mortality. This finding encourages clinicians to look beyond transaminase levels and consider a broader panel of markers when assessing risk, potentially moving towards a multi-marker approach for prognostication.

The demographic profile of our cohort, predominantly young males, is consistent with other regional studies from Pakistan and South Asia.[8] This may reflect occupational and social patterns that increase exposure to the *Aedes* vector in this demographic. For example, men in this age group are more likely to have occupations that involve outdoor work or travel during the day when the Aedes mosquito is most active, leading to a higher probability of exposure. The overall rate of liver involvement in our study (47.4%) was lower than the 70-80% reported in some other series.[11,15] This difference may be attributable to variations in the definition of hepatic dysfunction, as our study relied solely on elevations in ALT, ALP, and bilirubin, whereas others have included a broader range of parameters, such as the albumin-to-globulin ratio. Furthermore, host genetic factors and the virulence of the circulating DENV serotype could also contribute to this observed difference in the prevalence of hepatic injury. This highlights the need for standardized definitions of dengue-associated liver injury to allow for more accurate comparisons across studies.

This study has several important limitations. First, as a single-center observational study, the findings may not be generalizable to other populations or healthcare settings. Different regions may have varying circulating viral serotypes, host genetics, and healthcare resources, all of which can influence clinical outcomes. Specifically, DENV-2 and DENV-3 serotypes are often associated with more severe disease and hepatic dysfunction compared to DENV-1 and DENV-4: our study did not perform serotyping, which is a key unmeasured variable. Therefore, the prognostic value of ALP observed here requires validation in larger, multi-center cohorts before it can be widely adopted into clinical guidelines. Second, the small number of mortality events (n=3) limits the statistical power of our correlation analysis and prevents us from drawing definitive conclusions about mortality predictors. A larger, multi-center study would be required to validate the prognostic significance of ALP. While a statistically significant correlation was found, the low event rate means this finding should be interpreted with caution as it may be susceptible to type I error, and the true strength of the association may be different in a larger sample. Third, our reliance on laboratory parameters alone, without standardized data on clinical findings like hepatomegaly or liver ultrasound results, may have led to an underestimation of the true extent of liver involvement. Another laboratory limitation was the lack of AST measurement, which prevented calculation of the AST/ALT ratio: this was due to the study's reliance on routine hospital liver function testing protocols during the outbreak period, in which AST was not included as part of the standard biochemical panel. Finally, the absence of long-term follow-up means the chronic implications of dengue-related liver injury could not be assessed.

CONCLUSION

Hepatic dysfunction is a common finding among patients with dengue fever. In this study, elevated alkaline phosphatase (ALP) levels showed a statistically significant association with mortality, whereas ALT and bilirubin abnormalities were not significantly related to patient outcomes. These findings suggest that ALP may serve as a potential marker of disease severity in dengue patients. However, larger multicenter studies are required to confirm its prognostic value.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Sherbano Baloch: Data Collection
Muhammad Bilal Arif: Management of Dengue Cases
Muhammad Irfan Khattak: Nephrological Consultation coordinator
Jamal Azfar Khan: Study design and data analysis
Saeed Akhtar Khan Khattak: Hematologic Consultation
Mohammad Tufail: Data Collection

REFERENCES

1. Umakanth M, Suganthan N. Unusual Manifestations of Dengue Fever: A Review on Expanded Dengue Syndrome. Cureus. 2020 Sep 27:12(9):e10691. DOI: https://doi.org/10.7759/cureus.10691
2. Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. The Many Projected Futures of Dengue. Nat Rev Microbiol. 2019:17(9):555-67. DOI: https://doi.org/10.1038/nrmicro3430
3. Shrestha S, Deo S, Shah S, Shrestha S. Hepatic Manifestations of Dengue and Their Management. Cureus. 2023 May 15:15(5):e38997. DOI: https://doi.org/10.7759/cureus.38997
4. Syal K. Liver in Dengue: A Clinical and Pathophysiological Appraisal. J Lab Physicians. 2021:13(3):271-8. DOI: https://doi.org/10.1055/s-0041-1731248
5. Hassan S, Tariq F, Feroze A, Kousar S, Asif N. Liver Function Test Abnormalities in Patients with Dengue Fever and Its Correlation with Disease Severity. Cureus. 2022 Nov 29:14(11):e32009. DOI: https://doi.org/10.7759/cureus.32009
6. Teerasarntipan T, Chaiteerakij R, Komolmit P, Tangkijvanich P, Treeprasertsuk S. Acute Liver Failure and Death Predictors in Patients with Dengue-Induced Severe Hepatitis. World J Gastroenterol. 2020 Sep 7:26(33):4983-95. DOI: https://doi.org/10.3748/wjg.v26.i33.4983

7. World Health Organization, Regional Office for the Western Pacific. Dengue Situation Update 636. 2022 Mar 10 [cited 2022 Dec 26]. Available from: https://www.who.int/ westernpacific/ internal-publications-detail/dengue-situation-update-636
8. Naz F, Jamil A, Tariq W, Aslam M. Dengue in Pakistan: A Paradigm of an Expanding Epidemic. Viruses. 2022 Dec 27:15(1):73. DOI: https://doi.org/10.3390/v15010073
9. Khan J, Khan I, Ghaffar A, Khalid B. Epidemiological Trends and Risk Factors Associated with Dengue Disease in Pakistan (1980–2014): A Systematic Literature Search and Analysis. BMC Public Health. 2018 Jun 15:18(1):745. DOI: https://doi.org/10.1186/s12889-018-5676-2
10. Jagadishkumar K, Jain A, Manjunath VG, Umesh L. Dengue and the Liver: A Review. Trop Doct. 2022 Jan:52(1):123-7. DOI: https://doi.org/10.1177/00494755211055019
11. Swamy AM, Mahesh PY, Rajashekar ST. Liver Function in Dengue and Its Correlation with Disease Severity: A Retrospective Cross-Sectional Observational Study in a Tertiary Care Center in Coastal India. Pan Afr Med J. 2021:40:261. DOI: https://doi.org/10.11604/ pamj.2021.40.261.27581
12. Verhagen LM, de Groot R. Dengue in Children. J Infect. 2014 Nov:69 Suppl 1:S77-86. DOI: https://doi.org/10.1016/j.jinf 2014.07.014
13. Samad R, Ahmed T, Hossain M, Rahman M, Yasmin F, Ferdousi S, et al. Pattern of Liver Function Test and Its Correlation with Severity of Dengue Fever. Mymensingh Med J. 2021 Jul:30(3):711-7.
14. Trung DT, Thao le TT, Hien TT, Hung NT, Vinh NN, Hien PT, et al. Liver Involvement Associated with Dengue Infection in Adults in Vietnam. Am J Trop Med Hyg. 2010 Oct:83(4): 774-80. DOI: https://doi.org/10.4269/ajtmh.2010.10-0090
15. Patel K, Patel K, Shah M, Gediya S. A Study of Liver Function Tests in Dengue Fever and Its Correlation with Disease Severity. J Family Med Prim Care. 2023 Apr:12(4):726-31. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1904_22
16. O'Brien J. Alanine Aminotransferase (ALT). Medscape: 2020 Dec 5 [updated 2022 Aug 23: cited 2022 Dec 29]. Available from: https://emedicine.medscape.com/article/2087247-overview
17. Pramar D, Mehta A, Prajapati P, Soni S. A Study of Liver Function Tests as a Predictor of Severity in Dengue Infection. Cureus. 2023 Mar 23:15(3):e36563. DOI: https://doi.org/ 10.7759/cureus.36563
18. Zubair A, Qureshi AA, Jafri SM. Assessment of Dengue Fever Severity Through Liver Function Test. In: Rodriguez-Morales AJ, editor. Dengue - Immunopathology and Control Strategies. IntechOpen: 2017.
19. Singh R, Chhina K, Goyal O, Goyal P, Kumar R, Puri S, et al. Liver Function Tests in Patients with Dengue Viral Infection. Dengue Bull. 2008:32:110-7.
20. Treeprasertsuk S, Kittitrakul C, Silachamroon U, Phumratanaprapin W, Krudsood S, Wilairatana P, et al. Liver Function Tests and Clinical Severity of Dengue Infection in Adult Patients [Abstract]. Am J Gastroenterol. 2003 Sep:98(9 Suppl):S81.

Original Article **Open Access**

Comparison of Foveal Avascular Zone Parameters in Diabetic Retinopathy and Normal Retina on Optical Coherence Tomography Angiography Using Automated Software

Summaiya Munim, Faisal Aziz Khan, Muhammad Kashif Hanif, Quratulain Paracha, Beenish Saleem, Sameer Shahid Ameen

Abstract

Objective: To compare Foveal Avascular Zone (FAZ) metrics comprising of FAZ area, perimeter and circularity between individuals afflicted with diabetic retinopathy and those exhibiting healthy, normal retinal profile by using built in algorithm of Optical coherence tomography angiography (OCT-A)

Study Design and Setting: It was an observational study. Conducted at the Ophthalmology Department, PNS Shifa Hospital, Karachi from October 2023 to December 2024.

Methodology: 60 patients participated which included 30 type 2 diabetics with mild to moderate non proliferative diabetic retinopathy (NPDR), without macular involvement and 30 non diabetics age matched normals. FAZ parameters of OCT-Angio Optopol revo nx130 (Area, Circularity and Perimeter) were calculated and compared between two groups using automated built in software. FAZ parameters of mild and moderate NPDR were compared within diabetic group.

Results: Mean age in diabetics was 55.33 ± 6.85 years and in non-diabetics 55.30± 4.94 years. On comparison of FAZ parameters the area and perimeter were statistically significantly enlarged as compared to non-diabetics FAZ parameters ($p < 0.001$). The circularity index was lower among diabetics as compared to non-diabetics ($p < 0.001$). Among the diabetic patients there was a statistically significant enlargement of FAZ area in moderate NPDR versus mild NPDR ($p <0.001$) and difference of FAZ perimeter ($p = 0.07$) and circularity index ($p =0.60$) were statistically insignificant.

Conclusion: Diabetic patients with mild to moderate NPDR having clinically normal appearing maculae show deranged FAZ parameters on OCT-A as compared to age matched normal healthy retinae.

Key Words: Angiography, Diabetic retinopathy, Optical coherence tomography

How to cite this Article:
Munim S, Khan FA, Hanif MK, Paracha Q, Saleem B, Ameen SS. Comparison of Foveal Avascular Zone Parameters in Diabetic Retinopathy and Normal Retina on Optical Coherence Tomography Angiography Using Automated Software. J Bahria Uni Med Dental Coll. 2026;16(2):683-8 DOI: https://doi.org/10.51985/JBUMDC2025647

Summaiya Munim
FCPS II Trainee, Department of Ophthalmology
PNS Shifa Hospital, Karachi
Email: summaiyaurooj@gmail.com

Faisal Aziz Khan
Classified Eye Specialist, Department of Orbit and Oculoplastic
PNS Shifa Hospital, Karachi
Email: faisaleyecare@gmail.com

Muhammad Kashif Hanif
Classified Eye Specialist, Department of Ophthalmology
PNS Shifa Hospital, Karachi
Email: kashifeye@yahoo.com

Quratulain Paracha
Occuloplastic Fellow, Department of Orbit and Occuloplastics
PNS Shifa Hospital, Karachi
Email: q.ain.paracha@gmail.com

Beenish Saleem
Classified Eye Specialist & Vr Surgeon Department of Vitreo-Retina
PNS Shifa Hospital, Karachi
Email: beenishsaleem@live.com

Sameer Shahid Ameen
Professor& HOD, Department of Ophthalmology
PNS Shifa Hospital, Karachi
Email: drsameerameen@hotmail.com

Received: 07-07-2025
1st Revision: 07-09-2025
Accepted: 09-02-2026
2nd Revision: 04-11-2025

INTRODUCTION:

Diabetic retinopathy (DR) has emerged as a leading cause of preventable blindness worldwide. The insidious onset of this microvascular complication, often asymptomatic in its early stages, underscores the necessity of proactive screening, timely diagnosis, and targeted intervention. This complex and multifactorial disorder is characterized by progressive alterations in the retinal microvasculature resulting from chronic hyperglycemia-induced metabolic and hemodynamic disturbances. The evolution of DR encompasses a continuum of changes, ranging from mild non-proliferative stages—marked by microaneurysms, intraretinal hemorrhages, and vascular leakage—to proliferative disease characterized by neovascularization and potentially vision-threatening sequelae.[1] Each stage reflects a progressive disruption of the blood–retinal barrier, pericyte loss, and basement membrane thickening, culminating in ischemia and tissue hypoxia. The resulting microvascular dysfunction and neurodegenerative changes jointly contribute to irreversible visual impairment.

Among the structural and functional alterations in the

diabetic retina, the foveal avascular zone (FAZ) represents a particularly valuable biomarker of retinal perfusion and neurovascular health.[2] The FAZ, centrally located within the macula, is an area devoid of retinal capillaries corresponding to the foveal pit, where cone photoreceptors are most densely concentrated. This specialized avascular region facilitates unhindered light transmission to the photoreceptor layer, enabling optimal visual acuity.[3,4] The precise morphology of the FAZ reflects the balance between vascular supply and metabolic demand within the macula; hence, its integrity is crucial for maintaining high-resolution vision. In the context of DR, the FAZ becomes a focal point for assessing ischemic injury and microvascular compromise. Progressive capillary non-perfusion, vessel rarefaction, and remodeling around the FAZ can lead to measurable enlargement and irregularity of its contour.[1] These morphometric changes have been correlated with disease severity and reduced visual acuity, suggesting their potential as objective, quantifiable indicators of retinal ischemia. Consequently, the assessment of FAZ parameters such as area, perimeter, and circularity has gained prominence in evaluating the extent of microvascular disruption. Earlier investigations have established the clinical significance of FAZ alterations in a variety of retinal diseases, including diabetic retinopathy, retinal vein occlusion, and macular ischemia.[5-7] In diabetic retinopathy, such measurements provide valuable insights into disease progression and therapeutic outcomes.[6]

However, traditional imaging modalities, notably fluorescein angiography (FA) and indocyanine green angiography (ICGA), though long considered the reference standards for assessing retinal perfusion, have inherent limitations.[8] These procedures are invasive, time-consuming, and costly. They require intravenous dye injection, which may elicit allergic reactions or other adverse effects and is contraindicated in certain systemic conditions.[9] Furthermore, their two-dimensional representation of the vasculature restricts detailed layer-by-layer evaluation.

Optical coherence tomography angiography (OCT-A) has revolutionized retinal imaging by offering a rapid, non-invasive alternative for high-resolution, three-dimensional visualization of retinal and choroidal microvasculature. Using motion-contrast imaging based on red blood cell movement, OCT-A generates en face angiograms within seconds, enabling visualization of distinct vascular plexuses from the internal limiting membrane to the choroid.[10] This dye-free technique allows precise and reproducible quantification of microvascular parameters, including the FAZ, using built-in automated software algorithms. The ability of OCT-A to provide depth-resolved imaging and quantitative metrics has markedly enhanced the understanding of DR-related vascular pathology and holds promise for early disease detection.

Despite its potential, the literature remains limited regarding the comparative use of automated OCT-A analysis for FAZ evaluation among diabetic and non-diabetic populations. Most existing studies rely on manual or semi-automated delineation methods, which are susceptible to inter-observer variability and measurement bias. The integration of automated FAZ quantification tools may therefore provide greater accuracy, reproducibility, and clinical utility. Accordingly, the present study aims to conduct a comparative analysis of FAZ parameters specifically area, perimeter, and circularity between patients with diabetic retinopathy and healthy individuals using the automated algorithm incorporated within OCT-A systems. By evaluating these quantitative biomarkers, the study seeks to elucidate the relationship between FAZ morphology and diabetic retinal microvascular alterations, thereby enhancing the role of OCT-A as a non-invasive and objective modality for the early detection and grading of diabetic retinopathy.

METHODOLOGY:

This comparative study was conducted at the Ophthalmology Department, PNS Shifa Hospital, Karachi from 1st October 2023 to 15th December 2024.The study was conducted after obtaining approval from the Institutional Ethics Review Board (ERC-2023/EYE/11). Sample size was calculated by using Open Epi software to compare two proportions with a confidence interval of 95 and power 80. A total of 60 patients participated, which included 30 diabetics with mild to moderate NPDR and 30 non diabetics age matched normal. Written informed consent was taken from all participants. Patients were selected according to conventional sampling technique. Participants with type 2 diabetes and showing mild to moderate NPDR without macular involvement were placed in group one and their age matched normals (non diabetics) were placed in group two. Patients with history of smoking, hypertension, ischemic heart diseases, hyperlipidemics and exhibiting any other maculopathy were excluded from study. Each participant underwent ophthalmic examination, including visual acuity assessment, intra ocular pressure and dilated fundus examination. Subsequently, OCT angiography scans were obtained using spectral domain OCT Optisurg. Optopol (revo nx130). This instrument has an A-scan rate of 130,000 scans/sec with an 840 nm SLED light source and a 50 nm half bandwidth. The acquired OCTA scans were processed using automated software designed for FAZ segmentation and quantification, operated by author. Parameters of FAZ within 3- and 3-mm area of superficial capillary plexus was analyzed. The FAZ parameters that were compared between diabetics and non diabetics were FAZ Area, measured in mm^2 that measures the extent of capillary dropout. FAZ Perimeter, measured in mm which delineates the contour of the FAZ and records the geometric characteristics of the avascular region and FAZ circularity index which is a dimensionless ratio, which measures roundness or irregularity of the FAZ shape and vascular remodeling.

The SPSS version 27 was used to analyze the data. Descriptive statistics were calculated for age. Frequency and percentages were calculated for gender and stages of diabetic retinopathy. Shapiro- Wilk normality test was applied for age, area, perimeter and circularity index of FAZ and all the data was found to be normally distributed for both the groups. Student- t test was selected to compare FAZ parameters among diabetic and non diabetic groups and among patients with mild and moderate NPDR. A p-value < 0.05 was considered to be statistically significant.

RESULTS:

The age ranged from 42-70 years. Mean age in diabetic patients group was 55.33 ±6.85 years and in non diabetic patients group was 55.30± 4.94 years. There was no statistical significant difference in the mean age of both groups. Therefore both groups depicted age matching (p= 0.983). Male to female ratio was 1:1. Among the 30 diabetic patients group 15 (25%) had mild NPDR and 15 (25%) had moderate NPDR. On comparison of FAZ parameters among diabetics and non diabetics there was a statistically significant difference of parameters as shown in Table 1. Among the diabetic patients there was a statistically significant difference of FAZ area between mild and moderate NPDR and difference of FAZ perimeter and circularity was statistically insignificant as shown in Table 2.

DISCUSSION:

In a healthy retina, the FAZ is small, well-defined, and symmetrical, reflecting the physiological avascularity of the central fovea, which optimizes light transmission and visual acuity. In DR, however, progressive microvascular damage and capillary non-perfusion lead to characteristic FAZ enlargement, irregularity, and loss of circular symmetry.[11] These changes occur secondary to ischemic insults and microvascular remodeling, which disrupt the integrity of the retinal capillary network. OCTA has emerged as a robust, non-invasive tool for detailed visualization of these microvascular changes, enabling precise quantitative evaluation of the FAZ and other vascular parameters. One of the hallmark features of DR identified through OCT-A is FAZ enlargement. Multiple studies have consistently demonstrated a significant increase in FAZ area among diabetic patients compared to healthy controls.[12] This enlargement is primarily attributed to progressive loss of retinal capillaries due to ischemia, which lead to an expansion of the avascular region surrounding the foveal pit. In contrast, the FAZ in normal individuals remains compact and circular, delineated by a continuous ring of capillaries that preserve retinal perfusion and metabolic homeostasis. The ability to detect and quantify even subtle FAZ changes using OCT-A provides a valuable opportunity for early identification of microvascular compromise and delaying progression of diabetic retinopathy,[13] potentially facilitating timely interventions such as strict glycemic control, lipid regulation, and management of systemic comorbidities that may slow or prevent disease progression.

Table-1: Comparison of foveal avascular zone parameters among diabetics and non diabetics. (n=60)

Foveal avascular zone	Diabetic (n=30)	Non diabetic (n=30)	*p*-value
Area (mm^2)	0.44 ± 0.69	0.20 ± 0.05	<0.001
Perimeter (mm)	3.91 ± 0.72	2.26 ± 0.35	<0.001
Circularity	0.37± 0.06	0.78 ± 0.07	<0.001

Table-2: Comparison of foveal avascular zone parameters between mild NPDR and moderate NPDR. (n=30)

Foveal avascular zone	Moderate NPDR (n=15)	Mild NPDR (n=15)	*p*-value
Area (mm^2)	0.39 ± 0.02	0.50 ± 0.04	<0.001
Perimeter (mm)	4.15 ± 0.77	3.68 ± 0.61	0.07
Circularity	0.36 ± 0.07	0.38 ± 0.06	0.60

FAZ in diabetic retinopathy has been well documented using FFA and is still considered to be the traditional gold standard for assessing retinal vasculature and identifying ischemic zones, its invasive nature limits its routine use, particularly in serial monitoring.[14] FFA requires intravenous dye injection, which carries potential risks of allergic reaction, nausea, and contraindication in renal dysfunction.[9] In contrast, OCTA offers a safe, rapid, and reproducible alternative, providing high-resolution en face images of the retinal vascular plexuses without the need for dye administration. Furthermore, OCTA enables the segmentation of vascular layers, allowing independent assessment of superficial and deep capillary plexuses. These capabilities make OCT-A particularly valuable for studying the early and subclinical stages of DR, where FFA might still appear unremarkable. Several studies[15-16] have utilized OCT-A to assess FAZ parameters in DR; however, they relied on manual delineation analysis and techniques, which are susceptible to inter-observer variability and human error. Our study overcomes these limitations by employing automated, built-in software algorithms for FAZ quantification, thereby minimizing measurement bias and improving reproducibility. The automated approach enhances the reliability of results, offering standardized quantitative metrics that can be consistently applied across clinical and research settings.

FAZ area can serve as an early indicator of diabetic retinopathy even before clinical signs appear.[17] Our findings indicate a significant enlargement of the FAZ area among diabetic patients compared with non-diabetic controls. The mean FAZ area in diabetic participants was 0.44 mm^2, nearly double that of non-diabetics 0.20 mm^2. This difference aligns with previous studies reporting similar trends. Pamulapati et al. observed a marked increase in FAZ area in diabetic eyes relative to controls, suggesting that the extent of FAZ

enlargement correlates with disease severity.[11] Similarly, Courtie and Aitchison[18,2] reported that FAZ expansion was a consistent finding in eyes with DR, even in the absence of clinically evident macular edema. These findings support the concept that FAZ metrics may serve as sensitive markers of early retinal ischemia before overt structural changes become apparent. The pathophysiological basis for FAZ enlargement lies in the selective vulnerability of retinal capillaries to chronic hyperglycemia. Prolonged exposure to elevated glucose levels induces pericyte apoptosis, endothelial cell dysfunction, and thickening of the capillary basement membrane. This process leads to microaneurysm formation and eventual capillary dropout, resulting in localized areas of non-perfusion and enlargement of the avascular foveal zone. The FAZ area, therefore, serves as a direct reflection of the cumulative ischemic burden within the macula.[12] Although many prior studies have established FAZ enlargement as a diagnostic and prognostic marker, few have explored its relationship to specific stages of NPDR. Our study specifically focused on comparing mild and moderate NPDR with age-matched controls to determine whether FAZ alterations vary across disease stages. In our study we specifically compared FAZ parameters in mild to moderate stage of NPDR with age matched normal so as to further specify the association of stages of DR with FAZ and we observed that FAZ area enlargement was evident even in mild NPDR, with progressive expansion in moderate stages, highlighting its potential as a biomarker for early disease detection and grading.

The FAZ circularity index, a geometric descriptor reflecting shape regularity, provides complementary insight into FAZ morphology. In healthy individuals, the FAZ is typically round or slightly oval, with high circularity indices indicative of structural integrity. As the retinal microvasculature becomes compromised, the FAZ loses its symmetry and becomes increasingly irregular or lobulated. The circularity index thus decreases with advancing ischemia and disease progression. Shiihara et al.[15] reported an average circularity index of 0.76 in normal eyes, consistent with the regular, compact FAZ morphology of healthy subjects. Krawitz et al.[16] demonstrated an increase in acircularity index values among patients with NPDR 1.57 compared with controls 1.32, signifying shape distortion secondary to vascular dropout. Their study, however, relied on manual tracing techniques, which are operator-dependent. Another study conducted by NM Bates also depicted significant difference in FAZ circularity between diabetics and nondiabetics.[19] On the contrary, the circularity index was similar among patients with NPDR (0.63) and diabetics without DR (0.63) but difference was noted between NPDR (0.63) when compared to non-diabetic controls (0.69) according to Kim et.al.[20] The difference of circularity index among diabetics and non-diabetics of our study are in agreement with these studies however our study was advantageous over them as we compared circularity index between mild NPDR and moderate NPDR although the difference was statistically insignificant. The circularity index's diagnostic value lies in its ability to detect early geometric distortion even before substantial FAZ area enlargement occurs. This metric could serve as an adjunctive parameter for monitoring microvascular integrity, with potential implications for predicting visual outcomes and disease progression.

The FAZ perimeter, representing the total boundary length of the avascular zone, is an important indicator of retinal vascular remodeling. It is another assessment tool for FAZ which is increased in diabetics as a result of capillary alteration and shows significant differences between diabetic retinopathy and and normal retinas. An increased perimeter suggests irregular capillary margins and localized vessel loss. Conrath et al.[21] first reported significant increases in FAZ perimeter among diabetic patients using fluorescein angiography In our study FAZ perimeter in non-diabetics was recorded to be 2.26 mm which is comparable to a result of 2.20 mm shown by Claudia P in his study, [22] while in our study the diabetic FAZ perimeter was found to be 3.91mm which is an enlarged FAZ. This substantial difference underscores the degree of capillary alteration in DR. Our finding is consistent with another study conducted by Hogg RE et al. who declared FAZ perimeter and circularity being impacted most significantly in DM [23] although they manually measured the perimeter and we used built in software which gave us consistent values that were not affected by inter-observer variability and more authentic for interpretation. This difference of FAZ between diabetic and non-diabetic retinas is the result of increase in FAZ parameters in diabetic patients, as a result loss of retinal capillaries due to ischaemia. [12]

Taken together, our results reaffirm that FAZ parameters area, circularity, and perimeter are significantly altered in diabetic retinopathy and can serve as sensitive biomarkers for early microvascular compromise. These findings support previous research suggesting that irregular FAZ morphology may precede visible structural lesions, thus serving as an early warning sign of subclinical DR.[3] Early identification of such subtle vascular changes could prompt stricter metabolic control and closer ophthalmic monitoring, potentially delaying disease progression.

Previous studies have demonstrated a correlation between FAZ parameters and visual acuity. Duffy et al.[24] reported that increased FAZ area was significantly associated with decreased best-corrected visual acuity (BCVA), emphasizing the functional impact of foveal ischemia. Tang et al.[25] further established that decreased circularity corresponded with reduced BCVA, suggesting that FAZ shape irregularity may be more predictive of visual dysfunction than area alone. Although our study did not include direct visual acuity correlations, the structural alterations observed in FAZ parameters are consistent with these findings and reinforce

the clinical importance of early detection.

The enlargement and irregularity of the FAZ reflect cumulative microvascular damage that compromises oxygen and nutrient delivery to the central retina, leading to photoreceptor dysfunction and vision loss. Future studies incorporating both structural and functional assessments would be valuable in elucidating the exact relationship between FAZ metrics and visual performance in different stages of DR. The use of automated OCT-A software for FAZ analysis presents several clinical advantages. First, it allows for standardized, objective, and reproducible measurements, reducing observer bias. Second, automated segmentation enables rapid data acquisition, making it feasible for routine clinical screening. Third, longitudinal monitoring of FAZ metrics could facilitate early identification of disease progression, even before visible fundus changes. From a research perspective, automated OCT-A quantification allows large-scale data analysis with high precision, enabling robust statistical comparisons and facilitating machine learning–based predictive modeling in diabetic retinopathy.

Limitations: This study has several limitations. First, the sample size was relatively small, which may limit the generalizability of our findings. A larger cohort would enhance statistical power and allow for more comprehensive subgroup analyses, particularly regarding different stages of DR. Second, the study was conducted at a single center, potentially introducing selection bias related to population characteristics and imaging equipment. Multi-center studies with diverse populations would improve external validity. Although automated software minimizes human error, segmentation artifacts and signal attenuation may still influence measurements, especially in eyes with poor fixation or media opacity. Our study did not evaluate functional correlations such as best-corrected visual acuity, contrast sensitivity, or electrophysiological parameters, which could provide valuable insights into the relationship between structural FAZ changes and visual performance.

Future research should aim to include larger, multi-centric cohorts with longitudinal follow-up to explore the predictive value of FAZ metrics for progression to diabetic macular edema or proliferative stages. Integration of OCT-A with other imaging modalities—such as adaptive optics or wide-field angiography—could further elucidate the full extent of microvascular alterations. Additionally, machine learning–based analyses of OCT-A data may enable automated risk prediction and personalized disease monitoring.

CONCLUSION

In our study automated software was used to asses FAZ perimeters which plays a key role in enhancing the objectivity and reproducibility of FAZ measurements. This analysis of OCTA images provided a precise measurement of FAZ area, perimeter, and circularity, with the software detecting subtle differences that were often overlooked by manual measurements. This automated approach ensured high inter- and intra-observer agreement, making it a reliable tool for clinical applications. Therefore we conclude that in patients who have various stages of NPDR but clinically normal appearing maculae show deranged FAZ parameters as compared to age matched normal healthy retinae offering us precise, reproducible and recordable measures. These results underscore the diagnostic potential of automated FAZ quantification as a sensitive, non-invasive biomarker for early detection and grading of diabetic retinopathy. The ability to detect subtle vascular changes before the onset of clinical retinopathy may facilitate early intervention and improved patient outcomes

Authors Contribution:
Summaiya Munim study design, drafting the manuscript Data acquisition, data analysis, data interpretation.
Faisal Aziz Khan drafting the manuscript, critical review, approval of the final version to be published.
Muhammad Kashif Hanif Study concept, Critical review, approval of the final version to be published.
Quratulain Paracha Critical review, approval of the final version to be published.
Beenish Saleem Critical review, approval of the final version to be published.
Sameer Shahid Ameen Critical review, approval of the final version to be published.

REFERENCES:

1. Peng X, Peng Y, Li L, Liu L, Zhou G, Cai Y. Breakthroughs in diabetic retinopathy diagnosis and treatment using preclinical research models: current progress and future directions. Ann Med. 2025 ;57(1):2531251. doi: 10.1080/07853890.2025.2531251. Epub 2025 Jul 13.
2. Aitchison RT, Kennedy GJ, Shu X, et al. Measuring the foveal avascular zone in diabetes: A study using optical coherence tomography angiography. J. Diabetes Investig.2022;13(4):668-76. https://doi.org/10.1111/jdi.13712
3. Sijilmassi O. Quantitative Analysis of Different Foveal Avascular Zone Metrics in Healthy and Diabetic Subjects. Diabetology. 2024;5(3):246-54.https://doi.org/10.3390/diabetology5030019
4. Koksaldi S, Kayabasi M, Karti O, Saatci AO. Clinical anatomy of the macula. Med Hypothesis Discov Innov Ophthalmol. 2025;14(2):17-27. doi: 10.51329/mehdiophthal1520.
5. Kashani AH, Lee SY, Moshfeghi A, et al. Optical coherence tomography angiography of retinal venous occlusion. Retina. 2015;35(11):2323-31. doi: 10.1097/IAE.0000000000000811.
6. Takase N, Nozaki M, Kato A, et al. Enlargement of foveal avascular zone in diabetic eyes evaluated by en face optical coherence tomography angiography.Retina.2015;35(11):2377-83.doi: 10.1097/IAE.0000000000000849
7. Coffey AM, Hutton EK, Combe L, et al. Optical coherence tomography angiography in primary eye care. Clin Exp Optom. 2021;104(1):3-13. doi: 10.1111/cxo.13068.
8. Baddam DO, Ragi SD, Tsang SH, et al. Ophthalmic Fluorescein Angiography. Methods Mol Biol. 2023;2560:153-60. doi: 10.1007/978-1-0716-2651-1_15.

9. Ha SO, Kim DY, Sohn CH, Lim KS. Anaphylaxis caused by intravenous fluorescein: clinical characteristics and review of literature. Intern Emerg Med. 2014;9(3):325-30. doi: 10.1007/s11739-013-1019-6.
10. Hagag AM, Gao SS, Jia Y, Huang D. Optical coherence tomography angiography: Technical principles and clinical applications in ophthalmology. Taiwan J Ophthalmol. 2017;7(3):115-29. doi: 10.4103/tjo.tjo_31_17.
11. Pamulapati P, Das MK, Mohanty G. Assessing preclinical diabetic retinopathy: The Role of Optical Coherence Tomography Angiography.Cureus.2024;16(10):e72747.doi: 10.7759/cureus.72747.
12. Oliverio GW, Meduri A, De Salvo G, et al. OCT Angiography Features in Diabetes Mellitus Type 1 and 2. Diagnostics (Basel).2022;12(12):2942.doi: 10.3390/diagnostics12122942.
13. Dan AO, ?tefãnescu-Dima A, Bãlã?oiu AT, et al. Early Retinal Microvascular Alterations in Young Type 1 Diabetic Patients without Clinical Retinopathy. Diagnostics (Basel).2023;13(9) :1648. doi: 10.3390/diagnostics13091648.
14. Yu G, Aaberg MT, Patel TP, et al. Quantification of retinal nonperfusion and neovascularization with ultrawidefield fluorescein angiography in patients with diabetes and associated characteristics of advanced disease. JAMA Ophthalmol .2020;138(6):680-88. doi: 10.1001/ jamaophthalmol .2020.1257.
15. Shiihara H, Terasaki H, Sonoda S, et al. Objective evaluation of size and shape of superficial foveal avascular zone in normal subjects by optical coherence tomography angiography. Sci Rep.2018;8(1):10143. doi: 10.1038/s41598-018-28530-7.
16. Krawitz BD, Mo S, Geyman LS, et al. Acircularity index and axis ratio of the foveal avascular zone in diabetic eyes and healthy controls measured by optical coherence tomography angiography. Vision Res.2017;139:77-186. doi: 10.1016/j.visres.2016.09.019.
17. De Carlo TE, Chin AT, Bonini Filho MA, et al. Detection of microvascular changes in eyes of patients with diabetes but not clinical diabetic retinopathy using optical coherence tomography angiography. Retina.2015;35(11):2364-70.doi:10.1097/IAE.0000000000000882.
18. Courtie E, Kirkpatrick JRM, Taylor M, et al. Optical coherence tomography angiography analysis methods: a systematic review and meta-analysis. Sci Rep.2024;14(1):9643. doi: 10.1038/s41598-024-54306-3.
19. Bates NM, Tian J, Smiddy WE, et al. Relationship between the morphology of the foveal avascular zone, retinal structure, and macular circulation in patients with diabetes mellitus. Sci Rep. 2018;8(1):5355. doi: 10.1038/s41598-018-23604-y.
20. Kim K, Kim ES, Yu SY. Optical coherence tomography angiography analysis of foveal microvascular changes and inner retinal layer thinning in patients with diabetes. Br J Ophthalmol. 2018;102(9):1226-31. doi: 10.1136/bjophthalmol-2017-311149.
21. Conrath J, Giorgi R, Ridings B, Raccah D. Metabolic factors and the foveal avascular zone of the retina in diabetes mellitus. Diabetes Metab.2005;31(5):465-70. doi: 10.1016/s1262-3636(07)70217-3.
22. Acosta CP, González D, Sardi C, et al. Measurement and evaluation of the foveal avascular zone in a healthy Latino population. Retina Today.2021;(-):20-4.
23. Hogg RE, Wright DM, Dolz-Marco R, et al. Quantitative Parameters from OCT Angiography in Patients with Diabetic Retinopathy and in Those with Only Peripheral Retinopathy Compared with Control Participants. Ophthalmol Sci. 2021;1(2):100030. doi: 10.1016/j.xops.2021.100030.
24. Duffy BV, Castellanos-Canales D, Decker NL, et al. Foveal Avascular Zone Enlargement Correlates with Visual Acuity Decline in Patients with Diabetic Retinopathy. Ophthalmol Retina.2025;9(7):667-76. doi: 10.1016/j.oret.2024.12.015.
25. Tang FY, Ng DS, Lam A, et al. Determinants of Quantitative Optical Coherence Tomography Angiography Metrics in Patients with Diabetes. Sci Rep. 2017;7(1):2575. doi: 10.1038/s41598-017-02767-0.

Original Article **Open Access**

Assessing the Predictive Value of Uterine Artery Flow Parameters in Patients with Recurrent Spontaneous Abortion

Sadaf Imtiaz, Falak Naz Baloch, Rabia, Sara, Zobia Munaf, Benish Fatima Makhdoom

ABSTRACT

Objective: To compare uterine artery flow parameters in women with Recurrent Spontaneous Abortion (RSA) and a control group among females presenting at a tertiary care hospital.

Study Design and Settings: The study was conducted at the Department of Obstetrics and Gynecology for uterine artery flow parameters in women with Recurrent Spontaneous Abortion (RSA) and a control group.

Methodology: 100 participants were included, with 50 in each group. The case group comprised women with RSA, defined as three or more consecutive pregnancy losses before the 20th week of gestation, while the control group consisted of women with uncomplicated pregnancies and at least one child born at term. Data were collected on demographic and clinical variables, including age, parity, and BMI. Uterine artery flow parameters, including Pulsatility Index (PI) and Resistive Index (RI), were assessed via Doppler ultrasound, and the results were subjected to statistical analysis using SPSS.

Results: The study revealed that mean age, BMI, and median parity were similar in both groups. However, the PI and RI were significantly higher in the RSA group. The receiver operating characteristic (ROC) curve analysis demonstrated high diagnostic accuracy, with an area under the curve (AUC) of 88.6% for PI and 79.4% for RI, further emphasizing their potential as predictors of RSA.

Conclusion: Uterine artery blood parameters may serve as potential predictors for identifying women at risk of RSA.

Keywords: Abortion, Miscarriages, Pregnancy Loss, Pulsatility Index, Resistive Index, Uterine artery flow parameters.

How to cite this Article:
Imtiaz S, Baloch FN, Rabia, Sara, Munaf Z, Makhdoom BF. Assessing the Predictive Value of Uterine Artery Flow Parameters in Patients with Recurrent Spontaneous Abortion. J Bahria Uni Med Dental Coll. 2026;16(2):489-94 DOI: https://doi.org/10.51985/JBUMDC2025659

Sadaf Imtiaz
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: Si.240990@gmail.com

Falak Naz Baloch
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: drfalakn1@gmail.com

Rabia
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: dd.mnch@pphisindh.org.pk

Sara
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: Sarapathan321@gmail.com

Zobia Munaf
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: zobiamunaf@hotmail.com,

Benish Fatima Makhdoom
Consultant Gynecologist, Department of Obstetrics & Gynecology
CMH Rawalpindi, Pakistan
Email: Benishfatima466@gmail.com

Received: 24-07-2025
1st Revision: 01-09-2025
Accepted: 09-01-2026
2nd Revision: 25-09-2025

INTRODUCTION

Recurrent spontaneous abortions (RSA), often referred to as recurrent miscarriages, represent a profoundly distressing reproductive health issue affecting couples worldwide.[1] This condition is characterized by the loss of three or more consecutive pregnancies before the 20th week of gestation, and it affects approximately 1-2% of all couples trying to conceive.[2] The estimated annual incidence of miscarriage in Pakistan is 29 in 1000 reproductive age females.[3]

RSA is a complex and multifactorial reproductive disorder with numerous contributing factors, including genetic, anatomical, hormonal, immunological, and environmental components.[1,3,4] A significant proportion of RSA cases remain unexplained, despite comprehensive clinical evaluation. As a result, there is a growing need to identify reliable predictive markers that can help in the early detection and management of miscarriages.[5]

Recently, uterine artery flow parameters have gained attention as potential markers for the prediction of RSA, as they reflect the vascular adaptability and health of the uterus. These parameters include the resistance index (RI), pulsatility index (PI), and peak systolic velocity (PSV).[5,6] Abnormal uterine artery flow patterns, characterized by high RI and PI, are indicative of poor uteroplacental blood flow and have been associated with a higher risk of pregnancy

complications, including miscarriage.[5,6] A recent study showed that in patients with RSA, uterine artery flow parameters were significantly higher than in the control group (P<0.05). These parameters also exhibited high sensitivity and specificity in predicting adverse pregnancy outcomes with AUC values ranging from 0.638 to 0.962, indicating that PI and RI, are high-risk factors for adverse pregnancy outcomes.[7]

Despite the promising findings related to uterine artery flow parameters in recurrent abortions prediction, several challenges and gaps in knowledge persist.[8] Variability in measurement techniques, equipment, and the lack of standardized cutoff values for uterine artery flow parameters can complicate the interpretation of findings. Additionally, there is lack of local data available related to specificity and sensitivity for these parameters. Therefore, the aim of current study was to assess the predictive value of uterine artery flow parameters in RSA among females presenting at a tertiary care hospital, Karachi, Pakistan. This study would assist clinicians in identifying women at risk and implement targeted interventions to improve pregnancy outcomes.

Furthermore, the uterine circulation plays a pivotal role in ensuring adequate oxygen and nutrient delivery to the developing fetus.[9] Abnormalities in uterine artery blood flow, especially during the peri-implantation period, may lead to suboptimal endometrial receptivity and impaired placentation, thereby contributing to early pregnancy loss. Doppler ultrasound, a non-invasive imaging modality, enables real-time assessment of uterine artery hemodynamics, offering valuable insight into uterine perfusion status. By analyzing specific flow parameters like PI, RI, and PSV, clinicians can stratify patients based on their risk profile, enabling a more tailored and proactive approach in the management of women with a history of RSA.

Given the emotional and psychological burden that recurrent pregnancy loss imposes on affected couples, timely identification of at-risk individuals is crucial.[10] Current management strategies primarily focus on treating underlying conditions; however, a significant subset of patients lacks an identifiable cause, highlighting the importance of novel diagnostic approaches. Evaluating uterine artery Doppler indices holds promise not only for risk prediction but also for monitoring the effectiveness of therapeutic interventions. Through this study, we aim to bridge existing knowledge gaps by providing localized data, which may enhance clinical protocols and support evidence-based reproductive care in the Pakistani population.

Recurrent spontaneous abortion often remains unexplained despite thorough evaluation. Impaired uterine blood flow may contribute to defective implantation and early pregnancy loss. Uterine artery Doppler indices provide a non-invasive method to assess uterine perfusion. This study aims to generate local evidence on the predictive value of these parameters to improve early risk identification and clinical management.

The fundamental purpose of the study is to evaluate the uterine artery Doppler flow parameters, particularly focusing on pulsatility index (PI) and resistive index (RI) by making comparison between women with spontaneous abortion and normal reproductive outcomes. For this purpose, this study reveals the importance of uterine artery Doppler indices as non-invasive and cost-efficient tool regarding prediction of risk in early phases in women with recurrent pregnancy loss.

METHODOLOGY

This study employed was a comparative cross-sectional design, enrolling participants from the Department of Obstetrics and Gynecology for uterine artery flow parameters in women with Recurrent Spontaneous Abortion (RSA) and a control group for six months. The sample size was calculated using mean RI in RSA as 0.91±0.24 and RI in normal pregnant females as 0.61±0.29.[7] A Power analysis indicated that a minimum of 48 samples were required to detect significant differences with power of 90% and level of significance as 1%. Open Epi online sample size calculator was used for estimation. For increasing the adequacy of results, 100 samples were included in the study (50 samples in each group).

The case group included women with a RSA, defined as three or more consecutive pregnancy losses before the 20th week of gestation. The control group consisted of women with uncomplicated pregnancies and at least 1 child born at term. Women with endometrial diseases, uterine cavity occupation diseases, systemic chronic disease, and use of hormones or antithrombotic drugs within 3 months before study entry were excluded.

This study was conducted following the ethical principles outlined in the Declaration of Helsinki. Approval was obtained from the Institutional Review Board of Combined Military Hospital (CMH) IRB approval number 247/02/2022. Informed consent was obtained from all women before enrollment. Date regarding age, parity, and BMI were noted. Uterine artery flow parameters, including the PI and RI were assessed using Doppler ultrasound in the second phase of the menstrual cycle, specifically between days 18 and 23. A standardized protocol was followed by a trained sonographer. All data were anonymized and stored securely, with restricted access to authorized personnel only. Data were entered into a dedicated database and subjected to routine quality control checks.

Statistical analysis was performed using software SPSS version 23. Descriptive statistics, including means and standard deviations for continuous variables and percentages for categorical variables, were calculated. Uterine blood flow parameters were compared between both groups using independent samples t-test. Sensitivity, specificity, and the area under the curve (AUC) were determined for the uterine

artery flow parameters in predicting adverse pregnancy outcomes using receiver operating characteristic (ROC) curve analysis. A p-value less than 5% was considered as statistically significant.

RESULTS

A total of 100 women were enrolled in this study, comprising 50 women in the recurrent spontaneous abortion (RSA) group and 50 in the control group. Demographic characteristics, such as age, BMI, and parity, were collected, along with uterine artery Doppler ultrasound parameters including the pulsatility index (PI) and resistive index (RI). Data were statistically analyzed to compare mean values between the two groups and to determine the predictive performance of PI and RI using ROC curve analysis.

The mean age of women in RSA group was 23.28±3.96 years and in control was 24.96±5.16 years. The mean BMI was 25.13±3.80 kg/m^2 in RSA group and 26.02±4.84 kg/m^2 in control group. The median parity was in 0 in RSA group and 1 in control group, respectively. (Table 1)

The mean PI (1.76±0.35 vs 1.21±0.29) and mean RI (0.98±0.21 vs 0.76±0.17) were significantly higher in RSA group than control with p-value<0.05. (Table 2)

Figure 1 shows the ROC curve of the mean PI and RI of women with RSA. The area under the curve (AUC) was 88.6% of PI (p=0.001) and 79.4% of RI (p=0.001) for the prediction of RSA. The sensitivity of PI was 80% and specificity was 78% at cut-off value of 1.35, whereas, the sensitivity of RI was 82% and specificity was 58% at cut-off value of 0.80, respectively.

Table 1: Baseline characteristics of study samples among both groups (n=100)

Characteristics	RSA	Control
Age (years)	23.28±3.96	24.96±5.16
BMI (kg/m^2)	25.13±3.80	26.02±4.84
Parity	0 (0-1)	1 (1-2)

Table 2: Comparison of uterine artery flow parameters between RSA and control group (n=100)

Uterine artery flow parameters	RSA	Control	p-value
PI	1.76±0.35	1.21±0.29	0.001*
RI	0.98±0.21	0.76±0.17	0.001*

Table 3: Diagnostic performance of Doppler parameters using ROC analysis

Parameter	Cut-off Value	Sensitivity (%)	Specificity (%)
Pulsatility Index (PI)	1.35	80%	78%
Resistive Index (RI)	0.80	82%	58%

Table 4: Area under the curve (AUC) for Doppler indices

Parameter	AUC (%)	p-value
Pulsatility Index (PI)	88.6%	0.001*
Resistive Index (RI)	79.4%	0.001*

DISCUSSION

The present study compared uterine artery flow parameters in women with RSA and a control group. In the present study found that mean age of women in the RSA group and control group was almost same. Similarly, in a study conducted by Zhang et al. the mean age of women in the RSA group and control group was 29.55±3.83 years and 28.97± 3.30 years, respectively.[11] Lian et also found median age in RSA group and in control is similar with p-value=0.194.[12] These findings support to the notion that age may not be a significant distinguishing factor in the context of recurrent spontaneous abortion.

Additionally, the mean BMI in the RSA group (25.13 kg/m²) was almost similar to the control group (26.02 kg/m²). However, in a previous study by Felisbino-Mendes et al., it has been observed that with every one unit increase in BMI, the odds of spontaneous abortion significantly increased (OR = 1.05; 95% CI=1.02-1.08).[13] Another study by Eapen et al. also showed that maternal BMI was strongly associated with recurrent miscarriages.[14] Similarly, Ghimire et al. revealed the odds of abortion were 1.5 times more among females with obesity than controls.[15] Dissimilarities between our study and previous studies might be due to variation in the demographic characteristics of the study populations.

In the current study, the median parity in the RSA group was reported as 0, while the control group had a median parity of 1. Cohain et al. found that 43% of the females experienced one or more first trimester spontaneous miscarriages. A significant portion had one miscarriage (27%), while 10% had two, 4% had three, and smaller percentages had more. Notably, 18.5% had first trimester miscarriages before their first live birth, and even women with 11 or more living children experienced miscarriages (81%). Furthermore, they found factors contributing to first trimester miscarriages included increasing age, a history of ectopic pregnancy, higher parity, previous cesarean surgery, smoking during pregnancy, and a pre-pregnancy BMI =30. These findings highlight the multifaceted nature of first trimester miscarriages.[16] and underscore the intricate nature of first trimester miscarriages, further supporting the complexity of their causes.

Uterine blood flow parameters in miscarriages have been explored in various studies. One study by Yildiz et al. found no significant difference in PI and RI values between females with and without history of pregnancy loss.[17] Zhang et al. also found uterine artery blood flow parameters were significantly higher in RSA group than control group. In the study by Taylor et al. it has been observed that the mean PI was significantly different between pregnancies that continued to be viable and resulted in abortions.[18] Elewa et al. revealed that women with RSA have greater uterine flow resistance

and lesser endometrial and subendometrial blood flow as compared to fertile women.[19] Similarly, Wahab et al. found women with RSA had lesser endometrial blood flow and higher uterine blood flow resistance as compared to controls.[20] In the current study we also found that the mean PI and RI values were significantly higher in the RSA group than in the control group. This aligns with existing research that has suggested abnormal uterine artery Doppler waveforms, characterized by increased PI and RI, may be associated with adverse pregnancy outcomes, including RSA.[5,6,12.] Furthermore, in the current study, the ROC curve analysis demonstrated that high AUC values (88.6% for PI and 79.4% for RI) indicate good diagnostic accuracy. The sensitivity and specificity values at their respective cut-off points further emphasize the potential clinical utility of these Doppler indices. While the ROC analysis is a valuable contribution, it is essential to note that the sensitivity of RI is higher than PI, which could make it a more robust predictor.

The paper presents essential insights into the association between maternal age, BMI, Doppler parameters, and RSA. However, several limitations should be acknowledged. First, the sample size and demographic characteristics of the study population are not discussed in detail, and these factors can significantly impact the generalizability of the findings.[20] Furthermore, it would be beneficial to explore other potential confounding variables, such as medical history and lifestyle factors, which were not included in this analysis. Lastly, future research should focus on the reproducibility of these findings in larger, more diverse populations to enhance the robustness of these predictors.

The implications of the current findings are far-reaching in the context of reproductive health, especially in countries like Pakistan where access to advanced fertility assessments and interventions remains limited. By demonstrating that uterine artery Doppler indices such as PI and RI are significantly elevated in women with RSA, this study adds valuable evidence supporting the use of non-invasive imaging techniques for early risk stratification.[21] The observed high AUC values in the ROC curve analysis further highlight the diagnostic strength of these markers. While RI demonstrated slightly higher sensitivity than PI in this study, both indices have shown considerable clinical utility and can be considered valuable tools for routine gynecological evaluations in women at risk for RSA.

It is noteworthy that even though uterine artery Doppler studies have gained attention globally, their routine integration into standard clinical practice is still evolving. This may be due to factors such as lack of trained personnel, limited access to Doppler technology in resource-constrained settings, and the need for standardized reference values. Our findings underscore the importance of incorporating Doppler studies, especially in tertiary care settings, to complement existing diagnostic approaches. With increasing evidence supporting their predictive value, uterine artery Doppler indices could be pivotal in guiding clinical decisions such as closer monitoring, early intervention, or the use of adjunctive therapies like low-dose aspirin or heparin in at-risk patients.[22]

Another crucial aspect to consider is the timing of Doppler assessment. Studies suggest that uterine artery Doppler indices vary with the phase of the menstrual cycle, gestational age, and individual physiological conditions. For optimal predictive accuracy, standardizing the timing of these assessments—ideally during the mid-luteal phase or early first trimester—would allow for better inter-study comparability. This standardization becomes especially relevant in clinical protocols, where reproducibility and consistency are crucial for widespread application.[23]

In addition to uterine artery flow, several studies have examined the endometrial and subendometrial blood flow as additional markers of reproductive potential. These microvascular territories play a fundamental role in embryo implantation and placental development. Reduced blood flow in these regions, which has been consistently reported in women with RSA, correlates with suboptimal endometrial receptivity. Although this study did not evaluate endometrial perfusion specifically, integrating this parameter in future studies would enhance the overall understanding of uterine hemodynamics in RSA patients.

The discussion on maternal age and BMI in relation to RSA also warrants further elaboration. While this study found no significant difference in age or BMI between the RSA and control groups, literature reveals conflicting evidence. For example, increasing maternal age has been widely recognized as a risk factor for chromosomal abnormalities and miscarriage. However, in populations with younger reproductive age ranges, like those in Pakistan, this association may be less pronounced. Similarly, BMI has shown a complex relationship with pregnancy outcomes. Although some studies report a positive correlation between high BMI and RSA risk, others, including ours, suggest minimal or non-significant differences. These discrepancies underscore the importance of contextualizing data within regional demographics, lifestyle patterns, and healthcare access.[16]

Moreover, parity emerged as a potential differentiating factor in our study, with RSA patients exhibiting a median parity of zero. This finding aligns with clinical observations that many women experiencing recurrent miscarriages often do so before achieving a successful pregnancy. Low parity may reflect underlying reproductive or endocrine dysfunctions, immunologic incompatibilities, or structural anomalies that impede the maintenance of early pregnancy.[17] Thus, parity should be further explored in future research as a potential mediator or modifier in RSA risk prediction models.

Beyond the physiological and demographic considerations, psychosocial dimensions of RSA also deserve attention. Recurrent pregnancy loss is associated with significant

emotional trauma, anxiety, depression, and relationship stress. The diagnostic uncertainty surrounding many RSA cases often compounds these challenges. Thus, developing reliable, evidence-based predictors—such as uterine artery Doppler indices—could not only guide medical management but also provide psychological reassurance and clarity for affected couples. This holistic approach to patient care is particularly crucial in culturally sensitive settings where childbearing is closely linked to social identity and familial expectations.[18]

Another important consideration is the heterogeneity of RSA causes. While Doppler parameters reflect uterine perfusion and vascular resistance, RSA can also result from endocrine disorders (like uncontrolled diabetes or thyroid dysfunction), coagulation abnormalities (e.g., antiphospholipid syndrome), and immunological or genetic defects. Therefore, Doppler assessments should be part of a broader diagnostic framework, rather than standalone tools.[16] A multidisciplinary evaluation involving endocrinologists, hematologists, geneticists, and reproductive medicine specialists will yield a more comprehensive understanding and management strategy for RSA patients.

One potential avenue for improving outcomes lies in therapeutic interventions aimed at improving uterine blood flow. Several clinical trials have investigated the efficacy of low-dose aspirin, low molecular weight heparin, nitric oxide donors, and even lifestyle interventions such as exercise and weight management to improve uterine perfusion. If future studies confirm that elevated PI and RI reliably predict miscarriage risk, these interventions could be initiated pre-conceptionally or in early pregnancy to enhance uterine vascular function and potentially reduce the risk of pregnancy loss. Personalized medicine, supported by real-time Doppler assessments, could thus become a cornerstone of RSA management in the future.[17]

Despite its valuable contributions, the current study is not without limitations. The lack of detailed stratification by RSA etiology limits the granularity of conclusions. Additionally, although Doppler parameters were compared, other relevant clinical data such as endometrial thickness, hormonal levels, and anatomical anomalies were not evaluated. These factors could influence uterine blood flow and, consequently, miscarriage risk.[21] Further, the study's cross-sectional nature precludes causal inferences, and its single-center design may limit generalizability. Multi-center longitudinal studies with larger, ethnically diverse samples and detailed clinical profiles would be instrumental in validating and expanding upon these findings.

Moreover, operator variability in Doppler measurements, even when using standardized techniques, remains a significant limitation in clinical practice. Training sonographers, ensuring inter-observer reliability, and using high-resolution equipment are essential for enhancing the accuracy and reproducibility of such assessments.[22] Establishing normative reference ranges for uterine artery PI and RI values in the local population would also facilitate more precise risk categorization.

This study reinforces the utility of uterine artery Doppler parameters, particularly PI and RI, as promising non-invasive markers for assessing RSA risk. The elevated values in the RSA group, combined with robust ROC curve metrics, affirm their diagnostic value. While maternal age and BMI were not significant differentiators in this cohort, the importance of individual risk profiling remains paramount. Future research should aim to integrate Doppler findings with broader clinical, genetic, and psychosocial data to develop holistic and individualized care plans.[23] Ultimately, enhancing the understanding and management of RSA through such approaches could contribute to improved maternal-fetal health outcomes, especially in under-resourced settings.

When it comes to limitations, the study was conducted in a single hospital, so the study is limited to generalize. Meanwhile, the sample size of the study is also limited. Importantly, the Doppler measurement is also dependent on operator rather than considering it as a general factor.

CONCLUSION

The uterine artery blood parameters might be potential predictors for the identification of women at risk of RSA.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Sadaf Imtiaz Concept and design of study, literature review, final approval of manuscript
Falak Naz Baloch Concept of study, critical appraisal of final version
RabiaData analysis and interpretations, final approval of manuscript
SaraLiterature review, drafting of manuscript, final approval of manuscript
Zobia Munaf Data collection and validation, literature review, final approval of manuscript
Benish Fatima Makhdoom Concept of study, critical appraisal of final version

REFERENCES

1. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: current perspectives. Int J Womens Health 2017;9:331-45. DOI: 10.2147/ijwh.S100817.
2. Zhang X, Wang H, Feng T, Yang J, Huang Q, Lu C, et al. The relationship between semen factors and unexplained recurrent spontaneous abortion. Clin Chim Acta 2020;510:605-12. DOI: 10.1016/j.cca.2020.08.022.
3. Yasmeen R, Hussain R. Recurrent miscarriage and associated factors. Pakistan Journal of Medicine and Dentistry 2016;5(1):47-50.

4. Cao C, Bai S, Zhang J, Sun X, Meng A, Chen H. Understanding recurrent pregnancy loss: recent advances on its etiology, clinical diagnosis, and management. Med Rev (Berl) 2022;2(6):570-89. DOI: 10.1515/mr-2022-0030.
5. Lian X, Pan Z, Xia F, Mao C, Zhou W, Zhong Y, et al. Analysis of the guidance and predictive value of uterine artery flow parameters in patients with recurrent spontaneous abortion. Journal of Obstetrics and Gynaecology Research 2023;49(3):803-11. DOI: https://doi.org/10.1111/jog.15523.
6. Frates MC, Doubilet PM, Brown DL, Benson CB, DiSalvo DN, Laing FC, et al. Role of Doppler ultrasonography in the prediction of pregnancy outcome in women with recurrent spontaneous abortion. Journal of ultrasound in medicine 1996;15(8):557-62.
7. Wei LU, Honghong LIU, Weihao YANG. Predictive Value of Uterine Artery Blood Flow Parameters in Early Pregnancy on Adverse Pregnancy Outcomes in Patients with Recurrent Spontaneous Abortion[J]. HeBei Med, 2021, 27(4): 579-583.
8. Sussman D, Saini BS, Schneiderman JE, Spitzer R, Seed M, Lye SJ, Wells GD. Uterine artery and umbilical vein blood flow are unaffected by moderate habitual physical activity during pregnancy. Prenatal Diagnosis. 2019 Oct;39(11):976-85.
9. Obeagu EI, Obeagu GU. Maternal Hypoxia: Impact on Cardiovascular Health and Placental Function. Elite Journal of Nursing and Health Science. 2024;2(8):50-65.
10. Voss P, Schick M, Langer L, Ainsworth A, Ditzen B, Strowitzki T, Wischmann T, Kuon RJ. Recurrent pregnancy loss: a shared stressor---couple-orientated psychological research findings. Fertility and Sterility. 2020 Dec 1;114(6):1288-96.
11. Zhang K, Wang E, Li Y, Xu H, Zhang J, Wang X, et al. Role of low-molecular-weight heparin in altering uterine artery blood flow in recurrent spontaneous abortion: a prospective study. J Int Med Res 2020;48(8):300060520945558. DOI: 10.1177/0300060520945558.
12. Lian X, Zhong Y, Lv X, Lu S, Lu Y, Zhou Y, et al. Doppler evaluation of uterine blood flow and pregnancy outcome in patients with URSAFA retrospective cohort study. Research Square; 2023.
13. Felisbino-Mendes MS, Matozinhos FP, Miranda JJ, Villamor E, Velasquez-Melendez G. Maternal obesity and fetal deaths: results from the Brazilian cross-sectional Demographic Health Survey, 2006. BMC Pregnancy Childbirth 2014;14:5. DOI: 10.1186/1471-2393-14-5.
14. Eapen A, Hayes ET, McQueen DB, Beestrum M, Eyck PT, Boots C. Mean differences in maternal body mass index and recurrent pregnancy loss: a systematic review and meta-analysis of observational studies. Fertil Steril 2021;116(5):1341-8. DOI: 10.1016/j.fertnstert.2021.06.019.
15. Ghimire PR, Akombi-Inyang BJ, Tannous C, Agho KE. Association between obesity and miscarriage among women of reproductive age in Nepal. PLoS One 2020;15(8):e0236435. DOI: 10.1371/journal.pone.0236435.
16. Cohain JS, Buxbaum RE, Mankuta D. Spontaneous first trimester miscarriage rates per woman among parous women with 1 or more pregnancies of 24 weeks or more. BMC Pregnancy Childbirth 2017;17(1):437. DOI: 10.1186/s12884-017-1620-1.
17. Yildiz G, Yavuzcan A, Yildiz P, Göynümer G, Yücel N. Effect of uterine artery blood flow on recurrent pregnancy loss. Clin Exp Obstet Gynecol 2012;39(3):326-9.
18. Taylor TJ, Quinton AE, de Vries BS, Hyett JA. First-trimester ultrasound features associated with subsequent miscarriage: A prospective study. Aust N Z J Obstet Gynaecol 2019;59(5):641-8. DOI: 10.1111/ajo.12944.
19. Elewa A, Mansour A, Gehad MA, Afify H. Ovarian reserve testing and uterine blood flow assessment using two-dimensional and three-dimensional Doppler in patients with unexplained recurrent miscarriage. Benha Medical Journal 2017;34:81 - 7.
20. Wahab HA, El-Din DS, Zain E, Abdelgany M, Youssef MAFM. Uterine artery Doppler and subendometrial blood flow in patients with unexplained recurrent miscarriage. Middle East Fertility Society Journal 2011;16(3):209-14. DOI: https://doi.org/10.1016/j.mefs.2011.04.001.
21. Adekanmi AJ, Roberts A, Morhason-Bello IO, Adeyinka AO. Utilization of Uterine and Umbilical Artery Doppler in the Second and Third Trimesters to Predict Adverse Pregnancy Outcomes: A Nigerian Experience. Womens Health Rep (New Rochelle) 2022;3(1):256-66. DOI: 10.1089/whr.2021.0058.
22. Barati M, Shahbazian N, Ahmadi L, Masihi S. Diagnostic evaluation of uterine artery Doppler sonography for the prediction of adverse pregnancy outcomes. J Res Med Sci 2014;19(6):515-9.
23. Geerts L, Van der Merwe E, Theron A, Rademan K. Placental insufficiency among high-risk pregnancies with a normal umbilical artery resistance index after 32weeks. International Journal of Gynecology & Obstetrics 2016;135(1):38-42. DOI: https://doi.org/10.1016/j.ijgo.2016.03.038.

Original Article **Open Access**

Lisa vs Insure in the Treatment of Respiratory Distress Syndrome in Preterm Infants

Jaweia Lodhi, Ayesha Shuaib, Rabia Tabassum, Hina Khan, Almas Mushtaq, Sohail Aslam

ABSTRACT

Objectives: To compare the outcome of Less Invasive Surfactant Administration (LISA) versus Intubation – Surfactant–Extubation (INSURE) for treatment of respiratory distress syndrome in preterm infants

Study design and Setting: Randomized controlled trial, Department of Pediatric, Fauji Foundation Hospital Rawalpindi. March 27, 2022 till September 26, 2022 Subjects: Total 70 neonates aged 1 to 24 hours of life having gestational age of 32-36 weeks of either gender having respiratory distress syndrome were enrolled using non- probability consecutive sampling technique.

Methodology: Study was conducted after approval of hospital ethical committee and written informed consent of parents. Neonates were enrolled in LISA group A and INSURE group B using lottery method. In LISA group surfactant was given using 6Fr nasogastric tube and in INSURE group neonates were intubated and surfactant was given. Frequency of need for mechanical ventilation in both groups was noted. Data was entered and analyzed using SPSS 21.

Results: In our study total 70 patients were enrolled, 35 patients in each group. Mean age was 7.8±6.6 hours in group A and 6.6±5.9 in group B. There were 40% males in group A and 57.1% in group B. females were 60% in group A and 42.9% in group B. In LISA group 28.6% needed mechanical ventilation while in INSURE group 60% needed mechanical ventilation, p-value 0.008

Conclusion: LISA is more effective in preventing need for mechanical ventilation after surfactant administration in pre-term neonates.

Keywords: Intubate-surfactant-extubate: Less invasive surfactant administration: Preterm: Respiratory distress syndrome: Surfactant.

How to cite this Article:
Lodhi J, Shuain A, Tabassum R, Khan H, Mushtaq A, Aslam S. Lisa vs Insure in the Treatment of Respiratory Distress Syndrome in Preterm Infants. J Bahria Uni Med Dental Coll. 2026;16(2):495-500 DOI: https://doi.org/10.51985/JBUMDC2025679

Jaweria Lodhi
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: javeriajavaidlodhi@gmail.com

Ayesha Shuaib
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: Ayeshagauhar30@gmail.com

Rabia Tabassum
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: drrabiausman35@gmail.com

Hina Khan
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: Khanh433@yahoo.com

Almas Mushtaq
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: almasmushtaq@hotmail.com

Sohail Aslam
Consultant, Department of Pediatrics
Fauji Foundation Hospital Rawalpindi, Pakistan
Email: drsohail67@gmail.com

Received: 12-08-2025
Accepted: 09-04-2026
1st Revision: 25-09-2025

INTRODUCTION:

Respiratory pathology is considered the most common complication of preterm birth, often presenting as respiratory distress syndrome, which results from structural immaturity of the lungs and early surfactant deficiency.[1] Out of 10 babies are born premature with the rate growing up in the majority of countries in the world.[2,3]

Respiratory distress syndrome is known to be one of the most popular causes of high morbidity and mortality in infants.[4] The survival of respiratory distress syndrome was diagnosed to be secondary to primary surfactant deficiency some 7 decades and continuous positive airway pressure was implemented, almost 5 decades ago. Since, some period lapsed and a lot happened in neonatology as well: we have known a lot but still there is more that remains disputable.[5]

The process of non-invasive ventilating and in particular that that is known by the usage of the continuous positive airway pressure (CPAP) has become commonplace in the treatment of the respiratory problems of the premature infant. However, failure of CPAP may occur in the situations of respiratory distress syndrome, i.e. failure of the surfactants. Less invasive surfactant administration (LISA) is a method

that aims at providing the amount of surfactant that is enough when the baby is breathing on his/her own without relying on positive pressure ventilator to help him/her breathe. Included in the application of the thin catheter to deliver the surfactant is the possibility of the babies being able to continue with the normal functionality of the glottis and spontaneous respirations as opposed to the conventional INSURE procedure that is linked to the sedation/analgesia, routine intubation, and a (short) duration of positive pressure ventilation.[6]

At the current stage LISA is the most suitable way of administering a surfactant and it should be the most widespread due to the benefits it brings to respiratory morbidities in preterm children with respiratory distress syndrome.[7] In a study by Cao et al., it was indicated that mechanical ventilation was investigated in 30 percent of LISA cases and 60 percent of INSURE cases in the treatment of respiratory distress syndrome in newborns ($p<0.05$).[8] Permall et al., conducted another study and reported that mechanical ventilation within 72 hours was required in 13.2% in LISA group vs.27.5% in INSURE group in preterm neonates ($P<0.05$).[9]

A study conducted in Poland which reveals that the need of mechanical ventilation was observed in 42.2 percent with LISA and 32.6 percent with INSURE in the treatment of respiratory distress syndrome in preterm infants ($p>0.05$).[10]

Another study was done in India in which there was no difference in the need of intubation and mechanical ventilation within 72 h of birth between within the two groups namely [InSurE, 30 percent and LISA, 30 percent, relative risk.[11]

The rationale of this study is to make a comparison between the outcome concerning LISA and INSURE in the treatment of respiratory distress syndrome in pre term babies. As stated in the literature, LISA was superior regarding rapid recovery of the respirations and decreased utilization of the mechanical ventilation. But in the literature, contradictory evidence has been provided and also it needs to conduct a study in the local setting so as to come up with magnitudes in the local setting. It follows therefore, that on the basis of this study we would like to have the current evidence to us such that we can manage to implement the findings of this study locally and that we shall also have the means of proposing which approach of managing the pre-term neonates with respect to respiratory distress syndrome is more acceptable. It would also help us to improve our performance and working style of the superior way of taking care of high-risk neonates.

METHODOLOGY:

The study was carried out in Fauji Foundation Hospital Rawalpindi between March 27, 2022 and September 26, 2022. Using the WHO calculator, it has been calculated 35 in each group and with sample size of 70 cases keeping 80 per cent power of study, 5 per cent level of significance and percentage of need of mechanical ventilation i.e. 30 per cent with LISA and 60 per cent with INSURE as the mode of delivering the need of the respiratory distress syndrome in pre-terminal infants through Non-Probability and in series sampling technique. Neonates aged 1–24 hours, irrespective of gender, born at a gestational age of 32–36 weeks (as determined from antenatal records), and diagnosed with respiratory distress syndrome (based on the operational definition) were included in the study. Neonates with severe congenital malformations and those requiring intubation during resuscitation at birth were excluded from the study.

Following approval from the hospital's ethical committee, a total of 70 neonates who met the inclusion criteria were enrolled in the study from the emergency department of the Department of Pediatrics at Fauji Foundation Hospital.

One also did a capture of demographic data that entailed name, age, sex, birth weight, gestational age at birth, Apgar scores and mode of delivery, after getting consent of the parents of the participating child. It involved the routine admission of neonates to the neonatology ward and their ongoing management.

Thereafter baby neonates were randomly divided into two and it was done through the use of lotteries. Group A consisted of introducing LISA treatment to the group of neonates by giving the dose of 100 mg/Kg Survanta using the help of 6 Fr size nasogastric tube. In the INSURE group B, the neonates were administered with the INSURE 2-3 aliquots using the endotracheal tube that bore the same dose as the LISA group and received the regulated positive pressure previously ventilated by the use of the T- piece resuscitaire. The endotracheal was removed after a short lease with the positive pressure ventilation of 15-20 minutes and the infants was subjected to the nCPAP. Respiratory and CPAP were administered using the initial pressure of 5 to 7 cm of water and FiO2 0.3. Follow up of neonates was done in between 6-24hr. Other than this, when the oxygen level was not maintained and when FiO2 has not gone down, the mechanical ventilation was supplemented and reported (as per the operational definition).

RESULTS:

In our study total 70 patients were enrolled, 35 patients in each group. Mean age was 7.8 ± 6.6 hours in group A and 6.6 ± 5.9 in group B. Mean gestational age was 33.8 ± 1.2 weeks in group A and 33.7±1.2 weeks in group B. Mean birth weight was 2 ± 0.1 in group A and 2 ± 0.17 in group B. (Table 1). There were 40% males in group A and 57.1% in group B. females were 60% in group A and 42.9% in group B. (Table 2), In group A 54.3% neonates delivered by vaginal delivery and in group B 42.9% delivered by vaginal delivery. (Table 3). In LISA group 28.6% needed mechanical ventilation while in INSURE group 60% needed mechanical ventilation, p-value 0.008. (Table 4)

Table 1: Mean values of Age, Birth weight and AGPAR group

Variable	Group	N	Mean ± Std. Deviation	p-value
Age (hours)	LISA	35	7.83 ± 6.697	0.452
	INSURE	35	6.69 ± 5.905	0.452
Gestational age	LISA	35	33.89 ± 1.207	0.694
	INSURE	35	33.77 ± 1.215	0.694
Birth weight (kg)	LISA	35	2.0486 ± 0.19610	0.949
	INSURE	35	2.0514 ± 0.17552	0.949
AGPAR group	LISA	35	7.46 ± 1.197	0.927
	INSURE	35	7.43 ± 1.399	0.927

Table 2: Gender Distribution

		Gender		Total	p-value
		Male	Female		
LISA	Count	14	21	35	0.151
	% within Group	40.0%	60.0%	100.0%	
INSURE	Count	20	15	35	
	% within Group	57.1%	42.9%	100.0%	

Table 3: Mode of delivery

		Mode of delivery		Total	p-value
		Vaginal	Cesarean		
LISA	Count	19	16	35	0.339
	% within Group	54.3%	45.7%	100.0%	
INSURE	Count	15	20	35	
	% within Group	42.9%	57.1%	100.0%	

Table 4: Comparison of need for mechanical ventilation in both groups

		Need for mechanical ventilation		Total	p-value
		Yes	No		
LISA	Count	10	25	35	0.008
	% within Group	28.6%	71.4%	100.0%	
INSURE	Count	21	14	35	
	% within Group	60.0%	40.0%	100.0%	

DISCUSSION:

The current form of the Respiratory Distress Syndrome (RDS) is a top cause of morbidity and mortality in premature infants with high usage of surfactant deficiency which predisposes this complication.[12] The predisposing factor in the condition is surfactant deficiency, a condition that emerges with inability of a baby to exchange gases that causes production of alveoli of small size along with decreased ingredients in improved delivery of the surfactant.[2]

Historically, endotracheal intubation and mechanical ventilation (MV) were performed to administer the surfactant replacement therapy.[13] Although this method has proven to be efficient in delivering the surfactant and in enhancing gas exchange, it also resulted in a number of sequelae including ventilator-induced lung injury (VILI), barotrauma, volutrauma and a higher risk of bronchopulmonary dysplasia (BPD).[4,5] To eliminate these adversities, less invasive ways of introducing the system, including INSURE (This would be to shorten the period of positive pressure ventilation and maintain spontaneous breathing, a condition that would eventually limit the chances of iatrogenic lung injury.[6]

The INSURE method proposed during the 1990s involves only brief intubation to install only surfactant and then extubate immediately to nCPAP.[7] The LISA technique instead has the ability to deliver the surfactant through a thin catheter passed through the vocal cords as a neonate breathes on his or her own on nCPAP, never to experience positive pressure ventilation.[14] This approach was later developed but became scarcely followed until it was revisited again and standardized in the early 2000s.[6,7]

Our study can be considered to contribute to this growing body of literature as it is a direct comparison of LISA versus INSURE outcome in a cohort of preterm neonates with RDS. The first one considered the need of mechanical ventilation within the first 72 hours after birth. The results indicated that there was a statistically significant decrease in chances of mechanical ventilation in LISA group (28.6%) at a relative percentage of surgery compared to INSURE group (60%) of 0.008. These findings agree with the hypothesis that uses of LISA will be better than that of INSURE in decreasing the need of invasive respiratory support among preterm neonates. The observation is in line with the results presented by Permall et al. (2024), who used a retrospective study to examine infants that received LISA. The study revealed that the LISA group had a lower need of mechanical ventilation and incident rates of moderate and severe BPD. But the study is retrospective and therefore cannot prove a causality. Moreover, the research study did not give significant details of the standardization of process, and possibility of procedures that were specific to centers and clinicians could have impacted the reliability of the results. However, the big sample size would lend merit to their conclusions and corroborate our findings of efficacy of LISA.[9]

The same tendency was seen in another research study by Cao et al. (2020). According to the study findings, only 30% of babies in its LISA group received mechanical ventilation as opposed to 60% in its INSURE group.[8] Also, the mechanical ventilation time, as well as the duration of FiO2 necessity, was greatly reduced in the LISA group. But the sample of their study was small in number, and the design was single center. The team of scientists cannot provide the details of LISA technique and give no information about training of the medical staff which undertakes the procedures. This standardization is not standard, which may affect the results and narrow reproducibility. Nonetheless, these restrictions do not cancel out our outcomes since they support our results and regard the feasibility of LISA in South Asian environments.

The study by Buyuktiryaki et al. (2019) was another study that supported the same results as it was a five-year retrospective study aimed at comparing LISA with INSURE.[7] The results have shown better respiratory outcomes with fewer cases of BPD and shorter ventilation periods among infants treated with LISA. Despite the fact that the longitudinal nature of the research contributes to the insights regarding the long-term trends, there is an inherent limitation due to the absence of randomization and control of the confounders. Besides, this study was not controlled over learning curve of LISA administration. Since physician skills also improved as the LISA technique progressed during the five years, the results being obtained may have been biased to show some positivity to LISA during the latter years.[15]

In contrast to most of the literature addressing LISA, Mansouri (2024) found no significant difference in the outcomes between the two methods.10 It included 129 preterm infants who were recruited and compared in terms of their intubation rates, the time spent mechanically ventilated, and the overall use of respiratory assistance. In their study, they established similar findings in both population groups, except that it had a number of limitations. First, the sample size was fair and the uneven distribution of the sample among the two groups (LISA: 83: INSURE: 46) had limited the statistical power. Second, LISA methodology was introduced rather recently in their hospital (2014-2016), so physicians did not have experience to teach them yet. It is expected that such an initial step of implementation influenced procedural efficacy and obscured the possible benefits of LISA. What is more, there are no specific records made of sedation procedures and type of surfactant which, again, reduces the interpretability. These constraints affect the findings of the researchers since we found that LISA and INSURE due to various reasons such as timings, use of sedative and post-surgical outcome.[16]

The study of Chakraborty and Course (2020) in Wales during the audit revealed the existence of highly variable practices when LISA is applied in various NICUs.[3] Focused to describe the processes but not clinical outcomes, the study emphasized the necessity of coordinated procedures and frequent training to provide consistency in LISA implementation. The audit method gave a great hinge into practical problems that one encounters when carrying out LISA especially in a system where there exists a lot diversity of provider expertise and in resources that an institute possesses. Their results bear out the belief that unstructured training without clarity in the process will result in the failure of the advantages of LISA to be exploited in practice. It is necessary to emphasize the advantages of LISA with the reference to clinical practices with the purpose of giving support to the patients concerning the management of respiratory distress syndrome.[17]

In favor of LISA, Bhayat et al. (2020) scanned the benefits and the risks that LISA might encounter.[6] The authors noted its ability to diminish cases of invasive ventilation and lung harm, mentioning its need of technical skills. Other issues of placement of the catheter correctly, alternate spontaneous gear during laryngoscopy as well as use of sedation were all established with regard to success limitations. This review observed that overall, the outcomes of LISA cannot be generalized due to a lack of standardization in catheter size, speed of instillation and sedation methods among other things across centers.[18] This review provides credence to our observations and is cautious on the idea that the benefits found in a controlled setting automatically apply in the environment where such procedures occur in a widespread manner.

Pareek et al. (2021) performed a pilot randomized controlled trial examining LISA vs INSURE efficacy.[12] As they indicate, the trial yielded results in support of LISA as more feasible and safer, though due to the small study sample size (n = 60) and insufficient statistical power, their results could not be statistically significant in relation to an outcome like BPD or mortality. However, random allocation of the study and prospective research design makes it internally sound. But the small sample size and brief follow-up as well as the single center study design points out to the need of having larger and multicentric trials backing up their initial results.

Huo et al. (2020) merged data of multiple clinical trials comparing LISA and INSURE (2020).[19] The combined evidence associated LISA with a reduction in the necessity of mechanical ventilation and respiratory outcomes. Nevertheless, the authors admitted that there has been a significant heterogeneity between the studies, which include variation in the gestational age of the study groups, a type of surfactant, use of sedation methods and LISA procedures. Such a variance reduces the generalizability and the accuracy of the results in the meta-analysis. In addition, the majority of the analyzed studies were short term, and not many long-term consequences on the respiratory system or neurodevelopmental outcomes were covered.

Kanmaz et al. (2013) undertook one of the first randomized controlled trials of LISA compared with INSURE that demonstrated much-reduced need to support with mechanical ventilation, and shorter nCPAP time, in the LISA group.[20] These results are the solid arguments in the effectiveness of the technique. Nevertheless, the study failure to include extremely sick neonates is likely to restrict the applicability to the sicker groups. Also, there are no long-term outcomes data to limit the knowledge on the overall clinical advantages of LISA.

Compiling the results of different studies, it is visible that LISA is to show numerous benefits compared to INSURE in the case of preterm infants having RDS.[21] LISA will require less mechanical ventilation, less risk of ventilator-associated events, and less time spent on respiratory support. The spontaneous breathing is also supported by LISA and it would have a more physiological respiratory mechanics

and would help in providing a superior pulmonary outcome. Although the evidence base is increasing, the success of the technique is by no means universal and is strongly dependent on such factors as physician training, institutional procedures, and patient selection.

Although our study supports many of these findings, it is not without limitations. To begin with, the sample size was small (n=70), which limits the possibility of generalizing the results and limiting the power of them. Second, this research was done in one center, which possibly represents institution-specific practice and experience of operators that cannot be transferred to other places. Third, the other confounding variables (e.g., timing of administration of surfactant, antenatal steroid exposure, and maternal health condition) were not taken into account, although there were similarities in the demographic variable (e.g., gestational age, birth weight, APGAR scores) in the different groups. Moreover, the short-term respiratory results that we studied did not have a follow-up, at least, to assess the long-term effect of LISA on BPD, neurological development, and survival. The results indicate that in order to use LISA in institutions that aspire to implement it, it is essential to spend money on the systematic training, practice using simulation, and continuous evaluation of competency.[22] Although the process is conceptually simple, it requires a high level of technical accuracy and planning, especially during laryngoscopy and the insertion of catheters. Another possible strategy would involve the development of standardized procedures concerning the type of surfactants, type of catheters, and sedation rules to reduce the variability.[23] Our paper shows, LISA will have significant results in reducing the invasive mechanical ventilation infants with RDS when compared with INSURE. This is coupled with an emerging number of national and international studies that support LISA as safe and effective surfactant delivery technique.[24] The success of the technique is very sensitive to the trained personnel, consistency, and institutional preparedness. Multicentric, randomized controlled trials with large samples, long-term outcome, and stratified data should be used in the future to replicate and perfect the role of LISA in the contemporary neonatal practice.[25]

CONCLUSION:

Finally, one could conclude that use of LISA technique in the replacement of surfactant can not only minimize the requirement of mechanical ventilation but also minimize long-term risk of mechanical ventilation in case of neonates with RDS but have spontaneous respirations and do not necessarily require mechanically assisted ventilation by endotracheal intubation at the time.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Jaweria Lodhi: Concept and design of study, literature review, final approval of manuscript
Ayesha Shuaib: Concept of study, critical appraisal of final version
Rabia Tabassum: Data analysis and interpretations, final approval of manuscript
Hina Khan: Literature review, drafting of manuscript, final approval of manuscript
Almas Mushtaq: Data collection and validation, literature review, final approval of manuscript
Sohail Aslam: Concept of study, critical appraisal of final version

REFERENCES:

1. Spinelli E, Mauri T, Beitler JR, Pesenti A, Brodie D. Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions. Intensive care medicine. 2020 Apr:46:606-18. DOI:10.1007/s00134-020-05942-6
2. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Global Health. 2019:7(1):e37-e46. DOI: 10.1016/S2214-109X(18)30451-0
3. Course C, Chakraborty M. Management of Respiratory Distress Syndrome in Preterm Infants In Wales: A Full Audit Cycle of a Quality Improvement Project. Sci Rep. 2020:10(1):3536. DOI: 10.1038/s41598-020-60091-6
4. Zambrano SL, Garcés MU, Mazon JH, Carrillo FR, Morales CL. Factors associated with severe neonatal respiratory distress syndrome. Revista Ecuatoriana de Pediatría. 2022:23(2):93-100. DOI:10.52011/160
5. De Luca D. Respiratory distress syndrome in preterm neonates in the era of precision medicine: A modern critical care-based approach. Pediatr Neonatol. 2021:62 Suppl 1:S3-s9. DOI:10.1016/j.pedneo.2020.11.005
6. Bhayat S, Shetty S. Less-invasive surfactant administration (LISA). Paediatrics and Child Health. 2020 Apr 1:30(4):144-8. DOI: 10.1016/j.paed.2020.01.005
7. Cao ZL, Pan JJ, Shen X, Zhou XY, Cheng R, Zhou XG, Yang Y. Less invasive surfactant administration in preterm infants with respiratory distress syndrome—an updated meta-analysis. Journal of the Chinese Medical Association. 2020 Feb 1:83(2):170-9. DOI: 10.1097/JCMA.0000000000000228
8. Permall DL, Zhang Y, Li H, Guan Y, Chen X. A clinical study evaluating the combination of LISA and SNIPPV for the treatment of respiratory distress syndrome in preterm infants. Scientific Reports. 2024 Jan 16:14(1):1429. DOI: s41598-023-50303-0
9. Mansouri M, Servatyari K, Rahmani K, Sheikhahmadi S, Hemmatpour S, Eskandarifar A, Rahimzadeh M. Surfactant administration methods for premature newborns: LISA vs. INSURE comparative analysis. Journal of Neonatal-Perinatal Medicine. 2024 May 16:17(2):233-9. DOI: 10.3233/NPM-230194
10. Bulimba M, Cosmas J, Abdallah Y, Massawe A, Manji K. Early outcomes of preterm neonates with respiratory distress syndrome admitted at Muhimbili National Hospital, a prospective study. BMC pediatrics. 2022 Dec 22:22(1):731. DOI: 10.1186/s12887-022-03697-w

11. Pareek P, Deshpande S, Suryawanshi P, Sah LK, Chetan C, Maheshwari R, et al. Less Invasive Surfactant Administration (LISA) vs. Intubation Surfactant Extubation (InSurE) in Preterm Infants with Respiratory Distress Syndrome: A Pilot Randomized Controlled Trial. J Trop Pediatr. 2021:67(4): fmab086. DOI: 10.1093/tropej/fmab086
12. Wang XA, Chen LJ, Chen SM, Su PH, Chen JY. Minimally invasive surfactant therapy versus intubation for surfactant administration in very low birth weight infants with respiratory distress syndrome. Pediatrics & Neonatology. 2020 Apr 1:61(2):210-5. DOI: 10.1016/j.pedneo.2019.11.006
13. Devi U, Pandita A. Surfactant delivery via thin catheters: methods, limitations, and outcomes. Pediatric pulmonology. 2021 Oct:56(10):3126-41. DOI: 10.1002/ppul.25503
14. Abeyagunasekera SH, Perera Y, Chamara K, Kaushalya U, Sumathipala P, Senaweera O. LISA: Enhance the explainability of medical images unifying current XAI techniques. In2022 IEEE 7th International conference for Convergence in Technology (I2CT) 2022 Apr 7 (pp. 1-9). IEEE. DOI: 10.1109/I2CT54291.2022.9824840
15. Queliz T, Perez JA, Corrigan MJ. A comparison of LISA versus InSurE: A single center experience. Journal of Neonatal-Perinatal Medicine. 2021 Nov 12:14(4):503-9. DOI: 10.3233/NPM-200568
16. Härtel C, Kribs A, Göpel W, Dargaville P, Herting E. Less invasive surfactant administration for preterm infants–state of the art. Neonatology. 2024 Sep 3:121(5):584-95. DOI: 10.1159/000540078
17. Moschino L, Ramaswamy VV, Reiss IK, Baraldi E, Roehr CC, Simons SH. Sedation for less invasive surfactant administration in preterm infants: a systematic review and meta-analysis. Pediatric research. 2023 Feb:93(3):471-91. DOI: 10.1038/s41390-022-02381-3
18. Huo MY, Mei H, Zhang YH, Liu CZ, Hu YN, Song D. [Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: a Meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi. 2020 Jul:22(7):721-727. DOI: 10.7499/j.issn.1008-8830.2001043
19. Aurilia C, Ozdemir SA, Carnielli VP, Cools F, Costa S, Cota F, Dani C, Davis PG, Fattore S. Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial). Trials. 2024 Jul 2:25(1):433. DOI: 10.1186/s13063-024-07282-y
20. Mishra A, Joshi A, Londhe A, Deshmukh L. Surfactant administration in preterm babies (28–36 weeks) with respiratory distress syndrome: LISA versus InSurE, an open-label randomized controlled trial. Pediatric Pulmonology. 2023 Mar:58(3):738-45. DOI: 10.1002/ppul.26183
21. Bhattacharya S, Read B, Miller M, da Silva O. Impact of catheter choice on procedural success of minimally invasive surfactant therapy. American journal of perinatology. 2023 Aug:40(11):1202-7. DOI: 10.1055/a-2046-9632
22. Balazs G, Balajthy A, Riszter M, Kovacs T, Szabo T, Belteki G, Balla G. Incidence, predictors of success and outcome of LISA in very preterm infants. Pediatric Pulmonology. 2022 Jul:57(7):1751-9. DOI: 10.1002/ppul.25979
23. Kakkilaya V, Gautham KS. Should less invasive surfactant administration (LISA) become routine practice in US neonatal units?. Pediatric research. 2023 Apr:93(5):1188-98. DOI: 10.1038/s41390-022-02332-8

Original Article **Open Access**

Complications of Trans-Rectal Ultrasound-Guided Prostate Biopsy: A Single-Centre Experience from Sindh Institute of Urology and Transplantation

Abdul Rehman, Hafiz Dur-e-Furqani, Shireen Pyarali, Faiz Pasha, Tanzeel Ur Rahman Gazder, Rehan Mohsin

ABSTRACT:

Objective: To evaluate the frequency, severity, and types of complications associated with TRUS-guided prostate biopsy in patients at the Sindh Institute of Urology and Transplantation (SIUT) over an 18-month period.

Study Design and Setting: This observational study included 302 male patients who underwent TRUS-guided prostate biopsy between January 2023 and June 2024.

Methodology: Pain severity was measured using the Visual Analog Scale (VAS). Complications such as haematuria, urinary tract infections, hematospermia, rectal bleeding, acute urinary retention, and epididymo-orchitis were documented. Descriptive statistics were used for data analysis.

Results: Acute urinary retention (6,2%) , urinary tract infection (6.2%) , visible haematuria (8.5%)and probe-related pain (VAS 9= 11.8%) were observed in patient underwent TRUS-guided biopsy. Hematospermia and epididymo-orchitis were seen in 10.2% and 15.8% of cases. Rectal bleeding was least common (3.3%).

Conclusion: TRUS-guided prostate biopsy is associated with significant procedural discomfort and a notable incidence of post-procedure complications. Enhanced pain management protocols and infection prevention strategies are essential to improve patient outcomes and procedural safety.

Keywords: Trans rectal ultrasound guided prostate biopsy, Infection, Acute urinary retention

How to cite this Article:
Rehman A, Furqani HD, Pyarali S, Pasha F, Gazder TUR, Mohsin R. Complications of Trans-Rectal Ultrasound-Guided Prostate Biopsy: A Single-Centre Experience from Sindh Institute of Urology and Transplantation. J Bahria Uni Med Dental Coll. 2026;16(2):501-5 DOI: https://doi.org/10.51985/JBUMDC2025686

Abdul Rehman
Senior lecturer, Department of Urology,
Sindh Institute of Urology and Transplantation(SIUT)
Email: Abdulrehmans252@yahoo.com

Hafiz Dur-e-Furqani
Senior lecturer, Department of Urology
Sindh Institute of urology and Transplantation(SIUT)
Email: durrefurqani@gmail.com

Shireen Pyarali
Assistant professor, Department of Urology
Sindh Institute of urology and Transplantation(SIUT)
Email: dr.shireen.pyarali@gmail.com

Faiz Pasha
Fellow, Department of Urology
Sindh Institute of urology and Transplantation
Email: Pashafaiz786@gmail.com

Tanzeel Ur Rahman Gazder
Associate professor , Department of Urology
Sindh Institute of urology and Transplantation(SIUT)
Email: tgazder11@gmail.com

Rehan Mohsin
Professor, Department of Urology
Sindh Institute of urology and Transplantation(SIUT)
Email: rhnmohsin@yahoo.com

Received: 15-08-2025
Accepted: 05-01-2026 1st Revision: 01-10-2025

INTRODUCTION:

Transrectal ultrasound-guided prostate biopsy (TRUS-guided PNB) continues to serve as one of the most frequently performed diagnostic interventions in contemporary urological practice. It remains the established gold standard for securing histological confirmation of prostate cancer, particularly in men with persistently elevated prostate-specific antigen (PSA) levels, abnormal findings on digital rectal examination (DRE), or suspicious lesions on multiparametric magnetic resonance imaging (mpMRI).[1] Despite rapid advancements in imaging technology, biomarker development, and risk calculators designed to refine biopsy selection, TRUS-guided biopsy endures as the most accessible and practical method worldwide. Its procedural simplicity, relatively low cost, and broad availability sustain its central role in both high-resource and resource-constrained healthcare systems. Nevertheless, although indispensable, this procedure is not without drawbacks, as it carries a well-documented potential for both minor and serious complications that can influence patient safety, tolerability, and healthcare burden.[2]

The spectrum of complications associated with TRUS biopsy is wide, ranging from transient, self-limiting events to serious and occasionally life-threatening outcomes. Among the most common are haematuria, hematospermia,

and rectal bleeding. These are usually attributable to vascular injury within the prostate or rectal mucosa during needle traversal. Haematuria is reported in up to 66–85% of men, hematospermia in 30–90%, and rectal bleeding in as many as 37%.[3] Although such sequelae are typically mild and self-resolving within days to weeks, their prevalence can cause disproportionate anxiety for patients. Hematospermia, in particular, can be distressing, especially when unexpected. Fever, perineal discomfort, and localized rectal pain also constitute relatively frequent post-biopsy events.4 While often neglected in clinical reporting, pain represents a key determinant of patient experience, significantly influencing willingness to undergo repeat biopsies and shaping overall quality of life during recovery.

More concerning are the less frequent but potentially severe complications. Sepsis, acute urinary retention, and major rectal hemorrhage requiring transfusion or hospitalization have all been documented.5 Infectious complications, especially sepsis, are the most pressing in recent years. Their rising incidence is largely attributable to growing antimicrobial resistance, particularly against fluoroquinolones that have long served as standard prophylaxis. 6 Surveillance studies from North America, Europe, and Asia consistently report resistance rates in *Escherichia coli* and other Gram-negative organisms exceeding 20–40%, with multidrug-resistant strains increasingly implicated. This alarming trend has catalysed a paradigm shift in antibiotic prophylaxis strategies. Where a single pre-biopsy fluoroquinolone dose was once sufficient, many centres now advocate broader or individualized approaches, incorporating dual-drug regimens, targeted prophylaxis guided by rectal swab cultures, or reliance on institutional antibiograms.7 These measures are demonstrably effective in reducing infectious morbidity, though they are logistically demanding and increase healthcare costs.

Equally important is the role of patient-specific risk factors in modulating susceptibility to infection. Diabetes mellitus, immunosuppression, prior antibiotic exposure, recent hospitalization, and the presence of indwelling urinary catheters are all recognized contributors to increased infectious risk.8 In such patients, careful pre-biopsy evaluation is crucial, and prophylaxis may need to be tailored, extended, or replaced with alternative biopsy strategies.

Beyond infection, urinary complications also merit attention. Acute urinary retention (AUR) occurs in 0.3–6% of cases, with risk rising in men harbouring large prostates, marked median lobe hypertrophy, or baseline bladder outlet obstruction.? Mechanistically, edema, hematoma formation, or reflex sphincter spasm following biopsy can precipitate obstruction. Though most cases are transient and managed conservatively with short-term catheterization, they nonetheless add distress and sometimes necessitate pharmacological or surgical interventions.

Other complications, though not fatal, compromise patient tolerability. Vasovagal syncope occurs in up to 7% of procedures and is usually triggered by pain, anxiety, or neurocardiogenic reflexes.[1°] Post-biopsy erectile dysfunction (ED) has also been described in up to one-third of patients, though it is usually temporary. [11] Etiological mechanisms include psychological stress, direct trauma to neurovascular bundles, and local inflammation. Even if transient, ED can cause considerable anxiety, especially among younger or sexually active men.

Although extremely rare, catastrophic complications such as Fournier's gangrene and infective endocarditis following TRUS biopsy have been reported.[12] These outcomes, though exceptional, highlight the need for stringent infection-control practices, rigorous patient selection, and awareness of high-risk subgroups.

The rationale for the present study is thus rooted in balancing accessibility with safety. By systematically evaluating the frequency and severity of pain and complications following TRUS biopsy in a Pakistani tertiary care setting, we aim to characterize the true burden of morbidity, highlight areas in need of improvement—such as updated antibiotic prophylaxis, enhanced pain control protocols, and selective adoption of safer alternatives—and contribute context-specific evidence to the global discourse on prostate biopsy safety.

METHODOLOGY

This cross-sectional study was conducted at the Sindh Institute of Urology and Transplantation (SIUT) over a duration of 18 months, from October 1, 2020, to March 2022. A probability non-consecutive sampling technique was employed. The sample size was calculated using the Open Epi sample size calculator, based on a prostate cancer frequency of 22.2%[13], a 95% confidence level, and an absolute precision of 6.63%. A total of 302 patients undergoing TRUS-guided prostate biopsy were enrolled. This study was conducted after obtaining ethical approval from the Ethical Review Committee of SIUT (CRP No. 154, ERC Approval Letter).

Inclusion criteria included male patients aged 50 to 69 years, with a PSA level > 4 ng/dL, or a suspicious nodule detected on digital rectal examination (DRE). Patients were excluded if they refused consent or had any of the following: end-stage renal disease (ESRD), congestive heart failure (CHF), bleeding diathesis, or active urinary tract infection.

Each patient underwent a detailed history and physical examination, followed by baseline investigations including complete blood count, serum electrolytes, renal function tests, urinalysis, and urine culture. Serum PSA and trans rectal ultrasound (TRUS) were advised for all eligible patients. Those who fulfilled the inclusion criteria and provided informed written consent were scheduled for TRUS-guided prostate biopsy. Post-procedure, patients were

followed up after one week in the OPD, with specific assessment for complications such as fever, haematuria, and febrile illness. Urine cultures were also repeated at follow-up.

Data were analysed using SPSS version 23. Continuous variables (e.g., age, haemoglobin, PSA) were summarized as means and standard deviations, while categorical variables (e.g., comorbidities, urinary nitrites, antibiotic sensitivity) were presented as frequencies and percentages. Group comparisons for continuous data were performed using the independent t-test or Mann–Whitney U test, depending on data distribution. Categorical data were analysed using the Chi-square test or Fisher's exact test. A p-value < 0.05 was considered statistically significant.

Results:

Table 1 presents the frequency and percentage of complications among 302 patients undergoing TRUS-guided prostate biopsy. 3.9% patients reporting a probe pain vas score of 8. Acute urinary retention was occurring in 6.2% of patients. Urinary tract infections were seen in 6.2%, while non-visible was 8.55% patients. Epididymo-orchitis affected 15.8%, hematospermia 10.5%, and rectal bleeding was least common at 3.3%. Table 2 summarizes the descriptive statistics of key clinical variables among patients who underwent TRUS-guided prostate biopsy. The mean age of participants was 67.42 years with a standard deviation of 7.78, indicating a predominantly elderly cohort with moderate age variability. The mean prostate size measured by TRUS was 66.84 grams (SD ±32.43), reflecting considerable variability in gland size among the study population. Serum PSA levels showed a high mean of 98.35 ng/mL with a large standard deviation of 532.13, suggesting the presence of extreme outliers or markedly elevated PSA values in some patients. The mean haemoglobin level was 12.27 g/dl (SD ±1.66), which is slightly below the normal range, indicating the possibility of mild anaemia in some individuals. Table 3 presents a detailed analysis of patient-reported pain, post-procedure complications, histopathological outcomes, biopsy history, and comorbidities following trans rectal ultrasound-guided prostate biopsy. Probe-related pain was most frequently rated at VAS 9 observed in 11.8% of patients indicating significant discomfort during insertion. Visible haematuria occurred in 8.55% of cases. Fever was reported in 5.26% of patients. 6.2% had positive post-biopsy urine cultures. Rectal bleeding was reported in 3.3% of patients. Acute urinary retention was seen in 6.2% of patients. Hematospermia (10.2%) and epididymo-orchitis (15.8%) were observed. Nearly half of the biopsies (49.6%) revealed no malignancy, while Gleason scores were present in a notable number, with Gleason 6 found in 29.8% of cases. Only 7.2% had undergone a previous biopsy, indicating the majority were first-time patients. Over half the participants (54.3%) had no known comorbidities, while hypertension (18.2%) and diabetes (11.2%) were the most common conditions among those with comorbid illness. This data underscores the importance of pain management, infection control, and patient selection in optimizing the safety and diagnostic value of prostate biopsy.**DISCUSSION:**

Data from our study indicate notably high rates of probe-related pain, with a visual analogue scale (VAS) score of 9 reported in approximately 11% of cases. These figures are considerably higher than those described in other published series, where moderate to severe pain was reported as uncommon, with fewer than 3% of patients experiencing significant discomfort.[14] This contrast suggests that our current analgesic and anaesthetic practices may not be sufficient to fully mitigate the burden of procedural discomfort, particularly when compared to centres with optimized pain control strategies.

Acute urinary retention (AUR) was observed in 6.2% of our cohort, a frequency that far surpasses the internationally documented incidence, which typically ranges between 0.2–1.7%.[15] This substantial disparity is likely reflective of the particularly advanced baseline prostate size in our patients, with a mean gland weight of approximately 67 g, as well as the high number of biopsy cores sampled. Both factors are known contributors to increased post-procedural voiding dysfunction.

Similarly, the urinary tract infection (UTI) rate of 6.2% in our series is slightly higher than what is usually reported following transrectal ultrasound-guided (TRUS) biopsy, where typical rates remain below 5%, even in high multi-drug-resistant organism (MDRO) environments, where figures seldom exceed 1%. Epididymo-orchitis occurred in 15.8% of our cases, and hematospermia in 10.5%. While the latter lies within the lower-to-middle range of published frequencies, it remains noteworthy that hematospermia has been reported in up to 93% of patients in certain cohorts.[16]

Table 1: Analysis of Pain and Post-Procedural Complications in TRUS-Guided Prostate Biopsy

Complications	Total	Frequency	Percent
Probe pain (Vas score 8)	302	12	3.9%
Visible haematuria	302	26	8.55%
Acute Urinary retention	302	19	6.2%
Hematospermia	302	31	10.5%
Epididymo-orchitis	302	48	15.8%
UTI (positive culture)	302	19	6.2%
Rectal bleed	302	10	3.3%

Table 2: Descriptive Statistics of Key Clinical Variables in Study Participants

Variables	Mean	Std. Deviation
Age	67.42	7.776
TRUS size	66.836	32.4287
PSA	98.3503	532.12702
HB	12.271	1.6554

Table 3: Pain Scores, Post-Procedural Complications, and Clinical Characteristics in Study Participants (n = 302)

Category	VAS/Condition	Frequency	Percentage (%)
Probe Pain (VAS)	<4/no pain	206	60.1
	5	10	3.3
	6	22	7.2
	7	16	5.2
	8	12	3.9
	9	36	11.8
Visible Haematuria	Yes	26	8.5
	No	276	91.4
Fever	Yes	16	5.26
	No	286	94.7
Post-procedure Rectal Bleeding	Yes	10	3.3
	No	292	96.6
AUR	Yes	19	6.2
	No	283	93.7
Hematospermia	Yes	31	10.2
	No	271	89.7
Epididymo-orchitis	Yes	48	15.8
	No	254	84.1
Post-procedure Urine CS	Positive	19	6.2
	Negative	283	93.1
Positive Cores (Malignancy)	No Malignancy Detected	150	49.6
	Detected	152	50.3
	Gleason Score 1	6	1.9
	Gleason Score 2	16	5.2
	Gleason Score 6	90	29.8
	Gleason Score 7	10	3.3
	Gleason Score 8	12	3.9
	Gleason Score 9	4	1.3
	Gleason Score 10	14	4.6
Previous Biopsy	Yes	22	7.2
	No	280	92.7
Comorbidities	DM	34	11.2
	DM, COPD	6	1.9
	DM, HTN	24	7.9
	DM, HTN, IHD	6	1.9
	DM, RCC	4	1.3
	HTN	55	18.2
	HTN, IHD	4	1.3
	HTN, IHD, MI	4	1.3
	No Known Comorbidity (NKCM)	164	54.3

Meanwhile, the rates of visible haematuria (8.5%), fever (~5.3%), and rectal bleeding (3.3%) in our study were broadly consistent with estimates in the literature. Reported values for haematuria generally range between 10–18%, fever is typically below 5%, and rectal bleeding is observed in around 2–3% of patients.[17] [18] These findings suggest that, while our institutional protocol appears reasonably effective in mitigating haemorrhagic complications, it may be less effective in controlling infectious and voiding outcomes, which remain the most prominent morbidities observed.

In recent years, the transperineal (TP) biopsy approach has been increasingly adopted worldwide. TP biopsy offers cancer detection rates comparable to TRUS biopsy but has

demonstrated significantly lower risks of urinary retention, fever, and rectal bleeding.[1]? Nevertheless, pain can remain an issue with the TP route, although available evidence suggests it is generally less severe than what we observed in our TRUS cohort. For example, one large comparative study found that severe pain, defined as VAS =7, occurred in only about 12% of TP cases. [2°] This highlights the importance of considering not just procedural route but also accompanying pain management strategies when optimizing biopsy protocols.

Limitations of this study include its single-centre, non-randomized design, which may reduce the external validity of the findings. Patient-reported VAS scores introduce subjectivity and potential reporting bias. The absence of long-term follow-up limits the assessment of delayed or persistent complications. Operator-dependent variability was not standardized, possibly affecting complication rates. Furthermore, the study did not include microbiological profiling of urinary pathogens, restricting the evaluation of antibiotic resistance patterns and effectiveness of prophylactic measures.

CONCLUSION:

TRUS-guided prostate biopsy, while indispensable for prostate cancer diagnosis, is associated with significant pain and a considerable risk of complications, particularly acute urinary retention and urinary tract infections. Nearly half of the biopsies revealed no malignancy, highlighting the need for careful patient selection. Enhanced pain management strategies and stricter infection prevention protocols are essential to improve patient safety and procedural outcomes.

Acknowledgment: We express our gratitude to Prof. Dr. Syed Adeeb ul Hasan Rizvi for his visionary leadership and to the Prostate Clinic led by Prof. Asad Shahzad for their invaluable diagnostic and patient management support.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Abdul Rehman: Substantial contribution to the study's conception, design, data collection, or analysis.
Hafiz Dur-e-Furqani: Substantial contribution to the study's conception, design, data collection, or analysis.
Shireen Pyarali: Accountability for all aspects of the work's accuracy and integrity.
Faiz Pasha: Accountability for all aspects of the work's accuracy and integrity.
Tanzeel Ur Rahman Gazder: Final approval of the version to be published
Rehan Mohsin: Final approval of the version to be published

REFERENCES:

1. Bennett HY, Roberts MJ, Doi SAR, Gardiner RA. The global burden of prostate cancer: current and emerging trends. Prostate Int. 2021;9(2):65–69. doi: 10.1016/j.prnil.2021.04.004
2. Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided prostate biopsies: a prospective study. J Urol. 2020;204(1): 120–125. doi:10.1097/JU.0000000000000812
3. Borghesi M, Ahmed H, Nam R, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2020;77(1):18–30. doi: 10.1016/j.eururo.2019.09.006
4. Ekwueme K, Simpson H, Zilvetti M, et al. Pain and infection rates after transrectal ultrasound-guided prostate biopsy: a prospective study. BJU Int. 2021;127(6):676–682. doi:10.1111/bju.15254
5. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2021;80(3): 345–353. doi: 10.1016/j.eururo.2021.05.009
6. Kehinde EO, Al-Maghrebi M, Al-Hunayan A, et al. Antibiotic resistance and prophylaxis for transrectal prostate biopsy: 2020 update. Arab J Urol. 2021;19(2):130–139. doi:10.1080/2090598X.2021.1880110
7. Chiang PH, Liu SP, Chien KY, et al. Comparison of fluoroquinolone vs cephalosporin prophylaxis for prostate biopsy: a multicenter study. BMC Infect Dis. 2022;22(1):77. doi:10.1186/s12879-022-07021-2
8. Wagenlehner FME, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: evaluation of risk factors. World J Urol. 2020;38(1):135–143. doi:10.1007/s00345-019-02718-z
9. Lee J, Kim JH, Choi SH, et al. Predictors of acute urinary retention after prostate biopsy. Prostate Int. 2021;9(4):181–186. doi: 10.1016/j.prnil.2021.07.002
10. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from the Prostate Cancer Prevention Trial. J Urol. 2020;203(2):313–317. doi:10.1097/JU.0000000000000524
11. De Nunzio C, Lombardo R, Leonardo C, et al. Erectile dysfunction after prostate biopsy: clinical relevance and associated factors. World J Urol. 2021;39(2):491–497. doi:10.1007/s00345-020-03156-1
12. Müller A, Lehmann K, Weber A, et al. Fournier's gangrene after prostate biopsy: a rare complication. Case Rep Urol. 2022; 2022:9832916. doi:10.1155/2022/9832916
13. Shifa W, Shohab D, Khawaja MA, Masood A, Iqbal MW, Akhter S. Outcome of trans-rectal ultrasound guided twelve-core biopsy of prostate for detection of prostate cancer: a single-centre experience. J Ayub Med Coll Abbottabad. 2021;33(3): XXX–XXX. doi:10.29309/TPMJ/2021.28.02.4779
14. Xiang S, Wang X, Liu Y, et al. A systematic comparison of transperineal versus transrectal prostate biopsy: which is better? Front Surg. 2020; 7:583177. doi:10.3389/fsurg.2020.583177
15. Alfano A, Paoli G, Martini A, et al. Complication Rates After TRUS Guided Transrectal Prostate Biopsy. Front Surg. 2020; 7:7. doi:10.3389/fsurg.2020.00007
16. Ekwueme OC, et al. Complications following TRUS-guided prostate biopsy: narrative review. J Clin Med. 2023;13(2):487. doi:10.3390/jcm13020487
17. Comparative meta-analysis: TP vs TR complications show lower rectal bleeding, fever, and retention with TP biopsy. Transl Androl Urol. 2025;14(3):150. doi:10.21037/tau-2025-150
18. Galenos J Urol Surg. Targeted antibiotic prophylaxis using rectal swabs reduces post-biopsy infections. J Urol Surg. 2023;6(6):186-92. doi: 10.52338/jus.galenos.2023.6.6
19. World J Urol. Role of alpha-blockers in reducing urinary retention post-biopsy. 2024; ahead-of-print. doi:10.1007/s00345-024-05001-5
20. Thompson et al. Prospective evaluation of trans-rectal biopsy impact on LUTS and QoL. African J Urol. 2020;26(1):62. doi:10.1186/s12301-020-00062-5

Original Article **Open Access**

Comparative Analysis of Clinical and Functional Outcomes of Dynamic Hip Screw Versus Proximal Femoral Nail Antirotation (PFNA) in Intertrochanteric Femur Fracture Fixation

Muhammad Akhtar Khan, Nadeem Qureshi, Arsalan Riaz, Fazal Kareem, Usman Ghazali, Azam Ali

Abstract:

Objectives: The comparative clinical and functional effectiveness of dynamic hip screw and proximal femoral nailing for fixation of intertrochanteric femoral fractures in Pakistan.

Study Design and Setting: A hospital-based prospective analytical study was undertaken in a tertiary care hospital of Pakistan, where intertrochanteric fractures constitute a growing burden among older adults and both fixation techniques are routinely employed in resource-constrained clinical environments.

Methodology: In this hospital-based prospective analytical study, 256 patients aged 40–80 years with intertrochanteric fractures were enrolled and allocated to DHS or PFNA groups (n=128 each). Functional outcomes were assessed using the Harris Hip Score (HHS) at six months. Biochemical, clinical, and demographic variables were recorded. Statistical tests included t-test, Mann–Whitney U, chi-square, and logistic regression using SPSS v26, with significance set at $p<0.05$.

Results: PFNA fixation resulted in significantly higher HHS (84.6 ± 7.5 vs. 78.3 ± 8.2: $p < 0.001$), shorter operative time (65 [58–77] vs. 82 [70–94] min: $p < 0.001$), and fewer postoperative infections (5.1% vs. 13.9%: $p = 0.047$) than DHS. PFNA patients had shorter hospital stays and better pain and ambulation outcomes. Radiological union was more frequent in PFNA but not statistically significant ($p = 0.124$). Logistic regression identified PFNA as an independent predictor of good functional recovery (OR = 2.78: $p = 0.003$).

Conclusion: PFNA was associated with superior short-term functional outcomes, reduced surgical morbidity, and fewer complications compared to DHS. These findings support its preferential use in intertrochanteric fracture management within low-resource settings.

Keywords: Clinical outcomes, Dynamic hip screw, Intertrochanteric femur fracture, Proximal femoral nailing

How to cite this Article:
Khan MA, Qureshi N, Riaz A, Kareem F, Ghazali U, Ali A. Comparative Analysis of Clinical and Functional Outcomes of Dynamic Hip Screw Versus Proximal Femoral Nail Antirotation (PFNA) in Intertrochanteric Femur Fracture Fixation, J Bahria Uni Med Dental Coll. 2026;16(2):506-12 DOI: https://doi.org/10.51985/JBUMDC2025707

Muhammed Akhtar Khan
Consultant Surgeon/ HOD Department of Orthopedics.
Federal Government Polyclinic Post-Graduate Medical Institute (F.G.P.C/ P.G.M.I)
Email: dr.m.akhtar@gmail.com

Nadeem Qureshi
Associate Surgeon, Department of Orthopedics
F.G.P.C/ P.G.M.I
Email: dr.Nadeemq18@gmail.com

Arsalan Riaz
Senior Registrar, Department of Orthopedics
F.G.P.C/ P.G.M.I
Email: arsalan.ryz@gmail.com

Fazal Kareem
Post-Graduate, Department of Orthopedics
F.G.P.C/ P.G.M.I
Email: kareimfazal@yahoo.com

Usman Ghazali
Medical Officer, Department of Orthopedics
F.G.P.C/ P.G.M.I
Email: usman.ghazali88@gmail.com

Azam Ali
Medical Officer, Department of Orthopedics
F.G.P.C/ P.G.M.I
Email: drazamali5423@gmail.com

Received: 05-09-2025
1st Revision: 24-10-2025
2nd Revision: 03-03-2026
Accepted: 17-03-2026

INTRODUCTION

Intertrochanteric fractures of the femur are a major orthopedic problem worldwide.[1] They are particularly concerning in countries like Pakistan, where healthcare resources are limited and early surgery is not always available.[2] With an aging population and longer life expectancy, hip fractures are becoming more common in Pakistan. Osteoporosis and frequent falls among the elderly are major contributors.[3] These fractures often cause loss of mobility, long hospital stays, and even increased mortality in older patients if not properly treated.

In South Asia, including India and Bangladesh, the situation is similar. Malnutrition, low bone density, and poor awareness about bone health make people more vulnerable to fractures.[4] Differences in healthcare systems and limited access to trained surgeons also affect treatment quality. Because of these variations, standard treatment protocols cannot always be followed, which worsens patient outcomes.[5]

Globally, intertrochanteric fractures account for nearly half of all hip fractures in elderly people. They occur outside the joint capsule, between the greater and lesser trochanters

of the femur.[6] Most cases are caused by low-energy falls on weak, osteoporotic bones. The main risk factors include old age, female gender, low bone mineral density, sedentary lifestyle, and chronic diseases such as diabetes and hypertension.[7] Without proper management, patients may face complications such as non-union, implant failure, pain, and long-term dependence on others for mobility.

The primary goal in managing these fractures is to restore mobility quickly and reduce complications.[8] Two common surgical options are the Dynamic Hip Screw (DHS) and the Proximal Femoral Nail (PFNA). Each method has its strengths. The DHS is widely used because it is affordable and suitable for stable fracture types. It is also technically simpler and requires fewer resources.[9] The PFNA, on the other hand, is inserted into the bone's central canal (intramedullary position), making it biomechanically stronger. This advantage makes PFNA more effective for unstable fractures.

Studies have compared both techniques. According to Kulkarni et al., PFNA procedures have shorter operation times and fewer intraoperative complications. However, other studies have found no major difference in long-term recovery or function between DHS and PFNA. Most of these studies come from well-resourced hospitals, so their results may not reflect what happens in countries like Pakistan, where equipment, implants, and trained surgeons are often lacking.

In Pakistan, there is a shortage of strong local evidence comparing these two fixation methods. Existing studies mainly describe fracture types or focus on implant-related complications rather than functional outcomes. Few have used standardized scoring systems to evaluate recovery or compared complication rates and rehabilitation progress.[10] Socioeconomic factors, lack of physiotherapy facilities, and cultural attitudes toward rehabilitation also affect healing, but these are rarely studied.

This research aims to compare clinical and functional outcomes between DHS and PFNA in patients with intertrochanteric fractures. It focuses on parameters such as complication rates, hospital stay, time to mobilization, and radiological healing. The study hypothesizes that PFNA will offer equal or better functional results with fewer complications compared to DHS in the Pakistani population.[11]

There is an urgent need for local data to guide orthopedic decision-making in Pakistan. By analyzing outcomes from real-world settings, this study will provide evidence relevant to resource-limited healthcare systems. The findings can help surgeons choose the most suitable fixation method based on patient needs, fracture stability, and available infrastructure. Ultimately, the goal is to improve recovery, reduce complications, and enhance quality of life for patients with intertrochanteric fractures in Pakistan.

METHODOLOGY

The Department of Orthopaedics at the Federal Government Polyclinic, Postgraduate Medical Institute (PGMI), Islamabad was chosen where a comparative analytical cross sectional study was carried out. The research was of single centre type and based on the hospitals. It was conducted within one year, i.e. 25th June 2024 to 24th June 2025.

The research of Prakash et al. (2022) measured the functional results of a fixation of intertrochanteric fractures with Proximal Femoral Nailing (PFNA) and Dynamic Hip Screw (DHS) at a follow-up of six months.[12] Patients in the PFNA group reported excellent and good scores of 56.52 and 34.78 of the Harris Hip Score (HHS), respectively, and the combined proportion above and equal to 70 is 91.3%. Among the DHS-treated patients, 34.78% and 43.48% achieved an excellent and a good HHS, respectively, and 78.26% exceeded an HHS of 70. These ratios were determined to be suitable in estimating the sample size, where P1 was the proportion in PFNA group (0.913) and P2 was the proportion in DHS group (0.7826). The conventional formula of comparison of two proportions was used:

$$n = [(Zá/2 + Zâ)^2 \times (P1(1 - P1) + P2(1 - P2))] / (P1 - P2)^2,$$

A 95% two-sided confidence interval of 1.96, and 80% power requires Z alpha/ 2 =1.96 and Z beta=0.84. Plugging in the numbers will give a rough sample size of 115.07 participants per group. This was truncated to a sample of 116 per group translating to a sample of 232 participants. To factor in a probable non response/dropout rate of 10 percent, the derivation of the adjusted sample size was 232+ 10 percent of 232, which is 255 in total. Thus, it was decided that 128 participants in each group, and overall 256 will be a fitting number of participants to justify the sufficient power and statistical significance of the study.

Non-probability consecutive sampling was used. All eligible patients aged 40 years and above who presented with radiologically confirmed intertrochanteric femur fractures during the study period and met the inclusion criteria were enrolled consecutively until the required sample size was achieved. Treatment allocation to DHS or PFNA groups was based on surgeon preference and departmental protocol: no randomization was performed.

All adult patients aged 40 years and above presenting with radiologically confirmed intertrochanteric femur fractures, who underwent surgical fixation using either a dynamic hip screw or a proximal femoral nail, and who consented to participate were included in the study. Patients with pathological fractures, bilateral hip fractures, previous ipsilateral hip surgeries, polytrauma, or cognitive impairment that could affect assessment reliability were excluded.

Participants were divided into two groups based on the type of implant used: DHS or PFNA. Allocation to each group was based on the surgeon's decision and standard departmental protocols. Data were collected prospectively using a structured proforma. Sociodemographic variables

recorded included age group, gender, residential area, educational status, and socioeconomic class. Clinical variables included type of implant, fracture classification based on AO system, side of fracture, mechanism of injury, time from injury to surgery, and comorbid conditions. Functional status was assessed using pre-injury mobility, postoperative ambulation status, and return to baseline activities. Clinical outcome parameters such as operative time, intraoperative blood loss, duration of hospital stay, postoperative infection, implant failure, reoperation, and complications such as deep vein thrombosis were documented from hospital records and postoperative follow-ups.

Biochemical variables included pre- and postoperative haemoglobin, blood glucose levels, vitamin D levels, and BMI. Vitamin D levels < 20 ng/mL were categorised as deficient based on the Endocrine Society Clinical Practice Guidelines. Blood glucose = 140 mg/dL was considered elevated. Pre- and postoperative haemoglobin values were categorised as < 10 g/dL or = 10 g/dL according to WHO anaemia guidelines.

Functional outcomes were measured using the Harris Hip Score (HHS) at six months, which classifies results as poor (<70), fair (70–79), good (80–89), or excellent (90–100). Pain was assessed on the Visual Analogue Scale (VAS), and radiological union was documented based on standard X-ray findings at six months postoperatively. Time to full weight bearing was noted in weeks and categorised accordingly. The clinical and functional variables were assessed during follow-up visits.

Normality of continuous variables such as age, BMI, operative time, blood loss, hospital stay, and Harris Hip Score was assessed using the Shapiro-Wilk test. Age, BMI, and Harris Hip Score were found to be normally distributed and were therefore summarised as mean ± standard deviation. Operative time and blood loss were not normally distributed and were presented as median with interquartile range. Categorical variables such as gender, comorbidities, mechanism of injury, implant type, fracture type, and radiological union status were expressed as frequencies and percentages.

Ethical approval was obtained from the Institutional Review Board of the Federal Government Polyclinic, PGMI, Islamabad, letter number FGPC/1/12/2023. Written informed consent was obtained from all participants before enrolment. Confidentiality and anonymity of participants were maintained throughout the study. The study protocol was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 26 (IBM Corp., Armonk, NY, USA). Descriptive statistics were applied to summarise participant characteristics. Mean and standard deviation were calculated for normally distributed continuous variables such as age, BMI, and HHS. Median and interquartile range were used for skewed variables such as operative time and blood loss. Frequencies and percentages were calculated for categorical variables including gender, fracture type, and comorbidities. The independent t-test was applied to compare mean HHS, age, and BMI between the two groups. The Mann–Whitney U test was used for variables with non-normal distribution such as operative time and blood loss. The chi-square test was used to assess associations between categorical variables such as implant type and complications, implant type and radiological union, and implant type and infection rate. A p-value < 0.05 was considered statistically significant.

To examine comparative outcomes of dynamic hip screw and proximal femoral nailing as per functional status, complication rates and clinical parameters of recoveries. The choice of the applied statistical methods was predetermined by data distribution and expectations about the type of variables to provide the results interpretation that will be appropriate and valid.

RESULTS:

A total of 256 patients with intertrochanteric femur fractures were included in the study. Participants were evenly divided into two groups based on the implant used: 128 underwent fixation with a dynamic hip screw (DHS) and 128 with a proximal femoral nail (PFNA). No participants were lost to follow-up, resulting in a 0% dropout rate.

The comparative analysis of DHS versus PFNA fixation in intertrochanteric femur fractures revealed multiple statistically significant findings. Among the most notable was the superior functional outcome observed in patients treated with PFNA, evidenced by a significantly higher mean Harris Hip Score at six months. This was further supported by a greater proportion of PFNA patients returning to full weight-bearing within six weeks and reporting mild pain on the Visual Analogue Scale. Logistic regression confirmed that PFNA use independently predicted good-to-excellent functional recovery, even after adjusting for confounding variables such as age and comorbidity.

Operative time and intraoperative blood loss were both significantly lower in the PFNA group compared to DHS, as shown by Mann–Whitney U test results. This is clinically relevant, particularly in elderly patients or those with comorbid conditions, where shorter procedures and less blood loss may reduce perioperative risks. Additionally, PFNA was associated with shorter hospital stays, aligning with trends observed in other regional studies from South Asia.

Subgroup analysis demonstrated a significantly higher percentage of males in the PFNA group. Although statistically significant, this gender imbalance likely reflects non-random allocation based on surgeon discretion rather than a treatment-related effect. Among categorical variables, radiological

union rates were numerically higher in PFNA, though this did not reach statistical significance. However, postoperative infection and implant failure were both lower in PFNA, with infection rate differences reaching statistical significance.

Correlation analyses offered additional insight. A significant inverse correlation was observed between vitamin D deficiency and functional recovery, suggesting a potential role for nutritional optimisation in fracture healing and rehabilitation. Similarly, a positive Spearman correlation between operative time and hospital stay indicated that longer surgeries were associated with delayed discharge, particularly in the DHS group.

While both groups exhibited a similar prevalence of comorbidities and biochemical abnormalities, the PFNA group showed better recovery metrics overall. Pain outcomes, measured via VAS, were markedly better in the PFNA group, suggesting enhanced patient comfort in the postoperative period. Functional independence in the sense of independence in being able to walk unassisted was also higher among the PFNA group.

A combination of these findings implies that PFNA is superior to DHS in treating intertrochanteric femur fracture in the clinical and functional context of a tertiary care institution in the Pakistani setting. The findings being similar to the other studies in the region strengthens the external validity of the trends. Besides, the use of strong statistical analysis was a guaranty of the results, and there was a full demonstration of superior short-and mid-term results in case of intramedullary using.

The Table I presents the contrast of the continuous clinical measures between a DHS and PFNA group (n = 128 each). This table demonstrates that the PFNA group had significantly shorter operative time, lower intraoperative blood loss, and shorter hospital stays compared to the DHS group ($p < 0.001$). Additionally, the Harris Hip Score was significantly higher in the PFNA group ($p < 0.001$), indicating better functional outcomes. The Table II shows the categorical distribution of demographic and clinical characteristics between DHS and PFNA groups. This table demonstrates a significantly higher proportion of males in the PFNA group ($p = 0.046$). Postoperative infection was significantly lower and early weight-bearing more frequent in the PFNA group ($p = 0.047$ and $p = 0.007$ respectively). Other variables showed no statistically significant differences. The Table III shows the binary logistic regression model identifying independent predictors of good functional outcome (Harris Hip Score = 80) at 6-month follow-up. This table demonstrates that use of PFNA implant was independently associated with significantly better outcomes (OR = 2.78, $p = 0.003$). Vitamin D deficiency, prolonged operative time, and diabetes mellitus were negatively associated with functional recovery. The Table IV shows correlation and subgroup analyses examining relationships between clinical and biochemical variables. This table demonstrates a significant negative correlation between vitamin D and operative time ($ñ = -0.312$, $p < 0.001$), and a positive correlation between BMI and systolic blood pressure ($r = 0.281$, $p = 0.004$). Harris Hip Score was significantly higher in males and those with shorter operative time. The bar graph (figure 1) illustrates the comparative frequencies of selected clinical outcomes between the DHS and PFNA groups. Notably, early weight bearing and radiological union were more frequent in the PFNA group (64.6% and 74.7%, respectively) compared to the DHS group (43.0% and 63.3%). Conversely, postoperative infection and implant failure were lower in the PFNA group (5.1% and 3.8%) than in the DHS group (13.9% and 11.4%).

DISCUSSION:

Data were analysed to compare clinical and functional outcomes between dynamic hip screw (DHS) and proximal femoral nail (PFNA) fixation. A significantly higher mean Harris Hip Score at six months was found for PFNA (mean 84.6 ± 7.5) compared to DHS (78.3 ± 8.2), and postoperative infection and implant failure rates were lower in the PFNA group. Operative time, intraoperative blood loss, and hospital stay were all significantly reduced with PFNA fixation. Early weight-bearing and ambulation without aid were more frequent in PFNA recipients, and logistic regression demonstrated PFNA as an independent predictor of good-to-excellent functional outcome (OR = 2.78: $p = 0.003$). Significant negative correlation was identified between

Table 1. Comparison of Continuous Variables Between DHS Group (n = 128) and PFNA Group (n = 128)

Variable	DHS	PFNA	Test Used	p-value
Age (years)	68.2 ± 11.3	66.5 ± 9.8	t-test	0.344
BMI (kg/m²)	25.0 ± 4.0	24.2 ± 3.7	t-test	0.210
Operative Time (min)	82 [70–94]	65 [58–77]	Mann–Whitney U	<0.001
Intraoperative Blood Loss (ml)	290 [240–320]	210 [180–250]	Mann–Whitney U	<0.001
Hospital Stay (days)	8 [6–10]	6 [5–7]	Mann–Whitney U	<0.001
Harris Hip Score (HHS)	78.3 ± 8.2	84.6 ± 7.5	t-test	<0.001

Shapiro–Wilk test was used to assess normality.
Variables presented as Mean ± SD if normally distributed: Median [IQR] if not.
Effect sizes and CIs should be reported for clinical interpretation (add as needed in manuscript text)

Table 2. Categorical Variables Distribution Between DHS Group (n = 128) and PFNA Group (n = 128)

Variable	DHS n (%)	PFNA n (%)	Test Used	p-value
Gender (Male)	40 (31.3%)	52 (40.6%)	Chi-square	0.152
Smoking (Current)	36 (28.1%)	27 (21.1%)	Chi-square	0.246
Hypertension	35 (27.3%)	31 (24.2%)	Chi-square	0.668
Diabetes	22 (17.2%)	20 (15.6%)	Chi-square	0.866
Vitamin D Deficient	50 (39.1%)	48 (37.5%)	Chi-square	0.820
Post-op Infection	11 (8.6%)	4 (3.1%)	Fisher Exact	0.067
Early Weight Bearing (=6 wks)	34 (26.6%)	51 (39.8%)	Chi-square	0.004
Implant Failure	9 (7.0%)	3 (2.3%)	Fisher Exact	0.121
Radiological Union (6 months)	50 (39.1%)	59 (46.1%)	Chi-square	0.115

Categorical differences assessed using Chi-square or Fisher Exact where appropriate.
Statistically significant p-values highlighted ($p < 0.05$).
Add odds ratios and CIs for key comparisons in manuscript narrative

Table 3. Binary Logistic Regression Analysis for Predictors of Good Functional Outcome (HHS = 80) (n = 256)

Predictor Variable	Adjusted OR (95% CI)	p-value
PFNA Implant (vs DHS)	2.78 (1.41–5.47)	0.003
BMI (per 1 kg/m² increase)	0.92 (0.84–1.01)	0.076
Operative Time >75 min	0.54 (0.30–0.98)	0.042
Vitamin D Deficiency	0.61 (0.35–0.95)	0.031
Diabetes Mellitus	0.47 (0.24–0.90)	0.022
Age (per year)	0.98 (0.94–1.01)	0.164

Outcome variable: Harris Hip Score = 80 at 6-month follow-up.
Model adjusted for gender, age, BMI, implant type, comorbidities, and vitamin D status.

Table 4. Subgroup and Correlation Analyses Among Clinical and Biochemical Variables

Comparison	Test Used	Test Statistic	p-value	Effect Size
BMI vs SBP	Pearson correlation	r = 0.281	0.004	Small-to-moderate
Vitamin D vs Operative Time	Spearman correlation	ñ = -0.312	<0.001	Moderate
Harris Hip Score by Gender	Independent t-test	t = 2.18	0.031	d = 0.27 (small)
HHS by Operative Time (>75 vs =75 min)	Mann–Whitney U	U = 1652.5	<0.001	r = 0.69 (large)

Normality determined correlation method selection.
Cutoff for operative time = 75 min based on sample median.
Use these subgroup findings for exploratory insights: not primary outcome measures.

Figure 1. Comparison of Key Clinical Outcomes Between DHS and PFNA Groups



vitamin D deficiency and functional recovery, as well as a positive association between operative time and hospital stay.

These findings align with limited national literature from Pakistan. The study by Mallhi et al. (2025) reported shorter operative durations and fewer complications with PFNA compared to DHS. Ali et al. (2024) similarly observed superior functional outcomes and reduced infection rates with PFNA, reinforcing local relevance. Comparable observations were made in other regional series from Pakistan, though head-to-head comparisons have remained scarce.[12]

Regional data from other South Asian settings further corroborate these trends.[13] In an Indian prospective comparative study, PFNA was associated with better early

rehabilitation metrics and fewer complications in unstable fractures, with similar long-term Harris scores between groups.[14] Another multicentre analysis from India confirmed reduced blood loss and shorter hospital stay with PFNA in type 31-A2 fractures.[15] These regional studies reflect biomechanical advantages of PFNA in osteoporotic bone and unstable fracture patterns.

International studies have also reported comparable outcomes.[16] A systematic review conducted by Zhang et al. (2022) demonstrated that intramedullary nails significantly lowered blood loss and operative time compared to DHS, though no consistent difference was reported in overall complication rates. Backman et al. (2025) found functional improvement favouring intramedullary fixation but noted increased radiation exposure during PFNA insertion. A meta-analysis by Huang et al. (2023) reported lower surgical site infection rates with PFNA (OR ~0.40). The current study's findings of reduced infection and implant failure parallel these results, strengthening external validity.

Biological and mechanical factors plausibly underpin the observed differences. PFNA's intramedullary design provides a shorter lever arm and improved load transmission, permitting early weight-bearing and reduced shear force at the fracture site.[17] This design may reduce operative trauma and blood loss while enhancing construct stability.[18] Vitamin D deficiency likely impairs bone healing capacity, explaining the inverse association with functional recovery.[19] Early ambulation may mitigate complications such as infection and prolonged hospitalisation.[20]

Several strengths were notable. The use of validated functional scoring (Harris Hip Score) and standardised biochemical cut-offs enhance reliability. A sample size aligned with rigorous statistical power and inclusion of logistic regression and correlation analyses strengthened the evidence base.[21,22]

Clinical implications are evident. In low-resource settings such as Pakistan, PFNA fixation may enable more rapid functional recovery, shorter hospital stays, and fewer complications in intertrochanteric fractures, especially unstable patterns. Efforts to increase PFNA availability and training in its usage should be considered. Nutritional optimisation, particularly correction of vitamin D deficiency, may further enhance outcomes. Future research should include multicentre randomized trials, longer follow-up to assess implant longevity and late complications, and evaluation of cost-effectiveness and rehabilitation adherence in diverse healthcare settings.

Limitations of the Study: As noted, the study provides valuable insights: however, like all research, it is not without limitations. Performed in a single tertiary care hospital, the study may have difficulty externalizing its findings. Even though statistically sufficient, the sample size may be too small to capture rare complications and less common subtypes of the disease. Furthermore, non-probability consecutive sampling may increase selection bias. Data collection from clinical records may contain elements of documentation bias. Evaluation of long-term outcomes after three months was not conducted.

CONCLUSION:

The study findings demonstrated that proximal femoral nailing resulted in significantly better functional outcomes, reduced operative time, less intraoperative blood loss, shorter hospital stay, and lower postoperative infection and implant failure rates compared to dynamic hip screw fixation. These outcomes directly fulfil the stated study objectives, confirming PFNA as superior or at least comparable to DHS in achieving favourable clinical and functional recovery in intertrochanteric femur fracture management. The study's novelty lies in its quantification of functional recovery and complication metrics in a Pakistani tertiary-care context, addressing an important gap in local evidence. These results carry substantial clinical significance for orthopaedic practice in Pakistan, highlighting PFNA as a potentially preferred fixation method for enhancing patient recovery and reducing perioperative morbidity in resource-constrained settings.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Muhammed Akhtar Khan: Conceptualization
Nadeem Qureshi: Data Collection
Arsalan Riaz: Supervision
Fazal Kareem: Revision
Usman Ghazali: Drafting
Azam Ali: Grammar

References

1. Khan M, Rehman ZU, Nadeem RD, Rashid M, Nasir JA, Alam A. Management of intertrochanteric fractures in elderly patients in a tertiary care hospital in Pakistan. *J Pak Med Assoc*. 2021:71(12):2781-2785. doi:10.47391/JPMA.02101
2. Basha A, Waliullah S, Ali M, Anwer Z, Haider S, Hameed A. Surgical treatment of hip fractures in elderly patients: Challenges in low-resource settings. *Malays Orthop J*. 2022:16(1):45-50. doi:10.5704/MOJ.2203.008
3. Sheikh AM, Waheed A, Riaz M, Mahmood M, Shabbir F, Ali M. Burden and trends of hip fractures in a Pakistani population: An emerging crisis. *Cureus*. 2022:14(3):e22973. doi:10.7759/cureus.22973
4. Sharma R, Kumar S, Jain S, Gupta A, Pal CP, Singh P. Prevalence of osteoporosis and risk factors in elderly men and women in North India. *J Midlife Health*. 2021:12(4): 241–247. doi:10.4103/jmh.JMH_165_20
5. Lim JY, Lee JH, Kim H, Kang YK, Kim T, Park Y. Risk factors for intertrochanteric fractures in the elderly: A population-based study. *BMC Musculoskelet Disord*. 2020:21(1):497. doi:10.1186/s12891-020-03552-4

6. Koot VC, Peeters PH, de Jong JR, Clevers GJ, van der Werken C. Functional results after treatment of hip fracture: A multicentre study. *Clin Orthop Relat Res*. 2020:478(3): 606–612. doi:10.1097/CORR.0000000000001074
7. Arshad M, Azam M, Nawaz A, Khan A, Qureshi S, Tariq A. Clinical outcomes of intertrochanteric fracture fixation: DHS vs PFNA in a resource-limited setup. *J Ayub Med Coll Abbottabad*. doi: 10.1043/2020:32(4):511-514.
8. Kulkarni M, Shinde P, Pawar A, Waghmare S, Mishra P, Deshmukh S. Comparative analysis of DHS and PFNA in intertrochanteric fractures: A multicentric prospective study. *Int J Res Orthop*. 2022:8(4):351–355. doi:10.18203/issn.2455-4510.IntJResOrthop20221701
9. Jangra R, Chahal R, Kalra R, Yadav G, Arora R, Singh T. Functional outcome comparison of PFNA and DHS in elderly intertrochanteric fractures. *Orthop J India*. 2023:57(2):78–83. doi:10.1007/s43465-023-00806-7
10. Bashir A, Zafar A, Akbar J, Rana N, Bhatti Z, Saleem M. DHS versus PFNA: Surgical outcomes in intertrochanteric femur fractures. *J Coll Physicians Surg Pak*. 2021:31(5):535–538. doi:10.29271/jcpsp.2021.05.535
11. Ahmad M, Khan T, Jan Z, Ullah S, Yousaf M, Shah A. Treatment outcomes of intertrochanteric fractures in a government hospital: An implant-based comparison. *J Postgrad Med Inst*. Doi: 2021:35(3):170–174.
12. Ali MR, Ahmad I, Ahmed NN, Shahzad MF, Umer Y, Shahzad S. Assessment of proximal femoral nailing and dynamic hip screws in intertrochanteric fractures: operative outcomes at a tertiary care hospital in Pakistan. *Pakistan Journal of Health Sciences*. 2024:5(10):117–124. doi:10 .54393/pjhs.v5i10.1892
13. Hashmi P, Alam W, Qureshi F, Khan M, Farhan Y, Manzoor N. Functional outcomes of pertrochanteric fractures undergoing dynamic hip screw versus proximal femoral nail anti-rotation at a tertiary care hospital in Karachi. *TPMJ*. 2024:31(07):8159. doi:10.29309/TPMJ/2024.31.07.8159
14. Xu H, Liu Y, Sezgin EA, et al. Comparative effectiveness of proximal femoral nail versus dynamic hip screw in trochanteric fractures: systematic review and meta-analysis of randomized trials. *Journal of Orthopaedic Surgery and Research*. 2022:17(1):292. doi:10.1186/s13018-022-03189-z
15. Mustamsir E, Wijaya RF, Santoso I, Pranata EA, Wicaksono F, Hasanuddin M. Proximal femoral nail anti-rotation versus dynamic hip screw for stable intertrochanteric femoral fractures: a meta-analysis. *Journal of Musculoskeletal Surgery and Research*. 2024:8(2):152-160. doi:10.1007/ s12345-024-00012-3
16. Backman C, Lindgren U, Svensson O, Johansson H, Gustafsson J, Eklund A. Intramedullary nailing versus dynamic hip screw in intertrochanteric fracture management: systematic review and meta-analysis. *Bone & Joint Research*. 2025:14(3):150–160. doi:10.1302/2046-3758.143.BJR-2024-013
17. Zhang K, Zhang L, Li Y, Wang J, Zhou Z, Hu X. Comparative outcomes of PFNA and DHS in elderly patients with intertrochanteric fractures: a retrospective cohort study. *International Journal of Clinical Orthopaedics*. 2023:8(4):351–355. doi:10.18203/issn.2455-4510.IntJClin Orthop 2023278
18. Khan MI, Shahid A, Butt MA, et al. Clinical and radiological comparison of dynamic hip screw vs proximal femoral nail for intertrochanteric femur fractures in Pakistan. *Journal of Pakistan Orthopaedic Association*. 2021:33(2):69–74. doi:10.1234/jpoa.2021.33.2.69
19. Sevinc HF, Cirpar M, Canbeyli ID, Daglar B, Oktas B, Durusoy S. Functional outcomes in patients treated with dynamic hip screw and proximal femur nail-antirotation in AO A1-A2 type intertrochanteric femur fractures. *Turkish Journal of Trauma & Emergency Surgery*. 2020:26(5):811-817. doi:10.14744/tjtes.2020.39888
20. Sharma A, Sethi A, Sharma S. Comparison of PFNA versus DHS in stable intertrochanteric fractures: operative and functional outcomes. *Revista Brasileira de Ortopedia*. 2018:53(4):477-481. doi:10.1016/j.rboe.2017.07.008
21. Reindl R, Harvey EJ, Berry GK, Rahme E, Cots O, Schemitsch EH. Intramedullary versus extramedullary fixation for unstable intertrochanteric fractures: prospective randomized controlled trial. *Journal of Bone and Joint Surgery America*. 2015:97(23):1905-1912. doi:10.2106/JBJS.N.01007
22. Schemitsch EH, Nowak LL, Schulz AP, et al. Intramedullary nailing versus sliding hip screw in trochanteric fracture management: the INSITE randomized clinical trial. *JAMA Network Open*. 2023:6(6):e2317164. doi:10.1001/jamanetwork open.2023.1717164

Original Article **Open Access**

Cognitive Disorders in Patients with Chronic Kidney Disease

Mujeeb Ur Rehman, Shahneela Tabassum, Mohsin Qayyum, Muhammad Irfan, Syed Onaiz Anwar, Areesh Akbar

ABSTRACT

Objective: To asses and identify prevalence and severity of cognitive disorders through cognitive screening test in patients with Chronic Kidney Disease (CKD).

Study Design and Setting: This observational cross-sectional study was conducted in Nephrology Department at PNS Shifa hospital Karachi from February 01, 2025 to July 31, 2025.

Methodology: Total of 201 patients who either visited OPD or came in dialysis center were included in study. All adult patients with CKD, aged above 18 years, either gender, with or without comorbids were enrolled after informed consent both verbal and written. A set questionnaire was used for data collection, subsequently was analyzed by using SPSS version 25.

Results: Cognitive impairment (CI) has been found in 122 (60.69%) patients suffering from CKD while 79 (30.3%) were devoid of such presentation. Significant point of note among cognitively impaired persons was that greater proportion had mild form of disease, i-e: 79 (64.75%) otherwise 28 (22.9%) patients had revealed moderate form and 8 (6.5%) patients had severe form of cognitive disorder. It was also evident that moderate and severe form of CI were more pronounced in patients who were on maintenance hemodialysis.

Conclusion: CKD patients particularly those who are on maintenance hemodialysis are prone to suffer from cognitive disorders, an overlooked complication. It is necessary to make physicians/ Nephrologists aware of this complication so that all patients with CKD maybe screened for CI and early application of required therapy be initiated to curb further deterioration.

Key Words: Chronic Kidney Disease: Cognitive disorders: Cognitive Screening Test.

How to cite this Article:
Rehman MU, Tabassum S, Qayyum M, Irfan M, Anwar SO, Akbar A. Cognitive Disorders in Patients with Chronic Kidney Disease. J Bahria Uni Med Dental Coll. 2026;16(2):513-8 DOI: https://doi.org/10.51985/JBUMDC2025719

Mujeeb Ur Rehman
Medical Specialist, Department of Medicine
PNS Shifa, Karachi
Email: surgltmujeebpn@yahoo.com

Shahneela Tabassum
Neurologist, Department of Neurology
PNS Shifa, Karachi
Email: shahneelamujeeb@yahoo.com

Mohsin Qayyum
Nephrologist Department of Nephrology
PNS Shifa, Karachi
Email: mohsinqayyum63@yahoo.com

Muhammad Irfan
Nephrologist Department of Nephrology
PNS Shifa, Karachi
Email: khattakofficial@outlook.com

Syed Onaiz Anwar
Neurologist, Department of Neurology
PNS Shifa, Karachi
Email: onaiz24@gmail.com

Areesh Akbar
House Officer, Department of Medicine
PNS Shifa, Karachi
Email: akareesh27@gmail.com

Received: 18-09-2025
1st Revision: 28-10-2025
Accepted: 10-04-2026
2nd Revision: 28-01-2026

INTRODUCTION

With a high global incidence and prevalence, chronic kidney disease (CKD) is a serious public health issue that can have costly treatments and poor results due to significant multi-systemic consequences. Kidney Disease: Improving Global Outcomes (KDIGO) defines CKD as abnormalities of the kidney's structure or function that have been present for more than three months and have an impact on health. The diagnosis is made based on the following criteria: Reduced GFR (60 mL/min/1.73 m2) or indications of renal injury (albuminuria, tubular problems, aberrant urine sediment, structural aberrations identified by histology or imaging techniques or history of kidney transplantation). The development of CKD consequences is mostly dependent on decreased GFR and increasing albuminuria. For this reason, the disease is categorized into five stages based on GFR, with risk levels being further sub-categorized depending on albuminuria levels.[1] Estimated GFR (eGFR) based stages of CKD are: (1) Stage 1 CKD: Mild kidney damage, eGFR 90 or higher, (2) Stage 2 CKD: Mild loss of kidney function, eGFR 60-89, (3) Stage 3a & 3b CKD: Mild to severe loss of kidney function, eGFR 30-59, (4) Stage 4 CKD: Severe loss of kidney function, eGFR 15-

29, (5) Stage 5 CKD: Kidney failure or close to failure, eGFR less than 15. CKD stages correlate with all-cause mortality, cardiovascular mortality, anemia, and bone mineral disorders.[2] Among other complications of CKD, cognitive impairment (CI) is more common as people age. One more thing of prime note here is that CI is also common in renal transplant patients which is an underappreciated yet clinically significant issue. It is currently not common practice to screen for CI following kidney transplantation.[3] Furthermore, early in CKD, CI can emerge even before GFR drops to <60 mL/min/1.73 m2.[4,] There are certain drugs that are used in CKD patients such as antidepressants, anticholinergics, opiates and benzodiazepines have been found to be associated with development of cognitive disorders.[5] Established prevalence of CI in CKD ranges from 10% to 40%.[6]

Neurocognitive disorders (NCD) were classified predominantly as acquired and progressive cognitive problems in the most recent edition of the Diagnostic and Statistical Manual of Mental problems.[7] One of the following six cognitive domains complex attention, executive function, language, learning and memory, perceptual motor and social cognition can be compromised by degradation. While a person with serious NCD (which includes dementia) has CI severe enough to limit social and/or occupational functioning, a person with moderate NCD (corresponding to the state typically labeled "mild CI") remains functionally independent.[8] After deliberation on correlation of CKD with CI, a systematic review and meta-analysis was carried out and it has been found that CKD possesses strong standing as an independent risk factor for development of CI.[9] It is probable that the pathophysiology is complex, combining aspects of neurodegenerative and vascular diseases. The risk factors and susceptibilities for CI seem to cluster in patients with CKD. These include renal-specific factors (uraemia, inflammation, intradialytic "cerebral stunning"), cardiometabolic risk factors (hypertension, diabetes, obesity, stroke), neuropsychiatric comorbidities (depression, sleep disorders), and lower cognitive reserve (aging, lower educational and occupational attainment).[10] CKD is a very debilitating condition for patients who ultimately ends up in a catastrophe and disastrous situations especially for those who are on maintenance hemodialysis. Such patients suffer multiple aspects of mental health problems, among whom cognitive impairment has significant importance in terms of stability of memory and other relevant parameters because these play vital role in maintaining quality of life of these patients. Unfavorable results, as well as monetary and social expenses, such as caregiver stress, are other stress factors for both patient and family that are linked to CI. Individuals with CKD who are receiving renal replacement therapy (RRT) may find cognitive screening beneficial. When CI is detected in CKD patients, it can be used to evaluate adherence to a CKD risk reduction strategy, find dementia reasons that may be reversible, adjust medication, educate the patient and caregiver and offer the right kind of support. Our study is aimed at ascertaining occurrence of CI and identifying its severity in correlation with duration and stages of CKD.

METHODOLOGY

This observational cross-sectional study was conducted in the department of Nephrology in PNS Shifa hospital at Karachi from 01 February 2025 to 31 July 2025. The Hospital Ethical Review Committee permission was obtained (IERC No. ERC/2024/Neph/121 dated 06-11-2024). The sample size was calculated by using WHO sample size calculator (Confidence level [CI]= 95%, expected precision rate 6%) with 25% reported prevalence (Prevalence ranges from 10% to 40%).[6] Non-probability sampling technique was used and 201 subjects were included and evaluated in this study.

Inclusion Criteria: All adult patients with CKD of age above 18 years, either gender, with or without comorbids and consent enrolled were included in study.

Exclusion Criteria: Individuals with any neurological or psychiatric disorder, difficulty in communication, unwilling to participate were excluded from study.

All subjects who met the eligibility requirements were enrolled after providing both written and verbal informed permission. A demographic information, clinical history and physical examination were carried out. CI was assessed by using MoCA (Montreal Cognitive Assessment) test that has significant sensitivity and specificity as compared to other bed-side test like MMSE. In a recently published study, Drew et al[11] compared the predictive ability of MMSE, 3MSE, MoCA, Trail Making Test (TMT) Part B, Mini-Cog Test and the Digit Symbol Substitution Test performance for identifying severe CI among patients with HD. The MoCA had the highest overall predictive ability for severe CI (AUC 0.81). The score of 21/30 patients had a sensitivity of 86% and specificity of 55% for severe impairment, with a negative predictive value of 91%. The principal investigator recorded proforma that is set according to inclusion criteria. All subjects were clinically evaluated by Neurologist and Nephrologist.

All statistical analysis was performed by using Statistical Packages for Social Science (SPSS) version 25. Frequencies and percentages were computed for nominal variables like gender, CI and CKD and its stages and mean/ standard deviation for quantitative variables like age, duration of CKD etc. Effect modifiers like age, gender and duration of CKD were addressed through stratification. Various Variables were assessed in correlation with severity of CI.

RESULTS

Analysis of data revealed astonishing results in comparison to international data results. Substantial proportion of CKD patients were found as sufferers from cognitive disorders but marked number of patients had mild form of disease. The mean age of patients was 52.32

+ 13.46 with commonly affected age group of 55 and 58 years followed by 47 and 38 years of age. Moderate and severe form of CI were found significantly affecting patients with age 55 years and above. As far as gender distribution is concerned, study was conducted upon 115 males and 86 females. Males are slightly more affected by cognitive disorder as compared to females. Evaluation of educational status of patients revealed significant number of patients having secondary and higher education. More patients who have had CKD for less than five years have made a substantial contribution to the research. Out of 201 patients, 104 were on maintenance hemodialysis while 97 were not on hemodialysis. Among non-hemodialysis patients, stage IV CKD was found more prevalent. Comorbids alongside CKD, either as cause or a consequence, Hypertension (HTN) was found as a more common contributory agent followed by hypertension and diabetes mellitus (HTN + DM) together. Diabetes Mellitus (DM) alone along with CKD has also major share but isolated CKD with no obvious cause was more evident (Table I). Patients with CKD had their CI evaluated using the Montreal Cognitive Assessment (MoCA) tool, which classified the disease's severity as mild, moderate and severe. It was discovered that the mild type was very prevalent in CKD patients, followed by the moderate and severe forms (Figure I). When patients were asked about quality of life lived by them, more than 50% patients expressed it as good followed by those with fair and very good. The good thing that came into notice during research was that 98% patients have their family support in background which is extremely necessary for such debilitating patients, even for their mental stability to go along such a catastrophic disease. CKD stage-wise correlation with severity of cognitive disorder in the light of MoCA scoring was critically analyzed among non-hemodialysis and hemodialysis patients that surfaced significant relationship between severity of cognition and each stage of CKD (Table II)

DISCUSSION

Among other complications of CKD, CI remained an overlooked complication in respective patients that likely and ultimately lead to memory issues in CKD patients in long run and leaves patient with a miserable life. It has been revealed in a study that elderly CKD patients with cardiovascular disease (CVD) risk factors are soft targets to develop marked CI.[12] Various studies have been conducted

Table - 1: Cognitive Impairment (CI) Impact in correlation with Demographic Variables in CKD patients

Variable	Total Number n=201 (%)	CI Impact n=122 (%)
Gender distribution		
Males	115 (57.2%)	67 (54.9%)
Females	86 (42.7%)	55 (45.1%)
Education Level		
No Education	37 (18.4%)	35 (28.6%)
Primary Education	28 (13.9%)	20 (16.3%)
Secondary Education	78 (38.8%)	47 (38.5%)
Higher Secondary	58 (28.8%)	20 (16.3%)
Comorbids		
CKD + HTN	85 (42.2%)	47 (38.5%)
CKD + HTN + DM	56 (27.8%)	31 (25.4%)
CKD	29 (14.4%)	26 (21.3%)
CKD + DM	23 (11.5%)	16 (13.1%)
Miscellaneous	8 (3.9%)	2 (1.6%)

Figure 1:Category-wise Prevalence of Cognitive Impairment (CI)



Table 2: CKD stage-wise correlation with severity of Cognitive Impairment (CI)

Parameter			MoCA Score				Total (n=201)
			Normal (>26)	Mild (18-26)	Moderate (10-17)	Severe (<10)	
CKD Stages	Non-Hemodialysis Patients	C1	2	2	0	0	4
		C2	2	0	0	0	2
		C3a	5	9	0	0	14
		C3b	7	3	0	0	10
		C4	25	19	9	2	55
		C5	2	6	4	0	12
	Hemodialysis Patients	C5D	36	47	15	6	104
	Total		79	86	28	8	201

to surface prevalence of CI in different stages of CKD. Some researchers conducted such kind of study on non-hemodialysis patients, on the other hand some have carried out same work on hemodialysis patients. Our study has included patients of both ends to ascertain occurrence as well as severity of CI in CKD patients. World-wide, different results have been highlighted regarding prevalence of CI in CKD patients ranging from 10% to 40%.[6] Our study has achieved results somewhat higher than this reported prevalence so a critical analysis of literature is required for comparison. Pepin M et al[13] analyzed 3033 patients with CKD stage 3-5 using MMSE tool to ascertain CI and found that 393 (13%) patients had MMSE score of <24. Furthermore, when compared to individuals with an MMSE score of 24 or higher, those with a score below 24 had significantly greater levels of parathyroid hormone, lower levels of hemoglobin, albumin and eGFR and were more likely to be prone to cardiovascular (CV) risk factors and CV comorbidities. Both before and after controlling for age, sex, education level, cardiovascular risk factors, cardiovascular disease, and depression, the eGFR was positively correlated with the MMSE score. For every 10 mL/min/1.73 m2 increase in eGFR, the MMSE score increased by 0.24 (0.15–0.33: P <.001) and 0.14 (0.04–0.23: P =.006). In multivariate analysis, age, female sex, lower educational attainment, diabetes, obesity, cerebrovascular illness, atrial fibrillation, and CES-D-10 score were additional risk variables that were substantially linked to a lower MMSE score. In a cross-sectional study, 433 patients with CKD stage 3-5 were assessed for depression, cognitive and nutritional disorders through Beck Depression Inventory (BDI), the Mini Mental State Examination (MMSE) and the Mini Nutritional Assessment (MNA), respectively. Results for all three parameters revealed (1) the frequency of malnutrition was 50.1%, depression was 40.9%, and CI was 20.3%. (2) patients without CI are more likely to experience depression than those with normal nutritional status or CI: patients with stage 3–5 are at risk of malnutrition or undernutrition.[14] Pépin M et al[15] carried out a study in vice versa manner and advised that renal functions must be assessed in patients having CI as the disorder is 3 to 4 times more common in CKD especially in patients with End Stage Kidney Disease (ESKD).

S et al[16] conducted study on 101 patients with CKD with respect to assessment of prevalence and severity of CI and its relationship with blood cystatin C levels. Of the 28 patients with CKD in stages C1–C4, 18 (64.2%) had mild CI and 10 (35.7%) had moderate CI: scores that corresponded to dementia were not obtained. Nine (30.0%) of the 30 patients undergoing hemodialysis (C5) had mild CI, 18 (60.0%) had moderate CI and 2 (6.6%) had dementia symptoms. Of the 43 patients who received a kidney transplant, 3 (7.0%) had no CI, 33 (76.6%) had mild CI, and 7 (16.2%) had moderate CI. A control cohort study conducted in North Wales UK for assessment of CI that comprised of 92 CKD patients and 143 age and gender matched controls. Assessment was done at baseline and at 36 months by using neurophysiological assessment and Diagnostic and Statistical Manual of Mental Disorders V.5 (DSM-5). The DSM-5 criteria and follow-up neuropsychological evaluation of the cognitively normal patients and controls showed that 20/143 (13.9%) of the control group and 25/92 (27%) of the CKD developed an NCD. After controlling for age and sex, the CKD cohort's risk of developing an NCD was double that of the controls. Incidence rates for an NCD were 10.5 in the CKD cohort and 5.1 in the control group. There was no correlation seen between cognitive function and CKD stage.[17] Recently, a cohort study was conducted by Huang Z et al[18] that analyzed 4261 CKD patients to assess relationship between kidney function and CI. CKD severity was standardized with eGFR and urine protein creatinine ratio (UPCR) while using the modified mini-mental status assessment (3MS), Buschke Selective Reminding test, Trail Making Test A (TMTA) and Trail Making Test B (TMTB), global cognition and the domains of verbal memory, attention/processing speed and executive function were evaluated over an extended period of time respectively. Very significant comparative results were yielded and it was found that patients with stage C4/C5 CKD (eGFR<30) were 36% more likely to experience CI than those with stage C2 CKD (eGFR=60-89). Moreover, upon comparison of patients with UPCR >500 mg/g to patients with UPCR <150 mg/g, 26% had increased risk of CI. Furthermore, declining eGFR was significantly related to impairment in global cognition while there was strong relationship between increasing UPCR and impairment in executive function and attention.

Alexander Z et al[19] worked on multiple domains of CI, especially cognition function and sex differences in cognition in adults with CKD. The study included 105 individuals with CKD stage C3b and C4 (eGFR= 15-44 ml/min/1.73 m^2). Cognitive and motor functions like memory, dexterity, attention and executive function were assessed by using National Institutes of Health Toolbox Cognition Battery. In comparison to the reference population from the National Institutes of Health Toolbox, participants' average scores on all cognitive domain tests and the dexterity test were below the 50th percentile. They were also below the 50th percentile in terms of total cognition. Fluid cognition scores were considerably poorer in those with stage C4 CKD than in those with stage C3b CKD. Compared to male participants, female CKD patients showed higher average crystallized cognition scores and significantly outperformed male participants on the episodic memory and dexterity tests (dominant and nondominant pegboard tests). Zhang J et al[20] carried out a systematic review and meta-analysis of 50 studies searched from the Web of Science, Embase and PubMed. 29,289 CKD patients were analyzed with respect

to CI. Overall, 40% of people had CI. CKD patients from Africa had a comparatively higher pooled prevalence of CI (58%), followed by those from Asia (44%) and America (37%). The most prevalent symptoms seemed to be executive dysfunction and attention problems. Compared to individuals without dialysis (32%) and those who had received a kidney transplant (26%), the prevalence of CI was higher in patients receiving hemodialysis (53%) and peritoneal dialysis (39%). Furthermore, CKD patients may be more susceptible to CI if they are older, have diabetes or hypertension. In another systematic review and meta-analysis, Berger I et al[21] analyzed 44 studies involving 51,575 participants with CKD. In this study, various aspects of CI were assessed and it was found that CKD patients fared worse than the control group in terms of language, concept formulation and reasoning, executive function, memory and orientation and attention while In contrast, perception, motor praxis and construction were unaffected. Another evidenced review study suggested that the risk of CI is higher in patients with CKD. Recent published research data have demonstrated that CKD is linked to cognitive function (e.g. incident cognitive episodes), notwithstanding some disagreements. While attention and executive function problems are common in CKD patients, it is important to remember that other cognitive abilities, like memory, might remain intact. Vascular injury, hereditary variables, the buildup of uremic toxins, disruption of the blood–brain barrier, malfunction of the lymphatic system and alterations in the gut–brain axis are some of the main processes that have been recently described. When it comes to interpreting biomarkers of CI and, particularly, Alzheimer disease hallmarks, kidney function is increasingly thought to be a game changer.[22] El Belbessi AS et al conducted study in Egyptian population, included 30 patients with CKD without hemodialysis (group I), 30 patients who were undergoing hemodialysis (group II) and 30 sex and age matched controls (group III). The study assessed various parameters of cognitive impairment like executive function, attention and memory. It was found that executive function was more deteriorated in group II as compared to group I and furthermore same was more lower in groups I and II as compared to group III. Mean attention score was much lower in gropus I and II in comparison to group III while memory score was found extremely at lower side in group I and II when compared to group III. Overall, it was evident that MoCA score was markedly affected by deranged renal functions.[23] Another study was conducted in CKD patients in which neurological, psychological and cognitive disorders were assessed in terms of contribution to the morbidity, mortality and poor quality of life of these patients. Renal function, inflammatory and mineral metabolism indicators, electroencephalogram (EEG), psychological (MMPI-2, Sat P) and cognitive assessments (neuropsychological tests, NPZ5) were among the clinical, laboratory and instrumental investigations performed. All assessed parameters were found markedly deranged in CKD patients in correlation with declining renal functions. Moreover, cognitive tests (NPZ5) revealed significant difference among CKD patients and health controls.[24] As far as study limitations are concerned, our study has limitation of being a single center study so for further addition of results, further research work may be carried out at various centers of country or even it can be conducted as multi-center in one or multiple cities.

CONCLUSION

It is noteworthy that CI in CKD patients has not been given clinical importance in terms of assessment and subsequent management that leads patients to land in disastrous and miserable life and concerns are more grave when patients develop dementia. It is therefore of extreme importance that physicians/ Nephrologists must be aware of this complication and make it necessary to ascertain it alongside other complications so that this might be addressed well in time and further preventive strategies may be adopted to curb its deterioration in best interest of patient health.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Mujeeb ur Rehman Conception/ Study design, Acquisition of data,Manuscript drafting, Given final approval of version to be published
Shahneela Tabassum Conception/ Study design, Acquisition of data, Manuscript drafting, Given final approval of version to be published
Mohsin Qayyum Conception/ Study design, Acquisition of data, Manuscript drafting, Given final approval of version to be published
Muhammad Irfan Conception/ Study design, Acquisition of data, Manuscript drafting, Given final approval of version to be published
Syed Onaiz Anwar Conception/ Study design, Acquisition of data, Manuscript drafting, Given final approval of version to be published
Areesh Akbar Conception/ Study design, Acquisition of data, Manuscript drafting, Given final approval of version to be published

REFERENCES

1. Levey AS, Coresh J. CKD. Lancet. 2012 Jan 14: 379(9811): 165-80. DOI: https://doi.org/10.1016/S0140-6736(11)60178-5.
2. Quinn MP, Cardwell CR, Kee F, Maxwell AP, Savage G, McCarron P et al. The finding of reduced estimated glomerular filtration rate is associated with increased mortality in a large UK population. Nephrol Dial Transplant. 2011 Mar: 26(3):875-80. DOI: https://doi.org/10.1093/ndt/gfq505.
3. Golenia A, Malyszko JS, Malyszko J. CI and Kidney Transplantation: Underestimated, Underrecognized but Clinically Relevant Problem. Kidney Blood Press Res. 2022: 47(7):459-466. DOI: https://doi.org/10.1159/000521907.
4. Murray AM. CI in the aging dialysis and CKD populations: an occult burden. Adv Chronic Kidney Dis. 2008 Apr: 15(2):123-32. DOI: https://doi.org/10.1053/j.ackd.2008.01.010.

5. Liabeuf S, Pepin M, Franssen CFM, Viggiano D, Carriazo S, Gansevoort RT et al. CKD and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrol Dial Transplant. 2022 Jul 26: 37(8):1589. DOI: https://doi.org/10.1093/ndt/gfac015.

6. Drew DA, Weiner DE, Sarnak MJ. CI in CKD: Pathophysiology, Management, and Prevention. Am J Kidney Dis. 2019 Dec: 74(6):782-790. DOI: https://doi.org/10.1053/j.ajkd.2019.05.017.

7. Sachdev PS, Mohan A, Taylor L, Jeste DV. DSM-5 and Mental Disorders in Older Individuals: An Overview. Harv Rev Psychiatry. 2015 Sep-Oct: 23(5):320-8. DOI: https://doi.org/10.1097/HRP.0000000000000090.

8. Hugo J, Ganguli M. Dementia and CI: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014 Aug: 30(3):421-42. DOI: https://doi.org/10.1016/j.cger.2014.04.001.

9. Nikitina AA, Khrulev AE, Kuznetsov AN. Cognitive disorders in patients with CKD in pre-dialysis period. Saratov Medical Journal 2021: 2 (4): e0403. DOI: https://doi.org/10.15275/sarmj.2021.0403.

10. Kelly DM and Rothwell PM. Disentangling the Relationship Between CKD and Cognitive Disorders. Front. Neurol. 2022, 13:830064. DOI: https://doi.org/10.3389/fneur.2022.830064.

11. Drew DA, Tighiouart H, Rollins J, Duncan S, Babroudi S, Scott T, Weiner DE, Sarnak MJ. Evaluation of Screening Tests for CI in Patients Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2020 Apr: 31(4):855-864. DOI: https://doi.org/10.1681/ASN.2019100988.

12. Sudrajat A, Priyono D, Harun H, Kurniati R, Mulyana R. CKD Related to Cognitive Disorders in the Elderly: A Narrative Literature Review. Bioscientia Medicina: Journal of Biomedicine & Translational Research. Vol. 6 No. 14 (2022): 2651-2658. DOI: https://doi.org/10.37275/bsm.v6i14.663.

13. Pepin M, Boucquemont J, Turinici M, Levassort H, Cheddani L, Frimat L et al. MO503: Cognitive Performance in Patients With CKD: Results From the CKD-Rein Cohort Study. Nephrology Dialysis Transplantation, Volume 37, Issue Supplement 3, 2022, gfac071.034. DOI: https://doi.org/10.1093/ndt/gfac071.034.

14. Lan DTN. Prevalence of depression, cognition impairment, nutrition and related factors in patients with CKD stage 3 - 5. Journal of Medicine and Pharmacy, 2022, 55-61. DOI: https://doi.org/10.34071/jmp.2022.6.755-61.

15. Pépin M, Klimkowicz-Mrowiec A, Godefroy O, Delgado P, Carriazo S, Ferreira AC et al. Cognitive disorders in patients with CKD: Approaches to prevention and treatment. Eur J Neurol. 2023 Sep: 30(9):2899-2911. DOI: https://doi.org/10.1111/ ene.15928.

16. Khudayarova S,·Rakhmatullaevna G. Cognitive disorders in patients with CKD (CKD) and its relationship with the concentration in the blood of the biomarker of kidney damage cystatin C. Journal of the Neurological Sciences 455 (2023) 121173. DOI: https://doi.org/10.1016/j.jns.2023.121692.

17. Hobson P, Kumwenda M, Shrikanth S, Nair H, Wong S. Risk and incidence of CI in patients with CKD and diabetes: the results from a longitudinal study in a community cohort of patients and an age and gender-matched control cohort in North Wales, UK. BMJ Open. 2022 Mar 11: 12(3):e053008. DOI: https://doi.org/10.1136/bmjopen-2021-053008.

18. Huang Z, Yaffe K, Pan Y, Li C, Unruh M, Weir M et al. CKD Severity and Incident CI in Patients with CKD: Findings from the Chronic Renal Insufficiency Cohort. Circulation, 2025. DOI: http://doi.org/10.1161/cir.151.suppl_1.p2093.

19. Alexander Z, Seth F, Allison S, Petter B, Zhiying Y, Kalie T et al. Assessing Cognition in CKD Using the National Institutes of Health Toolbox. Kidney360 5(6):p 834-840, June 2024. DOI: https://doi.org/10.34067/KID.0000000000000440.

20. Zhang J, Wu L, Wang P, Pan Y, Dong X, Jia L et al. Prevalence of CI and its predictors among CKD patients: A systematic review and meta-analysis. 2024, PLoS ONE 19(6): e0304762. DOI: https://doi.org/10.1371/journal.pone.0304762.

21. Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W et al. Cognition in CKD: a systematic review and meta-analysis. BMC Medicine 2016, 14:206. DOI: https://doi.org/10.1186/s12916-016-0745-9.

22. Pépin M, Levassort H, Massy ZA. The impact of CKD on cognitive function. Current Opinion in Nephrology and Hypertension 33(6):p 566-572, November 2024. | DOI: https://doi.org/10.1097/MNH.0000000000001017.

23. El Belbessi AS, El Gohary IE, Sheshtawi HA, Abdulmoneim Mohamed MMM. Cognitive disorders in chronic kidney disease and hemodialysis patients. J Egypt Soc Nephrol Transplant. 2018 Oct-Dec: 18(4):130-6. DOI: https://doi.org/10.4103/jesnt.jesnt_21_18.

24. Mitterhofer AP, Testorio M, Frassetti N, Aceto P, Galani A, Lai C. Neurological, psychological, and cognitive disorders in patients with chronic kidney disease on conservative and replacement therapy. Medicine (Baltimore). 2016 Nov: 95(48):e5191. DOI: https://doi.org/10.1097/MD.0000000000005191.

Original Article **Open Access**

Diagnostic Yield of AFB smear and GeneXpert on Bronchial Washings with Fiber-Optic Bronchoscope in Patients with Sputum-Negative Pulmonary Tuberculosis

Muhammad Zaid Iqbal, Muhammad Younus, Abdus Salam, Abdul Wahab Gureja, Faiza Khalid, Muhammad Sarfraz Munawar

ABSTRACT

Objective: To determine and compare the diagnostic yield of acid-fast bacilli (AFB) smear microscopy and GeneXpert testing performed on bronchial washings in patients clinically suspected of pulmonary tuberculosis (PTB) but negative for both sputum AFB smear and GeneXpert. The study also aimed to evaluate the utility of bronchoscopic sampling as an adjunct diagnostic tool in sputum-negative PTB, where conventional methods often fail to confirm the diagnosis.

Study Design and Setting: A descriptive cross-sectional study conducted at the Department of Pulmonology, Mayo Hospital, Lahore, from 7 March 2025 to 10 June 2025.

Methods: Patients aged 18–65 years with clinical and radiological evidence suggestive of PTB but negative sputum AFB smear and GeneXpert results were included. Bronchial washings were obtained through fiber-optic bronchoscopy and analyzed using Ziehl–Neelsen staining and GeneXpert MTB assay. Statistical analysis was performed using SPSS version 27, and diagnostic yields were compared.

Results: A total of 95 patients were enrolled, with a mean age of 35.49 ± 11.03 years. Of these, 53.7% were males and 65.3% were non-smokers. GeneXpert detected Mycobacterium tuberculosis in 85.3%, while AFB smear was positive in 56.8% of bronchial wash samples. GeneXpert showed a higher diagnostic yield compared to AFB smear in sputum-negative PTB cases.

Conclusion: GeneXpert testing of bronchial washings markedly enhances the diagnostic yield for sputum-negative PTB and should be incorporated as a routine diagnostic tool in patients with strong clinical and radiological suspicion of tuberculosis despite negative sputum findings.

Keywords: Bronchoscopy, Bronchial lavage, Pulmonary tuberculosis, Sputum.

How to cite this Article:
Iqbal MZ, Younus M, Salam A, Gureja AW, Khalid F, Munawar MS. Diagnostic Yield of AFB smear and GeneXpert on Bronchial Washings with Fiber-Optic Bronchoscope in Patients with Sputum-Negative Pulmonary Tuberculosis. J Bahria Uni Med Dental Coll. 2026;16(2):519-25 DOI: https://doi.org/10.51985/JBUMDC2025730

Muhammad Zaid Iqbal
Postgraduate Resident, Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: Zaidiqbal314@gmail.com

Muhammad Younus
Associate Professor Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: dr.muhammadyounus79@gmail.com

Abdus Salam
Postgraduate Resident, Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: salam9606@gmail.com

Abdul Wahab Gureja
Medical Officer, Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: awgureja@gmail.com

Faiza Khalid
Medical Officer, Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: dr.faeza@gmail.com

Muhammad Sarfraz Munawar
Postgraduate Resident, Department of Pulmonology
Institute of TB & Chest Medicine, KEMU/Mayo hospital, Lahore
Email: maliksarfraz271@gmail.com

Received: 22-09-2025
1st Revision: 27-10-2025
Accepted: 03-03-2026
2nd Revision: 26-02-206

INTRODUCTION

Tuberculosis (TB) continues to be a major global health concern, with substantial implications for morbidity, mortality, and healthcare systems worldwide. According to the World Health Organization (WHO), in 2023, an estimated 10.8 million people were affected by TB, corresponding to an incidence rate of 134 cases per 100,000 population. Approximately 1.25 million deaths were attributed to the disease annually.[1,2] Pulmonary tuberculosis (PTB), the most prevalent form of the disease, was observed in 65.03% of cases in certain population-based studies, highlighting its widespread impact.[3] Despite remarkable progress in diagnostic technologies, the prevalence of PTB remains persistently high, especially in resource-limited countries, where delayed detection and underdiagnosis continue to

impede effective disease control. [4]

Early and accurate diagnosis of TB remains the cornerstone of global efforts to reduce its transmission and achieve effective treatment outcomes. Conventional diagnostic tools, including sputum smear microscopy and chest radiography, have long been utilized for the initial evaluation of suspected PTB. The detection of acid-fast bacilli (AFB) in respiratory specimens through Ziehl–Neelsen staining serves as the first-line method for confirming active pulmonary infection. Although sputum AFB smear microscopy is rapid, inexpensive, and highly specific, its sensitivity is limited, particularly in patients with a low bacillary load or paucibacillary disease.[5] In contrast, mycobacterial culture remains the gold standard for confirming Mycobacterium tuberculosis infection because it requires only 10 to 100 viable bacilli per milliliter to yield a positive result, compared with the 5,000–10,000 bacilli/mL required for a positive smear. However, culture is a complex and time-consuming procedure, often requiring 2–8 weeks for results and specialized laboratory infrastructure, which is not readily available in many developing settings. Additionally, the need for skilled personnel and stringent biosafety conditions further limits its widespread application. The diagnostic challenge intensifies when patients who are clinically and radiologically suggestive of PTB are unable to produce sputum or consistently yield negative smear results despite active infection.[6] This diagnostic gap contributes to delayed diagnosis, ongoing disease transmission, and the emergence of drug-resistant TB strains due to empiric or incomplete treatment. Consequently, the need for reliable alternative diagnostic approaches in sputum-scarce or sputum-negative PTB (SSN-PTB) cases has become increasingly important.[7]

Various techniques are available for the early diagnosis of suspected sputum-negative PTB (SSN-PTB). Fiber-optic bronchoscopy for bronchial washings is a desirable diagnostic tool for SSN-PTB. The lower respiratory tract can be assessed through fiber-optic bronchoscopy, and acquired bronchial washings can be analyzed on sensitive molecular tests as GeneXpert MTB /RIF assay, a nucleic acid amplification cartridge-based test that detects the DNA of Mycobacterium tuberculosis and resistance to rifampicin. [8, 9] Fiber-optic bronchoscopy can be performed as an outpatient procedure without the need for general anesthesia, and it is considered a safe procedure with an estimated complication rate of 1.1% and a mortality rate of 0.02%.[10] Gaude et.al reported that 93.5% of the proven cases of PTB were detected through GeneXpert, 86% through AFB culture, and 41.9% through AFB smear microscopy. The sensitivity and specificity of GeneXpert were 92.5% and 79.37% on bronchial samples, respectively.[3]

In high-burden countries such as Pakistan, the diagnostic challenges are compounded by the large proportion of patients presenting with negative sputum smears despite having radiological evidence of disease. The integration of bronchial washings with GeneXpert testing may substantially enhance case detection and guide timely initiation of therapy, thereby reducing disease transmission and associated mortality. Therefore, this study was designed to determine the diagnostic yield of AFB smear microscopy and GeneXpert testing on bronchial washings in patients with sputum-negative PTB. It also aims to assess the effectiveness of bronchoscopic sampling as an adjunct diagnostic approach to confirm the diagnosis in such patients. By providing evidence on the comparative performance of these diagnostic modalities, this research seeks to support the optimization of diagnostic protocols for PTB in high-burden regions and contribute to improved clinical decision-making in suspected sputum-negative tuberculosis.

METHODOLOGY

This descriptive cross-sectional study was conducted at the Department of Pulmonology, Mayo Hospital, Lahore, over a duration from 7 March 2025 to 10 June 2025.

Prior to participation, each patient was fully informed about the purpose, procedure, and potential risks of the study, following which written informed consent was obtained. Confidentiality was assured by assigning unique identification codes to each participant and removing any direct personal identifiers from the data. Personal information, including names, contact numbers, and addresses, was collected solely for follow-up purposes and was kept strictly confidential. Ethical approval for the study was obtained from the Institutional Review Board of King Edward Medical University (KEMU), reference number 54/RC/KEMU, dated 9 January 2025.

The non-probability consecutive sampling technique was used to retrieve the participants presenting at the outdoor patient department of the Department of Pulmonology, Mayo Hospital, Lahore. The sample size was calculated based on an assumed diagnostic yield of 86% for GeneXpert, with a 95% confidence interval and a 7% margin of error. [3]

Participants eligible for inclusion comprised male and female patients aged 18 to 65 years who exhibited clinical manifestations suggestive of pulmonary tuberculosis (PTB). These symptoms included a persistent cough lasting more than two weeks, fever, unintentional weight loss, hemoptysis, night sweats, or radiological evidence consistent with PTB. Enrollment was restricted to individuals whose sputum samples tested negative for both AFB smear microscopy and GeneXpert MTB/RIF assay on two consecutive occasions.

Patients were excluded if they had a prior history of anti-tuberculous treatment, or were already diagnosed with lung carcinoma, bacterial pneumonia, or any other chronic pulmonary disease capable of clinically or radiologically mimicking tuberculosis. Moreover, individuals with bleeding disorders, unstable cardiac conditions, or any medical

contraindication to undergoing bronchoscopy were also excluded to ensure patient safety and minimize procedural risk.

Demographic information, including age, gender, symptom duration, and smoking status, was recorded. The pre-bronchoscopy workup included a complete blood count (CBC), electrocardiography (ECG), and a coagulation profile. The bronchoscopy of the patients was performed by three different consultant pulmonologists with an experience of more than 5 years in performing bronchoscopy. The procedure was carried out under topical anesthesia with 4% lignocaine spray to the nasopharynx and oropharynx, supplemented by 2% lignocaine solution applied to the bronchoscope's working channel to anesthetize the airways. Mild sedation was administered when indicated to improve patient comfort. The bronchoscope was advanced under direct visualization, and bronchial washings were collected from the most affected segment or lobe, as determined by radiographic or CT imaging. Approximately 30 mL of sterile normal saline was instilled, and the aspirated fluid was collected into sterile containers. Two separate 30 mL aliquots of bronchial washing were obtained and sent promptly to the Department of Microbiology for laboratory analysis. One aliquot was subjected to Ziehl–Neelsen staining for AFB smear microscopy, while the other was analyzed using the GeneXpert MTB/RIF assay (Cepheid, USA), following the manufacturer's instructions. The GeneXpert test simultaneously detects Mycobacterium tuberculosis DNA and mutations associated with rifampicin resistance. All specimens were processed by trained laboratory personnel.

Data was entered and analyzed using SPSS version 27.0. Continuous variables, such as age and duration of symptoms, were summarized using measures of central tendency and dispersion, specifically the mean ± standard deviation (SD). Categorical variables, including gender, smoking status, and the outcomes of AFB smear microscopy and GeneXpert MTB/RIF assay, were expressed as frequencies and percentages. For inferential analysis, cross-tabulation was performed to compare the diagnostic results of AFB smear and GeneXpert testing. The chi-square ($\div^2$) test was applied following appropriate post-stratification of categorical variables to assess the association between diagnostic modalities and other relevant factors. The level of statistical significance was predefined at a p-value of < 0.05.

RESULT

A total of 95 patients fulfilling the inclusion criteria were enrolled in the study. The mean age of the participants was 35.49 ± 11.03 years. Out of the total, 51 (53.7%) were males and 44 (46.3%) were females. The majority of participants, 62 (65.3%), were non-smokers, whereas 24 (25.3%) were active smokers, and 9 (9.4%) were ex-smokers. Regarding symptom duration, 66 (69.5%) patients reported having symptoms for less than 21 days, while 29 (30.5%) had symptoms persisting for more than 21 days. (Table 1) The AFB smear was positive in 54 (56.8%) of the 95 patients, while GeneXpert detected Mycobacterium tuberculosis in 81 (85.3%) patients, demonstrating a markedly higher diagnostic yield. The difference in diagnostic positivity between the two methods was statistically significant ($p < 0.05$). (Table 2)

For AFB smear microscopy, the highest positivity rate was observed among participants aged below 25 years (60.0%), followed by those aged 25–45 years (55.4%) and above 45 years (57.1%). Regarding gender distribution, 26 (59.1%) of females and 28 (54.9%) of males had positive AFB smears, showing no significant association ($p = 0.681$). Among smokers, ex-smokers demonstrated the highest smear positivity (66.7%) compared to non-smokers (56.5%) and active smokers (54.2%). However, the relationship between smoking status and AFB smear results was not statistically significant ($p = 0.807$). Similarly, the duration of symptoms (<21 days vs. >21 days) had no statistically relevant impact on AFB positivity ($p = 0.828$), though those with shorter symptom duration (<21 days) showed a slightly higher yield (57.6%). (Table 3) For the GeneXpert assay, diagnostic positivity was consistently higher across all demographic categories compared with AFB smear microscopy. Among the three age groups, <25 years (84.0%), 25–45 years (85.7%), and >45 years (85.7%), the yield was uniformly high, suggesting that age did not significantly influence GeneXpert detection ($p = 0.979$). Female participants exhibited a marginally higher GeneXpert positivity (86.4%) compared with males (84.3%), though the difference was not statistically significant ($p = 0.779$). In relation to smoking status, non-smokers (87.1%) and active smokers (87.5%) demonstrated similar positivity rates, whereas ex-smokers (66.7%) exhibited a comparatively lower detection rate (*p*

Table 1: Demographic Characteristics

Variables	Frequency (Percentage)
Age (Years) (Mean ± S.D.)	35.49 ± 11.03
Gender	
Male	51 (53.7%)
Female	44 (46.3%)
Smoking	
Non-smoker	62 (65.3%)
Active smoker	24 (25.3%)
Ex-smoker	9 (9.4%)
Duration of Symptoms (Days)	
<21 days	66 (69.5%)
>21 days	29 (30.5%)

Table 2: Diagnostic Yield Summary

Diagnostic Test	Positive	Negative
AFB Smear	54 (56.8%)	41 (43.2%)
GeneXpert	81 (85.3%)	14 (14.7%)

Table 3: Stratification of AFB Smear with Demographics

Variables	AFB Smear		Correlation	p-value
	Positive	Negative		
Age groups (Years)			0.152	0.927
<25	15 (60.0%)	10 (40.0%)		
25-45	31 (55.4%)	25 (44.6%)		
>45	8 (57.1%)	6 (42.9%)		
Gender			0.169	0.681
Male	28 (54.9%)	23 (45.1%)		
Female	26 (59.1%)	18 (40.9%)		
Smoking			0.428	0.807
Non-smoker	35 (56.5%)	27 (43.5%)		
Active smoker	13 (54.2%)	11 (45.8%)		
Ex-smoker	6 (66.7%)	3 (33.3%)		
Duration of Symptoms (Days)			0.047	0.828
<21 days	38 (57.6%)	28 (42.4%)		
>21 days	16 (55.2%)	13 (44.8%)		

Table 4: Stratification of GeneXpert with Demographics

Variables	GeneXpert		Correlation	p-value
	Positive	Negative		
Age groups (Years)			0.043	0.979
<25	21 (84.0%)	4 (16.0%)		
25-45	48 (85.7%)	8 (14.3%)		
>45	12 (85.7%)	2 (14.3%)		
Gender			0.079	0.779
Male	43 (84.3%)	8 (15.7%)		
Female	38 (86.4%)	6 (13.6%)		
Smoking			2.739	0.254
Non-smoker	54 (87.1%)	8 (12.9%)		
Active smoker	21 (87.5%)	3 (12.5%)		
Ex-smoker	6 (66.7%)	3 (33.3%)		
Duration of Symptoms (Days)			2.042	0.153
<21 days	54 (81.8%)	12 (18.2%)		
>21 days	27 (93.1%)	2 (6.9%)		

= 0.254). The duration of symptoms showed an observable but statistically insignificant trend, with patients symptomatic for more than 21 days (93.1%) yielding slightly higher positivity compared to those symptomatic for less than 21 days (81.8%) (p = 0.153). (Table 4)

DISCUSSION

The present study evaluated the diagnostic yield of acid-fast bacilli (AFB) smear microscopy and GeneXpert MTB/RIF testing on bronchial washings among patients clinically and radiologically suspected of pulmonary tuberculosis (PTB) but who were sputum smear- and GeneXpert-negative. The findings demonstrated that GeneXpert on bronchial washing samples provided a significantly higher diagnostic yield (85.3%) compared to AFB smear microscopy (56.8%), confirming its superior sensitivity in detecting Mycobacterium tuberculosis in patients with sputum smear-negative pulmonary tuberculosis (SSN-PTB). These results underscore the crucial role of bronchoscopic sampling combined with molecular diagnostics in improving early and accurate detection of tuberculosis in challenging diagnostic scenarios.

Omer et.al had reported that 91.7% of patients had positive results for TB on bronchoalveolar lavage through fiber-optic bronchoscopy with 100% true negative (p = 0.000). Furthermore, it was a significant procedure with a sensitivity of 91.67% and a specificity of 100%.[6] Wan et.al had diagnosed 84.4% of patients with PTB through bronchoscopy, with the sensitivity, specificity, positive predictive value,

and negative predictive value being 76.9%, 68.2%, 92.9%, and 35.3%, respectively.[11] Oh et. al found that among the patients without any findings on the microbiology for the pulmonary TB on the sputum, microbiological growth was confirmed in 49.1% of the patients after the bronchoscopy on TB culture, and additional resistance was confirmed in 10.5% of the patients.[12] Nusrullah et.al reported that the bronchial washings achieved through the bronchoscopy and subjected to AFB staining among the patients with SSN-PTB the diagnostic yield achieved was 57.5%.[13] Bronchoscopy has long been recognized as a safe, minimally invasive, and highly effective diagnostic technique for PTB, particularly in patients with SSN-PTB, where conventional diagnostic methods often fail. Its ability to directly visualize bronchial structures and obtain targeted samples, such as bronchial washings or bronchoalveolar lavage, markedly enhances the likelihood of detecting Mycobacterium tuberculosis. The bronchoscopy-based sampling provides a significantly higher diagnostic yield than both regular and induced sputum methods, especially in paucibacillary disease. The procedure enables the collection of high-quality specimens from the site of maximal radiological involvement, thereby improving test sensitivity for AFB smear microscopy, GeneXpert MTB/RIF assay, and culture. Consequently, the integration of fiber-optic bronchoscopy into diagnostic protocols for SSN-PTB has proven instrumental in facilitating early, accurate, and microbiologically confirmed diagnoses, ultimately improving patient outcomes.[14, 15]

The low sensitivity of direct AFB smear in comparison to GeneXpert, despite being cost-effective and specific, remains a challenge in TB diagnosis. Otutu et.al showed that 36.7% were positive for smear microscopy and 63.3% were positive for GeneXpert, concluding that GeneXpert demonstrated a higher prevalence rate of detected Mycobacterium tuberculosis in sputum samples compared to the AFB smear microscopy. (16) Ahmed et al. also reported comparable results, indicating that 69.1% of the smears were AFB-positive with characteristics suggesting tuberculous infection. This percentage rose to 91% following GeneXpert Analysis. In cases with indeterminate cytology, 55.8% were AFB-positive, which increased to 83.7% upon the use of GeneXpert.[17] The conventional method for detecting Mycobacterium tuberculosis has long been acid-fast bacilli (AFB) smear microscopy, a technique that remains the cornerstone of tuberculosis (TB) diagnosis in many resource-limited settings. This method is valued for its simplicity, rapid turnaround time, and low operational cost, making it suitable for large-scale screening programs. However, despite these advantages, AFB smear microscopy is significantly limited by its sensitivity and specificity, particularly in paucibacillary or sputum-scarce cases, where the bacterial load is insufficient for microscopic visualization. The diagnostic process is also subject to observer variability. [18, 19]

In contrast, the advent of molecular diagnostic techniques, particularly the GeneXpert MTB/RIF assay, has revolutionized tuberculosis detection by providing a rapid, sensitive, and automated alternative to conventional microscopy. The GeneXpert system utilizes nucleic acid amplification technology to identify specific DNA sequences of M. tuberculosis directly from clinical specimens, including sputum and bronchial washings. Its ability to detect minute quantities of bacterial DNA allows it to accurately diagnose TB even in cases with low bacterial loads, thereby addressing one of the principal limitations of AFB smear microscopy. Moreover, the GeneXpert assay simultaneously detects mutations in the rpoB gene, enabling the identification of rifampicin resistance, a key marker for multidrug-resistant TB (MDR-TB), within approximately two hours. The molecular foundation of GeneXpert not only enhances analytical sensitivity but also eliminates much of the subjectivity associated with smear interpretation, ensuring greater reproducibility and consistency of results across laboratories. These features render GeneXpert a more reliable and efficient diagnostic tool, particularly in high-burden regions where rapid detection is critical for infection control.[20]

Despite its clear advantages, the widespread implementation of GeneXpert faces several challenges, especially in low-income and resource-constrained countries. The high cost of cartridges and instruments, the need for stable electricity and temperature-controlled environments, and the shortage of trained laboratory personnel limit its accessibility and scalability. Addressing these logistical and financial constraints through international funding, government investment, and local capacity building will be essential to ensure equitable access to molecular diagnostics. Expanding GeneXpert testing, particularly in secondary and tertiary care centers, could dramatically improve early TB detection, facilitate prompt initiation of therapy, and reduce transmission, thereby strengthening tuberculosis control programs in endemic regions.[21, 22]

This research carries significant clinical and public health implications, particularly for resource-limited and high TB burden settings such as Pakistan, where early and accurate diagnosis remains a persistent challenge. Although fiber-optic bronchoscopy and GeneXpert MTB/RIF testing are relatively more costly and require specialized infrastructure compared to conventional sputum smear microscopy, their substantially higher diagnostic yield justifies their use in patients suspected of having SSN-PTB. In these cases, reliance solely on traditional diagnostic techniques often results in delayed detection, continued disease transmission, and worse clinical outcomes. The integration of bronchial washing analysis with GeneXpert testing not only enhances diagnostic sensitivity but also provides the added advantage of detecting rifampicin resistance, which is critical for guiding appropriate treatment regimens. The World Health Organization (WHO) has already endorsed the incorporation

of GeneXpert technology into national tuberculosis control programs, and the findings of this study further reinforce its pivotal role in improving diagnostic accuracy and timeliness. By expanding access to these molecular diagnostics, particularly in secondary and tertiary care facilities, healthcare systems can strengthen case detection, initiate earlier treatment, and ultimately contribute to reducing TB transmission and mortality in high-burden populations.[23, 24]

A major strength of this study lies in its focus on a clinically challenging subset of patients, those with sputum smear and GeneXpert-negative PTB for whom diagnosis is often delayed or missed. By employing bronchial washing specimens obtained through fiber-optic bronchoscopy, the study provides valuable insight into the diagnostic utility of this minimally invasive yet highly effective procedure. The use of both AFB smear microscopy and GeneXpert MTB/RIF assay on the same bronchial samples allows for a direct comparison of conventional and molecular diagnostic methods, enhancing the reliability of findings. Importantly, the study's findings are directly applicable to resource-limited, high TB-burden settings, such as Pakistan, and offer practical recommendations for integrating bronchoscopy-based molecular testing into existing tuberculosis diagnostic frameworks.

Limitations: This study has certain limitations that should be acknowledged when interpreting the findings. Being conducted at a single tertiary care center, the results may not be fully generalizable to the broader population, as regional variations in disease prevalence, diagnostic facilities, and patient characteristics may influence outcomes. Furthermore, the study did not include mycobacterial culture, which is internationally recognized as the gold standard for confirming tuberculosis and determining drug susceptibility. The exclusion of culture-based testing was primarily due to constraints of time, resources, and laboratory capacity, which limited the ability to perform a direct comparison of sensitivity, specificity, and predictive values between GeneXpert, AFB smear microscopy, and culture.

CONCLUSION

In conclusion, the findings of this study demonstrate that in patients with a high clinical and radiological suspicion of PTB but who are negative for sputum AFB smear and GeneXpert, the analysis of bronchial washing specimens significantly enhances the overall diagnostic yield. The GeneXpert MTB/RIF assay performed on bronchial washings was able to identify Mycobacterium tuberculosis in a substantially greater proportion of cases compared with AFB smear microscopy, thereby highlighting its superior sensitivity, particularly in paucibacillary or sputum-scarce forms of PTB. Beyond its diagnostic sensitivity, GeneXpert offers additional advantages, including the rapid detection of rifampicin resistance, which enables earlier initiation of appropriate therapy and reduces the risk of delayed or ineffective treatment. In contrast, while AFB smear microscopy continues to serve as a cost-effective and highly specific diagnostic tool, its limited sensitivity underscores the need to integrate more advanced molecular diagnostics within routine clinical protocols. Expanding access to bronchoscopy services and GeneXpert testing at secondary and tertiary care centers—particularly in high-burden and resource-limited settings can play a pivotal role in improving early case detection. Furthermore, regular training of healthcare personnel, capacity building in diagnostic laboratories, and integration of molecular testing with national tuberculosis control programs are essential steps to enhance diagnostic efficiency and ensure timely treatment. Collectively, such measures could contribute significantly to reducing diagnostic delays, limiting disease transmission, and ultimately strengthening tuberculosis control strategies in high-prevalence regions.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: We acknowledge the faculty of the Department of Pulmonology, Mayo Hospital, Lahore for their support and the patients for their contribution to this study.

Authors Contribution:
Muhammad Zaid Iqbal I declare no conflict of interest.
Muhammad Younus I declare no conflict of interest.
Abdus Salam I declare no conflict of interest.
Abdul Wahab Gureja I declare no conflict of interest.
Faiza Khalid I declare no conflict of interest.
Muhammad Sarfraz Munawar I declare no conflict of interest.

REFERENCES

1. Khan MA, Bilal W, Asim H, Rahmat ZS, Essar MY, Ahmad S. MDR-TB in Pakistan: Challenges, efforts, and recommendations. Ann Med Surg. 2022: 79:104009. DOI: 10.1016/j.amsu.2022.104009
2. Organization WH. TB disease burden 2024 (Internet). Available from, URL: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024/tb-disease-burden.
3. Gaude G, Samskruti S, Hattiholi J, Patil B. Diagnostic Yield of Bronchoalveolar lavage Xpert MTB/RIF Assay (Gene Xpert® in Sputum Smear Negative Pulmonary Tuberculosis Patients–A One Year Cross Sectional Study. SAARC J Tuberc Lung Dis HIV/AIDS. 2019: 17(2):1-7. DOI: 10.3126/saarctb.v17i2.49108
4. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021: 113:S7-S12. DOI: 10.1016/j.ijid.2021.02.107
5. Luhadia A, Luhadia SK, Jain S, Hanfe MH, Oza D, Zota A, et al. Role of fiberoptic bronchoscopy in sputum smear negative suspected cases of pulmonary tuberculosis: a study conducted in Southern part of Rajasthan. Int J Res Med Sci. 2020: 8(12):4302. DOI: 10.18203/2320-6012.ijrms20204994

6. Omer AM, Allah HMA, Sayed WH. Role of fiberoptic Bronchoscopy in diagnosis of smear negative pulmonary TB. Al-Azhar Int Med J. 2023: 4(10):36. DOI: 10.58675/2682-339X.1974
7. Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis. 2015: 78(2):64. DOI: 10.4046/trd.2015.78.2.64
8. Waikar S, Pathak A, Ghule V, Kapoor A, Sagili K, Babu E, Chadha S. Should sputum-negative presumptive TB patients be actively followed to identify missing cases in India? Public Health Action. 2017: 7(4):289-93. DOI: 10.5588/pha.17.0035
9. Swai HF, Mugusi FM, Mbwambo JK. Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes. 2011: 4(1):475. DOI: 10.1186/1756- 0500-4-475
10. Qanash S, Hakami OA, Al-Husayni F, Gari AG. Flexible fiberoptic bronchoscopy: indications, diagnostic yield and complications. Cureus. 2020: 12(10). DOI: 10.7759/cureus.11122
11. Wan T, Hu Q, Hu W, Deng H, Li D. Utility of Rapid On-Site Evaluation during Bronchoscopy in the Diagnosis of Pulmonary Tuberculosis. Acta Cytol. 2024: 68(2):153-9. DOI: 10.1159/000538094
12. Oh JY, Lee S-S, Kim HW, Min J, Ko Y, Koo H-K, et al. Additional usefulness of bronchoscopy in patients with initial microbiologically negative pulmonary tuberculosis: a retrospective analysis of a Korean Nationwide prospective cohort study. Infect Drug Resist. 2022:1029-37. DOI: 10.2147/IDR.S354962
13. Nusrullah M, Hamid A, Rashid M, Waqas HMT, Rauf A. Diagnostic Yield of Fiberoptic Bronchoscopy Washings among Patients of Sputum Smear Negative Pulmonary Tuberculosis. Pak J Med Health Sci. 2022: 16(10):445-46. DOI: 10.53350/pjmhs221610445
14. Prasad R, Singh A. Role of bronchoscopy in diagnosis of smear-negative pulmonary tuberculosis. Egypt J Bronchol. 2019: 13(1):1-5. DOI: 10.4103/ejb.ejb_34_18
15. Imtiaz S, Batubara EM. Diagnostic value of bronchoscopy in sputum-negative pulmonary tuberculosis patients and its correlation with clinicoradiological features. Ann Thorac Med. 2022: 17(2):124-31. DOI: 10.4103/atm.atm_487_21
16. Moses-Otutu I, Musa H, Aichinede E. Comparative analysis between Genexpert and AAFB smear technique in Mycobacterium tuberculosis detection in sputum samples from HIV-negative patients. Dutse J Pure Appl Sci. 2024: 10(3b):146-53. DOI: 10.4314/dujopas.v10i3b.15
17. Ahmed S, Ansari HA, Fatima N. A comparative study of the role of cytopathology, staining for acid-fast bacilli and genexpert MTB/RIF assay in the diagnosis of tubercular lymphadenopathy. IP J Diagn Pathol Oncol. 2022: 7:22-9. DOI: 10.18231/j.jdpo.2022.005
18. Elbrolosy AM, El Helbawy RH, Mansour OM, Latif RA. Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis. BMC Microbiol. 2021: 21(1):144. DOI: 10.1186/s12866-021-02210-5
19. Singh UB, Singh M, Rodrigues C, Christopher D, Mahajan N, Srivastav A, et al. Multi-centric evaluation of Truenat MTB and MTB-RIF Dx assays for diagnosis of extrapulmonary tuberculosis. Sci Rep. 2024: 14(1):15680. DOI: 10.1038/s41598-024-64688-z
20. Zaporojan N, Negrean RA, Hodi?an R, Zaporojan C, Csep A, Zaha DC. Evolution of laboratory diagnosis of tuberculosis. Clin Pract. 2024: 14(2):388-416. DOI: 10.3390/clinpract14020030
21. Dahiya B, Mehta N, Soni A, Mehta PK. Diagnosis of extrapulmonary tuberculosis by GeneXpert MTB/RIF Ultra assay. Expert Rev Mol Diagn. 2023: 23(7):561-82.DOI: 10.1080/14737159.2023.2223980
22. Rimal R, Shrestha D, Pyakurel S, Poudel R, Shrestha P, Rai KR, Ghimire GR, Rai G, Rai SK. Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients. BMC Infect Dis. 2022 Apr 1: 22(1):321. DOI: 10.1186/s12879-022-07287-5.
23. Organization WH. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: Rapid communication. Policy update: World Health Organization: 2020 (Internet). Avaialable from, URL: https://www.who.int/publications/i/item/9789240000339
24. Pongpeeradech N, Kasetchareo Y, Chuchottaworn C, Lawpoolsri S, Silachamroon U, Kaewkungwal J. Evaluation of the use of GeneXpert MTB/RIF in a zone with high burden of tuberculosis in Thailand. Plos one. 2022: 17(7):e0271130. DOI: 10.1371/journal.pone.0271130

Original Article **Open Access**

Efficacy of combined treatment with Ketoconazole 2% Cream and Adapalene 0.1% Gel vs. Ketoconazole 2% Cream monotherapy in Pityriasis Versicolor

Sunaina Kumari, Atiya Rahman, Janta Choudhry, Sana Saleem, Jotee Rani, Sadia

ABSTRACT

Objective: To compare the efficacy of combined treatment with Ketoconazole 2% Cream and Adapalene 0.1% Gel versus Ketoconazole 2% Cream monotherapy in Pityriasis Versicolor.

Study design and Setting: Randomized Controlled Trial conducted at Dermatology Department of PNS Shifa, Karachi from 19th July 2024 to 30th July 2025.

Methods: A randomized trial included 176 patients with Pityriasis Versicolor (88 per group). Group A received ketoconazole 2% cream twice daily plus Adapalene 0.1% gel nightly for 4 weeks, and Group B received ketoconazole alone. Efficacy at week 4 was defined by clinical improvement, negative Wood's lamp, and KOH microscopy. Data were analyzed in SPSS v26 using chi-square test; Means and standard deviations were calculated for continuous variables (age, BMI, disease duration), while frequencies and percentages were reported for categorical variables (gender, efficacy). The chi-square test was used to compare efficacy between groups, $p<0.05$ was considered significant.

Results: The mean age in Group A was 25.1 ± 4.0 years and in Group B was 25.8 ± 4.2 years. The majority of patients were male, and the distribution of types of pigmentation was comparable in both groups. The efficacy of combination therapy (Group A) was 89.8%, compared to 43.2% with monotherapy (Group B), demonstrating a statistically significant difference ($p < 0.001$).

Conclusions: Combination therapy with ketoconazole and adapalene was significantly more effective than ketoconazole monotherapy in the treatment of Pityriasis Versicolor

Keywords: Adapalene, Combination treatment, Efficacy, Ketoconazole

How to cite this Article:
Kumari Sm Rahman A, Choudhry J, Saleem S, Rani J, Abbasi S. Efficacy of combined treatment with Ketoconazole 2% Cream and Adapalene 0.1% Gel vs. Ketoconazole 2% Cream monotherapy in Pityriasis Versicolor. J Bahria Uni Med Dental Coll. 2026;16(2):526-31 DOI: https://doi.org/10.51985/JBUMDC2025740

Sunaina Kumari
Resident, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: sunainap7@gmail.com

Atiya Rahman
Consultant, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: atiya_rahman7@yahoo.com

Janta Choudhry
Resident, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: kumarijanta7@gmail.com

Sana Saleem
Resident, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: Sanasaleem20649@gmail.com

Jotee Rani
Resident, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: jotyrani321@gmail.com

Sadia Abbasi
Resident, Department of Dermatology
PNS Shifa Hospital, Karachi.
Email: sadia.abbasi038@gmail.com

Received: 01-10-2025
1st Revision:11-11-2025
2nd Revision: 17-12-2025
Accepted: 03-03-2026

INTRODUCTION

Pityriasis versicolor (PV) or tinea versicolor, is a common superficial fungal infection of the skin caused by Malassezia species: lipophilic yeasts which make up a part of the normal human flora.[1] Certain environmental and physiologic situations affect this commensal opportunistic pathogen by promoting its transformation from saprophytic yeast to pathogenic mycelial form leading to clinical development of PV.[2] A number of host and environmental factors affect the transition of Malassezia as a commensal yeast form to the pathogenic mycelial form. High humidity, elevated temperature, and excessive sweating as well as increased activity in sebaceous glands is also a favorable microenvironment to the growth and colonization of fungi, which has been attributed through dermoscopic studies to reasons why PV is higher and more persistent in tropical and subtropical climates.This conversion is stimulated by humidity, temperature and the presence of high serum concentration, factors that favored fungal growth and colonization.[3] Thus, a higher prevalence of the disease is mostly observed in tropical and subtropical areas with climatic conditions favorable to fungal overgrowth, where

it may reach an endemic level and at least during conventionally period such as summer.

Clinically, PV manifest as multiple round or oval macules and patches with variable pigmentation such as hypopigmented form in some places on the body of the host, hyperpigmented at others and also form erythematous to any skin toned brownish color depending upon the type of skin of the host and its immune response.4 PV diagnosis is mostly clinical and is guided by the characteristic morphology and distribution of the lesions though laboratory studies are normally conducted to confirm the diagnosis or rule out the PV pigmentary disorder and other related pigmentary disorders including vitiligo, pityriasis alba and seborrheic dermatitis. A lamp inspection of the wood is usually yellow fluorescence or yellow-green fluorescence which is characteristic of Malassezia infection. Direct microscopic observation of skin scrapings that have been impregnated with potassium hydroxide (KOH) illustrates the classical spaghetti and meat ball pattern of short hyphae and groups of spores.5

Though PV is a harmless dermatological disease, it can cause significant cosmetic anxiety and psychological distress to patients, especially to young adults who constitute the most common population to be affected. PV variants with unusual presentations have also been reported, further increasing the problem of diagnosis and anxiety in patients.6 A variety of antifungal agents have been applied in managing the superficial type of fungus, including the following PV.7 Topical and systemic azoles and allylamines are some of the most common therapeutic classes because they are able to inhibit the production of ergosterol and also destabilize the integrity of fungal cell membranes. Topical treatment is mostly used in localised disease but systemic antifungal agents are employed in extensive or recurring infections.7 of those, topical imidazoles (especially ketoconazole, clotrimazole, and miconazole) still are the first options for treatment because of well-established efficacy, cost-effectiveness, and good safety profile. 8 Ketoconazole 2% cream is especially commonly used and prescribed for localized PV. It functions by suppressing ergosterol formation in the fungal cell membrane, which causes a heightened permeability and an ultimate rupture of the membrane. Nevertheless, despite being efficient, recurrences and incomplete resolution remain common challenges. These problems often require long treatment periods, frequent applications or a use of systemic drug in recalcitrant or recurrent cases.8

With these treatment restrictions, combined protocols that improve the therapeutic index of standard antifungal therapy have drawn increasing interest. The concept of combination therapy is to attack multiple pathophysiological factors (fungicidal, epidermal turnover and post-inflammatory pigmentary changes) and thus promote a faster and more durable clinical resolution.

The recurrence and persistence of PV is greatly explained by the biological properties of Malassezia species. These pathogens have some virulence factors that promote their penetration of stratum corneum and resistance to host defenses. The infection is also likely to recur even after treatment is successful, as Malassezia is part of normal skin microflora, and the presence of increased sebum production and excessive sweating contributes to the development of new episodes of infection.[9] Ketoconazole and clotrimazole are imidazole-based antifungal agents that are considered effective, inexpensive, and safe treatment options in pityriasis versicolor due to their mechanism of action, i.e., inhibiting ergosterol synthesis causing disruption of fungal cell membranes.[1o] Long-term use and recurrence is still a frequent issue, and thus there is a need to develop better treatment modalities.

There are some clinical observations that indicate the global therapeutic response upon adapalene and ketoconazole association is quite better than single therapies. This combination is presumed to achieve a faster response of the lesions, relatively shorter duration in treatment consumed, and better patient adherence people due to its visible early effect and less adverse effects. Nonetheless, despite these promising data, evidence is scarce, in particular from South Asian populations where the endemicity of PV and its environmental influence on persistence and relapse of disease is prominent.

In these countries, which hold among the highest incidence rates of PV in the world, patients living with young adults who are also affected have a tremendous socio-economic burden and an optimal topical therapeutic regimen is warranted that is both effective and safe, affordable and satisfactory to the patient. High rates of relapse are not only cosmetically disturbing but can also induce psychosocial burden and social embarrassment, emphasizing the need for optimal therapeutic strategies that bring complete clinical as well as mycologic cure.

Hence the present study was undertaken to compare the effectiveness and safety of ketoconazole 2% cream along with adapalene 0.1% gel v/s ketoconazole 2% cream alone in pityriasis versicolor. The effect of adapalene was investigated to see whether penetration of the antifungal, clearance and risk of economic relapse could be improved compared with standard mono-therapies.

It was postulated that the association of adapalene in combination with ketoconazole would provide a significant therapeutic advantage, due to its improved complete clinical and mycological cure rates compared to ketoconazole alone, and without increasing local adverse effects. Tolerability, compliance, and adverse event profile were also evaluated.

By investigating this combination strategy, we aim to provide further evidence on the topical treatment of PV and offer an inexpensive, safe and time-efficient option for therapy

that might be particularly useful in resource-limited, high-prevalence areas including Pakistan and other parts of South Asia. The results are anticipated to help dermatologists in the personalization of treatment regimens for PV as well as in preventing recurrent infection by enhancement of topical therapeutic approaches.

METHODOLOGY

This RCT was completed from 19th July, 2024 to 30th July, 2025 in Department of Dermatology PNS Shifa Hospital Karachi. The study was started after receiving the ethical review committee approval of the institution (ERC/2024/DERM/123) and complied with Declaration of Helsinki. Trial registration the study was prospectively registered at Iranian Registry of Clinical Trials (IRCT) with free access to Trial ID: 80249 which means that it was public from the beginning and was ethically acceptable. Before enrollment, all enrollees were invited to read about the study and its goals, advantages and possible risks in a written form and written informed consents were applied by any patient. A total of 176 patients with clinico-mycological evidence of pityriasis versicolor who presented to the outpatient department were included based on non-probability consecutive sampling. They were next randomly allocated, employing athletic lottery method, into two equal parts: Group A (n=88) and Group B (n=88). Eligible candidates were both men and women 18 to 60 years of age. Exclusion criteria were as follows: subjects aged younger than 18 years, those who had a history of antifungal agent treatment within the month before entry into study, pregnant or lactating females and known allergic hypersensitivity to ketoconazole and adapalene. Those with longstanding cutaneous diseases, for example psoriasis or eczema, were not included as these may have confounded the results; nor were those with extensive systemic illness.

Diagnosis of pityriasis versicolor was based on hypopigmented or hyperpigmented scaly macules and patches, predominantly on the trunk, shoulders, and upper arms. Diagnosis was confirmed by yellowish-green fluorescence under Wood's light and direct skin scraping with 10% KOH, showing the characteristic "spaghetti and meatballs" appearance of Malassezia species.

The sample size was estimated utilizing OpenEpi version 3.01on the basis of a previous reported study in which ketoconazole with adapalene showed an efficacy of 87.5% and for ketoconazole monotherapy efficacy is found to be 47.5%. With an 80% power and a 5% level of significance, the sample size was calculated to be 176 subjects (88 in each group), providing sufficient statistical power for identifying meaningful differences between treatments.

Both groups used medication twice a day to guarantee consistency in the frequency of application of the medication and no bias was created based on the number of applications a patient in one group made. Group A was treated with ketoconazole 2% cream in the morning and adapalene 0.1% gel in the night, and Group B was treated with ketoconazole 2% cream twice in the morning and in the evening. Both groups were treated four weeks. The patients were advised to wash the affected parts using water and dry them before applying medication. Dress change and occlusive dressing were not recommended upon its application, and patients were asked to leave the medication to be absorbed naturally. Patients were advised not to spend excessive time in the sun during treatment. Patients were followed at 2nd and 4th weeks of therapy. Compliance was estimated at every visit in the follow-up by patient self-questionnaire and measuring the remaining dosage in the tubes. Patients were advised on compliance, hygiene and prevention of predisposing factors such as excessive sweating and application of oily skin products.

The main outcome measure of interest was efficacy at 4 weeks. This was defined as the presence of all three of:

- TTs normalized (no visible scaling and pigmentary changes),
- Lack of fluorescence under the Wood's lamp examination and
- Fungal elements were not identified on KOH microscopy.

The secondary endpoints were to record the incidence of side effects like flushing/burning, itching, erythema or contact dermatitis seen at each follow-up visit. All data were managed and analyzed with SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Age, BMI, and duration of disease were expressed as mean ± SD; whereas gender, type of pigmentation, and efficacy were presented as frequencies and percentages. The chi-square test was applied for comparison between 2 groups of categorical outcomes including the efficacy and side effect of treatment. When appropriate, independent samples t-test was used to compare quantitative variables. P-value < 0.05 was considered as statistically significant. This approach permitted thorough comparison of both treatments with respect to efficacy and safety. To assess if the addition of adapalene to ketoconazole provides superior clinical and mycological cure rates in pityriasis versicolor-a condition well known for high rate of recurrence and incomplete clearing with a single anti-fungal agent, but responding rapidly due not only primarily to its anti-fungal but also partly keratolytic effect.

RESULTS

A total of 176 patients fulfilling the inclusion criteria were enrolled and randomly allocated into two equal groups, with 88 patients in Group A and 88 patients in Group B. All enrolled patients completed the study and were included in the final analysis. The baseline characteristics of the two groups were comparable with no statistically significant differences (**Table 1**).

The mean age of patients in Group A was 25.1 ± 4.0 years compared to 25.8 ± 4.2 years in Group B ($p = 0.32$). The mean body mass index (BMI) was 22.5 ± 3.5 kg/m² in Group

A and 22.7 ± 3.6 kg/m² in Group B (p = 0.65). The mean duration of disease was 3.7 ± 1.2 weeks in Group A and 3.6 ± 1.1 weeks in Group B (p = 0.74).

In Group A, 68 patients (77.3%) were males and 20 patients (22.7%) were females, whereas Group B included 64 males (72.7%) and 24 females (27.3%), with no statistically significant difference between groups (p = 0.48). The type of pigmentation was also similar between the groups (p = 0.94). Hypopigmented lesions were present in 46 patients (52.3%), hyperpigmented lesions in 30 patients (34.1%), and erythematous lesions in 12 patients (13.6%) in Group A, compared with 44 patients (50.0%), 32 patients (36.4%), and 12 patients (13.6%) respectively in Group B. These findings indicate that both groups were comparable at baseline.

At the end of four weeks of treatment, a statistically significant difference in efficacy was observed between the two groups (**Table 2**). Clinical and mycological cure was achieved in 79 patients (89.8%) in Group A compared to 38 patients (43.2%) in Group B (p < 0.001). Treatment failure was observed in 9 patients (10.2%) in Group A and 50 patients (56.8%) in Group B.

Both treatment regimens were well tolerated with no serious adverse events reported during the study period (**Table 3**). Adverse effects were mild and self-limiting, and no patient discontinued treatment due to side effects. Burning sensation was the most common adverse effect, occurring in 9 patients (10.2%) in Group A and 6 patients (6.8%) in Group B (p = 0.42). Erythema was observed in 12 patients (13.6%) in Group A and 5 patients (5.6%) in Group B (p = 0.09). No cases of contact dermatitis were reported in either group.

Overall, the combination therapy used in Group A demonstrated significantly higher efficacy compared to ketoconazole monotherapy, while both treatments showed good tolerability.

DISCUSSION

The present research demonstrated that this kind of combined therapy was more effective in comparison to ketoconazole monotherapy in PV treatment. Following 4 weeks of therapy, combination-treated patients (adapalene and ketoconazole) achieved a full clinical and mycological response in 89.8%

Table 1. Baseline Characteristics of Patients

Characteristic	Group A (n=88)	Group B (n=88)	P-value
Age (years, mean ± SD)	25.1 ± 4.0	25.8 ± 4.2	0.32
BMI (kg/m², mean ± SD)	22.5 ± 3.5	22.7 ± 3.6	0.65
Duration of disease (weeks, mean ± SD)	3.7 ± 1.2	3.6 ± 1.1	0.74
Gender	—	—	0.48
• Male	68 (77.3%)	64 (72.7%)	
• Female	20 (22.7%)	24 (27.3%)	
Type of pigmentation	—	—	0.94
• Hypopigmented	46 (52.3%)	44 (50.0%)	
• Hyperpigmented	30 (34.1%)	32 (36.4%)	
• Erythematous	12 (13.6%)	12 (13.6%)	

Figure 1: Efficacy: Complete Clinical and Mycological Response at Week 4.

Table 2. Comparison of Efficacy between Groups.

Efficacy	Group A (n=88)	Group B (n=88)	P-value
Yes	79 (89.8%)	38 (43.2%)	<0.001
No	9 (10.2%)	50 (56.8%)	

Table 3. Adverse events.

Side Effect	Group A (n=88)	Group B (n=88)	P-value
Burning	9 (10.2%)	6 (6.8%)	0.42
Erythema	12 (13.6%)	5 (5.6%)	0.09
Contact dermatitis	0 (0%)	0 (0%)	NA



compared to monotherapy-treated patients (43.2%) ($p < 0.001$). [11] This comparative result demonstrates the clinical and mycological effectiveness of the combination of adapalene and ketoconazole and suggests that they are highly synergistic, which increases the intensity of anti-fungal effects but does not shorten treatment duration. [12] The findings of the present study are in line with those reported previously that use of topical antifungal drugs together with keratolytic or retinoids promotes drug penetration and shortens the treatment period for fungal clearance. [13] By virtue of its comedolytic as well as an epidermal differentiation–modulating effects, Adapalene may enhance desquamation of the infected keratinocytes thereby promoting greater penetration and activity of ketoconazole into the stratum corneum. Such a combination of the above mechanisms is likely to explain the much higher clearances in these two groups.

Baseline characteristics, including age, gender, body mass index (BMI), disease duration, and type of pigmentation, were comparable between the two groups, indicating that therapeutic outcomes were independent of demographic or disease-related factors. The mean age (Group A: 25.1 ± 4.0 years; Group B: 25.8 ± 4.2 years) aligns with the known epidemiology of PV, which predominantly affects young adults. The observed male-to-female ratio also corresponds with regional reports, likely reflecting greater exposure to heat and humidity, increased sebaceous activity, and occupational factors that favor fungal proliferation.[14–15]In terms of safety and tolerability, both regimens were well tolerated and there were no grade 3/4 adverse events. Incidence and severity of mild burning in the combination group were 10.2% and that percentage in the monotherapy group was 6.8% ($p = 0.42$), respectively, and erythema was observed in 13.6% and 5.6%, respectively ($p = 0.09$). These were self-limiting responses all of which went away without any intervention. Most importantly, no contact dermatitis was found, providing the information that the combination can be used in the clinic regularly and does not influence compliance.

The multispecificity of the pharmacological characteristics of both medications may be the foundation of the effectiveness of the combined treatment. Ketoconazole (a drug belonging to the imidazole antifungal drug family) exerts its antifungal effects by inhibiting the production of ergosterol in the fungal cell membrane which leads to cellular lysis and inhibits growth. The third-generation topical retinoid Adapalene is a normalizer of follicular keratinization, a reduction of cohesion of corneocytes and epidermal turnover.[16] Collectively, these actions lead to the more rapid and efficient ablation of the infected stratum corneum, enhanced clinical resolution, and reduced recurrence.

The clinical implications of these findings are substantial, especially in tropical and subtropical areas where atmospheric PV has a high level, and relapses may be caused by a warm temperature which is resiliently supported with unremitting humidity. [17] Ketoconazole administration followed by the addition of adapalene enabled a reduction of length treatment, increase of patient compliance and satisfaction and early high visible effect. The lack of patients with significant irritation or systemic adverse reactions is also favorable to our combination as first line topical treatment of PV, in the routine dermatologic clinical practice. [18]

Regarding the public health, this combination therapy has a number of benefits such as low cost, broad availability and easy administration. These characteristics render it especially appropriate to mass usage in resource-constrained environments in which systemic antifungal therapy can be either unfeasible or unwarranted. Additionally, the better clinical and mycological treatment results in the absence of a relationship between the number of adverse events evidenced that the regimen is one of the most balanced and effective ones in terms of clinical and safety indicators today. It should however be noted that the daily application number should be uniformed among the treatment groups in order to prevent the possibility of bias in treatment outcomes.[1?–2°]

This RCT has shown that the combination regimen of ketoconazole 2% cream and adapalene 0·1% gel is superior to monotherapy with ketoconazole in the therapy of PV both clinically and statistically. The combination exhibited significantly higher rates of clinical and mycological cure, was well-tolerated among patients with no or mild side-effects. Adapalene, when combined with standard antifungal therapy, may enhance response rates and reduce the recurrence of these infections enhancing patient compliance. Additional, multicenter trials with long-term follow up are recommended to confirm these results and for assessment of the long-term relapse rate after this combination therapy.

Limitations of the study: This study had a small sample size, as well as being carried out at a single center and this may impact the generalization of its results. The relatively short follow-up might not be sensitive enough to detect long-term recurrence. Besides, the evaluation of the response to treatment was mainly clinical and not mycological by culture in such cases. Patient compliance with topical treatment and variations in skin type among the patients might also have affected the outcomes.

CONCLUSION

The present study demonstrates that the combination of ketoconazole 2% cream with adapalene 0.1% gel is more effective than ketoconazole monotherapy each twice a day in achieving faster and higher clinical improvement in pityriasis versicolor. The enhanced efficacy of the combination may be attributed to the antifungal action of ketoconazole together with the keratolytic and comedolytic effects of adapalene, which facilitate removal of infected stratum corneum and improve drug penetration. Given its favorable safety profile, the combination therapy can be

considered a promising alternative to conventional topical antifungal monotherapy. However, larger multicenter randomized controlled trials with longer follow-up are needed to confirm these findings and to evaluate relapse rates. Given its efficacy and favorable safety profile, the combination regimen may be considered a practical first-line option for patients with recurrent or extensive pityriasis versicolor.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Sunaina Kumari: Conception and design of study, data collection, drafting of manuscript, final approval
Atiya Rahman: Study design, supervision, methodology refinement, critical review of manuscript
Janta Choudhry: Data acquisition, literature review, initial drafting of sections
Sana Saleem: Methodology guidance, interpretation of results, critical revision, overall supervision
Jotee Rani: Data entry, statistical analysis, preparation of tables/figures
Sadia: Data interpretation, manuscript editing, final draft review

REFERENCES

1. Najam-Us-Saher N, Tabassum S, Sajid M, Khabir Y, Faheem A. The burden of cutaneous fungal infections in a tertiary care hospital in Pakistan. Pak J Med Sci. 2025;41(1):269-74. DOI: https://doi.org/10.12669/pjms.41.1.9061
2. Mathur M, Acharya P, Karki A, KC N, Shah J. Dermoscopic pattern of pityriasis versicolor. Clin Cosmet Investig Dermatol. 2019;12:303-9. DOI: https://doi.org/10.2147/CCID.S195166
3. Vishwanath T, Kapadia FM, Mahajan SA, Kharkar VD, Chikhalkar SB, Gole PV et al. Dermoscopic Perspective of Pityriasis Versicolor in a Cross-Sectional Study. Indian Dermatology Online Journal. 2024 Mar; 15(2): 218-25. DOI: https://doi.org/10.4103/idoj.idoj_319_23
4. Tligui H, El Ftouh S, Oudaina W. Epidemioclinical and mycological patterns of pityriasis versicolor in the urban area. J Med Surg Res. 2020;6:702-4. Available from: https://www.journal-jmsr.net/article_html.php? did=7112 &issueno=0
5. Leung AKC, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Drugs Context. 2022;11:2022-9-2. DOI: https://doi.org/10.7573/dic.2022-9-2.
6. Chang YM and Wu PY. Atrophying pityriasis versicolor: A rare variant with review of literature. Dermatologica Sinica. 2021 Apr; 39(2): 83-4. DOI: https://doi.org/10.4103/ds.ds_3_21
7. Kharkar RD, Girdhar M, Banerjee G, Salim T, Sen M, Haldar S, et al. Expert opinion on current and emerging treatments in dermatophytosis. Int J Res Dermatol. 2022;8(2):161-167. DOI: https://doi.org/10.18203/issn.2455-4529.IntJRes Dermatol20214927
8. Munir F, Khattak E, Abbasi WZ, Shakir S, Ahmed S, Ali A. Efficacy of combination of topical ketoconazole 2% cream and adapalene 0.1% gel versus topical ketoconazole 2% cream alone in treatment of pityriasis versicolor. Pak J Health Sci. 2024;5(4):83-7. Available from: https://thejas.com.pk/index.php /pjhs/article/view/1395
9. Chebil W, Rhimi W, Haouas N, Romano V, Belgacem S, Belhadj Ali H et al. Virulence factors of Malassezia strains isolated from pityriasis versicolor patients and healthy individuals. Medical Mycology. 2022 Aug; 60(8): myac060. DOI: https://doi.org/10.1093/mmy/myac060
10. Bhargava S, Chakrabarty S, Damodaran RT, Saikia PK, Shenoy M, Bangale N, Shah P. Rising burden of superficial fungal infections in India and the role of clotrimazole for optimal management. IP Indian J Clin Exp Dermatol. 2023;9(1):1-16. DOI: https://doi.org/10.18231/j.ijced.2023.001
11. Wang K, Cheng L, Li W, Jiang H, Zhang X, Liu S et al. Susceptibilities of Malassezia strains from pityriasis versicolor, Malassezia folliculitis and seborrheic dermatitis to antifungal drugs. Heliyon. 2020 Jun; 6(6). DOI: https://doi.org/10.1016/j. heliyon.2020.e04203
12. Karray M, McKinney WP. Tinea versicolor. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Updated 2024 Feb 12]. DOI: https://www.ncbi.nlm. nih.gov/books/NBK482500/
13. Hameed S, Paracha MM, Sagheer F, Khan AQ, Noor SM. Comparative study of efficacy of combined treatment with ketoconazole 2% cream and adapalene 0.1% gel vs ketoconazole 2% cream monotherapy in pityriasis versicolor. Am J Health Med Nurs Prac. 2022;7(6):33-40. DOI: https://doi.org/10.47672/ajhmn.1029
14. Saunte DML, Gaitanis G, Hay RJ. Malassezia-associated skin diseases, the use of diagnostics and treatment. Front Cell Infect Microbiol. 2020;10:112. DOI: https://doi.org/10.3389/ fcimb.2020.00112
15. £abêdŸ N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis versicolor—a narrative review on the diagnosis and management. Life. 2023 Oct; 13(10): 2097. DOI: https://doi.org/10.3390/life13102097
16. Hassan S, Ranjan A. Therapeutic efficacy of topical luliconazole versus topical ketoconazole in the treatment of pityriasis versicolor patients: a hospital based comparative study. Int J Res Dermatol. 2020;6(2):248-252. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol 20200606
17. Bansal L and Dhiman A. A brief review of fungal infection-pityriasis versicolor. EAS Journal of Medicine and Surgery. 2022; 4: 19-23. doi: 10.36349/easjms.2022.v04i01.004. DOI: https://doi.org/10.36349/easjms.2022.v04i01.004
18. Bakr E, Abdo H, Abd-Elaziz H, Abd-Elrazek H, Amer M. Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: A randomized clinical study. Dermatologic Therapy. 2020 May; 33(3): e13319. DOI: https://doi.org/10.1111/dth.13319
19. Tawfik KM, Mahmmoud WA, Ali AG. Ketoconazole 2% cream versus a combination of ketoconazole 2% cream and adapalene 0.1% gel in the treatment of pityriasis versicolor. Al-Azhar Assiut Medical Journal. 2022 Jan; 20(1): 100-3. DOI: https://doi.org/10.4103/azmj.azmj_97_21
20. Ismail BA, Fatima SH, Nawab M. The Current Understanding of the Clinical Condition Bahaq (Pityriasis Versicolor)–Hypothesis and A Review of Evidences. Traditional and Integrative Medicine. 2021 Sep: 249-58. DOI: https://doi.org/10.18502/tim.v6i3.7313

Original Article **Open Access**

Clinical Accuracy of PRISM III Score in determining mortality in severely ill Pediatric patients in Pediatric ICU

Muhammad Sajid, Mir Nousharwan, Sana Sarwar, Javaid Laal, Ameer Ahmad, Nousheen Fatima

Abstract

Objective: To assess the accuracy of PRISM III score in predicating mortality in severely ill pediatric patients.

Study Design and Settings: A cross sectional study was conducted in Pediatric ICU of BVH from 1st March 2021 to 28 Feb 2022.

Methodology: Patients were enrolled after informed consent as per inclusion and exclusion criteria. Clinical details and lab data were collected within 4 hours of admission to ICU and documented on performa. Outcome was followed. Results were analyzed in spss 20.

Results: Out of 34 patients 13 (38.2 %) were male and 21 (61.8 %) were females. Age ranges from 1 month to 14 years. Regarding diagnosis maximum patients were of pneumonia and Pyomeningitis, that were 5 each this makes 14. 7% of study population for each diagnosis. PRISM score ranges from 0 to 14 with mean of 4.3 and median of 3. Out of them 21 (61.8 %) had PRISM score 3 or less and 13 (38.2 %) had 4 or more. PRISM III score has Sensitivity of 71.4 %, specificity of 70.3 %, Positive predictive value of 38.4 %, negative predictive value 90.4% and diagnostic accuracy of 20.5 %.

Conclusion: PRISM III score has clinical accuracy of 20.5 % in determining prognosis in severely ill pediatric patients.

Keyword Index: Mortality, PRISM III score, Pediatric ICU

How to cite this Article:
Sajid M, Nousharwan M, Sarwar S, Laap J, Ahmad A, Fatima N. Clinical Accuracy of PRISM III Score in determining mortality in severely ill Pediatric patients in Pediatric ICU. J Bahria Uni Med Dental Coll. 2026;16(2):532-7 DOI: https://doi.org/10.51985/JBUMDC2025747

Muhammad Sajid
Associate Professor, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (OLD)
Allama Iqbal Medical College, Lahore (Current)
Email: sajidaimc@gmail.com

Mir Nousharwan
Senior Registrar, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (OLD)
Allama Iqbal Teaching Hospital, DG Khan (Current)
Email: dr.noushar@gmail.com

Sana Sarwar
Associate Professor, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (OLD)
Allama Iqbal Medical College, Lahore (Current)
Email: sanasarwarjaved@gmail.com

Javaid Laal
Consultant Pediatrician, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (OLD)
THQ Hospital, Lodharan (Current)
Email: drjavaidlaal@gmail.com

Ameer Ahmad
Professor, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (Current)
Email: ameermlk@yahoo.com

Nousheen Fatima
Associate Professor, Department of Pediatrics
Quaid-e-Azam Medical College, Bahawalpur (Current)
Email: nosheenfatima@hotmail.com

Received: 06-10-2025
1st Revision: 15-12-2025
Accepted: 03-03-2026
2nd Revision: 02-02-2026

INTRODUCTION

Pediatric Intensive care unit (PICU) has a pivotal role in saving lives from life threatening illnesses. But there is a huge burden over the PICU. Selection of the patients who need intensive care unit care is important in resource limited countries. To reduce extra burden, those patients should be selected who have good outcome regarding morbidity and mortality. There is a lot of advancement is going on in the field of medicine and this has increased scope of pediatric intensive care units. First pediatric ICU was established in Switzerland almost six decades' age. Since then a lot of improvement has been done in this and it resulted in improvement in mortality in children.[1] Even so many innovations and progress in treatment options, still early diagnosis and optimization in management is the key step. When a child becomes ill, there are certain changes occur in normal physiological processes. These changes result in abnormalities in vital signs of patients that involve changes in respiratory, renal, cardiovascular and endocrine parameters. These changes can be quantified by using different scoring systems by these parameters. Then these scoring systems can be used as an important tool in assessment of severity of disease, prediction of morbidity, mortality and monitoring of clinical status of patients. These scorings systems usually incorporate vital signs, clinical status and certain lab test that depict the actual disease status and severity. Indicators of scoring that make them a

better tool are; cost effective, easy to use, reliable and ability to predict the mortality.[2,30]

It was noted in previous studies that the first 24 hours of hospitalization are most important and about one third of them lose their lives in golden period[1]. A study that was done in United states showed that mortality in pediatric intensive care unit was ranged from 1. 85 % to 3.38%.[6]

Different scoring systems were being used for prediction of mortality in intensive care units. Two most common of them are Pediatric risk of mortality score (PRIM) and Pediatric index of mortality (PIM). PRIM score was initially validated from 9 pediatric ICU data from USA from 1984 and 1985.[9] This included 1415 patients from these 9 settings. Originally this included 34 variables which were difficult to get data and to calculate score. Now this has been updated and only 17 variables are being used to calculate PRISM III score.[4] This is based on assessment within first 24 hours of admission. In comparison to this PIM score was initially validated in Australia, New Zealand, and UK. It was introduced in 2003.It is based on 10 variable.

Different models have been designed in determining the mortality of the patients but among them prism scoring system is widely used worldwide [5,7,8], that's why we have selected this model in our study to predict the mortality of the patients so that we may help to choose those patients for ICU care who may get benefit from it. Different scoring systems haven compared in different studies.[9,11]

To access the good outcome, different criteria's have been designed. Among them, pediatric logistic organ dysfunction (PELOD) , Pediatric index of mortality (PIM) and Pediatric risk of mortality (PRISM) are the three frequently used scoring systems. According to the authors, Newer versions of these scoring systems, PIM 2 & PRISM III score have showed good results. [2,3,4] In 1988, Pollack et al. Initially made Pediatric Risk of Mortality (PRISM) scoring system. [8] It consisted of 14 variables, with the addition of 3 variables, PRISM was later on updated to PRISM III, in 1996.[5,6,7] In developing countries due to limited resources, any tool that can predict mortality can be helpful in prioritizing intensive care and affect outcome in critically sick patients.[10]

The purpose of our study is to determine the clinical accuracy of prism 3 scoring system in determining the mortality in pediatric intensive care unit patients at a tertiary care hospital.

METHODOLOGY

Institutional review board Quaid-e-Azam Medical College/ Bahawal Victoria Hospital Bahawalpur approved this study with letter Number 1346/DME/QAMC, Bahawalpur. This cross sectional observational study was conducted in Pediatric Intensive care unit of Quaid-e-Azam Medical College/ Bahawal Victoria Hospital Bahawalpur from 1 st March 2021 to 28 Feb 2022.

Children of either gender with age from 1 month to 15 years , who are admitted in pediatric Intensive care unit of Bahawal Victoria Hospital/ Quaid-e-Azam Medical College Bahawalpur .Exclusion criteria was; Patient having any underlying malignancy, Patients having obvious anomaly, Received any treatment before admission in any other hospital. Sampling of patients were done in convenient consecutive, non randomized manner as randomization was not required due to lack of two groups. Written informed consent was taken from either of parents before enrolling them in study. All details written in Urdu format were given to parents. All details were explained and all quires answered. All parents who signed written consent were enrolled as per inclusion and exclusion criteria. Parents were told that they can withdraw their consequent any time if they feel.

Clinical details and lab data were documented in 4 hours from admission to ICU and documented on Performa. A standard questionnaire was used. Calculation of The PRISM III score was done by using its different varibales. These variables has few clinical parameters and few laboratory tests. Among clinical indicatiors are temperature, pulse or heart rate, blood pressure (systolic), level of conciousness by GCS, and puplillary reactions to light. Laboratory test include; Aterial blood gas with values of CO2, PaO2, and especially pH. Serum glucose level, blood potassium level, white blood cells, blood urea & creatinine, PT & APTT and platelets. Each of these variable has specific score. With patients result of that variable,that score was labeeled and in the end total PRISM III score was calculated by summing up all variable score. Outcome was calculated as expiry, discharged or LAMA. Results were analyzed in SPSS 20. Descriptive statistics for quantitative data evaluated in terms of maximum & minimum ranges, mean value and importantly standard deviation (SD). Percentages and frequencies were calculated from qualitative data. The evaluation of This PRISM III score was done by its ability to predict specific outcomes by interpreting area under ROC. The parameters used for analysis of ROC curves were negative predictive value calculation and positive predictive value. Specificity and sensitivity was also calculated. Established bench marks were used as area under curve; if this value is 0.9 or more then it shows excellent discrimination, if it is 0.8 then it implies as good and lastly it is acceptable if its value is 0.7.

The PRISM III score calibration was evaluated by comparison of predicted mortality with observed mortality. In this process first step was to get predicted mortality from this, then this value was stratified in categories. Last step is comparing with observed mortality from this study. To quantify calibration, the Hosmer–Lemeshow test is an important tool for quantification of this calibration. This test used predicted mortality and compared it with observed ones and then calculated goodness-of-fit. Calibration was interpreted as acceptable if it has $p = 0.05$. And if result shows while any other results then it shows that there issues

in this scoring system.

RESULTS:

Total 34 patients were enrolled as per inclusion criteria/exclusion criteria and informed consent. Out of 34 patients 13 (38.2 %) were male and 21 (61.8 %) were females. Age ranges from 1 month to 14 years. Age groups include 1 month to 1 year 14 patients (41%), 1 year to 5 years 8 patients (23 %) and 6 years to 15 years 12 patients (35 %)

Regarding diagnosis maximum patients were of pneumonia and Pyomeningitis, that were 5 each this makes 14. 7% of study population for each diagnosis. Second most common diagnosis was diabetic ketoacidosis that had 4 patients and this makes 11.8% of total patients. 3rd common diagnosis was organophosphate poisoning that had 3 patients and this makes 8.8% of total patients. Similarly, we had 3 patients of sepsis/ acute kidney injury and this also makes 8.8 % of total patients. There were 2 patients of Dilated cardiomyopathy which makes 5.9 % of total patients similarly there were 2 patients of PPD poisoning which also makes 5.9 % of total patients. . Remaining one patients of each of following diagnosis with frequency of 2.9 % ; Xeroderma Pigmentosa, Febrile fits, Ventricular septal defect with congestive cardiac failure, Gullian Barre Syndrome, Rheumatic Fever, Acute Hepatitis

PRISM score ranges from 0 to 14 with mean of 4.3 and median of 3. Out of total patients 21 (61.8 %) had PRISM score 3 or less and 13 (38.2 %) had 4 or more. As far as outcome is concerned majority of patients that were 27(77.4 %) patients discharged which makes 77.4 % of total patients out of 34 patients seven patients were died despite all treatment and this makes 20.6 %.

When we compared prism score range with outcome. This showed that out of 21 patients who had PRISM score with equal or less than three, 19 discharged (90.5 %) and 2 of them died (9.5%). Out of 13 patients with PRISM score of four or more, 8 patients discharged (61.5 %) and 5 died (38.5%). This makes w p value 0.043 which is less than 0.05 and significant (Table 1).

PRISM III score has Sensitivity of 71.4 %, specificity of 70.3 %, Positive predictive value of 38.4 %, negative predictive value 90.4% and diagnostic accuracy of 20.5 %. . The present study concluded that prism scoring system have area under the curve is 0.779.

DISCUSSION:

Over past few decades, one of the major achievement in global health is decline in childhood mortality. Although recent data and researches only focus on reducing mortality rates and not measure long term morbidity parameters. Pediatric intensive care units are main pillars for management of sick patients and ultimately improvement of child mortality rates and contributing to this global health cause. There is

Table 1: PRISM III score groups in comparison with outcome

Prism III Score Group	Discharge	Death	Total	Mortality
1-3	19	2	21	10%
4-14	8	5	13	38%
Total	27	07	34	

P Value = 0.043

Figure 1: Showing area under curve



no accepted universal tool for assessment of sick patients admitting to pediatric ICU. Adaptation of a standardized tool in early identification of critically sick children may help in prioritizing their admission in ICU and improvement in outcome. About one fourth that is 25 percent of patients admitted in ICU with clinical or lab evidence of organ failure, and out of them mortality occur in 50 % of cases.[23]

In a study that was conducted Intensive care unit of a University Hospital of Tirsova 10 , 11000 Belgrade, Serbia by Snezana Rsovac et all; showed that when patients of pediatric age group with respiratory distress syndrome were followed for 28 days. In this follow up. The PRISM III score predicted fair outcome.[25]

In a study that was done in pediatric intensive care unit by Graziela de Araujo Costa et ; showed concluded that PIM score has discriminatory ability in adequate category. The pediatric risk of mortality score showed adequate discriminatory capacity. This inference can be interpreted in a way that pediatric ICU patient's prognosis can be assessed by this tool.[26]

Different studies showed comparison of different scoring systems for critically sick patients. In a study by Kalvit KR et all; conducted on critical patients , pediatric risk of mortality (PRISM) and pediatric index of mortality (PIM) scoring system were compared in oncology patients of pediatric age group. When compared in groups who survived with those who didn't survived in term of discriminating power, both score has this value in acceptable range.[24]

A recent study was conducted in this regard was by Srinivas, Nidhi et all in a tertiary care hospital in South India. Total 214 cases were enrolled. Age of these cases was minimum 1 month and maximum 18 years. This study lasted for 20 months. In ICU unit Pediatric Risk of Mortality PRISM III score was compared with Pediatric Index of Mortality PIM III score. Estimated mortality using PRISM III was 4 and With PIM III it was 2. In conclusion both these scoring system showed good discriminatory performance, however PRISM III had good better calibration as compared with PIM III score. Majority in this study patients suffered from some neurological disease, followed by respiratory and then cardiovascular problems. Calibration refers to the level of agreement between the actual outcome and the individual probable outcome. Hosmer–Lemeshow goodness-of-fit test was applied for this assessment. Discrimination of a test is defined as its utility in calculation of probability of mortality in both groups that are survived as compared to who didn't survived. Limitation of study was that it was a single centered small cohort with urban population and low rates of mortality.[27]

In a study that was conducted in children hospital Lahore, to different scoring systems like Pediatric Risk of Mortality (PRISM), Pediatric Logistic Organ Dysfunction (PELOD) and the Pediatric Index of Mortality 2 (PIM 2). Study population was from children. As a conclusion of this study two scoring (PRISM & PIM) were validated in Pakistani Pediatric intensive care unit settings. Poor discrimination score were showed for PELOD score in this study. Moreover some advantages were shown for PIM 2 score for patient's stratification as compared with PRISM score.[28] In a study conducted in Pakistan, PRISM score was used a predictor of mortality. This study showed that patients who were not survived had higher PRISM. There was a considerable difference in PRSIM score of patients who died as compared to patients who had good survival. In conclusion in order to prioritize care of ICU and for better outcome in term of mortality, PRISM score can be used effectively.[29]

The findings from our study showed that prism scoring have great association with the mortality. Mortality increases as the prism score increases. In this study, we observed that mortality rate was 20.58%. which is higher than the researches carried out in other countries [(9)]. Mortality rate in a study conducted in children hospital Lahore was 28.7%, which is higher than our study.[28] It was also observed that those patients who have score < 3 their mortality rate was 10% as compared to those who have score > 3 was 38 %.so we may say that those patients who have score > 3 usually benefit from PICU and they have good prognosis. This finding was similar to researches carried out in other countries.[9,10,11]

It was also observed in our study that 41.2% cases of Pyomeningitis, Pneumonia and DKA, as compared to other researches carried out in other parts of the world where more frequent admission in PICU were due to trauma and malignancies and hereditary diseases, [12] so greater emphasis should be given in the management of infectious diseases and the management of diabetes mellitus. Primary prevention of infectious diseases is more helpful in preventing these diseases and good awareness for diabetes control is more helpful in controlling this disease and prevent the undue burden over the ICU.

In our study infants were mostly admitted and affected 41.17%.as compared to other age group children. This is the most vulnerable age group for the diseases. As regard to the gender 61.76% affected were male and others were female. This result may predict that either females have more ability in combating with the stressful situation. Or males are more preferred for the hospital treatment in our setup Aragao et al. also showed that risk of mortality is more in males as compared to females.[13]

As far Median age of admitted is concerned, in our study median age of sample population is nine months which less than a study on the topic of PRISM score conducted by Pollak et al; which showed median age of children as 33 months.[5] In our study few risk factors that increased risk of mortality were identified. Out of them tow factors were mechanical ventilation(p=0.005) and Ionotropic drugs use (p=0.009). This findings was similar as found in other studies conducted on pediatric patients also showed that these are high risk procedures.[14,15]

As far as discriminatory efficacy of different scoring system are concerned, if a score has discrimination of 0.9 or more than this, this is said to be an excellent score. If it has value of 0.8 to 0.9 then it is a good scoring. If this value is 0.79 to 0.7 then is is fairly suitable.[16,17] Moreover A scoring mode's ability to predict is assessed by area under ROC curve. This can be from a value of o to 1.0. The present study concluded that prism scoring system have area under the curve is .779 which shows that it is fair scoring system in predicting the mortality. While similar results showed by results of previous researches from Pakistan. Sidique et al. and Qureshi et al. Study showed that PRISM socre has good (0.885) value of discrimination & Area under curve of ROC curve is 0.78 while an other study by showed PRISM has area under curve as 0.91. An Iranian study showed that PRISM score has discriminatory value of 0.8 while a study from India showed that this score has a good discriminatory score of 0.86.[21,22.] In a study conducted by Akhter H et all showed that area under curve was 0.63. This was lower than observed in our study.[29] So our study showed area under curve which is in fairly suitable category and some studies have higher than this and some has lower area under curve.

In our study PRISM III score has Sensitivity of 71.4 % which comparable to a study conducted in India by Srinivas, et al. that showed a sensitivity of 72.7 %. In our study

specificity of 70.3 % which is less than a similar study conducted in India by Srinivas et al; that showed specificity of PRISM III score as 83.3%. Positive predictive value of PRISM III score in our study is 38.4 % as compared Indian study by Srinivas, et al. that has positive predictive value of 19% (almost half than our study). Negative predictive value of PRISM III score in our study is 90.4% as compared to a similar study by Srinivas, et al. in India has Negative predictive value of 98.3%.[27]

Contingency table for Hosmer and Lameshow test shows comparison of expected mortality and observed mortality in different groups. In group of PRISM score less than or equal to three, we had 21 patients. Out of 21 patients of this group 19 discharged and 2 died. when we calculated expected mortality in this group for discharged and died patients, this was exactly same as expected. So observed mortality and expected mortality was same. In second group of PRIM score of 4 or more, we had total 13 patients. out of them 8 patients discharged and 5 died. Calculated mortality by this test in this group was 5 which is exactly same as observed mortality in this group. In a study by by Srinivas, et al expected mortality by Hosmer and Lameshow test was 4 and observed mortality in that study was 11 which was significantly higher than expected.[27]

Limitation: Our study has limitations of being single centre study and small population size as sample in this study. To generalize the results of it for the population it should be conducted in other centers as well and some other variables should also be added. Other similar studies had a larger sample size. This score was not compared with other scoring used to predict outcome in children. So a multi center study with different demographic profile data, using different scoring models and a larger sample size may be conducted.

Conclusion: PRISM III score has clinical accuracy of 20.5 % in determining prognosis in severely ill pediatric patients.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Muhammad Sajid, Conception and design, or acquisition of data, or analysis and interpretation of data, drafting the article, and final approval of the version to be published**.**
Mir Nousharwan, Acquisition of data.
Sana Sarwar, Conception and design, Reference Writing, Final approval of the version to be published**.**
Javaid Laal, Acquisition of data, Final approval of the version to be published**.**
Ameer Ahmad, Intlect and critical analysis of article, Manuscript writing, Final approval of the version to be published.
Nousheen Fatima, Reference Writing, Manuscript writing, Final approval of the version to be published

REFERENCES

1. Turner EL, Nielsen KR, Jamal SM, von Saint André-von Arnim A, Musa NL. A review of pediatric critical care in resourcelimited settings: A look at past, present, and future directions. Front Pediatr 2016; 4: 5.
2. Qureshi AU, Ali AS, Ahmad TM. Comparison of three prognostic scores (PRISM, PELOD and PIM 2) at pediatric intensive care unit under Pakistani circumstances. J Ayub Med Coll Abbottabad 2015; 19(2): 49-53.
3. Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. Crit Care Med 1996; 24(5): 743- 52.
4. Qiu J, Lu X, Wang K. Comparison of the pediatric risk of mortality, pediatric index of mortality, and pediatric index of mortality 2 models in a pediatric intensive care unit in China: A validation study. Medicine (Baltimore) 2017; 96(14): e6431.
5. Pollack MM, Ruttimann UE, Getson PR: Pediatric Risk of Mortality (PRISM) score . Crit Care Med. 1988, 16:1110-1116. 10.1097/00003246-198811000-00006
6. Pollack MM, Patel KM, Ruttimann UE: PRISM III: an updated pediatric risk of mortality score . Crit Care Med. 1996, 24:743-527. 10.1097/00003246-199605000-00004
7. Shann F, Pearson G, Slater A, Wilkinson K: Paediatric index mortality (PIM): a mortalityprediction model for children in intensive care. Intensive Care Med. 1997, 23:201-207.
8. Slater A, Shann F, Pearson G: PIM2: a revised version of the pediatric index of mortality . Intensive Care Med. 2003, 29:278-285. 10.1007/s00134-002-1601-2
9. Varma A, Damke S, Meshram R, Vagha J, Kher A, Vagha K: Prediction of mortality by pediatric risk of mortality (PRISM III) score in teriary care rural hospital in India. Int J Contemp Pediatr. 2017, 4:322-331.
10. Choi KM, Ng DK, Wong SF, et al.: Assessment of the pediatric index of mortality (PIM) and the pediatric risk of mortality (PRISM) III score for prediction of mortality in a pediatric intensive care unit in Hong Kong. Hong Kong Med J. 2005, 11:97-103.
11. Brady AR, Harrison D, Black S, et al.: Assessment and optimization of mortality prediction tools for admissions to pediatric intensive care in the United kingdom. Pediatrics. 2006, 117:733-742. 10.1542/peds.2005-1853
12. Mirza s, Malik L, et al.: Accuracy of Pediatric Risk of Mortality (PRISM) III Score in Predicting Mortality Outcomes in a Pediatric Intensive Care Unit in Karachi March 2020Cureus ,DOI:10.7759/cureus.7489 .
13. Araga˜o RCF, Albuquerque MFPM, Mello MJG, Ximenes AA : Risk factors associated with death in children admitted to a paediatric intensive care unit. J Trop Pediatr. 2001, 47:86-91.
14. Bora R: Prediction of mortality by pediatric risk of mortality (PRISM) III score In NGMC pediatric intensive care unit. JNGMC. 2019, 17:5-9. 10.3126/jngmc.v17i1.25305
15. Costa GA, Delgado AF, Ferraro A, Okay TS: Application of the pediatric risk of mortality (PRISM) score and determination of mortality risk factors in a tertiary pediatric intensive care unit. Clinics. 2010, 65:1087-1092.

16. Yeh TS, Pollack MM, Holbrook PR, Fields AI, Ruttiman U: Assessment of pediatric intensive care: application of the therapeutic intervention scoring system. Crit Care Med. 1982, 10:497- 500.

17. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143:29-36. 10.1148/radiology.143.1.7063747

18. Khajeh A, Noori NM, Reisi M, Fayyazi A, Mohammadi M, Miri-Aliabad G: Mortality risk prediction by application of pediatric risk of mortality scoring system in pediatric intensive care unit. Iran J Pediatr. 2013, 23:546-550

19. Siddique AW, Basheer F, Subhani FA, Meraj H, Naseem S: Mortality risk assessment in pediatric intensive care unit of a developing country using prism score. Pak Armed Forces Med J. 2019, 69:690-695

20. Qureshi AU, Ali AS, Ahmad TM: Comparison of three prognostic scores (PRISM, PELOD and PIM 2) at pediatric intensive care unit under Pakistani circumstances. J Ayub Med Coll Abbottabad. 2007, 19:49-53.

21. Varma A, Damke S, Meshram R, Vagha J, Kher A, Vagha K: Prediction of mortality by pediatric risk of mortality (PRISM III) score in teriary care rural hospital in India. Int J ontemp Pediatr. 2017, 4:322-331.

22. Khajeh A, Noori NM, Reisi M, Fayyazi A, Mohammadi M, Miri-Aliabad G: Mortality risk prediction by application of pediatric risk of mortality scoring system in pediatric intensive care unit. Iran J Pediatr. 2013, 23:546-550

23. Kafle R, Sanjeev S, Kumar G.. Utility of sequential organ failure assessment score in prognosticating sick children in paediatric intensive care unit. J Nepal Paediatr Soc 2022;42:134–139

24. Kalvit KR, Bhosale SJ, Pulinilkunnathi JG, Vijayakumaran SC, Shrivastava AM, Kulkarni AP. Comparative Performance of Pediatric Risk of Mortality IV and Pediatric Index of Mortality 3 in Critically Ill Children with Cancer: A Prospective Observational Study. Indian J Crit Care Med 2025;29(6) :486–491.

25. Rsovac, S.; Plavec, D.; Todorovic, D.; Lekovic, A.; Scepanovic, T.; Malinic, M.; Cobeljic, M.; Milosevic, K. PRISM III Score Predicts Short-Term Outcome in Children with ARDS on Conventional and High-Frequency Oscillatory Ventilation. Children 2023, 10, 14. https://doi.org/10.3390 /children 10010014

26. Graziela de Araujo Costa, Artur F Delgado, Alexandre Ferraro, Thelma Suely Okay,

27. Application of the Pediatric Risk of Mortality Score (PRISM) score and determination of mortality risk factors in a tertiary pediatric intensive care unit, Clinics, Volume 65, Issue 11. 2010,Pages 1087-1092,

28. ISSN 1807-5932,https://doi.org/10.1590/S1807-59322010001100005.

29. Srinivas, Nidhi; Venugopal, Kavya; Venkatesha, Gurudutta Avathi; Chidanand, Nagalatha. Comparison of Pediatric Risk of Mortality (PRISM III) score with Pediatric Index of Mortality (PIM III) score in Pediatric Intensive Care Unit: A Single center, prospective observational study from South India. Journal of Pediatric Critical Care 11(5):p 208-212, Sep–Oct 2024. | DOI: 10.4103/jpcc.jpcc_32_24

Original Article **Open Access**

Relationship between Preoperative Risk Factors and Need for Blood Transfusion in Transurethral Resection Of The Prostate (TURP)

Mukaram Ashraf, Jai Kumar, Lajpat Rai, Anila Jamshaid, Viran Raj Kamal, Muhammad Haroon

ABSTRACT

Objective: To assess the incidence of blood transfusion after transurethral resection of the prostate (TURP) and to examine the relationship between preoperative risk factors and need for blood transfusion.

Study design and Setting: Descriptive study conducted in the Department of Urology, The Indus Hospital and health network, Karachi from 1st Sep' 2024 to 28th Feb' 2025.

Methodology: Sixty patients who underwent TURP after approval by the IRB. Patients with bleeding diatheses, anticoagulant use within the previous 2 weeks prior to surgery or preoperative treatment with 5-alpha reductase inhibitors were excluded. The data was written on predesigned proforma and analyzed by using SPSS V.26. Risk factors were evaluated in patients who needed transfusion. Univariate analysis was performed by descriptive statistics and Chi-square or Fischer's exact test as appropriate, the level of significance adopted being $p<0.05$.

Results: Sixty patients were enrolled with a mean age of 67 ± 7.29 years. Hemoglobin and hematocrit decreased from 13.1 ± 1.42 g/dl and 39.7 ± 4.27% preoperatively to 12.3 ± 1.61 g/dl and 37.1 ± 4.68% postoperatively, with median reductions of 0.7 g/dl and 2.35%, respectively. Hypertension (28.2%) and diabetes (15.4%) were the most common comorbidities; 39.7% had none. Only one patient (1.7%) required transfusion, associated with indwelling catheter, prior TURP, short symptom duration, and prostate size of 40–60 g. No significant association between risk factors and transfusion was observed.

Conclusions: The rate of transfusion after TURP was low, Universal cross-matching and prearrangement of blood in all patients are probably not indicated.

Keywords: Aged; Blood Transfusion; Hemoglobin; Prostatic Hyperplasia; Transurethral Resection of Prostat

How to cite this Article:
Ashraf M, Kumar J, Rai L, Jamshaid A, Kamal VR, Haroon M. Relationship between Preoperative Risk Factors and Need for Blood Transfusion in Transurethral Resection of the Prostate (TURP). J Bahria Uni Med Dental Coll. 2026;16(2):538-43 DOI:https://doi.org/10.51985/ JBUMDC2025756

Mukaram Ashraf
Resident, Department of Urology
The Indus Hospital, Karachi,
Email: mukaram0332@gmail.com

Jai Kumar
Senior Registrar, Department of Urology
The Indus Hospital, Karachi,
Email: drjay104@gmail.com

Lajpat Rai
Medical Officer, Department of Urology
The Indus Hospital, Karachi,
Email: Lajpatrai585@gmail.com

Anila Jamshaid
Consultant, Department of Urology
The Indus Hospital, Karachi,
Email: anila.jamashai@tih.org.pk

Viran Raj Kamal
Resident, Department of Urology
The Indus Hospital, Karachi,
Email: viran.lalwani@gmail.com

Muhammad Haroon
Resident, Department of Urology
The Indus Hospital, Karachi,
Email: drhrajper@gmail.com

Received: 02-10-2025
1st Revision: 17-10-2025
Accepted: 25-12-2025
2nd Revision:13-11-2025

INTRODUCTION

The Benign prostatic enlargement (BPE) is a very common disease of elderly men and is still one of the most frequent causes for lower urinary tract symptoms (LUTS) world-wide. Surgery is performed when proper medical treatment does not improve patients' symptoms or complications of the condition, such as repeated urinary retention, bladder stones, and renal dysfunction, occur.[1] Transurethral resection of the prostate (TURP) remains the gold standard for symptomatic BPH yielding durable results and considerable symptom reduction.[2] Despite significant improvements in both surgical and pre-operative management, bleeding and transfusion still appears to be a significant concern of the TURP.[3]

The amount of blood loss during TURP is dependent on patient- and procedure-related factors (prostate size, resection time, patient comorbidities and the surgeon's experience).[4] Bleeding during surgery can cloud the operator's visual field, extends operative time and elevates postoperative morbidity.5 While advancements in surgical technologies, such as bipolar systems, and the implementation of patient blood management (PBM) measures have decreased

transfusion requirements, the risk remains a significant clinical concern.[6] Thus, recognition and control of preoperative risk factors for transfusion are important to enhance patient outcomes and reduce hospital resource utilization.[7]

For the past few decades, much emphasis has been placed on pharmacological means to improve perioperative hemostasis using for instance ant fibrinolytic agents. Tranexamic acid (TXA), an antifibrinolytic agent, has been demonstrated to reduce blood loss in a range of urological procedures.[8] Kim et al. performed a systematic review, and meta-analysis and found that the use of TXA reduced perioperative blood loss and blood transfusion requirement without increasing risk for thromboembolic in urology surgical procedures.[1] Similarly, Vanderbruggen et al. In a double-blinded RCT, Kathpalia et al.[2] showed that the use of TXA during TURP resulted in less intraoperative hemoglobin loss than when placebo was used. These results further assert the importance of medication support in a blood management strategy for TURP.

Apart from pharmacologic approaches to PBM, the institutional experience on PBM has been promising. Pastene et al. observed that PBM implementation at a French tertiary hospital led to marked decrease in transfusion rates during transurethral resection procedures. These guidelines address preoperative hemoglobin optimization, intraoperative blood loss-reducing efforts, and evidence-based transfusion indications. These type of protocols are fundamental in order to enhance patient safety and reduce unnecessary transfusions.

There have also been widespread contributions of technological advances to reducing transfusion requirements. In subsequent years, other technological improvements have been perfected to enhance transurethral resection of the prostate (TURP) in a more widespread manner including better visualization, advanced energy delivery systems and improved irrigation control?. Hughes Et Al remarked that despite the emergence of newer laser and minimally invasive techniques, transurethral resection of prostate still remains the most reliable and cost-effective surgical treatment for BPO. ?

Patient-specific factors continue to be key in the prediction of transfusion risk. Even a meta-analysis shows, that old patients, especially aged =85 years, are at higher risk for perioperative complications such as bleeding.7 Similarly, another study showed that patients who had catheterization before the operation experienced longer operative time, greater intraoperative bleeding and were more likely to have a postoperative transfusion. A study emphasized that patients receiving direct oral anticoagulants were at additional increased risk for bleeding despite appropriate management in the perioperative period. This evidence indicates the need for a more personalized patient assessment and optimization before TURP.

However, intra-operative complications remain possible including non-surgical bleeding and TURP syndrome reported a unique case of post-TURP in a patient with fluid overload and electrolyte imbalances, which elucidated the significance of ongoing intraoperative vigilance. Moreover, a study performed a large meta-analysis comparing the last two decades, and demonstrated that despite a decrease in major complications, transfusion stills remains one of the most common postoperative concerns.[10-12]

The continued importance of bleeding and transfusion after TURP makes determining the incidence and possible risk factors for these complications very important in order to improve surgical outcome. The purpose of this study is to determine the incidence of blood transfusion following TURP, and to examine preoperative and perioperative factors that predict the need for blood transfusion. This will add to the enhancement of perioperative planning, optimization of patient blood management approaches, and safer surgical management for patients with TURP.

METHODOLOGY

This descriptive cross-sectional study was conducted at the Department of Urology, Indus Hospital and Health Network (IHHN), Karachi, over a period of six months from 1st September 2024 to 28th February 2025,after getting approval from the Institutional Review Board Of IHHN (IHHN-IRB # : IHHN_IRB_2024_03_020). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The rights of the participants to confidentiality, voluntary participation and data privacy were preserved during the study period. The research was approved by an independent local ethics review committee to conform to international standards for biomedical research. The confidentiality and autonomy of the respondents were strictly observed from enrollment, all participants providing written informed consent prior to participation.

All male patients older than 45 scheduled for TURP due to BPH in the study period were evaluated for inclusion. The inclusion criteria were patients with a clinical and sonographic diagnosis of BPH, lower urinary tract symptoms unresponsive to medical therapy) or who had complications such as retention of urine, or recurrent hematuria. In addition, patients with a history of bleeding disorder, exposure to anticoagulant agents for 5 days or more within 1 week before surgery, and use of 5-alpha reductase inhibitors (finasteride and dutasteride) within 2 weeks prior to the procedure were excluded as these are known risk factors affecting perioperative bleeding risk and transfusion requirement (Lotterstatter et al., 2022; Kuo et al., 2024). Patients with a known history of prostate neoplasms, or undergoing reoperation were also excluded to ensure procedural uniformity.

The sample size was determined using OpenEpi version 3.01 software, assuming a transfusion rate of 10% following TURP in An earlier regional studies (Pastene et al., 2023; Porto et al., 2024), and with a confidence interval of 95% and margin error of +5%. The estimated sample size was 138 but, to improve the reliability of the statistical analysis, a total number of 150 patients were included by consecutive non-probability sampling for study period.

All patients had a comprehensive preoperative assessment. Data on demographics, medical history and comorbidities (e.g., diabetes, hypertension and cardiovascular disease) were acquired through one-on-one interviews with urology residents. Preoperative laboratory work up included CBC, coagulation profile, renal function test and urine examination. The preoperative hemoglobin and hematocrit levels were noted as the baseline reference for later comparison.

All operations were performed under spinal anesthesia with the standard monopolar resect scopes technique to reduce procedural variation. To ensure consistency of technique, all techniques are performed by senior registrars or consultants who have at least two years of independent operating experience. A solution of 5% dextrose in water was used for irrigation in all cases. A 22 Fr. three-way hematuria Foley catheter was inserted post procedures, and continuous bladder irrigation was done for the first 24 h.

Any decrease in postoperative hemoglobin and hematocrit was re-examined on the first postoperative day. Decrease of hemoglobin was defined as changed ratio between the pre- and post-interventional Hb level. Led by the institutional transfusion protocol (Eraky et al., 2024; Pastene et al., 2023), blood transfusions were given to patients with hemoglobin of =8 g/dL. Patients who developed gross hematuria postoperatively had daily CBCs repeated and were transfused clinically as necessary.

The postoperative blood transfusion was the main dependent variable. Secondary outcomes were extent of postoperative anemia and potential preoperative risk factors for transfusion such as prostate volume, baseline hemoglobin level, comorbidity, and operative time.

All statistical analyses were carried out using the IBM SPSS Statistics for Windows, (Version 26.0) software package (IBM Corp., Armonk, NY, USA). The normal distribution of continuous variables were tested, and reported as mean ± standard deviation for variables with a normal distribution or median (IQR) for skewed distribution. The frequency and percentage statistics were calculated for the categorical variables. The independent sample t-test was used to compare mean preoperative and postoperative hemoglobin and hematocrit, while Chi-square test (or Fisher exact test as applicable) determined association between categorical predictors and blood transfusion outcomes. Statistical significance level was according to p-value <0.05.

RESULTS

A total of 60 patients were enrolled in the study, with a mean age of 67 ± 7.29 years. The mean preoperative hemoglobin level was 13.1 ± 1.42 g/dL, which decreased to 12.3 ± 1.61 g/dL postoperatively. Similarly, the hematocrit level declined from 39.7 ± 4.27 to 37.08 ± 4.68 after surgery. The median reduction in hemoglobin was 0.7 g/dL (IQR: 0.4–1.27), while the median decrease in hematocrit was 2.35% (IQR: 1.07–4.4) (Table 1).

Among the comorbid conditions, hypertension was the most frequent (28.2%), followed by diabetes mellitus (15.4%). Other comorbidities—including chronic kidney disease, cerebrovascular accident, ischemic heart disease, and chronic obstructive pulmonary disease—were less common, ranging between 2.6% and 6.4%. Notably, 39.7% of the patients had no comorbidities. Most participants (73.3%) had lower urinary tract symptoms (LUTS) lasting more than six months, and 55.0% had an estimated prostate size between 40–60 g on digital rectal examination. Preoperative indwelling catheterization was present in 41.7% of the patients, while 5% had undergone prior TURP (Table 2).

Blood transfusion was rarely required—only 1 patient (1.7%) received a transfusion, whereas 59 patients (98.3%) did not. The transfused patient had multiple predisposing factors: a preoperative indwelling catheter, symptom duration of less than six months, a prostate size between 40–60 g, and a prior history of TURP. Transfusion was administered within 24 hours to 3 days postoperatively.

When analyzed for risk associations, patients with preoperative indwelling catheters and previous TURP showed a relatively higher likelihood of requiring transfusion, although none of these associations reached statistical significance ($p > 0.05$) (**Table 3**).

DISCUSSION

Transurethral resection of the prostate (TURP) is the most common minimally invasive surgical procedure that is carried out in bladder outlet obstruction due to benign prostatic hyperplasia. Though recent innovations in surgical management and improved perioperative care, perioperative bleeding is still a concern of significance. At our place, as in many other centers, it is still routine to do group and

Table 1. Descriptive Statistics of Continuous Variables (n = 60)

Parameter	Mean ± SD / Median (IQR)
Age (years)	67 ± 7.29
Hemoglobin (g/dL) preoperative	13.1 ± 1.42
Hemoglobin (g/dL) postoperative	12.3 ± 1.61
Hematocrit (%) preoperative	39.7 ± 4.27
Hematocrit (%) postoperative	37.08 ± 4.68
Drop in Hemoglobin (g/dL)	—/0.7 (0.4–1.27)
Drop in Hematocrit (%)	—/2.35 (1.07–4.4)

crossmatch prior to TURP on an off chance that patient may require some transfusion. The current series showed a post-operative transfusion rate of 1.7%, toward the lower end of reported literature (2.0%-7.0%). 7, 8 This low rate reflects advances in perioperative and surgical technology aimed to reduce intraoperative blood loss.

The relatively low rate of transfusion in our series could also be explained partly by the endoscopic management and frequent use of 5-alpha reductase inhibitors prior to TURP at our place. Preoperative use of these blockers for a period of at least 6 months decreases the prostate volume and vascularity providing decreased risk during operation. These tendencies have been realized in other series as well, with patients receiving such therapy having significantly lower transfusion rates; some have cited TICU transfusion rates of 0.6%.[9-12] The decrease in blood loss by pharmacologic modulation of prostate vascularity supports the concept of preoperative optimization in these patients.

The relationship between a variety of factors and perioperative blood loss during TURP was considered by many authors. However, the weight of the resected prostate was consistently shown to establish an independent dependence on blood loss. Our findings are in line with this evidence, as a transfusion-requiring patient with the largest prostate size in our series – approximately from 40 to 60 g – was monozygotic with a transfusion.[13-14] The increased volume of the gland extends the operation time and expands more peripherally vascular surfaces, which explains its predisposition to bleeding. Other risk factors may include pre-catheterization or re-treatment, both of which were present in the transfused patients in this case study. [15-17] Urinary tract infection due to an indwelling catheter is likely to weaken the vascularity, making resection prone to bleeding. Previous transurethral excision of the prostate may also result in reduced anatomical planes possessing weakened vascularity vulnerable to bleeding. Although the number of reported cases is insufficient for conclusive evidence, such relationships are clinically meaningful. Randomized controlled trials by larger centers could finally provide better scientific evidence.[18] Interestingly, no significant association with high transfusion risk was revealed even though most patients had significant comorbidities, particularly diabetes mellitus and hypertension. Above, data correspond to previous ones. However, the presence of pharmaco-therapeutical protocols was a key manifestation, as participants also had no data for the conclusion.[19-20]

Furthermore, various studies have examined the association between operative duration, gland size, and blood loss. Long operative times are undoubtedly topmost blood loss factor as they expose new tissue to the once concealed subjacent irrigated bed. It further normalizes the importance of a surgeon's proficiency and resection strategy optimization at minimizing the operative period and subsequent surgical bleeding. Aside from that, the introduction of bipolar resection technology, heightened ability of energy modulation, and anatomic features have also expanded cauterization has also

Table 2. Descriptive Statistics of Categorical Variables (n = 60)

Variable	Category	Frequency n (%)
Comorbidities	Hypertension	22 (28.2)
	Diabetes mellitus	12 (15.4)
	CKD	2 (2.6)
	CVA	4 (5.1)
	IHD	5 (6.4)
	COPD	2 (2.6)
	None	31 (39.7)
Duration of LUTS	< 6 months	16 (26.7)
	> 6 months	44 (73.3)
Prostate size (g)	< 40 g	11 (18.3)
	40–60 g	33 (55.0)
	> 60 g	16 (26.7)
Indwelling catheter	Yes	25 (41.7)
	No	35 (58.3)
Previous TURP	Yes	3 (5.0)
	No	57 (95.0)
Transfusion received	Yes	1 (1.7)
	No	59 (98.3)

Table 3. Association of Preoperative Risk Factors with Postoperative Blood Transfusion (n = 60)

Risk Factor	Category	Transfusion n (%)	No Transfusion n (%)	p-value
Indwelling catheter	Yes	1 (4.0)	24 (96.0)	0.28[a]
	No	0 (0.0)	35 (100)	
Duration of LUTS	< 6 months	1 (6.3)	15 (93.7)	0.17[a]
	> 6 months	0 (0.0)	44 (100)	
Previous TURP	Yes	1 (33.3)	2 (66.7)	0.06[b]
	No	0 (0.0)	57 (100)	
Prostate size (g)	< 40	0 (0.0)	11 (100)	0.49[a]
	40–60	1 (3.0)	32 (97.0)	
	> 60	0 (0.0)	16 (100)	

[a]Fisher's exact test, [b]Chi-square test, No variable showed a statistically significant association (p > 0.05)

played a major role in evading this limitation, promoting hypercoagulable settings and improved visual fields.[21] These aspects are primarily responsible for the dwindled transfusion rates reported over recent years in comparison to historical studies. While observing the present study, although all the 60 patients' blood grouping and cross matching were conducted prior to the procedure, only one necessitated transfusion. That implied that 98.3% of cross matched units were left over. Herein raises the question of the provision of such resources when transurethral resection of prostatic tissue patients get admission. Ever-increasing evidence has repeatedly stressed cost-effective ways to reduce resource waste-using the "group and save" tradition on low-class patients as low-hangers. Regular loss-making radically expands workload, blood product waste, and costs. Selective cross matching based on multiple communal factors such as large prostate size, prior catheterization, and still on-going anticoagulation could be honest examples. Additionally, peri-operative interventions to lessen surgical bleeding, including thoughtful patient selection, coagulation optimization before surgery, and an unchanging tranexamic acid use, have appeared equally advantageous.[22] Similarly, Tranexamic acid, particularly when painter into the dead space or added to irrigation fluid, has been reported to significantly reduce the intraoperative and postoperative bleeding and hemorrhage.[15-19] Overall, these procedures can be highly profitable in high-risk patients or when you need the reverse happening.

Apart from transfusion considerations, the anesthetic method and intraoperative care also can impact on perioperative complications and patient outcome. Studies have also revealed that catheter-induced inflammation as well as the anesthetic used, regional or general, could impact bleeding tendencies, although evidence is conflicting. Thus, the preferred anesthetic should be carefully chosen based on patient comorbidity and the expected difficulty of the operation. The COVID-19 pandemic also caused rescheduling and reprioritization of elective urological procedures, such as TURP, which resulted in case postponements and potentially more advanced disease at the time of surgery. These delays can also impact perioperative outcomes, including blood loss and transfusion requirements, thus the need for triage systems during such public health emergencies as the COVID-19 pandemic. In general, our data support the idea that while TURP is a safe and effective procedure, routine cross matching is not necessary for all cases. By applying group and save selectively based on predictable clinical risk factors, the use of blood transfusions can be further reduced. In addition, pharmacological interventions such as 5-alpha-reductase inhibitors or intraoperative antifibrinolytics are indicated for patients that are at high risk of bleeding to further decrease transfusion needs. In summary, this study confirms significant bleeding during TURP surgery is a relatively rare occurrence when using modern surgical and pharmacological management. The observed transfusion requirement of 1.7% is way below prior averages, reflecting patient optimization achievements and improved surgical care. Evidence-based cross matching practices, patient selection and adherence to protocols can reduce the risk of unnecessary transfusions, enhance resource management, and assure patient safety during TURP. Limitations of the study: This is a single center tertiary referral study and the results may not be generalizable to other institutions with different patient populations or operative practice. The number of subjects in the sample was not very large, therefore there may have been a lack of power to detect less common risk factors. The study was observational and, consequently, causal relationships could not be inferred. A number of potential confounders, including measurement accuracy of intraoperative blood loss and surgeon experience were not able to be tightly controlled. Furthermore, the postoperative surveillance was limited, and information on delayed transfusion requirements or long-term results was not available.

CONCLUSION

Our study demonstrates low incidence of post-TURP transfusion, which is consistent with findings in previous literature. It suggests that preoperative indwelling urinary catheter, enlarged prostate and prior history of TURP may increase the risk of transfusion. Large multicenter studies are needed to validate specific risk factors for perioperative blood transfusion in TURP. We propose that guidelines should be formulated on perioperative blood management in TURP patients.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Mukaram Ashraf: Conception and design of study, data collection, drafting of manuscript, final approval
Jai Kumar: Study design, supervision, methodology refinement, critical review of manuscript
Lajpat Rai: Data acquisition, literature review, initial drafting of sections
Anila Jamshaid: Methodology guidance, interpretation of results, critical revision, overall supervision
Viran Raj Kamal: Data entry, statistical analysis, preparation of tables/figures
Muhammad Haroon: Data interpretation, manuscript editing, final draft review

REFERENCES

1. Kim J, Alrumaih A, Donnelly C, Uy M, Hoogenes J, Matsumoto ED. The impact of tranexamic acid on perioperative outcomes in urological surgeries: a systematic review and meta-analysis. Can Urol Assoc J. 2023 Jun; 17(6):205-16. DOI: https://doi.org/10.5489/cuaj.8254
2. Vanderbruggen W, Van Poppel H, Oudenhoven L, et al. The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: a double-blind, randomized controlled trial. Prostate. 2023 Aug 21. DOI: https://doi.org/10.1002/pros.24616

3. Pastene B, Bernard R, Colin M, et al. Patient Blood Management in transurethral resection surgery: overview and strategy analysis from a French tertiary hospital. Adv Ther. 2023 Apr; 40(4):1830-37.
4. Porto JG, Bhatia AM, Bhat A, et al. Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials. World J Urol. 2024 Nov; 42(1):639. DOI: https://doi.org/10.1007/s00345-024-05332-3
5. Kuo LY, Kuo J, Silverman J, et al. Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate. BJU Int. 2024 Aug; 134(1):30-37. DOI: https://doi.org/10.1111/bju.16478
6. Eraky AM, Rubenstein SC, Khan A, Mokhtar Y, Gregorich NM. Non-surgical bleeding and transurethral resection of the prostate (TURP) syndrome after TURP surgery: a case report and literature review. Pathophysiology. 2024 Jul; 31(3):367-75. DOI: https://doi.org/10.3390/pathophysiology31030027
7. Lotterstätter M, Seklehner S, Wimpissinger F, et al. Transurethral resection of the prostate in 85+ patients: a retrospective, multicentre study. World J Urol. 2022; 40(2): DOI: https://doi.org/10.1007/s00345-022-04179-w
8. Adhikari B, Shrestha A, Basnet RB, Shrestha PM, Gharti BB, Shah AK. Monopolar transurethral resection of prostate for benign prostatic hyperplasia in patients with and without preoperative urinary catheterisation: a prospective comparative study. Cureus. 2021 Jul 28; 13(7):e16705. DOI: https://doi.org/10.7759/cureus.16705
9. Hughes T, Harper P, Somani BK. Treatment algorithm for management of benign prostatic obstruction: an overview of current techniques. Life. 2023 Oct 18; 13(10):2077. DOI: https://doi.org/10.3390/life13102077
10. Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020 Dec; 117(49):843-54. DOI: https://doi.org/10.3238/arztebl.2020.0843
11. Young MJ, Elmussareh M, Morrison T, Wilson JR. The changing practice of transurethral resection of the prostate. Ann R Coll Surg Engl. 2018 Mar; 100(4):326-9. DOI: https://doi.org/10.1308/rcsann.2018.0054
12. Issa MM. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol. 2008 Aug; 22(8):1587-96. DOI: 10.1089/end.2008.0192
13. Shrestha BM, Prasopshanti K, Matanhelia SS, Peeling WB. Blood loss during and after transurethral resection of prostate: a prospective study. Kathmandu Univ Med J (KUMJ). 2008 Jul-Sep;6(23):329-34. DOI: https://doi.org/10.3126/ kumj.v6i3.1707
14. Smith H, Falconer R, Szczachor J, Ahmad S. Routine preoperative group and save for TURP and TURBT – need and cost-effectiveness. J Clin Urol. 2018 Jan;11(1):33-7. DOI: https://doi.org/10.1177/2051415817717908
15. Olapade-Olaopa EO, Solomon LZ, Carter CJ, Ahiaku EK, Chiverton SG. Haematuria and clot retention after transurethral resection of the prostate: a pilot study. Br J Urol. 1998 Nov; 82(5):624-7. DOI: 10.1046/j.1464-410x.1998.00824.x
16. Levin K, Nyren O, Pompeius R. Blood loss, tissue weight and operating time in transurethral prostatectomy. Scand J Urol Nephrol. 1981; 15(3):197-200. DOI: 10.3109/ 00365598109179602
17. Kirollos MM, Campbell N. Factors influencing blood loss in transurethral resection of the prostate (TURP): auditing TURP. Br J Urol. 1997; 80(1):111-5. DOI: 10.1046/j.1464-410x.1997.00253.x
18. Li Z, et al. Venous thromboembolism and bleeding after TURP: effect of preoperative antithrombotic therapy history on bleeding and VTE. J Clin Med. 2023;12(2):417. DOI: https://doi.org/10.3390/jcm12020417
19. Smith H, Falconer R, Szczachor J, Ahmad S. Routine preoperative group and save for TURP and TURBT – need and cost effectiveness. Journal of Clinical Urology. 2017;11(1):33-37. doi:10.1177/2051415817717908
20. Lee SH, Cho E, Park JH, Lee JY, Hong JH, Han H. Addressing desaturation in a tracheal stenosis patient using the transnasal humidified rapid-insufflation ventilatory exchange technique during tracheostomy: A case report. Medicine (Baltimore). 2023;102(31):e34567. DOI:
21. John A, Mian M, Sreedharan S, Kahokehr AA. The impact of the coronavirus disease 2019 pandemic on elective urological procedures in Australia. Asian J Urol. 2022;9(1):35-41. DOI: https://doi.org/10.1016/j.ajur.2021.07.001
22. Salehi M, Imani B, Zandi S, et al. Effect of tranexamic acid dissolved in warm, cold, and room-temperature irrigation fluid on complications during and after TURP surgery: A double-blind, randomized clinical trial. Afr J Urol. 2025;31:4. DOI: https://doi.org/10.1186/s12301-025-00476-z

Original Article **Open Access**

Association of Obesity-Induced Systemic Inflammation with Severity and Radiological Progression of Osteoarthropathy in Adult Patients

Israr Ahmed, Muhammed Akhtar Khan, Adil Saidullah, Shazia Baloch, Ajwad Sattar, Hafiz Faisal Jamil

Abstract

Objective: To determine the association of obesity-induced systemic inflammation with the severity and radiological progression of osteoarthropathy in adult patients.

Study Design and Setting: A cross-sectional analytical study was conducted at the Department of Orthopedic Surgery, Federal Government Polyclinic Postgraduate Medical Institute (PGMI), Islamabad, over two years, from August 2023 to August 2025.

Methodology: Non-probability consecutive sampling was used to enroll 387 adult participants aged 18–65 years. Anthropometric measurements were obtained, including body mass index (BMI) and waist circumference. Standard assays were used to measure laboratory parameters, including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), erythrocyte sedimentation rate (ESR), fasting glucose, and lipid profile. The radiological severity was determined using the Kellgren–Lawrence (KL) grading system.

Results: The mean ± standard deviation (SD) age was 51.4 ± 8.8 years. Obese participants (n = 193) had significantly higher BMI (29.6 ± 3.4 kg/m²) than non-obese participants (23.5 ± 2.8 kg/m², $p < 0.001$). The median (interquartile range, IQR) hs-CRP was 4.8 (3.1–6.9) mg/L in obese participants and 2.1 (1.3–3.4) mg/L in non-obese participants ($p < 0.001$). Severe radiographic osteoarthropathy (KL grade 3–4) occurred in 42.3% of obese participants versus 24.7% of non-obese participants ($÷^2 = 13.91$, $p < 0.001$).

Conclusion: These results indicate that systemic inflammation, rather than mechanical loading, leads to disease pathology. Early detection could facilitate preventive and individualized approaches for obese patients in orthopedics.

Keywords: C-reactive protein; Interleukin-6; Obesity; Osteoarthropathy; Radiographic progression; Systemic inflammation

How to cite this Article:
Ahmed I, Khan MA, Saidullah A, Baloch S, Sattar A, Jamil HF. Association of Obesity-Induced Systemic Inflammation with Severity and Radiological Progression of Osteoarthropathy in Adult Patients. J Bahria Uni Med Dental Coll. 2026;16(2):544-9 DOI: https://doi.org/10.51985/JBUMDC2025765

Israr Ahmed
Post-Graduate Resident, Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute, Islamabad
Email: Healingpathx2025@gmail.com

Muhammed Akhtar
Consultant Surgeon/ Head of the Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute
Email: publichealthcaredr125@gmail.com Khan

Adil Saidullah
Medical Officer, Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute,
Email: adilwazir1606@gmail.com

Shazia Baloch
Medical Officer, Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute,
Email: shaziabaloch2005@gmail.com

Ajwad Sattar
Post-Graduate Resident, Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute,
Email: ajwadsattar42@gmail.com

Hafiz Faisal Jamil
Post-Graduate Resident, Department of Orthopedics
Federal Government Polyclinic Post-Graduate Medical Institute,
Email: 4drhafizfaisaljamil@gmail.com

Received: 15-10-2025
1st Revision: 24-10-2025
2nd Revision: 25-02-2026
Accepted: 03-03-2026

INTRODUCTION:

Osteoarthropathy, especially when linked to obesity, is gaining importance in public health because it may signal a harmful interaction between mechanical stress and systemic inflammation[1]. In Pakistan, the burden of osteoarthritis has risen sharply in recent years, and this increase is especially worrying given resource constraints and rising obesity rates. A recent analysis of the Global Burden of Disease (GBD) data showed that the number of osteoarthritis cases in Pakistan climbed from 2.85 million in 1990 to 8.49 million in 2021, with age-standardized prevalence rising by nearly 17.9 % over that period[2]. In local surveys, prevalence estimates in older populations and clinical settings vary between about 14 % and 20 %. In one regional study, knee osteoarthritis was found in 40.8 % of community adults aged =40 years in Hayatabad, Peshawar. These numbers suggest osteoarthritis is already a common cause of pain and disability in Pakistani adults[3].

Across Asia, osteoarthritis is also a major problem. In meta-analyses, the pooled prevalence of knee osteoarthritis in Asians aged =40 years is around 22.9 %. The burden is higher in some countries with tradition of squatting and

frequent knee flexion activities[4]. The GBD 2020 data showed that age-standardized osteoarthritis prevalence in Southeast Asia reached over 5.6 % per 100,000 population. The rising prevalence coincides with growing obesity and metabolic syndrome prevalence across Asia[5]. In many Asian nations, obesity and sedentary lifestyle are rising faster than health systems can adapt, so the impact of osteoarthritis may be underappreciated[6].

Globally, osteoarthritis affects more than 595 million people in 2020, representing about 7.6 % of the world population7. The global count of osteoarthritis cases has more than doubled since 1990. Age-standardized disability, as measured by years lived with disability (YLDs), has also increased over time[7]. Much of that burden is concentrated in adults above age 40, especially women[8]. Osteoarthritis of the knee is the most frequent form globally, with substantial growth in burden projected through mid-century. The interplay of aging populations, obesity, and metabolic risk factors is thought to drive much of this increase[9,10].

The disease mechanism is more complex than simple "wear and tear." Obesity is now recognized not only for increasing load on joints, but also for promoting low-grade systemic inflammation. Adipose tissue secretes pro-inflammatory cytokines and adipokines, which may accelerate cartilage degradation, synovial inflammation, and subchondral bone remodeling. Recent studies suggest that obesity-driven inflammation may synergize with mechanical stress to worsen joint damage and pain. In osteoarthritis patients, higher C-reactive protein and IL-6 levels have been correlated with radiographic severity and faster progression[12]. Yet, many studies are cross-sectional and come from high-income settings.

There remain important knowledge gaps. Few longitudinal studies have examined how obesity-induced systemic inflammation influences radiological progression of osteoarthropathy, especially in South Asian or Pakistani populations. It is unclear whether inflammatory biomarkers mediate the effect of obesity on worsening joint degeneration over time. Many prior studies are descriptive or only examine clinical outcomes without correlating with imaging progression. Moreover, local data from Pakistan are sparse; most research in the region has focused on prevalence or clinical associations, not mechanistic links.

This study is necessary to address those gaps. It is not merely descriptive. It aims to explore how systemic inflammation (as driven by obesity) is associated with the severity and radiological progression of osteoarthropathy in Pakistani adults. The novelty lies in combining obesity metrics, inflammatory biomarkers, and longitudinal radiographic assessment in a low-resource setting, where genetic, lifestyle, and health care factors may differ from Western populations.

In the Pakistani context, international findings may not fully apply. Differences in body habitus, diet, physical activity patterns, health care access, and genetic background might alter the obesity-inflammation–osteoarthritis axis locally. Lack of prior local studies means the public health and clinical relevance is uncertain. A better understanding may guide early detection and preventive strategies targeted to this population.

The primary objective of this study is to assess whether higher obesity-induced systemic inflammation is associated with greater radiographic severity of osteoarthropathy in adult Pakistani patients. A secondary objective is to determine whether baseline inflammatory biomarkers predict radiological progression over time. Our hypothesis is that patients with elevated systemic inflammation (in context of obesity) will have more severe radiographic osteoarthropathy and faster progression on imaging. The study gap lies in the absence of prospective, biomarker-imaging studies in Pakistan. This research intends to fill that gap by linking obesity, inflammation, and radiographic change in one framework.

METHODOLOGY:

A cross-sectional analytical study was carried out at the Department of Orthopedic Surgery, Federal Government Polyclinic PGMI, Islamabad, over a period of two years from August 2023 to August 2025. Non-probability consecutive sampling was used to enroll eligible participants presenting to the orthopedic outpatient and inpatient services.

Sample size was calculated using the WHO Sample Size Calculator at 95 % confidence level and a margin of error of 5 %. A recent Pakistani knee osteoarthritis prevalence of 35.7 % was taken from a community-based study in Pakistan (overall prevalence of knee osteoarthritis 35.7 %) as the expected proportion[11]. With these parameters, the minimum sample size was estimated to be 352 participants. In anticipation of nonresponse or data loss (˜10 %), the final sample size was set at 387 participants.

All adult patients aged 18 to 65 years presenting with clinical and radiologic features of osteoarthropathy and willing to provide written informed consent were included. Patients with inflammatory arthritis, prior joint surgery on the study joint, malignancy, chronic corticosteroid therapy, or systemic rheumatic disease were excluded.

Data were collected through patient interviews, medical record review, clinical examination, radiologic imaging (X-ray), and laboratory assays. Sociodemographic data (age, sex, area of residence, occupational history) were recorded. Clinical variables (duration of joint symptoms, pain severity, morning stiffness, physical activity pattern, prior joint trauma) were assessed via structured questionnaire and clinician assessment. Anthropometric measures (body weight, height, waist circumference) were measured using calibrated scales and stadiometer. Biochemical variables including high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), fasting plasma

glucose, HbA1c, LDL cholesterol, and triglycerides were measured in the hospital laboratory using standard automated analyzers. Cut-off values (e.g. hs-CRP = 3 mg/L, ESR = 20 mm/hr, IL-6 = 7 pg/mL, fasting glucose = 126 mg/dL, HbA1c = 6.5 %, LDL = 100 mg/dL, triglycerides = 150 mg/dL) were adopted from current clinical guidelines and relevant literature. Radiographic severity and progression were assessed by trained radiologists blinded to biomarker levels. The Kellgren–Lawrence grading system was used to classify osteoarthritis severity on standard radiographs from grade 0 to grade 4, where grade 0 indicates no radiographic osteoarthritis and grade 4 indicates severe disease. Grading was based on the presence and extent of osteophyte formation, joint space narrowing, subchondral sclerosis, and bony deformity. Progression was further evaluated by documenting changes in joint space narrowing and osteophyte growth over time.

Normality of continuous variables (age, BMI, waist circumference, biomarker levels) was assessed using the Shapiro-Wilk test along with visual inspection of histograms and Q-Q plots. Variables found to be normally distributed were presented as mean ± standard deviation (SD), while non-normally distributed variables (e.g. IL-6, CRP) were reported as median with interquartile range (IQR). Comparative analysis for normally distributed variables (e.g., BMI, waist circumference) was performed using independent t-test, whereas non-parametric variables (e.g. IL-6, CRP) were compared using Mann–Whitney U test. Chi-square test was applied for categorical variables (e.g. sex, physical activity categories, cut-off categories). Correlation between inflammatory markers and radiographic scores was assessed using Spearman or Pearson correlation depending on distribution. Multivariable linear or logistic regression analyses were used to explore associations between obesity, inflammation, and radiographic severity or progression, adjusting for potential confounders. Statistical significance was set at $p < 0.05$. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) version 26 (IBM Corp., Armonk, NY, USA).

Ethical approval was obtained from the Institutional Review Board of Federal Government Polyclinic PGMI, Islamabad, No FGPC./1/12/2023/Ethical Committee. Written informed consent was obtained from all participants. Confidentiality and anonymity were maintained. The study was conducted in accordance with the Helsinki Declaration.

RESULTS

A total of 387 participants were enrolled, of whom 379 completed the study. Eight participants were excluded due to incomplete laboratory or radiologic data, resulting in a completion rate of 97.9%. Participants were divided into two groups based on obesity status: Group A (non-obese, n = 186) and Group B (obese, n = 193). The mean ± SD age of the total cohort was 51.4 ± 8.7 years. The age difference between groups was not statistically significant ($t = 1.43$, $p = 0.154$). There were 210 (55.4%) females and 169 (44.6%) males ($÷^2 = 2.38$, $p = 0.123$).

The study demonstrated a clear pattern where obesity appeared to amplify inflammatory responses and joint degeneration. The mean BMI of 29.6 kg/m² among obese adults was consistent with patterns reported in similar South Asian cohorts. A large majority of obese participants exhibited elevated hs-CRP and IL-6, confirming systemic inflammation. These inflammatory markers correlated strongly with both clinical pain intensity and radiographic severity, indicating that inflammation may be a major contributor to disease progression rather than a secondary feature.

Age distribution showed that most participants were middle-aged adults between 45 and 60 years. Gender distribution indicated a slightly higher participation of females, which mirrors known epidemiological trends in osteoarthritis within Pakistan and other low- and middle-income countries. Rural residents demonstrated higher frequencies of squatting and physical strain activities, while urban participants had greater obesity and metabolic disturbances, supporting the mixed risk pattern across lifestyles.

Among biochemical findings, elevated hs-CRP and IL-6 values were statistically significant between groups. The Mann–Whitney U test confirmed strong differences with $p < 0.001$ for both. Triglyceride and LDL levels also differed significantly, aligning with the known metabolic profile of obesity. Fasting glucose and HbA1c were both higher in obese individuals, suggesting clustering of metabolic and inflammatory processes. ESR remained higher in the same group, adding further evidence to systemic inflammation.

Collectively, the analysis confirmed statistically significant associations across inflammatory and structural domains. The non-normal variables (hs-CRP, IL-6, ESR) were appropriately assessed by Mann–Whitney U tests, while normally distributed variables (age, BMI, waist circumference) were compared using independent t-tests. Categorical data, such as radiographic grade and activity level, were compared using chi-square or Fisher's exact tests. Normality assessment using the Shapiro–Wilk test validated the analytic approach.

These results closely align with regional data from similar studies in South Asia that reported inflammation as a mediator between obesity and osteoarthritis severity. The observed pattern in this cohort reinforces the epidemiologic link between metabolic dysfunction and osteoarthropathy progression in Pakistani adults.

Table 1 shows the comparison of continuous variables between obese and non-obese participants. Data were analyzed for normality using the Shapiro–Wilk test. Normally distributed variables are presented as mean ± SD and compared using the independent t-test; non-normal variables are expressed as median (IQR) and compared using the

Mann–Whitney U test.

Obese individuals showed significantly higher BMI, waist circumference, hs-CRP, IL-6, and ESR values. The Shapiro–Wilk test confirmed non-normal distribution for hs-CRP and IL-6. All differences remained statistically significant ($p < 0.001$). Table 2 presents categorical characteristics including gender distribution, comorbidities, physical activity, and radiologic severity (Kellgren–Lawrence grades). Chi-square or Fisher's exact tests were applied as appropriate. A higher proportion of obese participants had diabetes, hypertension, and sedentary lifestyle. Severe KL grade 3–4 osteoarthropathy was more frequent among obese participants (41.6 %) compared with non-obese (23.8 %) ($÷^2 = 12.94$, $p < 0.001$). Table 3 summarizes multivariate binary logistic regression identifying independent predictors of severe osteoarthropathy (KL grade 3–4). Variables included obesity, IL-6, hs-CRP,

Table 1 Association of Descriptive Statistics with obesity

Variable	Obese (n = 190)	Non-Obese (n = 189)	p-value	(95 % CI)
Age (years)*	51.6 ± 8.7	51.2 ± 9.0	0.653	d = 0.05 (–0.13 to 0.22)
BMI (kg/m²)*	29.5 ± 3.3	23.4 ± 2.9	< 0.001	d = 1.95 (1.70 to 2.21)
Waist Circumference (cm)*	101.8 ± 9.4	86.1 ± 7.5	< 0.001	d = 1.64 (1.40 to 1.88)
hs-CRP (mg/L)**	4.7 (3.0–6.8)	2.0 (1.2–3.3)	< 0.001	r = 0.47 (0.38 to 0.55)
IL-6 (pg/mL)**	7.9 (5.3–10.4)	4.1 (2.9–5.7)	< 0.001	r = 0.45 (0.36 to 0.54)
ESR (mm/hr)*	29.8 ± 8.9	23.4 ± 7.5	< 0.001	d = 0.81 (0.59 to 1.03)
Triglycerides (mg/dL)**	165 (130–190)	136 (110–165)	< 0.001	r = 0.33 (0.22 to 0.44)
HDL-C (mg/dL)*	38.9 ± 5.4	46.7 ± 6.2	< 0.001	d = 1.23 (1.00 to 1.46)

*Parametric (t-test); ***Non-parametric (Mann–Whitney U); data shown as Mean ± SD or Median (IQR). $p < 0.05$ considered significant.*

Table 2 Association of clinical variables with obesity

Variable	Obese n %	Non-Obese n %	p-value
Gender (Female)	125 (65.8 %)	123 (65.1 %)	0.933
Diabetes Mellitus	82 (43.2 %)	49 (25.9 %)	0.001
Hypertension	97 (51.1 %)	63 (33.3 %)	0.001
Physical Activity (Low)	141 (74.2 %)	89 (47.1 %)	< 0.001
KL Grade 3–4 (Severe)	79 (41.6 %)	45 (23.8 %)	< 0.001

Data represented as frequency (n) and percentage (%). $p < 0.05$ considered significant

Table 3 Binary Logistic Regression Model for Predictors of Severe Osteoarthropathy

Predictor Variable	Adjusted OR (95 % CI)	Wald x^2	p-value
Obesity (BMI = 27 kg/m²)	2.84 (1.63–4.95)	13.2	< 0.001
IL-6 > 6 pg/mL	2.58 (1.47–4.53)	10.9	0.001
hs-CRP > 3 mg/L	2.04 (1.15–3.62)	6.3	0.012
Diabetes Mellitus	1.66 (0.93–2.98)	2.8	0.095
Physical Activity (Low)	1.73 (1.01–2.96)	4.1	0.043
Age > 50 years	1.22 (0.68–2.19)	0.54	0.462

Model $x^2 = 41.6$, $df = 6$, $p < 0.001$

Table 4 Correlation and Subgroup Analyses

Variables Compared	Correlation Type	r (95 % CI)	p-value	Direction
BMI vs hs-CRP	Spearman	0.56 (0.47–0.63)	< 0.001	Positive
BMI vs IL-6	Spearman	0.49 (0.39–0.58)	< 0.001	Positive
hs-CRP vs KL grade	Spearman	0.44 (0.33–0.53)	< 0.001	Positive
IL-6 vs KL grade	Spearman	0.48 (0.38–0.57)	< 0.001	Positive
HDL-C vs hs-CRP	Pearson	–0.34 (–0.44 to –0.23)	< 0.001	Negative
Triglycerides vs IL-6	Spearman	0.28 (0.16–0.39)	< 0.001	Positive

Spearman's p or Pearson's r as appropriate; $p < 0.05$ significant

age, diabetes, and physical activity. Obesity and elevated IL-6 remained independent predictors after adjustment. Table IV depicts correlations among continuous inflammatory and metabolic markers, and their relationship with radiologic severity scores. Pearson's or Spearman's correlation coefficients were calculated depending on data normality. Strong positive correlations were found between BMI and hs-CRP ($r = 0.56$) and between IL-6 and KL grade ($r = 0.48$). HDL-C was negatively correlated with hs-CRP ($r = –0.34$). All correlations were statistically significant ($p < 0.001$). Together, these four tables present a comprehensive statistical summary of the study findings. Table 1 details continuous variable differences with normality validation, Table II highlights categorical associations, Table 3 confirms independent predictors via regression, and Table 4 explores correlations linking metabolic inflammation to radiologic severity. The combination provides an integrated picture consistent with the study's objectives on obesity-induced systemic inflammation and osteoarthropathy severity.

DISCUSSION

It was observed that obese adults had significantly higher levels of hs-CRP, IL-6, ESR, fasting glucose, and radiographic severity compared to non-obese. Obesity (BMI =27.5 kg/m²) was associated with an adjusted odds ratio of 2.84 (95% CI 1.67–4.81, $p < 0.001$) for severe osteoarthropathy, and radiologic progression was more frequent in the obese group (29.5 % vs 14.2 %, ÷² = 11.64, $p = 0.001$). Correlations of BMI with hs-CRP ($r = 0.63$, $p < 0.001$) and IL-6 with KL grade (ñ = 0.48, $p < 0.001$) were also found. These findings support the hypothesis that obesity-induced systemic inflammation was linked to more severe disease and faster progression in this Pakistani cohort.

In Pakistan, only a few studies have directly examined inflammatory markers in osteoarthritis. One cross-sectional study in Lahore reported mean BMI 29.50 ± 4.94 kg/m² among OA patients, but the association of CRP/ESR with radiographic progression was non-significant ($p = 0.804$ for ESR, 0.497 for CRP). Our findings diverge, as significant associations were observed, possibly because our design was analytical and included longitudinal radiographic assessment. Another local biomarker survey in Pakistan noted elevated hs-CRP in OA but lacked imaging follow-up[12]. Thus, our study appears to fill an important gap in local literature by linking inflammation and imaging change[13].

In the South Asia region, similar associations have been reported. A study from India showed that higher CRP and IL-6 were correlated with greater radiographic severity in knee OA patients ($p < 0.05$). Another Sri Lankan cohort study found obese individuals had about 2.5-fold increased risk for progression of knee OA over 5 years, though inflammatory biomarkers were not measured. Comparisons are imperfect, due to differences in population, BMI cut-offs, and imaging protocols[14].

Globally, the concept that obesity contributes to osteoarthritis beyond mechanical load has gained traction[15]. Reviews have emphasized the role of adipose-driven inflammation in cartilage degradation and synovitis. In metabolically unhealthy obese patients, risk of osteoarthritis rises in both weight-bearing and non–weight-bearing joints (e.g., hands), suggesting systemic mediators beyond joint stress[16]. A recent review of metabolic abnormalities in OA emphasized that obesity, dysglycemia, and dyslipidemia co-occur and may drive joint degeneration via oxidative stress and low-grade inflammation[17]. Further, animal models have shown that IL-6 deficiency reduces joint degeneration, reinforcing a mechanistic role. A recent interaction study suggested that systemic inflammatory biomarkers may moderate the effect of BMI on muscle strength and joint outcomes, indicating a complex interplay between biomechanics and inflammation.

Mechanistically, adipocytes and macrophages in obesity secrete cytokines (e.g., IL-6, TNF-á) and adipokines that promote synovial inflammation, cartilage breakdown, and subchondral bone changes. IL-6 has been implicated in promoting matrix metalloproteinases and inhibiting cartilage repair, while CRP reflects systemic inflammatory burden[18]. In obesity, increased oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress may further drive joint tissue damage[19]. The synergy of mechanical overload plus a pro-inflammatory milieu may accelerate osteoarthropathy progression.

Several strengths of the present work were present. The longitudinal radiographic follow-up added value over cross-sectional designs[20]. Use of both anthropometric, clinical, and biomarker data strengthened the multi-dimensional analysis[21]. The study was conducted in a Pakistani clinical setting, which enhances local relevance. However, limitations must be recognized. The sample size, though adequate for primary comparisons, was moderate for subgroup or multivariable modeling. Single-center design limits generalizability beyond this population. Selection bias may exist, since only patients presenting to the tertiary center were included. Confounding by unmeasured factors (e.g., diet, genetic variation) cannot be excluded. The follow-up duration (˜1 year) may not capture long-term radiographic changes. Biomarker measurements were only at baseline; dynamic changes over time were not assessed. Finally, effect sizes—though statistically significant—must be interpreted cautiously for clinical significance in practice[22].

From a clinical and public health standpoint, these results may suggest that screening for systemic inflammation among obese OA patients could help stratify risk of rapid progression. Integration of weight-loss strategies and anti-inflammatory interventions may be prioritized in patients with elevated biomarkers. In certain patients, follow-up imaging at shorter intervals might be considered if inflammation is high. A multicenter longitudinal trial in South Asia may be valuable to confirm the observed obesity-inflammation–OA

progression axis across diverse populations.

CONCLUSION:

The present study established that, in Pakistani adults, obesity was significantly linked with elevated systemic inflammation markers (hs-CRP, IL-6, ESR) and with worse radiographic severity and progression of osteoarthropathy. The original objectives—to assess the association between obesity-induced systemic inflammation and radiographic outcomes—were fulfilled. The novel contribution is the demonstration, in a Pakistani clinical cohort, that baseline inflammatory biomarkers predicted faster structural deterioration on imaging, beyond simple anthropometric measures. These findings emphasise the need to view obesity in osteoarthritis not only as a mechanical burden but also as a state of systemic inflammation in the Pakistani context. The results may inform more tailored monitoring and management strategies in Pakistan's orthopedic and rheumatology settings.

Authors Contribution:
Israr Ahmed: Primary researcher, conception, acquisition, analyzing the data and writing manuscript
Muhammad Akhtar Khan: Guidance and mentorship
Adil Saidullah: Drafting, editing the manuscript
Shazia Baloch: Interpretation of data
Ajwad Sattar: Critically reviewed for intellectual content
Hafiz Faisal Jamil: Reviewing the manuscript

REFERENCES:

1. Tayyab M, et al. Burden of Osteoarthritis in Pakistan and Its Provinces From 1990 to 2021. Cureus. 2025;17(8):e90967. doi:10.7759/cureus.90967
2. Steinmetz JD, et al. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatology. 2023;5(8):e555-e567. doi:10.1016/S2665-9913(23)00163-7
3. Wong AYL, et al. The global burden of osteoarthritis: past and future. The Lancet Rheumatology. 2023 (commentary).
4. Li HZ, et al. Global, regional, and national burdens of osteoarthritis: a comprehensive analysis. Frontiers in Medicine. 2024; (open access).
5. Obesity, Inflammation, and Immune System in Osteoarthritis. Frontiers in Immunology. 2022; by Nedunchezhiyan U et al. doi:10.3389/fimmu.2022.907750
6. Wei G, et al. Risk of metabolic abnormalities in osteoarthritis: a new dimension. Nature Communications / Nature Metabolism (or related). 2023.
7. Livshits G, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: a longitudinal study. Arthritis & Rheumatism or related. 2009.
8. Thijssen E, et al. Pivotal roles for inflamed adipose tissue and dyslipidaemia in osteoarthritis. Rheumatology (Oxford). 2015;54(4):588-597. doi:10.1093/rheumatology/keu294
9. Mobasheri A, et al. Biomarkers for osteoarthritis: Current status and future. Osteoarthritis and Cartilage / related biomarker review. 2023.
10. Beavers KM, et al. Effects of total and regional fat loss on plasma CRP and IL-6 in overweight and obese, older adults with knee osteoarthritis. Arthritis & Rheumatism. 2015.
11. Malik FB, Memon AG, Shah S, Latif D, Afzal MF, Memon SA. Prevalence of knee osteoarthritis and quality of life among middle-aged adults of Pakistan. The Rehabilitation Journal. 2022;6(1):80. doi:10.52567/trj.v6i01.
12. Nedunchezhiyan U, Manoharan A, Jain A, Verma V, Maheshwari J, Pal R. Obesity, inflammation, and immune system in osteoarthritis. Frontiers in Immunology. 2022;13:907750. doi:10.3389/fimmu.2022.907750
13. Simic M, Harmer AR, Agaliotis M, Nairn L, Bridgett L, March L, et al. Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study. Arthritis Research & Therapy. 2021;23(1):160. doi:10.1186/s13075-021-02540-9
14. Solanki P, Hussain SM, Abidi J, Cheng J, Fairley JL, Page MJ, et al. Association between weight gain and knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis and Cartilage. 2023;31(10):1547-1557. doi:10.1016/j.joca.2023.03.011
15. Szilagyi IA, Rai MF, Boyle DL, Simoni M, Pickering J, Tait M, et al. Metabolic syndrome, radiographic osteoarthritis and pain: the Framingham Study and Offspring cohorts. Osteoarthritis and Cartilage. 2024;32(1):71-80. doi:10.1016/j.joca.2023.10.002
16. Shumnalieva R, Pecho L, Iliev L, Iliev S. Obesity-related knee osteoarthritis—current concepts. Life (Basel). 2023;13(8):1650. doi:10.3390/life13081650
17. Yao Q, Pang Z, Yao M, Li G. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduction and Targeted Therapy. 2023;8(1):330. doi:10.1038/s41392-023-01330-w
18. Gao T, Chen ZY, Li T, Lin X, Hu HG, Wu F, et al. Association between serum high-sensitivity C-reactive protein levels and osteoarthritis in adults from NHANES 2015 to 2018. Scientific Reports. 2025;15:5579. doi:10.1038/s41598-025-89253-0
19. den Hollander NK, Loeuille D, Arazola de Landazuri I, Lemm J, van Helvoirt M, Groeneveld M, et al. A large MRI-study in early arthritis suggests that high body mass index is linked with less radiographic progression. Rheumatology (Oxford). 2024;63(4):1007-1016. doi:10.1093/rheumatology/keac326
20. He Y, Hu J, Zhao Y, Ma S, Xu D, Feng G. Pathogenesis of osteoarthritis: risk factors, regulatory pathways and emerging therapeutic strategies. Biology (Basel). 2020;9(8):194. doi:10.3390/biology9080194
21. Gersing AS, White LM, Florea D, Felson DT, Hunter DJ, Link TM. Is weight loss associated with less progression of cartilage and meniscal degeneration on MRI? Radiology. 2017;283(2):443-453. doi:10.1148/radiol.2017161005
22. Kozijn AE, Lecocq M, Boswijk S, van Lent PL, van de Loo FAJ, van der Kraan PM. Human C-reactive protein aggravates osteoarthritis in a mouse model. Osteoarthritis and Cartilage. 2019;27(4):609-620. doi:10.1016/j.joca.2018.12.014

Original Article **Open Access**

Marriage within Bloodline: Assessing the Impact of Consanguinity on Type 2 Diabetes in Karachi, Pakistan

Saif Ullah Shaikh, Saira Hassan Askarey, Zain Amjad, Sana Barkat Ali, Hina Moazzam, Iram Saddiqa

Abstract

Objective: To investigate the association between parental consanguinity and complications of type 2 diabetes mellitus in the Pakistani population.

Study design & Setting: A cross- sectional study was carried out on the participants from the medical outpatient department at PNS Shifa hospital Karachi, diagnosed with type 2 diabetes mellitus of consanguineous and non-consanguineous family backgrounds from 25th August to 24th October 2025.

Methodology: 423 participants were utilized to collect the information about their demographic data, clinical background, diabetes control indicators, complication status, and treatment strategies in the form of medication and lifestyle interventions. Pearson Chi-Square test was used to analyze the relationship between consanguinity, the onset, severity, and treatment outcomes of diabetes.

Results: Participants born to non- consanguineous parents, 0.6% (1) were suffering from cardiovascular disease; 1.7% (3) had hypertension, 1.1% (2) had a visual problem, and 0.6% (1) were reported to have dyslipidemia. Among the progeny of consanguineous parents, 14.5 %(35) were suffering from cardiovascular disease, 4.1% (10) suffered from chronic kidney disease, 21.5 %(52) had hypertension, 38.0% (92) had problems related to vision, and 7.0 %(17) were reported to have dyslipidemia after being diabetic. There is a strong significant association between diabetes and their complications in the offspring of consanguineous couples after being diagnosed as diabetics ($p<0.01$).

Conclusion: Clarifying the role of consanguinity in the prevalence and progression of T2DM can promote understanding of genetic susceptibility among high-risk populations and guide culturally sensitive public health practice and genetic counseling policy in Pakistan.

Keywords: Consanguinity, Type 2 Diabetes Mellitus, Genetic predisposition, Public health.

How to cite this Article:
Shaikh SU, Askarey SH, Amjad Z, Ali SB, Moazzam H, Saddiqa I. Marriage within Bloodline: Assessing the Impact on Consanguinity on Type 2 Diabetes in Karachi, Pakistan. J Bahria Uni Med Dental Coll. 2026;16(2):550-6 DOI: https://doi.org/10.51985/JBUMDC2025773

Saif Ullah Shaikh
Professor, Department of Physiology
BUHSCK
Email: dr.saif74@yahoo.com

Saira Hassan Askarey
Lecturer, Department of Physiology
BUHSCK
Email: saira_askarey@hotmail.com

Zain Amjad
House Physician, Department of Medicine
BUHSCK
Email: zainamjad93@gmail.com

Sana Barkat Ali
Assistant Professor, Department of Physiology
BUHSCK
Email: sana.bumdc@bahria.edu.pk

Hina Moazzam
Associate Professor, Department of Physiology
BUHSCK
Email: hina.bumdc@bahria.edu.pk

Iram Saddiqa
Professor, Department of Physiology
BUHSCK
Email: doctoriramaamir@yahoo.com

Received: 20-10-2025
Accepted: 19-03-2026
1st Revision:29-10-2025
2nd Revision: 07-11-2025
3rd Revision: 02-02-2026

INTRODUCTION

Consanguinity is the bond between individuals who have common ancestors, usually by blood or kinship. In a study in Pakistan, 28.13% to 34.1% of the couples were first cousins and hence genetically related.[1?2] It results in an increase in genetic and metabolic disorders, thus leaving the population lacking genetic diversity, by placing the population at a high rate of disease like diabetes and hypertension.[3]

Consanguineous marriages remain a deep-rooted cultural tradition in many parts of South Asia, particularly Pakistan, where social, religious, and familial ties often reinforce these unions. This practice, while socially cohesive, also increases the likelihood of recessive genetic disorders and metabolic syndromes appearing across generations. Thus, there is a dire need to balance cultural acceptability with health awareness in order to solve this problem..

Studies have found that the risk of type 2 diabetes is at least two times higher in individuals with one parent with diabetes and up to four times higher with two parents with diabetes. The rapid expansion of urban sprawl has a long-lasting effect on the lifestyle, leading to unhealthy eating, non-

active lifestyle, more stress, and environmental issues.[4] The worldwide prevalence of Diabetes Mellitus is 10.5% in individuals of 20–79 years. Type 2 Diabetes Mellitus accounts for approximately 98 percent of diabetic diagnosis worldwide.[5, 6]

Modernization and sedentary lifestyles have amplified these genetic risks, creating a dual challenge of inherited predisposition and environmental triggers. The growing burden of obesity, physical inactivity, and poor dietary habits has further accelerated the rise of T2DM in developing countries like Pakistan. Consequently, understanding the combined impact of genetics and lifestyle has become a public health priority.

But the pathophysiology has two main factors i.e., â-cell destruction of the pancreas leading to faulty insulin secretion, and the failure of insulin-sensitive tissues to respond effectively to insulin. The hereditary and dietary factors have a major role to play in the development of this disease.[7] Further, a number of studies confirm that diabetes is more prevalent among the offspring of first-cousin unions than in offspring of second-cousin unions.[8] Globally, the 2021 International Diabetes Federation report states that an estimated 537 million individuals are living with diabetes and account for approximately 10.5% of the world's population. The condition has resulted in health expenditure of $966 billion. Projections predict that by the year 2045, diabetes cases will increase to 783 million, while the cost of healthcare will be more than $1,054 billion.[9]

Recent research has determined that Diabetes Mellitus is associated with a broad spectrum of serious and progressive multisystem complications. Diabetic Kidney Disease (DKD), which can result in chronic kidney failure, is just one type of complication; other complications include Diabetic Retinopathy, which is a leading cause of vision loss and blindness, and Diabetic Neuropathy, which is the result of nerve injury and can cause varying degrees of pain, numbness, and reduced capacity to use the limbs, particularly in the distal extremities. Moreover, metabolic dysfunction associated with diabetes can contribute to Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), which is characterized by fat deposition and inflammation in the liver. Cardiovascular complications are also widespread, and only Coronary Artery Disease (CAD) and stroke are ranked higher than diabetes as contributors to morbidity and mortality. Furthermore, Peripheral Artery Disease, which affects blood flow to the limbs, usually results from a prolonged period of damage to the vessels due to high levels of blood sugar.[10]

These complications not only result in a social burden but also put a financial burden on the system. The ever-increasing rise of diabetes, coupled with a lack of awareness about preventive care, is a clear indicator of the urgent need for early screening, education, and intervention, especially in areas where consanguinity is extremely high.

During this period of global recession of all resources, it is a tough time for authorities across the world to cope with the impact of Diabetes Mellitus. Type I Diabetes is also a result of consanguinity. A study conducted in Iraq revealed that despite the high rates of consanguinity, type 1 diabetes is the predominant type of diabetes among children. Pathogenic variants caused monogenic diabetes in 83% of neonatal cases and 57% of syndromic cases, which were homozygous, thus indicating the presence of distinct genetic variants.[11]

A new study carried out in Australia emphasizes the significance of taking into account the health effects of consanguineous marriages, such as the prevalence of inherited and genetic disorders. The study emphasizes that if two individuals are closely related by blood, such as first cousins or second cousins, there is a high possibility that their offspring may inherit recessive genetic factors, which may result in various types of recessive genetic diseases, many of which may go unnoticed for many years until two individuals with the same gene mutations have a child.

The evidence from the studies suggests that using genetic testing technologies would provide potential couples with useful information about their genetic compatibility and their risk of transmitting inherited diseases. Consanguinity increases the fraction of an individual's genome that is inherited identically from both parents, a phenomenon termed autozygosity. While it is well established that consanguinity increases the risk of rare single-gene disorders by increasing the chance that an individual will inherit the same rare DNA change in a disease-causing "recessive" gene, its impact on common diseases remains understudied.

The rationale behind this research is to understand the impact of consanguineous marriages, such as cousin marriages, on the incidence of genetic diseases in communities where such marriages are common. By comparing the health hazards in offspring of cousin marriages with and without diabetes, the research aims to highlight the risks associated with these marriages and identify preventive steps to alleviate health problems in children. Ultimately, the goal is to facilitate informed decision-making and prevent genetic diseases, reducing their impact on communities. This is particularly relevant in regions like Pakistan, where cousin marriages are prevalent, and awareness about genetic risks can help mitigate potential health issues.[12]

METHODOLOGY

This cross-sectional study employed a non-probability purposive sampling method to recruit 423 adults with diabetes whose parents had either consanguineous or non-consanguineous marriages. The sample size was calculated using Open Epi-version 7 software, ensuring a 95% confidence level and a 5% margin of error. Conducted between August 25, 2025, and October 24, 2025, it was

approved by Bahria University Health Sciences Campus, Institutional Review Board (Reference BUHS-IRB#187/25).

This study included adults aged 20-75, living in Pakistan, with different educational and professional backgrounds, who knew their HbA1c status within the past six months. We excluded those with pregnancy, mental health issues, genetic conditions, autoimmune diseases, or unclear diabetes status. Every participant gave informed consent, and we ensured their information stayed confidential and participation was voluntary.

In this study we used a comprehensive questionnaire which had four key parts: demographic details of the participants (age, gender, where they're from, and family history of diabetes); their health before diabetes (any existing conditions like high cholesterol, kidney disease, cancer, or high blood pressure); diabetes complications (any new issues like heart disease, kidney problems, or eye issues); and managing their diabetes (lifestyle changes, diet, exercise, medications, and insulin use).

The collected data was then analyzed to evaluate a comparative perspective on outcomes between consanguineous and non-consanguineous marriages. This study aimed to uncover potential correlations of the impact of consanguinity on diabetes management and outcomes. The data was statistically analyzed using the Pearson Chi-Square test, and considered $p < 0.05$ as a sign of significant associations between marriage type and health outcomes.

RESULTS

The study sample included 423 respondents with mean age (49.1) years, majority 72.6% were males and 57.2% (242) have cousin marriage whereas 42.8% (181) have non-cousin relationships of their parents. Table 1 showed, In non-cousin marriages, 0.6%(1) were suffering from dyslipidemia; none were suffering from kidney disease, 1.1%(2) had hypertension, and 0.6%(1) were reported to have cancer as compared to cousin marriages with 15.7% (38) were suffering from dyslipidemia, 1.2%(3) were suffering from chronic kidney disease, 8.3% (20) had hypertension, and 0.4%(1) were reported to have cancer. There is a statistical significant risk of health conditions like dyslipidemia and hypertension in the off springs of consanguineous couples before the diagnosis of diabetes ($p<0.01$).

Table 2 reports the association of diabetes with associated conditions in the offspring of Consanguineous couples as well as non-consanguineous couples after being diagnosed as diabetic.

Among the children's of non-cousin marriage, 0.6%(1) were suffering from cardiovascular disease; none suffered from chronic kidney disease, 1.7% (3) had hypertension, 1.1% (2) had a visual problem, and 0.6% (1)were reported to have dyslipidemia. Among the progeny of cousin marriage, 14.5 %(35) were suffering from cardiovascular disease, 4.1% (10) suffered from chronic kidney disease, 21.5 %(52) had hypertension, 38.0% (92) had problems related to vision, and 7.0 %(17) were reported to have dyslipidemia after being diabetic. Table 2 showed a strong significant association between diabetes and their complications in the offspring of consanguineous couples after being diagnosed as diabetics ($p<0.01$).

Table 3 reports the treatment plan followed by the participants to maintain their blood sugar levels. Among the progeny of non-cousin marriage, 5.5% followed regular physical exercise, 5.0% avoided sugar in their diet, 3.9% injected insulin, and 6.1% used oral medications. Among the progeny of cousin marriage, 80.6% followed physical exercise, 78.9% avoided sugar in the diet, 22.3% injected insulin, and 74.8% used oral medications with statistically significant p-value = 0.01 respectively.

DISCUSSION

This study assessed the impact of parental consanguinity on the prevalence, severity, and complications of Type 2 Diabetes



Table 1: Risk of other health conditions in offspring of consanguineous couples

Were you suffering from any other health conditions before the diagnosis of diabetes?		non-cousin marriage		cousin marriage		p-value
		n	%	n	%	
Cholesterol (dyslipidemia)	Yes	1	0.6	38	15.7	<0.01*
	No	180	99.4	204	84.3	
kidney diseases	Yes	0	0.0	3	1.2	0.13
	No	181	100.0	239	98.8	
Hypertension	Yes	2	1.1	20	8.3	<0.01*
	No	179	98.9	222	91.7	
Cancer	Yes	1	0.6	1	0.4	0.83
	No	180	99.4	241	99.6	

*p<0.05 was considered statistically significant using the Pearson Chi-Square test

Table 2: Association of diabetes-related with other health conditions

Have you been diagnosed with any other condition after being diabetic?		*Parents' marriage*				*p-value*
		non-cousin marriage		*cousin marriage*		
		n	*%*	*n*	*%*	
cardiovascular disease	Yes	1	0.6	35	14.5	<0.01*
	N o	180	99.4	207	85.5	
chronic kidney disease	Yes	0	0.0	10	4.1	<0.01*
	N o	181	100.0	232	95.9	
Hypertension	Yes	3	1.7	52	21.5	<0.01*
	N o	178	98.3	190	78.5	
eye problems	Yes	2	1.1	92	38.0	<0.01*
	N o	179	98.9	150	62.0	
Cholesterol	Yes	1	0.6%	17	7.0	<0.01*
	N o	180	99.4%	225	93.0	

*p<0.05 was considered statistically significant using the Pearson Chi-Square test

Table 3: Management strategies followed by the participants

		non-cousin marriage		*cousin marriage*		*p-value*
		n	*%*	*n*	*%*	
Physical exercise	Yes	10	5.5	195	80.6	<0.01*
	No	171	94.5	47	19.4	
Avoiding sugar	Yes	9	5.0	191	78.9	0.13
	No	172	95.0	51	21.1	
Injecting insulin	Yes	7	3.9	54	22.3	<0.01*
	No	174	96.1	188	77.7	
Oral medicines	Yes	11	6.1	181	74.8	0.83
	No	170	93.9	61	25.2	

*p<0.05 was considered statistically significant using the Pearson Chi-Square test

Mellitus (T2DM) among adults in Karachi. The findings of this study clearly show that the offspring of consanguineous marriage are more prone to pre-diabetic states such as hypertension and dyslipidemia and complications arising after the diagnosis of diabetes, such as cardiovascular complications, chronic renal failure, and visual disturbances. For instance, before the diagnosis of diabetes, dyslipidemia was experienced by 15.7% of the patients with consanguineous marriage compared with merely 0.6% of the patients with non-consanguineous marriage. Hypertension was also experienced by 8.3% and 1.1% of the patients with consanguineous and non-consanguineous marriage, respectively. After the diagnosis of diabetes, the differences are more marked with 14.5% of the patients with consanguineous marriage experiencing cardiovascular complications compared with merely 0.6% of the patients with non-consanguineous marriage. These differences are significant at $p < 0.01$.

This is consistent with larger epidemiological trends observed in South Asia. Nielsen et al. had highlighted couple concurrence of diabetes, as well as co-morbidities such as hypertension and dyslipidemia, among urban Indians and Pakistanis, emphasizing socioeconomic and household factors that may contribute to these risks.[13] Our study contributes to their research by adding a new dimension of consanguinity, a genetic factor, to this risk scenario. Another study by Samad et al. had highlighted a high rate of consanguinity among Pakistani diabetics, emphasizing the impact of cultural factors on disease prevalence.[14] The genetic impact of such marriages is critical, where one study had highlighted how populations that result from such inbred marriages have a high prevalence of deleterious recessive alleles, which not only increase risk for monogenic disease states but also for complex metabolic disorders such as T2DM.[15] Our study's observation of a high prevalence of dyslipidemia and hypertension among consanguineous children, even before disease onset, is consistent with this genetic risk.

The genetic pathways that underlie this association are important in understanding the link between consanguinity and metabolic disease. Saeed et al. have identified a high rate of genetic mutations that are associated with severe childhood obesity in an inbred group from Pakistan, which is a significant risk factor for T2DM in children.[16] This study is followed by another study by Niazi et al., in which they have identified genetic mutations that are responsible for obesity in children from Pakistan.[17] Our study extends this understanding by demonstrating that not only are children from a consanguineous marriage more prone to obesity-related conditions such as dyslipidemia and hypertension, but they are also more prone to complications from diabetes such as nephropathy and retinopathy after diagnosis itself. Sami et al. have elaborated on the role of genetics and environmental factors in the development of diabetes and have shown that although our study does not include genetic analysis in it, the high degree of association between consanguinity and disease severity does point to the role of genes and environmental factors that may be exacerbating them.[18]

The impact of consanguinity on the management of diabetes and its complications is of significant public health importance. Shahid et al. found that impaired fasting glucose was strongly related to family history and parental consanguinity, and thus there was a need for screening in these populations early.[19]Our research corroborates this and also illustrates that children of consanguineous parents do more diabetes self-care activities, i.e., physical activity and dietary change, probably because of higher disease load and perception.

Family history of metabolic syndrome was also emphasized by Bener et al. as one of the essential risk factors, especially in very endogamous populations, suggesting targeted education.[20] Chauhan et al. highlighted how consanguinity affects nutritional status,

which is a confounding factor with metabolic risk factors.[21] All these studies highlight that, while designing prevention and control strategies for diabetes, there is a need to take into account genetic counseling and education about the risks of consanguinity.

A research conducted among 94 people in the Bahawalpur area of Pakistan resulted in the conclusion that there is a complex interrelationship existing between the genetic and environmental factors in the development of diabetes among this population group and reiterated the findings of previous research studies conducted in the South Asian population. Moreover, they also stress the need for screening programs and interventions, as well as the continued research in the genetics of diabetes for its effective management among this population.[22]

The above findings have also been reflected in the recent literature. Samad et al. have demonstrated a significant link between consanguinity and the development of Type 2 Diabetes in the Pakistani population. This again reflects the importance of the contribution of genetic factors and the cluster effect of consanguinity.[14] Jan et al. have also demonstrated the presence of novel genetic mutations for T2DM in the Pashtun population. This reflects the importance of the genetic isolation of the population and the increased likelihood of the development of diabetes.[23] Again, a study by Ali et al. has reaffirmed the importance of the above findings by showing that patients with a positive family history of diabetes and consanguinity among the parents had significantly higher levels of fasting blood glucose.[24]

The sociocultural factors also play an important role in the above findings. Hussain.R have shown that the knowledge of the genetic risks of inbreeding is low in the Pakistani population. The social acceptability of marrying cousins is much higher than the health implications.[25] Similarly, Bener et al. and Hussain.R. have shown that not only is there an increase in the prevalence of diabetes, but there is also an increase in the severity of complications through gene-environmental interactions.[20,25] Hamamy emphasized the role of pre-conception counseling and community education in populations where there is a high rate of consanguinity to alleviate the genetic burden of common metabolic disorders.[26 27]

All these studies have highlighted that Type 2 Diabetes in Muslim populations with high rates of consanguinity is a multifactorial problem that incorporates genetic, cultural, and environmental factors. Genetic counseling, screening, and community education can go a long way in alleviating this problem in high-risk populations.

Limitations of the study: It is imperative to note that even with the established associations; there is a need to consider the limitations of the study. The major limitation of the study is the fact that the associations established cannot be used to make any inferences regarding the causation of consanguinity and the risk of acquiring T2DM. This is because the study did not employ a longitudinal design. In addition, the fact that the study did not collect data on genetics and lifestyle factors, including diet, exercise, socioeconomic factors, and environmental factors, is a major limitation. Each of these factors is very important in explaining the mechanisms of each of the factors. They may also explain how genetics and lifestyle factors interact in the progression of T2DM.

To build on the above findings, it is suggested that future longitudinal and molecular studies, including genetic profiling, environmental, and lifestyle assessments, be undertaken. This will assist in clarifying the intricacy of the link between consanguinity, genetic predisposition, and environmental factors in the aetiology of T2DM. However, the above findings will assist in providing evidence to healthcare providers, researchers, and public health officials with regard to public health encouragement, engagement, and education in the community with regard to genetic education and the practice of consanguineous marriage.

CONCLUSION

Thus, in regions where high levels of consanguinity exist, early hypertension, dyslipidemia, and complications of diabetes should be a priority for those with a history of cousin marriage. Genetic counseling integration, both in primary care settings and pre-marital settings, could also help reduce future disease burden. Lastly, appropriate cultural-sensitive public health programs need to be established to address the cumulative effects of consanguinity and lifestyle factors that have led to the epidemic of diabetes in Karachi, etc.

Furthermore, increasing awareness about genetic risks associated with close-kin marriages could prove to be a key factor in future prevention. Primary health care professionals need to be trained to identify high-risk families, providing them with appropriate lifestyle modifications from an early age.

Genetic risk assessment needs to be included in public health programs, which could further help refine prevention strategies, especially in regions where high levels of endogamy exist. Addressing all these factors could help reduce the increasing prevalence of Type 2 Diabetes in Pakistan, creating a better metabolic future for generations to come. Therefore, progress towards sustainability would depend on a concerted effort by health institutions, education systems, and governments to ensure that decisions about marriage, as well as health habits, are made with adequate information. Future studies would thus focus on pinpointing certain genetic factors that increase the risk of metabolic disorders in families with consanguinity, thus helping to address these issues more effectively. Thus, Pakistan would look towards a brighter future with reduced instances of diabetes and other hereditary illnesses.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Saif Ullah Shaikh: Principal Investigator, Conception & design, Drafting the article & critical analysis
Saira Hassan Askarey: Manuscript writing & Acquisition of data
Zain Amjad: Manuscript writing & Acquisition of data
Sana Barkat Ali: Manuscript writing & Acquisition of data Worked for important intellectual content
Hina Moazzam: Acquisition of data analysis & Interpretation of data, Revised it Critically for final approval
Iram Saddiqa: Revised it critically for important intellectual content and final approval to be published

REFERENCES

1. Hajjaji M, Khadmaoui A, El Bakkali M. The practice of consanguineous marriage and the risk of diabetes among offspring in the province of Tetouan (Morocco). Arab Gulf Journal of Scientific Research. 2024 Jan 5;42(1):30-43. https://doi.org/10.1108/AGJSR-08-2022-0134
2. Ahmad SF, Hameed A, Jehangir M, Khttak JZ. Molecular study of a consanguineous family with autosomal recessive mental retardation and speech disorder. Molecular Biology Research Communications. 2013 Feb 23;1(2):83-93. doi: 10.22099/mbrc.2013.1098
3. Fareed M, Kaisar Ahmad M, Azeem Anwar M, Afzal M. Impact of consanguineous marriages and degrees of inbreeding on fertility, child mortality, secondary sex ratio, selection intensity, and genetic load: a cross-sectional study from Northern India. Pediatric research. 2017 Jan;81(1):18-26. DOI https://doi.org/10.1038/pr.2016.177
4. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus—An overview. International journal of molecular sciences. 2024 Feb 4;25(3):1882.https://doi.org/10.3390/ijms25031882
5. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, Dalton BE, Duprey J, Cruz JA, Hagins H, Lindstedt PA. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023 Jul 15;402(10397):203-34. • DOI: 10.1016/S0140-6736(23)01301-6
6. Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, Beran D. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021 Dec;64(12):2741-50. https://doi.org/10.1007/s00125-021-05571-8
7. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020 Aug 30;21(17):6275. DOI: 10.3390/ijms21176275
8. Albishi LA, AlAmri E, Mahmoud AA. Relationships among consanguinity, family history, and the onset of type 1 diabetes in children from Saudi Arabia. Primary Care Diabetes. 2022 Feb 1;16(1):102-6.DOI: 10.1016/j.pcd.2021.09.002
9. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports. 2024 Mar;7(3):e2004. https://doi.org/10.1002/hsr2.2004
10. M³ynarska E, Czarnik W, Dzie¿a N, Jêdraszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J, Franczyk B. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. International journal of molecular sciences. 2025 Jan 27;26(3):1094. https://doi.org/10.3390/ijms26031094
11. Amaratunga SA, Hussein Tayeb T, Muhamad Sediq RN, Hama Salih FK, Dusatkova P, Wakeling MN, De Franco E, Pruhova S, Lebl J. Paediatric diabetes subtypes in a consanguineous population: a single-centre cohort study from Kurdistan, Iraq. Diabetologia. 2024 Jan;67(1):113-23. • DOI https://doi.org/10.1007/s00125-023-06030-2
12. Subramanian S. The Abundance of Harmful Rare Homozygous Variants in Children of Consanguineous Parents. Biology. 2025 Mar 19;14(3):310. https://doi.org/10.3390/ biology 14030310
13. Nielsen J, Shivashankar R, Cunningham SA, Prabhakaran D, Tandon N, Mohan V, Iqbal R, Narayan KV, Ali MK, Patel SA. Couple concordance in diabetes, hypertension and dyslipidaemia in urban India and Pakistan and associated socioeconomic and household characteristics and modifiable risk factors. J Epidemiol Community Health. 2023 May 1;77(5):336-42. DOI: 10.1136/jech-2022-219979
14. Samad AA, Qureshi SI, Rathore AM, Ahmed A, Rasool W, Noori S, Qayyum SN, Kakar MT. Consanguinity among individuals with diabetes in Pakistan: A cross-sectional study. PLOS Global Public Health. 2025 Jul 24;5(7):e0004964. https://doi.org/10.1371/journal.pgph.0004964
15. Ali N, Mclean C, Rehman H. Faulty genes: consanguinity in the Pakistani community. Ethnicity and Inequalities in Health and Social Care. 2012 Jun 15;5(2):43-51. https://doi.org/10.1108/17570981211286787
16. Saeed S, Arslan M, Manzoor J, Din SM, Janjua QM, Ayesha H, Ain QT, Inam L, Lobbens S, Vaillant E, Durand E. Genetic causes of severe childhood obesity: a remarkably high prevalence in an inbred population of Pakistan. Diabetes. 2020 Jul 1;69(7):1424-38. https://doi.org/10.2337/db19-1238
17. Niazi RK, Gjesing AP, Hollensted M, Have CT, Borisevich D, Grarup N, Pedersen O, Ullah A, Shahid G, Shafqat I, Gul A. Screening of 31 genes involved in monogenic forms of obesity in 23 Pakistani probands with early-onset childhood obesity: a case report. BMC medical genetics. 2019 Sep 5;20(1):152. https://doi.org/10.1186/s12881-019-0886-8
18. Sami A, Javed A, Ozsahin DU, Ozsahin I, Muhammad K, Waheed Y. Genetics of diabetes and its complications: a comprehensive review. Diabetology & Metabolic Syndrome. 2025 Jun 2;17(1):185. • DOI https://doi.org/10.1186/s13098-025-01748-y
19. Shahid A, Saeed S, Rana S, Mahmood S. Family History of Diabetes and Parental Consanguinity: Important risk for Impaired Fasting Glucose. Annals of King Edward Medical University. 2011;17(3):280-. DOI: https://doi.org/10.21649/akemu.v17i3.550
20. Bener A, Darwish S, Al-Hamaq AO, Yousafzai MT, Nasralla EA. The potential impact of family history of metabolic syndrome and risk of type 2 diabetes mellitus: In a highly endogamous population. Indian journal of endocrinology and metabolism. 2014 Mar 1;18(2):202-9.

21. Chauhan BG, Yadav D, Jungari S. Association between consanguineous marriage and child nutritional outcomes among currently married women in Pakistan. Clinical Epidemiology and Global Health. 2020 Mar 1;8(1):38-44. DOI: 10.1016/j.cegh.2019.04.003

22. Waseem M, Sultana T, Irfan M, Arshad R, Ullah F. Pedigree Analysis of Diabetes Mellitus in Multigenerational Families from Bahawalpur, Pakistan: Inheritance Patterns and Genetic Risk Factors. International Journal of Diabetes in Developing Countries. 2025 Jun 23:1-9. DOI : https://doi.org/10.1007/s13410-025-01518-6

23. Jan A, Zakiullah, Ali S, Muhammad B, Arshad A, Shah Y, Bahadur H, Khan H, Khuda F, Akbar R, Ijaz K. Decoding type 2 diabetes mellitus genetic risk variants in Pakistani Pashtun ethnic population using the nascent whole exome sequencing and MassARRAY genotyping: A case-control association study. PLoS One. 2023 Jan 27;18(1):e0281070. https://doi.org/10.1371/journal.pone.0281070

24. Ali A, Taj A, Ahmed MU, Tabrez E. Frequency of impaired fasting glucose in first degree relatives of Type-II diabetic patients and its association with Body Mass Index. Pakistan journal of medical sciences. 2020 Mar;36(3):407. doi: 10.12669/pjms.36.3.57

25. Hussain R. Lay perceptions of genetic risks attributable to inbreeding in Pakistan. American Journal of Human Biology. 2002 Mar;14(2):264-74. https://doi.org/10.1002/ajhb.10034

26. Younis M, Sasikala K, Anand AV, Iqbal J, Kailash S, Hura MU. Genetic analysis, health issues and consanguineous marriage in Muslim community. Int J Sci Res Sci Technol. 2018;4(2):100–107. https://www.res.ijsrst.com/IJSRST184126

27. Hamamy H. Consanguineous marriages: preconception consultation in primary health care settings. J Community Genet. 2012 Jul;3(3):185–92. DOI: 10.1007/s12687-011-0072-y

Original Article **Open Access**

Early Response Evaluation of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Triphasic Computed Tomography

Nasrullah, M. Saqib Qamar Ishaqi, Abdul Waheed, Abdul Razaque, Syed M. Shah Nawaz, Kashif Shazlee

ABSTRACT

Objective: To aim of this study was to evaluate the early tumor response of hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE) using triphasic computed tomography (CT).

Study Design and Setting: This was a retrospective study conducted at Indus Hospital & Health Network, Karachi.

Methodology: A total of 102 patients were included for six months study between 1st February 2025 and 31st July 2025. Tumor response was assessed 6 weeks post-TACE according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The Chi-square test was applied to test statistical significance of differences across response categories, with a p-value of <0.05 considered statistically significant.

Results: CR was observed in 36% and PR in 32% of patients, giving an overall response rate of 68%. SD was seen in 20% and PD in 12%. Triphasic CT demonstrated a diagnostic accuracy of 88%, with sensitivity of 85% and specificity of 90%. Inter-rater agreement was substantial ($\hat{e} = 0.82$, $p < 0.001$). Patients with Child-Pugh class A liver function showed higher response rates (76%) compared to Child-Pugh class B (50%), though this was not statistically significant ($p = 0.09$).

Conclusion: Triphasic CT is a reliable and reproducible imaging modality for early assessment of tumor response following TACE in HCC. It provides high diagnostic accuracy and can guide treatment decisions.

Keywords: Carcinoma, Hepatocellular; Contrast Media; Liver Function Tests; Reproducibility of Results; Tomography, X-Ray Computed.

How to cite this Article:
Nasrullah, Ishaqi MSQ, Waheed A, Razaque A, Nawaz SMS, Shazlee K. Early Response Evaluation of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Triphasic Computed Tomography. J Bahria Uni Med Dental Coll. 2026;16(2):557-62 DOI: https://doi.org/10.51985/JBUMDC2025775

Nasrullah
Fellow, Department of Radiology
Indus Hospital
Email: nasryaqoob1423@gamil.com

M. Saqib Qamar Ishaqi
Consultant, Department of Radiology
Indus Hospital
Email: Sqishaqi@Yahoo.com

Abdul Waheed
Fellow, Department of Radiology
Indus Hospital
Email: abdulwaheed5001@gmail.com

Abdul Razaque
Consultant, Department of Radiology
Indus Hospital
Email: Abdulrazak3205@gmail.com

Syed M. Shah Nawaz
Consultant, Department of Radiology
Indus Hospital
Email: Drshani80@yahoo.com

Kashif Shazlee
Consultant, Department of Radiology
Indus Hospital
Email: Kashifshazlee@gmail.comReceived:

Received: 20-10-2025
Accepted: 09-04-2026
1st Revision:10-11-2025
2nd Revision: 10-03-2026
3rd Revision: 01-04-2026

INTRODUCTION

Hepatocellular carcinoma (HCC) contributes to a significant proportion of cancer-related mortality. The most common primary malignancy involved is the liver, and it usually occurs in the setting of chronic liver disease, specifically cirrhosis resulting from infection with viral hepatitis and alcohol use or nonalcoholic fatty liver disease (NAFLD).[1] The incidence of HCC is increasing worldwide, and it remains a major health problem, particularly for its advanced, dominant, aggressive, and poor prognosis.[2] Nevertheless, most patients present at an intermediate or late stage when curative treatments, including liver transplantation or surgical resection, are not available.[3]

Transarterial chemoembolization (TACE) is one of the most widely used palliative treatments for patients with an intermediate stage of HCC. It is the preferred approach because it's minimally invasive, yet it involves combining local chemotherapy with embolization to target liver tumors. It delivers chemotherapeutic agents to the tumor by embolization, blocking their blood supply, thereby causing ischemia and necrosis of the tumor tissue.[4] When combined with the conduction procedure (the thermal ablation of liver cancer), the procedure is particularly effective for patients

with single or multiple, unresectable HCC, and for patients in whom the liver function remains preserved, it has been proven to improve survival.[5]

Clinical practice routinely uses contrast-enhanced ultrasonography (CEUS) or magnetic resonance imaging (MRI) to assess HCC response to TACE.[6] Despite these limitations, these modalities have less accessibility, and are costlier and less available, especially in resource-limited settings.(5) Triphasic CT, the technique of imaging the liver in three phases, arterial, portal venous, and delayed, has become a crucial method for evaluating HCC because it allows for more detailed evaluation of tumor vascularity, viability, and necrosis.[7, 8]

It is enriched in the arterial phase to depict the tumor's hypervascular nature, a characteristic of HCC, to assist in delineating the primary tumor as well as satellite nodules. Tumor perfusion and vascular invasion are further assessed during the portal venous phase, as well as areas of necrosis in the delayed phase, which are important for evaluating the therapeutic impact of TACE.[9]

Several studies have tried to find the criteria of response assessment after TACE for HCC; mRECIST is the most common one that is being used. This system classifies the response based on changes in tumor size and tumor necrosis.[10] In the mRECIST, a complete response (CR) is the absence of any viable tumor, and a partial response (PR) is a reduction in the size of the viable tumor. We have shown these criteria to correlate survival outcomes and are commonly used for evaluating HCC response to TACE.[11, 12]

Triphasic CT offers a promising solution in this particular context. Detailed analysis of tumor behavior during multiple phases of contrast enhancement provides a more complete and accurate assessment of tumor necrosis, vascularity, and TACE response. As CT is widely used and the first studies are promising, we hypothesize that triphasic CT can reliably and accurately assess early tumor response to TACE, thereby enhancing treatment outcomes in HCC. The current investigation was designed to evaluate the early response of HCC to TACE with triphasic CT, and to examine the early response of hepatocellular carcinoma following transarterial chemoembolization with triphasic CT.

METHODOLOGY

The present retrospective study was conducted at a single institution, Indus Hospital & Health Network, Karachi, for six months 1st February 2025 and 31st July 2025. The ethical approval for the study protocol was obtained from the Institutional Review Board (IRB) of Indus Hospital & Health Network, Karachi (IRB approval no: IHHN_IRB_2024_09_029, Dated: 25th September, 2024).

Sample size was calculated using the OpenEpi sample size calculator for 95% confidence level, an expected response rate of 79.0% and margin of error of approximately 8%, the required sample size was 102.[13] The study population comprised patients with clinical, imaging, or histopathological confirmation of hepatocellular carcinoma (HCC) who underwent transarterial chemoembolization (TACE) as a primary treatment modality for unresectable disease. A non-probability consecutive sampling technique was employed, and all eligible patients during the study period were included until the required sample size was achieved.

Patients were eligible for inclusion if they had available triphasic computed tomography (CT) imaging before TACE and follow-up imaging at six weeks post-procedure. Patients who had received systemic therapy before TACE or who presented with extrahepatic metastasis were excluded due to incomplete imaging records.

Demographic and clinical information, including age, sex, liver function status, and etiology of liver disease, was extracted from medical records. Patients were treated with TACE performed by interventional radiologists according to a standardized protocol. Using local anesthesia, a microcatheter was advanced through the femoral artery under fluoroscopic guidance and placed to selectively infuse therapy into the hepatic artery main branch supplying the tumor.

Triphasic CT (Multidetector, Canon, Japan) was performed before and after TACE. Imaging protocol included arterial, portal venous, and delayed phases. The arterial phase (30–40 sec after contrast), to demonstrate tumor hypervascularity; portal venous phase (60–70 sec after contrast) to assess washout and liver perfusion, and delayed phase (3–10 min after contrast) to look for residual enhancement or necrosis. All images were digitally archived and reviewed independently by two experienced radiologists blinded to the clinical outcomes and each other's evaluations.

Tumor response was assessed using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC. 14,15 Complete response was defined as complete necrosis with no arterial phase enhancement, partial response as a =30% decrease in the sum of tumor diameter(s) for target lesion(s), progressive disease as a =20% increase in tumor size, and stable disease as findings that did not meet criteria for either response or progression. The main outcome measure was tumor response at 6 weeks after TACE, while secondary outcomes were inter-rater agreement and diagnostic performance of triphasic CT for detecting viable tumor tissue.

All data were inputted and analysed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to summarize the baseline demographic and clinical characteristics, with categorical variables reported as frequencies and percentages, and continuous data as mean ± standard deviation (SD). Tumor response rates were computed as proportions, and the overall response rate (complete plus partial response) was assessed. Paired sample

t-tests were used to compare mean tumor size pre- and post-TACE, with results presented as mean difference and p-values. Tumor enhancement changes over categories were compared using McNemar's test or Chi-square test for two paired categorical variables. Treated calcification and performed surrender analyses of studies to compare testality findings between treatment response rates against characteristics by patients like age, or Autoscholes-Pugh scores (Chi-square test for categorical variables). Rates of complications were reported as frequencies and percentages. Inter-rater agreement between the two radiologists was assessed using Cohen's kappa statistic. We defined statistical significance as a p-value of <0.05, and all statistical tests were two-tailed.

RESULTS

Study one used data from 102 patients with hepatocellular carcinoma (HCC) who underwent transarterial chemoembolization (TACE). The patients' average age was 59.4 ± 7.8 years. The study population consisted of 64.7% males and 35.3% females. Hypertension (44.1%) and diabetes mellitus (32.4%) were the most frequent comorbid conditions. Hepatitis C was the most prevalent type, present in a little more than half of patients (52.9%), and 23.5% had hepatitis B; two-thirds of patients had preserved liver function (Child-Pugh A, 66.7%), while one-third were Child-Pugh B. (Table 1). Overall response rate was 72.4% (39.2% complete, 33.3% partial). Stable disease was reported in 19.6% particiants, and 7.8% had progressive disease. Overall, 72.5% of patients exhibited a favorable response. (Table 2). The mean tumor size significantly decreased from 7.4 ± 2.3 cm before TACE to 5.2 ± 1.8 cm after TACE (p<0.001), with a mean reduction of 29.8%. (Table 3). Evaluation of arterial phase enhancement indicated substantial devascularization in tumor tissue post-TACE. Before treatment, 60 patients demonstrated progressive improvement, whereas this reduced to 18 patients following TACE (p<0.001). A total of 62 patients showed minimal or no improvement after treatment, indicative of successful necrosis induction. (Table 4). Stratified analysis demonstrated significantly greater response rates in patients aged =60 years and with Child-Pugh A cirrhosis. Complete response was obtained in 52.5% of patients =60 years vs 27.1% with >60 years (p=0.011). Also, patients with Child-Pugh A disease had better outcome (CR 45.3%) than Child-Pugh B (24.7%) (p=0.015). (Table 5). Overall, complications of the procedure were minimal and self-limiting. The most common complication was fever (19.6%), followed by abdominal pain (14.7%). Nausea and transient elevation of liver enzymes were seen in 7.8% and 9.8% patients, respectively. (Table 6)

Table 1. Demographic and Clinical Characteristics of Patients (n=102)

Variable	n (%)
Age (Mean ± SD)	59.4 ± 7.8
Male	66 (64.7)
Female	36 (35.3)
Hypertension	45 (44.1)
Diabetes Mellitus	33 (32.4)
Cardiovascular Disease	12 (11.8)
Hepatitis C	54 (52.9)
Hepatitis B	24 (23.5)
Child-Pugh A	68 (66.7)
Child-Pugh B	34 (33.3)

Table 2. Tumor Response by m RECIST Criteria

Response	n (%)
Complete Response	40 (39.2)
Partial Response	34 (33.3)
Stable Disease	20 (19.6)
Progressive Disease	8 (7.8)

Table 3. Tumor Size Reduction After TACE

Variable	Pre-Treatment	Post-Treatment	p-value
Tumor Size (cm)	7.4 ± 2.3	5.2 ± 1.8	<0.001
% Reduction	–	29.8 ± 10.5	–

Table 4. Tumor Enhancement Pre- and Post-TACE

Category	Pre-Treatment (n)	Post-Treatment (n)	p-value
Significant	60	18	<0.001
Moderate	28	22	0.032
Minimal	14	44	<0.001
None	0	18	<0.001

Table 5. Tumor Response by Age and Child-Pugh Score

Variable	CR (%)	PR (%)	SD (%)	PD (%)	p-value
=60 years	52.5	30.5	13.5	3.5	0.011
>60 years	27.1	36.2	25.4	11.3	
Child-Pugh A	45.3	35.2	15.4	4.1	0.015
Child-Pugh B	24.7	29.7	26.3	19.3	

Table 6. Post-TACE Complications

Complication	n (%)
Fever	20 (19.6)
Abdominal Pain	15 (14.7)
Elevated Liver Enzymes	10 (9.8)
Nausea	8 (7.8)

DISCUSSION

This study demonstrates that triphasic CT is a suitable imaging modality for the initial evaluation of hepatocellular carcinoma (HCC) response to transarterial chemoembolization (TACE) with overall response rate (CR+PR) of 68% and high diagnostic accuracy. This study is consistent with previous work describing the efficacy of triphasic CT in distinguishing viable from necrotic tumor

tissue in the HCC setting post TACE. The observed response rate of 68% is close to the results of Lee et al. (2023) of approximately 86.80% early response rate in patients who were imaged using similar protocols.[16] We find that triphasic CT is a reliable tool for the response evaluation and can identify changes in tumor viability within hours after treatment.

This study also validates the reproducibility of triphasic CT for response evaluation in patients with HCC, with the substantial inter-rater agreement observed (ê = 0.82). This high degree of agreement supports the use of triphasic CT for clinical decision-making in a multidisciplinary clinical setting. Consistent with Promsorn (2024) who has reported kappa values over 0.8 for CT TACE response assessments, TACE response assessed on CT was demonstrated to be reliable as well.[1] Arterial, portal venous, and delayed images combined are used to assess tumor vascularity and necrosis, and by combining the three, radiologists can make a consistent assessment of the tumor. The agreement at this level is critical in real-world contexts where the consistency of the interpreted image is used to determine the subsequent image-guided treatment and management.

Triphasic CT, with a sensitivity of 85% and specificity of 90% in detecting viable tumor tissue, had a total accuracy of 88%. Similar to Hasan et al. (2025), these findings correlate with diagnostic accuracy in the assessment of HCC viability post-TACE above 95.83% using triphasic CT.[17] This also supports the belief that the delayed phase in triphasic CT is particularly important to distinguish viable from necrotic tissue, since sustained enhancement often correlates with residual viable tumor. The high specificity seen implies that triphasic CT is specific enough to rule out viable tumor tissue and reduce the number of false positives that could require further treatments.

Child-Pugh Class analysis was performed in the subgroup and the response rate for Child Pugh A was 76%, which is significantly higher than the response rate for Child Pugh B at 53%, that difference, however, was not statistically significant. Our findings are consistent with these, who previously demonstrated that in HCC, treatment outcomes are compromised by liver function status, with patients with preserved liver function reporting improved responses to TACE.[18, 19] While this trend was not statistically significant it does suggest that liver function is a factor in TACE efficacy and thus future studies on this therapy should consider stratifying by liver function to improve the level of treatment personalization.

Results of this study further support the successful use of triphasic CT in early assessment of response to TACE in HCC. The findings support what previous studies have found, and we posit that triphasic CT provides valuable insight into treatment response and its use in this process.[20,21] Additional research may be done to combine other imaging biomarkers or techniques for more specific and more sensitive detection of viable tumor tissue following TACE to improve patient outcomes and treatment precision.

This study demonstrates that triphasic CT is a reliable, effective imaging modality for evaluation of early response to TACE in patients with hepatocellular cancer. Triphasic CT has an overall response of 68% and is highly accurate for determining tumor viability and therapeutic efficacy early after the procedure. The high inter-rater agreement also further supports its relative reproducibility and ultimately clinical utility. Moreover, study outcomes indicate that patients with preserved liver function (Child-Pugh A) achieve better treatment results although further studies are needed.

Collectively, these findings further confirm that triphasic CT is the dominant imaging modality used for early post-TACE assessment and may facilitate rapid reprogramming of treatment planning. Triphasic CT provides significant advantages, yet limitations such as image artifacts following TACE should also be considered. Future studies using more sophisticated approaches in imaging and biomarkers that directly predict viable tumor and necrotic tumor tissue may overcome these limitations. Conclusively, triphasic CT is a robust early response assessment modality for HCC patients undergoing TACE, which in turn led to better patient management and care.

In conclusion, TACE is a clinically feasible disease-modifying intervention with beneficial effects in patients with hepatocellular carcinoma and unresectable disease. Almost 75% of patients showed an advantageous tumor response by the degree of reduction in tumor size and arterial phase enhancement consistent with the TACE mechanism (devascularization/necrosis induction). Younger patients and Child-Pugh A score were more likely to benefit from TACE, suggesting that intervention should take place before hepatic decompensation reaches significant levels. These findings support triphasic CT imaging as a valid method of assessing treatment response and aiding future therapeutic decisions. The incorporation of these research findings into clinical practice may facilitate better patient selection, informed follow-up strategies, and timely consideration of additional treatment strategies if needed.

CONCLUSION:

Triphasic CT has a 68% overall response rate and is very precise in determining tumor viability and response to therapy within a short period after the intervention. The substantial inter-rater agreement further supports its comparative reproducibility and clinical usefulness. Furthermore, the study results suggest potential trends indicating patients with preserved liver function (Child-Pugh A) may achieve better treatment responses, although additional studies are required.

Both of these findings support the continued use of triphasic CT as the main imaging modality for early post-TACE

assessment and thus will hopefully allow timely re-evaluation of treatment planning. Triphasic CT has significant advantages; however, limitations, including imaging artifacts following TACE, should be noted. In future studies, more advanced imaging techniques and biomarkers may be utilized in order to address these limitations and improve the ability to differentiate viable from necrotic tumor tissue.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Nasrullah: Substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; Drafting the article & revising it critically for important intellectual content; Final approval of the version to be published.
M. Saqib Qamar Ishaqi: Acquisition of data, analysis and interpretation of data; Drafting the article, Final approval of the version to be published
Abdul Waheed: Acquisition of data, revising it critically for important intellectual content, Final approval of the version to be published.
Abdul Razaque: Drafting the article, Final approval of the version to be published
Syed M. Shah Nawaz: Drafting the article, Final approval of the version to be published
Kashif Shazlee: Analysis and interpretation of data, Final approval of the version to be published.

REFERENCES

1. Promsorn P, Yamaguchi T, Kosaka H, Aoi K, Yoshida K, Matsushima H, Matsui K, Shimoda S, Kaibori M, Naganuma M. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib. Mol Clin Oncol. 2024;21(3):63. doi: 10.3892/mco.2024.2761.
2. Wang C, Wang M, Zhang X, Zhao S, Hu J, Han G, Liu L. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Transl Med. 2020;8(8):541. doi: 10.21037/atm.2020.02.113.
3. Abdelhamed MS, Elsharawy FA, Youssef MA, Omar H. Comparative study for identification of feeding arteries of hepatocellular carcinoma by 3D reformatted CT angiography and digital subtraction angiography during transcatheter arterial chemoembolization (TACE). Egypt J Hosp Med. 2024;95(1):1601-07.
4. Yao L, Gao Z, Wei X, Wang S, Cao W, Deng W, Li X, Zhang Z, Wang S, Zhang Y, Liu R, Xie Y, Li M. Application of nanotechnology in TACE treatment of liver cancer. Int J Nanomedicine. 2025;20:9621-39. doi: 10.2147/IJN.S527518.
5. Werida RH, Abd El Baset OA, Askar S, El-Mohamdy M, Omran GA, Hagag RS. Efficacy of doxorubicin and lipiodol therapy by transarterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms. Expert Rev Anticancer Ther. 2024;24(10): 1009-20. doi: 10.1080/14737140.2024.2391364.
6. Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY). 2021;46(8):3579-95.doi:10.1007/s00261-021-03059-y.
7. Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current imaging diagnosis of hepatocellular carcinoma. Cancers (Basel). 2022;14(16):3997. doi: 10.3390/cancers14163997.
8. Alhanafy AM, Abd Elbary NM, Elwarkky MS, Esmail EG, Abd Elghani AE. Low-dose aspirin in combination with transarterial chemoembolization in treatment of unresectable hepatocellular carcinoma. Egypt J Hosp Med. 2024;94:18-22.
9. Justaniah AI, Omar MA, Tashkandi AM. Ischemic stroke post-transradial chemoembolization. Arab J Interv Radiol. 2024;8(1):46-8. doi: 10.1055/s-0044-1779493.
10. Taher MY, Hassouna E, El Hadidi A, El-Aassar O, Bakosh MF, Shater MS. Serum CYFRA 21-1 and CK19-2G2 as predictive biomarkers of response to transarterial chemoembolization in hepatitis C-related hepatocellular carcinoma among Egyptians: a prospective study. J Clin Exp Hepatol. 2025;15(1):102405. doi: 10.1016/j.jceh.2024.102405.
11. Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, Ramaiya NH. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e211136. doi: 10.1001/jamanetworkopen.2021.1136.
12. Elhadad A, Niazi GE, Elnaggar H. The value of PET/CT combined with complementary MRI in the follow-up of hepatocellular carcinoma after transarterial chemoembolization. Ain Shams Med J. 2024;75(1):141-50. doi: 10.21608/asmj. 2023.244158.1179.
13. Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol. 2020;35(2):305-13. doi: 10.1111/jgh.14816.
14. Lewis S, Cedillo MA, Lee KM, Bane O, Hectors S, Ma W, Wang P, Stocker D, Morris DV, Pinato D, Sung M, Marron T, Schwartz M, Taouli B. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdom Radiol (NY). 2022;47(3):969-80. doi: 10.1007/s00261-021-03386-0.
15. Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open. 2022;12(6):e052294. doi: 10.1136/ bmjopen-2021-052294.
16. Lee M, Shin HP. Efficacy of transarterial chemoembolization (TACE) for early-stage hepatocellular carcinoma. Medicina (Kaunas). 2023;59(12):2174. doi: 10.3390/medicina59122174.
17. Hasan N, Asad S, Qureshi A, Fariha A, Sattar J, Shah SH. Diagnostic accuracy of quantitative washout in diagnosing hepatocellular carcinoma. Insights J Health Rehabil. 2025;3(3):685-92. doi: 10.71000/ajs39t47.
18. Makarova E, Fan X, Farooqi I, Bakhl K, Murphy TE, Stonesifer ES, et al. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. J Liver Transplant. 2025;17:100257. doi: 10.1016/j.liver.2024.100257.
19. Majeed AA, Shaikh H, Azam SMZ, Al Qamri N, Khalid R,

Shaikh AB. Efficacy and safety of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and assessment of health related quality of life (HRQoL) using CLDQ©. J Health Rehabil Res. 2024;4(1):1678-84. doi: 10.61919/jhrr.v4i1.715.

20. Tipaldi MA, Ronconi E, Lucertini E, Krokidis M, Zerunian M, Polidori T, Begini P, Marignani M, Mazzuca F, Caruso D, Rossi M, Laghi A. Hepatocellular carcinoma drug-eluting bead transarterial chemoembolization (DEB-TACE): outcome analysis using a model based on pre-treatment CT texture features. Diagnostics (Basel). 2021;11(6):956. doi: 10.3390/diagnostics11060956.

21. Khamis ERH, Sherif MF, Teama AH, Abd-Elhalim KM. Post-chemoembolization of hepatocellular carcinoma: a role of computed tomography and MRI in prediction of treatment response. Tanta Med J. 2024;52(3):203-14. doi: 10.4103/tmj.tmj_28_24.

Original Article **Open Access**

Association of Carotid Intima Media Thickness with the Extent of Angiographically Proven Coronary Artery Disease

Jahanzeb Ibrahim, Elishba Qazi, Zuhoor Uddin, Kalsoom Nawab, Sahib Noor, Laila Haleem

ABSTRACT

Objective: To evaluate the association between carotid intima-media thickness (CIMT) with the extent of angiographically proven coronary artery disease (CAD).

Study Design and Setting: A cross-sectional study was conducted at Khyber Teaching Hospital (KTH), Peshawar.

Methodology: The study included 65 patients receiving diagnostic coronary angiography and was conducted from 1st April 2025 to 30th September 2025. Cardiovascular risk factors were among the baseline clinical and demographic features that were documented. High-resolution B-mode ultrasonography was used to measure CIMT. The degree of CAD was classified as either no CAD, single-vessel, two-vessel, or three-vessel disease, and its severity was measured using the Gensini score. Regression and correlation models were used to examine relationships between CIMT and angiographic results. The diagnostic accuracy of CIMT for predicting obstructive CAD was assessed using receiver operating characteristic (ROC) curve analysis.

Results: The mean age of participants was 56.2 ± 9.8 years, with 64.6% males. Obstructive CAD was present in 75.4% of patients. CIMT increased progressively with the extent of CAD, from 0.68 ± 0.10 mm in patients without CAD to 1.02 ± 0.13 mm in those with three-vessel disease ($p < 0.001$). CIMT showed a strong positive correlation with the Gensini score ($p < 0.001$). ROC analysis demonstrated good diagnostic accuracy (AUC = 0.82).

Conclusion: CIMT is a reliable, non-invasive marker that correlates with the severity of CAD and can aid in early risk stratification and clinical decision-making.

Keywords: Carotid Intima-Media Thickness; Coronary Angiography; Coronary Artery Disease; Gensini Score; Risk Factors; Ultrasonography

How to cite this Article:
Ibrahim J, Qazi E, Uddin Z, Nawab K, Noor S, Haleem L. Association of Carotid Intima Media Thickness with the Extent of Angiographically Proven Coronary Artery Disease. J Bahria Uni Med Dental Coll. 2026;16(2):563-9 DOI: https://doi.org/10.51985/JBUMDC2025776

Jahanzeb Ibrahim
Post Graduate Trainee, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: jahanzebibrahim@gmail.com

Elishba Qazi
Post Graduate Trainee, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: ebancazee@gmail.com

Zuhoor Uddin
Post Graduate Trainee, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: mrzet@gmail.com

Kalsoom Nawab
Associate Professor, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: kalsoomnawab@gmail.com

Sahib Noor
Post Graduate Trainee, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: drsak7623@gmail.com

Laila Haleem
Post Graduate Trainee, Department of Radiology
MTI- Khyber Teaching Hospital Peshawar
Email: mustafahaleem@gmail.com

Received: 20-10-2025
1st Revision: 21-12-2025
Accepted: 06-04-2026
2nd Revision:18-03-2026

INTRODUCTION

A significant portion of the burden of atherosclerotic cardiovascular disease, which is still the primary cause of morbidity and mortality globally, is attributed to coronary artery disease (CAD). Therefore, early detection of subclinical atherosclerosis is essential for risk assessment, primary prevention, and prompt intervention. It has long been suggested that carotid intima-media thickness (CIMT), which is determined by B-mode ultrasonography of the common carotid artery, is a noninvasive proxy for systemic atherosclerosis and vascular aging. As a simple, reproducible imaging metric, CIMT promises to bridge the gap between traditional risk scoring and direct assessment of arterial pathology, and has consequently been the subject of intense study for its association with the presence and extent of angiographically proven CAD.[1, 2]

Physiologically, CIMT reflects both adaptive and pathological changes in the arterial wall, including medial hypertrophy, intimal thickening, and early atheroma formation. These changes often mirror coronary atherosclerosis because they share systemic risk factors like hypertension, dyslipidaemia, diabetes, and smoking. Drive

diffuse arterial remodeling. However, CIMT and coronary plaque differ in some pathobiological attributes. CIMT measures wall thickness but does not fully capture plaque burden, composition, or vulnerability, which are features that determine clinical events. Accordingly, the debate has shifted from whether CIMT correlates with cardiovascular risk to how well it predicts the presence, extent, and anatomical severity of CAD on coronary angiography.[2, 3]

Epidemiologic cohort studies and meta-analyses have repeatedly shown that increased CIMT is associated with higher rates of cardiovascular events and incremental risk over conventional factors in some populations.[4, 5] Nevertheless, the magnitude and clinical utility of that association vary by age, measurement protocol (mean vs. maximum CIMT, which arterial segment is measured), and whether carotid plaque is present, plaque burden often being a stronger predictor than intima-media thickening alone. Recent systematic appraisals emphasize that heterogeneity in CIMT definitions and measurement techniques limits direct comparability between studies and complicates translation into practice.[6, 7]

When investigators have compared CIMT directly with angiographic findings, results are mixed but informative. Higher CIMT values are linked to the presence of obstructive CAD and multivessel disease, according to many cross-sectional studies that involve individuals who have been sent for coronary angiography. This supports the idea that CIMT serves as a measure of generalized atherosclerotic load. At the same time, other studies demonstrate only weak or modest correlations, particularly when plaque characteristics or coronary calcification are considered, underscoring that a thickened intima-media is only one facet of a complex systemic process [7, 8]

Investigators have explored combining CIMT with biochemical markers, like lipid parameters, inflammatory indices, or homocysteine, and with carotid plaque assessment to improve the prediction of angiographic CAD and acute coronary syndromes. Several contemporary cohorts have demonstrated that models incorporating carotid plaque presence or plaque burden outperform models using CIMT alone for identifying significant coronary stenosis. Moreover, subgroup analyses suggest age-dependent differences in predictive power; CIMT may be more informative in middle-aged individuals than in the very young or elderly, where competing structural and degenerative changes confound interpretation.[7, 9, 10]

Clinical implications stem from these empirical observations. If CIMT reliably reflects the extent of angiographic CAD, it could be used to triage symptomatic patients, refine risk estimates in persons with intermediate risk scores, or monitor response to therapies that target atherosclerotic progression. Conversely, if the association is weak or inconsistent, overreliance on CIMT could misclassify patients and divert resources from more informative tests like coronary CT angiography or invasive angiography when clinically indicated. Therefore, clarifying the strength and determinants of the CIMT–CAD relationship, particularly in populations undergoing coronary angiography, is essential.[11, 12]

Coronary artery disease (CAD) is still one of the leading causes of death globally, and preventing negative consequences and managing the condition effectively depend on early detection. A non-invasive indicator of subclinical atherosclerosis, carotid intima-media thickness (CIMT), has drawn more attention as a possible proxy for coronary atherosclerotic load. Assessing CIMT may assist in identifying those at risk of substantial CAD without the need for invasive procedures because the pathophysiological causes of atherosclerosis in the carotid and coronary arteries are similar. The purpose of this study was to assess the relationship between the degree of angiographically confirmed coronary artery disease and carotid intima-media thickness.

METHODOLOGY

This analytical cross-sectional study was conducted in the Department of Radiology, Khyber Teaching Hospital, Peshawar, over a period of six months from 1st April 2025 to 30th September 2025. The objective of the study was to determine the association between carotid intima-media thickness (CIMT) and the extent of angiographically proven coronary artery disease (CAD). Ethical approval for the study was obtained from the Institutional Research and Ethics Board of Khyber Medical College, under approval number 281/DME/KMC dated 21 March 2025.

The sample size was calculated using OpenEpi software based on the expected prevalence of obstructive coronary artery disease of 20%, a confidence level of 95%, and a margin of error of 8%. The sample size of the study was 96 patients, but a total of 65 patients were included in the study through the study period owing to time and resource constraints. [13]

A consecutive sampling technique was employed. Patients aged 18 years and above, referred for diagnostic coronary angiography due to suspected CAD, were enrolled. Exclusion criteria included a history of coronary interventions such as coronary artery bypass grafting or percutaneous coronary intervention, known carotid artery disease or prior carotid intervention, poor acoustic windows on ultrasound, pregnancy, severe systemic illness such as end-stage renal or liver disease, and inability to cooperate with the procedure. Arterial diseases like cardiomyopathies, chronic obstructive pulmonary disease, lung diseases affecting the coronary circulations especially hypoxic diseases and valvular heart diseases were also excluded.

A structured proforma was used to gather data. Before registration, all individuals gave their informed consent. Age, sex, and cardiovascular risk factors like hypertension, diabetes mellitus, dyslipidemia, smoking history, and family

history were recorded, as well as clinical presentations such as stable angina or acute coronary syndrome. Additionally documented were baseline laboratory tests such as the fasting lipid profile and the fasting blood glucose, or HbA1c. To ensure temporal consistency, carotid ultrasonography was done either two weeks after the surgery or before angiography, whenever feasible. A consultant radiologist of over five years' experience in vascular ultrasonography performed all ultrasound tests and was blinded to angiographic results.

Carotid intima-media thickness was measured using high-resolution B-mode ultrasonography with a 7.5–12 MHz linear array transducer. Patients were examined in a supine position with the head slightly extended and rotated contralaterally. Measurements were taken from the far wall of the common carotid artery, one centimeter proximal to the carotid bulb, on both sides. A minimum of three measurements was obtained from each side, and the mean CIMT was calculated. Maximum CIMT and the presence of focal carotid plaques, defined as focal wall thickening of 1.5 mm or greater than 50% of the surrounding intima-media thickness, were also documented. All ultrasound examinations were performed by an experienced radiologist who was blinded to the angiographic results in order to reduce observer bias.

Coronary angiography was performed using the standard Judkins technique.[14] All angiograms were reviewed by a consultant interventional cardiologist who was blinded to the CIMT findings. These procedures were conducted by skilled consultant interventional cardiologists in accordance with the standard practice in the clinics; but, all angiographic results were analyzed and confirmed by one consultant interventional cardiologist to ensure consistency in evaluation. Coronary artery disease severity was quantified by two approaches: first, by the number of vessels showing 50% or greater luminal stenosis, categorized as single-, double-, or triple-vessel disease; and second, by calculating the Gensini score[15], which provides a weighted estimate of both the severity and anatomical location of stenotic lesions, thereby reflecting the overall burden of coronary atherosclerosis. A score was assigned to each constriction in a coronary artery according to the percentage of blockage (e.g., 25, 50, 75, 90, 99, and 100). The scores were then weighted based on the position of the blockage in the coronary arteries and all the scores were summed to come up with the total Gensini score which is proportional to the severity of the coronary artery disease in general.

Data analysis was conducted using SPSS version 26. Continuous variables such as age, body mass index, CIMT, and Gensini score were expressed as mean with standard deviation or as median with interquartile range, depending on their distribution. Categorical variables, including sex, diabetes mellitus, hypertension, smoking, and the presence of CAD, were expressed as frequencies and percentages. The association between CIMT and angiographic extent of blockage was assessed using Pearson correlation coefficients. Comparisons of CIMT across categories of CAD were evaluated using analysis of variance or the Kruskal–Wallis test. Multivariable linear regression analysis was performed to assess the independent association between CIMT and the Gensini score after adjusting for conventional risk factors. Logistic regression was also applied to evaluate CIMT as a predictor of obstructive CAD, defined as luminal stenosis of 50 percent or greater. The diagnostic performance of CIMT was further assessed by receiver operating characteristic curve analysis. A p-value =0.05 was considered statistically significant.

RESULTS

A total of 65 patients were included in the study with a mean age of 56.2 ± 9.8 years. Among them, 64.6% were male, and 35.4% were female, with a mean body mass index (BMI) of 27.4 ± 3.9 kg/m². Regarding cardiovascular risk factors, 60.0% were hypertensive, while 43.1% had diabetes mellitus. Dyslipidemia was observed in 52.3%, and 29.2% were current smokers. A positive family history of coronary artery disease (CAD) was present in 32.3%, whereas 67.7% reported no such history. Upon angiographic evaluation, 75.4% of patients had obstructive CAD (=50% stenosis), whereas 24.6% did not have any obstructive disease. In terms of vessel involvement, 24.6% of patients had no angiographically visible CAD, whereas 27.7% had single-vessel disease, 23.1% had two-vessel disease, and 24.6% had three-vessel disease. The study population's median Gensini score was 42 (IQR: 28–68). (Table 1) The mean CIMT values for patients without CAD were 0.68 ± 0.10 mm, those with single-vessel disease were 0.82 ± 0.12 mm, and those with two- and three-vessel disease were 0.91 ± 0.11 mm and 1.02 ± 0.13 mm, respectively. Post-hoc analysis confirmed that CIMT was significantly higher in all CAD categories compared to patients without CAD, and the difference between groups was statistically significant ($p < 0.001$). (Table 2) The Gensini score, which measures the angiographic severity of coronary artery disease, showed a high positive correlation with carotid intima-media thickness (CIMT). There was a higher association between the maximum CIMT and the Gensini score ($r = 0.66$, $p < 0.001$) than there was between the mean CIMT and the Gensini score ($p < 0.001$)**.** (Table 3) (Figure 1) CIMT was identified as an independent variable significantly associated with the severity of coronary artery disease in the multivariable linear regression analysis. A 5.8-point increase in the Gensini score was statistically linked to every 0.1 mm increase in CIMT ($p < 0.001$). Higher Gensini scores were also substantially correlated with increasing age ($p = 0.009$). Clinical risk variables independently linked to severe CAD included smoking ($p = 0.021$), diabetes mellitus ($p = 0.028$), and hypertension ($p = 0.019$). (Table 4) ROC curve analysis was used to evaluate the diagnostic efficacy of carotid intima-

media thickness (CIMT) for predicting obstructive coronary artery disease (CAD). As shown in the image, CIMT demonstrated strong discriminative ability to distinguish between patients with and without obstructive CAD, with an area under the curve (AUC) of 0.82. With a positive predictive value (PPV) of 89.1% and a negative predictive value (NPV) of 57.7%, the ideal cutoff value of 0.85 mm produced a sensitivity of 78.6% and a specificity of 75.0%. (Figure 2) CIMT was independently associated with the presence of obstructive coronary artery disease (=50% stenosis) in the logistic regression analysis. The risks of obstructive CAD increased 1.48 times for every 0.1 mm rise in CIMT ($p < 0.001$). Additionally, there was a significant correlation between age and the risks of obstructive CAD, with the odds rising by 5% for each extra year of age ($p = 0.046$). (Table 5)

Table 1. Baseline Demographic, Clinical, and Angiographic Characteristics of Study Participants (n = 65)

Variable	n (%) / Mean ± SD
Age (years)	56.2 ± 9.8
Sex	
Male	42 (64.6)
Female	23 (35.4)
BMI (kg/m²)	27.4 ± 3.9
Hypertension	
Yes	39 (60.0)
No	26 (40.0)
Diabetes Mellitus	
Yes	28 (43.1)
No	37 (56.9)
Dyslipidemia	
Yes	34 (52.3)
No	31 (47.7)
Current Smoker	
Yes	19 (29.2)
No	46 (70.8)
Family History of CAD	
Positive	21 (32.3)
Negative	44 (67.7)
Obstructive CAD (=50% stenosis)	
Present	49 (75.4)
Absent	16 (24.6)
Number of Vessels Involved	
None	16 (24.6)
Single-vessel	18 (27.7)
Two-vessel	15 (23.1)
Three-vessel	16 (24.6)
Gensini Score Median (IQR)	42 (28–68)

Table 2. Association of of CIMT across the Extent of Coronary Artery Disease

CAD Category	Mean CIMT (mm) ± SD	p-value*
No CAD (n=16)	0.68 ± 0.10	
Single-vessel (n=18)	0.82 ± 0.12	0.002
Two-vessel (n=15)	0.91 ± 0.11	<0.001
Three-vessel (n=16)	1.02 ± 0.13	<0.001

*ANOVA test used for comparison across groups. Post hoc analysis showed significant differences between the no-CAD group and each CAD group.

Table 3. Correlation between Carotid Intima-Media Thickness and Gensini Score

Variable	Correlation Coefficient (r)
Mean CIMT (mm) vs. Gensini score	0.61 (Pearson)
Maximum CIMT (mm) vs. Gensini score	0.66 (Pearson)

Figure 1: Scatter plot showing the correlation between mean carotid intima-media thickness (CIMT) and Gensini score.



Table 4. Multivariable Linear Regression Analysis of Factors Associated with Gensini Score

Predictor Variable	â (95% CI)	p-value
CIMT (per 0.1 mm increase)	5.8 (3.1 – 8.5)	<0.001
Age (years)	0.42 (0.11 – 0.74)	0.009
Male (gender)	4.6 (–3.2 – 12.3)	0.24
Hypertension	7.1 (1.2 – 13.0)	0.019
Diabetes mellitus	6.4 (0.7 – 12.1)	0.028
Dyslipidemia	3.9 (–2.4 – 10.2)	0.22
Smoking	5.5 (0.9 – 10.1)	0.021

Table 5. Logistic Regression for CIMT as Predictor of Obstructive CAD (=50% stenosis)

Predictor Variable	Odds Ratio (OR)	95% CI	p-value
CIMT (per 0.1 mm increase)	1.48	1.21 – 1.80	<0.001
Age (per year)	1.05	1.00 – 1.10	0.046
Hypertension	1.82	0.74 – 4.50	0.19
Diabetes mellitus	2.05	0.84 – 5.01	0.11
Smoking	1.67	0.63 – 4.41	0.30

Figure 2: The ROC curve showing the diagnostic performance of CIMT in predicting obstructive CAD, with an AUC of 0.82



DISCUSSION

In this study, CIMT demonstrated a strong and independent association with the angiographic burden of coronary atherosclerosis. Mean CIMT correlated positively with the Gensini score (r = 0.61), and maximum CIMT correlated even more strongly (r = 0.66). Each 0.1 mm increment in CIMT was associated with a 5.8-point increase in Gensini score in multivariable analysis, and CIMT predicted obstructive CAD with an AUC of 0.82 (optimal cutoff 0.85 mm; sensitivity 78.6%, specificity 75.0%). These results indicate that higher carotid wall thickness closely parallels more extensive coronary disease in a population referred for coronary angiography.

Our findings are concordant with a number of contemporary studies that have reported meaningful associations between carotid arterial indices and coronary atherosclerotic burden. A prospective single-centre study by Verma and Katyal (2022) in a South Asian population found that mean CIMT was higher in patients with angiographically confirmed CAD and that CIMT independently predicted the presence of CAD, although their report suggested a weaker or inconsistent relationship with angiographic severity indices (Gensini and SYNTAX) in some analyses.[16] In contrast, several other cohorts have reported stronger, graded relationships between CIMT and severity measures: a multicentre series of patients reported higher mean CIMT in those with multivessel disease and showed moderate discriminatory performance (AUCs in the 0.70–0.80 range) for detecting significant coronary stenoses, findings that closely mirror our observed AUC of 0.82 and the stepwise increase in mean CIMT across none to single to two and to three-vessel disease in our data.[4, 17]

Differences between studies in effect sizes and diagnostic accuracy likely reflect methodological and population heterogeneity. Measurement protocols like mean versus maximum CIMT, site of measurement, common carotid vs bulb/internal carotid, sonographer experience, and whether carotid plaque was separately assessed are all important modifiers. Studies that incorporate plaque assessment or plaque burden commonly report that plaque variables add incremental predictive value and often outperform CIMT alone for detecting severe or complex coronary disease. For instance, population analyses and clinical cohorts from the last several years emphasize that focal carotid plaque, rather than diffuse intima-media thickening alone, may better reflect advanced atherosclerotic burden and improve agreement with coronary imaging. Our protocol recorded plaque presence but focused the primary analyses on CIMT. The relatively high AUC we observed suggests that in our sample, CIMT captured a substantial portion of systemic atherosclerotic burden, yet augmenting models with plaque metrics might further enhance discrimination, as other investigators have reported.[17, 18]

The magnitude of the association we observed (â = 5.8 Gensini points per 0.1 mm CIMT) is clinically interpretable: small measurable changes in arterial wall thickness correspond to meaningful differences in angiographic disease burden. This parallels the pattern reported in other mid-sized angiographic cohorts in which per-unit increases in CIMT were associated with higher coronary scores or greater odds of multivessel disease. Still, not all studies found identical results. Verma et al. 2022 reported that while CIMT predicted the presence of CAD, its correlation with severity scores was weak in their sample, an observation that cautions against universal generalization and highlights the role of sample composition, age distribution, and prevalence of risk factors.[16]

Our multivariable models also showed that traditional risk factors, age, hypertension, diabetes, and smoking, retained independent associations with angiographic severity, consistent with large contemporary cohorts. Importantly, CIMT remained an independent predictor even after adjusting for these covariates, supporting its added value beyond routine clinical risk markers. This supports the potential role of CIMT as a non-invasive adjunct to risk stratification in patients with intermediate clinical suspicion where the pretest probability of CAD is uncertain. Several recent studies recommend precisely this pragmatic use, combining carotid imaging with clinical and biochemical markers to improve patient selection for downstream testing.[17, 19, 20]

In practical terms, the present results add to the accumulating evidence that CIMT is a useful, widely available, low-cost imaging biomarker that correlates with the extent of coronary atherosclerosis. Our data suggest an optimal CIMT cutoff (0.85 mm) with good sensitivity and specificity for obstructive CAD in this referral population, a performance similar to several contemporary reports. Still, clinicians should interpret CIMT alongside clinical risk factors and, where available,

carotid plaque assessment or coronary CT imaging rather than as a standalone gatekeeper. Future research should focus on larger, multicentre cohorts with standardized CIMT and plaque protocols, combined prediction models that formally integrate CIMT, plaque burden, biomarkers, and clinical scores, and prospective studies assessing whether CIMT-guided diagnostic strategies improve patient-centred outcomes or reduce unnecessary invasive testing.

The results of this study demonstrate the significance of carotid intima-media thickness (CIMT), a straightforward, affordable, and non-invasive indicator that has a good correlation with the prevalence of coronary atherosclerosis. When deciding whether to do invasive coronary angiography on patients with intermediate cardiovascular risk, CIMT assessment may be used as an additional tool for risk stratification in standard clinical practice. The observed cutoff value of 0.85 mm, with good sensitivity and specificity, suggests that CIMT can help identify patients more likely to harbor significant coronary artery disease (CAD), thereby guiding earlier preventive interventions or more targeted diagnostic testing.

Furthermore, CIMT may provide additional value beyond established risk scores like Framingham or ASCVD calculators because it continues to be an independent predictor of CAD severity even after controlling for traditional risk factors. Incorporating CIMT into clinical algorithms could allow earlier identification of high-risk individuals who might otherwise be underestimated by traditional scoring systems alone. In addition, CIMT screening may be especially relevant in resource-limited settings where advanced imaging modalities such as coronary CT angiography or invasive angiography are not readily available.

A surrogate marker for evaluating the efficacy of preventive measures, including statin therapy, antihypertensives, and lifestyle changes, may also be provided by routine CIMT monitoring. However, CIMT should not be viewed as a replacement for established diagnostic modalities; rather, it should be integrated with clinical history, risk factor assessment, and, where indicated, imaging of carotid plaque or coronary arteries. In this way, CIMT can enhance early detection, improve patient selection for invasive testing, and ultimately contribute to reducing the burden of cardiovascular morbidity and mortality.

Limitations: There are limitations to consider when comparing our results to the literature. First, our sample size (n = 65) is modest compared with some larger cohorts; while our estimates were statistically robust, smaller samples are more susceptible to sampling variability and may overestimate effect sizes. Second, temporal proximity between CIMT measurement and angiography was controlled but not identical in every subject; although we limited the interval to two weeks, interval events or medical therapy changes could alter plaque dynamics. Third, measurement heterogeneity remains a universal caveat; different sonographers, ultrasound systems, and measurement protocols across studies complicate direct head-to-head comparisons. Finally, most prior studies and ours are observational and cross-sectional, limiting causal inference about progression; longitudinal studies that track CIMT change and progressive coronary plaque development would be most informative.

CONCLUSION:

Carotid intima-media thickness (CIMT) is shown in this study to be an independent predictor of angiographic severity in addition to being substantially correlated with the existence and severity of coronary artery disease (CAD). Its potential as a non-invasive proxy for the burden of coronary atherosclerosis is shown by the steady increase in CIMT readings across single-, double-, and triple-vessel disease. Crucially, CIMT is a useful clinical tool for CAD risk stratification and early diagnosis, as evidenced by the diagnostic accuracy indicated by an AUC. Routine cardiovascular risk assessment that includes CIMT monitoring may help identify high-risk individuals early, lessen the need for invasive procedures, and ultimately direct preventive measures to lessen the burden of coronary artery disease.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Jahanzeb Ibrahim: Intro, Literature Review, data collection, Data analysis.
Elishba Qazi: Literature Review, data collection, result.
Zuhoor Uddin: Literature Review, data collection, Data analysis.
Kalsoom Nawab: Review the article, Result and Data analysis.
Sahib Noor: Literature Review, Data Collection.
Laila Haleem: Data Collection, Data analysis.

REFERENCES:

1. Kab³ak-Ziembicka A, Przew³ocki T. Clinical Significance of Carotid Intima-Media Complex and Carotid Plaque Assessment by Ultrasound for the Prediction of Adverse Cardiovascular Events in Primary and Secondary Care Patients. J Clin Med. 2021 Oct 9;10(20):4628. Doi: 10.3390/jcm10204628..
2. Polak JF, Backlund JC, Budoff M, Raskin P, Bebu I, Lachin JM; DCCT/EDIC Research Group. Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. J Am Heart Assoc. 2021 Dec 21;10(24):e022922. doi: 10.1161/JAHA.121.022922.
3. Parkkila K, Kiviniemi A, Tulppo M, Perkiömäki J, Kesäniemi YA, Ukkola O. Abdominal aorta plaques are better in predicting future cardiovascular events compared to carotid intima-media thickness: A 20-year prospective study. Atherosclerosis. 2021 Aug;330:36-42. doi: 10.1016/j.atherosclerosis.2021.06.925.
4. Abeysuriya V, Perera BPR, Wickremasinghe AR. Regional and demographic variations of Carotid artery Intima and Media Thickness (CIMT): A Systematic review and meta-analysis. PLoS One. 2022 Jul 12;17(7):e0268716.

5. Magri CJ, Xuereb S, Xuereb RA, Xuereb RG, Fava S, Galea J. Sleep measures and cardiovascular disease in type 2 diabetes mellitus. Clin Med (Lond). 2023 Jul;23(4):380-386. Doi: 10.7861/clinmed 2022-0442.
6. Ling Y, Wan Y, Barinas-Mitchell E, Fujiyoshi A, Cui H, Maimaiti A, Xu R, Li J, Suo C, Zaid M. Varying Definitions of Carotid Intima-Media Thickness and Future Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023 Dec 5;12(23):e031217. doi: 10.1161/JAHA.123.031217.
7. Ge J, Jing F, Ji R, Tian A, Su X, Li W, He G, Pu B, Lei L, Lu J, Li J. Age-Related Trends in the Predictive Value of Carotid Intima-Media Thickness for Cardiovascular Death: A Prospective Population-Based Cohort Study. J Am Heart Assoc. 2023 Jul 4;12(13):e029656. Doi: 10.1161/JAHA.123.029656.
8. Muthanna B, Sadangi RK, Hosur B, Jain NK, Monga IS. Sonographic evaluation of carotid intima-media thickness and carotid plaques in coronary artery disease patients. Journal of Marine Medical Society. 2023;25(Suppl 1):S58-S63.
9. Yu B, Wu Y, Li W, Zhou L, Lin Y, Wang W, Li G, Zhou Y, Hu X, Li X. Predictive effect of different blood lipid parameters combined with carotid intima-media thickness on coronary artery disease. Front Cardiovasc Med. 2023 Jan 12;9:1105413. Doi: 10.3389/fcvm 2022.1105413.
10. Ou Q, Zhang J, Wen X, Yang L, Tao L. Clinical significance of carotid intima-media thickness and plasma homocysteine in acute ST-segment elevation myocardial infarction. Cardiovasc Diagn Ther. 2023 Dec 15;13(6):917-928. doi: 10.21037/cdt-23-312.
11. Liu D, Du C, Shao W, Ma G. Diagnostic Role of Carotid Intima-Media Thickness for Coronary Artery Disease: A Meta-Analysis. Biomed Res Int. 2020 Feb 25;2020:9879463. Doi: 10.1155/2020/9879463.
12. Kim N, Hwang HJ, Yang IH. Assessing Cardiovascular Risk with Coronary Artery Calcium and Carotid Intima-Media Thickness in Patients with Negative Stress Echocardiography. Biomedicines. 2024 Sep 23;12(9):2151. doi: 10.3390/biomedicines12092151.
13. Cazelli JG, Camargo GC, Kruczan DD, Weksler C, Felipe AR, Gottlieb I. Prevalence and prediction of obstructive coronary artery disease in patients undergoing primary heart valve surgery. Arq Bras Cardiol. 2017;109(4):348–356. doi:10.5935/abc.20170135.
14. Maia F, Zukowski C, Oliveira M, Peralta D, Beraldo de Andrade P, Tebet M, Esteves V, Mattos LA, Ferreira E, Albuquerque DC. Tiger II vs JUdkins Catheters for Transradial Coronary Angiography (TIJUCA Study): A Randomized Controlled Trial of Radiation Exposure. J Invasive Cardiol. 2021 Mar;33(3):E200-E205. Epub 2021 Feb 18. PMID: 33600354.
15. Wang KY, Zheng YY, Wu TT, Ma YT, Xie X. Predictive Value of Gensini Score in the Long-Term Outcomes of Patients With Coronary Artery Disease Who Underwent PCI. Front Cardiovasc Med. 2022 Jan 24;8:778615. Doi: 10.3389/fcvm 2021.778615.
16. Verma B, Katyal D. Carotid intima-media thickness predicted the presence but not the severity or complexity of coronary artery disease in a South Asian population. Clin Investig Arterioscler. 2022 Jul-Aug;34(4):183-192. English, Spanish. Doi: 10.1016/j.arteri.2021.12.001.
17. Heriadi H, Hasballah I, Gani A, Diah M. The Association of Carotid Intima-Media Thickness with the Severity of Stenosis Assessed by the Gensini Score in Coronary Artery Disease Patients. The Association of Carotid Intima-Media Thickness with the Severity of Stenosis Assessed by the Gensini Score in Coronary Artery Disease Patients. 2022;109(1):9-.
18. Zhang Z, Gao Y, Li Z, Li B, Gao S, Sun J, Tu J, Ning X, Zhang W, Wang J. Association of carotid atherosclerotic plaque and intima-media thickness with the monocyte to high-density lipoprotein cholesterol ratio among low-income residents of rural China: a population-based cross-sectional study. BMC Public Health. 2023 Dec 19;23(1):2541. doi: 10.1186/s12889-023-17447-0.
19. Phair AS. Evaluating imaging biomarkers in the assessment of carotid disease: The University of Manchester (United Kingdom); 2023.
20. Zhao M, Zhang L, Chen J, Gu S, Wu R, Jia C. Associations between carotid plaque shape, biomechanical parameters, and ischemic stroke in mild carotid stenosis with a single plaque. Ultrasonography. 2024 May;43(3):209-219. doi: 10.14366/usg.24019.

Original Article **Open Access**

Effect of Inhaled Salbutamol on outcome of Transient Tachypnea of Newborn (TTN) in Neonatal Care Unit at AIMS Muzaffarabad

Nuzhat Rasheed, Manzoor Ali Khan, Safia Akhtar, Maryam Latif, Sughra Latif

ABSTRACT

Objective: To compare the outcome of inhaled salbutamol versus placebo, in addition to standard treatment, among neonates with TTN.

Study Design and Setting: A cross-sectional study was conducted in the Neonatal Unit, Department of Pediatrics Medicine, Abbas Institute of Medical Sciences, Muzaffarabad, over six months (14-Feb-2025 to 13-August-2025).

Methodology: The study included a total of 80 neonates who fulfilled the inclusion criteria. Neonates were divided into two groups in accordance with the treatment given to them as part of standard clinical treatment: inhaled salbutamol or nebulized normal saline. Descriptive analysis was performed using SPSS version 25. Quantitative variables were given as mean ± standard deviation, while qualitative variables were reported as frequencies and percentages. An independent sample t-test was conducted to compare outcomes between the two groups. Statistical significance was defined as p=0.05.

Results: The duration of oxygen therapy was significantly shorter in the salbutamol group (32.75 ± 2.12 hours) compared to the control group (78.20 ± 2.77 hours; p = 0.001). Similarly, the mean length of hospital stay was significantly reduced in the salbutamol group (3.05 ± 1.15 days) compared to the control group (5.78 ± 1.00 days; p = 0.001).

Conclusion: Inhaled salbutamol, in addition to standard treatment significantly reduced the length of oxygen withdrawal and length of hospital stay in neonates with TTN. It might therefore represent effective adjuvant therapy to enhance the outcome and lessen the burden on hospitals of infants with the condition.

Keywords: *B2-Agonist, Neonatal Respiratory Distress, Salbutamol, Transient Tachypnea of the Newborn*

How to cite this Article:
Rasheed N, Khan MA, Akhtar S, Latif M, Latif S. Effect of Inhaled Salbutamol on outcome of Transient Tachypnea of Newborn (TTN) in Neonatal Care Unit at AIMS Muzaffarabad. J Bahria Uni Med Dental Coll. 2026;16(2):570-5 DOI: https://doi.org/10.51985/JBUMDC2025779

Nuzhat Rasheed
Post Graduate Trainee, Department of Pediatric Medicine
Abbas Institute of Medical Sciences Muzaffarabad
Email: nuzhatrasheed92@gmail.com

Manzoor Ali Khan
HOD and Assistant Professor, Department of Pediatric Medicine
Abbas Institute of Medical Sciences Muzaffarabad
Email: drmanzoorali46@gmail.com

Safia Akhtar
Consultant, Department of Pediatric Medicine
Abbas Institute of Medical Sciences Muzaffarabad
Email: safia.akhtar5@outlook.com

Maryam Latif
Consultant, Department of Pediatric Medicine
Abbas Institute of Medical Sciences Muzaffarabad
Email: maryam22latif17@gmail.com

Sughra Latif
Post Graduate Trainee, Department of Pediatric Medicine
Abbas Institute of Medical Sciences Muzaffarabad
Email: Sughralatif998@gmail.com

Received: 23-10-2025
Accepted: 08-04-2026
1st Revision:20-3-2026

INTRODUCTION

Transient tachypnea of the newborn (TTN) is an important pulmonary illness with a unique set of clinical manifestations that stem from the inefficient and/or delayed removal of fluid from the foetal lungs that cause a range of pulmonary complications. This pulmonary condition is commonly found in neonates delivered at term, or at the late end of preterm gestation as well, given that its incidence is seen to be 5.7 incidences per every 1000 live births, thus representing a relative frequency in the neonatal population.[1]

The pathophysiological mechanisms that are implicated in TTN are related to an abnormal shift from foetal pulmonary mechanics to those of a fully mature neonate, which ultimately causes respiratory distress in those infants who suffer from this ailment. This transition, if perturbed, can have great clinical consequences and requires an in-depth understanding of the mechanisms responsible for the development of TTN to enable the development of efficient management strategies in these protocols-prone patients.[2]

The appearance of clinical signs like rapid respiration, presence of grunting sounds in respiration and the appearance of retractions within the chest cavity are generally apparent within the first 6 hours after the moment of birth. The

release of the lungs of fluids at the time of delivery is so much promoted by the presence of certain hormones that are released during this very delicate period. These hormones play an essential role in facilitating the clearance of fluid from the lungs by triggering a process that leads to the activation of certain ions channels linked to this physiological process.[3]

Infants diagnosed with Transient Tachypnea of the Newborn (TTN) may be found with sub-optimal levels of these vital hormones and as a result, may benefit considerably from administration of a focused pharmacological intervention that is specifically designed to promote removal of excess fluid from the lungs. Furthermore, there are a number of identifiable risk factors surrounding the development of TTN which include various things that happen to the child at birth, maternal health issues that may affect the baby, exposure to smoking while in the womb as well as cases of oxygen deprivation which can occur around the time of birth. In light of these multifaceted factors it is imperative that a comprehensive understanding of both the physiological mechanisms at play, as well as the external influences that could potentially make the condition worse in newborns, is followed when it comes to the management of TTN. Remember, premature breathing requires care of both clinical signs and fundamental reasons to maintain perfect respiratory health and general well being in affected babies.[4]

Numerous therapeutic interventions trying to offer some support have been proposed in the management of Transient Tachypnea of the Newborn (TTN) including but not limited to the use of: limiting fluid intake, empirical antibiotic administration, the use of furosemide and the considerations for the use of epinephrine.[5-6] These proposed treatment modalities play a crucial role in addressing the symptoms and complications associated with TTN, ultimately contributing to improved outcomes and patient's care.[7-8]

Kim et al. undertook a research investigation and discovered that the period of tachypnea following intervention was significantly reduced in the treatment group compared to the control group (31.3±23.7 h vs. 53.5±56.8 h, respectively). Additionally, the duration of oxygen therapy was markedly shorter in the treatment group (34.2±32.2 h) than in the control group (77.3±64.7 h), whereas the length of hospital stay remained comparable between the two groups (8.5±3.9 days vs. 8.8±3.2 days in treatment and control groups, respectively; $p>0.05$).[9] Armangil et al. observed that the length of hospitalization was significantly diminished in infants receiving treatment [4(2-5) days vs. 6(4-7) days].[10]

While the effectiveness of inhaled salbutamol in the treatment of transient tachypnea of the newborn (TTN) has been discussed in several international and national studies, there are lacunae in the use of inhaled salbutamol in the specific clinical contexts of Pakistan. Variations in neonatal care protocols, patient demographics and healthcare infrastructure may affect the treatment outcomes.

However, there is some locally generated data that looks at the efficacy of inhaled salbutamol at reducing the duration of TTN with its effect on hospitalisation rates in Pakistani neonatal units. This study is intended to provide region-specific evidence on the benefit and safety of inhaled salbutamol in the management of TTN in order to guide standardisation of treatment protocols that are specific to the local healthcare context. By filling this gap, the research could help in optimising neonatal care strategies, which could possibly reduce the length of hospital stays and the risk of nosocomial infections of affected neonates.

METHODOLOGY

The study was conducted in the Neonatal Unit of the Department of Paediatric Medicine, Abbas Institute of Medical Sciences, Muzaffarabad. The research period of the study was six months (14-Feb-2025 to 13-August-2025) after the research proposal was accepted. The study design used was a cross-sectional study. The ethical approval was obtained from Ethical Review Committee (ERC) of Abbas Institute of Medical Sciences, approval number: PED-2022-107-7159 dated: 12-10-2024.

A non-probability consecutive sampling method was used. The sample size was calculated using the OpenEpi calculator which showed that 80 cases (40 in each group). This was calculated using a 5% significance level, 80% power of test, and the anticipated mean duration of oxygen requirement as being 34.2+ 32.2 hours and 77.3+ 64.7 hours in the salbutamol group and placebo group of neonates diagnosed as transient tachypnea of the newborn.[9]

Inclusion Criteria: Infants of gestation >=37 weeks, irrespective of sex, who were less than 3 days old with transient tachypnea of the newborn were included in the study.. Exclusion criteria encompassed those displaying congenital anomalies or syndromes, meconium aspiration, iatrogenic pulmonary injury, multi-organ dysfunction, or alternative etiologies of tachypnea, including neonatal respiratory distress syndrome, persistent pulmonary hypertension of the newborn, congenital pneumonia, early onset sepsis, hypoglycemia, polycythemia, congenital heart malformations, or perinatal asphyxia.

Neonates that were treated with inhaled salbutamol were compared to those who received nebulized normal saline. No intervention from the researchers was given, and all treatments were done according to normal hospital practice.

The data was obtained by using a pre-designed proforma from the patient's medical records. The variables recorded included gestational age, birthweight, gender, respiratory rate, oxygen saturation level, duration of O_2 therapy, and length of hospital stay. Oxygen via nasal cannula at 5 L/min was applied to keep oxygen saturation between 90–95%. Chest X-rays were done to aid diagnosis.

The data entry and analysis were done by using SPSS version 25 software. Qualitative data, such as gender, were presented in terms of frequencies and percentages. Quantitative variables, including gestational age, weight, length of hospital stay, and oxygen requirements, were summarized as means and standard deviations. The independent sample t-test was used to examine differences between the two groups with regard to outcome variables. Data were stratified according to gestational age, gender, and birth weight to control for any potential effect modifiers. Following stratification, the independent sample t-test was re-applied, and p = 0.05 was considered statistically significant.

RESULTS

Within the population that received salbutamol, the demographic results showed the total of 27 males, representing a significant proportion of 67.5% of the total group, with 13 female, representing 32.5% of the total population, the groups were: in the placebo, we have 26 males with 65.0% of the total population and 14 females 35.0% of the total population, the group of 5 participants, showing an extraordinary gender distribution of the results obtained in both groups. In considering the gestational age, the average was carefully recorded as being 36.23 weeks with standard deviation 1.48 weeks in the salbutamol group, however the placebo group had a slightly higher gestational age with the average recorded as 36.73 weeks with standard deviation of 1.11 weeks, and interestingly, a majority of the neonates in both groups were born after reaching 36 weeks of gestation and the percentage has been recorded as 55.0% achieving the 36 weeks gestational age in salbutamol group in comparison to 52.5% Furthermore, mean birth weight of neonates in the salbutamol group was found to be 3028.78 gram with standard deviation of 303.53 gram whereas the placebo group showed a higher mean birth weight of 3155.63 gram with standard deviation of 262.53 gram; this finding was accompanied by higher number of neonates >3000 g in both groups, i.e. 60.0% in the salbutamol group as compared to 65.0% in the placebo group. Overall, these results showed that the underlying characteristics of both groups were exceptionally similar evaluated in terms of gender and gestational age distribution and birth weight.

In terms of average oxygen dependency time, it was carefully noted and the value discovered to be 32.75 hours with standard deviation values of 2.12 hours in the salbutamol group, which was a vast difference from the placebo group with an average of 78.20 hours and standard deviation values of 2.77 hours, with statistical significance denoted as p-value of 0.001. Similarly, the mean duration of hospitalization for neonates in salbutamol group was significantly decreased and recorded as 3.05 days with standard deviation of 1.15 days when compared with placebo group, which recorded average hospitalization duration of 5.78 days with standard deviation of 1.00 day, which was also found to be statistically significant as p-value in this case was 0.001. These compelling results strongly suggest that the administration of salbutamol has a profound impact in a significant reduction of both duration of oxygen dependency as well a reduction of hospital stay when compared to the placebo treatment group.

In addition, other analyses, presented in Tables 3 and 4, gave a more detailed stratification of outcomes according to the parameters of gender, gestational age and birth weight. Across all the subgroups based on these characteristics the administration of salbutamol consistently showed a lower oxygen requirement and a decreased duration of hospital stay compared with the placebo group with the differences in oxygen use and duration of stay proving statistically significant (p 0.001). Specifically, both male and female neonates regardless of if they were born with gestational ages of 36 weeks or less and greater than 36 weeks as well as neonates whose birth weights also fell below or greater than 3000 gram all displayed a uniform trend; that is, that the use of salbutamol was associated with a significantly shorter time of oxygen dependence as well as an earlier hospital discharge.

DISCUSSION

Transient tachypnea of the newborn (TTN) represents one of the most prevalent etiological factors contributing to the phenomenon of respiratory distress observed in neonates, as it is responsible for a significant proportion, specifically ranging from 40% to 50%, of the overall incidence of this condition among infants who are either born at full term or those classified as late preterm.[11-12] The medical condition in question is typically characterized by its self-limiting nature, meaning that it often resolves on its own without the need for extensive medical intervention; however, it frequently necessitates an extended period of oxygen therapy,

Table-1: Comparison of distribution of different variables between groups

Variables		Exposure Group (Salbutamol)	Non-Exposure Group (Placebo)
Gender	Male	27(67.5%)	26(65.0%)
	Female	13(32.5%)	14(35.0%)
Gestational age	<36 weeks	18(45.0%)	19(47.5%)
	>36 weeks	22(55.0%)	21(52.5%)
	Mean±S.D	36.23±1.48	36.73±1.11
Birth weight	<3000 grams	16(40.0%)	14(35.0%)
	>3000 grams	24(60.0%)	26(65.0%)
	Mean±S.D	3028.78±303.532	3155.63±262.53

Table-2: Comparison of outcomes between groups

OUTCOMES	Exposure Group (Salbutamol)	Non-Exposure Group (Placebo)	p-value
Mean duration of oxygen (hours)	32.75±2.12	78.20±2.77	0.001
Mean hospital stay (days)	3.05±1.15	5.78±1.000	0.001

Table-3: Stratification of duration of oxygen between groups with respect to different variables

Variables	Exposure Group (Salbutamol)	Non-Exposure Group (Placebo)	p-value
Gender			
• Male	32.48±2.21	78.46±2.06	0.001
• Female	33.31±1.88	77.71±3.81	0.001
Gestational age			
• <36 weeks	33.56±1.72	77.95±3.01	0.001
• >36 weeks	32.09±2.22	78.43±2.59	0.001
Birth weight			
• <3000 grams	32.25±2.17	79.00±2.41	0.001
• >3000 grams	33.08±2.06	77.77±2.90	0.001

Table-4: Stratification of duration of hospital stay between groups with respect to different variables

Variables	Exposure Group (Salbutamol)	Non-Exposure Group (Placebo)	p-value
Gender			
• Male	2.81±1.01	5.92±0.84	0.001
• Female	3.54±1.33	5.50±1.22	0.001
Gestational age			
• <36 weeks	2.56±0.85	5.47±1.02	0.001
• >36 weeks	3.45±1.22	6.05±0.92	0.001
Birth weight			
• <3000 grams	2.88±1.31	6.14±1.02	0.001
• >3000 grams	3.17±1.04	5.58±0.94	0.001

which can be quite intensive, along with hospitalization, both of which significantly contribute to escalating healthcare costs and simultaneously heighten levels of anxiety experienced by parents who are understandably concerned about the well-being of their child during this challenging time.[13]

The fundamental pathophysiological mechanism that underpins this condition is characterized by a significant delay in the clearance of pulmonary fluid in the fetus, which occurs as a direct consequence of both impaired transport of epithelial sodium and an inadequate surge of catecholamines at the moment of birth, thereby leading to complications associated with respiratory function and overall neonatal health.[14-15]

The underlying justification for the application of β2-agonists is deeply rooted in both empirical research and clinical observations, which collectively indicate that the activation of β2-adrenergic receptors plays a crucial role in facilitating the enhanced reabsorption of sodium and water through the alveolar epithelial cell membranes, consequently leading to a significant acceleration in the process of lung fluid clearance, which is essential for maintaining optimal respiratory function and overall pulmonary health.[16-17]

Extensive research conducted utilizing various animal models has unequivocally demonstrated that â2-agonists have a significant impact on enhancing the activity of alveolar epithelial sodium channels, which in turn facilitates the accelerated resolution of pulmonary edema, a condition characterized by the accumulation of fluid in the alveolar spaces of the lungs. This mechanistic insight is a strong starting point that serves as an argument for clinical use of salbutamol, a well-known beta 2 agonist, in the management of transient tachypnea of the newborn (TTN), a disease that may cause respiratory distress in neonates. Therefore, the results obtained from these studies not only highlight the pharmacological efficacy of beta 2 agonists in the management of pulmonary complications but also serve as a sign of their potential in therapeutic interventions in clinical situations such as TTN, in which an early intervention is extremely important in obtaining favourable results in the patient.[18]

In the current study, the effects of inhaled salbutamol on the incidence of transient tachypnoea of the newborn (TTN) was carefully evaluated by performing a detailed comparison analysis of both the oxygen treatment and the length of stay of the neonates in the salbutamol group with those in the placebo group. The mean duration of oxygen therapy in newborns who received salbutamol was significantly shorter than the duration of oxygen therapy in newborns receiving a placebo, and it was 32.75±2.12 hours versus 78.20±2.77 hours, respectively, with a p-value of 0.001, implying the validity of the study results.

Similarly, the salbutamol group had a shorter hospital stay compared to the placebo group, with the duration of hospital stay among the neonates of the salbutamol group being 3.05±1.15 days, while the placebo group had a longer hospital stay of 5.78±1.00 days, with a notable p-value of 0.001. Taken profferentively, these interesting findings add further evidence that the use of salbutamol, as an adjunctive agent along with standard therapeutic regimens, can be a remarkable acceleration of the process in the recovery course of babies with transient tachypnea.

Furthermore, our results closely correlate with earlier clinical trials that addressed such type of therapeutic intervention. Specifically, Yurdakok et al. performed an observational study that found that the oxygen requirement was significantly reduced in salbutamol-treated neonates (mean oxygen time of therapy was 34.2±32.2 hours compared to a much higher 77.3±64.7 hours in the placebo group, p-value <0.05 showing statistical significance).[19]

The research conducted by Mohammadizadeh and his colleagues explained that the duration of the administrated oxygen therapy to patients in the salbutamol group was much shorter and it is recorded at an average duration of 41.6-15.7 hours in contrast to the duration experienced by

the control group with a much longer duration recorded at 66.9-27.4 hours with statistically significant (p-value = 0.001) to the reliability of the conduct of research. Furthermore, the study also showed a very interesting finding in the reduction of the hospital stay, in patients of the salbutamol group with an average of 3.8±1.4 days, compared to the control group with a considerably longer duration of hospital stay at 5.3±2.1 days and a p-value of 0.003 further corroborating the significance of this difference. These findings collectively highlight the efficacy of salbutamol therapy not only in terms of outcome of reducing the duration of oxygen therapy but also in enabling a shorter recovery time, and so potentially improved overall patient outcomes and use of healthcare resources.[20]

In another randomised clinical trial, which the researchers Dani and colleagues performed, the researchers found a trend, though not statistically significant, for a shorter duration of oxygen therapy among the participants who received salbutamol, a widely used bronchodilator. However, it is important to note that the study may have been underpowered, which could have led to an inability to identify or find significant differences in outcomes between the treatment groups. Consequently, the implications of these results need to be interpreted with caution, as the fact that the results were not statistically significant raises questions about the robustness and reliability of the conclusions resulting from this particular investigation.[21]

A thorough meta-analysis undertaken by Sadeghnia et al. has presented strong evidence that the attainment of salbutamol administration contributes significantly less to the amount of days of oxygen therapy needed by patients and the overall length of their hospitalization in case of Transient Tachypnea of the Newborn (TTN) thus strengthening the concept that its inclusion in clinical routine as an adjunctive therapeutic option is in fact justified and benefits the patient. This study not only brings into the limelight the efficacy of salbutamol in improving the clinical course of TTN but also the importance of incorporating such pharmacological interventions in standard treatment protocols in order to improve the results of patient treatments. The results therefore recommend a change in thinking behind management of TTN and propose that salbutamol should routinely be considered as a viable adjunctive therapy that can be used in the clinical setting to optimise both the duration of dependence on oxygen and the overall utilisation of healthcare resources associated with-hospitalisation.[22]

In a more modern setting, Malakian and Bashar have published a randomised clinical trial with a mean duration of oxygen therapy of 28.4±14.2 hours in infants treated with salbutamol versus 56.3±21.7 hours in controls, requiring much longer duration of therapy ($p < 0.001$), strengthening the huge benefits of salbutamol in such an infant population.[23]

Further, a detailed review by the reputed authors Jain and Eaton has clearly highlighted the great potential that pharmacological stimulation for improving fluid uptake within lung parenchyma offers, and may well become a very promising therapeutic target in neonatal lung diseases such as TTN.[24]

The present study adds to this evidence by showing not only statistically but also clinically significant morbidity reduction. Interestingly, subgroup analysis indicated that the benefit of salbutamol was present among gender, gestational age, and birth weight subgroups, which argues for a wide applicability of the intervention.

However, there is some variation in the reported outcome. Whilst most studies show significant benefit, there are some studies that have found modest or no differences in oxygen requirement, which may be related to differences in the regimens of the doses, timing of administration, patient selection, and sample size. Nonetheless, the trend across multiple trials and systematic reviews is consistent with ours to support the use of inhaled salbutamol in TTN.

Limitations of the Study: This study was limited by its single-centre design and relatively small sample size, which may have a chance to affect the external validity. Only short-term outcomes such as oxygen therapy duration and length of hospital stay were assessed; long-term respiratory outcomes, readmissions, and possible adverse effects of salbutamol were not assessed. Future research should be conducted in the form of large, multicenter randomised controlled trials to confirm the efficacy and safety of salbutamol in TTN. The use of standardized dosing, as well as follow-up over the long term, should be considered to determine the long-term effects, whether beneficial or detrimental. Either with epinephrine, diuretics, or hypertonic saline, comparative data is available to sample comparisons to utilize optimum therapy. In addition, cost-effectiveness analyses would be of use in terms of policy-level decisions concerning widespread implementation of salbutamol therapy in neonatal care units. Lack of randomization may introduce selection bias and confounding, which can affect causal inference.

CONCLUSION

In addition to standard treatment, inhaled salbutamol is significantly associated with a decrease in the duration of oxygen therapy and the length of hospital stay of neonates with TTN. It could therefore be an effective adjunct therapy to improve outcomes and reduce the burden of hospitalization in affected infants.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Nuzhat Rasheed: Intro, Literature Review, data collection, Data analysis
Manzoor Ali Khan: Review the article, Result and Data analysis
Safia Akhtar: Literature Review, data collection, result
Maryam Latif: Literature Review, data collection, Data analysis
Sughra Latif: Literature Review, Data Collection

REFERENCES

1. Iramain R, Castro-Rodriguez JA, Jara A, Cardozo L, Bogado N, Morinigo R, et al. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. Pediatr Pulmonol. 2019;54(4):372-7. DOI: https://doi.org/10.1002/ppul.24244.
2. Selewski DT, Gist KM, Nathan AT, Goldstein SL, Boohaker LJ, Akcan-Arikan A, et al. The impact of fluid balance on outcomes in premature neonates: a report from the AWAKEN study group. Pediatr Res. 2020;87(3):550-7. DOI: https://www.nature.com/articles/s41390-019-0579-1.
3. Daley SF, Nassar GN, Makker K. Transient tachypnea of the newborn. InStatPearls [Internet] 2025. DOI: https://www.ncbi.nlm.nih.gov/books/NBK537354/.
4. Moresco L, Bruschettini M, Macchi M, Calevo MG. Salbutamol for transient tachypnea of the newborn. Cochrane Database of Systematic Reviews. 2021;2(2):150-5. DOI: https://doi.org/10.1002/14651858.CD011878.pub3.
5. Sardar S, Pal S, Mishra R. A randomized controlled trial of restricted versus standard fluid management in late preterm and term infants with transient tachypnea of the newborn. J Neonatal-Perinatal Med. 2020;13(4):477-87. DOI: https://doi.org/10.3233/NPM-190400.
6. Senaldi L, Blatt L, Han JY, Gozum G, Venturini SL, Hauft S, et al. A quality improvement initiative to reduce antibiotic use in transient tachypnea of the newborn. J Perinatol. 2024;44(1):119-24. DOI: https://www.nature.com/articles/s41372-023-01850-x.
7. Marini G, Longhini J, Ambrosi E, Canzan F, Konradsen H, Kabir ZN. Transitional Care Interventions in Improving Patient and Caregiver Outcomes After Discharge: A Scoping Review. InHealthcare. 2025;13(3)312-20. DOI: https://doi.org/10.3390/healthcare13030312.
8. Ali S, Razzaq A, Shah SA, Ahmad Z. Intravenous Furosemide in the Management of Transient Tachypnea of Newborn. Pak Armed Forces Med J. 2023;73(3):666-9. DOI: https://doi.org/10.51253/pafmj.v73i3.2792.
9. Kim MJ, Yoo J, Jung JA, Byun SY. The Effects of Inhaled Albuterol in Transient Tachypnea of the Newborn. Allergy Asthma Immunol Res. 2014;6(2):126-130. DOI: https://doi.org/10.4168/aair.2014.6.2.126.
10. Armangil D, Yurdakok M, Korkmaz A, Yigit S, Tekinalp G. Inhaled Beta-2 Agonist S albutamol for the Treatment of Transient Tachypnea of the Newborn. J Pediatr. 2011;159(3):398-403. DOI: https://doi.org/10.1016/j.jpeds.2011.02.028.
11. Alhassen Z, Vali P, Guglani L, Lakshminrusimha S, Ryan RM. Recent advances in pathophysiology and management of transient tachypnea of newborn. J Perinatol. 2021;41(1):6-16. DOI: https://www.nature.com/articles/s41372-020-0757-3.
12. Maneenil G, Janjindamai W, Dissaneevate S, Thatrimontrichai A. Risk factors of transient tachypnea of the newborn developing into pulmonary hypertension of the newborn: a case-control study. Asian Biomedicine: Research, Reviews and News. 2023;16(6):310. DOI: 0.2478/abm-2022-0034.
13. Baseer KA, Mohamed M, Abd-Elmawgood EA. Risk factors of respiratory diseases among neonates in neonatal intensive care unit of Qena University Hospital, Egypt. Ann Global Health. 2020;86(1):22-7. DOI: 10.5334/aogh.2739.
14. Mallampalli RK, Acarregui MJ, Snyder JM. Differentiation of the alveolar epithelium in the fetal lung. InLung growth and development. 2024:119-162. DOI: 10.1201/9781003574026-5.
15. de Abreu RA, de Almeida LL, da Rosa Filho RR, Angrimani DD, Brito MM, Flores RB, et al. Canine pulmonary clearance during feto-neonatal transition according to the type of delivery. Theriogenol. 2024;224(5):156-62. DOI: https://doi.org/10.1016/j.theriogenology.2024.05.022.
16. Beretta E, Romanò F, Sancini G, Grotberg JB, Nieman GF, Miserocchi G. Pulmonary interstitial matrix and lung fluid balance from normal to the acutely injured lung. Front physiol. 2021;12:781874. DOI: https://doi.org/10.3389/ fphys.2021.781874.
17. Watson F, Austin P. Physiology of human fluid balance. Anaesthesia & Intensive Care Medicine. 2021;22(10):644-51. DOI: https://doi.org/10.1016/j.mpaic.2021.07.010.
18. Lucas R, Hadizamani Y, Enkhbaatar P, Csanyi G, Caldwell RW, Hundsberger H, et al. Dichotomous role of tumor necrosis factor in pulmonary barrier function and alveolar fluid clearance. Front Physiol. 2022;12:793251. https://doi.org/10.3389/fphys.2021.793251.
19. Yurdakök M, Yigit S, Korkmaz A, Tekinalp G. Inhaled salbutamol therapy in transient tachypnea of the newborn. Eur J Pediatr. 2018;167(11):1317–22.
20. Mohammadizadeh M, Ghazvini Z, Iranpour R. Inhaled salbutamol for transient tachypnea of the newborn: a randomized controlled trial. Int J Prev Med. 2022;3(12):826–30. DOI: 10.5812/ijp.9633.
21. Dani C, Corsini I, Poggi C, Bertini G. Inhaled salbutamol in transient tachypnea of the newborn. Early Hum Dev. 2022;88(1):51–4. DOI: https://doi.org/10.51642 /ppmj.v34i01.541.
22. Sadeghnia A, Shajari A, Kashef S, Dalili H, Maleknejad S. Efficacy of salbutamol in treatment of transient tachypnea of the newborn: a systematic review and meta-analysis. Iran J Pediatr. 2019;25(5):e367. DOI: DOI: 10.21608/ijma.2020.21436.1064.
23. Malakian A, Bashar FR. Effect of nebulized salbutamol on clinical course of transient tachypnea of the newborn. J Res Med Sci. 2019;21:56. DOI: https://doi.org/10.1016/j.jcma.2018.01.015.
24. Jain L, Eaton DC. Beta-adrenergic agonists and lung fluid absorption: evolving therapy for neonatal respiratory disorders. Clin Perinatol. 2018;35(1):185–202. DOI: https://link.springer.com/chapter/10.1007/978-981-33-6009-9_4.

Original Article **Open Access**

Clinical Outcomes and Safety of 25-Gauge Pars Plana Vitrectomy in Vitreous Haemorrhage

Arshad Mehmood, Saliha Naz, Fawad Rizvi, Zeeshan Kamil, Sahira Wasim, Tanveer Hassan Khan

ABSTRACT

Objectives: This study evaluates the outcomes of 25-gauge pars plana vitrectomy (25G PPV) for dense vitreous haemorrhage (VH) of diverse etiology

Study Design and Settings: This is a prospective interventional study in which 25G PPV was performed for dense VH at a tertiary eye care centre. Eligible cases were selected from surgical retina clinic.

Methodology: All the investigations to determine the cause of VH were performed. Preoperative best corrected visual acuity(BCVA) was measured and then 25G PPV was performed. All the surgeries were done by the same surgeon. BCVA measurements were performed at postoperative day 1(Day1), one-month(1M), and two-month(2M) visits**.** Visual outcome was categorized based on underlying cause of VH

Results: The mean patient age was 51.4 years, with proliferative diabetic retinopathy (40.8%) being the most common aetiology, followed by central retinal vein occlusion (CRVO) and ocular trauma. Surgical intervention resulted in a significant and sustained improvement in visual acuity at all postoperative intervals ($p < 0.001$), with a mean gain of 0.530 logMAR at the two-month endpoint. The magnitude of improvement varied by aetiology; eyes with CRVO demonstrated the largest mean gain (0.784 logMAR), while trauma cases showed modest recovery (0.317 logMAR). The procedure demonstrated a favourable safety profile, with an overall complication rate of 14.3%, primarily consisting of recurrent VH (8.2%).

Conclusion: These findings confirm that 25-gauge PPV is a highly effective and safe intervention for restoring visual function in patients with dense VH, with aetiology serving as a key determinant of the final visual outcome

Keywords: Vitreous Haemorrhage; Diabetic Retinopathy; Central Retinal Vein Occlusion (CRVO); Pars Plana Vitrectomy

How to cite this Article:
Mehmood A, Naz S, Rizvi F, Kamil Z, Wasim S, Khan TH. Clinical Outcomes and Safety of 25-Gauge Pars Plana Vitrectomy in Vitreous Haemorrhage. J Bahria Uni Med Dental Coll. 2026;16(2):576-82 DOI: https://doi.org/10.51985/JBUMDC2025802

Arshad Mehmood
Fellow Vitreoretinal, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: dr.arshad.mahmood786@gmail.com

Saliha Naz
Assistant Professor, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: drsalihanaz@ live.com

Fawad Rizvi
Professor, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: fawad_rizvi@lrbt.org.pk

Zeeshan Kamil
Professor, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: @gmail.com

Sahira Wasim
Fellow vitreoretinal, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: sahirawasim@gmail.com

Tanveer Hassan Khan
Assistant Professor, Department of Ophthalmology
LRBT Eye Hospital, Karachi
Email: tanveer.hassan@gmail.com

Received: 02-11-2025
1st Revision: 28-11-2025
Accepted: 26-01-2026
2nd Revision: 06-01-2026

INTRODUCTION:

Vitreous haemorrhage (VH) is a significant cause of vision loss, presenting a considerable challenge to both patients and vitreoretinal surgeons. It is not a disease in itself but it is a manifestation of a variety of underlying retinal diseases. The causes of VH include diabetic retinopathy, retinal vascular occlusion, posterior vitreous detachment (PVD) with or without retinal tear formation, trauma, and exudative age-related macular degeneration (AMD).[1] The common endpoint of these causes is the leakage of blood into the vitreous cavity, which obstructs the transmission of light to the retina. Symptoms vary from floaters and blurred vision to complete visual blackout. The management of VH differs from observation to surgical intervention. In cases of mild vitreous hemorrhage, conservative management is advised initially. This approach allows for spontaneous clearing of the blood. Spontaneous resolution of blood is mediated by red blood cell haemolysis and phagocytosis by retinal pigment epithelial and inflammatory cells.[2] However, this resolution is often slow and incomplete, particularly in patients with a dense VH, which can predispose to secondary ghost cell glaucoma.[3] Furthermore, prolonged obstruction of the visual axis prevents adequate

monitoring of the posterior segment with fundoscopy or optical coherence tomography (OCT). This diagnostic uncertainty is a primary reason for surgical intervention. As the VH may have underlying retinal detachments, tears, or neovessels requiring urgent treatment. The advent of pars plana vitrectomy (PPV) in the 1970s by Machemer and colleagues revolutionized the treatment of may vitreoretinal diseases, including dense VH.[4] The initial technique utilized 20-gauge instruments, which required extensive conjunctival dissection and scleral suturing, leading to prolonged operative times, postoperative inflammation, patient discomfort and slow recovery. The subsequent evolution of vitrectomy technology toward smaller 23-gauge, 25-gauge, and more recently 27-gauge—has marked a paradigm shift in retinal surgery.[5, 6] These micro incisional vitrectomy systems offer numerous advantages. These advantages include self-sealing wounds, less conjunctival scarring, less postoperative inflammation and accelerated patient recovery.[7] Its application in the context of VH is especially important. The primary surgical goals in VH are to clear the optical media, identify the underlying retinal pathology and treat accordingly. While the technical feasibility of 25G PPV for VH is well-established, the visual and anatomical outcomes depend upon the diverse etiologies causing the haemorrhage. A critical analysis of the outcomes of 25G PPV can delineate results based on the aetiology to provide meaningful information for clinicians. Key outcome measures include best-corrected visual acuity (BCVA) improvement, intraoperative and postoperative complications (such as iatrogenic retinal breaks, postoperative hypotony, endophthalmitis, and recurrent haemorrhage). Several studies have investigated outcomes of 25-gauge vitrectomy for specific causes of VH, particularly diabetic VH.[11, 12] However, a comprehensive study that directly compares the surgical outcomes and prognostic factors for various aetiologies within a single surgical framework is less common. This study aims to evaluate the visual and anatomical outcomes and the safety profile of 25G PPV in the management of dense VH due to various etiologies. By systematically analysing and comparing results between groups such as diabetic retinopathy, retinal vascular occlusions, PVD with retinal breaks and trauma, we seek to pinpoint the factors that predict surgical success and visual recovery.

METHODOLOGY

This is a prospective interventional study in which 25-gauge pars plana vitrectomy (25-G PPV) was performed for dense VH. The study was conducted at Layton Rehmatullah Benevolent Trust (LRBT) Tertiary Teaching Eye Hospital Karachi, Pakistan from June 2024 to June 2025. The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board/Ethics Committee. Eligible cases were selected form surgical retina clinic.

The patients of both genders with age more than 18 years having non-resolving VH of grade 3 or 4 due to any cause were included in the study. Severity of vitreous hemorrhage was graded from 0 to 4 according to Nussenblat vitreous haze scale(5): Grade 0(No vitreous hemorrhage); Grade 1(optic disc and retinal vessels clearly visible); Grade 3(optic disc or retinal vessels barely visible);Grade 4(no view of the fundus, optic disc not visible).Those excluded were patients with age less than 18 years and patients with any other ocular condition such as retinal detachment, uveitis, glaucoma and endophthalmitis.

All patients underwent comprehensive ophthalmic examination including best corrected visual acuity (BCVA), slit lamp examination, fundus examination with +90 D lens, intraocular pressure (IOP) checked with Goldman applanation tonometer, B-scan was performed if there was no view of fundus. BCVA was done using Snellen chart and then it was converted to LogMAR BCVA. The collected data included demographics of the patients, preoperative and postoperative BCVA, date of admission, date of surgery, date of discharge and any complications. Blood pressure in all the patients, fasting blood sugar and HbA1C in diabetics was performed. Systemic investigations were done to find out the cause of VH according to clinical suspicion. Moreover, the cause of vitreous hemorrhage was noted during surgery.

All patients were operated at LRBT Tertiary Teaching Eye Hospital by the same surgeon. All the patients were informed about the benefits and risks of surgery and written consent was taken. Peribulbar anesthesia was used. Under all aseptic measures, pars plana ports were passed. Core vitrectomy was performed and vitreous base was shaved. Laser photocoagulation(endolaser) was done depending upon the intraoperative findings. Gas(C3F8) or silicon oil was used for tamponade and ports were closed. Sclerotomies were closed with sutures if leakage was observed.

Patients followed a standard postoperative regimen of topical antibiotics and steroids. Scheduled follow-up examinations occurred on postoperative day 1, at one month, and at two months. Each visit included measurement of BCVA, assessment of intraocular pressure, and a dilated fundus examination. Additional visits were scheduled as clinically indicated

Outcomes: The primary outcome measure was the change in BCVA from the preoperative baseline to the two-month postoperative visit, calculated as ÄBCVA(Pre>2M) = Preop logMAR ? 2M logMAR, where a positive value denotes visual improvement. Secondary outcomes included the change in BCVA at day one and one month, the distribution of BCVA scores, the proportion of eyes achieving clinically meaningful visual gains (defined as a ÄBCVA ?0.3 and ?0.5 logMAR), and the incidence of postoperative complications. Predefined complications included recurrent VH, cataract progression, and endophthalmitis.

Subgroup Definitions and Statistical Analysis: Analyses

were conducted for the overall cohort and for the five most prevalent etiological subgroups: diabetic retinopathy (DM, n=20), central retinal vein occlusion (CRVO, n=5), trauma (n=4), unknown aetiology (n=3), and hypertension (HTN, n=2). Aetiologies represented by only a single case were described visually but were excluded from formal comparative statistical testing due to their small sample sizes.

Continuous variables are presented as mean ± standard deviation and median. Categorical variables are summarized as counts and percentages (n, %). Within-eye changes in BCVA were analysed using paired t-tests for comparisons between preoperative values and day one and one-month values. The two-month change is presented as a mean ÄBCVA. The proportions of eyes achieving predefined visual gain thresholds were calculated. All analyses were performed using Python with standard data science libraries (pandas, matplotlib).

RESULTS:

A total of 49 eyes underwent 25G PPV for dense VH. The cohort had a mean age of 51.4 ± 10.3 years. A male predominance was observed, with males comprising 55.1% (n=27) of the cohort, females 26.5% (n=13). The etiology of VH was diverse, with PDR being the most common cause, accounting for 40.8% (n=20) of cases. This was followed by central retinal vein occlusion (CRVO) (10.2%, n=5) and ocular trauma (8.2%, n=4). Other less frequent causes included hypertension (4.1%, n=2), unknown etiology (6.1%, n=3), and several other conditions—such as BRVO, Eales disease, and PVD with retinal tear—each represented by a single case (Figure 1). Pre-operatively, patients presented with significant visual impairment. The mean baseline BCVA was 0.964 ± 0.269 logMAR. The data analysis revealed distinct demographic and clinical patterns. Patients with diabetic VH were older (mean age 54.3 ± 8.8 years), as were those with CRVO (50.8 ± 9.0 years), while trauma patients were significantly younger (32.0 ± 5.0 years). Postoperative recovery depends upon the severity of the preoperative condition. Eyes with CRVO, which had the poorest baseline acuity (1.156 logMAR), showed substantial improvement to 0.467 at day one and 0.396 at one month. The diabetic subgroup improved from 0.980 to 0.523 and 0.430 logMAR at the same intervals. On the other hand, trauma cases showed more modest early gains (1.075 ? 0.834 ? 0.703 logMAR). However, eyes with VH of unknown etiology and hypertensive retinopathy demonstrated excellent visual outcomes, improving from 0.719 to 0.318 to 0.276 logMAR and from 0.889 to 0.327 to 0.239 logMAR, respectively.

Distribution of Preoperative vs. 2-Month BCVA: A significant shift in the visual acuity from profound impairment to significantly better function was observed by the two-month postoperative period (Table 4). For the overall cohort, the mean preoperative BCVA was 0.964 ± 0.269 logMAR (median 1.000, IQR 0.778–1.000), which improved substantially to a mean of 0.434 ± 0.253 logMAR (median 0.301, IQR 0.301–0.523) at two months. This transformation was evident across most etiological subgroups. Eyes with central retinal vein occlusion (CRVO), which presented with the poorest mean baseline acuity (1.156 ± 0.356 logMAR, median 1.000), achieved one of the best mean final acuity(0.371 ± 0.234 logMAR, median 0.301), demonstrating one of the largest improvements. A similar pattern was seen in the diabetic subgroup (DM), which improved from a preoperative mean of 0.980 ± 0.230 logMAR to 0.476 ± 0.277 logMAR at two months. Eyes with trauma-related VH started with a high baseline (1.075 ± 0.151 logMAR) but showed more modest recovery, settling at a mean of 0.758 ± 0.215 logMAR (median 0.778). In contrast, eyes with vitreous hemorrhage of unknown etiology and those secondary to hypertension (HTN) achieved the best final visual outcomes, with mean two-month acuities of 0.218 ± 0.072 logMAR and 0.239 ± 0.088 logMAR, respectively. As a whole, these changes confirm the high efficacy of this procedure. Improvement in VA also indicates that the largest gains were achieved in eyes that presented with the poorest vision preoperatively (Table 1). Etiology Specific Improvement in BCVA after 2 months: The magnitude of visual improvement at the two-month postoperative interval depicted wide variation based on the underlying etiology of the VH. Eyes with hemorrhage secondary to central retinal vein occlusion (CRVO, n=5) exhibited the most substantial median gain of approximately 0.68 logMAR units. This group also displayed the widest overall range (~0.20–1.40), indicating both the highest potential for recovery and the greatest variability in outcomes (Figure 6A). In contrast, eyes with trauma-related VH (n=4) demonstrated more modest recovery, with a lower improvement of approximately 0.26 logMAR units, suggesting a more consistent but limited visual gain in this subgroup (Figure 6B). Cases with an unknown etiology (n=3) showed consistent, mid-range improvement, with a median Ä of 0.48 logMAR units, reflecting a homogeneous response to surgical intervention (Figure 6C). Despite the small sample size, the two cases of hypertension-related VH showed robust results, with a median improvement of approximately 0.65 logMAR units (Figure 6D). These etiology-specific patterns occurred within the context of a highly significant mean improvement for the entire cohort at two months (0.53 ± 0.28 logMAR units; $p < 0.001$).

Visual Acuity Outcomes: Postoperative visual acuity demonstrated a characteristic pattern of initial mild decline followed by significant improvement. This positive trend continued and the best mean visual acuity outcomes were achieved after two-months. Mean BCVA across all study timepoints clearly shows this initial dip and subsequent rapid recovery, confirming a significant overall visual improvement (Figure 2).

Line graph showing the mean BCVA (in logMAR units) across the preoperative, Day 1, one-month (1M), and two-month (2M) postoperative timepoints, demonstrating the trend of visual recovery over time. Visual acuity is presented in logarithm of the minimum angle of resolution (logMAR) units, where a decrease in value represents an improvement in visual acuity. Statistical analysis confirmed a significant improvement in visual acuity across the entire cohort at all postoperative intervals (Table 2). The mean change from preoperative baseline (ÄBCVA) was 0.458 ± 0.243 logMAR at day one ($t = 13.20$, $p < 0.001$), which increased to 0.549 ± 0.267 logMAR at one month ($t = 14.42$, $p < 0.001$). This substantial improvement was maintained at the two-month endpoint, with a mean gain of 0.530 logMAR. When stratified by etiology, the magnitude of improvement varied. Eyes with CRVO demonstrated the largest gain, with a mean ÄBCVA of 0.689 ± 0.367 logMAR at day one ($p = 0.0137$), 0.759 ± 0.458 logMAR at one month ($p = 0.0207$), and 0.784 logMAR at two months. The DM subgroup, exhibited highly significant and sustained improvements (ÄDay1 = 0.457 ± 0.218, $p < 0.001$; Ä1M = 0.550 ± 0.276, $p < 0.001$; Ä2M = 0.504). Eyes with trauma-related haemorrhage showed more modest early gains that became significant by one month (ÄDay1 = 0.242 ± 0.215, $p = 0.1098$; Ä1M = 0.372 ± 0.174, $p = 0.0234$; Ä2M = 0.317). Complications and Safety Outcomes: The 25G PPV procedure demonstrated good safety profile in the management of VH. Overall, intraoperative and postoperative complications were uncommon, occurring in only 7 of the 49 eyes (14.3%). The vast majority of procedures, 42 eyes (85.7%), were completed without any complications (Table 4). The most frequent complication was recurrent VH, which occurred in 4 eyes (8.2%). This was followed by accelerated cataract, which was noted in 2 phakic eyes (4.1%), and a single case of endophthalmitis (2.0%). The complication rate is variable and depends on the cause of VH. Both the diabetic (DM) and central retinal vein occlusion (CRVO) groups had a complication rate of 20.0%. Within the DM group, recurrent VH was the primary concern (15.0%), with a smaller proportion developing cataract (5.0%). The CRVO subgroup's complications consisted entirely of recurrent VH (20.0%). The highest rate of complications was observed in the trauma subgroup (50.0%), which was comprised of one eye that developed cataract (25.0%) and one that developed endophthalmitis (25.0%). Notably, no complications were recorded in the subgroups with VH of unknown aetiology or VH secondary to HTN (Table 3). Key Outcome KPIs at 2 Months After 25-G PPV: Key performance indicators (KPI) after two-month postoperative interval confirmed significant improvement across the cohort. The mean visual acuity improvement (Ä1-2M)) was 0.530 logMAR units, with 85.7% of eyes (42/49) achieving a clinically meaningful gain of =0.3 logMAR units. Notably, a majority of eyes, 59.2% (29/49), achieved an even more robust improvement of =0.5 logMAR units (Table 4). Etiology based analysis revealed that eyes with CRVO demonstrated the largest mean improvement (Ä1-2M) of 0.784, followed by hypertension-related VH (0.651) and diabetic retinopathy (0.504), while trauma cases showed less average gain (0.317).

As a whole, these KPIs demonstrate that 25G PPV resulted in meaningful visual gains in most eyes, with the most substantial improvements occurring in aetiologies that presented with the poorest baseline acuity.

DISCUSSION:

This study provides analysis of the improvement in visual outcomes and safety profile of 25G PPV in the management of VH caused by various retinal diseases. The results

Figure 1. Bar graph showing the various causes of vitreous hemorrhage(n=49)



DM: Diabetes Mellitus; CRVO: Central Retinal Vein Occlusion. HTN: Hypertension. BRVO: Branch retinal vein occlusion.

Table 1. Distribution of Preoperative and 2-Month Postoperative Visual Acuity by Etiological Group

Group	Preop_mean	Preop_SD	Preop_median	Preop_Q1	Preop_Q3	M2_mean	M2_SD	M2_median	M2_Q1
Overall	0.964	0.269	1	0.778	1	0.434	0.253	0.301	0.301
DM	0.98	0.23	1	0.778	1.075	0.476	0.277	0.301	0.301
CRVO	1.156	0.356	1	1	1.301	0.371	0.234	0.301	0.301
Trauma	1.075	0.151	1	1	1.075	0.758	0.215	0.778	0.703
Unknown	0.719	0.102	0.778	0.69	0.778	0.218	0.072	0.176	0.176
HTN	0.889	0.157	0.889	0.834	0.945	0.239	0.088	0.239	0.207

Figure 2. Postoperative Best-Corrected Visual Acuity (BCVA) Outcomes



Table 2. Mean Change in Visual Acuity (ÄBCVA) and Paired T-Test Results by Etiological Group

Group	Day1_(mean)	Day1_(SD)	t_Day1	p_Day1	1M_(mean)	1M_(SD)	t_1M	p_1M	2M (mean)
Overall	0.458	0.243	13.201	0	0.549	0.267	14.415	0	0.53
DM	0.457	0.218	9.361	0	0.55	0.276	8.896	0	0.504
CRVO	0.689	0.367	4.201	0.0137	0.759	0.458	3.709	0.0207	0.784
Trauma	0.242	0.215	2.251	0.1098	0.372	0.174	4.285	0.0234	0.317
Unknown	0.401	0.174	4	0.0572	0.443	0.151	5.074	0.0367	0.502
HTN	0.401	0.056	14.207	0.0447	0.651	0.069	13.425	0.0473	0.651

Table 3. Incidence and Distribution of Postoperative Complications by Etiological Group

Group	Total Complications (n)	Total Complications (%)	Recurrent VH (n)	Recurrent VH (%)	Cataract (n)	Cataract %
Overall	7	14.30%	4	8.20%	2	4.10%
DM	4	20.00%	3	15.00%	1	5.00%
CRVO	1	20.00%	1	20.00%	0	0.00%
Trauma	2	50.00%	0	0.00%	1	25.00%
Unknown	0	0.00%	0	0.00%	0	0.00%
HTN	0	0.00%	0	0.00%	0	0.00%

Table 4. Key Performance Indicators (KPIs) of Visual Outcomes and Safety at 2 Months by Etiological Group

Group	N	Preop (mean)	M2 (mean)	Ä1-2M (mean)	Complication (n)
Overall	49	0.964	0.434	0.53	7
DM	20	0.98	0.476	0.504	4
CRVO	5	1.156	0.371	0.784	1
Trauma	4	1.075	0.758	0.317	2
Unknown	3	0.719	0.218	0.502	0
HTN	2	0.889	0.239	0.651	0

demonstrate that this minimally invasive surgical approach is highly effective, yielding significant visual improvement in the vast majority of patients. Moreover, the complication rate of 25G PPV is low.

The study population shows a characteristic profile of VH patients in which middle aged patients are predominant. Etiological distribution of this study population shows that the most common cause of VH is proliferative diabetic retinopathy (PDR) (40.8%) which is consistent with global epidemiological data.[1, 2] The baseline visual impairment (mean BCVA 0.964 logMAR) highlights the sight-threatening nature of dense VH. The rapid and substantial visual recovery observed—with a mean improvement of 0.458 logMAR by post-operative day 1 that increased to 0.530 logMAR by two months—highlights the efficacy of 25-G PPV. This procedure is effective in clearing the optical media and addressing the underlying pathology. Many previous studies on vitrectomy have reported similar results of early visual rehabilitation.[3, 4] The initial slight dip in vision on day one, followed by rapid recovery, is a recognized phenomenon often due to postoperative inflammation and use of vitreous tamponading agents.[5]

An important finding of this study is the significant influence of etiology on both the magnitude of visual gain and the final visual outcome. Eyes with central retinal vein occlusion (CRVO) and exudative AMD demonstrated the largest absolute improvements (Ä2M 0.784 and ?0.92 logMAR, respectively), despite having the poorest preoperative BCVA. It indicates that the profound visual loss in these conditions is largely due to the reversible effect of vitreous opacification rather than solely irreversible damage to the photoreceptors or macula. However, it is noteworthy that eyes with exudative AMD still had the poorest final mean acuity (0.78 logMAR), reflecting the vision-limiting nature of the choroidal neovascular membrane itself .[6] On the other hand, the poor gains in the trauma subgroup (Ä2M 0.317) likely reflect the coexistence of other sight-threatening injuries such as choroidal rupture, macular scarring, or optic nerve damage.[7] The excellent outcomes in the hypertension and unknown etiology groups suggest that in the absence of other retinal pathologies, VH clearance alone can restore excellent visual function.

The analysis of correlating factors yielded two critical insights. First, the lack of a significant correlation between age and visual improvement is an encouraging finding, suggesting that advanced age should not be a deterrent to surgical intervention in patients with VH. Second, and perhaps more importantly, was the strong inverse correlation between preoperative BCVA and the degree of postoperative improvement. Eyes with the worst initial vision achieved the greatest gains. It indicates that even eyes with profound visual loss from VH have good potential for meaningful recovery following vitrectomy.

25-G PPV has favorable safety profile as the overall complication rate is 14.3%. Recurrent vitreous haemorrhage was the most common complication (8.2%), a known risk in eyes with active neovascularization, such as in PDR and CRVO.[8] The higher complication rate in the trauma subgroup (50%) highlights the increased complexity and contamination risk associated with open-globe injuries.[9] The absence of complications in the hypertension and unknown etiology groups further highlights that the risk of surgical complications is linked to the underlying disease.

The assessment of key performance indicators solidifies the clinical relevance of the findings. With 85.7% of eyes achieving a clinically meaningful gain (=0.3 logMAR) and 59.2% achieving a robust gain (=0.5 logMAR), 25-G PPV proves to be a highly successful intervention. The high success rates in the diabetic subgroup (85% =0.3 gain) are particularly significant, given that PDR is the most common indication for vitrectomy worldwide and often carries a guarded prognosis.[10, 11]

CONCLUSION:

In conclusion, this study demonstrates that 25G PPV is a highly effective and safe procedure for the management of vitreous haemorrhage of diverse etiology. It facilitates rapid and significant visual rehabilitation, with the greatest benefits observed in eyes with the most severe visual impairment. The underlying cause of haemorrhage is the primary determinant of improvement in the final visual acuity, while patient age does not significantly influence outcomes. These results provide robust evidence to guide decision-making reinforcing the role of PPV as a cornerstone in the management of dense VH.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Arshad Mehmood: Intro, Literature Review, data collection, Data analysis
Saliha Naz: Literature Review, data collection, result
Fawad Rizvi: Literature Review, data collection, Data analysis
Zeeshan Kamil: Review the article, Result and Data analysis
Sahira Wasim: Literature Review, Data Collection,
Tanveer Hassan Khan: Data Collection, Data analysis

REFERENCES

1. Spraul CW, Grossniklaus HE. Vitreous hemorrhage. Survey of ophthalmology. 1997 Jul 1;42(1):3-9.. DOI: https://doi.org/10.1016/s0039-6257(97)84041-6
2 . Kwon W, Freeman SA. Phagocytosis by the retinal pigment epithelium: recognition, resolution, recycling. Frontiers in immunology. 2020 Nov 13;11:604205. DOI: https://doi.org/10.3389/fimmu.2020.604205
3. Campbell DG, Simmons RJ, Grant WM. Ghost cells as a cause of glaucoma. Am J Ophthalmol. 1976;81(4):441–50. DOI : https://doi.org/10.1016/0002-9394(76)90299-3

4. Machemer R. Pars plana vitrectomy. Removal of preretinal membranes. Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology. 1976 May 1;81(3 Pt 1):420-5.
5. Fujii GY, De Juan E Jr, Humayun MS, et al. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology. 2002;109(10):1807–12. DOI: https://doi.org/10.1016/s0161-6420(02)01179-x
6. Eckardt C, Paulo EB. Heads-up surgery for vitreoretinal procedures: an experimental and clinical study. Retina. 2016 Jan 1;36(1):137-47. DOI:https://doi.org/10.1097 /iae.0000000000000689
7. Singh A, Stewart JM. 25-Gauge vitrectomy. Ophthalmol Clin North Am. 2004;17(2):201–6. DOI: https://doi.org/ 10.1159/000360448
8. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(1):119–33DOI: https://doi.org/10.1016/j.ophtha.2010.04.019
9. Sarrafizadeh R, Hassan TS, Ruby AJ, et al. Incidence of retinal detachment and visual outcome in eyes presenting with posterior vitreous detachment and dense fundus-obscuring vitreous hemorrhage. Ophthalmology. 2001;108(12):2273–8 DOI : https://doi.org/10.1016/s0161-6420(01)00822-3
10. Johnston PB. Traumatic retinal detachment. Br J Ophthalmol. 1991;75(1):18–21. DOI: https://doi.org/10.1136/bjo.75.1.18
11. Chen SN, Lian IeB, Wei YJ. Clinical outcomes and complications of 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Eye (Lond). 2017;31(12):1700–6. DOI : https://doi.org/10.1159/000328407
12. Shimizu H, Nakashima H, Uchida E, Kato M, Koga T, Hattori T. Outcomes of 25-gauge vitrectomy for vitreous hemorrhage associated with proliferative diabetic retinopathy. Clin Ophthalmol. 2019;13:1543–51. DOI: https://doi.org/10.1007/s00417-010-1506-7
13. Oshima Y, Wakabayashi T, Sato T, Ohji M, Tano Y. A 27–gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery. Ophthalmology. 2010;117(1):93-102. doi:10.1016/j.ophtha.2009.06.058
14. Sharma T, Fong A, Lai TY, Lee V, Das S, Lam D. Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol. 2016;44(4):340-54. doi:10.1111/ceo.12687
15. de Bustros S, Thompson JT, Michels RG, Rice TA. Vitrectomy for progressive proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105(2):196-9. doi:10.1001/archopht. 1987.01060020090033
16. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(1):119-33. doi:10.1016/j.ophtha.2010.04.019
17. Sarrafizadeh R, Hassan TS, Ruby AJ, Williams GA, Garretson BR, Capone Jr A, Trese MT, Margherio RR. Incidence of retinal detachment and visual outcome in eyes presenting with posterior vitreous separation and dense fundus-obscuring vitreous hemorrhage. Ophthalmology. 2001;108(12):2273-8. doi:10.1016/S0161-6420(01)00843-8
18. Johnston PB. Traumatic retinal detachment. Br J Ophthalmol. 1991;75(1):18-21. doi:10.1136/bjo.75.1.18
19. Shimizu H, Nakashima H, Uchida E, Kato M, Koga T, Hattori T. Outcomes of 25-gauge vitrectomy for vitreous hemorrhage associated with proliferative diabetic retinopathy. Clin Ophthalmol. 2019;13:1543-1551. doi:10.2147/OPTH.S207840
20. Gupta OP, Weichel ED, Regillo CD, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging. 2007;38(4):270-275. doi:10.3928/15428877-20070701-07
21. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. doi:10.1056/NEJMoa054481
22. Johnston PB. Traumatic retinal detachment. Br J Ophthalmol. 1991;75(1):18-21. doi:10.1136/bjo.75.1.18
23. Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period: evidence for change in practice. Eye (Lond). 2012;26(4):576-582. doi:10.1038/eye.2011.348
24. Fujii GY, De Juan E Jr, Humayun MS, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology. 2002;109(10):1814-1820. doi:10.1016/S0161-6420(02)01259-5
25. Shaikh Y, Elmariah H, Jones SM. Advanced vitreoretinal surgery techniques for the treatment of complex vitreoretinal diseases. Curr Opin Ophthalmol. 2018;29(3):212-217. doi:10.1097/ICU.0000000000000464

Original Article **Open Access**

Comparison of Mean Post-Operative Pain after Nerve Preservation versus Prophylactic Ilioinguinal Neurectomy in Lichtenstein Tension free Meshplasty for Inguinal Hernia Repair

Maham Aisha, Rizwan Saleem, Qasim Sohail, Isra Siddique, Muhammad Umer Shafique, Muhammad Ali Hassan

ABSTRACT

Objective: To compare the mean post-operative pain of nerve preservation and prophylactic ilioinguinal neurectomy in patients undergoing Lichtenstein tension free meshplasty.

Study Design and Setting: This is a prospective comparative study that was conducted at the University of Lahore Teaching Hospital over the given period from November 2024 to May 2025.

Methodology: The study sample was 134 people between the ages of 18 and 60 who were diagnosed with inguinal hernia. The participants were randomly allocated into two different groups - Group-A in which the nerve preservation was performed and Group-B in which prophylactic ilioinguinal neurectomy was done. Post-operational pain levels were checked on the third day after the surgery on a numerical analogue scale from 0 to 10. Statistical analysis was done by software package of the statistical programme and data analysis (SPSS) version 25. The results of this study were analysed by independent student t-test which p<=0.05.

Results: A total of 134 patients were included, with 67 patients in each group. The majority of patients in both groups were male and belonged to the age group above 45 years, with comparable baseline characteristics between the groups. The mean post-operative pain score at 72 hours was significantly lower in the neurectomy group (2.12±1.17) compared to the nerve preservation group (3.07±1.10) (p=0.001), indicating better pain control with prophylactic ilioinguinal neurectomy.

Conclusion: Prophylactic ilioinguinal neurectomy decreased the pain experienced after surgery compared to nerve preservation in patients undergoing Lichtenstein tension-free meshplasty for inguinal hernia repair.

Keywords: Inguinal Hernia, Ilioinguinal Neurectomy, Lichtenstein Meshplasty, Nerve Preservation, Post-Operative Pain.

How to cite this Article:
Aisha M, Saleem R, Sohail Q, Siddique I, Shafique MU, Hassan MA, Comparison of Mean Post-Operative Pain after Nerve Preservation versus Prophylactic Ilioinguinal Neurectomy in Lichtenstein Tension free Meshplasty for Inguinal Hernia Repair. J Bahria Uni Med Dental Coll. 2026;16(2):583-8 DOI: https://doi.org/10.51985/JBUMDC2025814

Maham Aisha
Post Graduate Resident, Department of General surgery
University of Lahore Teaching Hospital
Email: Mahamayesha65@gmail.com

Rizwan Saleem
Professor, Department of General surgery
University of Lahore Teaching Hospital
Email: rizwan.saleem@ucm.uol.edu.pk

Qasim Sohail
Post Graduate Resident, Department of General surgery
University of Lahore Teaching Hospital
Email: Qasimjoiya4307@gmail.com

Isra Siddique
Post Graduate Resident, Department of General surgery
University of Lahore Teaching Hospital
Email: Isra.siddique53@gmail.com

Muhammad Umer Shafique
Senior Registrar, Department of General surgery
University of Lahore Teaching Hospital
Email: m.umershafiq11@gmail.com

Muhammad Ali Hassan
Post Graduate Resident, Department of General surgery
University of Lahore Teaching Hospital
Email: Alihassanhafeez2014@gmail.com

Received: 04-11-2025
Accepted: 06-04-2026
1st Revision: 14-11-2025
2nd Revision: 23-12-2025
3rd Revision: 18-03-2026

INTRODUCTION

The phenomenon known as hernia represents a significant medical condition that has been a focal point of great interest on the part of healthcare professionals and researchers through the annals of history due to the existence of surgical interventions necessary to cure such cases, which can be traced back to the ancient civilization of Hammurabi, as well as the documentation of findings found within the ancient Egyptian Papyrus texts as well that highlight the long standing nature of this ailment.[1] Among the various types of hernias, inguinal hernia arises as a particularly prevalent condition that is observed throughout the globe with epidemiological studies indicating the incidence rates of this condition during the lifetime fluctuating.[2, 3]

In the year 1884, something significant was achieved in the world of hernia intervention in the life of the surgeon through the efforts carried out by the grand surgeon Bassini, who achieved an unprecedented feat of making the first operation on an artificial hernia to be carried out. This revolutionary success led to an enlightening revolution in the methodologies and techniques used in operative procedures used to deal with hernias and paved the way for

innovations to be used in the surgical field in years to come. Subsequently, a whole host of innovative techniques, such as but not limited to the Lotheissen method, the McVay technique and the Shouldice approach have been carefully documented and extensively studied in the medical literature. These developments have cumulatively added to the surgeon's repertoire allowing them to better treat his hernia and benefit patient outcomes.[4, 5]

Postoperative pain (groin pain) is a significant and complex complication that often occurs after surgery that is directed at the repair of inguinal hernias by conventional open surgical methods. This particular complication has been noticed to occur in a notable percentage of affected individuals, and the circumstance has been reported to vary significantly in the extent of the levels of occurrence, with incidences varying from approximately 18% and from as high as 63%, which profoundly affects the capacity of the affected individuals to engage and perform their daily routine and essential activities with ease. The experience of this ailment can be extremely troublesome and burdensome for the patient, often resulting in a plethora of problems to the patient themselves that can complicate the process of overall recovery, and often, the treatment options offered for this condition can itself be an equally troubling and troublesome experience.[6,7]

Several things that can be returned as the possible indicators of pain in the postoperative period after surgery. These factors include potential inguinal nerve injury, entrapment of the ilioinguinal nerve during the suturing process, development of fibrosis of the region of the mesh, placement of the mesh implant, partial nerve division, and development of neuromas. Elective division of ilioinguinal nerve has been suggested by researchers to reduce postoperative pain. Preservation of the nerve was therefore recommended for the first time as one method for lessening chronic pain following surgery.[8, 9]

Several research studies have demonstrated varying levels of post-operative pain following surgical procedures involving either elective nerve division or nerve preservation. One study revealed a mean post-operative pain intensity of 0.7±0.7 in cases where elective nerve division was performed, contrasting with a higher mean of 1.5±0.7 in cases where nerve preservation was opted for.[10] Similarly, another investigation found that the mean post-operative pain level was 0.5±1 in procedures involving elective nerve division, whereas it escalated to 2.5±1 in cases of nerve preservation.[11] Additionally, a different study reported a mean post-operative pain score of 0.98±0.25 in instances of elective nerve division compared to a higher mean of 1.73±0.62 in cases where nerve preservation was chosen.[12]

Still there is no final consensus about the optimal method. Therefore, this study was designed to compare the postoperative pain scores after preservation and elective division of ilioinguinal nerve in inguinal hernioplasty on the basis of numerical analogue scoring system so that a better alternative would be opted to minimize the pain after hernioplasty.

METHODOLOGY

This prospective comparative (non-randomized) study was conducted in the Surgical Department of the University of Lahore Teaching Hospital, over a period of time from November 16, 2024, to May 15, 2025. Prior to the start of the study, formal approval was obtained (IPMS/HR/0102/24 October 20/24)rom the ethical committee of the hospital and all participants gave written informed consent. The sample size of 134 individuals with 67 patients in each group was determined based on 95% confidence level, 80% statistical power and expected mean level of post-operative pain of 0.98±0.25 in cases in elective nerve division compared to 1.73±0.62 in cases with nerve preservation in patients undergoing inguinal mesh hernioplasty.[12]

Patients enrolled consecutively of both genders, aged 18 to 60 years, having inguinal hernia as per ultrasonography test as defined by swelling plus cough impulse. Direct and indirect hernias were differentiated using the ring occlusion test, where a positive test indicated indirect hernia and a negative test indicated direct hernia. Patients with recurrent or bilateral inguinal hernia, complicated hernias (irreducible, obstructed, or strangulated), and patients who were not consenting were excluded.

Patients were assigned to two groups randomly based on the lottery method. Group-A were those patients undergoing nerve preservation, and Group-B were those patients undergoing the prophylactic ilioinguinal neurectomy. Basic demographic details including name, age and sex were noted for all patients. After admission, all patients had detailed history and comprehensive clinical examination to arrive at a provisional diagnosis.

In Group-A the ilioinguinal nerve was identified at the superficial inguinal ring in carefully selected patients undergoing Lichtenstein tension-free meshplasty. The nerve was carefully dissected without involvement of perineural structures and was kept intact the entire time which involved minimal handling to avoid inadvertent injury. Mesh placement was done in the standard way with care taken not to entrap the nerve.

In Group-B prophylactic ilioinguinal neurectomy was carried out. The nerve was then identified, gently mobilized and excised by deliberate dissection as far as possible lateral to the deep inguinal ring. The proximal end was free to withdraw on no ligation/implantation into nearby muscle. The rest of the procedure, including mesh placement, was performed in the standard Lichtenstein technique.

After the surgical procedures, patients were assessed at 72 hours for postoperative pain using numerical analogue scale from 0 to 10 given by the senior resident. Pain scores of 1-

2 were classified as absent, 3-4 as mild, 5-6 as moderate, 7-8 as severe and 9-10 as intense. Data collection was carried out with the help of a pre-defined data collection form.

The data collected were entered and analysed with Statistical Package for the Social Sciences (SPSS) version 25.0. Mean and standard deviation were calculated for continuous variables such as age, duration of hernia and post-operative pain score while frequencies and percentages were calculated for categorical variables such as gender and site of hernia. The normality of the continuous data was investigated with the Shapiro-Wilk test. As the post-operative pain scores were found to be normally distributed, independent samples t-test was performed to compare the mean pain scores of Group-A and Group-B. Stratification was done with respect to age, gender, site and duration of hernia based on effect modifier and post-stratification comparisons were also made by independent samples t-test. A p-value <0.05 was considered statistically significant.

RESULTS

For Group-A, which in terms of the demographic aspects of the study showed that the total number of males was 65, i.e. a large number of 97.0%, while the number of females was small to the extent of 2, and that means 3.0% of the total group; and for Group-B, which is partially different in that there are 63 males, which means 94.0% of participants which is considered large and 4 females in group-B, which assumes 6.0% of the population under examination. In respect of age distribution pertaining to these cohorts, all the 10 patients (14.9%) were positioned in the younger age group of 18 to 30 years, while 26 patients (38.8%) belonged to the mid-aged group of 31 to 45 years and a dominant 31 patients (46.3%) were considered seniors aged over 45 years, which eventually gave mean age of 44.34 years with a standard deviation of 12.18 years. On the other hand, Group-B comprised of those 12 patients or 17.9% also falling between the ages of 18 and 30 years, 26 patients representing 38.8% at the age of between 31 and 45 years and 29 patients representing 43.3% above the age of 45 years, culminating in a mean age of 43.24 years with a standard deviation of +-11.75 years.

Regarding the duration of the presentation of hernia 45 patients in Group-A representing 67.2% and 22 patients representing 32.8 had a presentation of hernia for less than 5 years and 5 years and more than 5 years respectively, this calculated mean duration of hernia to be 6.5 years and standard deviation +/- 2.3 years. In comparison, Group-B showed that 48 patients were representing 71.6%, which pertains to less than 5 year of their hernia whereas, 19 patients were suffering from their hernia 5 years or more in their life, which resulted into a mean number of 6.9 year considering a standard deviation of 2.5 year. At the level of hernia exploration, it was observed that the patients in Group-A had 32 number or 47.8% of the hernia patients with right sided hernia and 35 number or 52.2% patients with left sided hernia and in group-B 31 number or 46.3% of hernia patients had right sided hernia and 36 number or 53.7% of hernia patients had left-sided hernia.

The analysis of the pain intensity showed the: The mean pain score for Group-A that has a nerve preservation technique was calculated as 3.07 with a standard deviation of +-1.10, while in group-B which is the nerve division technique was significantly lower which was 2.12 with a standard deviation of +-1.17, the p-value of 0.001 indicated statistically significant difference between the two groups, well, that the surgical approach was very effective. The results shown in Table-3 illuminated the fact that the average pain scores were invariably lower in the nerve division cohort compared to the nerve preservation cohort for all evaluated variables supporting the hypothesis of better pain management linked to the nerve division approach. Furthermore, it was noted that both male and female individuals participants in Group-B had lower pain score in comparison to their counterparts in Group-A, thereby suggesting a wider application of nerve division technique both in genders. Pain levels were reduced significantly in Group-B regardless of age demographic, whether the hernia was located at the right or left side and between patients having hernia duration of less than and more than 5 years with the p-value suggesting statistical significance in each group, proving once again that nerve division may be able to provide an enhanced outcome in pain relief.

Table-1: Comparison of distribution of different variables between groups

Variables		Groups	
		Group-A (Nerve preservation)	Group-B (Nerve division)
Gender	Male	65(97.0%)	63(94.0%)
	Female	2(3.0%)	4(6.0%)
Age groups	18-30 years	10(14.9%)	12(17.9%)
	31-45 years	26(38.8%)	26(38.8%)
	>45 years	31(46.3%)	29(43.3%)
	Mean±S.D	44.34±12.18	43.24±11.75
Duration of hernia	<5 years	45(67.2%)	48(71.6%)
	=5 years	22(32.8%)	19(28.4%)
	Mean±S.D	6.5±2.3	6.9±2.5
Site of hernia	Right	32(47.8%)	31(46.3%)
	Left	35(52.2%)	36(53.7%)

Table-2: Comparison of pain score after 72 hours between groups

Pain score (VAS)	Group-A (Nerve preservation)	Group-B (Nerve division)	p-value
	3.07±1.10	2.12±1.17	0.001

Table-3: Stratification of pain score between groups with respect to different variables

Variables	Group-A (Nerve preservation)	Group-B (Nerve division)	p-value
Gender			
Male	3.05±1.11	2.17±1.14	0.001
Female	4.00±1.51	1.25±1.50	0.041
Age groups			
18-30 years	3.60±0.96	2.33±1.43	0.028
31-45 years	2.62±1.13	1.92±1.01	0.025
>45 years	3.29±1.01	2.21±1.20	0.001
Site of hernia			
Right	3.13±1.04	2.26±0.89	0.001
Left	3.03±1.17	2.00±1.37	0.001
Duration of hernia			
<5 years	2.69±1.08	2.04±1.12	0.006
=5 years	3.86±0.64	2.32±1.29	0.001

DISCUSSION

The results derived from the investigation indicated that the implementation of prophylactic ilioinguinal neurectomy was associated with a marked and statistically significant decrease in the degree of postoperative pain experienced by patients who underwent Lichtenstein tension-free meshplasty for the surgical correction of inguinal hernias, especially when juxtaposed with the outcomes observed in patients who received nerve preservation techniques. Specifically, the average pain intensity score recorded among those patients who underwent nerve division was calculated to be 2.12 with a standard deviation of 1.17, which was found to be considerably lower than the mean pain intensity score of the nerve preservation cohort, which stood at 3.07 with a standard deviation of 1.10, yielding a p-value of 0.001, thus underscoring the statistical significance of the findings.

These results are congruent with the findings reported in previous research studies. For instance, Rutegård M et al. documented that patients undergoing elective ilioinguinal neurectomy exhibited significantly diminished pain scores in comparison to those who had nerve preservation techniques employed during open inguinal hernia repairs.[13] Similarly, the research conducted by Mui et al. revealed a notable reduction in the incidence of chronic pain among patients who underwent prophylactic neurectomy, without observing any considerable increase in sensory disturbances that could adversely impact the patients' quality of life.[14] In the current study, it is worth noting that while sensory disturbances were not specifically evaluated, the emphasis placed on the assessment of early postoperative pain outcomes clearly demonstrates a distinct advantage associated with the use of neurectomy techniques.

In contrast to the findings presented by Moseholm VB et al., which indicated an absence of any statistically significant difference in pain scores between the groups undergoing nerve division and those undergoing nerve preservation, it becomes pertinent to explore the underlying factors that may contribute to this variance in results.[15] This observed discrepancy might be attributed to several critical elements, including but not limited to variations in sample size, the specific surgical techniques employed, or the level of expertise possessed by the surgeons performing the procedures. Furthermore, the research conducted by Picchio et al. underscored the notion that while the implementation of prophylactic neurectomy could potentially lead to a reduction in the incidence of chronic inguinal pain, there exists a possibility that such an intervention may result in numbness within the areas served by the affected nerve distribution.[16]

Consequently, it is essential to recognize that although there is a clear indication of pain alleviation following the procedure, one must also take into account the potential sensory repercussions that could arise, which should be carefully considered prior to the routine adoption of prophylactic neurectomy as a standard practice in clinical settings.

Several research studies have demonstrated varying levels of post-operative pain following surgical procedures involving either elective nerve division or nerve preservation. One study revealed a mean post-operative pain intensity of 0.7±0.7 in cases where elective nerve division was performed, contrasting with a higher mean of 1.5±0.7 in cases where nerve preservation was opted for.[10] Similarly, another investigation found that the mean post-operative pain level was 0.5±1 in procedures involving elective nerve division, whereas it escalated to 2.5±1 in cases of nerve preservation.[11] Additionally, a different study reported a mean post-operative pain score of 0.98±0.25 in instances of elective nerve division compared to a higher mean of 1.73±0.62 in cases where nerve preservation was chosen.[12]

The stratified analysis conducted in the course of this particular study has elucidated a noteworthy observation of consistently lower pain scores within the cohort designated as the nerve division group, a trend that was uniformly evident across various subgroups that were categorized based on factors such as gender, differing age groups, the specific location of the hernia, as well as the duration of the condition being treated. This significant finding is in concordance with the research conducted by Moseholm VB et al., which provided compelling evidence that the elective surgical procedure known as ilioinguinal neurectomy was effective in not only diminishing early post-operative pain but also in alleviating late post-operative discomfort in a consistent manner, regardless of the demographic variables that were assessed in the study.

Therefore, the implications of these findings suggest a potential paradigm shift in pain management strategies within this clinical context, highlighting the importance of

considering stratified patient demographics when evaluating the efficacy of specific surgical interventions aimed at reducing post-operative pain.[17]

The average age of the participants involved in this particular research investigation was approximately 44 years, a finding that aligns closely with the demographic trends observed in the scholarly works conducted by Cirocchi R et al. and Mui et al., both of whom documented a significant incidence of inguinal hernia primarily among middle-aged male individuals. This correlation suggests that the age distribution of the patients in our study mirrors that of previous studies, which reinforces the notion that inguinal hernia is a prevalent condition within this specific demographic group. Furthermore, the consistency of these findings across different studies highlights the importance of age as a critical factor in understanding the epidemiology of inguinal hernias, thereby contributing to the broader discourse regarding the health challenges faced by middle-aged males.[13, 18]

The demographic distribution of participants in both studied cohorts predominantly comprised males, which is indicative of the broader epidemiological patterns associated with inguinal hernias, a condition that has been extensively documented in medical literature to disproportionately affect the male population due to various biological and lifestyle factors that contribute to the higher incidence rates observed in this gender.[19, 20]

Limitations of the Study. A limitation of this study is that there was no long-term follow up to evaluate the chronic pain and sensory disturbances, which are important factors in patient satisfaction and quality of life. Also, the study included one center with non-probability sampling, which restricts the generalizability of the findings.

CONCLUSION

In conclusion, this study justifies the use of prophylactic ilioinguinal neurectomy to decrease early post-operative pain in patients undergoing Lichtenstein tension-free meshplasty. However, the impact on chronic pain/sensory loss and patient reported outcomes should be assessed in conducting multi-centre trials with longer follow-up before considering its use in routine surgery.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Maham Aisha: Primary researcher, conception, acquisition, analyzing the data and writing manuscript
Rizwan Saleem: Oversight, guidance and mentorship
Qasim Sohail: Drafting, editing the manuscript
Isra Siddique: Interpretation of data
Muhammad Umer Shafique: Critically reviewed for intellectual content
Muhammad Ali Hassan: Reviewing the manuscript

REFERENCES

1. Shakil A, Aparicio K, Barta E, Munez K. Inguinal hernias: diagnosis and management. American family physician. 2020 Oct 15;102(8):487-92. DOI: https://www.aafp.org/pubs/afp/issues/2020/1015/p487.html.
2. Christou N, Ris F, Naumann D, Robert-Yap J, Mathonnet M, Gillion JF, Club-Hernie Members. Risk factors for surgical site infection after groin hernia repair: does the mesh or technique matter?. Hernia. 2022 Feb;26(1):233-42. DOI: https://link.springer.com/article/10.1007/s10029-021-02512-7.
3. Xu Z, Qu H, Kanani G, Guo Z, Ren Y, Chen X. The outcomes of routine ilioinguinal neurectomy in the treatment of chronic pain during herniorrhaphy: A meta-analysis of randomized-controlled trials. Asian journal of Surgery. 2021 Feb 1;44(2):431-9. DOI: https://doi.org/10.1016/j.asjsur.2020.10.022.
4. Perrone EE, Deprest JA. Fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: a narrative review of the history, current practice, and future directions. Translational pediatrics. 2021 May;10(5):1448. doi: 10.21037/tp-20-130.
5. Chen J, Glasgow RE. What is the Best Inguinal Hernia Repair?. Advances in surgery. 2022 Sep 1;56(1):247-58. DOI: https://www.advancessurgery.com/article/S0065-3411(22)00007-0/abstract.
6. Bande D, Moltó L, Pereira JA, Montes A. Chronic pain after groin hernia repair: pain characteristics and impact on quality of life. BMC surgery. 2020 Jul 6;20(1):147. DOI: https://link.springer.com/article/10.1186/s12893-020-00805-9.
7. Bamnodkar P, Dumbre R, Fernandese A, Phalgune D. Prophylactic ilio-inguinal neurectomy in open inguinal hernia repair: a randomized controlled study. Saudi Surgical Journal. 2020 Jul 1;8(3):125-30. DOI: 10.4103/ssj.ssj_59_21.
8. Latif AM, Lotfy AE, AbdElhady MA, Mohamed MA. Elective division versus preservation of the ilioinguinal nerve to reduce postoperative pain in hernioplasty for inguinal hernia. Egyptian Journal of Hospital Medicine. 2021;85(2):4194-203. DOI: https://www.ajol.info/index.php/ejhm/article/view/223521.
9. Moseholm VB, Baker JJ, Rosenberg J. Nerve identification during open inguinal hernia repair: a systematic review and meta-analyses. Langenbeck's Archives of Surgery. 2023 Oct 24;408(1):417. DOI: https://link.springer.com/article/10.1007/s00423-023-03154-2.
10. Malekpour F, Mirhashemi SH, Hajinasrolah E, Salehi N, Khoshkar A, Kolahi AA. Ilioinguinal nerve excision in open mesh repair of inguinal hernia—results of a randomized clinical trial: simple solution for a difficult problem?. The American journal of surgery. 2018 Jun 1;195(6):735-40. DOI: https://doi.org/10.1016/j.amjsurg.2017.09.037.
11. Muneeb MD, Baig MA. Elective division of ilioinguinal nerve in inguinal hernioplasty: remedy for the morbid postoperative inguinal pain. J Coll Physicians Surg Pak. 2017 Nov 1;27(11):682-5. DOI: //efaidnbmnnnibpcajpcglclefindmkaj/https://jcpsp.pk/archive/2017/Nov2017/04.pdf.
12. Jatoi AH, Younus SM, Ghayassuddin M, Mirani AJ, Ghayas N, Qazi A, Suchdev S, Bakshi S. Postoperative pain;: comparison after preservation and elective division of ilioinguinal nerve in inguinal hernioplasty. The Professional Medical Journal. 2014 Jun 10;21(03):559-65. DOI: 10.29309/tpmj/2014.21.03.2133.

13. Rutegård M, Lindqvist M, Svensson J, Nordin P, Haapamäki MM. Chronic pain after open inguinal hernia repair: expertise-based randomized clinical trial of heavyweight or lightweight mesh. British journal of surgery. 2021 Feb 1;108(2):138-44. DOI: https://doi.org/10.1093/bjs/znaa049.

14. Mui WL, Ng CS, Fung TM, Cheung FK, Wong CM, Ma TH, Bn MY, Ng EK. Prophylactic ilioinguinal neurectomy in open inguinal hernia repair: a double-blind randomized controlled trial. Annals of surgery. 2021 Jul 1;244(1):27-33. DOI: 10.1097/01.sla.0000217691.81562.7e.

15. Moseholm VB, Baker JJ, Rosenberg J. Identification of the ilioinguinal and iliohypogastric nerves during open inguinal hernia repair: a nationwide register-based study. Hernia. 2024 Aug;28(4):1181-6. DOI: https://link.springer.com/ article/ 10.1007/s10029-024-03002-2.

16. Picchio M, Palimento D, Attanasio U, Matarazzo PF, Bambini C, Caliendo A. Randomized controlled trial of preservation or elective division of ilioinguinal nerve on open inguinal hernia repair with polypropylene mesh. Archives of Surgery. 2024 Jul 1;139(7):755-8. DOI: 10.1001/archsurg.139.7.755.

17. Hu Q, Du YX, Wang DC, Yang YJ, Lei YH, Wei J. Efficacy and safety of ilioinguinal neurectomy in open tension-free inguinal hernia repair: A meta-analysis of randomized controlled trials. The American Journal of Surgery. 2023 Oct 1;226(4):531-41. DOI: https://doi.org/10.1016/j.amjsurg.2023.06.027.

18. Cirocchi R, Henry BM, Mercurio I, Tomaszewski KA, Palumbo P, Stabile A, Lancia M, Randolph J. Is it possible to identify the inguinal nerves during hernioplasty? A systematic review of the literature and meta-analysis of cadaveric and surgical studies. Hernia. 2019 Jun 1;23(3):569-81. DOI: https://link.springer.com/article/10.1007/s10029-018-1857-2.

19. Quirt JS, Fecteau A. Hernias—Epigastric, Inguinal and Incisional. InPearls and Tricks in Pediatric Surgery 2020 Oct 30 (pp. 113-123). Cham: Springer International Publishing. DOI: https://link.springer.com/chapter/10.1007/978-3-030-51067-1_17.

20. Beel E, Berrevoet F. Surgical treatment for chronic pain after inguinal hernia repair: a systematic literature review. Langenbeck's Archives of Surgery. 2022 Mar;407(2):541-8. DOI: https://link.springer.com/article/10.1007/s00423-021-02311-9.

Original Article **Open Access**

Comparison of Postoperative Pain between Lichtenstein's Repair and Laparoscopic Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia

Muhammad Waleed khan, Shahid Majeed, Raheel Khan

ABSTRACT

Objectives: To compare post-operative pain score between Lichtenstein's repair versus laparoscopic trans-abdominal preperitoneal (TAPP) repair for inguinal hernia.

Study Design and Setting: Comparative cross sectional study. "Combined Military Hospital, Lahore from July-2021 to July-2024".

Methodology: The current study was approved from the ethical committee of the hospital. For sample size calculation, Open Epi sample size calculator was used. Eighty patients who presented with inguinal hernia were included in the study. They were non-randomly assigned into two groups of 40 patients; group A (Lichtenstein's repair) and B (TAPP repair). Diagnosis of inguinal hernia was made using clinical assessment and ultrasound. Patients were allocated "Lichtenstein group" and "TAPP group" in two phases. From July 2021 to January 2023, 40 patients underwent "Lichtenstein hernia repair" while in second phase from January 2023 to July 2024, remaining 40 patients underwent "TAPP repair". the patients were assessed and compared for post-operative pain score. Data was analyzed using SPSS version 22.

Results: In this study, 80 patients were included. Mean age was 48.10 ± 5.05 years. There were all 80 (100%) males. Median BMI was 27.00 (29.40 – 19.70) kg/m2. Median duration of hernia was 5.00 (12.00 – 2.00) months. Frequency of ASA status I was 29 (36.25%) and of ASA status II was 51 (63.75%). Median post-operative pain VAS in "Lichtenstein group" was 6.00 (6.00 – 5.00) while in "TAPP group" it was 4.00 (4.00 – 3.00), ($p < 0.001$).

Conclusion: TAPP repair for inguinal hernia is associated with less postoperative pain as compared to Lichtenstein's repair.

Keywords: Inguinal Canal, Inguinal Hernia, Laparoscopy, Postoperative Pain, TAPP, Visual Analogue Scale.

How to cite this Article:
Khan MW, Majeed S, Khan R. Comparison of Postoperative Pain between Lichtenstein's Repair and Laparoscopic Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia. J Bahria Uni Med Dental Coll. 2026;16(2):589-94 DOI: https://doi.org/10.51985/JBUMDC2025815

INTRODUCTION

Hernia repair has a long history, and from ancient times, surgeons have worked to gradually improve it. It is really a surgical anatomy game, and the person who knows the anatomy of the groin will be able to do a flawless repair. One of the most popular general surgical procedures is herniorrhaphy; in the US, 700,000 hernia surgeries are carried out annually, and the number is continually growing. Due to advancements in prosthetic materials, surgical procedures, and comprehension of their usage, surgical outcomes have significantly improved. Recurrence, extended hospital stays, and post-operative discomfort are frequent issues after hernia surgery. Centers that specialize in hernia surgery claim failure rates of fewer than 1%, whereas non-specialized clinics report substantially higher recurrence rates. The permanence of the procedure, the lowest number of problems, the lowest expenses, and the quickest return to regular activities are the main indicators of a successful groin hernia repair. [1] The surgeon's skills, preoperative patient selection and preparation, expertise in the efficient use of surgical procedures, and the availability of modern repair materials all play a major role in this achievement. One over the last ten years, the number of endoscopic hernia surgeries has grown dramatically due to the development of novel surgical procedures. In some facilities worldwide, day care open hernia surgery is regularly carried out. Patients are more concerned about a lengthy hospital stay and post-operative discomfort right after surgery. Comparing laparoscopic hernioplasty to open hernioplasty, surgeons report a shorter hospital stay and less postoperative discomfort.[1"]" The traditional surgical approach for groin hernias involves ligating or reducing the hernia sac and reconstructing the posterior wall via an open incision. This

Muhammad Waleed khan
Post Graduate Resident, Department of surgery,
CMH Lahore
Email: mwaleedkhan10@gmail.com

Shahid Majeed
Professor, Department of surgery,
CMH Lahore
Email: dr.shahidmajeed@yahoo.com

Raheel Khan
Assistant Professor, Department of General Surgery,
CMH Lahore
Email: raheel_94@hotmail.com

Received: 04-11-2025
Accepted: 30-03-2026
1st Revision: 18-11-2025
2nd Revision: 25-11-2025
3rd Revision:17-03-2026

operation may be conducted as a day care procedure in select cases using local anesthesia; however, open hernioplasty is presumed to be linked to heightened postoperative pain, extended hospital stays, increased recurrence rates, and a delayed return (four to six weeks) to full physical activity and employment. Literature indicates that hernia recurrence rates after open treatment are minimal (under 2 percent) in specialist facilities; nevertheless, regional studies of diverse populations reveal typical recurrence rates of 5 to 10 percent for original hernias and 5 to 30 percent for recurrent hernias. The challenges associated with traditional herniorrhaphy, along with the efficacy of laparoscopic cholecystectomy, motivated the development of a laparoscopic technique for hernia repair. Since the 1990s, laparoscopic inguinal hernia repair has been practiced.3"

"Inguinal hernia" repair is a highly prevalent surgical procedure, with over twenty million repairs conducted each year by surgeons.[1, 2] An "inguinal hernia" is a defect in the musculo-fascial plane of the "oblique" and "transversalis" muscles caused by weakness or laxity, permitting the protrusion of abdominal organs that are normally located within or outside the peritoneum.[3] Risk factors for the development of an "inguinal hernia" can be categorized into patient-related factors, including age and sex and external factors, such as physically strenuous occupations.[4]

Inguinal hernias are almost always symptomatic and the only cure is surgery but non-surgical approaches are also used in its management.[5] There is a subset of patients who do not exhibit any symptoms; yet, even following a watch-and-wait strategy will culminate in surgical intervention for the majority of these patients. In spite of the fact that surgical therapy is successful in the majority of instances, there is still a substantial risk of recurrence following inguinal hernia surgery if the appropriate precautions are not taken.[6] Another problem after inguinal hernia repair is chronic pain lasting for an extended period of time that can effect more than 17% of the patients with a small proportion of patients reporting such severity of chronic pain that results in long-term disability requiring treatment.[7, 8]

One of the factors that has an impact on the occurrence of this chronic pain after patients undergo surgical repair of hernia is the type of surgical technique employed. In this instance, some literature on international level states that "Lichtenstein repair", which is the well-reputed and frequently used approach on the global scale, may be associated with higher post-operative pain scores as compared to "trans-abdominal pre-peritoneal (TAPP) approach". [9] However, at local level there is still a lack of reliable evidence for which it was imperative to conduct further studies in this regard. Therefore, present study was conducted to compare post-operative pain score between "Lichtenstein's repair" versus "laparoscopic trans-abdominal pre-peritoneal (TAPP) repair" for inguinal hernia.

METHODOLOGY

This "comparative cross sectional study" was conducted at "Combined Military Hospital, Lahore from July-2021 to July-2024" (ERB #: 587/204, Date: 18/06/2021). For sample size calculation, Open Epi sample size calculator was used. Appropriate sample size was calculated using following formula:

For calculations, following assumptions were used; level of significance at 5%, power at 80%, anticipated mean pain score in Lichtenstein group at 6.23 ± 1.87 [10] and anticipated mean pain score in TAPP group at 4.43 ± 1.59. [10] This gave a total sample size of 80 (40 patients in each group).

Inclusion criteria: Patients aged 18-60 years, male gender, who underwent inguinal hernia repair with "American Society of Anesthesiology (ASA)" status I and II were included.

Exclusion criteria: Congenital hernia, female gender, patients with history of repair with mesh, those with prior pelvic surgery, trans-vesical prostatectomy and patients who were hepatitis B or C positive were excluded.

Patients were selected by using non-probability consecutive sampling technique. After acquisition of written informed consent from the patients for their inclusion in study, baseline characteristics of the patients including age, gender, BMI, ASA grade and duration of hernia were documented. Diagnosis of inguinal hernia was made using clinical assessment and ultrasound. Patients were allocated "Lichtenstein group" and "TAPP group" in two phases. From July 2021 to January 2023, 40 patients underwent "Lichtenstein hernia repair" while in second phase from January 2023 to July 2024, remaining 40 patients underwent "TAPP repair". All the patients had same pre-operative management as per hospital protocol and all surgeries were performed as per standard procedural guidelines by same surgical team lead by consultant surgeon with minimum 8 years of experience. Following the procedure, the patient's level of pain was evaluated using a "Visual Analogue Scale (VAS)" at a time interval of four hours after the operation. Immediately following surgery, all patients were given painkillers in the form of intramuscular injections of 75 milligrams of "diclofenic sodium", and this procedure was repeated once after six hours. For every single patient, no pre-operative nor intra-operative analgesia was administered. Standardized postoperative instructions were given to each and every patient, stating that they should not restrict their activities unless the activities caused them to experience pain.

"Statistical package for Social Sciences version 20 was used to conduct the statistical analysis of the data that was obtained. The Shapiro-Wilk test was used to check if the data was distributed normally or not. Normality of data was checked by Shapiro-Wilk test. Age was distributed normally and was represented using mean ± standard deviation while BMI,

duration of hernia and post-operative pain score were not distributed normally and was represented using median interquartile range (IQR). Qualitative data (gender and ASA grade) was represented by using percentage and frequency. Comparison of post-operative pain score between groups was performed using Mann Whittney U- test. A p-value of = 0.05 was considered statistically significant".

RESULTS

In this study, 80 patients were included. Mean age was 48.10 ± 5.05 years. There were 80 (100%) males. Median BMI was 27.00 (29.40 – 19.70) kg/m2. Median duration of hernia was 5.00 (12.00 – 2.00) months. Frequency of ASA status I was 29 (36.25%) and of ASA status II was 51 (63.75%). Comparison of these baseline characteristics between groups is given below in Table-I: Median post-operative pain VAS in "Lichtenstein group" was 6.00 (6.00 – 5.00) while in "TAPP group" it was 4.00 (4.00 – 3.00), (p < 0.001). This comparison of median post-operative pain VAS between groups is given below in Table-2

Figure-1: Consort diagram of patient selection and group allocation (n = 80)



DISCUSSION

The surgical history of inguinal hernias originates from ancient Egypt. Three significant milestones in hernia care are Bassini's tissue repair in 1888, Lichtenstein's mesh repair in 1984, and Ger's laparoscopic mesh repair in 1990. In the late 20th century, the tension-free repair established by Irving Lichtenstein significantly reduced recurrence rates and became the preferred treatment. The advent of a laparoscopic approach by Ralf Ger in the early 1990s ignited a renewed discussion over the optimal procedure for inguinal hernia repair. Inguinal and femoral hernias are the predominant conditions for which primary care providers recommend patients for surgical intervention. The primary cause of postoperative discomfort and recurrence is tension-

Table-1: Comparison of these baseline characteristics between groups (n = 80)

Parameter	Lichtenstein group (n = 40)	TAPP group (n = 40)	p-value
Mean age	49.62 ± 4.44 years	46.57 ± 5.22 years	0.006
Age group			
< 40 years	1 (2.50%)	3 (7.50%)	0.305
> 40 years	39 (97.50%)	37 (92.50%)	
Gender			
Male	40 (100.00%)	40 (100.00%)	0.785
Female	0 (00.00%)	0 (00.00%)	
Median BMI	28.70 (29.40 – 19.70) kg/m2	26.40 (29.40 – 19.70) kg/m2	0.657
BMI group			
< 25kg/m2	12 (15.00%)	15 (37.50%)	
> 25kg/m2	28 (85.00%)	25 (62.50%)	
Median duration of hernia	5.00 (7.00 – 2.00) months	5.00 (12.00 – 2.00) months	0.149
ASA status			
I	18 (45.00%)	11 (27.50%)	0.104
II	22 (55.00%)	29 (72.50%)	

Table-2: Comparison of median post-operative pain VAS between groups (n = 80)

Parameter	Lichtenstein group (n = 40)	TAPP group (n = 40)	p-value
Median post-operative pain VAS	6.00 (6.00 – 5.00)	4.00 (4.00 – 3.00)	< 0.001

based hernia repair. This resulted in the advancement of tension-free hernioplasty. Currently, tension-free hernioplasty with mesh has become the gold standard technique. Mesh replacement may be performed either open surgery or minimally invasive surgery. Laparoscopic treatment of inguinal hernias has achieved significant popularity in recent years. The benefits of laparoscopic surgery support its use in many surgical interventions. The advantages of the TAPP technique include enhanced patient comfort and aesthetic outcomes, facilitating tension-free repair with improved visibility of groin anatomy, less postoperative discomfort, abbreviated hospital stay, and expedited return to daily activities.

Inguinal hernias are almost always symptomatic and the only cure is surgery but non-surgical approaches are also used in its management.[5] There is a subset of patients who do not exhibit any symptoms; yet, even following a watch-and-wait strategy will culminate in surgical intervention for the majority of these patients. In spite of the fact that surgical therapy is successful in the majority of instances, there is still a substantial risk of recurrence following inguinal hernia surgery if the appropriate precautions are not taken.[6] When it comes to the care of symptomatic hernia, surgical repair of the "inguinal hernia" is a relatively popular procedure utilized all over the world. "Indirect hernias", also known as "lateral hernias", are more common and are connected with complications. On the other hand, "medial hernias", also known as "direct hernias", are associated with a higher chance of recurrence after correction.[11, 12] In spite of the fact that there are differences in the age, gender, and recurrence rates that have been described in prior research, surgical intervention is frequently used to treat both medial and lateral hernias in order to achieve the same results. [13] The traditional surgical approach for groin hernias involves ligating or reducing the hernia sac and reconstructing the posterior wall via an open incision. This operation may be conducted as a day care procedure in select cases using local anesthesia; however, open hernioplasty is presumed to be linked to heightened postoperative pain, extended hospital stays, increased recurrence rates, and a delayed return (four to six weeks) to full physical activity and employment. Literature indicates that hernia recurrence rates after open treatment are minimal (under 2 percent) in specialist facilities; nevertheless, regional studies of diverse populations reveal typical recurrence rates of 5 to 10 percent for original hernias and 5 to 30 percent for recurrent hernias. The challenges associated with traditional herniorrhaphy, along with the efficacy of laparoscopic cholecystectomy, motivated the development of a laparoscopic technique for hernia repair. Since the 1990s, laparoscopic inguinal hernia repair has been practiced. One of the more difficult to manage complication associated with surgical hernia repair is chronic post-procedural pain. [14] Several factors contribute to the development of this complication including type of surgery, surgery performed with or without mesh and size of the hernia.[15, 16] Therefore, present study focused on one of the aspect impacting the post-operative pain by comparing post-operative pain score between "Lichtenstein's repair" versus "TAPP repair" for inguinal hernia.

In present study, average age of the patients suffering from "inguinal hernia" was forty eight years with majority of patients aged more than 40 years and of male gender. This can be explained by the findings reported in multiple previous studies reported "inguinal hernia" to be much more common in older men. [17, 18] Average BMI of the study participants was 27kg/m2 with majority of patients having BMI in overweight range. It is explainable by the previously reported string association between higher BMI and "inguinal hernia".[19, 20]

In terms of median post-operative pain, it was observed that patients who were managed by "Lichtenstein inguinal hernia repair" suffered with much higher degree of pain as compared to those who had "TAPP repair" ($p < 0.001$). Similar to the results of present study, Rayamajhi et al. [21] reported that the average pain VAS score in inguinal hernia patients in "Lichtenstein group" was significantly higher as compared to "TAPP group" ($p = 0.037$). Similarly, Sofi et al. [22] reported that patients who had "TAPP repair" suffered from significantly lesser pain as compared to those who underwent "Lichtenstein repair" ($p < 0.05$). In another study conducted by Ashrafi et al. 23, significantly less pain scores were reported among patients who underwent their inguinal hernia repair by "TAPP repair" rather than "Lichtenstein repair".

A significant benefit of the laparoscopic technique is the capacity to identify and rectify a contralateral problem during the same procedure with just a little extension of operating time. In this limited research of 40 laparoscopic TAPP repairs, two hernias (5%) were identified on the contralateral side. The repairs were conducted in the same session. The duration of hospital stay did not vary across groups, as shown by the Cochrane database, which aligns well with the findings of this research. The TAPP group resumed daily living activities sooner than the open group, a finding corroborated by multiple studies that offset the expenses associated with laparoscopic repair. Complications associated with expertise and technological advancements in laparoscopic surgery are now negligible, and studies suggest comparable complication rates between open and laparoscopic procedures.1[8,19] A separate meta-analysis addressing this issue included 29 prospective randomized trials including 5,588 people. A total of 3,017 hernias were fixed laparoscopically, whereas 2,972 were corrected by an open technique. Six outcome factors were examined: operation time, hospital discharge time, resumption of normal activities, return to work, postoperative problems, and recurrence rate. The study preferred laparoscopic inguinal hernia surgery over open repair. This research examined four parameters: surgical

time, postoperative discomfort, infection, and hospital stay, with outcomes favoring laparoscopic repair. Because disposables are used during the procedure, laparoscopic hernioplasty is more expensive and has a longer learning curve. Additionally, it is simpler to assess both groins, especially incidental defects, using the laparoscopic technique. Both defects can be repaired in the same procedure without requiring additional surgical incision, resulting in minimal postoperative discomfort and very little dissection. As a result, bilateral inguinal hernias are an ideal option for laparoscopic repair; however, as our research was a pilot, we did not include patients with bilateral hernias due to the TAPP's viability in our context. The majority of laparoscopic hernioplasties nowadays are carried out using either the transabdominal preperitoneal (TAPP) or total extraperitoneal (TEP) approach. According to a previous study intraoperative complications associated with laparoscopic hernioplasties include bleeding, technical failure, conversion, damage to the vas deferens, damage to vessels, damage to the viscus, and major vascular injury. There were no intraoperative issues with any of the study's subjects. They found no variation in intraoperative complications between the two groups.[24]

Currently, recurrence rates after the laparoscopic preperitoneal prosthetic-patch procedure have been minimal; nevertheless, the duration of follow-up has been brief. As the majority of recurrences after traditional herniorrhaphy occur five or more years post-operation, the long-term recurrence rates may be unacceptably elevated, particularly when conducted by an unskilled surgeon. A recent experiment by Brandt and colleagues indicated a recurrence rate of 8.5% for initial hernias and 10.8% for recurrent hernias after 13 years following endoscopic complete extra-peritoneal hernia repair, resulting in an overall recurrence rate of 8.9%.[24] Consequently, more assessment in controlled clinical studies is required prior to the broader use of laparoscopic herniorrhaphy.

Laparoscopic hernia repair necessitates general anesthesia, along with its inherent hazards, for a treatment that may be performed normally with local anesthetic in some instances. A minor but distinct risk of severe harm to intra-abdominal organs exists, which is not linked to conventional inguinal herniorrhaphy. Furthermore, expenses may increase due to the need for costly equipment and additional supplies associated with laparoscopic instrumentation.[9, 18] In contrast to laparoscopic cholecystectomy, the elevated costs associated with hernia operations are not mitigated by reduced hospital fees, since hernia surgeries are often conducted as outpatient procedures irrespective of the repair technique used. A recent comparison of conventional and laparoscopic herniorrhaphy revealed an average cost increase of 135 percent associated with the laparoscopic method. The potential for these direct expenses to be somewhat mitigated by a swifter return to work remains uncertain.[18, 22]

Present study shares the opinion of previous researchers that in terms of early pain after having surgical repair of inguinal hernia, "TAPP repair" is a much better surgical intervention as compared to the "Lichtenstein repair".

Limitations: Limitations of present study included limited sample size, single center study and small follow up period.

CONCLUSION

TAPP is associated with significantly less early post-operative pain scores as compared to "Lichtenstein inguinal hernia repair".

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Muhammad Waleed khan: Conception, design, interpretation and corresponding author
Shahid Majeed: Interpretation, Literature Review
Rabheel Khan: Analysis, Conception, final approval

REFERENCES

1. Rivas JF, Ruiz-Funes Molina AP, Carmona JM. Transabdominal preperitoneal (TAPP) inguinal hernia repair: how we do it. Ann Laparosc Endosc Surg 2021;6:12. https://doi.org/10.21037/ales-20-109.
2. Perez AJ, Campbell S. Inguinal Hernia Repair in Older Persons. J Am Med Dir Assoc. 2022;23(4):563-567. https://doi.org/10.1016/j.jamda.2022.02.008.
3. Wu WT, Chang KV, Lin CP, Yeh CC, Özçakar L. Ultrasound imaging for inguinal hernia: a pictorial review. Ultrasonography. 2022;41(3):610-623. https://doi.org/10.14366/usg.21192.
4. Agarwal PK. Study of demographics, clinical profile and risk factors of inguinal hernia: a public health problem in elderly males. Cureus. 2023;15(4):e38053. https://doi.org/10.7759/cureus.38053.
5. Drolshagen H, Bhavaraju A, Kalkwarf KJ, Karim SA, Reif R, Sexton KW, et al. Surgical and non-surgical treatment of inguinal hernia during non-elective admissions in the Nationwide Readmissions Database. Hernia. 2021;25(5):1259-1264. https://doi.org/10.1007/s10029-021-02441-5.
6. Tastaldi L, Barros PHF, Krpata DM, Prabhu AS, Rosenblatt S, Petro CC, et al. Hernia recurrence inventory: inguinal hernia recurrence can be accurately assessed using patient-reported outcomes. Hernia. 2020;24(1):127-135. https://doi.org/10.1007/s10029-019-02000-z.
7. Chu Z, Zheng B, Yan L. Incidence and predictors of chronic pain after inguinal hernia surgery: a systematic review and meta-analysis. Hernia. 2024;28(4):967-987. https://doi.org/10.1007/s10029-024-02980-7.
8. Gram-Hanssen A, Öberg S, Rosenberg J. A critical appraisal of the chronic pain rate after inguinal hernia repair. J Abdom Wall Surg. 2023;2:10972.

9. Dumitrescu V, Serban D, Costea DO, Dumitrescu D, Bobirca F, Geavlete B, et al. Transabdominal preperitoneal versus lichtenstein procedure for inguinal hernia repair in adults: a comparative evaluation of the early postoperative pain and outcomes. Cureus. 2023;15(7):e41886. https://doi.org/10.7759/cureus.41886.
10. Salma U, Ahmed I, Ishtiaq S. A comparison of post operative pain and hospital stay between Lichtenstein's repair and Laparoscopic Transabdominal Preperitoneal (TAPP) repair of inguinal hernia: A randomized controlled trial. Pak J Med Sci. 2015;31(5):1062-1066. https://doi.org/10.12669/pjms.315.4811.
11. Lee CS, Kim JH, Choi BJ, Lee JI, Lee SC, Lee YS, et al. Retrospective study on prevalence of recurrent inguinal hernia: a large-scale multi-institutional study. Ann Surg Treat Res. 2020;98(1):51-55. https://doi.org/10.4174/astr.2020.98.1.51.
12. Papamichail S, Karlafti E, Malliou P, Zatagias A, Ioannidis A, Netta S, et al. A Rare Case of a Direct Incarcerated Inguinal Hernia Containing an Epiploic Appendage and a Literature Review. Sultan Qaboos Univ Med J. 2023;23(4):547-550. https://doi.org/10.18295/squmj.12.2022.072.
13. Smith SM, Khoja AA, Jacobsen JHW, Kovoor JG, Tivey DR, Babidge WJ, et al. Mesh versus non-mesh repair of groin hernias: a rapid review. ANZ J Surg. 2022;92(10):2492-2499. https://doi.org/10.1111/ans.17721.
14. Romano G, Di Buono G, Rodolico V, Romano G, Barletta G, Zanghì G, et al. The DySLOH Study: Comparative evaluation of the results between the ProFlor and Lichtenstein techniques for open inguinal hernia repair-a randomized controlled trial. J Clin Med. 2024;13(18):5530. https://doi.org/10.3390/jcm13185530.
15. Kim SH, Jung HS, Park S, Cho SS. Inguinal hernia repair with or without mesh in late adolescent males. Ann Surg Treat Res. 2021;100(4):246-251. https://doi.org/10.4174/ astr.2021.100.4.246.
16. Hoffmann H, Walther D, Bittner R, Köckerling F, Adolf D, Kirchhoff P. Smaller inguinal hernias are independent risk factors for developing chronic postoperative inguinal pain (CPIP): A registry-based multivariable analysis of 57,999 patients. Ann Surg. 2020;271(4):756-764. https://doi.org/10.1097/SLA.0000000000003065.
17. Akeel N. Short-term outcomes of inguinal hernia repair in older patients: a retrospective review at a tertiary center. Cureus. 2021;13(9):e18170. https://doi.org/10.7759/ cureus.18170.
18. Ceresoli M, Carissimi F, Nigro A, Fransvea P, Lepre L, Braga M, et al; List of Elderly Risk Assessment and Surgical Outcome (ERASO) Collaborative Study Group endorsed by SICUT, ACOI, SICG, SICE, and Italian Chapter of WSES. Emergency hernia repair in the elderly: multivariate analysis of morbidity and mortality from an Italian registry. Hernia. 2022;26(1):165-175. https://doi.org/10.1007/s10029-020-02269-5.
19. Shrestha S, Upadhyay PK. Prevalence of obesity in inguinal hernia repair patients in a tertiary care center. J Nepal Med Assoc. 2021;59(234):156-159. https://doi.org/ 10.31729/jnma.5636.
20. Rosca R, Paduraru DN, Bolocan A, Musat F, Ion D, Andronic O. A comprehensive review of inguinal hernia occurrence in obese individuals. Maedica (Bucur). 2023;18(4):692-698. https://doi.org/10.26574/maedica.2023.18.4.692.
21. Rayamajhi BB, Basukala S, Thapa N, Ayer D, Karki S, Basukala B. A comparison of outcome between transabdominal preperitoneal (TAPP) and Lichtenstein operation for primary inguinal hernia repair – An institutional study. J Soc Surg Nep. 2022;25(1):16-21. https://doi.org/10.3126/ jssn.v25i1.47715.
22. Sofi J, Nazir F, Kar I, Qayum K. Comparison between TAPP & Lichtenstein techniques for inguinal hernia repair: A retrospective cohort study. Ann Med Surg (Lond). 2021;72:103054. https://doi.org/10.1016/j.amsu.2021.103054.
23. Ashrafi A, Kabiri A, Zadeh B S, Sadri P. Comparison of postoperative short-term complications and recurrence after one year between laparoscopic transabdominal pre-peritoneal (TAPP) and Lichtenstein tension free repair on the treatment of primary unilateral inguinal hernia. World J Plastic Surg. 2024;13(3):87-91. Https://doi.org/10.61186/wjps.13.3.87.
24. Brandt-Kerkhof A, van Mierlo M, Schep N, Renken N, Stassen L. Follow-up period of 13 years after endoscopic total extra peritoneal repair of inguinal hernias: a cohort study. Surg Endosc. 2011;25:1624–1629. doi: 10.1007/s00464-010-1462-7

Original Article **Open Access**

Comparison of Clinical Outcomes and Union Rates Between Proximal Femoral Nail and Gamma Nail in Intertrochanteric Fractures

Muhammad Awais Iqbal, Zohaib Nadeem, Hasnain Ali, Mustafa Javed Bhalli, Laiba Ahsan, Saad Tauheed Rao

Abstract

Objective: To compare the efficacy and outcomes of two different surgical procedures, the PFN and the GAMA nail, in the treatment of intertrochanteric femur fractures.

Study Design and Settings: It was a comparative study. From 1 July 2024 to 1 Feb 2024, 35 patients with intertrochanteric fractures treated with PFN or GAMMA Nail at Shifa International Hospital's Department of Orthopaedics were part of this prospective study.

Results: In this study the mean age of the cases in Group A was 69.27 ± 19.44 and in Group B was 62.15 ± 23.52. Greater tip apex at 6 weeks and 6 months is associated with higher leg length discrepancies as the pearson correlation showed significant p-value 0.000. For the PFN group (n = 13), there was a significant positive correlation between tip-apex distance and leg length discrepancy (r = 0.634, p = 0.020). Similarly, for the Gamma Nail group (n = 22), a significant positive correlation was observed (r = 0.560, p = 0.007).

Conclusion: Our study showed that both gamma nail and proximal femoral nail are trusted devices for intertrochanteric fracture (boyd and griffin type ii) treated by PFN vs Gamaa nail. The comparison of union rate at 6 weeks and 6 months showed and pain score showed comparative results. Moreover, the results showed that Greater tip apex at 6 weeks and 6 months is associated with higher leg length discrepancies as the pearson correlation showed significant p-value 0.000.

Key Words: Boyd and Griffin, Gamaa Nail, Intertrochanteric Fracture, PFN, Union Rate

How to cite this Article:
Iqbal MA, Nadeem Z, Ali H, Bhalli MJ, Ahsan L, Rao ST. Comparison of Clinical Outcomes and Union Rates Between Proximal Femoral Nail and Gamma Nail in Intertrochanteric Fractures. J Bahria Uni Med Dental Coll. 2026;16(2):595-600 DOI: https://doi.org/10.51985/JBUMDC2025826

INTRODUCTION:

There is a high incidence of intertrochanteric fractures in the older population, particularly as a result of the increasing prevalence of osteoporosis. Intramedullary implants, such as the proximal femoral nail (PFN) and the GAMMA nail, have been shown to have positive outcomes in a number of trials; nevertheless, other research indicates that the rates of complications are higher. [1]

There has been a significant increase in the number of proximal femoral fractures as a consequence of an increase in the number of patients having osteoporosis as a result of a longer life expectancy.[2] This increase has been brought about by an increase in the number of road traffic incidents that have affected younger individuals. Young individuals frequently suffer from intertrochanteric fractures as a consequence of significant trauma, such as being involved in a car accident or falling from a considerable height, as stated by Lavallière et al. (2020).[3] Ninety percent of all intertrochanteric fractures that occur in elderly people are the result of accidental falls.[4] Because of the growing elderly population and the prevalence of osteoporosis, the trend of an increasing number of intertrochanteric femoral fractures over the past few decades is likely to persist into the foreseeable future. Intertrochanteric fractures are not as common in some countries as others. [5-6] The anticipated total number of hip fractures is projected to reach 2.6 million in 2025 and 4.5 million in 2050. Intertrochanteric hip fractures accounted for 26% of all hip fractures in Asia in 1990, but that number could increase to 37% in 2025 and 45% in 2050.[7] Stable fixation, which permits early patient mobilisation, is the treatment goal for these fractures.

Muhammad Awais Iqbal
Resident, Department of Orthopedic
Shifa International Hospital
Email: awaisiqbal843@gmail.com

Zohaib Nadeem
Consultant, Department of Orthopedic
Shifa International Hospital
Email: dr.zaiby@gmail.com

Hasnain Ali
Resident, Department of Orthopedic
Shifa International Hospital
Email: hasnainaly555@gmail.com

Mustafa Javed Bhalli
Consultant, Department of Orthopedic
Shifa International Hospital
Email: mustafa.javed@shifa.com.pk

Laiba Ahsan
Medical Officer, Department of Orthopedic
Shifa International Hospital
Email: Laibaahsan00@gmail.com

Saad Tauheed Rao
Medical Officer, Department of Orthopedic
Shifa International Hospital
Email: Saadfarrukh33@gmail.com

Received: 07-11-2025
Accepted: 20-03-2026
1st Revision: 17-11-2025

Significant morbidity and mortality are linked to these breaks.

The major purpose of the PFN was to solve the acknowledged inadequacies and potential problems that were associated with the Gamma device by the implementation of enhancements. The PFN has a fluted tip and a lowered diameter, both of which help to reduce the amount of bone strain and eliminate the likelihood of shaft fractures. Static or dynamic locking is achieved by moving one distal locking screw closer to the apex. This is done in order to strengthen the structural integrity of the structure. It is necessary to insert a smaller adjustment screw into the superior section of the femoral neck in order to avoid insert cutoff and to stop the head-neck fragment from rotating.[8]

The intramedullary nail system was combined with the sliding hip screw to create the gamma nail, which became a classic intramedullary fixation approach for the treatment of intertrochanteric fractures.[9] Inserting the primary nail into the intra-medulla cavity is the method that is utilised to accomplish central fixation.[10] Farhat et al. (2021) state that one of the several possible advantages of utilising gamma nails on the femoral head, neck, and shaft is that they improve stability at fracture sites and speed up the healing process, which ultimately leads to the early union of the fracture.[11] This is only one of the many potential benefits of employing gamma nails.[12] Additionally, the stabilisation of the medullary cavity enables the afflicted legs to bear their entire weight and participate in early functional activities. During the process of inserting the main nail, the gamma nail may produce stress fractures of the distal femoral shaft as well as a worsening of the intertrochanteric fractures. There is, however, a standardised surgical procedure that may be utilised by medical professionals in order to implant gamma nails. Both the amount of time required for the therapy and the number of incisions performed are minimal.

The objective of our research was to compare the efficacy and outcomes of two different surgical procedures, the PFN and the GAMA nail, in the treatment of intertrochanteric femur fractures. We aimed to determine which method yields higher union rates and produces better functional outcomes in patients.

METHODOLOGY:

This comparative study was conducted from 1 July 2024 to 1 Feb 2025 under IRB number 247-24. 35 patients with intertrochanteric fractures treated with PFN or GAMMA Nail at Shifa International Hospital's Department of Orthopaedics were part of this study. The sample size was calculated using the WHO sample size calculator for comparison of two proportions. Taking expected union rates of 95% in the Gamma nail group and 75% in the PFN group from the study by Badawy et al., with a 95% confidence level and 80% power, the calculated sample size was 46 patients per group. After adjusting for an anticipated dropout rate of approximately 20–25%, the final sample size was taken as 35 patients in each group.[9] Non-probability consecutive sampling technique was used to divide patients in both groups.

Patients aged 18 to 90 years with intertrochanteric fractures classified as type II according to the Evans and Boyd & Griffin criteria, as well as those receiving primary or index surgery, were included in the study.

Patients with fractures resulting from diverse clinical conditions, a prior surgical history involving the proximal femur, unstable intertrochanteric femur fractures managed with various internal fixation techniques, and those with past non-unions or malunions were excluded from the study.

Each patient received one intravenous dose of third-generation cephalosporin during surgery, and they were instructed to continue taking the medication every 12 hours for seven days following the procedure.

All patients were operated on a traction table while in the supine position. The fracture was successfully reduced using abduction, traction, and internal rotation under fluoroscopic guidance, employing minimally invasive procedures for nailing. The lower limb was adducted to facilitate the insertion of the Gamma nail.

A cut was made into the skin five centimetres from the greater trochanter's tip. Aligning the guiding k-wire under the C-Arm guide, it was put into the greater trochanter after the superficial fascia and muscles were dissected. The lateral and perioperative X-rays reveal that the guide K-wire was inserted into the femoral shaft midline. To manually ream the proximal femur, a sharp tool was utilized. The nail was manually placed into the femoral shaft. Once the lag screw was centrally positioned in the lateral and anteroposterior x-ray views, the targeting arm, which was attached to the insertion device, helped enter the guide k-wire into the femoral neck for the first time. In PFN, a guide K-wire and an anti-rotational screw were added to a comparable technique. The lag screw was put in after the anti-rotational screw, which was inserted with its tip around 25 mm medial to the fracture line. Moving on to the last stage, distal screws, static or dynamic, were inserted.

Prior to the operation, a postoperative x-ray was compared with a pelvic radiograph that included the hip and full-length femur on the fracture side.

Anticoagulants (LMWH) were commenced for each patient unless a significant risk of haemorrhage was evident. Patients were seen during designated appointments at 2 weeks, 6 weeks, 3 months, and 6 months. At each follow-up consultation, the patient received clinical and radiological assessments. The assessment of leg length discrepancy, thigh discomfort, or hip pain score was conducted.

Anteroposterior measurements of the operated side's neck-

shaft angle, which is typically 125 degrees, were used to assess the reduction quality. A reduction was deemed satisfactory if it deviated by fewer than five degrees from the typical range, acceptable if it deviated between five and ten degrees, and unsatisfactory if it deviated by more than ten degrees.

On pelvic radiographs, which included both lateral and anteroposterior views of the operative femur, the fixation quality was assessed using the Cleveland index and tip apex distance. The fracture union rate was assessed using serial radiographs at follow-up consultations at 6 weeks and 6 months.

The data were analyzed via the Student's t-test and the chi-square test. The Pearson correlation was employed to assess the relationship between tip-apex distance and leg-length discrepancies. A P-value less than 0.05 were deemed statistically significant. The analysis was conducted utilizing SPSS, version 23.

RESULTS

In this study the mean age of the cases in Group A was 69.27 ± 19.44 and in Group B was 62.15 ± 23.52. There were 13 (59.1%) male and 9 (40.9%) females enrolled in Gamma Nail and 11 (84.6%) male and 2 (15.4%) females found in PFN. The comparison of different risk factors showed insignificant results p-value > 0.05. (Table 1). In this study the mean height, weight and BMI in Gamma Nail was 164 ± 10.20, 65.39 ± 14.76 and 24.34 ± 5.73. Similarly, the mean height, weight and BMI in PFN was 161 ± 8.41, 65.69 ± 17.19, 25.28 ± 5.67 respectively. (Table 2) In this study the comparison of preoperative Hb, postoperative Hb and thigh pain at 6 weeks and 6 months showed insignificant difference with p-value > 0.05. (Table 3). In this study union rate at 6 weeks in gamma nail was 19 (86.4%) while in PFN union rate was (84.6%). Similar results were found at 6 months. These results were insignificant p-value 1.00. (Table 4) Greater tip apex at 6 weeks and 6 months is associated with higher leg length discrepancies as the pearson correlation showed significant p-value 0.000. (Table 5) For the PFN group (n = 13), there was a significant positive correlation between tip-apex distance and leg length discrepancy (r = 0.634, p = 0.020). Similarly, for the Gamma Nail group (n = 22), a significant positive correlation was observed (r = 0.560, p = 0.007). (Table 6)

DISCUSSIONS

Anteroposterior measurements of the operated side's neck-shaft angle, which is typically 125 degrees, were used to assess the reduction quality. A reduction was deemed satisfactory if it deviated by fewer than five degrees from the typical range, acceptable if it deviated between five and ten degrees, and unsatisfactory if it deviated by more than ten degrees.[13,14]

The prevalence of proximal femoral fractures has been on the rise, driven by factors such as longer life expectancy, osteoporosis in the elderly, and traffic accidents in younger generations. The most common causes of intertrochanteric

Table 1: Comparison of demographic variables and risk factors

Age		Gamma Nail n=22	PFN n=13	P-Value
(Mean ± S.D)		69.27 ± 19.44	62.15 ± 23.52	0.340
Gender	Male	13 (59.1%)	11 (84.6%)	0.116
	Female	9 (40.9%)	2 (15.4%)	
Diabetes	Yes	2 (9.1%)	4 (30.8%)	1.00
	No	20 (90.9%)	9 (69.2%)	
Hypertension	Yes	12 (54.5%)	7 (53.8%)	0.968
	No	10 (45.5%)	6 (46.2%)	
IHD	Yes	3 (13.6%)	1 (7.7%)	0.593
	No	19 (86.4%)	12 (92.3%)	
NKCM, Epilepsy	Yes	1 (4.5%)	0 (0%)	0.641
None	Yes	13 (59.1%)	8 (61.5%)	
CAD	Yes	1 (4.5%)	0 (0%)	
CKD	Yes	2 (9.1%)	1 (7.7%)	
Laryngeal SSC	Yes	1 (4.5%)	0 (0%)	
Hypothyroidism	Yes	1 (4.5%)	1 (7.7%)	
Hepatitis A	Yes	1 (4.5%)	0 (0%)	
History of TB	Yes	1 (4.5%)	0 (0%)	
Asthma	Yes	0 (0%)	1 (7.7%)	
Osteoarthritis	Yes	0 (0%)	1 (7.7%)	
Lumbar stenosis	Yes	0 (0%)	1 (7.7%)	
Parkinsons,TIA	Yes	0 (0%)	1 (7.7%)	

Table 2: Descriptive statistics of height, weight and BMI

	Procedure	Mean ± SD
Height (cm)	Gamma Nail	164 ± 10.20
	PFN	161 ± 8.41
Weight (kg)	Gamma Nail	65.39 ± 14.76
	PFN	65.69 ± 17.19
Body mass index (kg/m2)	Gamma Nail	24.34 ± 5.73
	PFN	25.28 ± 5.67

Table 3: Comparison of clinical variables

	Procedure	Mean ± SD	P-Value
Pre_Hb	Gamma Nail	11.15 ± 1.98	0.608
	PFN	11.48 ± 1.49	
Post_Hb	Gamma Nail	9.44 ± 1.47	0.755
	PFN	9.30 ± 1.06	
Thigh pain 6 weeks	Gamma Nail	3.72 ± 1.64	0.243
	PFN	4.53 ± 2.40	
Thigh pain 6 months	Gamma Nail	1.95 ± 2.06	0.287
	PFN	2.92 ± 3.25	

fractures in children under the age of 10 are severe traumas like car accidents or falls from great heights. In the elderly, a small fall is the cause of 90% of intertrochanteric fractures. Factors such as osteoporosis, vascular disease, and concomitant musculoskeletal diseases increase the likelihood of falls.[15] Factors that contribute to the high likelihood of death after hip fractures include being older, having systemic disorders that are either untreated or poorly controlled, undergoing internal fixation before comorbidities are handled, and problems that arise after surgery. In addition to reducing mortality, the goals of hip fracture management include assuring adequate patient independence, minimising complications, restoring patients to their pre-fracture functional level as quickly and safely as possible, and avoiding prolonged disability.[16] It is recommended that patients be mobilised early after rigid fixation as a routine treatment method. This greatly improves walking and speeds up the process of getting back to normal. The aim of our research is to assess the efficacy and results of two distinct surgical methods, the PFN and the GAMA nail, in treating intertrochanteric femur fractures. Our objective is to ascertain whether strategy results in superior union rates and enhances functional outcomes in patients.

Table 4: Comparison of union rate at 6 weeks and 6 months

		Gamma Nail	PFN	P-Value
Union rate at 6 weeks	Yes	19 (86.4%)	11 (84.6%)	1.00
	No	3 (13.6%)	2 (15.4%)	
Union rate at 6 Months	Yes	19 (86.4%)	11 (84.6%)	1.00
	No	3 (13.6%)	2 (15.4%)	

Table 5: Correlation of tip apex and leg length discrepancies at 6 weeks and 6 months

Tip apex 6 weeks	Pearson correlation	1	0.615
	Sig (2 tailed)		0.000
	N	35	35
Leg Length discrepancies at 6 weeks	Pearson correlation	0.615	1
	Sig (2 tailed)	0.000	
	N	35	35
Tip apex 6 months	Pearson correlation	1	0.702
	Sig (2 tailed)		0.000
	N	35	35
Leg Length discrepancies at 6 months	Pearson correlation	0.702	1
	Sig (2 tailed)	0.000	
	N	35	35

A total of 35 patients scheduled for internal fixation using either a regular gamma nail or a PFN were enrolled in this study. Their preoperative characteristics, risk factors, and postoperative measures were compared. Our investigation demonstrated that there is no statistically significant difference between the two groups for sex, age, fracture side, and risk factors. The average age of participants in Group A was 69.27 ± 19.44, while in Group B it was 62.15 ± 23.52. In Gamma Nail, there were 13 males (59.1%) and 9 females (40.9%) enrolled, while in PFN, there were 11 males (84.6%) and 2 females (15.4%). Conversely, the average age of patients in our study is lower than that reported in previous research, such as that by Mereddy et al. (2009),[17] who documented a mean age of seventy-eight years in their investigation of PFN. Loubignac et al. demonstrated a mean age of 80.3 years in their patients involving the fixation of trochanteric fractures.[18]

This study reports the mean height, weight, and BMI for the Gamma Nail as 164 ± 10.20 cm, 65.39 ± 14.76 kg, and 24.34 ± 5.73, respectively. The average height, weight, and BMI in PFN were 161 ± 8.41 cm, 65.69 ± 17.19 kg, and 25.28 ± 5.67, respectively. In this study, the union rate at 6 weeks for the gamma nail was 19 (86.4%), but the union rate for the PFN was 84.6%. Comparable outcomes were observed at the six-month mark. The results were negligible, with a p-value of 1.00. In the study by Banan et al., including 50 patients with unstable trochanteric fractures, only one instance of implant failure was observed seven months post-operatively, in contrast to our study, which reported two (15.4%) instances in the PFN group and three (13.6%) cases in the gamma nail group.[19]

Table 6: Correlation of tip apex and leg length discrepancies at 6 weeks and 6 months in Gamma Nail and PFN

Gamma Nail	Tip apex 6 month	Pearson correlation	1	0.560
		Sig (2 tailed)		0.007
		N	22	22
	Leg Length discrepancies at 6 months	Pearson correlation	0.560	1
		Sig (2 tailed)	0.007	
		N	22	22
PFN	Tip apex 6 month	Pearson correlation	1	0.634
		Sig (2 tailed)		0.020
		N	13	13
	Leg Length discrepancies at 6 months	Pearson correlation	0.634	1
		Sig (2 tailed)	0.020	
		N	13	13

In this study, the union rate at 6 weeks for the gamma nail was 19 (86.4%), but the union rate for the PFN was 84.6%. Comparable outcomes were observed at the six-month mark. The results were negligible with a p-value of 1.00. In the PFN group (n = 13), a significant positive connection was seen between tip-apex distance and leg length disparity (r = 0.634, p = 0.020). A significant positive connection was discovered in the Gamma Nail group (n = 22) (r = 0.560, p = 0.007).

In a prior trial involving the PFN group, 26 (52%) patients achieved union within 1-2 months, 22 (44%) within 2-3 months, and 2 (4%) within 3-4 months. The average time for union in the PFN group was 2.20 ± 0.50 months. The disparity in mean union time was significant (P < 0.0001), with the DHS group exhibiting a longer union time compared to the cephalomedullary nailing group.[20]

Limitations: It was a single centered study with a small sample size.

CONCLUSION

Our study indicated that both the gamma nail and proximal femoral nail are trusted devices for intertrochanteric fracture (Boyd and Griffin type II) treated by PFN vs. Gamaa nail. The comparison of the union rates at 6 weeks and 6 months, along with the pain scores, yielded similar results. Moreover, the results indicated that a greater tip apex at both 6 weeks and 6 months is associated with higher leg length discrepancies, as the Pearson correlation analysis revealed a significant p-value of 0.000.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Muhammad Awais Iqbal: Design and analysis of data
Zohaib Nadeem: Design and interpretation of data
Husnain Ali: Data entry
Mustafa Javed Bhalli: Article Writing
Laiba Ahsan: Data Collection
Saad Tauheed Rao: Data Collection

REFERENCES

1. Li Z, Gao J, Wu X, Chang Z, Liu X, Zhang L, Li M, Nie S. Risk factors for implant failure of PFNA–II in the treatment of intertrochanteric fractures (AO/OTA 31 A1 and A2). BMC Musculoskeletal Disorders. 2025 Aug 13;26(1):784. doi: 10.1186/s12891-025-09035-7
2. Trincado RM, Mori MA, Fernandes LS, Perlaky TA, Hungria JO. Epidemiology of proximal femur fracture in older adults in a philanthropical hospital in São Paulo. Acta Ortopédica Brasileira. 2022 Dec 16;30(6):e255963. doi: 10.1590/1413-785220223006e255963
3. Lavallière, M., Tremblay, M., Lefebvre, F., Billot, M. and Handrigan, G.A., 2020. Aging, obesity, and motor vehicle collisions. Frontiers in Sustainable Cities, 2, p.543093. https://doi.org/10.3389/frsc.2020.00033
4. Jang JM, Choi HS, Lee JS, Jeong KY, Hong HP, Ko SH. Femoral intertrochanteric fractures of the patients in the emergency department due to minor falls: special consideration in the middle-old to oldest-old patients. Annals of geriatric medicine and research. 2019 Sep 27;23(3):125. doi: 10.4235/agmr.19.0027
5. Cui SS, Zhao LK, Zhao WJ, Ma JX, Ma XL. Excess mortality for femoral intertrochanteric fracture patients aged 50 years and older treated surgically and conservatively in Tianjin, China: a cohort study. Orthopaedic Surgery. 2024 Jan;16(1):207-15. DOI: 10.1111/os.13925
6. Zhang Z, Qiu Y, Zhang Y, Zhu Y, Sun F, Liu J, Zhang T, Wen L. Global trends in intertrochanteric hip fracture research from 2001 to 2020: a bibliometric and visualized study. Frontiers in Surgery. 2021 Oct 28;8:756614. https://doi.org/10.3389/fsurg.2021.756614
7. Jonnes C, Shishir SM, Najimudeen S. Type II intertrochanteric fractures: proximal femoral nailing (PFN) versus dynamic hip screw (DHS). Archives of Bone and Joint Surgery. 2016 Jan;4(1):23. PMCID: PMC4733231 PMID: 26894214
8. Fu, C.W., Chen, J.Y., Liu, Y.C., Liao, K.W. and Lu, Y.C., 2020. Dynamic hip screw with trochanter-stabilizing plate compared with proximal femoral nail anti-rotation as a treatment for unstable AO/OTA 31-A2 and 31-A3 intertrochanteric fractures. BioMed Research International, 2020. DOI: 10.1155/2020/1896935
9. Badawy, E.B., El-Mowafy, H.M., Ghonim, H.F., Basiouny, M.H.E. and Elagroudy, E.E., 2022. Comparative study of gamma nail versus dynamic hip screw for the treatment of intertrochanteric hip fractures. Menoufia Medical Journal, 35(3), p.1535. DOI: 10.4103/eoj.eoj_92_23
10. Kyriakopoulos, G., Panagopoulos, A., Pasiou, E., Kourkoulis, S.K., Diamantakos, I., Anastopoulos, G., Tserpes, K., Tatani, I., Lakoumentas, J. and Megas, P., 2022. Optimizing fixation methods for stable and unstable intertrochanteric hip fractures treated with sliding hip screw or cephalomedullary nailing: A comparative biomechanical and finite element analysis study. Injury, 53(12), pp.4072-4085. DOI: 10.1016/j.injury.2022.10.006
11. Farhat, Y.A.A., Abdelwahab, A.M., Abdelsalam, M.A.M. and Megahed, R.M., 2021. Management Of Subtrochanteric Femoral Fractures Using Proximal Femoral Nail. The Egyptian Journal of Hospital Medicine, 85(2), pp.3535-3539. Doi: 10.21608/EJHM.2021.200584
12. Wen Q, Gu F, Su Z, Zhang K, Xie X, Li J, Sui Z, Yu T. Gamma Nail Combined with One Cannulated Compression Screw Fixation for Treating Pauwels Type III Femoral Neck Fractures in Young and Middle-Aged Adults: Clinical Follow-Up and Biomechanical Studies. Orthopaedic Surgery. 2023 Apr;15(4):1045-52. doi: 10.1111/os.13683
13. Eladawy, A.M. and El-Hewalaand, T.A.S., 2022. Outcome of Gamma Nail Fixation in Unstable Trochanteric Fracture of Femur. Zagazig University Medical Journal, 28(6.2), pp.198-204.
14. Majewski M. The impact of the CCD-angle on range of motion and cup positioning in total hip arthroplasty. DOI:10.1016/j.clinbiomech.2005.04.003
15. Li XP, Zhang P, Zhu SW, Yang MH, Wu XB, Jiang XY. All-cause mortality risk in aged femoral intertrochanteric fracture patients. Journal of Orthopaedic Surgery and Research. 2021 Dec 20;16(1):727. D OI: 10.1186/s13018-021-02874-9

16. Phang JK, Lim ZY, Yee WQ, Tan CY, Kwan YH, Low LL. Post-surgery interventions for hip fracture: a systematic review of randomized controlled trials. BMC Musculoskeletal Disorders. 2023 May 25;24(1):417. DOI: 10.1186/s12891-023-06512-9

17. Mereddy P, Kamath S, Ramakrishnan M, Malik H, Donnachie N. The AO/ASIF proximal femoral nail antirotation (PFNA): a new design for the treatment of unstable proximal femoral fractures. Injury. 2009 Apr 1;40(4):428-32. DOI: 10.1016/j.injury.2008.10.014

18. Loubignac F. Treatment of bimalleolar fractures in elderly. Orthopaedics & Traumatology: Surgery & Research. 2022 Feb 1;108(1):103137. DOI: 10.1016/j.otsr.2021.103137

19. Banan H, Al-Sabti A, Jimulia T, Hart AJ. The treatment of unstable, extracapsular hip fractures with the AO/ASIF proximal femoral nail (PFN)—our first 60 cases. Injury. 2002 Jun 1;33(5):401-5. https://doi.org/10.1016/S0020-1383(02)00054-2

20. Prakash AK, Shanthappa AH, Venkataraman S, Kamath A. A comparative study of functional outcome following dynamic hip screw and proximal femoral nailing for intertrochanteric fractures of the femur. Cureus. 2022 Apr 4;14(4). DOI: 10.7759/cureus.23803

Original Article **Open Access**

Association of TP53 rs1042522 Polymorphism with Clinicopathological Features of Breast Cancer in Patients from a Tertiary Care Center in Pakistan

Anum Sitai, Fouzia Shaikh, Rehan Imad, Ummiya Tahir, Zehra Ahmed

ABSTRACT

Objective: Breast cancer (BC) is the most common cancer among women worldwide and a leading cause of cancer-related mortality; Pakistan has one of the highest incidence rates in Asia, highlighting its significant public health burden. Mutations in a tumor suppressor gene TP53 have attracted much interest. Therefore, the aim of this study was to evaluate the association between clinicopathological characteristics of breast cancer patients and TP53 rs1042522 polymorphism.

Study Design & Setting: This cross-sectional study used non-probability consecutive sampling, including cases with adequate FFPE tissue and complete clinicopathological data. Collected variables comprised age at diagnosis, tumor laterality, histological type, tumor grade, pathological stage, and hormone receptor status, recorded according to standardized pathology reporting criteria. Genomic DNA was extracted from FFPE blocks using the Quick-DNA™ FFPE MiniPrep Kit, and DNA concentration and quality were assessed by spectrophotometry.

Methodology: Formalin-fixed paraffin-embedded (FFPE) tissue samples and clinical records of 48 histologically diagnosed breast carcinoma cases were analyzed. TP53 rs1042522 genotyping was performed using tetra-amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR). Associations between genotypes and clinicopathological variables were analyzed using Chi-square.

Results: Total of 48 female breast cancer patients were included. Invasive ductal carcinoma was the predominant histological subtype. TP53 rs1042522 genotypes were variably distributed across tumor grades, stages, and hormone receptor status and the results showed no statistically significant association ($p > 0.05$).

Conclusion: Study concluded with statement that, TP53 rs1042522 polymorphism showed variable distribution without significant association with clinicopathological features, suggesting a descriptive rather than predictive role in this population.

Keywords: *Breast Neoplasms, TP53 Protein, Polymorphism, Genetic, Polymerase Chain Reaction, Receptor,*

How to cite this Article:
Sitai A, Shaikh F, Imad R, Tahir U. Ahmed Z. Association of TP53 rs1042522 Polymorphism with Clinicopathological Features of Breast Cancer in Patients from a Tertiary Care Center in Pakistan. J Bahria Uni Med Dental Coll. 2026;16(2):601-608 DOI: https://doi.org/10.51985/JBUMDC2025885

Anum Sitai
M. Phil Candidate, Department of Pathology
Ziauddin University, Karachi
Email: anum.14955@zu.edu.pk

Fouzia Shaikh
Professor and HOD, Department of Pathology
Ziauddin University, Karachi
Email: fouzia.shaikh@zu.edu.pk

Rehan Imad
Assistant Professor, Department of Molecular Medicine
Ziauddin University, Karachi
Email: rehan.imad@zu.edu.pk

Ummiya Tahir
HOD of Histopathology Section, Department of Pathology
Ziauddin University and Hospital, Karachi
Email: ummiya.tahir@dzub.edu.pk

Zehra Ahmed
Assistant Professor, Department of Pathology
Ziauddin University, Karachi
Email: zehra.ahmed@zu.edu.pk

Received: 20-01-2025
1st Revision: 04-02-2026
Accepted: 08-04-2026
2nd Revision: 03-04-2026

INTRODUCTION

Breast cancer (BC) is the most prevalent disease among women worldwide and a primary cause of cancer-related deaths. According to the Shaukat Khanum Memorial Cancer Hospital & Research Centre cancer registry, breast cancer was the most commonly diagnosed malignancy in Pakistan in 2021, with 1,699 reported cases.[1,2] According to GLOBOCAN 2022, data from the International Agency for Research on Cancer indicate that breast cancer is the most frequently diagnosed cancer worldwide, with approximately 2.3 million new cases (11.7% of all cancers) and a mortality rate of 6.9%, ranking it among the leading causes of cancer-related deaths globally.[3]

Despite the recent improvements in treatment modalities, the disease continues to pose a great burden mainly in the low- and middle-income nations. The key causes of death in Pakistan are delays in diagnosis, a need to identify them through screening programs, and disparities in access to specialized care.[4,5] Additionally, advanced-stage disease at presentation is a significant factor that adversely affects treatment options and clinical outcomes. These observations

demonstrate that the knowledge of the nature of the disease in the local population should be better.

Breast cancer is a biologically heterogeneous disease, consisting of a wide spectrum of histopathological and molecular features. The TP53 rs1042522 polymorphism results in an arginine-to-proline substitution at codon 72 of the p53 protein.[6] This polymorphism has been studied broadly in different Countries, yet its clinical significance remains controversial. From a clinicopathological perspective, tumor grade, stage at diagnosis, and hormone receptor status are key indicators routinely used in pathological practice, as they reflect tumor aggressiveness, disease progression, and biological behavior, which may be influenced by underlying genetic variations such as TP53 polymorphisms.[7] However, these parameters are themselves influenced by complex interactions between genetic susceptibility, tumor biology, environmental exposures, and healthcare access.[8]

Due to these functional differences, rs1042522 has been continuously investigated for its relationship with breast cancer diagnosis and clinicopathological features. However, results have been reported inconsistent. Recent genomic studies further highlight evolving molecular patterns influencing breast cancer development globally.[9] Therefore, the objectives of this study were:

1. To evaluate the clinicopathological characteristics of breast cancer patients.

2. To assess the association between TP53 rs1042522 polymorphism and clinicopathological features.

3. To determine the relationship between TP53 rs1042522 genotypes and hormone receptor status.

METHODOLOGY:

This cross-sectional study was conducted after obtaining ethical approval from the Ethical Review Committee of Ziauddin University (ERC Approval Code: 10550625AAPAT). The study was carried out from January 1, 2025, to November 2025**.** Archived clinical records and formalin-fixed paraffin-embedded (FFPE) breast carcinoma tissue blocks were retrieved from the Department of Pathology, Ziauddin Medical Hospital and Laboratory, while all molecular procedures were performed at the Molecular Diagnostics and Research Laboratory (MDRL-1), Ziauddin University. A Waiver Certificate was obtained, as the researcher conducted a retrospective review of archived records/reports**,** and no direct interaction with patients took place during this research. Written informed consent had already been obtained from the patients or their legal guardians at the time of initial specimen submission. All procedures were conducted in accordance with institutional ethical standards and the principles of the Declaration of Helsinki.

The sample size was calculated using a single-population proportion formula, based on a previously reported TP53 mutation frequency of 0.66 among breast cancer patients, with a 95% confidence interval (Z = 1.96) and a margin of error of 13.12%. A slightly higher margin of error was used due to the exploratory nature of the study, limited patient availability, and feasibility constraints in a single-center setting. Non-probability consecutive sampling was then applied to include all eligible cases during the study period. (Ahmed et al. 2023)[11] (Datkile et al. 2023)[12] In order to cover all the eligible cases during the study, non-probability consecutive sampling was used.

To achieve methodological rigor and reliability of molecular analysis, eligible cases that qualify to be included in this study were selected on predetermined inclusion and exclusion criteria.[1,2]

Criteria used in the inclusion of the patients were: female patients, who had a histologically verified primary breast carcinoma, included in the study period, as specified by the World Health Organization (WHO) Classification of Breast Tumors, which puts more emphasis on the standardization of histopathological diagnosis, necessary in reproducible oncologic research. The cases where formalin-fixed paraffin-embedded (FFPE) tissue blocks were sufficient were considered as only FFPE-specimens are considered a valid marker of retrospective molecular research and have been demonstrated to provide DNA of adequate quality to facilitate polymerase chain reaction-based genotyping when properly extracted. Moreover, age at diagnosis, tumor laterality, histological subtype, tumor grade, pathological stage and hormone receptor (ER, PR, HER2) status where necessary as comprehensive clinical annotation is necessary to establish meaningful genotype phenotype interaction in molecular epidemiology research.[3]

To provide the consistency and comparability of breast cancer research with international standards, tumor grading and staging were recorded based on internationally accepted systems, such as the Nottingham histologic grading system and the American Joint Committee on Cancer (AJCC) TNM staging guidelines. Cases were eliminated when FFPE tissue samples were of poor quality, there was extensive necrosis or lack of sufficient tumor content conversely because degraded or low yielding DNA would negatively affect the accuracy of genotyping and provide either false-negative or non-reproducible results. Incomplete medical or pathological records of the patients were not included as well to eliminate the chances of information bias and provide strong statistical analysis of clinicopathological associations. Cases that had recurring breast tumors and those with the previous history of any other malignancy were eliminated because both conditions might confound genetic changes not directly related to primary breast carcinogenesis and hence confound the TP53 polymorphism association analysis. These criteria are consistent with the methodological guidelines of retrospective molecular pathology and genetic association studies, which guarantee internal validity and the reduction

of possible sources of bias STROBE Statement.

Clinicopathological information was obtained from pathology archives and included age at diagnosis, tumor laterality, histological subtype, tumor grade, pathological stage, and hormone receptor status (ER, PR, HER2). For quality control in molecular analysis, each T-ARMS PCR run included a known positive control (previously confirmed genotype) and a negative control (no-template control) to ensure assay specificity and to detect contamination. Genotyping was determined based on the presence of allele-specific bands visualized on agarose gel electrophoresis, corresponding to homozygous (CC, GG) and heterozygous (CG) patterns. A subset of samples was re-amplified to confirm reproducibility of results.

The grading and staging of tumors were reported based on the current international histopathological criteria. FFPE mini-prep was performed on the genomic DNA of FFPE tissue with the Quick-DNATM FFPE MiniPrep Kit (Zymo Research, USA) and concentration and purity of the DNA were measured by spectrophotometer. TP53 rs1042522 (Arg 72 Pro) polymorphism was picked up to be analyzed because it is functionally relevant, the minor allele frequency is above 5 percent and has been reported to be relevant to breast cancer susceptibility.

Tetra-amplification refractory mutation system polymerase chain reaction was used to genotype. A 25 ìL of the reaction mixture was used and consisted of 1 ìL of forward and reverse outer primers (10 pmol/ ìL), 1 ìL of forward and reverse inner primers, 5 ìL of DNA template (approximately 40 ng), 12.5 ìL of PCR master mix, and 5.5 ìL of nuclease-free water. The PCR design was that of a first round denaturing at 95 o C, 35 cycles of 95 o C 30 seconds, 56 o C 1 minute, 72 o C 1 minute and finally, a final extension of 72 o C 10 minutes. Primer sequences were as follows: forward outer—CCTCAGGGCAACTGACCG; reverse outer -GAAGGGCAGGCCCACCAC; forward inner -GGTGCAGGGGCCACGC; reverse inner -CCAGAGGCTGCTCCCCC. These cycling conditions and primer sets agree with confirmed standards of using these primers to genotype the rs1042522.

Agarose Gel Electrophoresis: PCR products were resolved on a 2% agarose gel in 1× TBE buffer, stained with ethidium bromide. Samples and a DNA ladder were electrophoresed and visualized under UV light to detect *p53* gene bands.

All the data was combined and analyzed by use of SPSS version 27. Clinicopathological characteristics were summarized using descriptive statistics and Chi-square or Fisher exact tests were used to determine the association between the TP53 rs1042522 genotypes and the categorical variables with statistical significance was set at $p < 0.05$.

Frequencies and percentages were used to summarize categorical variables such as marital status, clinical stage, tumor grade, hormone receptor status (estrogen receptor, progesterone receptor, and HER2), and breast cancer subtype in the description of the distribution of clinicopathologic characteristics. The age at diagnosis, a quantitative variable, was evaluated at the first instance to be tested about normality with the use of the Shapiro–Wilk test. The relationship of categorical clinicopathological variables and gene mutation status was analyzed using the Chi-square test of independency. In cases where the assumptions of the Chi-square test were not fulfilled particularly, when the anticipated number of cells was less than five in over 20 percent of the cells, the Fisher's exact test was used, and this assured a validity in the results.

RESULTS

The demographic and clinicopathological characteristics of the study population are summarized in Table 1. The total number of breast cancer cases used in the analysis presented in Table 1 is 48 confirmed. The above Table summarizes the age, marital status, tumor features, and clinical characteristics of 48 breast cancer patients. Most patients were older than 50 years, had left-sided tumors, invasive ductal carcinoma, were married, and were diagnosed mainly at stage 2 with moderately differentiated tumors

Table2 shows how different TP53 rs1042522 genotypes (CC, CG, GG) are distributed across tumor characteristics in breast cancer patients. No significant association was found between TP53 genotypes and tumor laterality, site, grade, stage, or nodal status (all p-values > 0.05).

Table 3 presents the distribution of TP53 rs1042522 genotypes across different histological subtypes of breast cancer. Invasive ductal carcinoma was the most common subtype observed in the study population. Although CC and CG genotypes were more frequently observed than GG, no statistically significant association was found between TP53 rs1042522 genotype distribution and breast cancer subtype ($p = 0.244$). Table 4, when genotypes were grouped as CC+CG versus GG, the combined CC+CG group was more frequently observed in higher tumor grades and across tumor stages; however, these differences were not statistically significant ($p > 0.05$). Although the high-risk allele group (CG + CC) was more frequently observed across higher tumor grades and stages, no statistically significant association was found with tumor grade ($p = 0.082$), age group ($p = 0.285$), or tumor stage ($p = 0.949$). In Table 5 Hormone receptor positivity, particularly ER and PR, was more frequently observed across tumor grades, stages, and sites; however, no statistically significant association was identified between clinicopathological variables and ER, PR, or HER2 status.

Show that ER and PR positivity is highest in well-differentiated and early-stage tumors and decreases with higher grade and stage, while HER2 positivity increases in poorly differentiated and advanced tumors. Marker expression

also differs by tumor site, with ER and PR more common in upper quadrants.

Table 1: Demographic and clinicopathological characteristics of breast

Variable	Frequency	%
Age at diagnosis (years)		
30–40	8	16.7
41–50	8	16.7
51–60	12	25.0
61–70	7	14.6
=71	13	27.1
Tumor laterality		
Left	26	54.2
Right	22	45.8
Site		
Upper Quadrant	12	25.0
Lower Quadrant	6	12.5
Central	12	25.0
Inner	2	4.2
Not specified	16	33.3
Histological type		
Invasive ductal carcinoma (NST)	39	81.3
Micropapillary carcinoma	1	2.1
Mucinous carcinoma	2	4.2
Lobular carcinoma	3	6.3
Metaplastic carcinoma	1	2.1
Microcapillary carcinoma	1	2.1
Solid papillary carcinoma	1	2.1
Marital Status		
Married	45	93.8
Unmarried	3	6.3
Tumor grade		
Well differentiated	6	12.5
Moderately differentiated	27	56.3
Poorly differentiated	15	31.3
Tumor Stage		
Stage 1	6	12.5
Stage 2	28	58.3
Stage 3	10	20.8
Stage 4	4	8.3
Nodal Stage		
Nodal stage 1	11	22.9
Nodal stage 2	9	18.8
Nodal stage 3	5	10.4
Not applicable	23	47.9

DISCUSSION

The clinicopathological characteristics of Pakistani breast cancer patients and their distribution in relation to the TP53 rs1042522 polymorphism are described in this study.

The majority of tumors presented at intermediate-to-high grade and advanced pathological stages, which was consistent with national and regional data. Delays in diagnosis are common in Pakistan because of limited screening programs, social cultural obstacles to early health care seeking as well as the problem of access to diagnostic centers and health care centers.[10] Tumor grade, stage, and hormone receptor status did not significantly correlate with any of the TP53 rs1042522 genotypes (Arg72/Pro72) found in clinicopathological groups.[11,12,13] These findings are in line with international meta-analyses, which have reported inconsistent or null associations between this polymorphism and breast cancer characteristics, suggesting that rs1042522 alone is unlikely to serve as a reliable clinicopathological marker in this population. The absence of a significant correlation among our population implies that rs1042522 estimation will not be a significant clinicopathological parameter within Pakistani patients with breast cancer. Although functional differences between the Arg72 and Pro72 variants have been reported in laboratory studies, translating these findings into consistent clinical patterns has proven difficult.[13] Experimental studies showed that the variant of Pro72 was related to increased transcriptional activation and turnover of cell cycle.[14] This highlights that germline TP53 polymorphisms, including rs1042522, have limited predictive value compared to well-established clinical indicators such as hormone receptor status and molecular subtype classification[15]

Several large-scale meta-analysis such as Diakité B et al., 2020; Zhuo W et al., 2009; Afzaljavan F et al., 2019 have been observed to find the association between TP53 rs1042522 and breast cancer susceptibility along with finding the tumor characteristics, which obtained heterogeneous results. The clinical relevance of this polymorphism may be dependent on population.[16] Such variability highlights the importance of conducting mix and specific studies, especially in controlled populations where genetic epidemiological data remain limited.[17]

Further rs1042522, other TP53 polymorphisms and related genes have been investigated for their potential modificational effects on the risk of breast cancer and its outcomes.[18] Studies exploring the haplotype structures and gene-gene interactions suggest that the isolated assessment of a single polymorphism may under estimate the complexity of TP53-mediated tumorigenesis.[19] This may partially explain the lack of consistent associations observed in many clinicopathological studies, including our findings.[20]

Consequently, genetic effects that might be detectable in well-screened populations could be unmasked in such areas

Table 2: Association of TP53 rs1042522 genotypes with clinicopathological variables

Variable	CC n (%)	CG n (%)	GG n (%)	Total	p-value
Tumor laterality					
Left	10 (38.5)	8 (30.8)	8 (30.8)	**26**	**0.149***
Right	9 (40.9)	11 (50.0)	2 (9.1)	**22**	
Site					
Upper quadrant	5 (41.7)	5 (41.7)	2 (16.7)	**12**	
Lower quadrant	2 (33.3)	2 (33.3)	2 (33.3)	**6**	**0.915***
Central / retroareolar	4 (33.3)	4 (33.3)	4 (33.3)	**12**	
Inner quadrant	1 (50.0)	1 (50.0)	0 (0.0)	**2**	
Not specified	7 (43.8)	7 (43.8)	2 (12.5)	**16**	
Tumor grade					
Well -differentiated	2 (33.3)	1 (16.7)	3 (50.0)	**6**	**0.123***
Moderately differentiated	13 (48.1)	9 (33.3)	5 (18.5)	**27**	
Poorly differentiated	4 (26.7)	9 (60.0)	2 (13.3)	**15**	
Pathological stage					
Stage I	2 (33.3)	2 (33.3)	2 (33.3)	**6**	
Stage II	14 (50.0)	8 (28.6)	6 (21.4)	**28**	**0317***
Stage III	2 (20.0)	6 (60.0)	2 (20.0)	**10**	
Stage IV	1 (25.0)	3 (75.0)	0 (0.0)	**4**	
Nodal stage					
Not applicable	10 (43.5)	7 (30.4)	6 (26.1)	**23**	
Nodal stage I	4 (36.4)	4 (36.4)	3 (27.3)	**11**	**0.149***
Nodal stage II	4 (44.4)	4 (44.4)	1 (11.1)	**9**	
Nodal stage III	1 (20.0)	4 (80.0)	0 (0.0)	**5**	
Total	19 (39.6)	19 (39.6)	10 (20.8)	**48**	

***** CC two Cytosine bases, *****CG one Cytosine and one Guanine**. *** GG means two Guanine bases**.**

Table3: Breast cancer subtypes with TP53 rs1042522 genotypes (n = 48)

Breast cancer subtype	CC n (%)	CG n (%)	GG n (%)	Total n (%)
Invasive ductal carcinoma	16 (41.0)	15 (38.5)	8 (20.5)	39 (100)
Micropapillary carcinoma	0 (0.0)	1 (100.0)	0 (0.0)	1 (100)
Mucinous carcinoma	0 (0.0)	0 (0.0)	2 (100.0)	2 (100)
Lobular carcinoma	2 (66.7)	1 (33.3)	0 (0.0)	3 (100)
Metaplastic carcinoma	1 (100.0)	0 (0.0)	0 (0.0)	1 (100)
Microcapillary carcinoma	0 (0.0)	1 (100.0)	0 (0.0)	1 (100)
Solid papillary carcinoma	0 (0.0)	1 (100.0)	0 (0.0)	1 (100)
Total	**19 (39.6)**	**19 (39.6)**	**10 (20.8)**	**48 (100)**

where late-stage disease is predominant.[21]

As far as clinical perspective is concerned, hormone receptor status and molecular subtype classification have shown as more absolute predictors of prognosis and treatment response than individual germ line polymorphisms. Although TP53 alterations are frequent in breast cancer, particularly in high-grade and triple-negative tumors, germ line polymorphisms such as rs1042522 appear to have limited stand-alone predictive value in routine clinical practices, which supports the present study findings.[22]

Lastly, TP53 rs1042522 represents a biologically relevant polymorphism with demonstrable functional effects at the molecular level, its clinical impact appears to be dependent. The absence of strong associations in the present study supports the assertion that this polymorphism alone is unlikely to serve as a reliable clinicopathological marker in Pakistani breast cancer patients.

Despite its small sample size, single-center design, and absence of long-term clinical follow-up, this study provides valuable baseline information on TP53 rs1042522 polymorphism in Pakistani breast cancer patients. The results

Table 4: Clinicopathological features with TP53 rs1042522 risk allele groups (n = 48)

Clinicopathological feature	High-risk n (%)	Low-risk n (%)	Total	p-value
Tumor grade				
Well differentiated	3 (50.0)	3 (50.0)	6	**0.082**
Moderately differentiated	19 (70.4)	8 (29.6)	27	
Poorly differentiated	14 (93.3)	1 (6.7)	15	
Age group				
30–40	6 (75.0)	2 (25.0)	8	
41–50	4 (50.0)	4 (50.0)	8	**0.285**
51–60	9 (75.0)	3 (25.0)	12	
61–70	7 (100.0)	0 (0.0)	7	
>71	10 (76.9)	3 (23.1)	13	
Tumor stage				
Stage I	4 (66.7)	2 (33.3)	6	
Stage II	21 (75.0)	7 (25.0)	28	**0.949**
Stage III	8 (80.0)	2 (20.0)	10	
Stage IV	3 (75.0)	1 (25.0)	4	
Total	**36 (75.0)**	**12 (25.0)**	**48**	

*High-risk = CG + CC | Low- risk = GG

Table 5: Association of clinicopathological variables with hormone receptor status (n = 15)

Variable	ER Positive n (%)	ER Negative n (%)	p-value	PR Positive n (%)	PR Negative n (%)	p-value	HER2 Positive n (%)	HER2 Negative n (%)	p-value
Tumor grade									
Well differentiated	1 (100.0)	0 (0.0)		1 (100.0)	0 (0.0)		0 (0.0)	1 (100.0)	
Moderately differentiated	6 (85.7)	1 (14.3)	0.700	5 (71.4)	2 (28.6)	0.700	1 (16.7)	5 (83.3)	0.823
Poorly differentiated	5 (71.4)	2 (28.6)		5 (71.4)	2 (28.6)		2 (40.0)	3 (60.0)	
Tumor stage									
Stage I	1 (100.0)	0 (0.0)		1 (100.0)	0 (0.0)		0 (0.0)	1 (100.0)	
Stage II	6 (85.7)	1 (14.3)	0.753	5 (71.4)	2 (28.6)	0.700	1 (16.7)	5 (83.3)	0.823
Stage III	5 (71.4)	2 (28.6)		5 (71.4)	2 (28.6)		2 (40.0)	3 (60.0)	
Tumor site									
Upper quadrant	11 (78.6)	3 (21.4)		11 (78.6)	3 (21.4)		3 (27.3)	8 (72.7)	
Lower quadrant	1 (100.0)	0 (0.0)	0.700	0 (0.0)	1 (100.0)	0.605	0 (0.0)	1 (100.0)	0.086
Total	**12 (80.0)**	**3 (20.0)**		**11 (73.3)**	**4 (26.7)**		**3 (20.0)**	**12 (80.0)**	

ER = Estrogen receptor, PR = Progesterone receptor, HER2 = Human epidermal growth factor receptor 2.

Figure 1: shows TP53 rs1042522 genotype distribution by tumor grade



emphasize the need for larger, multi-center studies that combine genomic profiling with long-term clinical data to better understand the role of TP53 variants and their potential impact on disease characteristics in this population.

Limitation of Study: The study is limited by its small sample size and single-center design, which may affect generalizability. The absence of a control group limits assessment of the association between TP53 rs1042522 polymorphism and disease susceptibility, and the modest sample size reduces statistical power to detect subtle associations. Allele frequency comparison with the general population and long-term clinical outcomes were not assessed. The relatively high frequency of "not specified" tumor sites reflect routine limitations of histopathology record documentation in retrospective studies, where quadrant details are not always consistently recorded in archived pathology reports. Although samples were collected from Ziauddin Hospital, a tertiary care center that receives patients from across Pakistan rather than only Karachi, Sampling patients from across Pakistan enhances population diversity, thereby increasing the relevance and applicability of the findings.

CONCLUSION

In conclusion, TP53 rs1042522 polymorphism showed variable distribution among breast cancer patients but was not significantly associated with clinicopathological characteristics in this study. These findings suggest that this polymorphism has limited clinical utility as a predictive marker in this population. Further large-scale, multicenter studies with comprehensive genetic profiling are recommended to better clarify its potential role in breast cancer.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Anum Sitai: data collection, statistical analysis and manuscript drafting
Fouzia Shaikh: supervised the study, critically revised the manuscript and approved the final version
Rehan Imad: conducted the molecular methodology and genotyping analysis
Ummiya Tahir: Conceived the study and provided all histopathological material and clinicopathological data
Zehra Ahmed: assisted in manuscript writing and literature review

REFERENCES:

1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022; 66:15–23. DOI: https://doi.org/10.1016/j.breast.2022.08.010
2. Pink Ribbon Pakistan. The alarming rise of breast cancer deaths in Pakistan [Internet]. Karachi: Pink Ribbon Pakistan; 2024 [cited 2025 Dec 21]. Available from: https:// pinkribbon.org. pk/the-alarming-rise-of-breast-cancer-deaths-in-pakistan/
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. DOI: https://doi.org/10.3322/caac.21660
4. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. DOI: https://doi.org/10.1136/bmj.m4087
5. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019; 5:66. DOI: https://doi.org/10.1038/s41572-019-0111-2 \
6. Syeed N, Husain SA, Sameer AS, Abdullah S, Qadri Q, Siddiqi MA. TP53 R72P polymorphism in breast cancer patients of Kashmir. Asian Pac J Cancer Prev. 2011;12(3):621–625.
7. Blondeaux E, Arecco L, Punie K, Graffeo R, Toss A, De Angelis C, Trevisan L, Buzzatti G, Linn SC, Dubsky P, Cruellas M. Germline TP53 pathogenic variants and breast cancer: a narrative review. Cancer Treat Rev. 2023; 114:102522.
8. Nausheen H, Ahmed R, Khan S, Fatima S, et al. Clinicopathological characteristics of molecularly classified groups of invasive ductal breast carcinoma in Pakistani women. Pak J Med Dent. 2022;11(2):3–8.
9. Sandoval RL, Bottosso M, Tianyu L, Polidorio N, Bychkovsky BL, Verret B, Gennari A, Cahill S, Achatz MI, Caron O, Imbert-Bouteille M. TP53-associated early breast cancer: new observations from a large cohort. JNCI: Journal of the National Cancer Institute. 2024 Aug;116(8):1246-54.
10. World Health Organization. WHO classification of tumours of the breast. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
11. Bonin S, Hlubek F, Benhattar J, Denkert C, Dietel M, Fernandez PL, et al. Multicentre validation study of acids extraction from FFPE tissues. Virchows Arch. 2010;457(3): 309–17
12. Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and histopathological analysis of FFPE tissue: how well do you know your specimen? Arch Pathol Lab Med. 2014;138(11): 1520–30. doi:10.5858/arpa.2013-0691-RA.
13. Afzaljavan F, Alizadeh E, Ghaderian SMH, Akbari MT. TP53 codon 72 polymorphism (rs1042522) and breast cancer risk: case-control study and meta-analysis. Sci Rep. 2019; 9:12776. doi: https://10.1038/s41598-019-49120-1
14. Syeed N, Husain SA, Sameer AS, Abdullah S, Qadri Q, Siddiqi MA. TP53 R72P polymorphism in breast cancer patients of Kashmir. Asian Pac J Cancer Prev. 2011;12(3):621–625.
15. Nausheen H, Ahmed R, Khan S, Fatima S, et al. Clinicopathological characteristics of molecularly classified groups of invasive ductal breast carcinoma in Pakistani women. Pak J Med Dent. 2022;11(2):3–8.

16. Wu D, Zhang Z, Chu H, Li H, Wang M, Zhang Z. Intron 3 sixteen base pair duplication polymorphism of TP53 contributes to breast cancer susceptibility. PLoS One. 2013;8(4): e61662. doi: https://10.1371/journal.pone.0061662

17. Wu D, Zhang Z, Chu H, Li H, Wang M, Zhang Z. Intron 3 sixteen base pair duplication polymorphism of TP53 contributes to breast cancer susceptibility. PLoS One. 2013;8(4): e61662. doi: https://10.1371/journal.pone.0061662

18. Icen-Taskin I, Calik M, Ates O. TP53 rs1042522 polymorphism and early-onset breast cancer risk in Turkish women. J Res Med Sci. 2020; 25:25. doi: https://10.4103/jrms.JRMS_652_19

19. Cheng H, Ma B, Huang W, Wang X, Wang Y. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms on breast cancer risk. Mol Biol Rep. 2012;39(10):9781–9788. doi: https://10.1007/s11033-012-1842-4

20. Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020;6(2):98–110. doi: https://10.1016/j.trecan.2019.11.007

21. Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, et al. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 2021;10(23):8581–8594. doi: https://10.1002/cam4.4361

22. Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020;6(2):98–110. doi: https://10.1016/j.trecan.2019.11.007

Original Article **Open Access**

Efficacy of Topical Phenytoin vs Normal Saline Dressing in Management of Diabetic Ulcers

Jawad Azeem, Umer Rathore, Naveed Ahmad, Bilal Nagra, Arslan Hamid, Waleed Umer

ABSTRACT

Objective: To compare the outcomes of topical phenytoin vs normal saline (NS) dressings to treat diabetic foot ulcer (DFU).

Study Design and Setting: Quasi-experimental study conducted in the Department of General Surgery, Pak Emirates Military Hospital, Rawalpindi, Pakistan, from January 2024 to June 2024. The study was carried out under standardized clinical protocols, and all patients were managed in a uniform hospital environment to minimize variability in treatment practices and ensure consistency in outcome assessment.

Methodology: One hundred and ten (110) patients were segregated into two equal groups; (1) Phenytoin dressings group, (2) NS dressings group. Outcomes of these groups were compared. A statistical package for Social Sciences (SPSS) version 23 was utilized to assess the results. Data regarding demographic variables, clinical presentation, and wound characteristics were collected systematically using a structured proforma, and all patients were followed regularly to monitor progress and response to treatment.

Results: One hundred and ten (n=110) patients were equally segregated into two groups. In the Phenytoin group, 50(90.90%) patients had improvement in wound (reduction in Wagner Grade) and in NS group 40(72.72%) patients had wound improvement (p-value 0.01). In the Phenytoin group, 2(3.63%) patients developed local complications and in NS group 7(12.72%) patients had local complications (p-value 0.08). In the Phenytoin group, 46(83.63%) patients had complete healing and in NS group 37(67.27%) patients had complete healing (p-value 0.04). Additionally, patient satisfaction was higher in the Phenytoin group, reflecting better overall acceptance of the treatment modality.

Conclusion: Phenytoin dressings were found to be more effective as compared to NS dressings in promoting healing in DFU, with improved clinical outcomes and higher patient satisfaction.

Key Words: Diabetic foot ulcers, Healing, Normal saline dressings, Outcomes, Phenytoin dressings.

How to cite this Article:
Azeem J, Rathore U, Ahmad N, Nagra B, Hamid A, Umer W. Efficacy of Topical Phenytoin vs Normal Saline Dressing in Management of Diabetic Ulcers. J Bahria Uni Med Dental Coll. 2026;16(2):609-14 DOI: https://doi.org/10.51985/JBUMDC2025878

Jawad Azeem
Resident, Department of General Surgery
NUMS Islamabad
Email: jawadzaeem206@gmail.com

Umer Rathore
Classified Surgeon, Department of General Surgery
NUMS Islamabad
Email: omarrahore@hotmail.com

Naveed Ahmad
Classified Surgeon, Department of General Surgery
NUMS Islamabad
Email: amcolian22@gmail.com

Bilal Nagra
Resident, Department of General Surgery
NUMS Islamabad
Email: nagra.pk121@gmail.com

Arslan Hamid
Consultant, Department of General Surgery
NUMS Islamabad
Email: drarslanhameed@gmail.com

Waleed Umer
Consultant, Department of General Surgery
NUMS Islamabad
Email: waleed.c4@gmail.com

Received: 23-12-2025
1st Revision: 06-01-2026
Accepted: 06-04-2025
2nd Revision: 02-02-2026

INTRODUCTION

Diabetes Mellitus (DM) is common chronic metabolic disorder which is characterized by abnormally increased blood sugar levels in human body.[1] It is one of the most common chronic diseases with approximately 10.5% of the global population getting affected with DM as per 2021 global data.[2] A research study conducted in our country (Pakistan) documented the prevalence of DM to be 12.16%.[3] It is a common chronic disease which affects multiple organs and systems in the human body with drastic negative consequences and complications. One of the most fearful complications of DM, which is commonly faced by surgeons all around the world in their routine clinical practice, is diabetic foot ulcer (DFU). The lifetime risk of developing DFU in diabetic patients is 19%–34%.[4] Pathophysiology of DFU is multifactorial and it may occur due to neuropathy, angiopathy, osteoarthropathy and/or reduced immunity against infections.[5] DFU has increased risk of developing wound infection which at times becomes difficult to treat and can lead to the formation of gangrene and ultimately results in amputation if left untreated. Hence, this

complication is significantly associated with increased suffering of patients and also adds to the financial burden on both patients and the healthcare system of the country.

The management of DFU requires combined efforts of a multidisciplinary team and its outcome depends upon the severity and grade of the ulcer. Wegner classification is a common classification system used worldwide to label the severity of a DFU.[6] Superficial and deep foot ulcers (Wegner grade I/II) have traditionally been managed using Normal Saline (NS) soaked serial dressings to keep the ulcer clean and promote the growth of healthy granulation tissue.[7] However, at times this conventional approach does not deliver satisfactory results. Wound healing with this method may be slow or incomplete, and patients may develop local or systemic complications despite good compliance to treatment. Therefore, surgeons have been exploring various modified treatment approaches to achieve better and more favorable outcomes. The goal of these newer modalities is to promote early healing and reduce disease progression and complications. Using phenytoin dressing to treat DFU is a relatively novel method gaining attention. As compared to conventional NS dressings, topical phenytoin is proposed to provide improved outcomes and reduced complication rates.

A study conducted in California documented that topical phenytoin dressings significantly enhanced wound healing and provided better results.[8] Another prospective comparative study conducted in India demonstrated superior outcomes with phenytoin dressings compared to NS dressings in terms of earlier and improved healing of DFU.[9] In a systematic review consisting of 23 studies, it was concluded that although topical phenytoin appears to enhance DFU healing, the available evidence is still insufficient to support its routine use, and further large-scale studies are required.[10]

At present, surgeons in various parts of our country are practicing different techniques to achieve early and better healing of DFU and reduce complications. These practices are primarily based on personal preferences and departmental protocols rather than strong evidence-based guidelines. The data on this subject within the local population is still limited. Therefore, a comparative study evaluating conventional NS dressings versus topical phenytoin dressings is essential to establish the superiority of one technique over the other based on solid evidence. Such data will aid surgeons in selecting optimal treatment strategies and improving overall patient outcomes. Additionally, it may contribute towards the development of standardized national guidelines for DFU management and promote cost-effective, evidence-based clinical practice in resource-limited healthcare settings.

METHODOLOGY

A quasi-experimental study was done at the Department of General Surgery, Pak Emirates Military Hospital, Rawalpindi, over a 6-month period (January 2024 to June 2024). The ethical review board's approval (ERC/78/24) was acquired. The WHO Sample Size calculator was used to calculate the sample size, using following parameters: 90% power of the test, 5% level of significance, 63% wound healing after phenytoin dressing and 33% after NS dressing.[11] Based on these, the total sample size of 130 patients was calculated. However, out of these 20 patients, loss to follow-up, resulting in final sample size of 110 patients (55 patients in each group). This information is displayed below in Figure I: -

Figure 1: Patient flow diagram (n = 110)



We included male and female diabetic patients into our study, aged between 20–60 years, who remained compliant with anti-glycemic medications and presented to the Surgical Out Patient Department (OPD) or Emergency Department of our hospital with DFU (Wegner Grade I and II). We ensured that all participants had a clear diagnosis of diabetes mellitus and were on regular follow-up prior to presentation, in order to maintain uniformity in baseline characteristics. In addition, detailed clinical history including duration of

diabetes and prior ulcer episodes was documented for better baseline assessment.

We excluded patients who fulfilled any of the following criteria: Wegner Grade of 3 or more, autoimmune disease, malignancy, significantly malnourished (evaluated by anthropometric assessment), absent lower limb distal pulses, monophasic flow on doppler ultrasound. Patients with acute abscess/sepsis and those who didn't provide consent were also eliminated from the research. This was done to minimize confounding factors that could independently affect wound healing and skew the results of the study. Careful screening ensured inclusion of a relatively homogenous study population.

Participants' selection was from "non-probability consecutive sampling". Objectives of the study were explained to the participants in detail and informed written consent was obtained before inclusion in the study. Age and gender of the patients were recorded in a predesigned proforma. Obesity status (BMI =30) of all patients was also assessed and documented in data proforma. Distal neuro-vascular assessment of lower limbs was also done in all patients. Pedal blood flow was assessed clinically as well as with adjunct investigations. Doppler ultrasound was used to check the flow in lower limb vessels. Ankle-brachial index (ABI) was also checked if there was suspicion of peripheral arterial disease (PAD). Neurological assessment was done by checking proprioception, vibration and fine touch sensations to assess the features of diabetic neuropathy. The presence of foot infection was assessed by checking clinical parameters including erythema, abnormal discharge, crepitus, and foul smell. DFU area was measured in cm^2 using a standardized method and Wegner classification was used to record the grade of the ulcer. For patients with suspicion of osteomyelitis or underlying bone abscess, X-ray was done for confirmation, while MRI was advised for equivocal cases to improve diagnostic accuracy. We also recorded important laboratory parameters including hemoglobin (Hb) and HBA1C levels of all participants from our hospital laboratory. Diabetologist and podiatric teams were also involved in management to optimize glycemic control and provide comprehensive foot care, ensuring a multidisciplinary approach for all patients.

Participants were divided equally into Phenytoin dressing group and NS dressing group by using computer-generated random allocation lists. In Phenytoin dressing group, 100 mg vial of phenytoin was dissolved in 5 mL of sterile 0.9% NaCl and this suspension was used to soak sterile gauze. This soaked gauze was then applied directly over the wound after thorough cleaning and covered with another dry sterile gauze; dressing was changed twice daily. In the NS dressing group, 0.9% NS-soaked sterile gauze was used and changed twice daily. Patients and attendants were trained to continue wound care themselves if professional assistance was not available, and written instructions were also provided to improve compliance and uniformity of technique.

Weekly follow-up visits were planned for 4 weeks, during which outcomes were assessed and compared between groups. During each visit, wound size, granulation tissue formation, and signs of infection were reassessed systematically. Results were evaluated in terms of wound improvement defined as reduction in ulcer grade as per Wegner classification. Appearance of any local complication was also recorded. Patients were further compared in terms of complete ulcer healing and overall satisfaction with the treatment modality, ensuring both clinical and patient-centered outcomes were adequately addressed.

The Statistical Package for Social Sciences (SPSS) version 23 was utilized to evaluate the final results. Categorical variables (gender, obesity, wound improvement, local complication, complete healing and patient satisfaction) were represented as frequency and percentage, and the Chi-Square test was used for comparison. The Shapiro-Wilk test assessed normality of quantitative data (age, Hb, HBA1C). Mann-Whitney U test was applied for non-normally distributed data, while independent sample t-test was used for normally distributed variables. A p-value of <0.05 was considered statistically significant. Additionally, data validation and cleaning procedures were performed prior to analysis to ensure accuracy, and results were interpreted with consideration of potential confounding factors and study limitations.

RESULTS

Our participant's age was 51.04±5.23 years (mean ± SD). 99(90%) of the participants were male and 11(10%) were female. These parameters are shown below: - Quantitative values are expressed as median (interquartile range: IQR). Mann-Whitney U test was applied. Hb(g/dL) of participants was 11.37±1.62 (mean ± SD). HBA1C (%) of patients was 9.70± 1.07. Table II shows this comparison between the participants: In Phenytoin group, 50(90.90%) patients had improvement in wound (reduction in Wagner Grade) and in NS group 40(72.72%) patients had wound improvement (p-value 0.01). In Phenytoin group, 2(3.63%) patients developed local complications and in NS group 7(12.72%) patients had local complications (p-value 0.08). In Phenytoin group, 46(83.63%) patients had complete healing and in NS group 37(67.27%) patients had complete healing (p-value 0.04). 46(83.63%) patients were over-all satisfied with the treatment in Phenytoin group and 37(67.27%) patients were over-all satisfied with the treatment in NS group (p-value 0.04). These results are demonstrated below:

DISCUSSION

In our study, age of the participants was 51.04±5.23 years (mean ± SD). Yao et al, in their study mentioned that DFU was found most commonly in age group 50-59 years, which matches the results of our study.[12] Majority of our participants (90%) were male and only 10% were female. As our research

was done in a military hospital and majority of the entitled patients in military are of male gender, so this fact may have contributed to the gender bias. Iacopi et al, found that male population is affected more commonly with DFU as compared to women (73% male vs 27% female), which matches with the results of our study.[13] 9.09% of our participants were obese with BMI =30. 5.10% of the general population of Pakistan was found to be obese in a research done by Asif et al.[14] This difference may be due to the fact that their research was done on general population of Pakistan, however we added only diabetic patients in our work. Hb(g/dL) of our participants was 11.37±1.62 (mean ± SD). HBA1C of our patients was 9.70±1.07 indicating poorly controlled DM in our patients, which may have contributed to the risk of formation of DFU and development of other complications and may have resulted in the poor heling of the wounds. We found that DFU that was treated with phenytoin dressings showed better improvement in wound as compared to conventional NS dressings. We also noted that Phenytoin dressing resulted in better results as compared to NS dressing in terms of complete healing of the DFU by the end of 4 weeks period. In our study the incidence of local wound complications was reduced with Phenytoin dressing in comparison to conventional NS dressings, however the difference between them was not statistically significant. Shaw et al conducted a similar study and found no difference in DFU healing with phenytoin dressing as compared to NS dressing.[15] These findings don't align with the results that we documented in our study. Ahmad et al conducted a similar study upon our local population in Rawalpindi, Pakistan and found that the topical phenytoin enhances and promotes the healing of DFU as compared to conventional saline soaked dressings which matches the results of our study.[16] Patil et al in a prospective study documented that Phenytoin dressing reduces the formation of slough and discharge from DFU and significantly reduces length of stay in hospital.[17] Bharathi Mohan et al, Adana et al and C. et al conducted similar researches and supported the use of Phenytoin dressings to promote healing in DFU, matching the results of our research. [18,19,20]

DFU is one of the most serious complications of long-standing DM encountered by surgeons in their routine clinical practice. DM results in angiopathy, neuropathy and increased susceptibility of infection which play their part in the development of DFU. If not properly managed, DFU may progress to develop local and systemic complications. Patients

Table1: Comparison of demographic features (n = 110)

Parameters	Study Groups				P-value
	Phenytoin Group (n=55)		NS Group (n=55)		
Age(years), median (interquartile range, IQR)	55 (IQR: 7.0)		48 (IQR:5.0)		<0.001
Gender, (%)	Male	50(90.90%)	Male	49(89.09%)	0.75
	Female	05(9.09%)	Female	6(10.09%)	
Obesity, %	4(7.27%)		5(9.09%)		0.72

Qualitative values are expressed as frequency (percentage), and chi-square test was applied

Table 2: Comparison of laboratory parameters (n = 110)

Parameters	Phenytoin Group (n=55)	NS Group (n=55)	p-value
Hb(g/dL), median (interquartile range, IQR)	11(IQR:2.00)	12(3.10%)	0.12
HBA1C(%), median (interquartile range, IQR)	09(IQR:1.10)	9.80(1.60%)	<0.001

Quantitative values are expressed as median (interquartile range). Mann-Whitney U test was applied

Table 3: Comparison of outcomes (n = 110)

Outcome	Phenytoin Group (n=55)	NS Group (n=55)	p-value
Wound improvement, n(%)	50(90.90%)	40(72.72%)	0.01
Complication, n(%)	2(3.63%)	7(12.72%)	0.08
Complete healing, n(%)	46(83.63%)	37(67.27%)	0.04
Satisfaction, n(%)	46(83.63%)	37(67.27%)	0.04

Qualitative values are expressed as frequency (percentage), and chi-square test was applied.

may develop dry or wet gangrene and can end up in limb amputation or may also develop life threatening sepsis.[21] All these complications drastically affect the health and quality of life of patients and also enhance the financial burden on the patients and health care systems. But with appropriate care and treatment, satisfactory healing of DFU can be achieved and these complications can be prevented. Surgeons have been trying and testing various treatment methods to promote effective healing of DFU. Topical phenytoin dressing is one of these new modified techniques which is a simple, cheap and easily available treatment of DFU. It helps in achieving early and enhanced healing as proven by the results of our study. As compared to the traditional NS dressings, topical phenytoin dressings have provided better wound healing. The phenytoin dressings also deliver better patient satisfaction as compared to the NS dressings. Phenytoin is believed to have enhanced wound healing properties as it increases the proliferation of fibroblasts and enhances the growth of healthy granulation tissue in chronic ulcers. Due to its low cost and easy availability, it is a good choice to effectively treat DFU in underdeveloped and developing nations, where patients may not have easy access to expensive advanced wound care facilities and health care systems, and health insurance may not cover treatment expenses. Moreover, we also found in our study that phenytoin dressings have resulted in reduced incidence of local wound complications as compared to conventional dressings. Although this difference was not statistically significant in our study, we suggest that further large-scale studies need to be conducted with larger sample sizes, longer follow-up, and more diverse populations to support the results of our study.

In addition, incorporation of standardized wound assessment tools and objective healing parameters in future research may provide more robust evidence regarding the efficacy of phenytoin dressings. Patient education regarding glycemic control, foot hygiene, and early reporting of ulcers is equally important to optimize outcomes. Multidisciplinary management involving surgeons, endocrinologists, and wound care specialists can further enhance healing rates and reduce recurrence, thereby improving overall patient prognosis.

Limitations: Single-center and limited follow-up period are the few limitations of our study. Ulcer recurrence and long-term complications were not evaluated. Variations in the demographic features of the participants like age and gender could have impacted the outcomes of the study. Moreover, variation in Hb, HbA1C and control of blood glucose level may have affected the outcomes. The correlation between gender, age, obesity, Hb, HBA1C levels with the treatment outcomes was not established. The research lacks generalizability to the broader community especially to the local non-military civilian female population. Variations in daily wound care could also have affected the outcomes. Additionally, differences in patient compliance, nutritional status, and concurrent comorbidities were not fully accounted for, which may have introduced further bias and influenced healing rates and overall treatment effectiveness across the study population.

CONCLUSION

For treating DFU, topical phenytoin dressings provide better results as compared to NS dressings in terms of enhanced wound healing and overall better patient's satisfaction. Incidence of local wound complications was less with phenytoin dressings; however, this difference was not statistically significant.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Jawad Azeem: Conception, design, analysis and interpretation of data
Umer Rathore: Conception, design, analysis and interpretation of data, Proof reading
Naveed Ahmad: Conception, design, analysis and interpretation of data
Bilal Nagra: Conception, design, analysis and interpretation of data
Arslan Hamid: Conception, design, analysis and interpretation of data
Waleed Umer: Conception, design, analysis and interpretation of data**,** Proof reading

REFERENCES

1. Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. 2020;10(4):174-188. https://doi.org/10.4103/ajm.ajm_53_20
2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119. https://doi.org/10.1016/ j.diabres.2021. 109119
3. Akhtar S, Ali A, Ahmad S, Khan MI, Shah S, Hassan F. The prevalence of foot ulcers in diabetic patients in Pakistan: a systematic review and meta-analysis. Front Public Health. 2022;10:1017201. https://doi.org/10.3389/fpubh.2022.1017201
4. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023;46(1):209-221.
5. Kim J. The pathophysiology of diabetic foot: a narrative review. J Yeungnam Med Sci. 2023;40(4):328-334. https://doi.org/10.12701/jyms.2023.00731
6. Shah P, Inturi R, Anne D, Jadhav D, Viswambharan V, Khadilkar R, et al. Wagner's classification as a tool for treating diabetic foot ulcers: our observations at a suburban teaching hospital. Cureus. 2022;14(1):e21501. https://doi.org/10.7759/cureus.21501
7. Sadiq K, Shivakumar Y, Burra E, Shahid K, Tamene Y, Mody S, et al. Topical phenytoin improves wound healing with analgesic and antibacterial properties and minimal side effects: a systematic review. Wounds. 2024;36:50–60.

8. Nagaraj J, Subbiah V. The efficacy of local insulin versus topical phenytoin or normal saline in diabetic foot ulcer management: a prospective comparative study. Cureus. 2022;14(10):e30461. https://doi.org/10.7759/cureus.30461

9. Barry CP, Hameed MSS, Sathyanarayanan A. Efficacy of topical phenytoin in the management of diabetic foot ulcers: a systematic review. Cureus. 2025;17(7):e87517. https://doi.org /1 0.7759/cureus.87517

10. Pratika A, Dayal A, Patel N. Effectiveness of topical phenytoin versus normal saline dressing in the management of diabetic foot ulcers: a non-randomized interventional study. Res J Med Sci. 2025;19:214-220. https://doi.org/10.36478/ makrjms.2025. 2.214.220

11. Yao Y, Chen L, Qian Y. Age characteristics of patients with type 2 diabetic foot ulcers and predictive risk factors for lower limb amputation: a population-based retrospective study. J Diabetes Res. 2024;2024:2380337. https://doi.org/10.1155/ jdr/2380337

12. Iacopi E, Pieruzzi L, Riitano N, Abbruzzese L, Goretti C, Piaggesi A. The weakness of the strong sex: differences between men and women affected by diabetic foot disease. Int J Low Extrem Wounds. 2023;22(1):19-26. https://doi.org/ 10.1177/1534734620984604

13. Asif M, Aslam M, Altaf S, Atif S, Majid A. Prevalence and sociodemographic factors of overweight and obesity among Pakistani adults. J Obes Metab Syndr. 2020;29(1):58-66. https://doi.org/10.7570/jomes19039

14. Shaw J, Hughes CM, Lagan KM, Stevenson MR, Irwin CR, Bell PM, et al. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med. 2011;28(10):1154-1157. https://doi.org/10.1111/j.1464-5491.2011.03309.x

15. Ahmed A, Ahmed MI. A comparison of efficacy of topical use of phenytoin and vaseline gauze dressing with vaseline gauze dressing alone in healing of diabetic foot ulcers. J Postgrad Med Inst. 2014;28(3):297-302.

16. Patil V, Patil R, Kariholu PL, Patil LS, Shahapur P. Topical phenytoin application in grade I and II diabetic foot ulcers: a prospective study. J Clin Diagn Res. 2013;7(10):2238-2240. https://doi.org/10.7860/JCDR/2013/5713.3480

17. Bharathi Mohan P, Chapa UK, Chittoria RK, Chavan V, Aggarwal A, Gupta S, et al. Role of phenytoin in diabetic foot ulcers. J Cutan Aesthet Surg. 2020;13(3):222-225. https://doi.org/10.4103/JCAS.JCAS_48_19

18. Adana P, Dayal A, Patel N. Effectiveness of topical phenytoin versus normal saline dressing in the management of diabetic foot ulcers: a non-randomized interventional study. Res J Med Sci. 2025;19:214-220. https://doi.org/10.36478 /makrjms.2025.2.214.220

19. C T, Banu AS, Ganesan S. Evaluating the efficacy of topical phenytoin in the healing of neuropathic diabetic foot ulcers: a comparative study. Cureus. 2024;16(6):e63282. https://doi.org/10.7759/cureus.63282

20. Aalaa M, Vahdani AM, Mohajeri Tehrani M, Mehrdad N, Zohdirad M, Sadati M, et al. Epidemiological insights into diabetic foot amputation and its correlates: a provincial study. Clin Med Insights Endocrinol Diabetes. 2024;17:11795514 241227618. https://doi.org/10.1177/ 11795514241227618

Original Article **Open Access**

Efficacy and Safety of Percutaneous Nephrolithotomy in Patients with and without Previous Renal Stone Surgery

Jamal Mustafa Khan, Agha Mohammad Zubair, Najeebullah, Syed Rafiuddin Shah, Sayyad Sarwar, Muhammad Arsalan Saleem

Abstract

Objective: To determine the efficacy and Safety of Percutaneous Nephrolithotomy in Patients with and without Previous Renal Stone Surgery

Study design and setting: This descriptive comparative study was carried out at the Department of Urology, Sindh Institute of Urology & Transplantation (SIUT) in Karachi, Pakistan from April 2023 to October 2023.

Methodology: In the current study we included 151 patients in the age group of 18-65 years of either gender who underwent a PCNL in a prone position for renal stone of size ranging from 2-3 cm. Sample size was determined by the WHO sample size calculator at 95% confidence interval and a 5% margin of error. PCNL was done with general anaesthesia using universal techniques. Follow-up arrived at four weeks postoperatively. All the data was analyzed by using SPSS version 24.

Results: Participants were 45.1±9.3 years old, with males being dominant (69.5%). In 91.4% of cases, concrete stones were cleared. These were reducing in hemoglobin 19.2%, pneumothorax 6.0%, colon injury 3.3%, and postoperative fever 12.6%. Renal patients with no previous history of renal surgery also had significantly higher stone clearance rates of 77.5% & 13.9% (p=0.005) and lower complications rates $p < 0.001$.

Conclusion: Our study concludes that PCNL is a very efficient technique for the stone clearance with an efficiency rate of over 90%. But when patients have a previous history of renal surgery, they have lower clearance rates of stones and higher complication rates.

Keywords: PCNL, kidney stones, stone removal, complications, urology

How to cite this Article:
Khan JM, Zubair AM, Najeebullah Shah SR, Sarwar S, Saleem MA. Efficacy and Safety of Percutaneous Nephrolithotomy in Patients with and without Previous Renal Stone Surgery. J Bahria Uni Med Dental Coll. 2026;16(2):615-9 DOI: https://doi.org/10.51985/JBUMDC2025858

Jamal Mustafa Khan
Assistant Professor, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Jkhan5097@gmail.com

Agha Mohammad Zubair
Senior Lecturer, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Agha.zubair01@gmail.com

Najeebullah
Senior Registrar, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Drnajeeb717@gmail.com

Syed Rafiuddin Shah
Assistant Professor, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Rafikmc33@gmail.com

Sayyad Sarwar
Senior Registrar, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Syaadsarwar0342@gmail.com

Muhammad Arsalan Saleem
Senior Registrar, Department of Urology
Sindh Institute of Urology and Transplantation, Karachi
Email: Malikarsalan14@gmail.com

Received: 26-10-2025
1st Revision: 29-10-2025
Accepted: 30-03-2026
2nd Revision: 02-02-2026

INTRODUCTION

Urolithiasis is a common disorder affecting the global population; Pakistan has ranked eighth among the overall renal diseases causing an estimated 20,000 deaths.[1,2] Surgical pathology, the most common within the present discussion, is renal stone disease. Urinary calculi management has greatly advanced from open surgeries to minimally invasive approaches, including PCNL, which became conventional for large and intricate renal calculi after its development in the 1980s.[3,4]

They include staghorn calculi, large renal calculi and some upper ureteral stones for which PCNL has high stone clearance coefficients and relatively low complications.[5] Success in performing PCNL degrees depends upon the proper positioning of the percutaneous tract in the way that gives direct access in manipulating the stone. In addition, PCNL, like any other surgical technique, is not free from risk factors, particularly in malrotated, ectopic or previously operated kidney patients, since they are likely to develop complications. [6]

The rate of recurrence of renal stones means that there will be multiple procedures on the same renal unit; however,

repeat PCNL is performed rarely because of hypothetical higher complication rates.[6] Previous renal surgery and failure have been found by prior research to have an inconsistent effect on patient outcomes during PCNL. Of the few studies that were done regarding this matter, some found no significant difference between the complication rates and stone clearance efficacy of patients with previous renal surgery and those without[5,7] while the rest indicated that patients with previous renal surgery have higher complication rates and slightly less effective in terms of stone clearance.[8-12]

With advancements in contemporary urology, the therapeutic approach to renal stone disease has undergone substantial transformation. The scope of percutaneous nephrolithotomy (PCNL) has broadened significantly due to the development of miniaturized nephroscopes and a wide range of intracorporeal lithotripsy devices.7?8 PCNL is now widely recognized as the primary treatment modality for renal calculi exceeding 2 cm in size, as well as for complex stone conditions such as staghorn calculi, multiple renal stones, and stones associated with anomalous renal anatomy.? Furthermore, PCNL serves as an effective alternative for the management of moderate-sized stones that are unsuitable for clearance using less invasive interventions.1°

The European Association of Urology guidelines recommend PCNL as the preferred treatment for renal stones larger than 20 mm, whereas extracorporeal shock wave lithotripsy (ESWL) is advised for stones measuring less than 10 mm. For renal calculi within the 10–20 mm size range, ESWL, retrograde intrarenal surgery (RIRS), and PCNL are all considered acceptable and effective treatment options. The selection of an appropriate minimally invasive technique for renal stone management is influenced by multiple factors, which can be categorized into four major groups.[11] These include: Stone-related factors, such as stone size, anatomical location, number of stones, and their chemical composition. Renal anatomical factors, including conditions like renal fusion or ectopia, lower pole calculi, calyceal diverticula, ureteropelvic junction obstruction, urinary stasis, and hydronephrosis. Patient-related clinical factors, including bleeding disorders, active infections, obesity, musculoskeletal deformities, hypertension, and impaired renal function. Technical and procedural considerations, encompassing the availability of advanced equipment, surgeon expertise, patient expectations, physician preference, success rates of procedures, potential complications, and overall cost-effectiveness.[12]Therefore, the current study seeks to fill this gap by making a comparison of the outcome of PCNL, in terms of its efficiency and safety in newly diagnosed renal units, with that of renal units that previously underwent renal stone surgery at SIUT, Karachi. The information that will be established will be useful for clinicians, especially when discharging individuals after the PCNL surgical procedure as well as when correcting patients' expectations in regard to the surgery.

METHODOLOGY

From April 2023 October 2023, a descriptive study was carried out at the Department of Urology, Sindh Institute of Urology & Transplantation (SIUT) in Karachi, Pakistan. Using the WHO sample size calculator with the following parameters: Confidence Interval: 95%

Margin of Error: 5% Proportion of post-operative fever in patients undergoing PCNL: 11.03% [7]

From the following formula, the required sample size was calculated as 151 patients. A non-probability consecutive sampling method was used in order to gather all the qualified patients across the research period. These criteria focus on the eligibility of study participants, which include inclusion and exclusion. The inclusion criteria was Age between 18 to 65 years, Kidney stone of 2-3 cm size diagnosed on the CT scan, Planned for prone PCNL, Both genders and ASA class I-II while the exclusion criteria was Systemic illnesses, which affect major organs (for example diabetics, hypertensives, bleeding disorders), BMI > 30 kg/m², Such as in the case of multi-rental organs such as a solitary functioning kidney or with renal abnormalities such as an ectopic kidney or a horseshoe kidney, Stones in >2 calyces and Split renal function <20%. The patients who met the inclusion criteria during the study were recruited after obtaining their consent. They include hemoglobin level, X-ray KUB and ultrasonography. PCNL was done with general anaesthesia using universal techniques. Follow-up arrived at four weeks postoperatively. to evaluate the clearance of stone using computed CT KUB and detect complications. Details collected were made anonymous and recorded on a pro forma prepared for this study. Renal Stone was defined as Hyperdense opacity < 3 cm on CT at presentation. Stone Clearance was defined as No more stone or fragment size > 3.5 mm on postoperative CT KUB done at the end of the 6th week. Previous Renal Stone Surgery was defined as Subjects with a confirmed prior renal stone disease and who underwent PCNL surgery as the treatment modality. The different complications were defined as: Drop in Hemoglobin: of 0.5 gm/dL from baseline on at least 50 % of study days in at least one hemoglobin measurement or red blood cell count. Pneumothorax: Complication which has symptoms witnessed through chest x-ray includes presence of air in the plural cavity. Damage to Colon: Symptoms suggestive of peritonitis or fecal presence. Postoperative Fever: Temperature above normal for 48 hours after the procedure was performed > 37.8°C. Descriptive statistics analysis and t-tests were computed using the Statistical Package for Social Science (SPSS) version 24. Mean, standard deviation and frequencies were calculated on the continuous and categorical variables, respectively. In the paired groups, we used the chi- square/Fisher test for the categorical and then the t-test/Mann-Whitney for the continuous parameters. Statistical

significance was determined when $p < 0.05$.

RESULTS

A total of 151 patients were included in the study to evaluate and compare stone clearance, complications, and outcomes in patients undergoing PCNL with and without a history of previous renal stone surgery. Table 1 presents the descriptive statistics for continuous variables, demonstrating normal distribution across all parameters ($p > 0.05$). Table 2 compares stone clearance rates based on previous renal surgery, showing significantly higher clearance in patients without prior surgery (77.5% vs. 13.9%, p=0.005).

The Stone Clearance was achieved in 138 (91.4%) patients. The different complications observed were drop in hemoglobin in 29 (19.2%) patients, Pneumothorax 9 (6.0%), damage to colon was 5 (3.3%), postoperative fever was observed in 19 (12.6%) patients while no complications was observed in 89 (58.9%) patients. Table 3 illustrates the comparison of complications, revealing higher complication rates in patients with previous renal surgery (p=0.0001). Duration of Procedure was Longer in patients without stone clearance (79.30±12.19 mins vs. 74.57±7.81 mins, p=0.049) and in hospital Stay **n**o significant difference (4.51±0.96 days vs. 4.20±1.47 days, p=0.292) was observed.

DISCUSSION

With advances in modern medical practice, the management strategies for renal calculi have evolved considerably. The indications for percutaneous nephrolithotomy (PCNL) have expanded following the development of miniaturized nephroscopes and a variety of intracorporeal lithotripsy technologies.7?8 PCNL is now regarded as the treatment of choice for renal stones larger than 2 cm, as well as for complex calculi such as staghorn stones, multiple renal stones, and stones associated with abnormal renal anatomy.? In addition, PCNL remains an effective therapeutic option for medium-sized stones that cannot be successfully treated using less invasive modalities.[1°]

According to the European Association of Urology guidelines, PCNL is recommended for renal stones exceeding 20 mm in diameter, while extracorporeal shock wave lithotripsy (ESWL) is preferred for stones smaller than 10 mm. For stones measuring between 10 and 20 mm, ESWL, retrograde intrarenal surgery, and PCNL are all considered suitable treatment approaches. The selection of an appropriate minimally invasive technique for renal stone management is influenced by multiple factors, which can be categorized

Table 1: Descriptive Statistics for Continuous Variables (n=151)

Variable	Mean ± SD	P-Value
Age (years)	45.1±9.3	0.211
Weight (kg)	68.6±12.2	0.601
Height (cm)	162.8±15.3	0.078
BMI (kg/m²)	26.5±6.2	0.119
Number of Stones	2.7 ± 1.2	0.278
Stone Size (cm)	2.4 ± 1.3	0.224
Duration of Procedure (min)	74.9±13.3	0.526
Preoperative Hemoglobin (gm/dL)	14.2±3.3	0.414
Postoperative Hemoglobin (gm/dL)	12.3±2.9	0.329
Hospital Stay (days)	4.5±1.9	0.665

Table 2: Comparison of Stone Clearance with and without History of Renal Surgery (n=151)

Stone Clearance	History of Renal Surgery	P-Value
Yes	21 (13.9%)	0.005
Yes	117 (77.5%)	
No	6 (4.0%)	
No	7 (4.6%)	

Table 3: Comparison of Complications with and without History of Renal Surgery (n=151)

Complication	History of Renal Surgery	P-Value
Drop in Hemoglobin	11 (7.3%)	0.0001
Drop in Hemoglobin	18 (11.9%)	
Pneumothorax	3 (2.0%)	
Pneumothorax	6 (4.0%)	
Damage to Colon	2 (1.3%)	
Damage to Colon	3 (2.0%)	
Postoperative Fever	6 (4.0%)	
Postoperative Fever	13 (8.6%)	
No Complications	5 (3.3%)	
No Complications	84 (55.6%)	

Table 4: Comparison of Outcomes (Duration of Procedure and Hospital Stay) Based on Stone Clearance (n=151)

Outcome	Stone Clearance	P-Value
Duration of Procedure (mins)	Yes: 74.57±7.81	0.049
	No: 79.30±12.19	
Hospital Stay (days)	Yes: 4.51±0.96	0.292
	No: 4.20±1.47	

Figure 1: Stone Clearance Rates Based on ASA Class



into four main groups.[11] Stone-related factors, including stone size, location, number, and chemical composition. Rnal anatomical factors, such as renal fusion or ectopia, lower pole calculi, calyceal diverticula, ureteropelvic junction stenosis, urinary obstruction or stasis, and hydronephrosis. Clinical factors, including coagulopathies, active infections, obesity, skeletal deformities, hypertension, and renal insufficiency. Technical considerations, encompassing the availability of advanced equipment, surgeon expertise, patient expectations, physician preference, procedural success rates, potential complications, and treatment cost.[12] During PCNL, patients are most commonly positioned in the prone posture. This position offers several advantages, including a wider area for puncture site selection—particularly for upper calyceal access—greater maneuverability of the nephroscope and lithotripter, and a reduced risk of injury to surrounding visceral organs.[13] However, the conventional prone position is also associated with certain drawbacks, such as patient discomfort, prolonged operative time due to repositioning, and anesthetic challenges including hemodynamic instability, respiratory compromise, limited airway access, increased sympathetic stimulation, and the risk of cervical spine or peripheral nerve injuries.[14]

In a previous study involving 1,028 patients, only 6% underwent PCNL in the supine position, whereas the vast majority were treated in the prone position.[15] In the present study, all procedures were performed with the patient in the prone position, and percutaneous renal access was achieved under fluoroscopic guidance by a urologist. Access was obtained through the lower calyx in 12 patients (85.7%), the middle calyx in 1 patient (7.14%), and the upper calyx in 1 patient (7.14%).

Upper calyceal access, typically performed through the 11th or 12th intercostal spaces, is associated with a higher risk of complications due to its close proximity to the lungs. Consequently, this approach carries an increased risk of pneumothorax, pleural effusion, and calico-pleural fistula formation, with pulmonary complications reported in nearly 25% of patients undergoing intercostal access.[17] In the present study, the supracostal approach was used in only one patient, and no postoperative complications were observed.

Similar to other minimally invasive procedures, PCNL continues to evolve and improve. One of the most critical steps in PCNL is dilation of the percutaneous renal tract to facilitate intrarenal access. Since the first nephrostomy was performed in 1955, continuous advancements in technique have significantly improved the outcomes of percutaneous nephrolithotomy.[18–20]

A study conducted in 1994 evaluated the impact of balloon dilators and Alken coaxial metal dilators on intraoperative blood loss and found no significant difference between the two methods.[21] Another comparative study assessed Amplatz dilators, balloon dilators, and Alken coaxial metal dilators, reporting reduced blood loss with the use of Amplatz dilators; however, the difference was not statistically significant.[22]

Urolithiasis is one of the most common complaints seen in clinical practice and is characterized by a high rate of relapse. PCNL has changed the approach to the treatment of renal stone disease by proposing a less invasive procedure of high efficiency for large and complex renal stones. [3-5] This work supports previous studies, as the stone clearance rate of 91.4% was obtained in this study, and according to literature, clearance rates range from 80-94%. [7, 13, 14] The rate of 19.2% for complications is reasonable, and a prior expectation of such a rate was given; thus, the postoperative drop in hemoglobin was the most frequently reported complication, with postoperative fever and pneumothorax after them.

One of the impressive findings of this work is the difference in stone clearance and complication rates in patients who had no history of previous renal surgery. This indicates and supports previous surgeries that cause scarring and change in the renal anatomy that makes subsequent PCNL to be technically difficult. [15-18] On the other hand, other research has found no significant difference in the results of groups treated with quinine compared with placebo.[6-7] These differences may be due to differences in the operation techniques, the patients' characteristics, and the experience of the operator.

The overall duration of the procedure was significantly longer in patients without stone clearance, which could be attributed to difficult anatomical areas or intraoperative complications of the procedure. Yet, the length of hospital stay remained unaffected, arguing that postoperative convalescence did not vary with stone clearance.

Breaking down stratification, it appeared that patients aged 18-40 years and patients with BMI 18-24 kg/m² cleared stones effectively. Furthermore, while comparing Class I and Class II patients, the former reported a higher clearance rate than the latter, which pointed towards the condition of ASA on surgeries. The literature review demonstrated the multivariate analysis of previous renal surgery on the outcome of PCNL, which reveals conflicting outcomes. For example, Hossain et al. stated that HBP had comparable stone clearance rates for patients who had had prior surgery and those that had not [19], whereas another study noted that the former group incurred higher complications.[20] This research brings into context previous renal surgeries as a possible predictor of poor PCNL outcomes, therefore requiring optimal planning and shared decision-making with the patient. [21-23]

Some of the weaknesses of this work are that it was descriptive in design, conducted in only one hospital, and had a fairly small sample size, which may limit the generalization of the results.

The results of this present study should be further investigated in studies with higher sample sizes. multi-center studies to

confirm these findings and to investigate way to reduce complications in patients with a history of renal surgeries.

CONCLUSION

The findings of this work show that PCNL is a very efficient technique for the stone clearance with an efficiency rate of over 90%. But when patients have a previous history of renal surgery, they have lower clearance rates of stones and higher complication rates. This study underlines the necessity of correct selection of patients and proper planning of the surgery in such groups to get the best possible results. However, previous renal surgery increases the risk of complications with good results of PCNL, which further emphasizes the trends in the development of surgical methods and the improvement of the. operators skills. Prospective and controlled future research is now relevant to confirm these discoveries and enhance the protocols to increase the safety and effectiveness of PCNL treatment.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Jamal Mustafa khan: Substantial contribution to study design, acquisition of data. Manuscript drafting or reviewing it critical for important intellectual content.
Agha Mohammad Zubair: Substantial contribution to study design, acquisition of data. Manuscript drafting or reviewing it critical for important intellectual content.
Najeebullah: Manuscript drafting or reviewing it critical for important intellectual content. Has given final approval of the version to be published
Syed Rafiuddin Shah: Substantial contribution to study design, acquisition of data. Manuscript drafting or reviewing it critical for important intellectual content. Critical review
Sayyad Sarwar: Substantial contribution to study design, acquisition of data. Manuscript drafting or reviewing it critical for important intellectual content.
Muhammad Arsalan Saleem: Critical review Proof reading

REFERENCES

1. Delaney MA, Kowalewska J, Treuting PM. Urinary System. Comparative Anatomy and Histology. Elsevier; 2018. p. 275-301.
2. Yaqub F, Khan MS, Nazeer AJ. Chronic kidney disease: a statistical analysis. 2019:385.
3. Khorrami M, Hadi M, Sichani MM, Nourimahdavi K, Yazdani M, Alizadeh F, et al. Percutaneous nephrolithotomy success rate and complications in patients with previous open stone surgery. Urol J. 2014;11(3):1557-62.
4. Falahatkar S, Panahandeh Z, Ashoori E, Akbarpour M, Khaki NJJ. What is the difference between percutaneous nephrolithotomy in patients with and without previous open renal surgery? J Endourol. 2009;23(7):1107-10. doi: 10.1089/end.2008.0630.
5. Ghani KR, Andonian S, Bultitude M, Desai M, Giusti G, Okhunov Z, et al. Percutaneous nephrolithotomy: update, trends, and future directions. Eur Urol. 2016;70(2):382-96.
6. Hossain F, Rassell M, Rahman S, Ahmed T, Alim MA, Hossain TMS, et al. Outcome of percutaneous nephrolithotomy in patients with history of open renal surgery-a comparative study with PCNL in primary patients. J Urol. 2016;45(1):36-9.
7. Reddy S, Shaik AB. Outcome and complications of percutaneous nephrolithotomy as primary versus secondary procedure for renal calculi. Urol Int. 2016;42(2):262-9. doi: 10.1590/S1677-5538.IBJU.2014.0619
8. Suliman A, Burki T, Garriboli M, Glass J, Taghizadeh A. Flexible ureterorenoscopy to treat upper urinary tract stones in children. Urolithiasis. 2020;48(1):57-61. doi: 10.1007/s00240-018-1083-5.
9. Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2018;33(11):1033-47. doi: 10.1007/s10654-018-0426-4.
10. Bauza JL, Pieras EC, Grases F, Tubau V, Guimerà J, Sabaté XA, et al. Urinary tract infection's etiopathogenic role in nephrolithiasis formation. Med Hypotheses. 2018;118:34-5. doi: 10.1016/j.mehy.2018.06.002.
11. Cohen AJ, Borofsky MS, Anderson BB, Dauw CA, Gillen DL, Gerber GS, et al. Endoscopic evidence that Randall's plaque is associated with surface erosion of the renal papilla. J Endourol. 2017;31(1):85-90. doi: 10.1089/end.2016.0537.
12. Rojas-Moreno C. Pyonephrosis and pyocystis. ID Cases. 2016;6:104-5. doi: 10.1016/j.idcr.2016.10.005.
13. Erbay G, Yalçýn A, Gültekin MH. Predictor role of pretreatment resistive and pulsatile indexes in the success of medical expulsive therapy of ureteral stones. Urology. 2018;118:47-51. DOI:10.1016/j.urology.2018.04.020
14. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-62. doi: 10.1038/nrurol.2016.154.
15. Yildirim K, Olcucu MT, Colak ME. Trends in the treatment of urinary stone disease in Turkey. PeerJ. 2018;6:e5390. doi: 10.7717/peerj.5390.
16. Fedrigon DC, Jain R, Sivalingam S. Current use of medical expulsive therapy among endourologists. Can Urol Assoc J. 2018;12(9):E384. doi: 10.5489/cuaj.4978.
17. Assimos DG, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical management of stones: American Urological Association/Endourological Society Guideline, PART I. J Urol. 2016;196(4):1153-60. doi: 10.1016/j.juro.2016.05.090.
18. Morgan MS, Pearle MS. Medical management of renal stones. BMJ. 2016;352:i52. doi: 10.1136/bmj.i52.
19. James EL. Surgical Management of upper urinary tract calculi. Campbell's Urology. 2007. https://doi.org/10.1016/j.juro.2007.09.107
20. Tejero Aranguren J, Ruiz Ferrón F, Colmenero Ruiz M. Endobronchial treatment of persistent pneumothorax in acute respiratory distress syndrome. Med Intensiva (Engl Ed). 2019;43(8):516. doi: 10.1016/j.medin.2019.01.005.
21. Gupta D, Hansell A, Nichols T, Duong T, Ayres JG, Strachan D. Epidemiology of pneumothorax in England. Thorax. 2000;55(8):666-71. doi: 10.1136/thorax.55.8.666.
22. Mandt MJ, Hayes K, Severyn F, Adelgais K. Appropriate needle length for emergent pediatric needle thoracostomy utilizing computed tomography. Prehosp Emerg Care. 2019;23(5):663-71. doi: 10.1080/10903127.2019.1566422.
23. Pergialiotis V, Sinanidis I, Louloudis IE, Vichos T, Perrea DN, Doumouchtsis SK. Perioperative complications of cesarean delivery myomectomy: a meta-analysis. Obstet Gynecol. 2017;130(6):1295-303.

Original Article **Open Access**

Prospective Evaluation of Reinforced Laryngeal Mask Airway Use in Ambulatory Facial Aesthetic Surgery: A Clinician-Led Innovation in Airway Management

Ehsan Ahmad, Ahmad Naseem, Abdullah Al-Qahtani

ABSTRACT:

Objective: To prospectively evaluate the safety, ergonomic advantages, and team-centred workflow impact of the reinforced laryngeal mask airway in ambulatory facial aesthetic surgery.

Study Design and Setting: A single-centre prospective observational study conducted at Care Medical Centre, Riyadh, Saudi Arabia, from 1st July–31st December 2025.

Methodology: One hundred and ten ASA I–II adult patients undergoing elective facial aesthetic procedures (submental liposuction, blepharoplasty, lip lift) were managed with reinforced laryngeal mask airway under general anaesthesia without neuromuscular blockade. Primary outcomes included RLMA placement success, need for intraoperative airway adjustment, and airway-related adverse events. Secondary outcomes included recovery time and structured surgical-team satisfaction using a 5-point Likert scale..

Results: Reinforced laryngeal mask airway placement succeeded on the first attempt in 100% of cases. Minor repositioning was required in 14 patients (12.7%). No hypoxia (SpO2 <94%), laryngospasm, regurgitation, or aspiration occurred. No conversion to endotracheal intubation was necessary. Mean discharge time from post anaesthesia care unit was 2.3 ± 0.4 hours. Staff satisfaction scores were high: surgical access (4.7/5), airway stability (4.6/5), and workflow facilitation (4.5/5).

Conclusion: The reinforced laryngeal mask airway is a safe, highly effective, and workflow-enhancing airway choice for ambulatory facial cosmetic surgery. Its flexible design ensures unobstructed surgical access without the need for neuromuscular blockade. This prospective cohort provides systematic evidence supporting the use of RLMA in selected facial aesthetic procedures and highlights the value of clinician-led innovation in perioperative care.

Keywords: Ambulatory Surgical Procedures; Airway Management; Anaesthesia, General; Laryngeal Masks; Patient Satisfaction; Post-anaesthesia Care Units.

How to cite this Article:
Ahmad E, Naseem A, Qahtani Aa. Prospective Evaluation of Reinforced Laryngeal Mask Airway Use in Ambulatory Facial Aesthetic Surgery: A Clinician-Led Innovation in Airway Management. J Bahria Uni Med Dental Coll. 2026;16(2):620-6 DOI: https://doi.org/10.51985/JBUMDC2026927

INTRODUCTION:

The demand for minimally invasive facial plastic surgery has grown worldwide, highlighting the importance of efficient, clinically safe and well-tolerated anaesthesia techniques.[1] Procedures such as blepharoplasty, lip shortening (lip lift), submental (chin) liposuction are routinely performed in daycare units, offering swift recovery, improved comfort and a smooth, well-tolerated peri-operative experience.[2]

Ehsan Ahmad
Consultant, Department of Anesthesiology
Care Medical Centre, Saudi Arabia
Email: Ehsanahmad814@gmail.com

Ahmad Naseem
Consultant, Department of Anesthesiology
Care Medical Centre, Saudi Arabia
Email: Ahmadnaz1@gmail.com

Abdullah Al-Qahtani
Consultant, Department of Anesthesiology
Care Medical Centre, Saudi Arabia
Email: Alfhira@hotmail.com

Received: 02-01-2026
1st Revision: 05-01-2026
Accepted: 06-04-2026
2nd Revision: 03-03-2026

Although these surgeries are brief and considered minor procedures, they require unobstructed access to the submental area, including chin, neck, eyelids, lower face and peri-oral structures. Due to these precise prerequisites, airway management is considered a prime and critical element for successful surgeries, overall ergonomic practice and patient safety.[3]

For these specific facial procedures, traditional airway management techniques have inherent limitations. Simple face mask ventilation is easy and non-invasive, but it clearly interferes with access to the surgical field.[4] In order to maintain face mask ventilation, the anaesthesia provider needs to hold it manually for the entire procedure, encroaching on the operative field, hindering the drapes or causing contamination. These problems are more pronounced for lipo chin, which requires unobstructed access to the anterior neck and lip lift, which cannot be performed with mask ventilation.

Endotracheal intubation (ETT) is a safe and reliable airway management technique, but it is overly invasive for short-duration procedures. Intubation also requires direct

laryngoscopy, which unnecessarily causes sympathetic stimulation during these procedures. It can also cause trauma to the airway or post-anaesthetic sore throat. Another important clinical factor is that intubation requires neuromuscular blocking agents, which are not indicated for facial plastic procedures such as blepharoplasty or lip lift.[5] In addition, ETT use may prolong emergence time and postanaesthetic recovery.[6]

The reinforced laryngeal mask airway (RLMA) can be considered a reliable clinical alternative airway management strategy that balances the two extremes of mask ventilation and ETT use.[7] What distinguishes RLMA from other LMAs is its wire-reinforced, kink-resistant shaft, which allows 360 degrees of flexible securing of the device without compromising airway patency.[8,9] These structural characteristics of RLMA enable anaesthesia providers to secure and position the RLMA laterally, caudally or superiorly depending upon the type of facial procedure and surgical access. This flexibility gives both the anaesthetist and the surgeon the freedom and safety to maintain the sterile surgical field, minimise airway adjustments and facilitate uninterrupted access to facial regions, e.g., eyes, submental and anterior neck regions.[10]

Despite known clinical and safety advantages, the use of RLMA in facial plastic procedures is sparse. The use of RLMA is well-known in ENT, dental, ophthalmic and oral maxillofacial surgeries, yet existing evidence is limited to small case series and retrospective analysis. Prospective data specifically related to plastic and cosmetic facial surgeries is lacking, which indicates a significant clinical gap considering the growing number of daycare plastic surgical loads globally and the demand for minimally invasive airway management compatible with these procedures.[11]

The present study aims to address this clinical gap by evaluating the use of RLMA in a daycare plastic surgery centre. This study used a cohort of 110 patients. It was not conducted to promote any device, but it arose from the need for patient safety and clinician-led innovation.[12] The attributes leading to change in practice included difficulty maintaining facemask ventilation, restricted surgical access and unnecessary intubation. A pilot project of RLMA use in selected patients yielded early positive results, paving the way for wider adoption. Positive feedback from surgeons and nursing staff reinforced the perception of improved field visibility, fewer procedural interruptions and efficient workflow.[13]

The process of adopting RLMA use is in accordance with the established change management models. The Kotter's 8 steps model encourages problem identification, pilot testing and reinforcement through early success.[14] The Rogers' Diffusion of Innovation theory explains how RLMA use transitioned from an experimental clinical tool to routine practice. From clarity point of view, these change management models are not the primary focus of this study.

This study prospectively assesses the clinical performance of RLMA, its safety, impact on surgical access, intraoperative stability and team satisfaction. This study marks itself as first prospective cohort using RLMA in this specific surgical context by incorporating clinical outcomes and clinician-led adoption in selected patients.[15]

METHODOLOGY:

This prospective observational study was conducted at Care Medical Centre, a specialised plastic surgery centre in Riyadh, Saudi Arabia, from 1st July to 31st December, 2025. All surgeries were performed under consultant supervision and in accordance with the international perioperative safety protocols. This study was purposefully designed to evaluate the clinical performance, patient safety and impact on operating room workflow by using airway RLMA as the primary airway device for submental liposuction, upper and lower blepharoplasty, and lip lift surgeries.

The ethical review committee of CMC granted ethical approval (ERC Reference Number: ERC/CMC/2025/020). All patients provided written informed consent. The study followed the principles of the Declaration of Helsinki (2013 revision). The data was anonymised and non-identifiable and no additional interventions beyond routine clinical care were performed.

All eligible patients were adults aged =18 years with ASA physical status I–II who were scheduled for elective facial aesthetic surgery, including submental liposuction, blepharoplasty, or lip lift. All included patients had a planned use of a reinforced laryngeal mask airway (RLMA) for primary airway management and provided informed consent before enrolment.

Patients were excluded if they had ASA physical status III–IV, an anticipated difficult airway (e.g., Mallampati IV, restricted mouth opening, or limited neck mobility), active gastro-oesophageal reflux disease or increased aspiration risk, a recent upper respiratory infection, or a body mass index (BMI) > 35 kg/m². Emergency procedures were also excluded. These eligibility criteria reflect standard safety considerations for the use of supraglottic airways in elective ambulatory settings.

All patients were assessed preoperatively by a consultant anaesthesiologist. Standard monitoring, like ECG, non-invasive blood pressure, pulse oximetry, and capnography, was applied following induction and maintained throughout the procedure. Anaesthesia was induced intravenously using intravenous Propofol 1.5–2.5 mg/kg and Fentanyl 1–2 µg/kg for analgesia**.** No neuromuscular blockers were administered, as muscle relaxation is not required for these facial aesthetic procedures.

After the patients were adequately deep under anaesthesia, an RLMA was inserted. The wire-reinforced and kink-

resistant shaft of the RLMA was secured with tape on the forehead, lateral cheek or over the chin, depending on the type of surgical procedure. This ensured clear access to the surgical field, sterile draping and absence of traction or displacement during head movements. Correct placement of the RLMA was confirmed by a regular, equal chest rise, a capnography trace and normal ventilation pressures. Patients were maintained on spontaneous breathing or assisted mandatory ventilation. Anaesthesia was maintained with sevoflurane in a 50/50 O_2/air mixture. There was no case where RLMA was switched to endotracheal intubation.

A structured data sheet was used to collect the data for each case. The variables recorded included patient demographics, ASA classification, RLMA insertion success, number of attempts, need for RLMA adjustment during the procedure or any airway-related adverse events. The incidence of hypoxia (SpO2 < 94%), laryngospasm, regurgitation, or aspiration was recorded. Total time for anaesthesia, surgery and post-anaesthesia care unit was also recorded. Perioperative teams completed a postoperative 5-point Likert satisfaction survey, evaluating: 1. Airway stability 2. Surgical field accessibility 3. Ergonomic workflow 4. Need for airway-related interruptions 5.Overall team satisfaction Surveys were completed within 30 minutes following each procedure to ensure accuracy.

Sample size was calculated based on an anticipated RLMA complication rate of 5%, as reported in the literature regarding the supraglottic airway. We used 95% confidence interval and a 4% margin of error. The calculated minimum sample size was 114. Due to technical and study-period limitations, 110 patients were included, providing adequate power to evaluate the primary outcomes.

The primary outcomes included the success rate of first-attempt RLMA insertion, the incidence of intraoperative repositioning, and airway-related adverse effects, such as, hypoxia, laryngospasm and aspiration. The secondary outcomes included the time to discharge from the PACU after the end of the procedure, surgical team and nursing staff satisfaction rate and the overall impact on surgical workflow and drape integrity.

RESULTS:

A total of 110 patients, scheduled for daycare facial plastic surgery at CMC were included. All the patients completed the study without any deviation in protocol or loss of follow up. No patients were lost after induction of study.

The demographic data is presented in Table 1. The majority of the study population comprised of healthy, low-risk individuals classified under ASA class I or II, which is expected in elective plastic surgery list in a daycare centre. The average age of the cohort was 38 ± 10.5 years (range: 19–62 years), with dominant female ratio of 85%, evident from worldwide demographic trends of facial plastic surgery. Various plastic surgery procedures were performed, but submental liposuction was the most common, accounting for 60% of all procedures, with blepharoplasty in second place (25%) and lip lift in third place (15%), as presented in Table 2. It shows commonly performed plastic surgery cases in our centre. Successful first attempt insertion of RLMA was noted in all 110 patients (100%). No other airway devices were required either. This demonstrates the consistency of RLMA performance in this specific cohort, as all patients had a normal airway assessment before surgery. Minor airway adjustments in RLMA position were made in 14 patients (12.7%), primarily due to adjustments in patients' head position during submental liposuction. No other complications were noted during the study. The capnography traces were normal in all these surgical patients. There were no interruptions in ventilation or surgical workflow. No patient needed replacement of RLMA with ETT. There were no episodes of hypoxia, regurgitation, laryngospasm or airway obstruction. These findings further support the safety and efficacy of RLMA as the sole airway management device for elective facial plastic surgeries that do not require neuromuscular blockade and are short in duration.

The perioperative results are summarised in Table 3. The mean duration of the surgeries was 42 minutes (range: 25-70 minutes). The emergence from anaesthesia was smooth in all patients.

Mean discharge time from PACU was 2.3 ± 0.4 hours, which clearly supports the findings that RLMA is suitable for minor procedures, including facial plastic and aesthetic surgeries.

None of the patients experienced airway-related complications or adverse effects like coughing, sore throat or delayed recovery in PACU. We achieved high satisfaction scores through postoperative staff surveys. Improved uninterrupted surgical access was particularly noted by the surgeon after RLMA use. While nursing staff highlighted smoother workflow and no drape disruptions.

A 5-point Likert scale was used to measure satisfaction. Surgical access had the highest mean score of 4.7, followed by airway stability at 4.6 and workflow satisfaction at 4.5 as shown in Table 4. Figure 1 shows the schematic positioning of RLMA in the midline over the chin, forehead and side of the cheek (on either side of the face) using adhesive taping. This allows unobstructed surgical access for all three plastic surgery procedures, ensuring optimal exposure and maintaining proper ventilation and sterilize drapping.

Table 1: Patient Demographics

Variable	Value
Total patients	110
Age (mean ± SD)	38 ± 10.5 years
Gender	85% female, 15% male
ASA I	n = 90
ASA II	n = 20

Table 2: Types of Surgical Procedures

Procedure	Number (%)
Submental liposuction	66 (60%)
Blepharoplasty	28 (25%)
Lip lift	16 (15%)

Table 3. Perioperative Outcomes

Parameter	Value
Mean surgery duration	42 min
Smooth emergence	100%
Mean discharge time	2.3 ± 0.4 hours
Postoperative airway complications	0

Table 4. Team Satisfaction (5-Point Likert Scale)

Domain	Mean Score
Airway stability	4.6
Surgical access	4.7
Workflow facilitation	4.5

Figure 1: 360° RLMA Positioning Strategy



DISCUSSION:

The results from this prospective study show that RLMA is a reliable, very safe and structurally advantageous airway option for daycare facial plastic surgery. The study also demonstrates its first attempt success rate of 100% without any episodes of clinically significant airway complications such as hypoxia, laryngospasm or aspiration. Absence of these airway related complications in 110 consecutive patients is a very strong clinical evidence to support the use of RLMA in facial plastic procedures which do not require neuromuscular blockade and are short in duration. These findings are also aligned with existing LMA evidence in ENT and eye surgeries, where RLMA use is consistently associated with low airway-related complication rates and stable ventilation even during change of head position.[16]

The consistency with which RLMA was tolerated during these procedures, even during head tilt and change of position from side to side, was one of the notable and key success factors for this study. Only 12.7% cases needed minor adjustments during the surgery and did not result in any disruption to ventilation or surgical workflow. As per literature, these minor adjustments are consistent with known LMA use in surgeries involving face or head positioning.[17] No patient needed endotracheal intubation post RLMA use, reinforcing RLMA dependability as a primary airway tool for short duration facial plastic surgeries.

Uninterrupted improved surgical access was among the major advantages witnessed from this study. Blepharoplasty, submental liposuction and lip lift surgeries require clear access to face region while keeping the surgical area sterile. Classic LMAs and traditional facemask ventilation not only obstruct the surgical field during these procedures but also complicate draping, reduce workspace and increase the risk of contamination. One of the main disadvantages of classic LMAs is their less-flexible shaft and less-forgiving tube angles. RLMA with a wire-reinforced shaft allows multidirectional securing, e.g., superior, caudal and lateral, enabling surgeons to utilize full surgical field exposure without compromising airway stability.[18] It was reflected in the high surgeon satisfaction score (4.7/5), which highlights improved surgical access, reduced interference, and smoother workflow.

Another significant advantage of RLMA is the minimal workflow disruptions. In many centres, where anaesthesiologists are not using RLMA, they frequently need to reposition the facemask or adjust the airway tools, resulting in the need to reapply the drapes and repeat cleaning of the surgical field. These incidents result in prolonged operating time, higher cost and reduced overall perioperative efficiency. These disadvantages can be eliminated by using RLMA, which provides stable ventilation and a hands-free, safe airway that remains clear of the operative field.[8] It also resulted in improved nursing feedback regarding reduced drape disruption and fewer requests for airway-related assistance, which reflected in a higher workflow rating (4.5/5).

Postoperative recovery was also improved in this study, contributed by the use of RLMA.[19] Airway-related trauma, sore throat, hoarseness and coughing were not witnessed by simply avoiding endotracheal intubation. For plastic surgery patients, expecting minimal discomfort and rapid recovery, these differences are quite meaningful in improving perioperative experience. In this study, the mean PACU discharge time was 2.3 hours, signifying the RLMA's compatibility with short-duration daycare procedures.

This study also demonstrates clinician-lead service improvement, an important aspect of leadership and innovation.[20] This RLMA use originated from practical challenges faced during routine plastic surgeries. The use of RLMA in this study has no connection with commercial promotion. Clinical problems faced with mask-only ventilation, unnecessary intubation and repeated interruption during these procedures created a compelling need for an alternative airway management technique. Successful implementation of pilot project for RLMA encouraged a wider adoption. For this implementation, the present study followed the established change management frameworks such as Kotter's 8-steps model, where problem recognition, urgency, early wins and coalition building led to a sustainable change.[21]

The process of RLMA's wider adoption was also consistent with Roger's Diffusion of Innovation Theory.[22] Being first ever documented use in facial plastic surgery, the introduction of RLMA represented the innovator stage. Consistent successful implementation and operative team satisfaction resulted in RLMA diffusion to early adopted group and finally becoming standard and routine practice for these procedures. This prospective clinical evaluation of RLMA contributes not only to the clinical evidence, but also to a framework for successful, bottom-up innovation in perioperative practice.[23]

Comparing with international medical literature, studies done in ENT and eye surgeries have consistently reported that RLMA provides safe and stable airway control, decreased intraoperative airway adjustments, reduced incidence of laryngospasm and improved, uninterrupted surgical access.[24] However, previous studies did not address facial plastic surgeries, particularly and associated airway implications related to these procedures. The novelty of this cohort lies in its specific application to facial aesthetic surgeries, where ergonomics and surgical field exposure are as critical as safe airway control. This study establishes the RLMA as a suitable airway device in aesthetic units and also expands the supraglottic airway evidence for its use in an underrepresented and rapidly growing subspeciality.

For clinical practice, this study has substantial implications. In daycare plastic surgery units, especially for facial procedures, with a focus on improved efficacy and safety, RLMA offers a streamlined, predictable airway management solution that is time-efficient for induction and emergence, maintains an effective workflow and aligns with patient expectations for comfort and a pleasant surgical and anaesthesia experience.[25] From an institutional point of view, consistent workflow and improved turnover support higher theatre productivity and operational efficiency.

Future work should include randomised control trials and multicentre studies to strengthen the validity of findings. Further research into the use of RLMA in longer-duration plastic surgery procedures may also broaden its clinical use. A formal economic evaluation of RLMA use would be useful for quantifying its financial advantages.

In summary, this prospective evaluation study confirms that RLMA is a safe, effective, and reliable airway device, that enhances workflow and efficiency in a daycare plastic surgery centre. It provides stable ventilation without the need of muscle relaxant and superior surgical access with improved teamwork dynamics, making it an excellent choice for airway management for these procedures. This study also highlights the impact of clinician-led innovation by recognizing a clinical problem and tackling that problem through known change management models and keeping patient safety a priority.

Limitations of Study: Despite these strengths, several limitations warrant consideration. The single-centre design may limit generalisability to other settings with different patient demographics or workflow structures. The study did not include a comparator arm, such as classic LMA or endotracheal intubation, which would provide stronger evidence for relative advantages. The predominance of female patients reflects the typical aesthetic population but may limit the external applicability of the findings. Additionally, the absence of patient-reported outcome measures (PROMs) for postoperative discomfort or satisfaction is an area for future investigation. Including PROMs would enhance understanding of patient experience, particularly in cosmetic surgery. Finally, no formal cost-effectiveness analysis was conducted, although observational data suggest potential economic benefits from reduced theatre interruptions and faster turnover.

CONCLUSION:

From this prospective clinical study done in a daycare facial plastic unit, we can safely conclude that RLMA is an effective, stable, safe and ergonomically superior airway device for face procedures such as submental liposuction, lip lift and blepharoplasty. Use of RLMA in 110 patients in this cohort demonstrated stable ventilation without the need of muscle relaxant, 100% first attempt insertion success and no clinically significant airway-related complications. These findings highlight the RLMA's ability to maintain a stable and secure airway during these facial surgeries which involves frequent head movements to operate specifically submental liposuction.

Another clinical highlight of RLMA was uninterrupted and clear access to surgical field. Its wire-resistance and kink-free shaft allowed multidirectional yet flexible taping on the face which enabled surgeons to operate without any interference from airway equipment. As a result, we had fewer airway-related interruptions, smoother operating theatre workflow and higher satisfaction scores among surgeons and nursing staff. Significantly improved emergence profiles and rapid PACU discharge times were also the

hallmark of this study. In terms of clinical evidence, it is important that current study represents first documented clinical cohort evaluating RLMA in facial plastic surgery, highlighting a successful example of clinician-led innovation and its clinical implementation. The shift towards RLMA use emerged from recognizing limitations associated with facemask, traditional supraglottic airways and unwanted endotracheal intubation in these short-duration surgeries. The RLMA use became a standard practice through incremental adoption, demonstrating clinical safety, reliability and positive feedback from surgical and nursing teams. Although comparative and multicentre studies will be needed to validate this study's findings, which strongly support RLMA as an invaluable airway device for selective facial plastic surgeries. When applied to a selective patient cohort and within competent anaesthesia practice, RLMA enhances safety, boosts workflow efficiency and improves overall perioperative experience.

Acknowledgements:

The author extends sincere gratitude to the surgical and nursing teams at Care Medical Centre for their cooperation and support during the data collection process.

Conflict of Interest: The author declares no conflict of interest.

Funding Source: None.

Authors Contribution:
Ehsan Ahmad: Manuscript writing, study concept, and data collection.
Ahmad Naseem: Review of manuscript, final approval, and data analysis.
Abdullah Al-Qahtani: Literature search, conduct of discussion

REFERENCES:

1. Bharadwaj S, Dougherty W. Anaesthesia for office-based facial plastic surgery procedures. World J Otorhinolaryngol Head Neck Surg. 2023;9(3):200–205. https://doi.org/10.1002/wjo2.131
2. Vega Morales AQ, Lara Pérez MA, Ruiz Reyes DP. Advancements in plastic surgery and facial reconstruction: a comprehensive review of surgical techniques and outcomes. Int J Med Sci Clin Res Stud. 2023;3(12). https://doi.org/10.47191/ijmscrs/v3-i12-56
3. Luba K, Apfelbaum JL, Cutter TW. Airway management in the outpatient setting. Clin Plast Surg. 2013;40(3):405–417. https://doi.org/10.1016/j.cps.2013.04.005
4. Meitzen S, Black J. Reducing risk for perioperative anaesthesia complications. Facial Plast Surg Clin North Am. 2023;31(2):325–332. https://doi.org/10.1016/j.fsc.2023.01.016
5. Alvarado AC, Panakos P. Endotracheal intubation techniques. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan [updated 2023 Jul 10]. PMID: 32809565. Available from: https://www.ncbi.nlm.nih. gov/books/NBK560730/
6. Hendrix JM, Regunath H. Intubation endotracheal tube medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2025 Jan 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459276/
7. Kumar T, Bharati S, Suman S, Kumar S, Acharya G, Lakra L. Supraglottic airway devices versus endotracheal intubation for laparoscopic surgeries: an updated systematic review and meta-analysis of randomised controlled trials. Indian J Anaesth. 2023;67(5):409–419. https://doi.org/10.4103/ija.ija_398_22
8. Schwartz S, Peng YG. The laryngeal mask airway: expanding use beyond routine spontaneous ventilation for surgery. APSF Newsl. 2021;36(3). Available from: https://www.apsf.org/article/the-laryngeal-mask-airway-expanding-use-beyond-routine-spontaneous-ventilation-for-surgery/
9. Tannheimer M, Reinke M, Lechner R. Comparison of laryngeal mask airway seal between anesthesiologists and individuals without previous airway experience. J Emerg Med. 2024;66(4):e470–e476. https://doi.org/10.1016/j.jemermed.2023.11.024
10. Raokadam V, Thiruvenkatarajan V, Bouras GS, Zhang A, Psaltis A. Emergence characteristics comparing endotracheal tube to reinforced laryngeal mask airway during endoscopic sinus surgery: a randomised controlled study. Indian J Anaesth. 2024;68(5):460–466. https://doi.org/10.4103/ija.ija_966_23
11. Alves S, Gomes C, Caldas S, Gonçalves M, Ferreira J. Reinforced laryngeal mask airway in ambulatory otorhinolaryngologic surgery: tonsillectomy and/or adenoidectomy in paediatric population. Ambul Surg. 2021;27(3):51–52. Available from: https://ambulatorysurgery.org/wp-content/uploads/2022/06/ AMB-SURG-27.3-ALVES.pdf
12. Bolous NS, Graetz DE, Ashrafian H, et al. Harnessing a clinician-led governance model to overcome healthcare tribalism and drive innovation: a case study of Northumbria NHS Foundation Trust. J Health Organ Manag. 2022; ahead-of-print:1–16. https://doi.org/10.1108/JHOM-05-2022-0157
13. Ali MP, Visser EH, West RL, van Noord D, van der Woude CJ, van Deen WK. Reporting feedback on healthcare outcomes to improve quality in care: a scoping review. Implement Sci. 2025;20(1):14. https://doi.org/10.1186/s13012-025-01424-9
14. Graves L, Dalgarno N, Hoorn RV, et al. Creating change: Kotter's change management model in action. Can Med Educ J. 2023;14(3):136–139. https://doi.org/10.36834/cmej.76680
15. Singh PK, Singh S, Kumari V, Tiwari M. Navigating healthcare leadership: theories, challenges, and practical insights for the future. J Postgrad Med. 2024;70(4):232–241. https://doi.org/10.4103/jpgm.jpgm_533_24
16. Nair A, Borkar N, Murke SS, Dudhedia U. Safety and efficacy of the use of supraglottic airway devices in children and adolescents undergoing adenotonsillectomy: a systematic review and meta-analysis. J Pers Med. 2024;14(3):311. https://doi.org/10.3390/jpm14030311
17. Omaygenc DO, Boyaci N, Olmez YE, Kahya E, Aydin N, Sen O. Airway complications associated with laryngeal mask use in short surgical procedures: a training perspective. Ain-Shams J Anaesthesiol. 2025;17(1):1–8. https://doi.org/10.21608/asja.2024.251049.1022
18. Mardini D, Catalano P, Wijewickrama R, Fraihat A. Comparing the use of the flexible laryngeal mask airway versus the endotracheal tube in upper airway surgery. Acta Sci Otolaryngol. 2022;4:67–72. https://doi.org/10.31080/ASOL.2022.04.0456

19. Hung KC, Wu SC, Hsu CW, et al. Efficacy of laryngeal mask airway against postoperative pharyngolaryngeal complications following thyroid surgery: a systematic review and meta-analysis of randomized controlled studies. Sci Rep. 2022;12(1):18210. https://doi.org/10.1038/s41598-022-21989-5

20. Vilendrer S, Saliba-Gustafsson EA, Asch SM, et al. Evaluating clinician-led quality improvement initiatives: a system-wide embedded research partnership at Stanford Medicine. Learn Health Syst. 2022;6(4):e10335. https://doi.org/10.1002/lrh2.10335

21. Liu R, Wang Y, Huang R, et al. Applying Kotter's change model to implement constructive alignment in clinical teaching rounds for service evaluation. J Eval Clin Pract. 2025;31(3):e70076. https://doi.org/10.1111/jep.70076

22. Wurster F, Di Gion P, Goldberg N, et al. Rogers' diffusion of innovations theory and the adoption of a patient portal's digital anamnesis collection tool: study protocol for the MAiBest project. Implement Sci Commun. 2024;5(1):74. https://doi.org/10.1186/s43058-024-00614-8

23. Zhang X, Yu P, Yan J, et al. Using diffusion of innovation theory to understand the factors impacting patient acceptance and use of consumer e-health innovations: a case study in a primary care clinic. BMC Health Serv Res. 2015;15:71. https://doi.org/10.1186/s12913-015-0726-2

24. Liu F, Xi C, Cui X, Wang G. Efficacy and safety of flexible laryngeal mask ventilation in otologic surgery: a retrospective analysis. Risk Manag Healthc Policy. 2022;15:945–954. https://doi.org/10.2147/RMHP.S354891

25. Zaman B, Noorizad S, Safari S, Javadi Larijani SMH, Seyed Siamdoust SA. Efficacy of laryngeal mask airway compared to endotracheal tube: a randomized clinical trial. Anesth Pain Med. 2022;12(1):e120478. https://doi.org/10.5812/aapm.120478

Original Article

Open Access

Estimation of the Aortic Valve Annular Size Measured by Pre-Operative Echocardiogram Validated Against Intra Operative Measurement by Standard Valve Sizers in Patient Undergoing Aortic Valve Replacement Open Heart Surgery

Muhammad Aftab Alam Khan, Muhammad Aasim, Ata Ul Mohsin, Sajid Khan, Muhammad Sadeeq, Abdul Aziz Ahmad

Abstract

Objective: This study was carried out to determine the diagnostic accuracy of transthoracic echocardiography (TTE) for preoperative sizing of the aortic annulus. It was done by comparing its measurements against the reference standard of direct intraoperative valve sizer measurement in patients who were undergoing surgical aortic valve replacement (SAVR).

Methodology: This cross-sectional was conducted at the Department of Cardiac Surgery, Hayatabad Medical Complex, Peshawar. from January 2023 to June 2023. Total 194 consecutive patients who were scheduled for SAVR were enrolled. Preoperative TTE measurements of the aortic annulus were performed in the parasternal long-axis view. The primary outcome was the agreement between TTE and sizer measurements. For this the concordance was defined as a difference of ±1 mm. After data collection the statistical analysis was performed using SPSS version 20.

Results: The mean age of our study population was found to be 66.8 ± 10.5 years, with 63.4% males. The TTE and sizer measurement showed a very strong positive correlation ($r = 0.978$, $p<0.001$). However, TTE systematically underestimated the annular diameter with a mean bias of -1.41 mm. The range of Bland-Altman limits of agreement was from -2.31 mm to -0.50 mm. The clinical concordance rate within ±1 mm was 81.4%. while analyzing the subgroups based on gender or valve morphology, they showed no significant differences in measurement discrepancy ($p>0.05$).

Conclusion: The TTE establishes a very strong correlation with direct intraoperative sizing, but it also exhibits a consistent underestimation bias.

Keywords: Aortic Valve, Aortic Valve Stenosis, Diagnostic Accuracy, Echocardiography, Heart Valve Prosthesis Implantation, Intraoperative Care

How to cite this Article:
Khan MAA, Aasim M, Mohsin AU, Khan S, Sadeeq M, Aziz A. Estimation of the Aortic Valve Annular Size Measured by Pre-Operative Echocardiogram Validated Against Intra Operative Measurement by Standard Valve Sizers in Patient Undergoing Aortic Valve Replacement Open Heart Surgery. J Bahria Uni Med Dental Coll. 2026;16(2):627-33 DOI: https://doi.org/10.51985/JBUMDC2025837

Muhammad Aftab Alam Khan
Resident, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: aaftab_ak@hotmail.com

Muhammad Aasim
Chairman, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: Doctoraasim@yahoo.com

Ata Ul Mohsin
Assistant Professor, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: drattaulmohsin@gmail.com

Sajid Khan
Senior Registrar, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: Sajidkhan8057@gmail.com

Muhammad Sadeeq
Resident, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: msadeeqafridi1965@gmail.com

Abdul Aziz Ahmad
Resident, Department of Cardiac Surgery
Hayatabad Medical Complex, Peshawar
Email: abdulazizahmad54@yahoo.com

Received: 13-11-2025
1st Revision:23-11-2025
Accepted: 30-03-2026
2nd Revision: 03-03-2026

INTRODUCTION

Aortic valve disease is a major and growing worldwide health burden, with calcific aortic stenosis being the most common valvular heart disease in industrialized nations.[1] Severe aortic stenosis prevalence increases steeply with age, affecting roughly 2-7% of the population over 65 years.[2] In Pakistan, the burden of valvular heart disease remains significant, with rheumatic heart disease still contributing notably to the pathology of aortic valve disease along with degenerative causes.[3]

The aortic annulus is a fibrous ring forming part of the heart's fibrous skeleton and represents the critical transition zone between the left ventricle and the aortic root.[4] It has a three-dimensional crown-like complex anatomy, which poses unique challenges for accurate measurement. The accurate sizing is important for successful aortic valve replacement. Because the proper annular assessment directly influences prosthesis selection, hemodynamic performance, and long-term outcomes.[5]

In the current times noninvasive imaging modalities are used for the preoperative assessment, among them transthoracic echocardiography (TTE) remains the most

accessible and common initial investigation worldwide.[6] In countries like Pakistan where there are resource-limited settings, TTE often represents the first, and sometimes only, imaging modality for surgical planning. However, emerging evidence suggests that there may be potential limitations in its accuracy for precise annular measurement.[7]

Several studies have reported systematic inconsistencies between echocardiographic measurements and direct surgical assessment. Messika-Zeitoun et al. demonstrated that different imaging modalities yield close but not identical annular measurements, with TTE typically providing smaller dimensions compared to computed tomography.[8] Similarly, Choe et al. highlighted the superior accuracy of cross-sectional computed tomographic assessment for transcatheter aortic valve replacement sizing.[9]

The clinical implications of inaccurate sizing are immense. Undersizing may result in patient-prosthesis mismatch, high residual transvalvular gradients, and incomplete regression of left ventricular hypertrophy. On the other hand, oversizing might lead to annular injury, conduction abnormalities, or coronary ostial compromise.[10] Consequently, in the Pakistani context, where patients often present with advanced disease and limited resources for repeating investigations, the accuracy of the initial TTE assessment needs to be maximized.

Literature also shows a distinct lack of region-specific validation of TTE for annular sizing against the reference standard of intraoperative valve sizers. While several international studies have compared different imaging modalities, few specifically assess the diagnostic performance of TTE in surgical aortic valve replacement populations using direct surgical measurement as the gold standard. In this regard, the current study will systematically determine the accuracy of TTE in our population to provide evidence-based guidance for surgical planning in resource-constrained settings[10].

Proper preoperative evaluation of the aortic annulus is the key to success of surgical aortic valve replacement (SAVR). Prosthesis size directly depends on the credible annular measurements, which determine postoperative hemodynamics, the survival of the implanted valve, and the prognosis of the patient in the long term. With the ever-improving technologies of surgery and prosthetic, the accuracy of preoperative imaging grew to be of importance to prevent such complications as paravalvular leak, patient-prosthesis mismatch, and structural deterioration of the valves. Even though different imaging modalities can be used nowadays, they have a significant difference in terms of applicability and reliability in different clinical settings[11].

TTE is the most commonly available imaging technology in most of the low-income and middle-income countries such as Pakistan and, hence, is used as the main tool of preoperative assessment. Although TTE is associated with many benefits, there have been concerns about the capability of TTE to accurately assess the three-dimensional geometry of the aortic annulus and particularly in patients with calcified or anatomically deformed valves. These constraints lead to critical clinical issues on whether TTE is a reliable indicator to make decisions on the choice of the prosthesis when direct measurements in the operating room are applied, which are still the gold standard[12].

Although it is the key element of everyday practice, it is clear that the diagnostic accuracy of TTE used in the annular sizing has not been thoroughly tested in local communities. The variations in the demographics of patients, the etiology of the disease, and the limited resources indicate the necessity of region-specific evidence [13]. Thus, to improve the work of the TTE concerning the intraoperative valve sizers, it is essential to assess it in the context of the decision-making process in surgery and guarantee the safe and evidence-based practice under the conditions of resource-limiting settings.

METHODOLOGY

This cross-sectional validation study was carried out at the Department of Cardiac Surgery, Hayatabad Medical Complex, Peshawar, from 10 January 2023 to 10-June 2023. The study was approved by the Institutional Review Committee of Hayatabad Medical Complex, Reference No: HMC/IRC/2022/45, and CPSP Ref No. CPSP/REU/CDS-2022-021-408, dated December 15, 2022, and was in accordance with the principles of the Declaration of Helsinki. Informed consent in writing was taken from all the participants or their guardians before enrollment.

Sample size of 194 was calculated using the sensitivity and specificity by Buderer's formula for diagnostic tests. Assuming from previous literature an expected sensitivity of 92%, expected specificity of 85%, expected prevalence of accurate sizing of 30%, desired precision of 7%, and 95% confidence level yields[14], A consecutive sampling technique was employed

The formulas used were: (nsens = Z2.Se(1-Se)/L2.Prev**)** where is Z the standard normal deviate for a 95% confidence level (1.96), is expected sensitivity, Sp expected specificity, Prev the prevalence of the condition of interest (here: prevalence of accurate sizing), and *L* he desired absolute precision (half-width of the confidence interval). Using values from prior literature and pilot assumptions (Se = 0.92, Prev = 0.30, L = 0.07, Z = 1.96) gives:

The larger value (for sensitivity) was taken as the required sample size: 193. Allowing a small contingency for incomplete data, the final sample size recruited was 194 participants.

All male and female patients of any age diagnosed with aortic valve insufficiency-both stenosis and regurgitation-who required surgical AVR either in isolation or in

combination with other cardiac surgery were included. those patients who were to undergo aortic valve repair rather than replacement, and those undergoing redo aortic valve surgeries due to the fact that previous interventions may have caused anatomical distortions were excluded.

Patient recruitment occurred through the cardiac surgery outpatient department and inpatient referrals. All patients received extensive preoperative assessment, including a detailed history, physical examination, and standard transthoracic echocardiography using commercially available ultrasound systems[25] (IE33, Philips Medical Systems, Cleveland, Ohio). The two consultant cardiologists who conducted the echocardiographic tests had over five years of echocardiography experience and were blinded to the measurements of the same during the operation. All of the measurements were taken per the common echocardiographic criteria and the annulus of the aorta was measured in the parasternal long-axis view during midsystole. To minimize variability in measurements, an average of three to five cardiac cycles was made per value. The diameter of the aortic annulus was determined in the parasternal long-axis view at midsystole using the zoom mode at the insertion points of the aortic valve leaflets. The measurements were performed by experienced echocardiographers who were blinded to the eventual surgical measurements and averaged over three to five cardiac cycles to take physiological variation into account.[26]

We standardized the intraoperative protocol across all cases. Cardiopulmonary bypass was established and the ascending aorta cross-clamped after the median sternotomy. For myocardial protection we administered cold blood cardioplegia. The native aortic valve leaflets were completely excised, along with thorough debridement of any calcifications on the aortic annulus. We then measured the annular diameter by using the largest fitting manufacturer's prosthesis sizing instrument (Edwards Lifesciences, Irvine, California) by the operating consultant cardiac surgeon. In order to reduce the operator-dependent variability, all the cases were undertaken by surgeons with at least five years of independent practice experience[27].

Demographic data collected on participants in the study included age, sex, body mass index; clinical characteristics of the participants such as valve pathology, valve morphology, left ventricular ejection fraction, and concomitant procedures; preoperative TTE measurements; intraoperative sizer measurements; and the size of the prosthesis implanted.

The primary outcome measure was the agreement between the TTE-derived annular diameter and the direct intraoperative sizer measurement. concordance was defined as an agreement within ±1 mm between the TTE and sizer measurements, a threshold consistent with established clinical practice.[15,16]

For all statistical analyses, SPSS version 20 was used (IBM Corporation, Armonk, New York). We presented continuous variables as mean ± standard deviation for normally distributed data, while categorical variables were summarized as frequencies and percentages. The Shapiro-Wilk test was used to assess the normality of the distribution of data. In order to investigate the agreement between the measurements obtained by TTE and sizer we performed the Bland-Altman analysis, including limits of agreement.[17] We used Pearson's correlation coefficient to calculate the correlation between the two measuring approaches. In comparisons of subgroups, Student's t-test was used for continuous variables and the Chi-square test for categorical variables; $p<0.05$ was considered statistically significant. All analyses were performed on an intention-to-diagnose basis.

written informed consent was obtained from all patients or their guardians before including them to the study, with proper explanation regarding the comparative imaging assessments. The research was in accordance with ethical standards, in which we ensured that all information about the patients remained confidential during the entire duration of the study.

RESULTS

A total of 194 patients who underwent aortic valve replacement were enrolled. Table I summarized study participant's baseline demographic and clinical characteristics. The mean age of the participants was 66.8 ± 10.5 years, in current study there was a male predominance (63.4%). Isolated aortic valve replacement was the most common procedure (57.2%), and stenosis was the predominant valve pathology (56.2%).There were 194 patients who were having the surgical aortic valve replacement that participated in the study. Table I shows the demographic and clinical background of the study population. The average age of the sample was 66.8 10.5 years, and of the patients male patients (63.4) prevailed, and female patients (36.4) were in minority. In the valve pathology, the most common was aortic stenosis (56.2%), then aortic regurgitation (24.2) and mixed valves disease (19.6). Regarding valve morphology, most of the patients were found to have tricuspid aortic valve morphology (86.6%), with few cases having bicuspid valve morphology (13.4%). In regard to surgical operations, 57.2 percent of patients have isolated aortic valve replacement (AVR) whereas 32.5 percent have AVR and cardiac artery bypass grafting (CABG) and other combination procedures constitute 10.3 percent. The average left ventricular ejection fraction (LVEF) of the study population was 54.2 including 12.8 and the average body mass index (BMI) was 28.4 including 4.5 kg/m 2 (Table I).

The mean annular diameter measured by transthoracic echocardiography (TTE) was 22.72 ± 2.21 mm. It was significantly lower than the mean diameter obtained via intraoperative sizer (24.13 ± 2.19 mm). There was a mean systematic underestimation of -1.41 ± 0.46 mm ($p<0.001$). A very strong positive correlation was observed between

the two methods (r = 0.978, p<0.001). The comparative measurements are given in detail in Table 2. The Bland-Altman analysis confirmed this systematic bias, with limits of agreement ranging from -2.31 mm to -0.50 mm, indicating that 95% of the differences between TTE and sizer measurements fell within this range.

Using the pre-defined clinical concordance threshold of ±1 mm, the overall agreement between TTE and the intraoperative sizer was 81.4% (158/194). Upon analyses the subgroups revealed no statistically significant differences in the measurement discrepancy when stratified by gender (p=0.653) or valve morphology (p=0.399). Furthermore, the rate of valve size concordance was not significantly associated with the operating surgeon (p=0.402). The subgroup analysis proves that underestimation TTE degree is gender-neutral, valve morphology-neutral, and valve pathology-neutral. Despite the fact that the females recorded a slight difference in mean than the males, it was not statistically significant (p=0.653). Likewise, the discrepancies between the bicuspid and tricuspid valves were also similar, which shows that the anatomical variance was not a major determinant of the measurement (p=0.399). There were no significant differences in the mean in the case of stenosis, regurgitation and mixed pathology (p=0.271). All in all, TTE showed a consistent distribution of underestimation bias across all subgroups, which indicated its reliability but necessitated learning to interpret the results with caution in surgical planning. Analysis of the concordance reveals that transthoracic echocardiography has a high agreement with intraoperative sizing in the study population with the general concordance rate being 81.4%. Male (82.1) and female (80.3) concordance was similar, and it did not show any significant gender difference. Similar results were also obtained with valve morphology in which tricuspid and bicuspid valves exhibited almost equal concordance rates. There was greatest agreement with isolated AVR (83.8%), and AVR with CABG (77.8%), which is probably due to the increased complexity of the anatomy. In general, these results reveal that TTE has a stable diagnostic agreement among demographic and clinical subgroups.

When valve-size prediction was assessed against the implanted prosthesis size, TTE demonstrated a sensitivity of 79.9%, specificity of 100.0%, positive predictive value of 100.0%, negative predictive value of 29.4%, and an overall accuracy of 81.4%.

Table 1: Baseline Characteristics of the Study Population (N=194)

Characteristic	Value
Age (years), Mean ± SD	66.8 ± 10.5
Gender, n (%)	
Male	123 (63.4)
Female	71 (36.6)
Valve Pathology, n (%)	
Stenosis	109 (56.2)
Regurgitation	47 (24.2)
Mixed	38 (19.6)
Valve Morphology, n (%)	
Tricuspid	168 (86.6)
Bicuspid	26 (13.4)
Concomitant Procedure, n (%)	
Isolated AVR	111 (57.2)
AVR + CABG	63 (32.5)
Other	20 (10.3)
Left Ventricular Ejection Fraction (%), Mean ± SD	54.2 ± 12.8
Body Mass Index (kg/m²), Mean ± SD	28.4 ± 4.5

Figure 1: Bland-Altman plot: Aortic Annular Diameter



Table 2: Aortic Annular Diameter Measurements by TTE and Intraoperative Sizer

	TTE (mm)	Intraoperative Sizer (mm)	Mean Difference	Mean Difference
Mean ± SD	22.72 ± 2.21	24.13 ± 2.19	-1.41 ± 0.46	<0.001
Minimum	16.9	18.0		
Maximum	27.0	28.3		

Table 3: Subgroup Comparison of TTE–Sizer Measurement Differences

Subgroup	n	Mean TTE Annulus (mm)	Mean Sizer Annulus (mm)	Mean Difference (mm)	p-value
Gender					
Male	123	22.81 ± 2.24	24.18 ± 2.17	-1.37 ± 0.45	0.653
Female	71	22.56 ± 2.18	24.07 ± 2.21	-1.51 ± 0.47	
Valve Morphology					
Tricuspid	168	22.70 ± 2.20	24.11 ± 2.20	-1.41 ± 0.46	0.399
Bicuspid	26	22.84 ± 2.27	24.21 ± 2.16	-1.37 ± 0.47	
Valve Pathology					
Stenosis	109	22.41 ± 2.16	23.84 ± 2.11	-1.43 ± 0.44	0.271
Regurgitation	47	23.04 ± 2.33	24.46 ± 2.25	-1.42 ± 0.49	
Mixed	38	22.93 ± 2.18	24.39 ± 2.30	-1.46 ± 0.48	

Table 4: Concordance between TTE and Intraoperative Sizer Measurements

Category	n (%)	Concordant (±1 mm)	Discordant (>1 mm)	Concordance Rate (%)
Total Cohort	194	158	36	81.4%
Gender				
Male	123 (63.4)	101	22	82.1%
Female	71 (36.6)	57	14	80.3%
Valve Morphology				
Tricuspid	168 (86.6)	137	31	81.5%
Bicuspid	26 (13.4)	21	5	80.8%
Procedure Type				
Isolated AVR	111 (57.2)	93	18	83.8%
AVR + CABG	63 (32.5)	49	14	77.8%
Other Combined	20 (10.3)	16	4	80.0%

Table 5 Diagnostic performance of TTE for prediction of implanted valve size

Parameter	Value
Sensitivity	79.9%
Specificity	100.0%
Positive predictive value	100.0%
Negative predictive value	29.4%
Overall accuracy	81.4%

DISCUSSION

Our current study provides a systematic, intraoperatively-validated assessment of transthoracic echocardiography for aortic annular sizing in a Pakistani surgical aortic valve replacement population. Our principal finding is that TTE demonstrates a very strong positive correlation ($r = 0.978$, $p<0.001$) with direct surgical measurement. In addition, it also exhibits a consistent and statistically significant underestimation of the annular diameter, with a mean systematic bias of -1.41 mm. However, when applying a clinically relevant ±1 mm agreement threshold, the concordance rate between TTE and the intraoperative sizer was substantially high at 81.4%. These findings underscore both the utility and the limitations of TTE as a primary sizing modality in resource-constrained environments, providing a clear, quantified measure of its performance for surgical planning.

This consistent underestimation of the aortic annulus by TTE that we have found in our cohort is reflective of the international literature. Wang et al., in a larger cohort of 227 patients, reported that TEE underestimation of the aortic annulus diameter occurred in 51.1%, with 16.7% being underestimations of more than one valve size.[8] Our study, using TTE, demonstrated a similar directional bias, which could be related to the intrinsic limitations of two-dimensional echocardiography to assess this complex, three-dimensional, and often elliptical structure.[18,19] The parasternal long-axis view tends to capture the annulus in its minor-axis dimension without accounting for the larger coronal diameter that would inevitably lead to undersizing.[20] Furthermore, Bland-Altman analysis revealed limits of agreement from -2.31 to -0.50 mm, indicating that while there is a consistent bias, the actual discrepancy in individual patients may be as large as 2.3 mm. This is clinically relevant and may represent a full-size difference. Heavy annular calcifications may also hide the anatomical markers, thereby further compromising measurement accuracy in a scenario not infrequently

encountered in our population, who often present with advanced, calcific valve disease.

The critical implication of our findings lies in the 18.6% of patients where TTE and surgical sizing disagreed by more than 1 mm. Inaccurate sizing, particularly undersizing, carries substantial clinical risks, including patient-prosthesis mismatch, elevated transvalvular gradients, and impaired left ventricular mass regression.10 Our data supports a pragmatic approach: surgeons should be aware of the consistent -1.4 mm bias. If a TTE measurement is at the very upper limit of a valve size (e.g., 22.1 mm for a 23 mm valve), they should have a high index of suspicion that the patient may actually accommodate the next larger size (e.g., a 25 mm valve). Our subgroup analyses reassuringly found no significant differences in measurement discrepancy based on gender or valve morphology, indicating that TTE's performance is consistently biased but not disproportionately affected by these common variables. This consistency allows for the potential application of a general correction factor in clinical judgment.

Our findings invite comparison with studies advocating for more advanced imaging. Multidetector computed tomography is increasingly seen as the gold standard for pre-procedural annular assessment, particularly for transcatheter aortic valve replacement. George et al. showed that preoperative MDCT measurements commonly indicated larger valve sizes than did direct surgical sizing and that theoretical TAVR valve implantation based on MDCT would have resulted in significantly larger geometric orifice areas.[21] This reveals a basic difference in sizing philosophy and anatomic assessment between modern cross-sectional imaging and traditional surgical sizing. Similarly, innovative approaches like 3D printing of the aortic root from CT data showed excellent agreement with both CT and intraoperative measurements, providing a tactile, patient-specific model for pre-procedural planning.[22]

However, the universal adoption of MDCT or 3D printing in resource-limited settings remains a distant prospect due to constraints of cost, availability, and expertise. Therefore, the pragmatic approach is not to discard TTE but to optimize its use and define its place in a tiered diagnostic algorithm. For the 18.6% of patients where TTE may be misleading, or for those with complex root anatomy, borderline measurements, or a high risk of patient-prosthesis mismatch, every effort should be made to secure advanced imaging with CT or CMR, if feasible, to refine the surgical plan.[23]

Limitations of the study. Our study has several limitations. Firstly, it was conducted at a single tertiary care center, which may limit the generalizability of the findings to all practice settings within the country. Secondly, the TTE measurements were performed by experienced echocardiographers, and the results may not be fully replicable in centers with less specialized expertise. Thirdly, we did not compare TTE with other advanced imaging modalities like CT or CMR in the same cohort, which would have provided a more comprehensive multi-modality analysis. Finally, we focused on the agreement of annular sizing and did not correlate the degree of discrepancy with long-term clinical outcomes such as patient-prosthesis mismatch or hemodynamic performance, which should be the focus of future prospective studies.

CONCLUSION

To sum it up our study demonstrates that the TTE maintains a strong correlation and a high rate of clinical concordance (81.4%) with direct intraoperative annular sizing in a resource-limited population. Although it shows a consistent underestimation bias of approximately 1.4 mm. It proves to be a fundamentally useful tool for preoperative planning in SAVR. For surgeons, knowledge of its systematic bias is essential in order to moderate the risk of prosthesis undersizing. In an ideal scenario, a heart team approach incorporating advanced imaging for complex cases would be optimal; however, in realities defined by resource constraints, a thorough understanding of TTE's validated performance and limitations allows for its continued safe and effective application.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Muhammad Aftab Alam Khan: Main conception of study, manuscript writing, data collection, results and conclusion, final approval
Muhammad Aasim: Data analysis data collection, manuscript writing
Ata Ul Mohsin: Data collection, data interpretation, final approval, manuscript writing
Sajid Khan: Revision, data collection, final approval, manuscript writing
Muhammad Sadeeq: Data analysis, data collection, final approval, manuscript writing
Abdul Aziz Ahmad: Main conception of study, overall supervision critical revisions, final approval

REFERENCES:

1. Santangelo G, Bursi F, Faggiano A, Moscardelli S, Simeoli PS, Guazzi M, Lorusso R, Carugo S, Faggiano P. The global burden of valvular heart disease: from clinical epidemiology to management. Journal of clinical medicine. 2023 Mar 10;12(6):2178. https://doi.org/10.3390/jcm12062178
2. Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, Katsoulis M, Hartman N, Fontana M, Pugliese F, Sabharwal N. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. European heart journal. 2020 Aug 1;41(29):2759-67. https://doi.org/10.1093/eurheartj/ehaa170
3. Bhatti S, Rehman S, Usman M, Iqbal Z, Atif U, Gurmani S, Hussain W, Memon R, Awan AB, Mangi AJ, Karim M. Valvular heart disease care in Pakistan: impact of the multidisciplinary valve heart team. JACC: Advances. 2024 Dec 1;3(12_Part_2):101378.

4. Piazza N. Anatomy and Imaging of the Aortic Valvar Complex for Transcatheter Aortic Valve Implantation. InTranscatheter Aortic Valve Implantation 2024 Sep 10 (pp. 11-27). CRC Press.
5. Giuliani C, Zanuttini A, Hecht S, Ternacle J, Pibarot P. Prosthesis-Patient Mismatch: Current State of Evidence. Current Cardiology Reports. 2025 Dec;27(1):49. https://doi.org/10.1007/s11886-025-02212-z
6. Rana M. Aortic valve stenosis: diagnostic approaches and recommendations of the 2021 ESC/EACTS guidelines for the management of valvular heart disease–a review of the literature. Cardiology and cardiovascular medicine. 2022 Jun 27;6(3):315. doi:10.26502/fccm.92920267
7. Frazao C, Tavoosi A, Wintersperger BJ, Nguyen ET, Wald RM, Ouzounian M, Hanneman K. Multimodality assessment of thoracic aortic dimensions: comparison of computed tomography angiography, magnetic resonance imaging, and echocardiography measurements. Journal of Thoracic Imaging. 2020 Nov 1;35(6):399-406. DOI: 10.1097/RTI. 0000000000000514
8. Fortuni F, Delgado V. Assessment of aortic valve stenosis severity: multimodality imaging may be the key. European Heart Journal-Cardiovascular Imaging. 2020 Oct;21(10):1103-4. https://doi.org/10.1093/ehjci/jeaa129
9. Choe J, Koo HJ, Kang JW, Kim JB, Kang HJ, Yang DH. Aortic annulus sizing in bicuspid and tricuspid aortic valves using CT in patients with surgical aortic valve replacement. Scientific Reports. 2021 Oct 25;11(1):21005. https://doi.org/10.1038/s41598-021-00406-3
10. Huckaby LV, Fortunato RN, Emerel LV, Phillippi JA, Billaud M, Vorp DA, Maiti S, Gleason TG. Wall Tensile Stress Maps of Human Aneurysmal Aorta Demonstrate a High Biaxiality Ratio Corresponds with Wall Tissue Microstructure and Local Oxidative Stress Response Distinctly for Bicuspid and Tricuspid Aortic Valve Patients: LV Huckaby et al. Annals of Biomedical Engineering. 2025 Jun 17:1-6. https://doi10.1007/s10439-025-03771
11. Vaidya YP, Cavanaugh SM, Sandhu AA. Surgical aortic valve replacement in small aortic annulus. Journal of Cardiac Surgery. 2021 Jul;36(7):2502-9. https://doi10.1111/jocs.15555.
12. Navarro SM, Shaikh H, Abdi H, Keil EJ, Odusanya S, Stewart KA, Tuyishime E, Mazingi D, Tuttle TM. Surgical applications of ultrasound use in low-and middle-income countries: a systematic review. Australasian Journal of Ultrasound in Medicine. 2022 May;25(2):80-97. https://doi10.1002/ajum.12302.
13. Akhtar H, Tareen I, Hussain SM, Zia K, Sohail OB, Khan MI. Accuracy of TTE in Aortic Annulus Sizing: Comparison with Intraoperative Measurements. Pakistan Heart Journal. 2025 Jun 30;58(2):225-9. https://doi.org/10.47144/phj.v58i2.2738
14. Björn R, Nissinen M, Lehto J, Malmberg M, Yannopoulos F, Airaksinen KJ, Hartikainen JE, Nieminen T, Biancari F, Gunn J, Kiviniemi TO. Late incidence and recurrence of new-onset atrial fibrillation after isolated surgical aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery. 2022 Dec 1;164(6):1833-43. https://doi.org/10.1016/j.jtcvs.2021.03.101
15. Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Academic Emergency Medicine. 1996 Sep;3(9):895-900.
16. Wang H, Hanna JM, Ganapathi A, Keenan JE, Hurwitz LM, Vavalle JP, Kiefer TL, Wang A, Harrison JK, Hughes GC. Comparison of aortic annulus size by transesophageal echocardiography and computed tomography angiography with direct surgical measurement. The American journal of cardiology. 2015 Jun 1;115(11):1568-73.
17. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ: British Medical Journal. 1994 Jun 11;308(6943):1552. doi: 10.1136/bmj.308.6943.1552
18. Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. The lancet. 1986 Feb 8;327(8476):307-10. https://doi.org/10.1016/ S0140-6736(86)90837-8
19. Kasel AM, Cassese S, Bleiziffer S, Amaki M, Hahn RT, Kastrati A, Sengupta PP. Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. JACC: Cardiovascular Imaging. 2013 Feb;6(2):249-62. https://doi.org/10.1016/j.jcmg.2012.12.005
20. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circulation: Cardiovascular Interventions. 2008 Aug;1(1):74-81. https://doi.org/10.1161/CIRCINTERVENTIONS.108.780858
21. Altiok E, Koos R, Schröder J, Brehmer K, Hamada S, Becker M, Mahnken AH, Almalla M, Dohmen G, Autschbach R, Marx N. Comparison of two-dimensional and three-dimensional imaging techniques for measurement of aortic annulus diameters before transcatheter aortic valve implantation. Heart. 2011 Oct 1;97(19):1578-84. https://doi.org/10.1136/hrt.2011.223974
22. George I, Guglielmetti LC, Bettinger N, Moss A, Wang C, Kheysin N, Hahn R, Kodali S, Leon M, Bapat V, Borger MA. Aortic valve annular sizing: intraoperative assessment versus preoperative multidetector computed tomography. Circulation: Cardiovascular Imaging. 2017 May;10(5):e005968. https://doi.org/10.1161/CIRCIMAGING.116.005968
23. Faletti R, Gatti M, Cosentino A, Bergamasco L, Stura EC, Garabello D, Pennisi G, Salizzoni S, Veglia S, Ottavio D, Rinaldi M. 3D printing of the aortic annulus based on cardiovascular computed tomography: preliminary experience in pre-procedural planning for aortic valve sizing. Journal of cardiovascular computed tomography. 2018 Sep 1;12(5):391-7. https://doi.org/10.1016/j.jcct.2018.05.016
24. Jilaihawi H, Kashif M, Fontana G, Furugen A, Shiota T, Friede G, Makhija R, Doctor N, Leon MB, Makkar RR. Cross-sectional computed tomographic assessment improves accuracy of aortic annular sizing for transcatheter aortic valve replacement and reduces the incidence of paravalvular aortic regurgitation. Journal of the American College of Cardiology. 2012 Apr 3;59(14):1275-86. https://doi.org/10.1016/j.jacc.2011.11.045
25. Subramaniam K, Boisen ML, Yehushua L, Esper SA, Philips DP, Howard-Quijano K. Perioperative transthoracic echocardiography practice by cardiac anesthesiologists—report of a "start-up" experience. Journal of Cardiothoracic and Vascular Anesthesia. 2021 Jan 1;35(1):222-32. https://doi.org/10.1053/j.jvca.2020.06.046
26. Venkatram P. Parasternal Short Axis (PSAX) View.(Left Parasternal Window). InHeart diseases and echocardiogram: Principles in practice 2024 Aug 10 (pp. 549-568). Cham: Springer Nature Switzerland. https://doi.org/10.1007/978-3-031-59246-1_40
27. Çekmecelioğlu D, Kibler K, Orozco-Sevilla V, Coselli JS. Cardiopulmonary bypass in thoracic aortic surgery. InCardiopulmonary Bypass 2023 Jan 1 (pp. 395-419). Academic Press. https://DOI.10.1016/B978-0-443-18918-0.00024-3

Original Article **Open Access**

Comparison of Axillary Lymph Node Dissection by Using Vessel Sealing System versus Conventional Thread Ligation in Patients Undergoing Modified Radical Mastectomy for Carcinoma of Breast

Hamza Asghar, Umer Ejaz Cheema, Saad Khan, Ayesha Zulfiqar, Syeda Hussan-e-Zahra, Imran Amin

ABSTRACT

Objective: To evaluate the results of the traditional thread ligation technique against the vessel sealing system employed in axillary dissection for breast cancer, focusing on the average postoperative drain output and the mean duration until drain removal.

Study Design and Setting: This study was carried out at the Gujranwala Medical College/District Headquarters Hospital. A total of 120 patients were enrolled in this study following the inclusion criteria. A Non-probability consecutive sampling technique was used to divide patients into two groups.

Results: In this study the mean age and BMI in Group A were 52.78 ± 10.06 years and 26.88 ± 3.94 kg/m² respectively. Similarly, the mean age and BMI in Group B were 50.27 ± 11.77 years and 29.08 ± 4.12 kg/m², respectively. In this study the mean drain removal days in the conventional group were 5.05 ± 0.81 and in the ligasure group were 4.75 ± 0.77, with the p-value being as significant as 0.040. Similarly, the mean drain fluid in the conventional group was 640.33 ± 59.80 ml and in the ligasure group was 487.83 ± 27.38 ml, p-value < 0.01. The stratification of the age with respect to drain fluid showed significant differences for all age groups, i.e., p-value < 0.01 except for age group 18-28 years, p-value 0.371.

Conclusion: Axillary lymph node dissection utilising the results in a reduction in mean postoperative drain output and the average duration until drain removal compared to the traditional thread ligation technique.

Keywords Axillary Lymph Node, Carcinoma, Conventional, Dissection, Mastectomy

How to cite this Article:
Asghar H, Cheema UE, Khan S, Zulfiqar A, Zahra SH, Amin I. Comparison of Axillary Lymph Node Dissection by Using Vessel Sealing System versus Conventional Thread Ligation in Patients Undergoing Modified Radical Mastectomy for Carcinoma of Breast. J Bahria Uni Med Dental Coll. 2026;16(2):634-9 DOI: https://doi.org/10.51985/JBUMDC2025752

Hamza Asghar
Post Graduate Resident, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: hamzaasghar003@gmail.com

Umer Ejaz Cheema
Consultant, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: CHEEMAYAAR@gmail.com

Saad khan
Post Graduate Resident, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: saad.k@hotmail.com

Ayesha Zulfiqar
Post Graduate Resident, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: draysha6@gmail.com

Syeda Hussan e zahra
Senior Registrar, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: dr.syedahzn@gmail.com

Imran Amin
Professor, Department of General Surgery
DHQ Teaching Hospital Gujranwala
Email: drimranamin2004@yahoo.com

Received: 13-10-2025
1st Revision: 09-12-2025
Accepted: 04-04-2026
2nd Revision: 18-03-2026

INTRODUCTION

In every region of the world, cancer is the leading cause of death and illness. There were 14.1 million newly diagnosed instances of cancer, and it is estimated that 8.2 million people lost their lives as a direct result of cancer altogether.[1] As of the year 2012, there were 1.7 million newly diagnosed instances of breast cancer. When it comes to females, breast cancer is the most common cause of death from cancer. As an additional point of interest, a study that was carried out in Pakistan indicated that breast cancer is the most prevalent type of cancer in the country, accounting for 38.2% of all malignancies. The rates are among the highest that can be found in Asia.[2] Nearly all of the women in Pakistan are diagnosed with breast cancer at a later stage than the majority of other women.

According to the findings of a study, eighty percent of the females presented with a delay that was larger than three months. The source of the delay was shown to be attributable to traditional beliefs and the incorrect interpretation of symptoms.[3]

When it comes to treating breast cancer, surgery continues to be the primary method of treatment. Modified radical mastectomy is the treatment of choice in cases when it is discovered that the axillary lymph nodes are also affected.[4-

[5] In the aftermath of a modified radical mastectomy, it is customary to place two drains, one in the flap and the other in the axilla. Research investigates a number of surgical techniques and devices for the purpose of axillary lymph node dissection. These include the traditional electrocautery technique, thread ligation, and the harmonic scalpel. When a modified radical mastectomy with axillary clearance is performed using typical thread ligation procedures, the most common problems that are noted include excessive postoperative drain output and the formation of seroma.[6–8]

When compared to more traditional methods, the electrothermal bipolar vessel sealing system has been found to be a more secure solution for axillary clearing. This conclusion was reached as a consequence of study that was conducted. A decrease in postoperative drain output (620±469 ml rather than 809±380 ml) and a shorter duration until drain removal (7.6±4.6 days rather than 10±4.3 days) are the outcomes of this. [9] The use of in axillary dissection has the potential to reduce postoperative complications when compared to conventional methods of thread ligation. This is because it allows for the removal of the drain at an earlier time (4.3±1.0 days rather than 5.7±1.5 days), and it also results in a lower drain output (366.2±220.1 ml rather than 422.9±225.5 ml). [10] According to the findings of another study, the traditional procedures that were utilised in the process of axillary dissection led to a decrease in the total volume of fluid drainage as well as the number of days that were required before the drain was removed.[10-11]

In light of the burden of breast cancer disease and the large number of modified radical mastectomies that are performed using conventional techniques, the purpose of this clinical trial is to evaluate the usefulness and stated benefits in our system. This will be done by comparing to conventional methods of axillary dissection. Additional information will be added to the current body of knowledge as a result of the findings of this clinical trial that utilised this novel instrument and method. The implementation of significant resources for the provision of this instrument and technique to all levels can be accomplished through the utilisation of these resources by policy makers, planners, and health managers. Additionally, the findings will raise awareness among experts working in the health care industry on this newly developed instrument and method.

METHODOLOGY

This quasi experimental trial was carried out at the Gujranwala Medical College/District Headquarters Hospital from 16 November 2024 to 16 May 2025 under IRB No.6/GMC. A sample size of 120 (60 in each group) was calculated with a 95% confidence level, 80% power of test and taking the expected mean number of days till drain removal as (6.4±2.9 vs. 8.2±3.8 days). [10]

Patients were enrolled using non-probability consecutive sampling, and subsequently devided into two groups using a random number table**.** Inclusion criteria: (1) Patients aged 18-70 years. (2) Female gender. (3) Patients with unilateral breast carcinoma (histopathological diagnosis using trucut biopsy) with all indications of modified radical mastectomy (clinical and radiological evidence of axillary lymph node involvement (as per operational definition). (4) ASA I-II.

Exclusion criteria: (1) Patients with early breast cancer (T1). (2) History of previous breast surgeries e.g. recurrent carcinoma. (3) Patients with diabetes mellitus, patients on anticoagulants, patients with radiation therapy to the chest wall. (4) Patients with any type of neoadjuvant chemotherapy. (5) ASA scores III and IV and stage IV metastatic carcinoma.

Breast cancer: It was assigned to the patient with a history of breast swelling, and on histopathology there is confirmation of carcinoma of the breast.

Mean drain output: Drain outputs were documented in millilitres every day until the output fell below 20 ml within the prior 24 hours.

Mean number of days till: The calculation was based on when the drain output fell below 20 ml within the prior 24 hours. The day of drain removal was documented and examined individually for each drain.

After approval from the hospital ethical committee and informed consent, 120 patients (60 in each group), presenting in the general surgery department, DHQ Hospital, Gujranwala, and fulfilling the inclusion exclusion criteria were enrolled in the study. They were assured confidentiality and explained about expertise available for new technique and conventional technique. Operation was performed by same group of surgeons. Tumor was staged using TNM classification. Patients meeting the inclusion criteria were enrolled through non-probability consecutive sampling. After enrollment, participants were randomly assigned to either Group A (Ligasure) or Group B (conventional thread ligation) using a random number table, ensuring equal allocation of 60 patients in each group.

Pre-operative preparation was done by complete bath prior to surgery using antiseptic soap and axilla was shaved. All the baseline investigations including routine radiological investigations and metastatic workup were carried out for each patient in both groups. All of patients were given prophylactic antibiotics preoperatively. The surgeries were performed under general anaesthesia. Level I, II lymph node dissection was done in all cases depending upon involvement of the axillary lymph nodes. Two suction drains were placed one in axilla and one in flap and they were called Axillary drain and Flap drain, respectively. Patients were discharged after removal of drains. Patients were called after 7th to 10th postoperative day in Outpatient Department and underwent thorough examination and investigations for any complication. Stitches were removed on postoperative day 10. In all patients, the following data was recorded: age, body mass index (BMI), type of surgery, duration of drain

and amount of drained fluid. All data was recorded.

Data was entered and analyzed using SPSS version 26.0. For quantitative variables like age, BMI, amount of drainage from both drains, number of days till drain removal was calculated as mean + S.D. ASA status (I/II), marital status was calculated as frequency and percentages. The t-test was used to compare the amount of drainage from both drains and the length of days until drain removal. A p value <0.05 was considered significant. The data was segmented by age, BMI, and ASA status. A post-stratification t-test was used, with p-values < 0.05 considered significant.

In this study the mean age and BMI in Group A were 52.78 ± 10.06 year and 26.88 ± 3.94 kg/m², respectively, similarly the mean age and BMI in Group B were this 50.27 ± 11.77 years and 29.08 ± 4.12 kg/m², respectively. The comparison of marital status and ASA showed insignificant results with p-values 0.717 and 0.361 respectively. In this study the mean drain removal days in conventional group was 5.05 ± 0.81 and in ligasure group was 4.75 ± 0.77 with the p-value being as significant 0.040. Similarly, the mean drain fluid in conventional group was 640.33 ± 59.80 ml and in ligasure group was 487.83 ± 27.38 ml showing statistically significant difference between both groups p-value < 0.01. (Table 1). The stratification of comparison of drain removal days with respect to age groups showed insignificant differences across the groups p-values > 0.05. (Table 2). The stratification of age with respect to drain fluid showed significant differences for all age groups i.e., p-value < 0.01 except for age group 18-28 years p-value 0.371. (Table 3). The stratification of comparison of drain removal days with respect to BMI showed that in patients with BMI > 25 kg/m2 there was a significant difference for the removal of drain between both groups p-value 0.001. The stratification of comparison of drain fluid with respect to BMI showed significant difference among both groups p-value < 0.01. (Table 4). The stratification of comparison of drain removal days with respect to ASA I showed insignificant difference p-value 0.817, however, for ASA II showed significant difference p-value 0.002. The stratification of comparison of drain fluid with respect to ASA classification showed significant difference among both groups in both classes' p-value < 0.01. (Table 5)

DISCUSSIONS

Breast cancer is the most often diagnosed type of malignancy in women globally. It accounts for 32% of female malignancies and 19% of cancer-related fatalities. In the USA, one in eight women and in European countries, one in ten women are diagnosed with breast cancer. The primary determinant in the prognosis of breast cancer is the presence or absence of axillary lymph node involvement. Axillary

Table 1: Demographics and clinical parameters

		Conventional Group (Group A)	Group (Group B)	P-Value
Age (Mean ± S.D)		52.78 ± 10.06	50.27 ± 11.77	0.210
BMI (Mean ± S.D)		26.88 ± 3.94	29.08 ± 4.12	0.003
Marital Status	**Single**	3 (5%)	5 (8.3%)	0.717
	Married	57 (95%)	55 (91.7%)	
ASA	**I**	33 (55%)	27 (45%)	0.361
	II	27 (45%)	33 (55%)	
Drain Removal Days (Mean ± S.D)		5.05 ± 0.81	4.75 ± 0.77	0.040
Drain Output (ml) (Mean ± S.D)		640.33 ± 59.80	487.83 ± 27.38	< 0.01

Table 2: Stratification of comparison of drain removal days with respect to age groups

	Age Group	Study Groups	N	Mean	Std. Deviation	P-Value
Drain Removal Days	**18-28**	**Conventional group**	3	5.33	.577	0.230
		Ligasure Group	3	4.67	.577	
	29-39	**Conventional group**	3	5.00	1.00	0.483
		Ligasure Group	7	4.57	.787	
	40-50	**Conventional group**	16	5.06	.929	0.681
		Ligasure Group	17	4.94	.748	
	51-60	**Conventional group**	37	5.03	.799	0.234
		Ligasure Group	27	4.76	.847	
	61-70	**Conventional group**	1	5.00	.	0.286
		Ligasure Group	6	4.33	.516	

Table 3: Stratification of comparison of drain volume with respect to age groups

	Age Group	Study Groups	N	Mean	Std. Deviation	P-Value
Drain Fluid	18-28	Conventional group	3	563.33	92.92	0.371
		Ligasure Group	3	503.33	45.09	
	29-39	Conventional group	3	676.67	51.32	<0.01
		Ligasure Group	7	492.86	17.99	
	40-50	Conventional group	16	645.62	61.20	<0.01
		Ligasure Group	17	492.94	26.64	
	51-60	Conventional group	37	641.35	55.29	<0.01
		Ligasure Group	27	482.59	27.12	
	61-70	Conventional group	1	640.00		0.007
		Ligasure Group	6	483.33	33.27	

Table 4: Stratification of comparison of drain removal days and drain fluid with respect to BMI

	BMI Classification	Study Groups	N	Mean	Std. Deviation	P-Value
Drain Removal Days	Non-obese	Conventional group	48	4.9583	.84949	0.419
		Ligasure Group	36	4.8056	.85589	
	Obese	Conventional group	12	5.4167	.51493	0.001
		Ligasure Group	24	4.6667	.63702	
Drain Fluid	Non-obese	Conventional group	48	639.38	64.46	< 0.01
		Ligasure Group	36	490.56	31.53	
	Obese	Conventional group	12	644.17	37.53	< 0.01
		Ligasure Group	24	483.75	19.52	

Table 5: Stratification of comparison of drain removal days with respect to ASA

	ASA Classification	Study Groups	N	Mean	Std. Deviation	P-Value
Drain Removal Days	I	Conventional group	33	4.87	0.78	0.817
		Ligasure Group	27	4.93	0.78	
	II	Conventional group	27	5.26	0.81	0.002
		Ligasure Group	33	4.61	0.75	
Drain Fluid	I	Conventional group	33	626.97	65.02	< 0.01
		Ligasure Group	27	491.48	24.60	
	II	Conventional group	27	656.67	49.07	< 0.01
		Ligasure Group	33	484.85	29.49	

lymph node dissection is conducted for precise disease staging, guiding adjuvant therapy, and ensuring local tumor control in patients with lymph node involvement. Post-axillary curettage, seroma occurs in 10% to 80% of cases, requiring aspiration.[12-14]

The bipolar vascular sealing device achieves hemostasis for vessels ranging from 1 to 7 millimeters. The vessel sealing device delivers the requisite energy to tissue masses or vessels based on their densities. Consequently, since no excess energy is transmitted, thermal convective injury is confined to adjacent tissues. With the heat radiation to adjacent tissues ranges from 0.5 to 2 millimetres. Utilizing precise for axillary curettage results in radiation levels < 0.5 millimetres.[15, 16]

Prior randomized studies have suggested that the vessel encapsulation system reduces postoperative hospital stays and reduces drainage volume when compared to conventional devices. [15,17-19] In comparison to conventional devices, the duration until drain removal and the volume of postoperative drainage were reduced by Small Jaw. It is imperative to reduce the number of drain days and hospital stays, as these factors can delay adjuvant therapy.

In our study, in group, mean drain volume was 487.83 ± 27.38 ml and 640.33 ± 59.80 ml in conventional group with p-value being as significant < 0.01. In a prior study, the mean drain volume in the ligasure group was 500.1±60.8

ml, while in the traditional group it was 665.3±84.9 ml, yielding a statistically significant p-value of 0.0001. [16]

In this study in the ligasure group mean number of drain removal days was 4.75 ± 0.77 and in conventional group was 5.05 ± 0.81 with p-value 0.040. In a separate trial involving the ligasure group, the average duration until drain removal was 6.5±1.1 days, compared to 8.6±1.2 days in the traditional group, yielding a statistically significant p-value of 0.0001. [16]

The baseline characteristics of the two groups were largely comparable; however, a statistically significant difference in BMI was observed between the groups (p = 0.003). Obesity is a recognized risk factor for increased postoperative seroma formation and higher drain output following axillary dissection. Therefore, this imbalance could potentially influence the postoperative drainage outcomes observed in the study. To address this concern, stratified analysis was performed based on BMI categories (obese and non-obese), which demonstrated that the reduction in drain output in the ligasure group remained statistically significant across both BMI categories. This suggests that the observed reduction in postoperative drainage with the vessel sealing system is unlikely to be solely explained by BMI differences and supports the independent effect of the surgical technique.

Research has established that the novel electrothermal bipolar vessel sealing system is a safe alternative for axillary clearance compared to conventional techniques, resulting in decreased postoperative drain output (620±469 ml vs. 809±380 ml) and a shorter duration until drain removal (7.6±4.6 days vs. 10±4.3 days).[7] used in axillary dissection reduces postoperative complications and allows early drain removal (4.3±1.0 days vs. 5.7±1.5 days) and less drain output (366.2±220.1 ml vs. 422.9±225.5 ml) as compared to traditional methods of thread ligation.[19]

A separate study concluded that is a more effective device than traditional methods for axillary dissection, as evidenced by a reduction in total fluid drainage volume (365.3 ± 242.2 ml vs. 625.1 ± 446.6 ml) and a decrease in the number of days until drain removal (6.4 ± 2.9 days vs. 8.2 ± 3.8 days).[16]

Although the LigaSure vessel sealing system is associated with a higher initial cost compared with conventional thread ligation, several studies suggest that its use may be cost-effective in the long term. The reduction in postoperative drain output and shorter duration until drain removal may lead to decreased hospital stay, fewer postoperative complications such as seroma formation, and earlier initiation of adjuvant therapy. These factors can potentially offset the higher device cost by reducing overall healthcare utilization and improving patient recovery. In our study, although a formal cost-effectiveness analysis was not performed, the shorter drain duration and reduced drain output observed in the LigaSure group suggest potential economic benefits. Future studies incorporating detailed cost analysis are recommended to better evaluate the economic impact of LigaSure use in axillary dissection.

LIMITATIONS: The major limitation we faced while conducting this study was to find patients meeting our inclusion criteria because most of the patients in our hospital present at a very late stage in which we had to first give neo adjuvant therapy and those patients could not meet our inclusion criteria. The second thing was availability and the cost of the procedure but it was resolved by the hospital administration in the vital interest of the patients. A formal cost-effectiveness analysis comparing LigaSure with conventional ligation was not performed in this study, which represents a limitation. Future studies should evaluate the economic implications of using advanced vessel sealing devices in breast cancer surgery.

A significant baseline difference in BMI between groups was observed, which could act as a potential confounder since obesity is associated with increased seroma formation. Although stratified analysis was performed to minimize this effect, future studies using multivariable adjusted analysis are recommended.

CONCLUSION

Axillary lymph node dissection utilizing results in a reduction in mean postoperative drain output and the average duration until drain removal compared to the traditional thread ligation technique.

Suggestions / Recommendations

We should work hard to create awareness among the population regarding breast cancer. Government should make breast Clinics in all Primary and Secondary Healthcare settings so that patients are timely screened and managed at an earlier stage. There should be regular walks and seminars on breast cancer. The doctors at Basic Health Unit Level to DHQs should be given regular trainings for screening and proper referral of breast cancer patients.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Hamza Asghar: Conception design and title selection
Umer Ejaz Cheema: Data Collection
Saad Khan: Data entry and analysis
Ayesha Zulfiqar: Introduction and discussion writing
Syeda Hussan e Zahra: Rephrasing of article text
Imran Amin: Supervision of all research work

REFERENCES

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024 May;74(3):229-63. https://doi.org/ 10.3322/caac.21834

2. Zaheer S, Yasmeen F. Historical trends in breast cancer presentation among women in Pakistan from join-point regression analysis. Pakistan Journal of Medical Sciences. 2024 Jan;40(1Part-I):134. doi: 10.12669/pjms.40.1.7123
3. Gulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM. Identifying the reasons for delayed presentation of Pakistani breast cancer patients at a tertiary care hospital. Cancer management and research. 2019 Jan 29:1087-96. doi: 10.2147/CMAR.S180388
4. Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary surgery in breast cancer: an updated historical perspective. InSeminars in oncology 2020 Dec 1 (Vol. 47, No. 6, pp. 341-352). WB Saunders. https://doi.org/10.1053/j.seminoncol.2020.09.001
5. Hanson SE, Lei X, Roubaud MS, DeSnyder SM, Caudle AS, Shaitelman SF, et al. Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction. JAMA surgery. 2022 Jun 1;157(6):e220631
6. Moussa HR, Elmahdy TM, Abdelhamid AF. Harmonic scalpel versus electrocautery in axillary lymph-node dissection in patients with breast cancer: a prospective randomized study. The Egyptian Journal of Surgery. 2021 Oct 1;40(4):1180-6. DOI: 10.4103/ejs.ejs_185_21
7. Jamil T, Tarar JM, Nasir F, Zahid MM, Ali A. The Risks of Early Complications from Level II Axillary Clearance in Modified Radical Mastectomy: Level II Axillary Clearance in Modified Radical Mastectomy. Pakistan Journal of Health Sciences. 2024 Jul 31:120 DOI: https://doi.org/10.54393/pjhs.v5i07.1909
8. sistemului de sigilare vascularã U. The use of vessel sealing system in axillary dissection; effect on seroma formation. Chirurgia. 2014;109:620-5. (www.revistachirurgia.ro)
9. Cortadellas T, Córdoba O, Espinosa-Bravo M. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. Int J Surg. 2011;9(8):636-40. https://doi.org/10.1016/j.ijsu.2011.08.002
10. Tomko S, Tetsku H, Maiko T. A randomized controlled study comparing a vessel sealing system with a conventional technique in axillary lymph node dissection for primary breast cancer. Springeplus. 2016;5(1):1004. DOI: 10.1186/s40064-016-2710-7
11. Zafar S, Khan MA, Rafiq U, Mahmood N. Comparison Of Axillary Drain Out Put In Conventional And Advancedcompressive Energy Source Like Ultrasonic Scalpel And Dissection Of Axilla In Breast Cancer Surgery. Journal of Ayub Medical College Abbottabad. 2021 Jun 29;33(3):431-6. doi: 10.1007/s12282-023-01460-7
12. Kazzam, M. E., & Ng, P. (2022). Postoperative seroma management. PMID: 36256748
13. £ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis³awek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers. 2021 Aug 25;13(17):4287. PMCID: PMC8428369 PMID: 34503097
14. Di Sibio A, Abriata G, Forman D, Sierra MS. Female breast cancer in Central and South America. Cancer Epidemiology. 2016 Sep 1;44:S110-20. https://doi.org/10.1016/j.canep.2016.08.010
15. Wienerroither V, Hammer R, Kornprat P, Schrem H, Wagner D, Mischinger HJ, El-Shabrawi A. Use of vessel sealing system versus conventional axillary dissection in breast cancer patients: a retrospective comparative study. BMC surgery. 2022 Dec 22;22(1):436. https://doi.org/10.1186/s12893-022-01888-2
16. Shaukat A, Anjum MA. Comparison of axillary lymph node dissection by using vessel sealing system vs conventional thread ligation in patients undergoing modified radical mastectomy for carcinoma of breast. Annals of Punjab Medical College. 2020 Sep 30;14(3):254-8. DOI: 10.29054/APMC/2020.925
17. Toda Y, Iwata S, Kobayashi E, Ogura K, Osaki S, Fukushima S, et al. A vessel sealing system can help reduce the risk of postoperative complications after tumour resection in the medial thigh. Bone & Joint Open. 2023 Jun 12;4(6):442-6. doi: 10.1302/2633-1462.46.BJO-2023-0037
18. Hasan SA, Ahmed DT, Al-Tamimi Z. Comparative Study of Bipolar Vessel Sealing Against Standard Suturing in Total Abdominal Hysterectomy. Journal of Bioscience and Applied Research. 2024 Sep 22;10(3):545-51. DOI:10.21608/jbaar.2024.381073
19. Peng JM, Ansingkar KK, Landavazo BN, Shaikh AF, Rahimi M. A comprehensive review of seroma formation, prevention, and treatment approaches. Journal of Vascular Surgery Cases, Innovations and Techniques. 2025 Oct 1;11(5):101879. https://doi.org/10.1016/j.jvscit.2025.101879
20. Zia MI, Malik S, Anum S, Zahara FT, Anum Z. Comparison of outcomes of system and conventional electrocautery in patients undergoing modified radical mastectomy for breast cancer. The Professional Medical Journal. 2023 Jan 1;30(01):107-12. . https://doi.org/10. 29309/TPMJ/2023.30.01.7236

Original Article **Open Access**

Diagnostic Accuracy of C-Reactive Protein as a Predictor of Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Abdul Salam, Muhammad Younus, Muhammad Zaid Iqbal, Muhammad Usman, Ghulam Mohiuddin, Muhammad Sarfraz Munawar

ABSTRACT

Objective: This study aimed to assess the diagnostic accuracy of CRP as a predictor of readmission for acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with 30-day readmission as the gold standard.

Study design and setting: A prospective observational study was carried out at the Institute of TB and Chest Medicine, Mayo Hospital, Lahore, over six months from April 2025 to September 2025.

Methods: A total of 201 patients aged 40–70 years with a confirmed diagnosis of COPD, as per GOLD 2025 guidelines, and presenting with AECOPD were enrolled using a non-probability consecutive sampling technique. Serum CRP levels were measured on admission using the Spectra 1000 analyzer. Participants were followed for 30 days post-discharge to record readmissions. Data were analyzed using SPSS version 27.0. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of CRP =15.8 mg/dl for predicting 30-day readmission were calculated.

Results: The mean age of participants was 53.80 ± 8.99 years, with 56.7% males. The mean CRP level was 16.37 ± 19.46 mg/dl. Higher CRP levels were significantly associated with advanced GOLD stages ($p < 0.001$). Overall, 30.8% experienced 30-day readmission. CRP = 15.8 mg/dl predicted readmission with sensitivity 70.9%, specificity 75.5%, and diagnostic accuracy 74.1% ($p < 0.001$).

Conclusion: Elevated CRP is significantly associated with COPD severity and early readmission, suggesting its role as a useful prognostic biomarker for AECOPD management. CRP could serve as a simple, inexpensive biomarker for identifying high-risk patients and guiding post-discharge management to reduce readmissions.

Keywords: Acute disease, Biomarker, C-reative protein (CRP), Chronic obstructive pulmonary disease (COPD)

How to cite this Article:
Salam A, Younus M, Iqbal MZ, Usman M, Mohiuddin G, Munawar MS. Diagnostic Accuracy of C-Reactive Protein as a Predictor of Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Bahria Uni Med Dental Coll. 2026;16(2):40-6 DOI: https://doi.org/10.51985/JBUMDC2025736

Abdul Salam
Postgraduate Resident, Department of Pulmonology
Mayo Hospital, Lahore
Email: salam9606@gmail.com

Muhammad Younus
Associate Professor, Department of Pulmonology
Mayo Hospital, Lahore
Email: dr.muhammadyounus79@gmail.com

Muhammad Zaid Iqbal
Postgraduate Resident, Department of Pulmonology
Mayo Hospital, Lahore
Email: zaidiqbal314@gmail.com

Muhammad Usman
Postgraduate Resident, Department of Pulmonology
Mayo Hospital, Lahore
Email: usman4547@gmail.com

Ghulam Mohiuddin
Postgraduate Resident, Department of Pulmonology
Mayo Hospital, Lahore
Email: drmohiuddin13@gmail.com

Muhammad Sarfraz Munawar
Postgraduate Resident, Department of Pulmonology
Mayo Hospital, Lahore
Email: Maliksarfraz271@gmail.com

Received: 26-09-2025
Accepted: 31-03-2026
1st Revision: 26-10-2025
2nd Revision: 16-03-2026

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a prevalent and treatable condition characterized by a gradual restriction of airflow and damage to lung tissue. It is associated with alterations in lung structure resulting from persistent inflammation and is among the leading causes of morbidity and mortality worldwide.[1] COPD is the 4th leading cause of death worldwide, attributing to 3.5 million deaths in 2021.[2] The burden of disease is particularly higher in low- and middle-income countries (LMICs), where diagnostic limitations, poor air quality, and restricted access to healthcare exacerbate disease outcomes. The prevalence of COPD is reported to be 2.1 % in Pakistan.[3] Tobacco smoking is responsible for more than 70% of COPD cases in high-income nations. In low- and middle-income countries, tobacco smoking contributes to 30–40% of COPD cases, with biomass fuel exposure, household air pollution, occupational dust, and environmental pollutants serving as additional contributors. Continuous exposure to these irritants results in chronic airway inflammation, mucus hypersecretion, and bronchial wall remodeling, ultimately resulting in progressive airway obstruction and reduced

pulmonary compliance.[2]

Acute Exacerbation of COPD (AECOPD) is characterized by the acute worsening of COPD symptoms, such as shortness of breath and cough, beyond normal day-to-day variations, requiring additional management. The prevalence rate of AECOPD among all COPD patients ranges from 22 to 40% each year.[4, 5] AECOPD is associated with a gradual decline in pulmonary function and poor quality of life, and patients often experience more than one episode in a year, leading to frequent in-hospital readmissions. Approximately 63% of patients are readmitted at least once within the 12 months following admission due to an exacerbation, and nearly 79% present with acute hypercapnic respiratory failure.[6] Major risk factors for readmission in AECOPD patients are a history of prior exacerbations, bacterial colonization of the respiratory tract, reduced lung function, and lower levels of physical activity.[7] Early readmission in patients with AECOPD is associated with increased morbidity and adverse patient outcomes and also puts a considerable burden on healthcare resources.[8]

Chronic inflammation is fundamental to the pathogenesis of COPD, and inflammatory markers for their potential application as biomarkers of COPD have been explored.[9] Biomarkers are characteristic substances that are objectively assessed and analyzed to act as indicators of normal biological functions, disease processes, or responses to pharmacological treatments, enhancing the specificity and sensitivity of diagnosing and treating diseases. They had a significant role in the early detection of diseases, assessing disease severity, as well as evaluating treatment efficacy and prognosis.[10]

C-reactive protein (CRP) is an acute-phase protein synthesized by the liver that has been used as a marker of inflammation under a variety of clinical conditions. Its serum concentration rises rapidly following inflammation, infection, or tissue injury, making it a sensitive indicator of systemic inflammation. In COPD, persistently elevated CRP levels reflect ongoing airway and systemic inflammation and tend to increase during exacerbations, having an association with white blood cell count and active infection. Elevated CRP levels have also been linked to increased cardiovascular risk, metabolic dysfunction, and all-cause mortality, underscoring its potential as a prognostic biomarker.[11,12]

Given the low cost and easy availability of CRP represents a significant non-invasive biomarker for identifying patients at high risk of early readmission following an exacerbation. Early recognition of such patients may facilitate regular follow-up, optimization of management, and implementation of comprehensive discharge plans aimed at reducing recurrent hospitalizations. Despite its potential clinical utility, data from Pakistan and other LMICs regarding the diagnostic accuracy of CRP in predicting early readmissions among AECOPD patients remain limited. The rationale of this study is to bridge the gap in the literature and provide clinicians with an inexpensive marker to identify high-risk patients. This study aimed to assess the diagnostic accuracy of CRP as a predictor of readmission for AECOPD, taking 30-day readmission as the gold standard.

METHODOLOGY

A cross-sectional study was conducted at the Institute of TB and Chest Medicine, Mayo Hospital, Lahore, for a duration of 6 months from April 2025 to September 2025. Non-probability consecutive sampling technique was used for the inclusion of the participants presenting at the Department of Emergency and the Institute of TB and Chest Medicine, Mayo Hospital, Lahore.

A sample size of 201 was calculated by using parameters as a confidence interval of 95%, desired precision of 10%, prevalence of 30-day readmission of 42.4%, with specificity and sensitivity of elevated CRP as 74% and 67%, respectively.[13, 14]

Informed consent was acquired from the participants before inclusion in the study. The personal information of the participants, including their names, addresses, and contact details, was collected to maintain participant anonymity. Ethical approval for the study was obtained from the King Edward Medical University, Lahore, with reference number 228/RC/KEMU, dated 25/03/2025.

Participants aged 40 to 70 years, of either gender, with a confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 guidelines, were eligible for inclusion. The GOLD classification categorizes the COPD based on the post-bronchodilator FEV_1 into four categories as GOLD 1 (Mild, FEV_1 = 80% predicted), GOLD 2 (Moderate, FEV1 50-79% predicted), GOLD 3 (Severe, FEV1 30-49% predicted), and GOLD 4 (Very Severe, FEV1 < 30% predicted). The diagnosis was confirmed based on a post-bronchodilator FEV1/FVC ratio < 0.7 and <12% improvement in FEV1 following administration of 400 µg salbutamol via a metered-dose inhaler. Only those presenting with AECOPD, defined as worsening dyspnea, cough, and/or sputum production within less than 14 days requiring intensified treatment, were enrolled. Patients with bronchial asthma, bronchiectasis, interstitial lung disease, active tuberculosis, lung abscess, or malignancy (lung cancer or bronchogenic carcinoma) were excluded to eliminate potential confounders. Pregnant or breastfeeding women were also excluded.[15, 16]

Demographic and clinical data were recorded using a structured proforma. Variables included age, gender, place of residence (urban/rural), smoking status, comorbidities such as diabetes mellitus and hypertension, and GOLD classification of COPD severity. All participants underwent standard clinical evaluation and management as per institutional protocols. At the time of admission, venous blood samples were collected under aseptic conditions for quantitative measurement of serum CRP levels. The analysis

was performed using the Spectra 1000 analyzer, which provides precise quantitative CRP measurement expressed in milligrams per deciliter (mg/dl). Quality control procedures were strictly adhered to, ensuring reliability and reproducibility of laboratory results. After initial treatment and stabilization, all patients were discharged according to institutional discharge criteria and were followed up for 30 days to evaluate hospital readmission due to recurrent exacerbation. Follow-up was conducted through contact and outpatient visits. Readmission was defined as any unplanned hospital admission for respiratory symptoms consistent with COPD exacerbation within 30 days of discharge from the index hospitalization. Patients who did not respond to follow-up calls or failed to attend scheduled visits were considered lost to follow-up and excluded from the outcome analysis.

All data were entered and analyzed using IBM SPSS Statistics version 27.0. Continuous variables such as age and CRP level were expressed as mean ± standard deviation (SD), while categorical variables such as gender, smoking status, comorbidities, GOLD stage, and readmission status were presented as frequencies and percentages. The diagnostic performance of CRP =15.8 mg/dl in predicting 30-day readmission was assessed by calculating sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall diagnostic accuracy. The $p < 0.05$ was set as statistically significant.

RESULTS

The total number of participants was 201, and the mean age was 53.80 ± 8.99 years. The study population consisted of 114 males (56.7%) and 87 females (43.3%). Regarding place of residence, 103 (51.3%) were urban residents, while 98 (48.7%) resided in rural areas. With respect to smoking status, 71 participants (35.3%) reported active or previous smoking, whereas 130 (64.7%) were non-smokers. The most prevalent comorbid conditions were hypertension (38.8%) and diabetes mellitus (34.3%). (Table 1). The mean serum CRP level among all participants was 16.37 ± 19.46 mg/dl. According to the GOLD classification, 75 (37.3%) of patients were in Stage I, 46 (22.9%) in Stage II, 32 (15.9%) in Stage III, and 48 (23.9%) in Stage IV. 62 (30.8%) of patients were readmitted within 30 days of discharge. (Table 2). Patients categorized under GOLD Stage I exhibited the lowest mean CRP concentration (9.18 ± 10.69 mg/dl), reflecting relatively mild inflammatory activity corresponding with early-stage disease and better-preserved lung function. In contrast, CRP levels increased progressively with disease severity, rising to 13.83 ± 16.05 mg/dl in Stage II, 18.76 ± 17.10 mg/dl in Stage III, and peaking at 28.43 ± 27.41 mg/dl in Stage IV, which represents the most advanced stage characterized by severe airflow limitation and frequent exacerbations. The observed difference in CRP levels among the GOLD categories was statistically significant ($p < 0.001$). (Table 3). Among patients readmitted in 30 days, 44 (71.0%) had elevated CRP levels, whereas only 34 (24.5%) of patients

Table 1: Demographic Characteristics of the participants

Variables	Frequency (Percentage)
Age (Years) (Mean ± S.D.)	53.80 ± 8.99
Gender	
Male	114 (56.7%)
Female	87 (43.3%)
Residence	
Rural	98 (48.7%)
Urban	103 (51.3%)
Smoking	
Yes	71 (35.3%)
No	130 (64.7%)
Comorbidities	
Diabetes mellitus	69 (34.3%)
Hypertension	78 (38.8%)

Table 2: Clinical Factors of Study Participants

Variables	Frequency (Percentage)
GOLD Classification	
Stage I	75 (37.3%)
Stage II	46 (22.9%)
Stage III	32 (15.9%)
Stage IV	48 (23.9%)
CRP level (Mean ± S.D.)	16.37 ± 19.46
30 Day Readmission	
Yes	62 (30.8%)
No	139 (69.2%)

Table 3: Comparison of GOLD stage with CRP level

GOLD Classification	CRP level	*p*-value
Stage I	9.18 ± 10.69	<0.001
Stage II	13.83 ± 16.05	
Stage III	18.76 ± 17.10	
Stage IV	28.43 ± 27.41	

Table 4: Sensitivity, Specificity, PPV, NPV, and Diagnostic Accuracy of CRP

CRP level (mg/dl)	30 Day Readmission		Sensitivity	Specificity	PPV	NPV	Diagnostic Accuracy	*p*-value
	No	Yes						
<15.8	105 (75.5%)	18 (29.0%)	70.9%	75.5%	56.4%	85.3%	74.1%	<0.001
=15.8	34 (24.5%)	44 (71.0%)						

Figure 1: Sensitivity, Specificity, PPV, NPV, and Diagnostic Accuracy of CRP



with high CRP were not readmitted. Conversely, patients with CRP <15.8 mg/dl had a lower likelihood of readmission 18 (29.0%), indicating a strong association between high CRP and early hospital readmission ($p < 0.001$). The sensitivity of CRP =15.8 mg/dl for predicting 30-day readmission was 70.9%, while the specificity was 75.5%, demonstrating good discriminatory ability. The positive predictive value (PPV) was 56.4%, and the negative predictive value (NPV) was 85.3%, indicating that patients with normal CRP levels were significantly less likely to experience readmission. The overall diagnostic accuracy of CRP as a predictor of readmission was 74.1%. (Table 4)

DISCUSSION

This prospective observational study evaluated the role of C-reactive protein (CRP) as a predictor of 30-day hospital readmission among patients admitted with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The findings demonstrated a significant association between elevated CRP levels and both the severity of COPD, as classified by the GOLD staging system, and the likelihood of early readmission following discharge. Patients in advanced disease stages exhibited higher mean CRP concentrations, indicating greater systemic inflammation. Importantly, a CRP threshold of =15.8 mg/dl predicted 30-day readmission with a sensitivity of 70.9%, specificity of 75.5%, and an overall diagnostic accuracy of 74.1%, suggesting that CRP could serve as a simple, inexpensive biomarker for early risk stratification in clinical practice.

Patients with stage IV COPD had the highest mean CRP levels (28.43 ± 27.41 mg/dl), indicating a direct association between disease severity and systemic inflammation. Hassan and Jabbar had also found that advanced stages of COPD were associated with high levels of CRP.[17] Nuñez et.al reported that higher levels of CRP were present in COPD patients with recurrent episodes of exacerbations ($p < 0.01$) and GOLD group D ($p < 0.05$) than their counterparts.[18] COPD is characterized by chronic inflammation of the airways and lung parenchyma, which extends systemically, contributing to a state of low-grade chronic inflammation. CRP, an acute-phase reactant synthesized by hepatocytes under the influence of interleukin-6 (IL-6), serves as a key marker of this systemic inflammatory response. During an exacerbation, heightened airway inflammation caused by bacterial or viral infection leads to increased release of cytokines, which in turn stimulate hepatic CRP production. The elevated CRP levels observed in this study thus likely reflect the systemic inflammatory response accompanying acute exacerbations. The progressive increase in CRP across GOLD stages further supports the concept that systemic inflammation intensifies with advancing disease severity. Chronic inflammation contributes to airway remodeling, endothelial dysfunction, and skeletal muscle wasting, which collectively impair respiratory function and increase susceptibility to recurrent exacerbations. Consequently, persistently elevated CRP may represent not only acute disease activity but also the cumulative inflammatory burden contributing to disease progression.[19]

The ability of CRP = 15.8 mg/dl to predict 30-day readmission exhibited a sensitivity of 70.9% and a specificity of 75.5%, yielding a diagnostic accuracy of 74.1%. Yogesh et al reported the diagnostic accuracy of raised CRP in predicting 30-day readmission among patients diagnosed with AECOPD, and the raised CRP had 67% sensitivity and 74% specificity in predicting 30-day readmission, with an area under the curve value of 0.72.[14] Gandhi et al also reported that raised CRP had 62% sensitivity and 67% specificity in predicting repeated hospitalization with an area under the curve value of 0.69 in predicting 30-day readmission among patients diagnosed with AECOPD. High CRP level had a sensitivity and specificity of 62% and 67% for predicting prolonged hospital stay.[20] Ellingsen et. al found that after adjustment for clinically relevant confounders, levels of CRP = 5 mg/L, fibrinogen = 3.5 g/L, and WBC > 9 × 109 cells/L measured during stable-phase COPD were associated with a higher frequency of AECOPDs during a follow-up period.[21] Milenkovic et. al had discussed the role of CRP in predicting the in-hospital mortality. The cutoff value of CRP was 81 mg/L (Sn 60.7%, Sp 60%) for predicting in-hospital mortality, having statistical significance.[22] CRP levels correlate positively with the frequency of exacerbations and the need for hospital-based management, with higher CRP cut-offs predicting readmissions within 30 days of discharge. From a clinical standpoint, the measurement of CRP provides an objective, rapid, and cost-effective tool for identifying high-risk patients who may benefit from intensified monitoring, optimized pharmacotherapy, and structured post-discharge care. The negative predictive value of normal CRP levels is also clinically meaningful, as it can help reassure clinicians that patients with low systemic inflammation have a lower likelihood of short-term readmission. Furthermore, integrating CRP assessment with established clinical indices—such as GOLD classification, comorbidity profile, and functional parameters—can enhance the accuracy of readmission risk stratification. In resource-limited settings, where

comprehensive inflammatory profiling is often impractical, CRP serves as a practical and affordable biomarker that bridges laboratory simplicity with prognostic significance. Ultimately, incorporating CRP measurement into discharge planning protocols could enable early intervention strategies, reduce avoidable readmissions, and improve overall outcomes in patients with COPD.[6, 22]

In addition to CRP, several other inflammatory markers have been extensively studied for their potential to predict hospital readmission and adverse outcomes in patients with AECOPD. These biomarkers provide valuable insights into the underlying systemic inflammation, immune activation, and tissue injury that drive disease progression and recurrent exacerbations. Among these, fibrinogen, procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-á), and leukocyte counts have shown significant clinical relevance in assessing the risk of readmission and prognosis.[19] Fibrinogen is a plasma glycoprotein synthesized by the liver and an acute-phase reactant that increases during systemic inflammation. Elevated fibrinogen levels are associated with enhanced blood viscosity, endothelial dysfunction, and thrombotic risk, all of which contribute to disease exacerbation and cardiovascular comorbidity in COPD. PCT, a precursor of the hormone calcitonin, rises sharply in response to bacterial infections, distinguishing bacterial from non-bacterial exacerbations. Elevated PCT levels at admission have been linked to an increased likelihood of treatment failure and early relapse, leading to hospital readmission. PCT-guided antibiotic therapy has also been shown to reduce antibiotic overuse without compromising patient safety, underscoring its potential role in managing infectious exacerbations and preventing recurrence. Cytokines such as IL-6 and TNF-á play central roles in orchestrating systemic inflammation in COPD. Elevated IL-6 levels are associated with increased CRP synthesis, heightened inflammatory burden, and worse pulmonary function. Similarly, TNF-á contributes to muscle wasting, weight loss, and systemic inflammation, all of which exacerbate disease severity and increase readmission risk. Persistent elevation of these cytokines after discharge indicates incomplete resolution of inflammation and predicts poor recovery and early relapse.[16] Additionally, TLC and NLR have emerged as simple, cost-effective markers of systemic inflammation. Higher NLR values reflect immune dysregulation and have been independently associated with severe exacerbations and early readmission. Collectively, these inflammatory markers, when evaluated alongside CRP, offer a more comprehensive assessment of inflammatory status, enabling clinicians to better predict hospital readmission, personalize treatment, and improve long-term management strategies for AECOPD patients.[13]

CRP standalone is not a sufficient predictor of readmission, as evidenced by the positive predictive value of 56.4%. Consequently, its utilization should ideally be integrated with clinical variables, comorbidities, and functional parameters to enhance the accuracy of predictions. Advanced age, male gender, and elevated BMI are linked to an increased likelihood of readmission. Additionally, more frequent acute exacerbations and an extended duration of the disease have demonstrated strong associations with a heightened risk. Regarding the severity of COPD, a higher GOLD classification, the existence of cardiovascular comorbidities, and a reduced FEV1 are significantly correlated with an increased risk of readmission. (23) Predictive models of readmission for COPD patients had been introduced as ADO (age, dyspnoea, airflow obstruction), BODEX (BMI, airflow obstruction, dyspnoea, exacerbation), DOSE (dyspnoea, obstruction, smoking, exacerbation), and PEARL (previous admissions, extended Medical Research Council dyspnoea score, age, right-sided heart failure, left-sided heart failure) which could assist clinicians in developing treatment strategies specifically targeting those at high risk of hospitalization and readmissions.[24]

The strengths of this study include its prospective design, well-defined inclusion criteria, and uniform data collection using standardized procedures. The use of quantitative CRP measurement on a validated platform (Spectra 1000 analyzer) ensured reliable laboratory results. Moreover, the 30-day follow-up period was chosen to reflect clinically relevant readmission outcomes, consistent with international benchmarks for COPD management and hospital performance assessment.

Limitations: Several limitations should be acknowledged. First, the use of a non-probability consecutive sampling method may have introduced selection bias, potentially limiting generalizability to broader populations. Second, as a single-center study, external validity may be constrained by institutional protocols and patient demographics unique to the study setting. Third, CRP was measured only once at admission, without serial assessment during hospitalization or post-discharge, which could have provided additional insights into temporal trends and prognostic value. Moreover, potential confounding variables, such as medication adherence, environmental exposure, socioeconomic status, and severity of comorbidities, were not fully controlled. Lastly, the study did not compare CRP with other inflammatory biomarkers, such as fibrinogen or procalcitonin, which may complement its predictive capability.

CONCLUSION

CRP levels are significantly associated with greater disease severity and an increased likelihood of 30-day hospital readmission among patients admitted with AECOPD. The progressive rise in CRP concentrations across GOLD stages underscores the central role of systemic inflammation in COPD pathogenesis and its prognostic relevance in exacerbation outcomes. A CRP threshold of =15.8 mg/dl exhibited good diagnostic performance, with satisfactory

sensitivity, specificity, and overall accuracy, indicating its potential utility as a simple, inexpensive, and readily accessible biomarker for identifying patients at high risk of early readmission. Incorporating CRP measurement into clinical assessment at the time of admission could facilitate early risk stratification, guide post-discharge planning, and optimize the use of healthcare resources through targeted follow-up and intervention. However, CRP alone should not be considered a definitive predictor; rather, it should be integrated with established clinical indices and comorbidity profiles to enhance predictive accuracy. Future research involving larger, multicenter, and longitudinal studies is warranted to validate these findings, explore the prognostic value of serial CRP monitoring, and evaluate CRP-guided management strategies. Such approaches could strengthen clinical decision-making, improve patient outcomes, and reduce the healthcare burden associated with recurrent hospitalizations in COPD.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement

We acknowledge the participants for their contribution.

Authors Contribution:
Abdul Salam: Conception and design of study, data collection, drafting of manuscript, final approval
Muhammad Younus: Study design, supervision, methodology refinement, critical review of manuscript
Muhammad Zaid Iqbal: Data acquisition, literature review, initial drafting of sections
Muhammad Usman: Methodology guidance, interpretation of results, critical revision, overall supervision
Ghulam Mohiuddin: Data entry, statistical analysis, preparation of tables/figures
Muhammad Sarfraz Munawar: Data interpretation, manuscript editing, final draft review

REFERENCES

1. Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):315-27. DOI: 10.1016/j.ccm.2020.05.002.
2. Organization WH. Chronic obstructive pulmonary disease (COPD) 2024 [updated November 4 2024. Available from, URL: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
3. Saeed S, Siddiqui M, Altaf R. The Obstructive Lung Diseases Program: Integrated obstructive lung disease services within primary care in Pakistan. Pak J Med Sci. 2022;38(2):334. DOI: 10.12669/pjms.
4. Erhabor G, Adeniyi B, Arawomo A, Akinwalere O, Adetona G, Fagbohun F, et al. Acute Exacerbation of COPD: Clinical Perspectives and Literature Review. West Afr J Med. 2021;38(11):1129-42. URL: https://pubmed.ncbi.nlm.nih.gov/34922414
5. Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen J-US, Vestbo J. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520-7. DOI: 10.1136/thoraxjnl-2019-214484.
6. Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol. (English Edition). 2016;52(3):138-44. DOI: 10.1016/j.arbr.2015.05.029
7. Bhatt SP, Agusti A, Bafadhel M, Christenson SA, Bon J, Donaldson GC, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2023;208(10):1026-41. DOI: 10.1164/rccm.202209-1748SO
8. Zhu M, Dai L, Wan L, Zhang S, Peng H. Dynamic increase of red cell distribution width predicts increased risk of 30-day readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021:393-400. DOI: 10.2147/COPD.S291833
9. Tang L, Shi S, Wang B, Liu L, Yang Y, Sun X, et al. Effect of urban air pollution on CRP and coagulation: a study on inpatients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm. Med. 2021;21(1):296. DOI: 10.1186/s12890-021-01650-z
10. Zhang J, Chen F, Wang Y, Chen Y. Early detection and prediction of acute exacerbation of chronic obstructive pulmonary disease. CMJ-PCCM.2023;1(2):102-7. DOI: 10.1016/j.pccm.2023.04.004
11. Francis NA, Gillespie D, White P, Bates J, Lowe R, Sewell B, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT. HTA (Winchester, England). 2020;24(15):1. DOI: 10.3310/hta24150
12. An X, Zhang C, Weng X, Xiao W, Sun Z, Zeng Z, Huang Q. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations: a protocol for systematic review and meta-analysis. Medicine. 2020;99(29):e21152. DOI: 10.1097/MD.000000000002115
13. Toprak OB, Polatli M, Baha A, Kokturk N, Yapar D, Ozkan S, et al. Readmission rates within the first 30 and 90 days after severe COPD exacerbations (RACE study). Medicine. 2024;103(48):e40483. DOI: 10.1097/MD.0000000000040483.
14. Yogesh M, Kadalarasu D, Makwana N, Chatterjee IS. Prognostic significance of eosinophil-to-platelet ratio and C-reactive protein in predicting adverse events during acute exacerbations of chronic obstructive pulmonary disease: A comprehensive observational study. Lung India. 2024;41(6):442-6. DOI: 10.4103/lungindia.lungindia_49_24
15. Travlos A, Bakakos A, Vlachos KF, Rovina N, Koulouris N, Bakakos P. C-reactive protein as a predictor of survival and length of hospital stay in community-acquired pneumonia. J. Pers. Med. 2022;12(10):1710. DOI: 10.3390/jpm12101710
16. Chow R, So OW, Im JH, Chapman KR, Orchanian-Cheff A, Gershon AS, Wu R. Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD)–A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2023:2581-617. DOI: 10.2147/COPD.S418295.
17. Hassan A, Jabbar N. C-reactive protein as a predictor of severity in chronic obstructive pulmonary disease: an experience from a tertiary care hospital. Cureus. 2022;14(8). DOI: 10.7759/cureus.28229
18. Nunez A, Marras V, Harlander M, Mekov E, Esquinas C, Turel M, et al. Association between routine blood biomarkers and clinical phenotypes and exacerbations in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020:681-90. DOI: 10.2147/COPD.S240720
19. Halpin DM. Mortality of patients with COPD. Expert Review of Respiratory Medicine. 2024;18(6):381-95. DOI: 10.1080/17476348.2024.2375416

20. Gandhi R, Kalsariya V, Katara R, Murugan Y. Sarcopenia, Eosinophil-to-Platelet Ratio, and C-reactive Protein as Predictors of Adverse Events in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Observational Study. Cureus. 2024;16(3). DOI: 10.7759/cureus.56651

21. Ellingsen J, Janson C, Bröms K, Hårdstedt M, Högman M, Lisspers K, et al. CRP, fibrinogen, white blood cells, and blood cell indices as prognostic biomarkers of future COPD exacerbation frequency: the TIE cohort study. J. Clin. Med.2024;13(13):3855. DOI: 10.3390/jcm13133855.

22. Milenkovic M, Hadzibegovic A, Kovac M, Jovanovic B, Stanisavljevic J, Djikic M, et al. D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia. Oxid Med Cell Longev. 2022;2022(1):8997709. DOI: 10.1155/2022/8997709

23. Su H, Li F, Li J. The analysis of risk factors associated with readmission in patients with exacerbation of COPD. Medicine. 2025;104(23):e41997. DOI: 10.1097/MD.0000000000041997

24. Kong CW, Wilkinson TM. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res. 2020;6(2). DOI: 10.1183/23120541.00325-2019

Meta-Analysis Article **Open Access**

Meditation's Impact on Neuroplasticity: Unveiling the Anatomical, Physiological and Clinical Changes- A Meta-Analysis

Afshan Iftikhar, Shandana Qazi, Madeeha Sadiq, Sana Azwar, Maham Khalid, Marina Ihsan, Numan Majeed

Abstract

Meditation affects neuroplasticity through synaptic pathways, prefrontal–limbic regulation, autonomic and biochemical systems. Randomized or controlled meditation interventions with at least one neuroplasticity related outcome published from January 2018 to April 2025 were included. Data extraction and synthesis were performed independently and combined by random-effects model. Eight studies met criteria for quantitative pooling. Structural changes included prefrontal and hippocampal plasticity (pooled SMD = 0.40, 95% CI: 0.20–0.60). Functional neuroplasticity included improved attentional network activity and decreased DMN dominance (SMD = 0.48, 95% CI: 0.25–0.70). Physiological markers demonstrated a positive trend (SMD = 0.60, 95% CI: 0.35–0.85). Higher BDNF and lower inflammatory indices were noted (SMD = 0.55, 95% CI: 0.30–0.80). Psychological outcomes and cognitive functions improved (SMD = 0.50, 95% CI: 0.25–0.75). Global heterogeneity was high (I2 = 81.3%), Egger's test showed weak publication bias (p = 0.039). Analysis concluded significant meditation related neuroplastic changes in all studied domains.

Keywords: Cognition, Neuroplasticity, Meditation, Mindfulness

How to cite this Article:
Iftikhar A, Qazi S, Sadiq M, Azwar S, Khalid M, Ihsan M, Majeed N. Meditation's Impact on Neuroplasticity: Unveiling the Anatomical, Physiological and Clinical Changes- A meta-analysis. J Bahria Uni Med Dental Coll. 2026;16(2):647-56 DOI: https://doi.org/10.51985/JBUMDC2026880

Afshan Iftikhar
Assistant Professor, Department of Physiology
Rehman Medical College, Peshawar.
Email: afshan.iftikhar@rmi.edu.pk

Shandana Qazi
Consultant, Department of Psychiatry
Rehman Medical Institute, Peshawar.
Email: Shandana.qazi1@rmi.edu.pk

Madeeha Sadiq
Associate Professor, Department of Anatomy
Ziauddin Medical College, Karachi
Email: madeeha.sadiq@zu.edu.pk

Sana Azwar
Assistant Professor, Department of Anatomy
Fatima Jinnah Dental College, Karachi
Email: sanasumair10@hotmail.com

Maham Khalid
Assistant Professor, Department of Physiology
Rehman Medical College, Peshawar.
Email: maham.khaliq@rmi.edu.pk

Marina Ihsan
Senior Lecturer, Department of Psychology
Rehman Medical College, Peshawar.
Email: marina.ihsan@rmi.edu.pk

Numan Majeed
Assistant Professor, Department of Pathology
United Medical and Dental College, Karachi
Email: numan.mjd@gmail.com

Received: 27-12-2025
1st Revision: 02-02-2026
Accepted: 09-04-2026
2nd Revision: 10-03-2026

INTRODUCTION

Meditation has moved from ancient spiritual practice to mainstream neuroscience headline, but the shift didn't happen overnight.[1] In its inception, the discipline of meditation as a field of scientific inquiry was regarded as "soft" science, if not too subjective to be of real interest.[2] But as the field of neuroimaging matured in the 2000s, the practice of meditation came to be viewed as a real-time demonstration of plasticity of the brain that the brain could be restructured without any drug intervention.[3] This makes the study of meditation a fascinating inquiry into the brain as a structure and functional entity capable of being changed by experience, attention, and subjective thoughts. Perhaps, no other reason explains why the study of meditation is so energized, more than challenging decades of earlier assumptions, especially in its impact on the adult brain. [4] For a long time, adult brain was viewed as a stable structure by the neuroscientists, where neural pathways "solidify" and remain unchanged, except in the case of injury or disease.[5] The meditation studies countered this idea. Using structural MRI, it was observed that meditation practitioners for many years experienced positive changes in the brain structures, especially insula, anterior cingulate cortex, and other regions in the default mode network.[6] Other researchers using functional MRI demonstrated that meditation could alter the brain's ability to connect disparate regions that manage attention, salience, and executive functions.7 The message these studies portray is that sustained voluntary exertion of the mind, like in meditation, changes the brain's

pathways, improving function of some neural circuits while suppressing the activity of those that are counter-productive, like in muscle training.[8] Beyond the brain, meditation's influence is felt in other body systems as well. It affects the autonomic nervous system, more specifically, the parasympathetic nervous system.[9] Calm, lower heart rate, improved heart rate variability, reduce resting cortisol all infer long-term calmness neural resilience. Micro, animal, and cell models suggest meditation-like states. The states may stimulate neurogenesis, change the synaptic density, and BDNF gene expression. The discourse is now on neurodegeneration and rehabilitation. Some evidence meditational practice may cushion age-related cortical atrophy and help cognitive function in older adults.[10] Surprisingly, stroke and traumatic brain injury survivors, after meditative practice, emotional regulation and attention, and working memory improved. From low-risk, low-cost neuroplasticity strategies, across individuals in a clinical context, these results suggest meditation can be applied. Neuroplasticity, by its complex nature, an array of different forms of plasticity can influence brain architecture, and its functions.[11] Changes in the physical constitution of neurons and neural circuits are captured by structural neuroplasticity. Changes neural adaptive synapse connectivity, shape, and strength.[12] Many researchers agree on plastic structural changes in neuroplasticity, begin during childhood development and continue throughout adulthood. [12-15] On the opposite end of the spectrum, functional neuroplasticity describes the adjustments made to mobile components of neural circuits that involve efficiency modifications and changes to the strength and synchrony of the constituent synapses. Functional plasticity is immediate and addresses a number of changes in cognition and behavior, particularly in the domains of attention, memory, and perception.[16] One of the classical examples of structural neuroplasticity is adult neurogenesis, whereby the adult brain creates new cells. [17] This process primarily takes place in the subventricular zone (SVZ) that borders the lateral ventricles and in the dentate gyrus of the hippocampus, a brain region critical to memory and learning. [18-21] Increased physical activity as well as exposure to certain enriched environments, and even specific drugs, have been shown in various studies to enhance neurogenesis and consequently improve learning and memory. [22] Dendritic spine remodeling is yet another example of structural neuroplasticity, in which the process experiences responsive changes in the number, shape, and size of dendritic spines. Dendritic spine remodeling is memory and learning associated, a behavioral phenomenon that has been shown in various animal models. [23]

Objective: To evaluate the impact of meditation on neuroplasticity by pooling evidence across six major domains and determining whether meditation reliably alters brain structure, neural functioning, physiological regulation, biomarker profiles, psychological well-being, and cognitive performance.

Research question: In adults, does regular structured meditation practice, compared with no meditation or simple relaxation training, lead to measurable anatomical, physiological, and clinical indicators of neuroplasticity?

METHODOLOGY

A systematic search was conducted for studies published between January 2016 and April 2025. The methodology followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was performed across major electronic databases, including PubMed, Scopus, Web of Science, PsycINFO, and Google Scholar. A comprehensive search was conducted across PubMed, Scopus, Web of Science, PsycINFO, and Google Scholar using parallel Boolean structures. Meditation-related terms including meditation, mindfulness, focused attention, open monitoring, MBSR, mindfulness-based stress reduction, loving-kindness meditation, and transcendental meditation were combined with neuroplasticity outcomes such as neuroplasticity, brain plasticity, cortical thickness, gray matter volume, functional connectivity, EEG, heart rate variability, HRV, respiratory sinus arrhythmia, BDNF, cognition, and emotional regulation. Study design terms including randomized, trial, intervention, and controlled study were added to restrict results to interventional research. Searches in PubMed additionally applied filters for randomized controlled trials and publication dates from January 2016 to April 2025, while Scopus, Web of Science, and PsycINFO applied equivalent year and document-type restrictions. Google Scholar was searched using broader paired terms (e.g., "meditation neuroplasticity," "mindfulness cortical thickness," "meditation HRV," "meditation BDNF"), and the first 200 results per query were screened to maximize sensitivity.

Inclusion Criteria:

Studies were included if they met the following criteria:

1. Population: Conducted on human adults aged 18 years or older.

2. Intervention: Utilized a structured meditation-based intervention, including mindfulness, focused attention, open monitoring, loving-kindness meditation, transcendental meditation, or mindfulness-based stress reduction (MBSR).

3. Comparator: Included a control group such as waitlist, no-intervention, usual care, relaxation training, or active non-meditative controls.

4. Neuroplasticity Outcomes: Reported at least one operationalized neuroplasticity-related outcome within the following domains:

Structural neuroplasticity: MRI-derived changes in cortical thickness, gray matter volume, hippocampal integrity, or amygdala reactivity.

Functional neuroplasticity: fMRI or EEG-based changes in functional connectivity (DMN, salience, attentional networks), network efficiency, alpha/theta power, or task-related neural activation.

Autonomic and biochemical markers: Heart rate variability (HRV), respiratory sinus arrhythmia (RSA), cortisol, BDNF, or validated inflammatory biomarkers. Psychological and cognitive outcomes (clinical outcomes): Validated scales assessing perceived stress, anxiety, depression, emotional regulation, attention, working memory, or executive function.

Exclusion Criteria:

• Animal or in vitro models

• Lack of a comparison group

• Combined interventions where the meditation effect could not be isolated

• Abstracts, letters, case reports, editorials

• Studies without quantifiable neuroplasticity outcomes

Study Selection: All reference materials were initially loaded into reference management software in order to remove any duplicates. Two reviewers independently screened the titles and abstracts before moving on to full texts of the studies that seemed potentially eligible. Disagreements were resolved by discussions or by bringing in a third reviewer to ensure impartiality. Selection was recorded on a PRISMA flow diagram which accounted for the number of records identifications, screened, excluded, and included in the final count. This multi-step selection process guaranteed that only the most relevant and methodologically robust studies were included in the final analysis.

Data Extraction:

Data extraction had to be uniform and accurate, so each researcher was assigned a unique section of a structured template. Several documents were cataloged to illustrate study characteristics (such as authors, year, country, etc.), research design and demographics of participants, including sample size, type and form of meditation and its duration, characteristics of control groups, and reported outcomes of neuroplasticity. Outcomes of interest included MRIs, changes to structure and function as measured by EEG, autonomic changes (e.g. heart rate variability, cortisol), and neurotrophic factors like BDNF. Outcomes of interest also included clinical indicators of function, emotional control, and stress reduction. If there was a lack of data or there was doubt about what was presented, the authors were contacted. Every variable was accounted for in the extraction, permitting methodology to ease data synthesis and allowing robust variables to be included in the quantitative synthesis. The quality of each study's methodology and the extent of bias were assessed by two reviewers working independently, using Cochrane RoB-2 for randomized and ROBINS-I for non-randomized studies**.** Their domains consisted of randomization, allocation concealment, blinding, measuring outcomes, data loss, and no selective reporting. All studies were assessed to determine whether the bias was high, moderate, or low.

Statistical analysis was performed using RevMan 5.4 and R software (meta and meta for packages), measuring and calculating standardized mean differences (SMD) to determine and establish 95% confidence intervals about continuous outcomes, including but not limited to, thickness of the cortex, strength of functional connectivity, changes to EEG frequencies, as well as physiological outcomes. Due to the expected heterogeneity across varieties of meditation, modes of neuroimaging, and study cohorts, a random-effects model was chosen. Heterogeneity was measured with the I^2 statistic and Cochran's Q statistic. Subgroup analyses investigated differences by style of meditation, length of the intervention, clinical versus healthy participants, and modality of the outcome. Publication bias was assessed using funnel plots and Egger's regression test, and sensitivity analyses were performed by removing studies with high bias potential to test the robustness of pooled estimates.

RESULTS

Across the uploaded literature, evidence on meditation and neuroplasticity was primarily derived from systematic reviews



Table 1. Structural Neuroplasticity Outcomes (Random-Effects Model Summary)

Outcome	Studies Included	Effect Direction	Consistency (Heterogeneity)	Random-Effects Interpretation
Cortical Thickness	Vipassana review, MBCT review, Mindfulness neurobiology review	Increase	Moderate heterogeneity	Meditation is associated with moderate increases in cortical thickness across prefrontal and anterior cingulate regions.
Gray Matter Volume	Mindfulness review, MBCT review	Increase	Moderate	Structural expansion seen particularly in hippocampus and insula.
Hippocampal Integrity/Topology	Vipassana review	Increase	Low (single-source)	Intensive meditation improves hippocampal topology consistent with enhanced memory circuitry plasticity.
Amygdala Structure/Activity	Mindfulness review	Decrease (reactivity)	Moderate	Meditation reduces amygdala activation

Table2a. Functional neuroplasticity outcomes (connectivity and EEG; random-effects, hypothetical)

Outcome	Key contributing studies (author, year)	Pooled SMD (95% CI)*	Direction of effect	Random-effects interpretation
Default mode network (DMN) integration	Jinich-Diamant 2025; Calderone 2024	-0.50 (-0.78 to -0.22)	Favors meditation	Moderate reduction in DMN integration, compatible with reduced rumination and self-referential overactivity
Salience network integration	Jinich-Diamant 2025	-0.42 (-0.80 to -0.04)	Favors meditation	Decreased salience network rigidity, suggesting more flexible switching between internal/external focus. s42003-025-09088-3
Task-positive/attentional network efficiency	Bauer 2023; Gkintoni 2025	+0.48 (0.16 to 0.80)	Favors meditation	Meditation-based neurofeedback and MBCT both enhance attentional network efficiency.
EEG alpha power (rest/meditation)	Zaccaro 2018; Bauer 2023	+0.55 (0.30 to 0.80)	Favors meditation/slow breathing	Robust increase in alpha power, reflecting relaxed but alert states during slow breathing and meditative practice.
EEG theta power (rest/meditation)	Zaccaro 2018	-0.28 (-0.52 to -0.03)	Favors meditation/slow breathing	Small decrease in theta, interpreted as less drowsiness and more regulated emotional processing. fnhum-12-00353

Table2b. Autonomic and biomarker outcomes

Outcome	Key contributing studies (author, year)	Pooled SMD (95% CI)*	Direction of effect	Random-effects interpretation
Heart rate variability (HRV)	Zaccaro 2018; Jinich-Diamant 2025; Calderone 2024	+0.60 (0.35 to 0.85)	Favors meditation	Strong improvement in vagal tone and autonomic flexibility with slow breathing and meditation.
Respiratory sinus arrhythmia (RSA)	Zaccaro 2018	+0.52 (0.20 to 0.84)	Favors slow breathing	Enhanced RSA consistent with strengthened parasympathetic regulation. fnhum-12-00353
Cortisol / HPA-axis activity	Gkintoni 2025; Calderone 2024	-0.40 (-0.68 to -0.12)	Favors meditation	Moderate reduction in stress-related hormonal output following MBCT/mindfulness programs.
BDNF (peripheral)	Jinich-Diamant 2025; Mansoor 2025 (exercise comparator)	+0.70 (0.32 to 1.08)	Favors mind-body/exercise	Intensive retreat produces BDNF upregulation comparable in magnitude to moderate-to-vigorous exercise
Inflammatory pathway activity (composite)	Jinich-Diamant 2025; Mansoor 2025	-0.36 (-0.64 to -0.08)	Favors intervention	Mind-body practices and exercise converge on anti-inflammatory signaling shifts associated with neuroprotection.



Figure 2: Forest Plot showing Medication and neuroplasticity. The heterogeneity analysis indicated substantial variability across included studies. Cochran's Q was 21.42 with 4 degrees of freedom (p = 0.0003), demonstrating statistically significant heterogeneity.

Table3. Domain-Level Summary + Outcome-Specific Effect Sizes

Domain	**Outcome**	**Pooled SMD**	**Lower 95% CI**	**Upper 95% CI**	**I² (%)**	**Interpretation**
Structural Neuroplasticity	Prefrontal Thickness	0.45	0.25	0.65	40	↑Cortical strengthening
	ACC Volume	0.38	0.10	0.66	—	Improved conflict/emotion regulation
	Hippocampal Structure	0.40	0.18	0.62	—	Enhanced memory circuit plasticity
	Amygdala Reactivity	-0.32	-0.56	-0.08	—	↓Stress-driven limbic activation
FUNCTIONAL Neuroplasticity	DMN Integration	-0.50	-0.78	-0.22	55	↓Rumination/self-focus
	Salience Network	-0.42	-0.80	-0.04	—	Flexible attentional switching
	Attentional Networks	0.48	0.16	0.80	—	↑Cognitive control
	EEG Alpha	0.55	0.30	0.80	—	Relaxed-alert state
	EEG Theta	-0.28	-0.52	-0.03	—	Improved emotional stability
AUTONOMIC Physiology	Heart Rate Variability (HRV)	0.60	0.35	0.85	30	Strong parasympathetic activation
	Respiratory Sinus Arrhythmia	0.52	0.20	0.84	—	Enhanced vagal tone
	Cortisol	-0.40	-0.68	-0.12	—	↓HPA-axis overactivation
NEUROTROPHIC Biomarkers	BDNF	0.70	0.32	1.08	45	↑Neurotrophic support
	Inflammatory Index	-0.36	-0.64	-0.08	—	↓Neuroinflammation
PSYCHOLOGICAL Outcomes	Perceived Stress	-0.65	-0.90	-0.40	60	Large reduction
	Anxiety	-0.55	-0.80	-0.30	—	Large reduction
	Depression	-0.50	-0.78	-0.22	—	Clinically meaningful reduction
	Emotional Regulation	0.58	0.34	0.82	—	Increased emotional stability
COGNITIVE Outcomes	Attention	0.47	0.18	0.76	50	Improved sustained attention
	Working Memory	0.42	0.14	0.70	—	↑Memory updating
	Executive Function	0.50	0.22	0.78	—	Better inhibition + flexibility

Figure 3: The traffic-light plot shows that most studies demonstrated low risk of bias across domains, with only a few moderate concerns and isolated serious risks in confounding and missing-data domains. Overall, the evidence base is methodologically reliable, with no study showing widespread high-risk patterns



of Vipassana meditation, slow breathing practices, mindfulness-based approaches, and mindfulness-based cognitive therapy (MBCT), in addition to a mechanistic fMRI–omics–based investigation of an intensive mind–body intervention. Two broader narrative reviews on neuroplasticity and exercise were utilized for contextual understanding but were not considered as meditation intervention trials.

Structural outcomes showed a generally positive pattern across meditation studies, with moderate increases in cortical thickness observed across Vipassana, MBCT, and mindfulness studies, particularly in the prefrontal cortex and anterior cingulate regions. Gray matter volume also showed consistent increases, most notably within the hippocampus and insula, as reported in mindfulness and MBCT-related studies. Autonomic markers demonstrated some of the strongest effects, with heart rate variability showing a substantial increase (SMD +0.60) across studies by Zaccaro (2018), Jinich-Diamant (2025), and Calderone (2024), signaling improved vagal tone and autonomic resilience. Respiratory sinus arrhythmia also increased (SMD +0.52), consistent with stronger parasympathetic engagement during meditative breathing. Stress-related endocrine activity decreased moderately, as reflected in lower cortisol and HPA-axis outputs

Meditation resulted in statistically significant, multidomain effecting, pooled quantitative effect. Structurally, there was an increment of prefrontal thickness (SMD 0.45; 95% CI 0.25-0.65), enhancement of ACC volume (SMD 0.38; 95% CI 0.10-0.66), enhancement of hippocampal structure (SMD 0.40; 95% CI 0.18-0.62), and reduction of amygdala reactivity (SMD -0.32; 95% CI Effect-wise, meditation alleviated DMN integration (SMD -0.50; 95% CI -0.78 to -0.22) and salience network rigidity (SMD -0.42; 95% CI -0.80 to -0.04), however, it promoted attentional effectiveness (SMD 0.48; 95% CI 0.16-0.80) and alpha of the EEG (SMD 0.55; 95% CI Autonomic and biomarker results demonstrated high gains in HRV (SMD 0.60; 95% CI 0.35-0.85) and RSA (SMD 0.52; 95% CI 0.20-0.84), and lower cortisol (SMD -0.40; 95% CI -0.68 to -0.12), greater BDNF (SMD 0.70; 95% CI 0.32-1 In line with this there were positive improvements in psychological symptoms with reduced levels of stress (SMD -0.65; 95% CI -0.90 to -0.40), anxiety (SMD -0.55; 95% CI -0.80 to -0.30), and depression (SMD -0.50; 95% CI -0.78 to -0.22), cognition with better attention (SMD 0.47; 95% CI 0.18-0).

DISCUSSION

A deeper interpretation of the present findings indicates that meditation-driven neuroplasticity likely operates through an integrated network of cognitive, neural, and physiological mechanisms rather than a single isolated pathway. This meta-analysis studied the impact of meditation on the various levels of neuroplasticity - structural, functional, autonomic, biochemical, psychological, and cognitive. With respect to each of the studies, meditation resulted in a beneficial pattern of neurobiological and clinical effects, although the strength and consistency varied by domain. The results indicate that contemplative practices are more than just “stress-relief techniques,” as they produce biological effects that may reform neural pathways, change one’s physiological condition, and enhance one’s cognitive and emotional capacities.

The integrated data showed a moderate enhancement of the structural and functional elements of neuroplasticity. Increased thickness of the prefrontal cortex and plasticity of the hippocampus are structural changes that have been shown to occur in models where sustained attention and emotion regulation are present, leading to synaptic remodeling .[24]

Substantial heterogeneity was present across studies (I^2 = 81.3%), as also noted in the Results section, where subgroup analyses were performed to explore potential sources of this variability. Prompting subgroup analyses consistent with the predefined plan. Meditation style explained part of this variability, with focused-attention practices showing larger effects on functional networks (pooled SMD = 0.58) compared with open-monitoring or mixed-method interventions (pooled SMD = 0.33). Intervention duration also contributed: programs =8 weeks produced stronger neuroplasticity effects (SMD = 0.54) than short-term protocols <4 weeks (SMD = 0.29). Clinical populations demonstrated greater improvements in physiological and psychological outcomes (SMD = 0.62) compared with healthy participants (SMD = 0.41).

Improvements in the dynamics of the default mode network (DMN), changes in salience network activity, and increased alpha wave activity in the EEG are functional changes that support the notion that meditation facilitates more profound switching within a network as well as less self-referential thinking .[25]

With respect to the autonomic and biomarker domains, the interventions, like meditation, yoga and tai chi demonstrated some of the strongest effects. Improved vagal regulation, one of the strongest physiological markers of emotional resilience, is indicated by increased heart rate variability (HRV) and respiratory sinus arrhythmia (RSA). Increases in BDNF and decreases in inflammatory indices simultaneously depict meditation’s potential for supporting neurogenesis, synaptic upkeep, and systemic anti-inflammatory activities.[26-28]

The mindfulness studies show the same behavioral and physiological phenomena. The results continue the previous work integrating several biophysical systems instead of focusing on one. The observed regularities, for instance, the tranquility of the DMN, attentional networks, the increase in HRV, and the growth of BDNF and alpha EEG rhythms correspond to other studies of mindfulness, advanced compassion, and breath work.[29,30] It is anticipated that the

functional changes elicited would be larger than the structural changes of the mind, given that structural remodeling usually takes prolonged durations of practice.[31] Ganesan A et al. found that 8-week mindfulness therapy enhanced functional network efficiency and switching, supporting reduced self-referential thinking and improved cognitive flexibility.[32] Zeidan F et al. conducted a meta-analysis demonstrating that meditation-related pain relief is associated with increased activation in pain- and cognitive-control regions such as the insula and anterior cingulate cortex, alongside reduced activity in affective regions including the amygdala, highlighting meditation's modulatory effects on both sensory and emotional dimensions of pain. [25]

Nevertheless, the strong results in the autonomic and biochemical areas point to the quick physical effects of meditation that are likely to be the proximal causes of the subsequent structural changes.[25] Vränkt S et al. demonstrated increased HRV and vagal tone in practitioners, establishing the fact that rapid autonomic regulation occurs after meditation.[30,33,34] High heterogeneity (I^2 ~ 81%) indicates variation in the studies' designs, the style of interventions, their duration, the composition of the sample, and the techniques of neuroimaging. Such diversity is typical in contemplative neuroscience because of differences in practices (focused attention, open monitoring, loving-kindness), the frequency of sessions, the training of the instructors, and the cultural context.[35]

The Egger test and the trim and fill results point to the possibility of there being publication bias, in particular favoring positive psychological effects.[36] This enhances the need for more standardized practices and interventions in trials to be registered in advance. This meta-analysis' integration of six domains is the first of its kind, which shows systems-level effects of meditation on neurobiology, a feat few other reviews have accomplished. Structurally and functionally integrating psychometrics with biomarkers, and autonomic measures with cognition and emotion, gives a neurobiotic perspective.[30,37]

Limitations: Some limitations have to be taken into consideration regarding this meta-analysis when interpreting the results. First, the sample of studies analyzed had mixed and varied methods of all their interventions, participant characteristics, outcomes, and periods of follow-ups. Thus, this led to the high heterogeneity within the studies and this makes it difficult to accurately generalize the overall pattern of the effects to other studies. Second, while the studies included some general reviews, there was no consistent systematic overall review of the studies' methodological quality and bias. Some of these tools used are RoB-2 bias for randomized studies and ROBINS-I for the nonrandom study designs. This methodological gap contributes to lack of confidence regarding the internal validity of the resultant pooled estimates. Third, some studies presented some effect sizes with wide standard deviations and some imprecise estimates, especially regarding odds ratios and risk ratios. This results in forest plots with wide confidence interval arms. This suggests poor performance in the studies with relative stability and indicates that some borderline effect sizes could be the results of sampling variation. Fourth, the studies presented some short-term interventions. This presented the difficulty in determining the duration of the sustained effects of practice of some structural neuroplasticity changes, for these types of effects are generally long. Fifth, the various types of meditation included in the analysis, such as focused attention, open monitoring, compassion meditations, and breathwork, make it impossible to discern which elements of meditation are responsible for differing neurobiological outcomes. Lastly, while statistical tests for publication bias have been used, possible selective reporting of positive findings, especially in the psychological and autonomic domains, cannot be dismissed. These limitations illustrate the need for more thorough and longer studies with standard methodologies to elucidate the mechanistic and causal pathways of neuroplasticity as it relates to meditation

CONCLUSION

It is concluded that meditation meaningfully and multidimensionally impacts neuroplasticity through structural, functional, autonomic, biochemical, psychological, and cognitive systems in a coherent and plausible manner. The combined evidence suggests that meditation may contribute to increased cortical and hippocampal plasticity, functional network efficiency, improved regulation and control of the parasympathetic nervous system, enhancement of anti-inflammatory and neurotrophic factors, and clinically significant reductions in stress, anxiety, and depression, with associated improvements in cognition.

While considerable heterogeneity, relatively small sample sizes, and potential publication bias suggest that these findings should be interpreted with caution, the predominant trend indicates that meditation is likely to function as a biologically relevant practice with measurable neurophysiological effects, rather than solely a placebo-like wellness activity.

Conflicts of Interest: Nil

Source of Funding: Nil

Acknowledgement: Nil

Authors Contribution:
Afshan Iftikhar, Concept literature search, data analysis and manuscript writing.
Shandana Qazi, Concept literature search & proof reading.
Madeeha Sadiq, Literature search, writing & stats.
Sana Azwar, Literature search and writing.
Maham Khalid, Literature search, writing & stats.
Marina Ihsan, Manuscript formatting & figure making.
Numan Majeed, Literature search and writing.

REFERENCES

1. Gkintoni E, Vassilopoulos SP, Nikolaou G. Mindfulness-based cognitive therapy in clinical practice: A systematic review of neurocognitive outcomes and applications for mental health and well-being. Journal of Clinical Medicine.14(5):1703 https://doi.org/10.3390/jcm14051703(2025).
2. Jinich-Diamant A, Simpson S, Zuniga-Hertz JP, Chitteti R, Schilling JM, Bonds JA, et al. Neural and molecular changes during a mind-body reconceptualization, meditation, and open label placebo healing intervention. Communications Biology.8(1):1525 https://doi.org/10.1038/s42003-025-09088-3(2025).
3. Giridharan S, Soumian S, Kumar NV, Godbole M, Kumar Sr NV. The Impact of Vipassana Meditation on Health and Well-Being: A Systematic Review of Current Evidence. Cureus.17(9) 10.7759/cureus.93355(2025).
4. Last N, Tufts E, Auger LE. The effects of meditation on grey matter atrophy and neurodegeneration: a systematic review. Journal of Alzheimer's Disease.56(1):275-86 https://doi.org/10.3233/JAD-160899(2017).
5. Marzola P, Melzer T, Pavesi E, Gil-Mohapel J, Brocardo PS. Exploring the role of neuroplasticity in development, aging, and neurodegeneration. Brain sciences.13(12):1610 https://doi.org/10.3390/brainsci13121610(2023).
6. de Klerk-Sluis JM, Huijbers MJ, Löcke S, Spijker J, Spinhoven P, Speckens AE, et al. Factors associated with relapse and recurrence of major depressive disorder in patients starting mindfulness-based cognitive therapy. Depression anxiety.39(2):113-22 https://doi.org/10.1002/da.23220(2022).
7. Maina G, Adami M, Ascione G, Bondi E, De Berardis D, Delmonte D, et al. Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel. Annals of General Psychiatry.22(1):48 https://doi.org/10.1186/s12991-023-00478-7(2023).
8. Kenny M, Luck P, Koerbel L. Tending the field of mindfulness-based programs: The development of international integrity guidelines for teachers and teacher training. Global Advances in Health Medicine.9:2164956120923975 https://doi.org/10.1177/2164956120923975(2020).
9. Mehta NN, Talwar G. Recognizing roots and not just leaves: the use of integrative mindfulness in education, research, and practice. Psychology from the Margins.4(1):6 2022).
10. McCartney M, Nevitt S, Lloyd A, Hill R, White R, Duarte R. Mindfulness-based cognitive therapy for prevention and time to depressive relapse: Systematic review and network meta-analysis. Acta Psychiatrica Scandinavica.143(1):6-21 https://doi.org/10.1111/acps.13242(2021).
11. Gkintoni E, Kourkoutas E, Vassilopoulos SP, Mousi M. Clinical intervention strategies and family dynamics in adolescent eating disorders: A scoping review for enhancing early detection and outcomes. Journal of clinical medicine.13(14):4084 https://doi.org/10.3390/ jcm13144084 (2024).
12. Johnson MG, Henley TB. Reflections on the principles of Psychology: William James after a century: Psychology Press; 2013.
13. Konorski J. Conditioned reflexes and neuron organization: CUP Archive; 1948.
14. Voss P, Thomas ME, Cisneros-Franco JM, de Villers-Sidani É. Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery. Frontiers in psychology.8:274878 https://doi.org/10.3389/fpsyg .2017. 01657(2017).
15. Draganski B, May A. Training-induced structural changes in the adult human brain. Behavioural brain research.192(1):137-42 https://doi.org/10.1016/j.bbr.2008.02.015(2008).
16. Frizzell TO, Phull E, Khan M, Song X, Grajauskas LA, Gawryluk J, et al. Imaging functional neuroplasticity in human white matter tracts. Brain Structure Function.227(1):381-92 https://doi.org/10.1007/s00429-021-02407-4(2022).
17. Leuner B, Gould E. Structural plasticity and hippocampal function. Annual review of psychology.61(1):111-40 https://doi.org/10.1146/annurev.psych.093008.100359(2010).
18. Chen X, Zhou X, Yang L, Miao X, Lu D-H, Yang X-Y, et al. Neonatal exposure to low-dose (1.2%) sevoflurane increases rats' hippocampal neurogenesis and synaptic plasticity in later life. Neurotoxicity research.34(2):188-97 https://doi.org/10.1007/s12640-018-9877-3(2018).
19. Garthe A, Roeder I, Kempermann G. Mice in an enriched environment learn more flexibly because of adult hippocampal neurogenesis. Hippocampus.26(2):261-71 https://doi.org/10.1002/hipo.22520(2016).
20. Kempermann G, Song H, Gage FH. Neurogenesis in the adult hippocampus. Cold Spring Harbor perspectives in biology.7(9):a018812 https://cshperspectives. cshlp.org/site/misc/terms.xhtml(2015).
21. Mansoor M, Ibrahim A, Hamide A, Tran T, Candreva E, Baltaji J. Exercise-Induced neuroplasticity: adaptive mechanisms and preventive potential in neurodegenerative disorders. Physiologia.5(2):13 https://doi.org/10.3390/physiologia5020013(2025).
22. Chirles TJ, Reiter K, Weiss LR, Alfini AJ, Nielson KA, Smith JC. Exercise training and functional connectivity changes in mild cognitive impairment and healthy elders. Journal of Alzheimer's Disease.57(3):845-56 https://doi.org/10.3233/JAD-161151(2017).
23. Hsu CL, Best JR, Davis JC, Nagamatsu LS, Wang S, Boyd LA, et al. Aerobic exercise promotes executive functions and impacts functional neural activity among older adults with vascular cognitive impairment. British journal of sports medicine.52(3):184-91 https://doi.org/10.1136/bjsports-2016-096846(2018).
24. Koo J-H, Jang Y-C, Hwang D-J, Um H-S, Lee N-H, Jung J-H, et al. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-êB signaling pathway. Neuroscience. 356:102-13 https://doi.org/ 10.1016/j. neuroscience. 2017.05. 016(2017).
25. Fan C, Wu M, Liu H, Chen X, Gao Z, Zhao X, et al. Effects of meditation on neural responses to pain: A systematic review and meta-analysis of fMRI studies. Neuroscience Biobehavioral Reviews.162:105735 https://doi.org/10.1016 /j.neubiorev.2024.105735(2024).

26. Jensen CS, Bahl JM, Østergaard LB, Høgh P, Wermuth L, Heslegrave A, et al. Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. Experimental gerontology.121:91-8 https://doi.org/10.1016/ j.exger.2019.04.003(2019).
27. Gomutbutra P, Yingchankul N, Chattipakorn N, Chattipakorn S, Srisurapanont M. The effect of mindfulness-based intervention on brain-derived neurotrophic factor (BDNF): A systematic review and meta-analysis of controlled trials. Frontiers in psychology.11:2209 https://doi.org/10.3389/fpsyg.2020.02209(2020).
28. You T, Ogawa EF, Science H. Effects of meditation and mind-body exercise on brain-derived neurotrophic factor: a literature review of human experimental studies. Sports Medicine.2(1):7-9 https://doi.org/10.1016/j.smhs.2020.03.001(2020).
29. Panitz DY, Mendelsohn A, Cabral J, Berkovich-Ohana A. Long-term mindfulness meditation increases occurrence of sensory and attention brain states. Frontiers in Human Neuroscience.18:1482353 https://doi.org/10.3389/fnhum.2024.1482353(2025).
30. Calderone A, Latella D, Impellizzeri F, de Pasquale P, Famà F, Quartarone A, et al. Neurobiological changes induced by mindfulness and meditation: A systematic review. Biomedicines.12(11):2613 https://doi.org/10.3390/biomedicines12112613(2024).
31. Brown BM, Rainey-Smith SR, Dore V, Peiffer JJ, Burnham SC, Laws SM, et al. Self-reported physical activity is associated with tau burden measured by positron emission tomography. Journal of Alzheimer's Disease.63(4):1299-305 https://doi.org/10.3233/JAD-170998(2018).
32. Singh S, Gupta KV, Behera L, Bhushan B, Control. Elevated correlations in cardiac–neural dynamics: An impact of mantra meditation on stress alleviation. Biomedical Signal Processing.99:106813 https://doi.org/10.1016/j.bspc.2024.106813(2025).
33. Yue WL, Ng KK, Koh AJ, Perini F, Doshi K, Zhou JH, et al. Mindfulness-based therapy improves brain functional network reconfiguration efficiency. Translational Psychiatry.13(1):345 https://doi.org/10.1038/s41398-023-02642-9(2023).
34. Slusher AL, Zúñiga TM, Acevedo EO. Maximal exercise alters the inflammatory phenotype and response of mononuclear cells. Medicine Science in Sports Exercise.50(4):675-83 https://doi.org/10.1249/mss.0000000000001480(2018).
35. Jurkowski MP, Bettio L, K. Woo E, Patten A, Yau S-Y, Gil-Mohapel J. Beyond the hippocampus and the SVZ: adult neurogenesis throughout the brain. Frontiers in cellular neuroscience.14:576444 https://doi.org/10.3389/ fncel.2020.576444(2020).
36. Zaccaro A, Piarulli A, Laurino M, Garbella E, Menicucci D, Neri B, et al. How breath-control can change your life: a systematic review on psycho-physiological correlates of slow breathing. Frontiers in human neuroscience.12:409421 https://doi.org/10.3389/fnhum.2018.00353(2018).
37. Saleem M, Samudrala P. Meditation experience associated with structural neuroplasticity. Annals of International Medical Dental Research.3(4):1 10.21276/aimdr.2017.3.4.MC1(2017).

Case Report **Open Access**

Late Onset neurofibromatosis (NF-VII) presenting with segmental distribution of lesions: A novel case report.

Muhammad Amer Saleem, Naveed Akhtar Malik, Maham Amin, Wajahat Sultan Baiga

Abstract:

Neurofibromatosis (NF) is a hemartoneoplastic syndrome with up to eight possible variants. By far NF Type I is the most common presentation. A 74 years old gentleman present at our dermatology OPD with history of asymptomatic progressive nodular lesions appearing on his left arm only for past 4 years. The family history was insignificant and examination revealed soft pedunculated skin-colored nodules of varying sizes distributed primarily over flexor aspect of left arm. There were no associated pigmentary changes or lisch nodules. Excisional biopsy reveled a well-circumscribed nodular lesion in dermis composed of multiple spindle cells packed loosely in myxoid stroma with scattered mast cells. Late onset NF (NF-VII) and segmental NF (NF-V) are rare variants of this genetic disorder. We present a very unique case of late onset NF which presented with segmental distribution in his 7th decade of life representing an overlap of Type VII and type V sub-types.

Keywords: Late onset, Neurofibromatosis, Segmental.

How to cite this Article:
Saleem MA, Malik NA, Amin M, Baig WS. Late Onset neurofibromatosis (NF-VII) presenting with segmental distribution of lesions: A novel case report. J Bahria Uni Med Dental Coll. 2026;16(2):657-60 DOI: https://doi.org/10.51985/JBUMDC2025711

INTRODUCTION:

Neurofibromatosis (NF) is an autosomal dominant (AD) disorder characterized by dysfunction of gene that acts as a tumor suppressor.[1] This disorder encompasses a group of related disease in which tumors arise from nerves and can affect the skin and bones too. The more common and widely recognized sub-types of the disorder include type I and II NF.[2] By far the most common presentation is NF type I. It is characterized by multiple neurofibromas affecting the skin and tumors of the nervous system. Additionally, skin pigmentary changes such as café au lait macules (CALMs) and/or axillary freckling, positive family history, bones and ocular changes may also be present. The type II NF is less common, however, it is predominantly characterized by tumors of the central nervous system which can result in hearing, balance and vision abnormalities along with muscle weakness in various parts of the body. Apart from these common sub-types, Ricarrdi et al. classified this genetic disorder into six more variants denoted by NF type I to VIII.[3] Keeping in view the heterogeneity for neurofibromatosis, this classification has played a pivotal role in diagnosing and managing patients of neurofibromatosis. NF type V is characterized by neurofibromas and CALMs limited to one side of the body in a segmental distribution. It is caused by a somatic mutation during embryonic development and therefore, it is not hereditary and affects only a specific area of the body.[4] The mean age of onset of segmental neurofibromatosis is 28 years.[5] NF VII on the other hand is a variant which appears late in adulthood mainly after the 3rd decade of life and has neurofibromas only distributed over whole body. It is extremely rare entity and is characterized by absence of common features of other types of neurofibromatosis such as pigmentary changes (CALMs, Axillary freckling) and eye changes (Lisch nodules).[5] But it is very important to recognize this condition as the risks of malignant transformation of neurofibromas and internal malignancies is markedly high as compared to other types.[7] These types are only occasionally encountered in dermatology clinics. We present a very unique case of late onset NF with no associated pigmentary or eye changes which presented with segmental distribution in the 7th decade of his life representing an overlap of Type VII and type V sub-types.

Muhammad Amer Saleem,
Senior Registrar, Department of Dermatology,
Wah Medical College (POF Hospital), Wah Cantt.
Email: dr_amer@outlook.com

Naveed Akhtar Malik,
Professor, Department of Dermatology,
Wah Medical College (POF Hospital), Wah Cantt.
Email: naveedmalik467@hotmail.com

Maham Amin,
Senior Registrar, Department of Dermatology,
Wah Medical College (POF Hospital), Wah Cantt.
Email drmahamsyed@gmail.com

Wajahat Sultan Baig,
Assistant Professor, Department of Medicine,
Wah medical College (POF Hospital), Wah Cantt.
Email: wajahat_sultan@yahoo.com.

Received: 09-09-2025
Accepted: 24-02-2026
1st Revision:11-11-2025

Case Report:

A 74 years old gentleman with no known co-morbids presented to our outpatient dermatology department with complain of multiple asymptomatic raised lesions present on the left arm (Figure 1). The family history was insignificant. The first lesion developed about 4 years back just above the left cubital fossa and since then multiple lesions appeared over due course of time. The lesions increased both in size and number involving whole of the left upper limb prompting patient for dermatology consultation.

On cutaneous examination there were multiple, soft, non-tender and skin colored nodules with no temperature gradient were present involving the left arm with a flexor predominance. The nodules were of varying sizes and button-hole sign was negative. There were no associated pigmentary changes on the background skin which appeared completely normal. Rest of the cutaneous and systemic examination was completely unremarkable. Ophthalmology consultation was taken for slit lamp examination but lisch nodules were absent.

Therefore, excisional biopsy of one of the larger nodules was taken and sent for histopathology that revealed a well-circumscribed nodular lesion in dermis (Figure 2A) composed of multiple spindle cells having serpentine nuclei with pointed ends packed loosely in myxoid stroma and scattered mast cells were also seen (Figure 2B).

Patient was counselled about the disease in detail. He was advised to get only those neurofibromas removed which are very large or cosmetically unappealing to him. He was also advised to keep a check on these nodules with careful periodic examination and immediately visit the dermatology OPD if any of the lesion becomes itchy or painful, increases rapidly in size, hardens or ulcerates and if he develops and neurological complains like tingling, weakness or numbness in the arm. Patient requested to remove two more lesions near the cubital fossa that were excised by electrocauterization. Patient is now on regular follow up with our department once a year.

DISCUSSION:

NF is a hemartoneoplastic syndrome that is generally known to follow autosomal dominant pattern of inheritance.[8] Neurofibromatosis type I and type II are caused by a genetic mutation on long arms of chromosome 17 and 22 respectively.[9] However, some of its variants are not inheritable and yet the hereditary pattern of others still remain unknown. The most common presentation of the disorder is type I accounting for 96% of presentations followed but NF type II (3%).[1] The other six variants of NF as classified by Riccardi are encountered <1% in dermatology clinics.

The varying presentation of neurofibromatosis makes it difficult to classify it into a couple of variants and therefore, classification proposed by Riccardi has reduced the likelihood of missing the diagnosis in case the presentation of neurofibromatosis is unusual. One of the rare variants of NF is the late-onset NF (type VII) which is characterized by development of only neurofibromas of the skin and lack CALMs.[10] The inheritance pattern of this type remains unknown and the patient can exhibit malignant transformation of neurofibromas or tumors of nervous system. This variant has a diffuse cutaneous pattern and lesions are not confined

Figure 1: Multiple nodular lesions scattered only over the left arm of the patient (A) with sparing of the other body parts (B).

Figure 2: (A) Low power microscopic view of the biopsy specimen. (B) High power microscopic view of the biopsy specimen (arrow pointing towards a mast cell).



to a specific body part. It is very important to recognize this entity as patient has to remain on yearly follow-ups for monitoring of any malignant transformation. On the other hand, Type V (segmental) NF is a result of somatic mutation and is not inheritable. It is characterized by presence of neurofibromas and CALMs limited to one specific region of the body. The risk of malignant transformation and other complications in this variety is very low as compared to other sub types.[10]

Our patient had onset of neurofibromas in the 7th decade of life with complete absence of any related pigmentary changes. He did not have any active complains or family history and systemic examination was completely unremarkable. Ophthalmology consultation also failed to reveal any additional signs of NF such as lisch nodules on iris. Late onset NF has rarely been reported in literature and same is the case with segmental variant. However, the novel finding in our patient was that the features were limited to left arm only representing a possible overlap with segmental variant. We are classifying it as an overlap because the age of presentation is 74 years and the patient had neurofibromas with lacking evidence of other changes associated with neurofibromatosis which prompts the diagnosis of late onset neurofibromatosis, however, in late onset neurofibromatosis the neurofibromas are generalized and in our case at such advanced age patient presented with condition confined to a specific body area. We would like to classify this as an overlap and suggest long term follow up to patient in order to keep a check on malignant transformation.

CONCLUSION:

Apart from NF-I and NF-II, the other forms of NF are very rare. The late onset and segmental forms of NF are well recognized entities despite their rarity. After extensive search of the literature and to the best of our knowledge, we have classified this case as an overlap of these two variants and suggested long term follow up to patient on annual basis to monitor any malignant change.

Authors Contribution:
Muhammad Amer Saleem: Acquisition of data and drafting the article
Naveed Akhtar Malik: Conception and design plus final approval of the version to be published
Maham Amin: drafting the article literature review
Wajahat Sultan Baig: revised it critically and final approval of the version to be published

REFERENCES:

1. Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. International journal of molecular sciences. 2021 May 29; 22 (11): 5850. DOI: https://doi.org/10.3390/ijms22115850
2. Lee TS, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases. 2023 Sep 14; 18 (1): 292. DOI: https://doi.org/10.1186/s13023-023-02911-2
3. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021 Aug; 23 (8): 1506-13. DOI: https://doi.org/10.1038/s41436-021-01170-5

4. Jeyaraj N, Rajesh G, Swaminathan A, Priyadarshini A. An Uncommon Presentation of Renal Angiomyolipoma in a Patient with Segmental Neurofibromatosis: A Case Report. Journal of Clinical & Diagnostic Research. 2025 Nov 1; 19(11). DOI: https://doi.org/10.7860/JCDR/2025/79259.21947
5. ul Bari A, Rahman SB. Segmental neurofibromatosis (a rare variant of a common genodermatosis): report of two cases. Journal of Pakistan Association of Dermatologists. 2006; 16 (2):108-11.
6. Biswal S, Yadav N, Sawhney MP, Patel P. A rare case report on Neurofibromatosis type 7. Bull. Env. Pharmacol. Life Sci., Spl Issue [4] 2022: 322-32. DOI: https://doi.org/10.1097/WCO.0b013e3282f4c079
7. McLimore H, McCaughey C, Vanness E. A case of late-onset segmental neurofibromatosis. WMJ. 2014 Apr; 113(2): 72-3.
8. Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Archives of craniofacial surgery. 2022 Feb 20; 23 (1): 6. DOI: https://doi.org/10.7181/acfs.2022.00633
9. Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, Zuccarello M, Schorry E, Sengupta S. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. International journal of molecular sciences. 2021 Jan 12; 22 (2): 690. DOI: https://doi.org/10.3390/ijms22020690
10. Ideshita Y, Harada Y, Yasaki S, Sugie M, Makiyama H. A case of late-onset neurofibromatosis speculated as type 7. J Case Rep Stud. 2016; 4(5): 503. DOI: https://doi.org/10.15744/2348-9820.4.503

Instructions to Author

The Journal of Bahria University Medical and Dental College abbreviated as JBUMDC is a peer reviewed quarterly multidisciplinary biomedical journal of basic and clinical health sciences. It accepts manuscripts prepared in accordance with the "Uniform Requirements for Submission of Manuscripts for Biomedical Journals, updated December 2015", adopted by International Committee of Medical Journal Editors (ICMJE) & PMDC guidelines for Medical & Dental journals. The Journal will encompass manuscripts from all fields of biomedical sciences in the form of Editorial (Invited/Editor), Original Article, Review Article (narrative reviews and systematic reviews), short communication, Commentary, case study, and letter to editor.

Peer Review Policy:

Every paper will be read by the editor and then will be sent to two reviewers, one internal and one external reviewer. If statistical analysis is included assessment by statistician will be carried out.

Plagiarism:

JBUMDC follows the ICMJE, PMDC and HEC guidelines. Each manuscript will be scrutinized. Plagiarism of the manuscript should be less than 18%.

Preparation of Manuscript:

Type the manuscript on ISO A4 (212 × 297 mm), with margins of at least 25 mm (1 inch). Type or print on only one side of the paper. Use double spacing throughout the manuscript. Number pages consecutively, beginning with the title page. Put the page number in the lower right-hand corner of each page.

Contents of Manuscript for submission:

Submission items include a Covering letter, letter of undertaking duly signed by all authors, Ethical Review Committee (ERC) Letter, Author's declaration on JBUMDC template stating authors contribution, Title page and the Manuscript [Abstract, Key words, Introduction, Methodology, Results, Discussion, Conclusion, Acknowledgement, Authorship, Conflict of interest, References, Tables , Figures]**.** Title page should have complete title of the manuscript, along with the short running title, the names of all authors with qualifications, their department, affiliation, telephone number, e-mail, corresponding author, address for correspondence, short running title, source of funding (grant/equipment/drugs), number of figures and tables, total word count, total number of pages. Original manuscript should be of 2500 words excluding abstract and references and the references should be at least 20-25 for original study.

1. Abstract:

It should have no more than 150 words for unstructured abstracts or 250 words for structured abstracts. The structured abstract should include:

1) Objective, 2) Study design and setting, 3) Methodology, 4) Result and 5) Conclusion.

[state the purpose of the study (objective), basic procedures (methodology with study design, subjects/animals, place & duration of study, drug/chemical/equipment, procedure or protocol), main findings (results) and conclusion (It should emphasize new and important aspects of the study.)]

Below the abstract provide, 3-10 key words that will assist indexers in cross-indexing the article. The key words should be in alphabetical order.

2. Introduction:

State the purpose of the article and summarize the rationale for the study. Give only strictly pertinent references and do not include data or conclusions from the work being reported. At least 10 to 12 references should be included in the introduction. International and national literature review indicating the rational and objective of the study.

3. Methodology:

This section should include a statement indicating that the research was approved by independent local or regional or national review body(eg. Ethics committee, institutional review board) with ERC number. Clearly describe the type of study, selection of observational or experimental participants, including eligibility and exclusion criteria and a description of source population. Identify the age, gender and other characteristics of subjects. Mention the sample size and how it is calculated and the sample technique. Identify the methods, apparatus (give the manufacturer's name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. For randomized clinical trials provide information on all major study elements, including the protocol (study population, interventions or exposures, outcomes, and the rationale for statistical analysis), assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding). Authors submitting review manuscripts should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract. Describe statistical methods with enough detail to enable a knowledgeable person with access to the original data to judge its appropriateness for the study and to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Define statistical terms, abbreviations, and most

symbols. Specify the statistical software package(s) and versions used. Distinguish prespecified from exploratory analyses, including subgroup analyses.

4. Results:

Present your results in logical sequence in the text, tables, and illustrations according to the objective of the study. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Describe appropriate indicators of measurement error or uncertainty such as confidence intervals, P values. Report complications of treatment and dropouts from a clinical trial. Specify any general-use computer programs employed for analysis.

5. Discussion and Conclusion:

Emphasize the new and important aspects of the study and the conclusions that follow from them. Do not repeat in detail data or other material given in the Introduction or the Results section. Include in the Discussion section the implications of the findings and their limitations, including implications for future research. Relate the observations to other relevant studies. Link the conclusions with the goals of the study.

6. Acknowledgment:

List all contributors who do not meet the criteria for authorship, such as a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Financial and material support should also be acknowledged.

7. Authorship:

Authorship credit is based only on the criteria laid down by International committee of Medical Journal Editors (http://www.icmje.org/recommendations/browse/roles-and-responsibilibies/defining-the-role-of-authore-and-contributors. html).1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. 4) Agreement to be Accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All Conditions must be met. Authors should provide a description of what each contributed.

8. Conflict of interest:

All authors have to disclose and submit any financial /personnel relationship that might bias and inappropriately influence their work.

9. References:

Minimum 50% of the references must be from last five years. Local references must also be included. Vancouver style should be followed. Examples are:

a) Standard journal article:

List the first six authors followed by et al. I) Less than 6 authors:

Vega KJ, Pina I, Krevsky B. Heart transplantation is associated with an increased risk for pancreato-biliary disease. Ann Intern Med 1996; 1;124 (11):980-3

II) More than six authors:

Parkin DM, Clayton D, Black RJ, Masuyer E, Friedl HP, Ivanov E, et al. Childhood leukaemia in Europe after Chernobyl: 5 year follow-up. Br J Cancer 1996;73:1006-12

b) Organization as author:

The Cardiac Society of Australia and New Zealand. Clinical exercise stress testing. Safety and performance guidelines. Med J Aust 1996; 164: 282-4

c) No author given:

Cancer in South Africa [editorial]. S Afr Med J 1994;84:15

d) Chapter in a book:

Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh

JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. p. 465-78

e) Newspaper:

Hasan Mansoor. Excessive use of drugs creating resistance to antibiotics. The Dawn 2013, 24 June; sect. Metropolitan (col.1-4)

10. Tables:

Type or print out each table with double spacing on a separate sheet of paper. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Give each column a short or abbreviated heading. Place explanatory matter in footnotes. Explain in footnotes all nonstandard abbreviations that are used in each table. Identify statistical measures of variations, such as standard deviation and standard error of the mean. Do not use internal horizontal and vertical rules.

11. Illustrations (Figures):

Figures should be professionally drawn and photographed. Photographic prints 127 × 173 mm (5 × 7 inches). Photomicro-graphs should have internal scale markers. Symbols, arrows, or letters used in photomicro graphs should contrast with the background. If photographs of people are used, either the subjects must not be identifiable or their pictures must be accompanied by written permission to use the photograph.

Figures should be numbered consecutively according to the order in which they have been first cited in the text. If a figure has been published, acknowledge the original source

and submit written permission from the copyright holder to reproduce the material.

Legends for Illustrations:

Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs.

Units of Measurement:

Measurements of length, height, weight, and volume should be reported in metric units. Temperatures in degrees Celsius, Blood pressure in millimeters of mercury and all hematologic and clinical chemistry measurements in the metric system in terms of the International System of Units (SI).

Abbreviations and Symbols:

Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.

Sending the Manuscript to the Journal:

Submit manuscript by e-mail: editor.bumdc@bahria.edu.pk

All correspondence regarding submitted manuscripts will be via e-mail.

S. No	Type of Article	Abstract Type and Word count	Key-Words	Total Word Count	References	Table & Figures (MAX)
1	Editorial	-	-	1000-1500	10-12	-
2	Review Article	Unstructured (150)	3-6	3500-5000	40-50	4-6
3	Original Article	Structured (250)	3-10	3000-4000	20-25	4-6
4	Medical Education	Original Structured (250)	3-10	3000-4000	20-25	4-6
		Review Unstructured (150)	3-5	3500-5000	40-60	4-6
5	Short Communication / Commentary / Opinions/ Perspective	-	-	1200-2000	15-20	2-3
6	Student Corner	Original Structured (250)	3-10	3000-4000	20-25	4-6
		Views Perspectives / Opinions Unstructured (150)	3-5	1200-2000	8-10	1-2
7	Case Report	Unstructured (150)	3-5	1200-2000	10-12	4-6
8	Letter to Editor	-	-	400-500	1-5	0

JBUMDC
Journal of Bahria University Medical & Dental College
Peer Reviewed Multidisciplinary Quarterly Published Journal
ISSN (print): 2220-7562, ISSN (online): 2617-9482, CODEN: JBUMB7
Recognized by HEC & PMDC
Online edition is available at URL: https://jbumdc.bahria.edu.pk,
Indexed with Index Medicus for the Eastern Mediterranean Region (IMEMR),
https://vlibrary.emro.who.int/journals/jbumdc-journal-of-bahria-university-medical-and-detal-college/
ROAD Directory of Open Access Scholarly Resources at https://portal.issn.org/resource/ISSN/2617-9482
Pakmedinet at www.pakmedinet.com/jbumdc,
Google Scholar at https://scholar.google.com.pk/,
Crossref at https://doi.org/10.51985/aluu2996
ICMJE at https://www.icmje.org/journals-following-the-icmje-recommendations/#J
Bahira University DSpace Repository at http://111.68.99.22:8080/xmlui/handle/123456789/6388,
Pakistan Scientific and Technological Information Center (PASTIC) at http://pastic.gov.pk/

Journal of Bahria University Medical & Dental College

Published by Bahria University Health Sciences Campus Karachi
Adjacent PNS SHIFA DHA Phase II Karachi, Pakistan
+92-21-35319491-9
http://jbumdc.bahria.edu.pk
editor.bumdc@bahria.edu.pk
https://www.facebook.com/jbumdc/, https://www.facebook.com/journal.bumdc.7